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Abstract 
Acute respiratory infections are a significant cause of global morbidity and mortality. 
Traditional strategies to combat such infections are vaccination and administration of 
anti-microbial agents, but these are frequently lacking in their efficacy and safety. In 
this thesis we examine the alternative strategy of manipulating the excessive immune 
response that occurs upon lung infection. Influenza is a viral respiratory pathogen that 
evokes a potent Thl driven response and significant immunopathology. Conversely, 
Cryptococcus neoformans is an encapsulated yeast, which induces a non-protective 
Th2 immune response that fails to eradicate the pathogen and ultimately culminates in 
dissemination to the brain and meningoencephalitis. Here we describe the therapeutic 
benefit of manipulating the myeloid immune compartment. 
The phagocyte NADPH oxidase assists in combating bacterial and fungal infections 
through the generation of superoxide radical. We demonstrate a role for NADPH 
oxidase (using knockout mice, Cybb tml mice) in macrophage homeostasis and the 
subsequent Thl driven immunity in the airways during influenza infection resulting in 
improved viral clearance. Similarly, the non-protective Th2 response to C. 
neoformans is heavily skewed to a protective Thl granulomatous response that 
promotes immunity to the fungus and limits dissemination to the brain. Similar results 
are obtained using a novel manganic porphyrin that scavenges reactive oxygen 
species. 
CD200, through it's interaction with the myeloid specific CD200 receptor, delivers an 
inhibitory signal to the myeloid compartment. Our understanding of the basic biology 
regarding the expression and function of this inhibitory interaction is still in its 
infancy. Here, we investigate these parameters both in vitro and in vivo in the context 
of respiratory infections. Subsequently, we elucidate how manipulation of such an 
interaction can modulate inflammation during respiratory infection with influenza and 
C. neoformans. 
Manipulation of these facets of the myeloid immune response provides protection 
against respiratory infection and has clear therapeutic potential. 
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EAE Experimental autoimmune encephalitis 
EAU 	 Experimental autoimmune uveoretinitis 
ELISA Enzyme Linked Immunosorbent Assay 
FAD 	 Flavin adenide dinucleotide 
FasL Fas Ligand 
Fc 	 Fragment crystallisable 
15 
FCS 	 Foetal calf serum 
FITC Fluorescein Isothiocyanate 
fMLP 	 N-Formyl-L-Methionyl-L-Leucyl-L-Phenylalanine 
FSC Forward Scatter 
GM-CSF 	Granulocyte macrophage-colony stimulating factor 
GXM Glucuronoxylomannan 
HA 	 Haemagglutinin 
H and E 	 Haematoxylin and Eosin 
HEPES N-(2-Hydroxyethyl) Piperazine-N'-(2-Ethanesulphonic acid) 
HIV 	 Human immunodeficiency virus 
HLA Human Leukocyte Antigen 
HPLC 	 High Performance Liquid Chromatography 
HRP Horse radish peroxidase 
HSP 	 Heat Shock Protein 
ICOS Inducible co-stimulatory molecule 
ICOSL 	 ICOS co-stimulatory molecule ligand 
IDO Indoleamine-2,3-dioxygenase 
IFN 	 Interferon 
Ig Immunoglobulin 
IgSF 	 Immunoglobulin superfamily 
Ion Ionomycin 
IL 	 Interleukin 
IRF Interferon regulatory factor 
ITAM 	 Immunoreceptor tyrosine based activation motif 
ITIM Immunoreceptor tyrosine based inhibitory motif 
kb 	 Kilobase 
kD Kilodalton 
KLH 	 Keyhole limpet haemocyanin 
L Ligand 
LAP 	 Latency associated protein 
LDH Lactose dehydrogenase 
LN 	 Lymph node 
LP S Lipopolysaccharide 
LTA 	 Lipoteichoic acid 
LTK63 Modified heat labile toxin of Escherichia coli 
M 	 Mol 
M cell 	 Microfold cell 
MAC Membrane Attack Complex 
MALT 	 Mucosal associated lymphoid tissue 
MBL Mannose-Binding Lectin 
MCP-1 	 Monocyte Chemotactic Protein-1 
M-CSF Macrophage-colony stimulating factor 
MDCK 	 Madine Darby canine kidney 
MEM Minimal essential medium 
MHC 	 Major Histocompatibility Complex 
MIR Macrophage immunoglobulin-like receptor 
MLN 	 Mediastinal lymph node 
MMP Matrix Metalloprotease 
MnTE-2-PyP 	Manganese (III) tetrakis (N-ethyl pyridinium-2-y1) porphyrin 
mRNA 	 Messenger Ribonucleic Acid 
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MW 	 Molecular weight 
Microgram 
NA 	 Neuraminidase 
NADPH 	 Nicotinamide adenine dinucleotide phosphate 
NALT Nasal associated lymphoid tissue 
NaOH 	 Sodium Hydroxide 
NK-143 Nuclear factor-x(3 
Ng 	 Nanogram 
NK cell 	 Natural killer cell 
NO 	 Nitric oxide 
OD Optical Density 
OX4OL 	 OX40 ligand 
OX4OL:Ig mouse OX40 ligand:mouse IgG1 fusion protein 
PAMP 	 Pathogen-Associated Molecular Patterns 
PBMC Peripheral Blood Mononuclear Cells 
PBS 	 Phosphate Buffered Saline 
PCA Passive cutaneous anaphylaxis 
PCR 	 Polymerase chain reaction 
PE Phycoerythrin 
PercP 	 Peridinin Chlorophyll Protein 
PFU Plaque forming unit 
Pg 	 Picogram 
Phox Phagocyte NADPH oxidase 
plg 	 Polymeric immunoglobulin 
pIgR Polymeric immunoglobulin receptor 
PK 	 Protein Kinase 
PLC Phospholipase C 
PMA 	 Phorbol-12-Myristate-13-Acetate 
PRR Pattern Recognition Receptors 
R 	 Receptor 
RANTES 	Regulated upon Activation in Normal T cells, Expressed and 
Secreted 
RBC 	 Red blood cell 
RNA Ribonucleic acid 
RNS 	 Reactive nitrogen species 
ROS Reactive Oxygen Species 
RPMI 	 Roswell Park Memorial Institute 
RSV Respiratory syncitial virus 
S. aureus 	Stapphylococcus aureus 
SD 	 Standard deviation 
SEM Standard Error of the Mean 
SH 	 Src homology 
SHIP SH2-containing inositol phosphatase 
SIgA 	 Secretory immunoglobulin A 
SIRP Signal regulatory protein 
SOD 	 Superoxide dismutase 
STAT Signal transducers and activators of transcription 
TCR 	 T Cell Receptor 
TGF-13 Transforming Growth Factor-13 
Thi 	 T helper 1 
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Th2 	 T helper 2 
TLR Toll-like Receptor 
TNF 	 Tumour Necrosis Factor 
Trl Type 1 regulatory T cell 
Treg 	 Regulatory T cell 
TREM Triggering receptor expressed on myeloid cells 
WHO 	 World health organisation 
XAO Xanthine oxidase 
XDH 	 Xanthine dehydrogenase 
XOR Xanthine oxidoreductase 
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Chapter 1— Introduction 
1.1 Epidemiology of respiratory infections 
The respiratory tract is a portal to the external environment, and as such is exposed to 
a vast array of potentially harmful antigens, with an estimated 10 000 micro-
organisms being inhaled every day. The respiratory tract can be viewed as a 
continuum that extends from the nasal cavity down to the alveoli with every site 
potentially being targeted by an array of bacterial, viral, fungal and other pathogenic 
organisms. The upper respiratory tract of most individuals is colonised by a diverse 
collection of commensal microflora which exert no detrimental effect on the host 
under normal physiological conditions. Conversely, the lower respiratory tract from 
the larynx down is essentially sterile so as to optimise the potential of the lung to 
partake in efficient gaseous exchange. Infection of the lungs would be highly 
deleterious to the host, and the development of an intricate and potent mucosal 
immune system generally restricts pathogen invasion and infection. However, 
pathogens have developed virulence factors to target and subvert immune effectors 
and facilitate infection. Respiratory infections can afflict anyone, but display an 
increased propensity when the immune status of the host is compromised or the 
invading pathogen is highly virulent. 
The Global Burden of Disease study of 2002 highlights acute respiratory infections as 
the third leading cause of global mortality, resulting in an estimated 3.9 million deaths 
each year 1. The World Health Organisation (WHO) illustrate that such acute 
respiratory infections are the most extensive burden of disease, responsible for an 
estimated number of disability adjusted life years (DALYs) approaching 100 million 
in 2001, exceeding that of HIV/AIDS, tuberculosis and other eminent infections (Fig. 
1.1a). Respiratory infections have remained a constant health burden for enumerable 
years, and are the most common and perhaps severe illness experienced by the 
populace, regardless of age or gender. In addition to the significant mortality 
associated with such infections, is the substantial morbidity and ensuing economic 
disruption. Furthermore, it must be appreciated that such infections 
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Figure 1.1. Epidemiology of respiratory infections. (a). The number of disability 
adjusted life years (DALYs) caused by the worlds most common infectious 
diseases). (b). The number of deaths attributed to respiratory infections in different 
regions of the world. 
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are not simply an affliction of the Western world but are indeed a more sizeable 
dilemma in developing countries where effective methods of prevention and cure are 
more underdeveloped (Fig. 1.1b). 
1.2 Innate Immunity to Respiratory Infections 
It is credit to the efficient, robust and multifaceted immune system that so few 
infective organisms compromise the integrity of the respiratory epithelium, and that 
most respiratory diseases are cleared rapidly after an acute episode of infection. The 
immune system can be viewed as a co-ordinated interplay between innate/non-
specific immunity and acquired/specific immunity. Innate immunity fulfils a highly 
significant role early in infection against a diverse array of pathogens and is critical to 
the development of the more pathogen specific adaptive immunity. 
1.2.1 Physical barriers 
The primary obstacle to micro-organisms entering the respiratory tract is an array of 
mechanical barriers that act to limit pathogen invasion beyond the respiratory 
epithelia. The nasal passage acts to filter any antigens greater than 10µm in diameter 
from progressing past the larynx, and further size exclusion is imparted by tight 
junctions between epithelial cells of respiratory mucosal surfaces, with membrane and 
paracellular spaces being impervious to large molecules. The respiratory epithelia are 
coated in a thick layer of mucus which acts to trap invading micro-organisms and 
prevent them gaining access to the underlying respiratory epithelia. Consequent 
ciliary movement and cough and gag reflexes act to displace foreign particles from 
the lumen of the respiratory tract. 
1.2.2 Cells of the innate immune response 
There are many effector cells that comprise the innate immune system, which exert 
potent anti-microbial activity, and are fundamental in the establishment of a rapid 
response to pathogen challenge. Some cells of the innate immune system are resident 
in the healthy lung of an uninfected individual, but there is further recruitment to 
inflammatory signals generated during infection. Such recruitment at appropriate 
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times is dictated by the temporal expression of a diverse array of chemoattractants and 
adhesion molecules that mobilise inflammatory cells to the site of infection and 
facilitate their infiltration (Fig. 1.2). Recognition of conserved microbial structures by 
cells of the innate immune system augments their activation leading to more potent 
anti-microbial capacity and greater release of an array of chemokines and cytokines 
that promote inflammation. Activation of innate mechanisms can be mediated by 
recognition of pathogen associated molecular patterns (PAMPs). PAMPs are 
expressed by a variety of pathogens but are not present in mammalian cells, allowing 
the distinction between self and non-self, and are recognised directly by the pattern 
recognition receptors (PRR) 2. 
PAMPs have not evolved to interact with the host immune system, they perform 
essential functions within the infectious agent and are highly conserved across 
species, allowing a limited number of PRRs to detect infection 3. PAMPs include 
lipopolysaccharide (LPS), the cytosine guanine (CpG) dinucleotide DNA motif, 
lipoproteins, peptidoglycan, flagellin and lipoteichoic acid (LTA). Toll-like receptors 
(TLRs) constitute an important family of receptors that recognize such PAMPs, and 
are considered to represent a significant mechanism for inducing production of anti-
microbial products and in the establishment of a rapid and potent immune response to 
infection. There are now acknowledged to be 10 distinct groups of TLRs, each 
recognizing distinct factions of microbial products. TLR2 recognizes lipoproteins, 
TLR4 LPS, TLR5 flagellin and TLR9 is specific for CpG motifs 4-11 
One mechanism of protection to respiratory pathogen infection is the production of 
anti-microbial peptides by resident leukocytes 12,13.  Production of these soluble 
mediators may be constitutive or induced via recognition of pathogen motifs and can 
impart both direct and indirect immunity towards the invading micro-organism. Table 
1.1 depicts some of the most significant microbicidal mediators that constitute the 
host's protective immune response 12-16. 
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Figure 1.2. Innate immune response to respiratory viral infection. Respiratory 
viruses primarily infect airway epithelia and cells such as macrophages that are 
resident to the naïve airways of the host. Infection of these cells elicits the 
production of antiviral mediators such as IFN-a, as well as an array of cytokines 
and chemokines (depicted as small circles) that form a gradient and cause further 
recruitment of inflammatory cells, such as neutrophils, from the blood and into the 
infected site. These cytokines will also act to activate cells within the infected 
tissue, evoking a heightened microbial capacity within macrophages, and 
activating NK cells to kill infected cells487. 
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Lysozyme Neutrophils, 
macrophages, 
eoithelial cells 
Defensins 	Phagocytes, 
lymphocytes, 
epithelial cells 
Surfactant 	Alveolar type II 
protein-AM cells 
Gram-positive bacteria 
Gram-positive.-
negative bacteria, 
mycobacteria, yeast, 
fungi, some enveloped 
viruses 
Carbohydrate PAMPs 
Anti-
microbial 
agent 
Lactoferrin Neutrophils, 	Bacteria 
macrophages, 
epithelial cells 
Source Target 	 Method of protection 
Type 1 IFNs Macrophages, 	Viruses 
epithelial cells 
Sequesters iron essential 
for microbes; 
Directly bactericidal ; 
Stimulates 02' production 
by macrophages 
Degradation of cell wall 
Permeabilises microbial 
membranes; 
Triggers alternative 
complement pathway 
Opsonisation, 
agglutination and 
neutralisation 
Limit viral replication; 
Activate macrophages and 
NK cells; Induce 
activation and 
differentiation of DCs; 
Adjuvants for T and B 
cells 
Table 1.1 Microbicidal mediators of the host's innate immune response to 
infection. 
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Macrophages are essential cells of the innate immune system and fulfil a pivotal role 
in immunosurveillance and are consequently fundamental to the establishment of a 
protective inflammatory response to infection. Alveolar macrophages are resident in 
the respiratory tract, comprising 95 % of all cells in the airways of uninfected 
individuals. They fulfil an important role in immune surveillance, recognizing 
invading pathogens and setting in motion microbicidal and inflammatory events 
necessary for the clearance of the invading pathogen 17. Macrophages also play an 
important role in the regulation of potentially harmful inflammation; maintaining 
immunological tolerance and respiratory homeostasis 17Alveolar macrophages express 
an assortment of receptors that facilitate recognition and phagocytosis of microbial 
pathogens, such as Fc, complement, mannose, Toll-like and an array of scavenger 
receptors. Ingested pathogens are subsequently exposed to toxic mediators, such as 
reactive oxygen species (ROS) and proteases that can kill the engulfed micro-organism 
18. Macrophages also secrete an array of other molecules that are anti-microbial 
including lysozyme, lactoferrin, and defensins which together confer resistance to an 
array of potential infective agents 12-16. 
Macrophages must communicate with other cells of the immune system not only to 
initiate inflammation but also resolve it. This is largely achieved through the secretion 
of cytokines. Cytokines derived from macrophages and proven to be important in 
pulmonary defence to infection include TNF, IL-12, IFN-y, IL-10, IL-1 and a selection 
of chemokines that govern recruitment of cells 17,19-21.  These cytokines increase the 
production of chemokines and promote the up-regulation of adhesion molecules on the 
endothelia and epithelia, facilitating the recruitment and diapedesis of neutrophils and 
lymphocytes into the lung. Macrophages are also an abundant source of IL-12, a 
cytokine fundamental to the establishment of a Thl immune response, and NK cell 
activation. Through the production of such cytokines, as well as their potential to act 
as antigen presenting cells (APCs), macrophages clearly also fulfil a fundamental role 
in orchestrating the development of an acquired immune response, critical to specific 
cell mediated and humoral responses. 
Dendritic cells (DCs) are another important APC that form a network in the 
submucosa of the nasopharynx, trachea and bronchial tree 22'23. These exhibit an 
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enhanced capacity to present antigen as a result of their constitutively augmented 
expression of several co-stimulatory molecules important in the activation of 
lymphocytes. At the site of infection, naive dendritic cells engulf and process 
pathogen for presentation, and are capable of migrating to draining lymph nodes to 
present the epitopes of the pathogen to effecor cells of the adaptive arm of the 
immune response 23'24 
Neutrophils represent another cellular component of the host's innate immune 
response, which like macrophages exhibit direct anti-microbial activity and release 
multiple cytokines. Neutrophils are an essential component of the host's armoury 
against many bacterial pathogens but also fulfil a significant role in protection against 
other microbial infections of the lung. Neutrophils are recruited rapidly from the 
periphery to the site of infection in response to various stimuli such as chemotactic 
proteins IL-8 and MIP-2 produced by lung macrophages and airway epithelial cells 
20,21,25  Once at the infected site, neutrophils are activated by local pro-inflammatory 
cytokines. Like macrophages, neutrophils are strongly phagocytic and exhibit a 
propensity for ingesting and killing invading pathogens 20'25-27. They also produce a 
number of cytokines such as TNF, 	IL-6 and MIP-2, which act to augment and 
refine the pro-inflammatory response 13'28. Eosinophils and basophils are other 
granulocytes found in the lung. Unlike neutrophils, these cells are poorly phagocytic, 
but secrete cytotoxic mediators such as major basic protein into the extracellular 
milieu in a process known as "frustrated phagocytosis". 
Finally, Natural Killer (NK) cells respond rapidly to viral infection and express a 
variety of surface receptors that survey the levels of MHC class I. If the NK cell 
detects reduced expression levels of MHC I, as may be evoked by viral infection, then 
it will proceed to kill it. NK cell cytoxicity is mediated by perforM and granzyme 
induced lysis, and there is also evidence that this cell type can mediate Fas dependent 
apoptosis. NK cells are activated by IL-12 derived from pulmonary macrophages and 
in turn generate IFN-y, which further activates the macrophage population. 
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I. 3 Reactive oxygen species and immunity to infection 
1.3.1 The NADPH oxidase and respiratory burst 
As described previously, one facet of innate immunity is the phagocytic barrier 
consisting of a variety of cells such as neutrophils and macrophages, which engulf the 
invading pathogen and subsequently destroy it via production of a number of 
antimicrobial and cytotoxic substances. One mechanism utilized by phagocytes to kill 
invading micro-organisms is the generation of reactive oxygen species (ROS) that are 
toxic to the pathogen. These ROS are generated via a membrane associated NADPH 
oxidase called the PHagocytic OXidase (PHOX) 18. NADPH oxidase is a multimeric 
membrane associated enzyme complex that utilizes molecular oxygen and the 
reducing power of NADPH to generate superoxide radical (02.1 18: 
NADPH + 202 NADP+ +202.- + 2H+ 
The generation of superoxide is coincident with the so-named "respiratory burst" of 
the phagocyte, which evokes a sudden and dramatic increase in the rate of oxygen 
consumption. A host of external stimuli induce the phagocyte to undergo the 
respiratory burst and the concomitant activation of the NADPH oxidase, and 
ultimately the generation of superoxide. Cited examples of such external stimuli 
include phagocytic prey, galectin-3, agonists of complement receptor 3 (CR3), PMA, 
ionomycin and 7-transmembrane receptor agonists (e.g. IL-8) 29-31. 
The phagocytic NADPH oxidase is located on the membranes of all professional 
phagocytes, but is also present on some poorly phagocytic cells such as B cells. It was 
originally anticipated that this enzyme was expressed primarily on the plasma 
membrane of such cells, proximally located to external environment. However, it is 
now known to also be located on the membranes of vesicles and granules, particularly 
in neutrophils 18,32 
The phagocyte NADPH oxidase is a multi-component enzyme complex that is 
composed of membrane associated and cytosolic components 32,33  (Fig. 1.3a). The 
core of the enzyme is comprised of the membrane bound flavocytochrome b558. This 
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Figure 1.3. NADPH oxidase and generation of reactive oxygen species. (a). 
The phagogocytic NADPH oxidase comprises of membrane associated (gp91 and 
p22) and cytosolic (p67, p4'7, p40) components. Following activation the cytosolic 
components are phosphorlated and translocate to the membrane to form an active 
complex which catalyses the formation of 02.-. (b). The 02 - produced by NADPH 
oxidase can be converted to an array of other ROS, by a variety of enzymes, that 
are toxic to pathogen invaders. 
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flavocytochrome is the site of the oxygen reduction that generates superoxide and 
comprises of two subunits, a 22 kDa protein (p22phox) and a 91 kDa glycoprotein 
(gp9lphox). Gp9lphox contains one flavin and two heme prosthetic groups, and it is 
these that mediate the transfer of electrons from the NADPH donor to the molecular 
oxygen substrate 33. When the phagocyte is in a resting state the cytosolic factors 
(p4Ophox, p47phox and p67phox) persist as a complex in the cytosol. Phagocytosis or 
appropriate stimuli can induce the union of all these components to form an active 
complex that catalyses the formation of superoxide. Activation elicits the 
phosphorylation of the cytosolic p47phox, which is subsequently translocated to the 
plasma membrane along with other cytosolic factors, where they interact via p67phox 
with flavocytochrome b558 to form an active complex that is capable of superoxide 
generation 34. 
1.3.2 Xanthine oxidase as a source of superoxide 
Xanthine oxidase (XAO) and xanthine dehydrogenase (XDH) are inter-convertible 
forms of the same gene product, namely xanthine oxidoreductase (XOR) 35'36. The 
enzymes are complex molybdopterin containing flavoproteins that consist of two 
identical sub units of approximately 145 kDa 37'38. XOR is synthesised as the 
dehydrogenase form, which predominates in mammalian cells, but can be readily 
converted to the active oxidase form by oxidation of sulphydryl residues or by 
proteolysis 38. Expression of XAO/XDH is up-regulated in response to a variety of 
stimuli, including hypoxia 39, anoxia 40, LPS and cytokines such as IFN-y and IL-1 
41,42. XDH has subsequently been demonstrated to be converted to XO by several 
signals including C5a, fMLP and TNF. 
One of XORs primary physiological roles is in the conversion of hypoxanthine to 
xanthine and xanthine to uric acid. Hypoxathine or xanthine bind to the active 
oxidized form of the enzyme (XAO) and donates two electrons to the molybdenum 
cofactor reducing it from MoVI to MoIV. In the process the substrate is hydroxylated 
by H2O at the molybdenum site, as their electrons are passed via two iron-sulphide 
residues to flavin adenide dinucleotide (FAD) within the enzymes active site. The 
reduced FAD can subsequently be re-oxidised to produce superoxide or hydrogen 
peroxide 43-45. In this manner XAO is capable of generating ROS. 
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XOR is widely distributed through various tissues, present in the liver. Intestines, 
lung, kidney, myocardium, brain and plasma 46-48. XAO serum levels have been 
reported to be significantly elevated in various pathological states such as hepatitis, 
inflammation, ischemia-reperfusion and carcinogenesis and the ROS generated by this 
enzyme are anticipated to cause oxidative damage 49-51  XAO is reported to have a 
role in the pathogenesis of acute lung injury. Indeed, hypoxia up-regulates XAO/XDH 
mRNA expression in pulmonary arterial endothelial cells 52, and XDHDCAO activity 
and gene expression have been shown to be increased in response to hypoxia, 
endotoxin and IL-1I3 in animal models of lung injury 42. Furthermore, inhibition of 
XAO/XDH was shown to prevent the development of pulmonary edema following the 
forementioned treatments, clearly implicating these enzymes in acute lung injury 42. 
1.3.3 Superoxide and downstream radicals exhibit anti-pathogenic potential 
The superoxide generated by the phagocytic NADPH oxidase exhibits potent anti-
pathogenic action, mediating the destruction of a host of invading microorganisms 
32,53-55 Furthermore, the superoxide can subsequently be converted to a vast array of 
ROS that are detrimental to the invading organism (Fig. 1.3b). The superoxide radical 
and other ROS are by their very nature reactive and can cause extensive and 
irreversible damage to cellular components with excessive superoxide being linked to 
lipid peroxidation, mitochondrial dysfunction and oxidation of other biomolecules 56. 
However, the pathogenic potential of reactive oxygen species has been suggested to 
be attributable to the role of these mediators in activating proteases that reside within 
the phagocytic vacuole 57. These proteases exhibit potent anti-microbial potential, and 
are activated through the generation of a hypertonic K+ rich alkaline environment 
within the phagocytic vacuole. The K+ crosses the membrane into these vacuoles 
through large conductance Ca2+ activated K+ channels, which are opened due to an 
oxidase induced membrane depolarization and elevated Ca2+ concentration 57. 
The critical role fulfilled by ROS in the control of pathogen burden is made clearly 
apparent by the genetic condition chronic granulomatous disease, whereby the 
afflicted individual is inherently deficient of a functional phagocytic oxidase, and 
30 
consequently exhibits a greater propensity to infection with bacterial and fungal 
agents 53'58. 
1.3.4 Reactive oxygen species as signalling moieties and regulators of the immune 
response 
The anti-pathogenic action of superoxide is not the exclusive role of this molecule, 
and there have recently been a plethora of studies dissecting the role of ROS in 
intracellular signalling 59'60 and in the regulation of immune cell function 61,62  
Superoxide acts as a second messenger and has been implicated in the induction of 
pro-inflammatory and apoptotic events. A great number of transcription factors are 
regulated by their redox state, and consequently reactive oxygen species have a 
significant influence on transcription of a vast array of genes. One transcription factor 
whose action is dictated by redox state, and which is of particular prevalence as a 
consequence of its indicative role in the transcription of pro-inflammatory cytokines 
and adhesion molecules, is NF-143 63. Furthermore, ROS are implicated in the 
induction of a programmed cell death pathway, an example being the cited potential 
of hydrogen peroxide to induce apoptosis in macrophages 64. 
1.4 Control of myeloid cells 
1.4.1 Receptors that modulate activity of the myeloid population 
The immune system must evoke a rapid and potent immune response to pathogen 
challenge in order to eradicate the invading organism, but must also exhibit a degree 
of subtlety to minimize inappropriate or over-exuberant inflammation and 
immunopathology 65,66  As previously discussed, myeloid cells represent a population 
of immune cells with pleiotropic functions that form a formidable barrier to combat 
the infective agent. However, their potency and permissiveness would implicate them 
in ensuing pathology if their activity is not regulated. This is achieved by soluble 
factors or cell contact dependent interactions 67. Cell contact dependent modulation of 
myeloid function offers more specificity and selectivity than the broad signals 
conferred by soluble mediators, capable of eliciting a signal at specific sites within a 
tissue and at specific stages of an immune response. Such cell contact dependent 
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regulation of the myeloid compartment can be mediated through receptors that are 
members of the Immunoglobulin superfamily (IgSF). The IgSF domain is the most 
abundant domain type in leukocyte surface proteins and receptors bearing these 
domains are frequently involved in control of the immune system. Receptors with 
IgSF domains that regulate myeloid activity include CD200R, CD172a (SIRP-a), 
TREM and macrophage Ig-like receptor (MIR) 68-70 (Fig. 1.4). 
1.4.2 CD200 — CD200R interaction and the regulation of myeloid cells 
The signal delivered to the myeloid cell through CD200 receptor is induced by 
ligation with CD200. CD200 (OX-2) was discovered approximately 20 years ago as 
an antigen present in rat brain and thymus 71. The rat CD200 protein was subsequently 
cloned and demonstrated to be a 41-4710a surface glycoprotein 72. CD200 has also 
now been cloned and characterised in mice and humans 73'74. CD200 is a 
transmembrane protein and a member of the Immunoglobulin-superfamily with 2 
extracellular Ig-SF domains 75. In mice, it is a protein of 269 amino acids constituting 
a hydrophobic signal peptide, a membrane distal Ig-V-like domain, a membrane 
proximal Ig-CH2-like domain, a transmembrane segment and a short cytoplasmic tail 
73'74. It possesses 6 N-linked glycosylation sites and shares structural homology to 
CD80/CD86. The cytoplasmic tail is only 19 amino acids long and shares no 
homology to signalling kinases, which, combined with the lack of ITIM/ITAM 
sequences or SH2/SH3 domains would imply that it is incapable of inducing an 
intracellular signal. 
CD200 exhibits an unusual distribution on specific cell types, which has been 
demonstrated to be virtually identical in mice, rats and humans 71'76'77. Thus far, 
CD200 expression has been reported on thymocytes, B cells, activated T cells, 
neurons, follicular dendritic cells, endothelium and cells in reproductive organs 71,76-80 
(Table 1.2). 
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Figure 1.4. Control of leukocytes can be mediated by cell-to-cell contact. 
Control of the immune system cells is partly mediated through cell—cell contact. 
Such cell contact interactions are important in T-cell activation by antigen 
presenting cells. Similarly, it is becoming apparent that a number of such proteins 
exist that are involved in the regulation of myeloid cells. CD200R and signal 
regulatory protein-a are examples of myeloid-specific receptors with 
immunoglobulin superfamily domains that can deliver inhibitory signals to the 
myeloid compartment487. 
Cell type CD200 CD200R 
T cell -/+ -/+ 
Activated T cell + -/+ 
Thymocyte + - 
B cell + - 
Mon./Macrophage - + 
Dendritic cell -/+ + 
Neutrophil - + 
Mast cell - + 
Basophil - + 
Endotheliim + - 
Epithelium -/+ - 
Neuron + - 
Table 1.2 Cellular expression of CD200 and CD200R. 
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The CD200 receptor was cloned by Barclay et al and shown to be closely related to 
CD200 and has most probably arisen through gene duplication 68. The receptor has 
subsequently been independently characterised in humans and mice 81'82. Like its 
ligand, CD200R is also a member of the immunoglobulin superfamily, with two 
extracellular IgSF domains 68. It possesses an unusually high number of N-linked 
glycosylation sites, with 8 identified in rats and 10 in mice 68'82. The cytoplasmic tail 
of CD200R is longer than that of the ligand being 67 amino acids in length. It 
contains three tyrosines residues as potential phosphorylation sites and is capable of 
signalling, implying that the action of CD200 is solely delivered through the receptor 
and is not bi-directional 68'82. One of these tyrosine residues is located within a NPXY 
motif, and a recent study in mast cells has demonstrated this residue to be 
phosphorylated upon ligation of the receptor 83. Furthermore, this phosphoryation 
leads to the recruitment of adaptor proteins Dok-1 and Dok-2, which are in turn 
phosphorylated and associate with RasGAP and SH2-containing inositol phosphatase 
(SHIP). Ultimately, this was demonstrated to inhibit the phosphorylation of ERKs, 
p38 and JNK 83. There have, however, been limited studies thus far citing the 
downstream signalling events from CD200R in other myeloid cells. 
The expression of the receptor is far more restricted than that of the ligand being 
largely confined to myeloid cells (Table 1.2). The expression profile of the receptor 
again appears to be conserved between mice, rats and humans and has thus far been 
described upon macrophages, dendritic cells, neutrophils, basophils and mast cells 
68,82-85. Though expression appears largely confined to myeloid cells, one study 
describes expression of CD200R on CD4+ T cells from peripheral blood in mice and 
humans, and further identified high levels of CD200R mRNA expression in Th2 
polarised T cells 82. Two groups have subsequently described an extended family of 
CD200R molecules 82,86  in addition to that previously discussed 68. It would thus 
appear that there exist four isoforms of CD200R in mice (R1-4) and two in humans 
(R1-2), yet the exact role of these other receptors as well as their natural ligands 
remains ambiguous. 
34 
1.4.3 CD200 knock out mice: a lesson in CD200R function 
The generation of knock out mice lacking CD200 provided the first and best clues as 
to the role of the CD200-CD200R interaction 76. Naive CD200 knock out mice exhibit 
an intrinsic defect, not in the cell types expressing CD200, but in those populations 
expressing the receptor. CD200 knock out mice exhibit increased numbers of CD1 1 b+ 
myeloid cells in the spleen (especially in young mice) with elevated numbers of 
splenic red pulp macrophages and a thicker marginal zone macrophage layer 76. 
Furthermore, elevated levels of the immunotyrosine activating motif (ITAM) 
containing intracellular DAP-12 were detected in CD200 knock out mice, within the 
marginal zone and on dendritic cells in T cell areas of the red pulp. This implies an 
elevated level of myeloid cell activation. Lymph nodes are slightly enlarged and 
exhibit an unusual tubular structure with no demarcation between nodes. Macrophage 
populations are again expanded and exhibit heightened activation. Microglia 
(macrophage-like cells of the CNS) also exhibit heightened activity, forming clumps 
reminiscent of that seen with inflammation or neural degeneration and express 
heightened levels of activation markers CD1 lb and CD45. 
These mice also exhibited a heightened propensity for developing autoimmune 
conditions, showing increased susceptibility to collagen induced arthritis (CIA) 76; 
experimental autoimmune uveoretinitis (EAU) 87,88,  a model for retinal inflammation; 
and experimental autoimmune encephalitis (EAE), a model of multiple sclerosis 76 
and a model for alopecia 89. Symptoms of these diseases are more rapid in CD200 
knock out mice and lesions contain greater macrophage numbers in a heightened 
activation state. These findings imply that CD200 fulfils a significant role in 
regulating macrophage activation and ensuing inflammation, and that the CD200-
CD200R interaction is important in down-regulating the activity of myeloid cells 
expressing CD200R 76'9°. 
1.4.4 Manipulation of the CD200 induced signalling pathway 
It is apparent that CD200 has the capacity to modulate myeloid cell activity in an 
inhibitory manner. Manipulation of the CD200-CD200R interaction has clearly 
defined an important role for these molecules in dictating the phenotype of the 
myeloid response in conditions characterised by excessive immunity. Furthermore, it 
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has become apparent that delivery of this inhibitory signal can be utilised 
immunotherapeutically to alleviate symptoms attributable to such excessive 
immunity. Several studies have cited the potential of manipulating the CD200-
CD200R axis during autoimmune conditions. CD200 knock out mice showed 
increased susceptibility to EAE, EAU and CIA 76'87'88 and subsequently antibodies 
that block the inhibitory signal have also been shown to exacerbate EAE and CIA 
68'76. Conversely, the administration of an agonistic antibody to CD200R or CD200:Fc 
fusion protein halts CIA disease progression and is also capable of reducing 
established arthritic disease 91'92. 
Similarly there is a clear role for CD200 in governing alloimmunity. In a murine 
model of spontaneous abortion, whereby an unusually high level of fetal loss is 
observed by breeding CBA and DBA/2 mice, administration of CD200:Fc 
significantly reduces abortion rates 93. Furthermore, whereas blockade of CD200 
signalling reduces graft survival 94, administration of CD200:Fc prolongs graft 
survival in both allotransplants and xenotransplants 95. Finally, with the observed 
expression of CD200R on mast cells 68'82, it would appear that there is a potential 
regulatory role for CD200 in governing allergy. Indeed, in a murine model of passive 
cutaneous anaphylaxis (PCA), the systemic administration of an agonistic antibody to 
CD200R inhibits FcER1-dependent responses 84. 
1.4.5 Basis of CD200 mediated inhibitory activity 
Though beneficial effects of signalling through CD200R are undeniable, it is not 
precisely known how the myeloid cell is modulated to evoke these 
immunosuppressive events. Recent studies demonstrate that CD200 signalling inhibits 
degranulation in mast cells and basophils 84'85 and production of IL-13 and TNF by 
mast cells 84. Furthermore, an agonistic antibody to CD200R was demonstrated to 
reduce IFN-y and IL-17 induced production of IL-6 in murine resident peritoneal 
macrophages, and reduce cytokine and chemokine production of CD200R transfected 
U937 cells 96. Therefore, it would appear that signalling through CD200R diminishes 
the pro-inflammatory potential of the myeloid compartment. Finally, ligation of 
CD200R on plasmacytoid dendritic cells causes an up-regulation of indolamine-2,3-
dioxygenase (IDO) expression and activity 97. IDO mediates the catabolism of 
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tryptophan leading to its immunosuppressive products being generated, and high 
levels of IDO expression are affiliated with inhibition of alloreactivity and enhanced 
Treg function 98-100 . 
1.5 Adaptive Immune response to respiratory Infection 
Fundamental to the resolution of infection and development of memory is the 
establishment of an acquired specific immune response, comprising both cell 
mediated T cell, and humoral B cell, responses. 
1.5.1 T Cell Classification 
T cells are a subset of lymphocytes that originate from the bone marrow and mature in 
the thymus. They are identified by the expression of CD3 and can be further 
categorised into two main subsets: CD4+ T helper (Th) lymphocytes and CD8+ 
cytotoxic (Tc) lymphocytes. CD4+ helper T cells exert their effector function 
primarily through the release of cytokines that activate and stimulate other cells. They 
also fulfil a significant role in antibody production by providing a critical signal for B 
cell activation through the CD4O-CD4OL interaction. Cytotoxic T cells are 
accomplished killers of infected and tumour cells, lysing infected cells via a 
perforin/granzyme dependent mechanism, which punches holes in the membrane of 
the cells or a Fas-dependent mechanism. CD8+ T cells are critical mediators in the 
resolution of viral infections, as a consequence of the intracellular nature of these 
pathogens. 
Traditional CD4+ and CD8+ T cells recognize antigen MHC complexes via a T cell 
receptor that possesses an a and a 13 chain. However, there are distinct T cell subsets 
that do not express the af3 TCR, but rather a receptor that is 16. These are often 
associated with mucosal sites and anticipated to infer protection of epithelial surfaces. 
Furthermore, there is a population of unique intraepithelial T cells (CD 103+) in the 
respiratory tract, which may possess an al3 or TS TCR. These T cells recognize generic 
immunological distress signals rather than pathogen specific motifs, and fulfil a 
significant role in the recognition and eradication of infected epithelial cells 1°1. 
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1.5.2 MHC Restriction and T Cell Activation 
Activation of both CD4+ and CD8+ T cell subsets requires interaction of the T-Cell 
Receptor (TCR) / CD3 complex with the antigenic peptide displayed on the Major 
Histocompatability Complex (MHC) of the Antigen Presenting Cell (APC). Antigenic 
products can be processed by distinct pathways and presented in conjunction with 
MHC class I or class II molecules. MHC I expression is universally observed on all 
nucleated cells and such presentation is important in the activation of CD8+ Tc cells. 
Conversely, MHC II expression is restricted to APCs (although it can be up-regulated 
on other cell types), and such presentation of antigenic peptide is responsible for the 
activation of CD4+ TH cells. 
However, this TCR / MHC interaction is generally insufficient to effectively activate 
naive T cells or the full repertoire of T cell responses. A second "co-stimulatory 
signal" is provided by surface molecules on the APC or by soluble factors (Fig. 1.5). 
The successful integration of two such signals results in the proliferation and 
differentiation of antigen specific T cells. The most well known co-stimulatory signal 
is the CD28/B7 pathway 102,103,103  which governs activation of naïve T cells. CD28 is 
constitutively expressed on the surface of both resting and activated T cells 104,105,105 
and interacts with B7-1 (CD80) 106  or B7-2 (CD86) 107 on the surface of an APC. 
Ligation of CD28 culminates in high-level interleukin 2 (IL-2) production, by 
increasing the transcription and the mRNA stability of this crucial T cell growth 
factor in both CD4+ and CD8+ T cell subsets 103,108,109  Such a co-stimulatory signal 
also up-regulates IL-4, IL-5, IL-8, IL-13, IFN-y and TNF 110,111,  and prevents anergy 
{Boussiotis, 1993 9952 /id;Gimmi, 1993 12443 /id;} or cell death by inducing the 
expression of the anti-apoptotic agent Bcl-XL both in vitro and in vivo 112,113  CD28 
fulfils a significant and fundamentally crucial role in the sustained proliferation of 
naive T cells and hence in facilitating their development into effector cells. 
1.5.3 The Ever-Growing Array of T Cell Costimulatory Molecules 
An array of other potential co-stimulatory interactions has recently been reported. 
Though these surface molecules undoubtedly have an impact on T cell activation 
when stimulated in conjunction with the TCR, their function appears distinct from the 
classical CD28 pathway, in that they are predominantly incapable of inducing IL-2 
production or preventing T cell AICD 114,115,  rather they play distinct roles at 
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Name Cell 
Expression 
Naïve T cell 
expression? 
Inducible 
cell surface 
expression 
Ligand Reference 
CD28 T cells ✓  01% 24hrs B7.1/B7.2 116 
ICOS T cells, NK 
cells 
t 12 hrs ICOSL 117 
OX40 
T, B cells, 
DCs, 
eosinophils 
t 24-48 
hrs 
OX4OL 118,119 
4-1BB 
T, B cells, 
DCs, 
macrophages 
, NK cells, 
eosinophils 
el% 24-48 
hrs 
4-1BBL 118,119 
CD27 T,B Cells ✓  t 24-48 
hrs 
CD70 120 
CD30 T, B cells t 24-48hrs CD3OL 121 
CD4OL 
T, B, NK 
cells, DCs 
basophils, 
mast cells, 
eosinophils, 
'1% 24-48hrs CD40 122 
CTLA-4 T cells Is 24-48hrs B7.1/B7.2 123 
Table 1.3 Summary of T cell co-stimulatory molecules. 
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different stages of T cell differentiation, on different T cell subsets and are crucial to 
the development of divergent effector functions 124. A summary of some key co-
stimulatory molecules is shown in Table 1.3 and Fig 1.5. 
1.5.4 T cell subsets 
The T helper subset can be subdivided into two broad groups, namely Thl and Th2, 
which are defined by the distinct cytokines that each subset produces (Table 1.4) 125-
127. The cytokine expression profiles of each signify the discrete functions 
implemented by each of these populations in an immune response. Thl derived 
cytokines are responsible for predominantly cell-mediated immune responses to 
intracellular pathogens 128'129, whereas the Th2 are important for antibody-mediated 
humoral response that combats extracellular pathogens 128,129  The distinction between  
Thl and Th2 subsets is not, however, as unambiguous as first seems and there have 
been discrepancies regarding exactly how each subset are defined. Some view the 
Thl/Th2 dichotomy not as discrete subsets, but rather as a continuum of different 
combinations of cytokines 130  Nonetheless, in an in vivo model, T cell clones show a 
dramatic bias towards one of the cytokine patterns denoted above and hence this 
clearly defines an important functional division of the immune system. 
Cytokines produced 
exclusively by Thl cells 
IL-2, IFNI and LT-a/TNF-13 
(lymphotoxin) 
Cytokines produced 
exclusively by Th2 cells 
IL-4, IL-5 and IL-6 
Cytokines produced 
predominantly by Thl cells 
TNF-a and GM-CSF 
Cytokines produced 
predominantly by Th2 cells 
IL-10, IL-13 and IL-21 
Cytokines produced equally 
by both Thl and Th2 cells 
IL-3 and TGF-13 
Table 1.4 Cytokines produced by Th subsets 
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ICOSL OX4OL  4-1BBL 
I LFA-1 TCR tCD28 CTLA-41 CD27 
ICAM IIMHC  B7 	 CD27L 
Activation Early effector Late effector 	Resting 
Expansion 	Survival 	memory 
APC 	APC APC 
Constitutive 
Induced 
APC APC APC 
Figure 1.5 T cell activation requires multiple signals. T-cell activation requires 
an ordered sequence of events. T cells scan the surface of antigen-presenting cells 
(APCs) for specific antigenic peptides that are expressed by major histocompatibility 
complex (MHC) class I or class II molecules. This is facilitated by the interaction of 
leukocyte function-associated antigen (LFA)-1 with T-cell binding to intracellular 
adhesion molecule (ICAM)-1 on the APC. Recognition of peptide—MHC by the T-
cell receptor (TCR) is not sufficient to fully activate the T cell. A second co-
stimulatory interaction between CD28 on the T cell and CD80 and/or CD86 (B7) on 
the APC is required. Expansion of activated T cells is then facilitated by additional 
co-stimulatory signals. CD27 is upregulated on activated T cells, as is inducible co-
stimulatory molecule (ICOS). During the later stages of the effector response, T-cell 
activation is reduced by the expression of CTLA-4, which competes with CD28 for 
binding to CD80 and/or CD86 (B7). To maintain T-cell activation and form the 
memory pool, additional signals are required. OX40, 4-1BB and CD30 are induced 
on T cells and bind to their respective ligands on APCs, providing a survival 
advantage. The interaction of OX40 with OX40 ligand also reduces the expression of 
CTLA-4. It is not yet known how long ICOS persists on T cells or whether co-
stimulatory molecules are present on memory cells (studies suggest that although 
CD27 is constitutive, it is downregulated on memory T cells). It is also unclear 
whether multiple co-stimulatory molecules exist on the same T cell. 
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Both subsets are derived from a common naïve precursor that upon Ag stimulation 
produces predominantly IL-2 before passing, via an intermediate (Th0), into one of 
the distinct polarized subsets 131433. The generation of a Thl or Th2 directed response 
is dictated by the cytokine milieu at the time of T cell activation 134'135 (Fig. 1.6), 
although the antigen dose and level of co-stimulation may also be important. The 
fundamental cytokines in the development of a Thl polarised immune response are 
IFN-'y and IL-12. The source of IL-12 at the time of T cell activation is predominantly 
macrophages and dendritic cells that have been infected with intracellular pathogen. 
IL-12 can also act on NK cells to provoke IFN-y production, which in turn drives 
macrophages to a heightened activational state augmenting their endogenous 
production of IL-12, which acts to further reinforce the Thl polarisation 136-138. 
The predominant cytokine in the development of a Th2 polarized response is IL-4, 
which is derived from a variety of sources 136  It is postulated that APC-derived IL-6 
is capable of provoking IL-4 production by naïve T cells. Furthermore, NK T cells, 
mast cells, eosinophils and basophils are all potential sources of IL-4 139-141. 
Another feature of the Thl/Th2 paradigm is the strong antagonism observed between 
populations, with the cytokine products being mutually inhibitory towards the 
differentiation and effector functions of the reciprocal phenotype 137,141,142.  Such 
antagonism reinforces development of distinct polarised T helper subsets and explains 
the strong bias observed in many infection models. 
In recent years it has become apparent that another population of CD4+ T cells, called 
regulatory T cells, exist that is quite distinct from T helper cells in their phenotype 
and function 143  This regulatory T cell family are specific T cell populations with 
suppressive properties important in the control of auto-aggressive immune responses. 
Interest in this population has escalated in recent years owing to their ability to 
prevent autoimmune disease, allograft rejection and intestinal inflammation 144-146. 
CD4+ regulatory T cells (Tregs) can be divided into two distinct subsets that exert 
differential suppressive mechanisms: the naturally occurring CD4+CD25+ Tregs, 
whose suppressive effects are mediated via cell contact and the inducible Th3 and 
Type 1 T regulatory cells (Trl), whose suppressive effects are contact independent 
and mediated through cytokines IL-10 and TGF-I3. 
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Figure 1.6. Thl versus Th2 cytokine polarisation. Helper CD4+ T cells are 
divided based on the cytokines they secrete. Differentiation to a Thl phenotype 
occurs in the presence of IL-12 and/or IFN-y. These cytokines are produced by 
natural killer (NK) cells, macrophages and DCs. A Th2 phenotype occurs in the 
presence of IL-4, which is provided by NK T cells and mast cells. Activation of 
the appropriate phenotype is essential for resolution of infection. Thl are 
important for cell mediated immunity whereas Th2 function in antibody 
mediated immunity458. 
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Naturally occurring CD4+CD25+ Tregs were originally described in the 1970s in mice 
147, and subsequent studies have shown that this subset of peripheral CD4+ T cells, 
expressing CD25 on their surface, are critical in the control of autoreactive T cells in 
vivo, with their depletion resulting in the development of various autoimmune 
diseases 148. Comparable populations with identical phenotype and function have 
subsequently been identified in rats and humans 149-151  These naturally occurring 
Tregs appear to originate in the thymus 152-156, and constitute 5-10% of peripheral 
CD4+ T cells. Studies in vitro have demonstrated this population to be anergic and 
suppressive, being capable of suppressing the proliferation of CD44-CD25" T cells in 
co-culture 157,158  This suppression is dependent on the CD4+CD25+ Tregs being 
activated through their TCR and requires cell contact with the CD4+CD25" T cells and 
evokes inhibition of IL-2 transcription in the responder population 149,157,159  The 
naturally occurring CD4+CD25+ Tregs have been further characterised by the 
expression of several activation markers such as glucocorticoid induced TNFR 
(GITR) family related protein, OX40, CTLA-4 and CD62L 160-162.  Whilst these 
markers have proved useful in the identification of this regulatory population in a 
naive immune system, there persists controversy regarding their role in mediating the 
suppression by these cells. It has been postulated that membrane bound TGF-13 may 
also be responsible for mediating the observed suppression, although this too remains 
controversial 163. More recently, the transcription factor Foxp3 has been demonstrated 
to be critical in the development and function of these Tregs in mice 154-156. 
The induced group of regulatory T cells are derived in the periphery from 
conventional CD4+CD25" T cells and can be further subdivided into two types: Trl 
cells 164,165  that produce large quantities of IL-10 and little TGF-13 and Th3 cells 
166m t., a. preferentially produce TGF-P. Trl cells have been generated from naïve CD4+ 
, 67 T cells in vitro through culturing with IL-10 1 	IL-10 and IFN-oc 164,168, or  
immunosuppressive drugs vitamin D3 and dexamethasone 169. The Trl cells generated 
proliferate poorly; generate large amounts of IL-10, some IL-5 and IFN-y and 
marginal or no IL-2 167. Their immunosuppressive properties are largely mediated 
through IL-10 and they are capable of preventing the development of T cell mediated 
. autoimmune responses 167,168,17QTh3 regulatory cells are induced in vivo through oral 
administration of antigen 171, and whilst their induction is antigen specific, their 
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suppression is not and is mediated through TGF-13 172. They are suppressive towards 
both Thl and Th2 cells and facilitate IgA production 173. Murine Th3 cells can be 
induced in vitro by administration of TGF-(3 to cultures and their expansion is further 
enhanced by the presence of IL-4 and IL-10 173. 
1.5.5 B cells and antibody production 
The other arm of the acquired immune response is antibody-mediated immunity 
imparted by B cells. B cells are bone marrow matured leukocytes that are specialized 
in recognition of antigen and subsequent expression and secretion of antigen specific 
antibodies. Antibodies (immunoglobulins) are produced exclusively by B cells and 
are important in binding pathogen and neutralising its virulence and helping to 
eliminate infection. B cell deficiency or defective B cell function significantly reduces 
the host's capacity to control infection 174,175  Activation and maturation of the B cell 
is required for the production of antibodies specific to the antigen encountered. The 
activation of naive B cells occurs in the T cells zones of secondary lymphoid organs, 
where the migrating B cell encounters antigen presented by follicular dendritic cells. 
The B cell is activated when antigen epitopes are specifically recognized by a surface 
bound immunoglobulin (IgM or IgD isotype). Further activation and maturation of the 
B cells into memory B cells and antibody producing plasma cells requires help from 
activated T cells through CD40:CD154 ligation, and is further aided and directed by 
the presence of T cell and follicular dendritic cell derived cytokines such as IL-2, IL-
4, IL-5, IL-10 and IL-12 176.184  This secondary stimulus facilitates the expansion of 
the antigen specific B cell, isotype switching and antibody secretion 185. This isotype 
switching involves a change in the Fc region of the B cell receptor, whilst its antigenic 
specificity is maintained. The isotype response is dictated by the localised T cell 
response and cause a switch to an IgA, IgG or IgE phenotype. 
There are five major antibody isotype subclasses: IgM; IgD; IgG; IgA and IgE. The 
effector function of each subtype is defined by the interaction of its heavy chain 
constant region (Fc) with other serum proteins or leukocyte Fc receptors. In this 
manner, the antibody produced may actively participate in the host defence by a 
variety of effector mechanisms. Some antibody isotypes (specifically IgG) can 
opsonise a particular pathogen, whereby surface antigens are recognised and bound by 
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the antibody in a manner that exposes the Fc region of the antibody to effector cells. 
Effector cells are subsequently brought into close proximity and the rate and 
efficiency of phagocytosis is increased, facilitating clearance of the pathogen. IgG 
isotypes can also bind pathogen and cause activation of the complement system, 
whereby a cascade of events ultimately leads to the formation of a membrane attack 
complex (MAC) where the antibody is bound leading to rupturing of the pathogens 
membrane 186. Antibodies may also recognize surface expression of pathogen epitopes 
on infected host cells and alert effector cells to eliminate the infected cell by secreting 
lytic enzymes and granules, in a process known as antibody dependent cellular 
cytotoxicity (ADCC) 187. Finally, certain antibody isotypes are important in the 
agglutination of foreign antigen. In this scenario secreted antibodies extensively 
cross-link antigens to form large complexes, which may hinder the ability of the 
pathogen to infect the host cell through steric hindrance or lead to clearance by 
complement fixation, ADCC or reticulo-endothelial filtration. IgM and IgA isotypes 
are excellent agglutinins and are subsequently found extensively at mucosal surfaces 
188 
1.5.6 T and B cells at mucosal sites 
The mucosal immune system can be structurally and functionally divided into two 
sites. Primarily, organised secondary lymphoid tissues confer the site for the 
sensitisation or induction phase of immunity, whereby antigen is taken up, processed 
and presented to naive T cells and B cells 189. Secondly, induced lymphocytes traffick 
to effector sites to engage other immune cells and exert a protective response. The 
mucosal associated lymphoid tissues (MALT) that are the key inductive sites for 
mucosal immunity have predominantly been studied in the respiratory tract and gut 
and are similar in structural organisation and cellular composition 189-191 (Fig 1.7). The 
secondary lymphoid tissue of the respiratory tract is the nasal associated lymphoid 
tissue (NALT) and in some animals bronchial associated lymphoid tissue (BALT). 
NALT has been well characterised in rodents, but has not been seen in humans 
although the lymphoid tissue of the Waldeyers ring is arguably analogous. Likewise, 
BALT is only variably present and its functional significance is not conclusive, 
although it displays all the attributes of secondary lymphoid tissue. 
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Figure 1.7. Immunological differences between the intestinal and respiratory 
mucosa. The mucosa of the gut (A) and lung (B) contain structural similarities. 
Both contain a single epithelial cell layer interdispersed with intraepithelial T and 
B lymphocytes (IEL, approx 20/100 epithelial cells). Beneath this is a diffuse 
scattering of cells termed the lamina propria. The gut has more resident 
lymphocytes than the lung owing to its high bacterial load. The gut also has 
more constitutive organised B cell follicles exemplified by the Peyer's patches of 
the small intestine. Specialised antigen sampling cells called M cells have been 
demonstrated in the gut but their presence in the lung still remains to be 
confirmed. These M cells transport antigenic material from the lumen to the 
lymphoid tissue in the lamina propria and the aggregated lymphoid cells of the 
Peyer's patch. Secretory dimeric IgA is an important anti-inflammatory antibody 
in both mucosal tissues. Dendritic cells (DCs), macrophages and NK cells 
comprise the innate immune cells. Alveolar macrophages are unique to the lung 
where they are thought to be immunosuppressive. 
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MALT display conserved structural features with sub-epithelial B cell and T cell rich 
areas that are clearly defined and segregated, and proximal APCs, such as dendritic 
cells and macrophages 189. Both NALT and BALT are characterised by several 
follicles where B cells are preferentially found, which subsequently develop 
secondary germinal centres after antigenic stimulation. These follicles are surrounded 
by more diffuse lymphoid tissue with the T cell zone, and the luminal side is covered 
by follicle associated epithelium. Antigen is directly sampled from the luminal 
compartment into the MALT by specialised epithelial cells known as microfold cells 
(M cells). M cells, whilst present in the gut, appear to be absent from the normal 
respiratory tract and are anticipated to be induced when airway and lung tissues are 
exposed to antigen 192. Antigen is subsequently taken up and processed by underlying 
APCs and presented to resident naive T cells and B cells. Having been sensitized to 
antigen, the activated lymphocytes mature and proliferate in draining lymph nodes. 
The effector cells exhibit a change in the expression of surface molecules L-selectin 
and a4137 whilst maturing, which consequently facilitates their exit from the inductive 
sites and into systemic circulation. Subsequently, the primed T and B cells migrate to 
mucosal effector sites where they mature further and exert effector functions that 
protect the mucosal surfaces 189. The predominant effector site of the mucosal 
immune response, where mature T cells and B cells migrate after induction, is the 
lamina propria. The lamina propria is a layer of connective tissue between the 
epithelia and the muscularis mucosa, and (at least in the gut) is the residence of a 
heterogenous group of lymphoid and myeloid cells. The large infiltrate of cells at this 
site confer protection should any pathogenic antigen compromise the integrity of the 
epithelial surface and besiege the mucosal site. The efferent inductive and effector 
phases of the mounted mucosal immune response culminates in a protective immune 
response that is mediated by effector CD4+ and cytotoxic CD8+ T cells and blast cells 
capable of producing significant quantities of IgA. 
1.5.7 Mucosal IgA. 
IgA is the predominant antibody in secretions at mucosal surfaces and is critical in 
protection against an array of pathogens (Fig. 1.8). IgA is always present in the 
respiratory tract of healthy, uninfected individuals 193  At mucosal surfaces, a 
secretory immunoglobulin system operates, which allows the transport of polymeric 
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immunoglobulins (pIg) across epithelia and into the lumen through interaction with 
poly immunoglobulin receptor (pIgR). The pIgR has a basolateral targeting sequence 
that directs the receptor from the trans Golgi network to the epithelial basolateral 
membrane where it can interact with J chain containing pIgs. The pIgR is 
subsequently endocytosed and delivered to basal early endosomes and may eventually 
be transported across the epithelia to the apical membrane in a process referred to as 
transcytosis 194  The pIgR/IgA complex is released after cleavage from the apical 
membrane into the mucosal lumen as secretory immunoglobulin-a (SIgA) 189,195  
IgA binds and neutralises pathogens in the lumen of the respiratory tract and 
consequently renders them incapable of invading the mucosal epithelia in a 
mechanism known as "immune exclusion". Relatively high levels of polyreactive 
natural SIgA are probably designed to offer a first line of defence and confer 
immediate protection before an adaptive response is elicited 196. Secondly, dimeric 
IgA may bind endocytosed pathogens during transcytosis across epithelial cells and 
transfer them back into the lumen (Fig. 1.8b). In this manner IgA mediates 
intraepithelial neutralisation of numerous viruses (e.g. influenza) 197. Furthermore, it 
has been demonstrated that IgA can bind pathogens that have already compromised 
the epithelial barrier into the lamina propria, forming immune complexes, and expel 
them selectively back into the airways (Fig. 1.8c). Finally, IgA may also activate 
FcaR expressing leukocytes to facilitate clearance of pathogen, through phagocytosis 
of IgA immune complexes, opsonin induced killing, ADCC and production of ROS, 
cytokines and other inflammatory mediators 70,198-204 
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Figure 1.8. IgA mediated protection at mucosal sites. Plasma B cells at mucosal 
sites such as the lung produce predominantly IgA in dimeric form where two IgA 
molecules are linked by a joining (J) chain. IgA is useful at such sites because it 
does not fix complement and is therefore non-inflammatory and is also resistant to 
degradation by proteases. Dimeric IgA binds to a polymeric Ig receptor (secretory 
component) on the basolateral surface of epithelial cells. This is then endocytosed, 
passed through the epithelial cell and released into the lumen where it can complex 
antigen. Complexed antigen then cannot gain access to the interior of the body 
(Immune exclusion, A). On its way through the epithelial cell dimeric IgA can pick 
up antigens already in the epithelial cell (B) and exclude them. Finally, antigens that 
have traversed the epithelial layer can be picked up by dimeric IgA before it binds 
secretory component and taken into the lumen (C)458. 
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1.6 Influenza 
1.6.1 Epidemiology of influenza infection 
Influenza infection is an acute respiratory disease that is one of the most persistent 
and important infectious diseases to have afflicted mankind throughout the ages. This 
extremely variable virus is highly contagious and is an omnipresent threat to the 
population, regardless of age or gender. Influenza is a global dilemma inducing 
seasonal epidemics that can affect 10 to 20% of the population with ensuing 
morbidity and mortality. Seasonal circulation occurs every winter and lasts between 8 
and 12 weeks in the UK 205. It is estimated that influenza A viral infections are 
responsible for between 10,000 to 20,000 deaths in the United Kingdom each year 206 . 
Furthermore, the World Health Organisation has recently decreed, "another influenza 
pandemic is inevitable and possibly imminent" (http://www3.who.int/whosis), an 
alarming prospect with reference to the devastation and fatalities experienced in the 
previous pandemics. The worst ever pandemic was the 1918 Spanish influenza which 
killed between 20 and 40 million people and infected approximately half of the 
world's population. Unusually, this pandemic was particularly fatal in young adults. 
The source of the Spanish flu is thought to be an avian reservoir, and similar 
pathogenicity was observed during the recent "bird flu" outbreak caused by an avian 
influenza A (H5N1) strain. To date the cumulative number of confirmed human cases 
of avian influenza A/ (H5N1) reported to the WHO is 246, with 144 deaths 
(http://wwvv.who.int/csr/disease/avian_influenza/country/cases_table_2006_09_14/en/  
index.html). 
Influenza infection is usually self-limiting, culminating in a local and systemic 
reaction, whereby the afflicted individual may experience fever, chills, headaches, 
coughing, myalgia and diarrhoea. However, there remain a significant proportion of 
patients who are considered to be at high risk of developing severe illness and 
complications, such as the elderly, the very young and the immuno-compromised 
207,208. Individuals possessing underlying medical conditions, such as cardiovascular 
disease, chronic bronchitis and asthma, also possess a heightened susceptibility to 
complications, with a greater percentage developing secondary bacterial infections 
that are frequently life threatening. Ultimately, the outcome of an infection is a 
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competition between a virus of considerable genetic and antigenic diversity and a 
multifaceted immune system. 
1.6.2 Classification and structure 
Influenza virus is a member of the family Orthomyxoviridae, and can be classified 
into three genera, namely types A, B and C 208. Influenza A was first discovered in 
1933 and acknowledged to be the most prominent and severe, being responsible for 
the seasonal epidemics and the devastating pandemics that sporadically afflict 
mankind 209. Influenza B and C were identified in 1940 and 1950 respectively, and are 
not recognised to present the same threat as type A 210. 
Influenza is an enveloped negative stranded RNA virus that is approximately 80- 
210,211 120nm in size 	(Fig. 1.9). The outer envelope comprises of a lipid bilayer from 
which hemagglutinin (HA) and neuraminidase (NA) glycoproteins project. These 
outer membrane proteins are functionally significant and are essential to the viability 
and replicative potential of the influenza virion, governing host cell entry and 
ultimately exit. The HA protein is fundamental for binding and subsequent fusion to 
the host cell, whereas the NA protein fulfils a critical role in preventing viral 
aggregation and aiding release of viral particles from the host cell post-replication. 
NA has also been implicated in aiding the transport of the virion through the 
respiratory tract 210-212. 
Positioned within the viral envelope exists the matrix protein M1, which interacts 
with both the cell genome and the nuclear export factor and facilitates viral assembly 
210,211. Also located within the envelope is viral protein M2, which forms an ion 
channel between the interior of the viral particle and its immediate environment, 
dictating the localised pH 210,211.  Maintenance of a low pH is mandatory for several 
viral activities, such as HA synthesis and virion uncoating. The RNA genome of 
influenza consists of 8-segmented genes, containing the genetic information for 
expression of 10 viral proteins, each encased by nucleoprotein (NP) 208,210.  In addition 
to the viral proteins already discussed, a further 3 proteins (PB2-, PB1- and PA-
encoded proteins) form a transcriptase complex and there are 2 non-structural 
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Figure 1.9. Influenza A Structure. a. Influenza A virus is an enveloped single-
stranded RNA virus. The genome consists of eight RNA segments, each of 
which is surrounded by nucleoprotein (NP) and contains the viral polymerase 
complex. MI membrane protein and glycoproteins HA and NA are associated 
with the lipid bilayer. The M2 and nonstructural protein 2 (NS2) are also found 
in virions, whereas NS1 is found only in virus infected cells. b. Electron 
Migrograph of Influenza virus. Virions are roughly sperical and about 200 nm in 
diameter. The envelope contains rigid "spikes" of haemagglutinin and 
neuraminidase which form a characteristic halo of projections around negatively 
stained virus particles 
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proteins, NS1 and NEP, that govern post-transcription. RNA control and viral 
assembly, respectively 210211. 
1.6.3 Antigenic diversity of influenza: Antigenic drift and shift 
Influenza A is responsible for extensive illness in humans owing to the considerable 
antigenic variability that it displays enabling it to successfully evade the host's 
neutralizing antibody repertoire. As discussed, influenza A expresses HA and NA on 
its surface. These glycoproteins are subject to extensive antigenic variation that is 
important for immune evasion and it is changes in these surface glycoproteins that are 
largely responsible for the observed epidemics and pandemics. There are to date at 
least 15 haemagglutinin subtypes and 9 neuraminidase subtypes. Widely circulating 
influenza strains within the human populace are restricted to 3 HA subtypes (H1-3) 
and 2 NA (N1-2), with the remaining subtypes being seen in viruses that persist 
within avian reservoirs. 
The antigenic variability that occurs within the influenza genome takes two forms: 
antigenic drift and antigenic shift. Antigenic drift occurs when genes encoding the 
surface glycoproteins undergo stepwise mutation, owing to the relatively low fidelity 
of the influenza RNA-specific RNA polymerase (replicase) which lacks proof reading 
5'-3' exonuclease activity. These mutations may lead to attenuated or non viable 
influenza, but some may provide a survival advantage, which will be selected for and 
expand. If the surface glycoproteins are sufficiently different that the host's antibodies 
are incapable of neutralizing it then the new strain is capable of causing disease, and 
frequently the observed seasonal epidemics. 
Antigenic shift is a far less frequent form of antigenic change but can lead to the 
devastating pandemics that occasionally plague mankind. Antigenic shift occurs when 
two different viruses from distinct host's (possibly different species) co-infect a single 
host and exchange genetic information. The ensuing reassortment of viral genome 
segments results in a new virus that possesses elements from each of the two original 
strains. Again the resulting virus may be attenuated or non-viable, but it may also be 
highly virulent and potentially pathogenic due to expression of novel surface proteins 
derived from the animal host virus. In this scenario, the human host may possess little 
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or no immunity to the novel surface proteins and the new variant can cause 
widespread disease through evasion of the host's immune response. 
1.6.4 Replication cycle 
Transmission of influenza between individuals is via virus laden liquid droplets that 
are expelled when the infected patient coughs or sneezes 210'213. The primary sites of 
infection of the infective virions are the epithelial cells of the upper respiratory tract, 
but influenza also possesses a propensity for invading macrophages and other 
leukocytes within this localised area 210,213,214  The virus has the potential to invade 
any cell that possesses a suitable receptor, notably those expressing a sialic acid 
containing cell surface glycoprotein 213'214. As previously discussed, attachment and 
fusion to the host cell is mediated through HA. HA exists as a native precursor termed 
HAO, which attaches the virion to cell surface receptors containing sialic acid, and is 
subsequently cleaved through the action of extracellular host proteases to yield HAI 
and HA2 210,215,216.  The virion is subsequently endocytosed to form an endosome with 
HA2 mediating the union between virus membrane and host cell 210,213  The low pH of 
the endosome induces a conformational change in the HA2 protein, culminating in 
enhanced proximity of viral and host cell membranes, and ultimately the fusion event 
210,211,213. Fusion subsequently leads to the liberation and nuclear import of viral 
nucleocapsids, which contains the crucial genetic code that dictates the amplification 
and generation of substantial viral progeny 210,211,213  (Fig. 1.10). 
The viral RNA genome, once localised within the host nucleus, is transcribed by viral 
RNA polymerases resulting in the synthesis of viral mRNAs. The mRNAs are 
subsequently transported to the cytoplasm of the host cell where they are translated to 
yield viral nucleoproteins and polymerases 211'213. The newly generated viral proteins 
are then re-directed towards the host nucleus where they assist in viral replication and 
further mRNA synthesis 211,213.  This positive feedback loop greatly amplifies the 
quantity of viral RNA and proteins, which are subsequently packaged to form viral 
nucleocapsids that are exported from the nucleus before budding from the host plasma 
membrane to form active virions 213. Hence the virus envelope is derived from host 
cell plasma membrane and the budding event is mediated via influenza neuraminidase 
protein. 
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Figure 1.10. Influenza A replication cycle. Initial virus/host interactions are mediated by 
HA binding to host cell sialic acid. The virus enters the cell by fusion of viral and host 
membranes in response to low pH in the endosomal pathway. The exposed nucleocapsid is 
then transported into the nucleus. Primary transcription occurs and viral mRNAs are 
transported into the cytoplasm for protein synthesis. Newly synthesized polymerases, NP, 
NS1, and NS2 are transported into the nucleus and viral RNA (vRNA) replication to 
secondary transcription take place. These transcripts encode for structural proteins. Viral 
nucleocapsids are assembled in the nucleus, transported into the cytoplasm to the plasma 
membrane, where budding and release of the fully assembled virus particle occurs. 
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1.6.5 Immunity to influenza 
Succeeding influenza infection, the multifaceted immune system of the host mounts 
an immediate response to restrict viral replication and limit the associated 
cytopathology and destruction. Infection of cells with influenza virus culminates in 
the activation of a host of transcription factors that co-ordinate the release of 
chemokines and cytokines. Subsequently, there is an induction of an anti-viral 
defence program and the enhanced recruitment of inflammatory cells, which together 
form a formidable barrier to combat viral burden and resolve infection. 
As previously discussed influenza primarily infects epithelial cells of the upper 
respiratory tract as well as proximally located leukocytes, and it is these cells that 
initially evoke a targeted response. Influenza infection triggers the activation of a 
variety of transcription factors, and although the mechanism of induction is somewhat 
of an enigma, it is postulated that it may be mediated via Toll like receptors and 
protein kinase R 213. Among the transcription factors actively induced are NF-kB 
(nuclear factor-kB), IRFs (IFN regulatory proteins), STATs (Signal Transducers and 
Activators of Transcription), AP-1 (Activating Protein-1), and NF-IL6 (nuclear factor 
of interleukin-6) 213,214,217.  The combined effect of these transcription factors is to 
induce transcription of a host of cytokines and chemokines that are aptly suited to 
combat the viral burden 213. 
Both epthelial cells and monocytes/macrophages are capable of eliciting chemokine 
release upon infection with influenza, although the exact nature of the evoked signal 
is divergent for the distinct cell types (Fig. 1.11). Epithelial cells primarily release 
RANTES, MCP-1 and IL-8, whereas monocytes/macrophages secrete MIP-1 a, MIP-
I P, RANTES, MCP-1, MCP-3, MIP-3a, and IP-10 218,219  The array of chemokines 
released ultimately favours the recruitment of blood mononuclear cells to the site of 
infection 220. Similarly, the cytokine profile of the discrete host cell is again distinct, 
with the monocytes/macrophages being the primary and most potent source of 
inflammatory and anti-viral cytokine release. IFN-a/13 is a critical cytokine in the 
containment and resolution of an influenza infection due to direct anti-viral effects, 
and potential to mediate the further recruitment of inflammatory cells 211,221-224. 
Monocytes/macrophages are the predominant source of type 1 interferons as well as 
57 
Influenza virus IFN-a/13 
7 
Epithelia 
Mac 
RANTES, 
IL-8, 
MCP-1 
RANTES, 
MIP-1a/13, 
MIP-3a, 
MCP-1/3, 
IP-10 
IL-113, IL-6, 
TNF 
IL-18 
idV • 0 • • • 
Endothelia 
Leukocyte 
extravasation 
Figure 1.11. Cytokine response elicited by influenza infection. Influenza 
virus primarily infects epithelial cells and leukoctyes of the upper respiratory 
tract, eliciting the release of a variety of chemokines and pro-inflammatory and 
anti-viral cytokines. This response acts to limit viral burden early in infection 
and promote an inflammatory infiltrate. 
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other pro-inflammatory cytokines TNF, IL-6 and IL-1, whereas infected epithelial 
cells are considerably inferior at eliciting such a cytokine response 214,222. 
IFN-or/P is a critical component of the hosts armoury against infection, as its intrinsic 
anti-viral activity fulfils a critical role early in infection in limiting viral replication 
and consequently providing sufficient time for a humoral and cell mediated response 
to be mounted. The function of IFN-a/13 as an anti-viral mediator is enhanced through 
its ability to up-regulate production of PKR, oligoadenylate synthetase and Mx, all of 
which confer natural viral resistance 224. Furthermore, IFN-a/(3 has a broader role, as 
it enhances the production of MCP-1, MCP-3 and IP-10, which augment the 
recruitment of monocytes/macrophages and Thl cells to the site of infection 213  In 
addition, IFN-a/(3 enhances antigen presentation by dendritic cells and macrophages 
via the up-regulation of MHC 224. It is also postulated to act as a cofactor in the 
development of a Thl response, being implicated in T cell survival, up-regulation of 
222,. the IL-12 receptor and in the expression of IFN-y by NK cells and T cells 213, 5  
Other pro-inflammatory cytokines play a significant role in the co-ordinated response 
critical to influenza immunity. IL-1(3 and TNF function to enhance the inflammatory 
response through augmentation of MCP-1 and MCP-3 213. These cytokines provoke 
the maturation of tissue macrophages and dendritic cells, hence invoking a primed 
antigen presentation system for the recruited T cells 213. IL-18, derived from influenza 
infected macrophages, also confers protective anti-viral immunity and aids the 
generation of a Thl response by acting in conjunction with IFN-a/P to induce IFN-y 
production from NK cells and T cells 213. 
Ultimately, to resolve viral infection effectively, the induction of an adaptive immune 
response is a pre-requisite and a combination of both cell-mediated and humoral 
components fulfil important roles. Antibodies specific to hemagglutinin and 
neuraminidase are fundamental to resistance to infection and subsequent recovery, as 
they act to neutralize viral infectivity and hinder viral release from infected cells. 
Cytotoxic T cells also confer a central role in resolution of viral infection via their 
cytopathic elimination of infected cells. These CD8+ T cells arrive at the site of 
infection at approximately day 3-4-post infection whereby they detect virus infected 
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cells, through recognition of conserved HA, NP and PB2 epitopes, and subsequently 
lyse them 210,226.  CD4+ Th cells also confer a significant role in resolution of influenza 
infection, primarily via the delivery of signals to the main effectors. In addition to this 
role in the facilitation of humoral and cell mediated responses, they may also have a 
lesser role as cytolytic effectors 210. 
The majority of studies that define the phenotype of the immune response to influenza 
infection have been conducted in mice. It is important to question to what extent the 
mouse model of influenza imitates the infection seen in man. Standard research with 
influenza in a murine model utilises mouse adapted strains of influenza A and B. 
However, even viral strains that are not mouse-adapted induce a toxic pneumonitis 
that is reduced by early treatment with antivirals such as amantidine and ribavirin 227. 
In the murine model, influenza virus is readily recovered from the lungs and follows a 
similar kinetics of infection to that in man. Virus titres in the lungs peak 4-6 days 
after infection and then declines, so that virus cannot be recovered by plaque assay at 
day 14. Symptoms of disease, like that in man, are dependent on the influenza strain 
and the dose of virus administered. As discussed above, during the first 3 days of 
infection in mice, infected epithelial cells and macrophages produce type-I IFN and 
TNFa, respectively. NK cells, in addition to their cytotoxic function, also contribute 
to the cytokine milieu releasing IFNy, TNF and GM-CSF, all of which activate APCs. 
This innate phase of the immune response contributes to the magnitude of subsequent 
T and B cell accumulation 228. Neutrophils are also prominent, and again, their 
numbers reflect the virulence and dose of virus. The cytokines produced, the 
composition of cells infiltrating the lung, and the disease parameters all replicate 
those observed during infection of man. 
1.7 Cryptococcus neoformans 
1.6.1 Structure and epidemiology 
Cryptococcus is a genus of encapsulated budding yeast (Fig. 1.12), of which there are 
at least 19 species existing as free-living saprophytes 229. The only species within the 
cryptococcus genus that is known to exert pathogenic potential is Cryptococcus 
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Figure 1.12. Cryptococcus neoformans. a. Schematic drawing of C. neoformans, 
depicting the extensive polysaccharide capsule. b. Transmission electron micrograph of 
budding C. neoformans, depicting the polysaccharide capsule 
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neoformans, the causative agent of the potentially life threatening 
meningoencephalitis called cryptococcosis 229. Sanfelice and Busse first identified 
Cryptococcus neoformans independently in 1885 and there are now two recognized 
varieties, namely Cryptococcus neoformans var. neoformans and Cryptococcus 
neoformans var. gattii 229,230.  These two varieties fall into 4 major serotypes, 
delineated A to D, which are defined by certain epitopes of the polysaccharide 
capsule. Cryptococcus neoformans var. neoformans possesses serotypes A or D, 
whereas serotypes B and C are restricted to Cryptococcus neoformans var. gattii 229. 
Cryptococcus neoformans var. gattii is confined to tropical and subtropical regions, 
infecting human beings only under exceptional circumstances, and postulated to be 
derived from flowering eucalyptus trees 231. Conversely, Cryptococcus neoformans 
var. neoformans exhibits a global distribution, with soil and avian reservoirs the 
primary source of transmission to man 231'232. It is this latter variety that constitutes 
the most potent threat to humans and will be the focus of this report. Cryptococcus 
neoformans var. neoformans is capable of eliciting disease in immunocompetent 
individuals, but immunologically compromised are at greatest risk 229. The lung 
represents the primary site of infection for this basidiomyceteous fungus but failure to 
control pathogen burden results in dissemination to extra-pulmonary tissues, with 
heightened propensity to the brain (Fig. 1.13). In the last 10 years clinical cases of 
cryptococcosis have escalated, the increase in numbers believed to be related to an 
increase in patients with underlying T cell deficiencies, such as individuals infected 
with AIDS and those treated with chemotherapeutic or immunosuppressive drugs. It is 
within the AIDS infected population that Cryptococcus neoformans is most 
devastating, with between 6 and 8 percent all AIDS patients developing cryptococcus-
associated meningitis. 
1.6.2 Replication 
C. neoformans is an encapsulated spherical yeast, which in its vegetative state varies 
in size from 5-10um in diameter 233. This budding yeast has the potential to engage in 
both asexual and sexual reproduction, although there is discrepancy regarding the 
extent of sexual reproduction that occurs in nature 234233'234. During this sexual 
reproduction, a and a mating haploid yeasts enter into a diploid 
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Figure 1.13 Cryptococcus neoformans primarily infects the lung, but can 
deisseminate to the brain causing meningoencephalitis. a. Methenamine silver 
(GMS) stained tissue section of lung showing typical encapsulated yeast cells of C. 
neoformans. b. X-ray showing pulmonary cryptococcal infection (right upper lobe). 
(Courtesy Prof. Tania Sorrell, Sydney NSW). c. Encapsulated yeast cells in brain 
tissue. Mucicarmine stain, 630X. d. MRI scans showing multiple cryptococcomas 
(white masses) in the brain. 
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state and subsequently undergo meiosis to yield haploid basidiospores, which 
ultimately develop into yeast cells again 233'234. It has been postulated that infection is 
initiated by inhalation of either desiccated, poorly encapsulated yeast cells or 
basidiospores 233. It has been claimed that penetration through the lung parenchyma is 
governed by strict size limitations imposed by alveolar spaces, and therefore the 
smaller size of the basidiospores (1.8-2um), and their resistance to desiccation, makes 
them a far more attractive candidate for the infectious particle 231. Furthermore, there 
has been recent evidence citing the dimorphism of cryptococcus, whereby the yeast 
form hyphae and haploid basidiospores in the absence of mating; an appealing 
prospect with regard to the confusion surrounding the extent of sexual reproduction 
that is seen in vivo 234'235 . 
Having gained entry into the host, the establishment of infection and the degree of 
pathogenicity is highly variable depending on the immunological status of the host 
and the virulence of the infecting strain of C. neoformans 229. The cryptococcal 
inoculum is invariably ineffective at establishing an infection in an immunocompetent 
host and is efficiently controlled and eradicated by the immune response. However, 
where the individual is immunocompromised, the host of virulence factors exhibited 
by the pathogen are suitably effective at evading the mounted immunological 
response, and facilitate dissemination of the fungus from the primary site of infection. 
1.6.3 Virulence factors 
Upon entry into the lung, the infective particle becomes rehydrated and develops the 
polysaccharide capsule that is essential for survival 229'233. Prior to capsule formation 
the fungus is particularly susceptible to phagocytosis by alveolar macrophages. To aid 
survival, C. neoformans has sialic acid terminal units on a number of glycoproteins 
that display anti-phagocytic potential early in infection 236. The mechanism by which 
the sialic acid residues mediate protection is ambiguous, but could be a consequence 
of their negative charge, mediating a repulsion towards the phagocyte, or the masking 
of underlying galactose residues in the fungal glycoproteins that can be recognised 
macrophage receptors 236. 
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The capsule is composed of a high molecular weight polysaccharide referred to as 
glucuronoxylomannan (GXM). The polysaccharide has a primary backbone of a-1,3-
D mannopyranose, with single residues of 13-D-xylopryanosyl and 13-D-
glucuronopyranosyl attached 237, and at least 4 genes have been determined to be 
essential to its formation (CAP59, CAP60, CAP64 and CAP10). Acapsular mutants 
that have been generated are avirulent and have an enhanced disposition to being 
phagocytosed by neutrophils, monocytes and macrophages 238-240  The reduction in 
phagocytosis imparted by the capsule also has repercussions regarding alteration of 
phagocyte phenotype, function and role in the mounting of an immune response. 
Primarily, the inability of the macrophage to phagocytose the organism reduces 
antigen presentation to recruited T cells 241  Furthermore, highly encapsulated 
organisms evoke a less substantial release of pro-inflammatory cytokines from 
243.  monocytes and macrophages 242, 	It has been postulated that the inability of these 
organisms to be phagocytosed limits the ensuing production of TNF, IL-113 and IL-6, 
whose levels are normally augmented by the phagocytic process. These cytokines are 
believed to be central to the control of cryptococcal infection, with TNF of particular 
importance to the development of protective immunity 244. 
GXM also activates the alternative complement pathway, eliciting the deposition of 
C3b and C3bi on the surface of C. neoformans. Such deposition would generally 
facilitate binding to the leukocyte specific C3 receptor with ensuing phagocytosis. 
However, the encapsulated Cryptococcus masks the bound complement fragments at 
sites beneath the capsule surface hence protecting the organism and depleting the 
hosts complement repertoire 245. Similarly, GXM binds IgG, an interaction that would 
ordinarily facilitate recognition by the Fc receptor of host phagocytes. Once again, 
however, the epitopes that interact with host antibody are primarily located beneath 
the capsular surface, thus hindering efficient targeting by phagocytes 245. 
The C. neoformans capsule also inhibits leukocyte migration from the bloodstream to 
the inflammatory site 246. Intravascular GXM inhibits L-selectin being discarded from 
the surface of neutrophils, hence preventing their infiltration into the tissue from the 
bloodstream 247. Furthermore, GXM and Ga1XM both bind CD18 ((3 chain of LFA-1) 
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on the surface of leukocytes, preventing the ensuing interaction with ICAM-1 and 
consequently hindering extravasation into the inflammatory site 248. 
Yet another mechanism of immune evasion, which is mediated by the capsule of 
Cryptococcus, is induction of a regulatory T cell population induced by GXM that in 
turn reduces humoral and cell mediated responses 249. This inhibition is potentially 
mediated via IL-10 that is evoked following infection with the encapsulated organism. 
This diminishes the release of pro-inflammatory cytokines cytokines and is thought to 
drive a Th2 rather than a protective Thl response. 
Another putative virulence factor utilised by Cryptococcus is the generation of 
melanin via the copper dependent enzyme laccase 250. Mutant Cryptococcus, deficient 
in melanin synthesis, possess no, or reduced, capacity to kill mice. The mechanism by 
which melanin is believed to elicit protection is undefined yet evidence from in vitro 
studies suggest that it is laid down on the inner aspect of the yeast cell wall and acts as 
a free radical scavenger 250. Similarly, the Cryptococcal product marmitol is thought 
to enhance survival and pathogenicity, potentially through its ability to scavenge 
hydroxyl radicals 251. Limited evidence suggests the presence of a cryptococcal 
derived superoxide dismutase (SOD) with free radical scavenging potential, a 
phospholipase that correlates with augmented virulence, and intrinsic proteolytic 
activities, which have been postulated to be implicated in pathogenicity 233. 
1.6.4 Immunity to Cryptococcus neoformans. 
In mice, protection from C.neoformans infection depends on the genetic background 
of the inbred strain used. Resistant mice (CBA, C.B-17, BALB/c) generally produce 
higher concentrations of type 1 cytokines in response to C.neoformans infection 252-
254. In contrast, susceptible strains (C57BL/6, C3H and B 1 0.D2) develop a Th2 
driven pulmonary eosinophilia and at the peak of pathogen burden up to 40% of 
airway cells are eosinophils 255. This response is non-protective and results in tissue 
damage resulting from degranulation and crystal deposition by eosinophils. The role 
of eosinophils in anti-fungicidal activity is controversial. Though in vitro studies 
show them capable of phagocytosing C. neoformans, this event in vivo has been more 
difficult to elucidate. Eosinophils have been observed juxtaposed to C. neoformans 
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and are thought to be involved in recruiting macrophages and T cells by the 
production of pro-inflammatory cytokines and chemokines. 
The phagocytosis of the yeast cell by the alveolar macrophage is central to the 
ensuing immune response through the early production of TNF, MCP-1, MrP-1 a, 
which are fundamental for subsequent cellular recruitment to the lung. The protective 
infiltrate comprises of T cells, macrophages, NK cells and granulocytes, with 
neutrophils found early in the pulmonary infiltrate and subsequently replaced by 
monocytes 256,257  The inflammation is granulomatous, with the primarily intracellular 
fungi being encased by an accumulation of inflammatory cells in the alveoli 230,256,258. 
It is thought that granuloma formation is primarily dependent upon CD4+ T cells and 
macrophage accumulation, encasing the yeast and preventing the organism from 
replicating and disseminating into the bloodstream 258. Furthermore, the macrophages 
fuse around the yeast, forming giant multinucleated cells and releasing hydrolytic 
enzymes into the interstitium 258. Formation of the granuloma is considered to 
correlate with resistance to Cryptococcus neoformans infection, with its absence 
associated with dissemination and potentially death. 
Specific T cell mediated immunity is critical to the protective immune response 
although no immunodominant antigen has been identified to date 231. CD4+ and CD8+ 
T cells are required for maximal recruitment, pulmonary clearance of pathogen and 
protection from dissemination 258-261.  IL-2 activated T cells, as well as localised NK 
cells, have the potential to directly bind and inhibit growth of Cryptococcus 
neoformans 262. Furthermore, there is evidence claiming that a protective T cell 
response is of a Thl phenotype, with mice deficient in Thl associated cytokines TNF, 
IFN-y, IL-12 and IL-18, all succumbing to infection 244,263-266.  TNF in particular is 
fundamental for cell recruitment, delayed type hypersensitivity and in direct 
cryptococcal killing. Furthermore, IFN-y and IL-12 are implicated in the assembly of 
a granuloma and suppression of dissemination, respectively. The IFN-y generated by 
the T cell infiltrate also augments the activation state of the resident macrophages, 
hence enabling them to eradicate infecting yeast, primarily through the generation of 
nitrite products 231. 
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1.8 Respiratory Infection Driven Pathology 
1.8.1 Pathology: Pathogen induced or Immunopathology 
Pathology and disease induced by respiratory infections is often attributed to the 
replication and cytoxicity of the pathogen alone. However, it is now understood that 
many of the manifestations of respiratory disease are evoked by the host's immune 
response to infection. The relative contributions of pathogen induced pathology and 
this immunopathology are variable and defined by the infective agent. 
Immunopathology may occur as a consequence of over-exuberance, or the induction 
of an inappropriate counter that is damaging rather than protective. If the pathogen is 
to be successfully eradicated, then some immunopathology may be unavoidable, but it 
is desirable to get the optimal balance between fighting infection and restricting 
collateral damage to surrounding tissue architecture and ensuing impairment of 
respiratory function. In the case of a viral infection such as influenza, the clinical 
signs of infection are closely linked to the over-exuberant immune responses to the 
pathogen. In contrast, the clinical manifestations of disease caused by Cryptococcus 
neoformans are primarily caused by the pathogen itself. These two quite distinct 
pathogens therefore pose quite different problems and strategies to combat the 
pathogen and alleviate illness and disease must take this in to consideration. 
1.8.2 Influenza driven pathology 
Influenza is highly cytopathic and induces extensive tissue damage at the site of 
infection, with significant submucosal oedema and shedding of epithelial cells. 
Influenza directly elicits significant aberration of tissue architecture following 
infection, with extensive cell death by cytolytic and apoptotic means. Influenza is 
capable of subverting host cell function by suppressing host gene transcription and 
protein synthesis, whilst promoting viral replication and production of virion particles 
267. Subsequently, infected host cells are subjected to a cytolytic death at 
approximately 20-40 hours post infection. Conversely, influenza can also elicit 
apoptosis of the invaded host cells, with virion proteins such as NA and NS1 
implicated in the regulation of the apoptotic program 267  
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There are many viruses that display minimal cytopathic potential, implying that a 
significant proportion of the extensive tissue damage and illness is attributable to the 
over-exuberance of the host's immune response. Whilst some pathology that 
accompanies influenza infection of the lung is directly attributable to the virus itself, a 
significant extent results from the over-exuberance of the host's immune response to 
the virus. 
Influenza infection elicits a potent pro-inflammatory response, with an abundance of 
cytokines and chemokines being released from epithelial cells and leukocytes. The 
release of these soluble mediators is fundamental to the control and resolution of 
influenza infection, but is also central to the development of many of the observable 
clinical and pathological manifestations. Mediators that are provoked by influenza 
infection and that have subsequently been demonstrated to correlate with increased 
illness and disease are TNF, IL-6, IL-8, IL-la, IL-l13, IFN-a, and various chemokines 
such as MIP-la 268-273 Investigations, using knock out mice and anti-cytokine 
strategies have implicated these cytokines and chemokines in lung inflammation, 
anorexia, excessive sleepiness and fever progression. The use of a neutralising 
antibody to TNF in a murine model of influenza induced pneumonia culminated in a 
significant reduction in lung pathology and prolonged survival 269. Similar 
investigations with anti-serum injection have defined IFN-a and IL-la as important 
mediators of the influenza induced fever 270. Influenza infected IL-113 and IL-6 knock 
out mice fail to display the same elevation in body temperature 271,272  and MIP-la 
knock out mice possess reduced mononuclear infiltrate and pulmonary edema 273. 
Both macrophages and neutrophils are recruited during influenza infection and as part 
of their anti-microbial arsenal they possess an NADPH oxidase that generates the 
highly reactive superoxide species. The superoxide generated by the phagocytic 
NADPH oxidase may be the causative agents of what may be referred to as "collateral 
damage", and the underlying determinant of immunopathology and disease. This is 
particularly evident in the lung, whereby oxidant-induced injury can cause extensive 
damage to lung epithelial cells and may in extremes lead to respiratory failure and 
death. ROS fail to discriminate between exogenous pathogens and the endogenous 
host tissue, and consequently are key mediators in pathology in a host of infections. 
Superoxide can react with nitric oxide, derived from inducible nitric oxide synthase 
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(iNOS) of macrophages, to form the peroxynitrite, which causes extensive tissue 
injury and mutagenesis through oxidation and nitration of various biomolecules 274. 
Indeed, excessive superoxide has been linked to lipid peroxidation, mitochondrial 
dysfunction, and inflammatory injuries. Treatment with superoxide dismutase (SOD), 
which breaks down superoxide, improves lung pathology and reduces lethality in 
influenza induced pneumonia 275. 
Though an efficient T cell response is crucial to the resolution of many viral 
infections, over-exuberance leads to immunopathology, airway occlusion and 
significant injury to alveoli epithelia. Many infection induced lung diseases are 
believed to be largely T cell mediated, with substantial accumulation of both CD4+ 
and CD8+ T cells in the alveolar spaces and / or the interstitium, which subsequently 
impedes efficient oxygen transfer and compromises lung function. CD8+ T cells are of 
particular prevalence as both key effectors of viral clearance due to their potent 
cytoxicity, and as significant mediators of pathology and illness. Influenza infection 
of T cell deficient mice compromises viral clearance, but attenuates inflammation 
with reduced histological evidence of lung injury. Furthermore, adoptive transfer of 
haemagglutin specific CD8+ CTLs into transgenic mice that constitutively express HA 
antigen in lung cells, leads to profound and lethal lung injury, with extensive 
alveolitis and abated gas exchange 276. Furthermore, lung inflammation and 
impairment of lung function following influenza infection is impingent upon the 
production of the Thl cytokine IFN-i by CD8+ T cells 277. 
1.8.2 Ctyptococcus neoformans Driven Pathology 
Pathology attributable to C. neoformans infection is a combination of pathogen 
induced and immunopathology, but is primarily attributable to the persistence of the 
pathogen itself. The persistence of the pathogen coupled with is considerable size and 
vast numbers represents a serious problem in an organ such as the lung whereby open 
airways must be maintained to support efficient gas exchange. However, the 
persistence of the pathogen will ultimately lead to chronic inflammation which will 
subsequently evoke considerable immunopathology. In mice, resolution of C. 
neoformans infection and prevention of dissemination to other sites is dependent on 
development of a Thl immune response (as seen in resistant BALB/c mice) 252-254. 
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Conversely, the generation of a Th2 response (as seen in susceptible C57BL/6 mice) 
leads to chronic pulmonary eosinophilia, unchecked fungal growth and dissemination 
to other organs 255. Similarly, in humans there is evidence that eosinophilia correlates 
with a non-protective response and an inability to clear C. neoformans infection. 
Eosinophils have been identified in the BAL fluid of patients infected with this fungal 
pathogen 278-281,  and is hypereosinophilia has been reported with disseminated 
cryptococcal disease 279. Similarly, C. neoformans causes summer type 
282,283 hypersensitivity pneumonitis in Japan 	and pulmonary eosinophilia is observed 
even in C. neoformnas infected immunocompetent individuals 279-281. The chronic 
pulmonary eosinophilia that occurs with failure to clear C. neoformans is strongly 
affiliated with the subsequent pathology. Persisting tissue eosinophilia results in tissue 
destruction due to the release of eosinophil derived mediators such as ROS, major 
basic protein and eosinophil cationic protein and the deposition of Charcot Leyden 
crystals 255. 
1.9 Treatment of Respiratory Infections 
Classically, vaccination and the administration of anti-microbial agents have been the 
primary strategies utilised to directly target the invading pathogen and confer 
protection. However, with ubiquitous problems of efficacy and safety, and the 
significance of immunopathology to disease status there is now intense research into 
new therapeutics that manipulate the host's mounted immune response. 
1.9.1 Vaccination. 
Many vaccination strategies have been applied worldwide with variable success 284. 
Whole killed influenza vaccines are successful and well tolerated, if under utilised, 
and afford 60-90% protective efficacy in children and adults 285. However, there is 
some evidence that these vaccines induce adverse reactions in juveniles and confer 
limited protection in the elderly 285,286.  There is immense antigenic variability in 
influenza as a result of the antigenic drifts and shifts in the surface proteins HA and 
NA. Consequently, the WHO is continually monitoring this variability in order to 
predict the influenza strains that will circulate the following year. These strains are 
then incorporated into a tri-valent vaccine currently with H1N1, H3N2 influenza A 
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virus and one influenza B virus. In addition, split influenza vaccines containing ether 
or detergent treated viral products, are currently in widespread use. However, there 
are concerns regarding the level of protection they confer, with limited 
immunogenicity in naïve individuals 287'288. Furthermore, infrequent hypersensitivity 
reactions such as oculorespiratory syndrome and Guillain-Barre syndrome have been 
reported. 
Cold-attenuated live vaccines have been used extensively for many years in the 
former Soviet Union with considerable success 289 and are now starting to be utilised 
in the US. It is anticipated that these vaccines may afford greater protection as they 
more intimately imitate natural influenza infections and should therefore elicit a 
broader immunological response and confer more long-lasting protection. Preliminary 
studies have shown live attenuated vaccines confer high protection 290, but concern 
persists regarding their safety, as it is feared that genetic exchange, as seen in 
pandemics, may occur between the attenuated vaccine and co-infecting virulent 
strains. DNA vaccines have been constructed encoding one or multiple influenza 
antigenic determinants, such as HA, NA, MP 1 and NSP-1. In mice, such vaccines 
evoke significant protection, eliciting a full range of humoral and cellular immunities 
291,292.  
Due to the antigenic variability continually displayed by influenza virus, a conserved 
M2 protein vaccine appears to be extremely promising, since its efficacy will be 
unperturbed by the extensive antigenic shift and drift in other proteins 293. The 
protection of many traditional vaccines is now being augmented by the co-
administration of appropriate adjuvants. Subunit influenza vaccines are now delivered 
with the adjuvant MF59 in some European countries, and afford increased 
neutralising antibody responses to both influenza A and B. Mucosal delivery of 
vaccines may be advantageous, but such delivery systems have displayed limited 
success. However, the incorporation of adjuvant derived from bacteria improves 
immunogenicity. 
There are at present no licensed vaccines currently available for the prevention of 
fungal infections. The insurgence of fungal opportunistic infections has highlighted 
the urgent requirement to develop effective treatments to combat such diseases. New 
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methods that aim to enhance immunity to the fungal pathogen are therefore a pre-
requisite for an applicable and effective therapy, and much focus is now being 
directed towards the generation of a protective vaccine. 
Cryptococcus neoformans exemplifies the problems that persist with existing 
treatments and the efforts that are being made to develop plausible vaccine 
candidates. There is at present a paucity of chemotherapeutic agents that offer relief 
from cryptococcal driven disease, and active vaccination has been heralded as a real 
possibility of preventing cryptococcosis in high risk patients. The cryptococcal 
polysaccharide capsule would represent a logical vaccine antigen 294, being capable of 
evoking a protective antibody response. Indeed, there exists unequivocal evidence 
that antibodies directed against the cryptococcal polysaccharide capsule enhance host 
protective immunity 295-297,  and a murine monoclonal antibody to GXM is currently in 
Phase 1 clinical trials in the USA 298. 
Vaccine candidates are also being investigated that will elicit a protective cell 
mediated response to C. neoformans, rather than merely a humoral response. Cell 
mediated immunity is critical to the resolution of this fungal pathogen and hence 
strategies to heighten this immune compartment would be desirable. Levitz and 
colleagues have demonstrated the potential of cryptococcal mannoprotein to stimulate 
T cell responses 299, and Mandel et al have shown the DHA 1 gene product to elicit 
delayed type hypersensitivity in mice 300 . 
1.9.2 Anti-microbial drugs 
The WHO has warned that a new influenza pandemic is possibly imminent, and there 
are concerns that current vaccines will be insufficiently immunogenic. In the outbreak 
of a pandemic there will be limited time between the detection of the causative strain 
and the requirement for a protective vaccine. The development of anti-viral drugs 
could be crucial at conferring protection in such a scenario, and are now receiving 
extensive research. There are currently two distinct classes of anti-influenza drugs 
available, those that inhibit the M2 ion channel and those that are neuraminidase 
inhibitors. Existing M2 ion channel inhibitors are =anticline and rimantidine, which 
while exhibiting definitive anti-viral potential have significant disadvantages. 
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Amantadine displays poor oral bioactivity with ensuing difficulties in successful 
administration, and there are serious deleterious side effects in the CNS, liver and 
kidneys. The drugs ineffectiveness against influenza B strains, and the rapid onset of 
post-treatment drug resistance also raise considerable concerns over its applicability 
as a plausible drug candidate 286. Rimantadine displays reduced neurotoxicity relative 
to amantadine but its availability is limited as are extensive investigations profiling its 
activity. Neuraminidase inhibitors, zanamivir and oseltamivir, function to prevent 
release of new infective virions from the host cell and subsequent dissemination. 
Clinical studies demonstrate the potential of these anti-viral agents to alleviate some 
early symptoms of influenza 301,302  Though generally regarded as being safe there 
persist some concerns, with zanamivir being implicated in occurrence of 
bronchospasms. Worryingly, there have been reports of the emergence of influenza 
strains that are now also resistant to neuraminidase inhibitors 303,304  Therefore, though 
the development of anti-viral drugs directed against influenza are highly desirable 
there still persist concerns over safety and increasing resistance. Furthermore, many 
of the symptoms of influenza may only become apparent when the influenza burden 
has started to diminish, questioning the applicability of such drugs in the practical 
prevention of illness and viral spread. 
No vaccine to elicit protection from C.neoformans is currently available and although 
still somewhat lacking in efficacy, infection is currently treated with a number of 
antifungal agents. Amphotericin B (AMB) is successfully used in all forms of 
cryptococcosis from pneumonia to meningitis and in the case of the latter, has a 60-
70% success rate 305. It is used on its own or in combination with the other widely 
used agent, flucytosine. Flucytosine has a superior penetration into the CSF than 
AMB but fungal resistance to this drug is common and treatment in meningitis results 
in a number of side effects, especially in AIDS patients 306,307  Due to the requirement 
for intact immune responses to control infection, C. neoformans is an ideal infectious 
model to explore the potential benefit of immuno-stimulatory drug strategies in the 
treatment of an ongoing infection. 
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1.9.3 Immunotherapeutics 
Due to the limited success of vaccination and anti-microbial agents, modulation of the 
host's immune response is now an intense area of research in the development of 
therapeutics for respiratory infections 308. Various strategies have been utilised to 
manipulate the over-exuberance of the host's response such as modulation of levels of 
inflammatory cytokines, T cell responses and education of the lung environment. The 
two respiratory pathogens influenza and C. neoformans pose quite different problems 
when elucidating potential immunotherapeutic strategies that will alleviate symptoms 
of disease. In the case of a viral infection such as influenza, the clinical signs of 
infection are associated with over-exuberant immune responses to the pathogen. In 
such situations, a reduction of this inflammation presents a novel strategy to treat 
infected individuals. In contrast, the clinical manifestations in diseases such as 
cryptococcosis are primarily caused by the pathogen. Therefore in this situation it 
would be beneficial to enhance immunity to the infectious agent. 
Cytokine therapy is a popular method utilised to combat pathology and illness 
induced by an inappropriate immune response. Cytokines play a paradoxical role in 
establishment of host immunity and frequently the ensuing pathology. Studies in 
antibody depletion have yielded promising results within the murine influenza model. 
TNF depletion alleviates weight loss, illness and pathology that are evoked by 
influenza infection 268. In addition, depletion and knock out studies of IFN-a, IL-la, 
IL-113, IL-6 , IL-8 and various MIPs and MCPs implicate these cytokines and 
chemokines in influenza associated fever, lethargy and anorexia 268-273. 
In some instances, insufficient immunity results in inadequate host defence and 
pathogen clearance. In such a scenario, depletion of immunosuppressive cytokines is 
beneficial. TGF-P is an immunosuppressive cytokine that deactivates macrophages 
and suppresses T cell function. TGF-I3 is secreted as an inactive homodimer bound to 
latency associated protein (LAP), and is activated extracellularly by dissociation from 
LAP. LAP can therefore be utilised as a novel method of cytokine depletion through 
reduction of TGF-P activity. Administration of LAP to BCG infected mice inhibits 
growth of BCG in the lung and enhances the antigen specific proliferation of T cells 
and IFN-y secretion 309. It is therefore apparent that the immunosuppressive cytokine 
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TGF-13 partially mediates the susceptibility of the lung to primary BCG infection, and 
depletion of TGF-f3 represents a plausible mechanism to confer heightened immunity 
in this and potentially other infections such as C. neoformans. Indeed, administration 
of DNA encoding TGF-I31 to C.neoformans mice reduced inflammation but 
compromised pathogen clearance 310  Similarly, chemokines and other molecules that 
mediate the trafficking and accumulation of cells at an infected site provide attractive 
targets for such neutralisation therapy 311. 
ROS and RNS are potent pathogenic mediators elicited by the host's immune 
response. Anti-oxidants therefore confer a feasible therapeutic agent since they will 
not only limit oxidative stress but will also limit the exuberance of the elicited 
response by suppressing ROS evocation of pro-inflammatory sequelae. Peroxynitrite 
is anticipated to be a causative agent of significant pathology and illness during 
influenza infections and various studies demonstrate the potential to limit lung 
damage and inflammation in murine models by reducing superoxide or nitric oxide 
levels. For example, over-expression of extracellular superoxide dismutase (SOD) 
reduces inflammation and lung injury during influenza infection 275. Suppression of 
ROS/RNS levels is complicated practically due to the paradoxical role of these 
mediators in protection and pathology, and the multifaceted functions they fulfil in 
host physiology and immunomodulation, which are only now being appreciated. 
T cells are another component of the host's immune response that are frequently the 
cause of extensive pathology. Several strategies have been employed to modulate host 
T cell responses to respiratory infection, such as depletion of T cells, reduced antigen 
presentation and inhibition of co-stimulation by B7. However, all of these 
mechanisms will not only target T cells activated in response to antigen challenge, but 
also the peripheral T cell repertoires and may render the host immunologically 
compromised. A novel mechanism to dictate host T cell responses is via modulation 
of the co-stimulatory signal imparted by OX40 312. OX40 is absent on naive T cells 
and up-regulated 1-2 days after antigen encounter. Therefore, investigation into this 
co-stimulatory signal has received heightened interest since its successful blockade 
could result in the selective targeting of only those T cell subsets that have recently 
encountered antigen. We have demonstrated the potential to interrupt OX40/0X4OL 
signalling, through the administration of OX40:Ig, during influenza infection of the 
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lung. Administration of OX40:Ig ameliorated T cell mediated immunopathology and 
illness 312. Furthermore, murine and human OX40 display significant homology, and 
human OX40 also reduces influenza-induced immunopathology in mice. Therefore, it 
is plausible that such a treatment may be applicable in humans. 
It is sometimes necessary to promote a protective T cell response if an infection is to 
be successfully resolved. During C. neoformans infection in susceptible strains 
(C57BL/6, C3H and BlO.D2) of mice, Th2 driven pulmonary eosinophilia develops. 
This response is non-protective and the mice fail to clear the pathogen leading to 
dissemination to the brain. It would therefore be advantageous to promote a Thl 
response if we are to successfully eliminate C. neoformans infection in this model. 
We have again manipulated the OX40 signalling pathway through the addition of an 
OX4OL:Ig which binds OX40 on the surface of T cells and promotes a heightened 
response 313. Addition of OX4OL:Ig during C. neoformans infection selectively 
enhances IFNI, secreting CD4+ T cells, reducing pulmonary eosinophilia and 
controlling C. neoformans burden. Therefore, one can envisage a plausible therapeutic 
role for manipulation of this late co-stimulatory molecule in promoting T cell 
immunity and selectively protecting from Th2 driven immunopathology. 
Selective T cell depletion offers another strategy to manipulate the host's immune 
response and limit pathology. In several diseases, discrimination must be made 
between a Thl and a Th2 response, with one conferring protection and the other 
eliciting damage, as is the case with C. neoformans. Selective depletion of a Thl or 
Th2 population of CD4+ cells may be beneficial, but it is first mandatory to determine 
stable, reliable markers for each subset against which therapy can be targeted. 
Markers specific to the Thl subset include chemokine receptors 1, 3 and 5 and 
interleukin-18 314-316, whereas those specific to Th2 CD4+ T cells are chemokine 
receptors 3 and 4, transcription factors c-maf and GATA-3 and orphan receptor 
Tl/ST2 314,317-319.  Selective depletion of T 1/ST2 expressing T cells alleviates 
eosinophilic lung disease to RSV 320 
In conclusion the effective management and treatment of respiratory infections 
persists as a ubiquitous dilemma, with current therapeutics deficient in efficacy and 
practicality (Table 1.5). The development of protective vaccines and potent anti-viral 
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agents, whose primary objective is eradication of the invading pathogen, would be 
optimal for conferring widespread protection and avoidance of all infection-induced 
pathological sequelae and illness. However, there remain significant deficiencies in 
these treatments with current vaccines incapable of conferring protection against the 
considerable heterogeneity elicited by the infective agent, and doubts persevering 
concerning the safety and immunogenicity of new vaccine candidates. Furthermore, 
current anti-viral agents are in many cases largely ineffective and there are increasing 
incidents of microbial resistance. More significantly, much of the illness and 
symptoms of respiratory infections only become apparent when viral burden has 
begun to subside, leaving the practicality of administrating these drugs a considerable 
dilemma. The significant immunopathological component of respiratory illness makes 
modulation of immune responses an attractive therapeutic candidate. These treatments 
would be highly applicable in alleviation of symptoms and recuperation from illness, 
following failure of traditional vaccines and anti-viral agents to rapidly resolve 
infection. However, immune manipulation is not without its downside and treatments 
must consider the specific pathogen infection, and the genetics, age and 
immunological status of the host. Infection history and the presence of co-infections 
must also dictate the applicability and direction of such treatments as manipulation of 
a particular facet of the immune response may alleviate illness associated with one 
infection, yet enhance the severity of another. Furthermore, many of the plausible 
targets of immune modulation possess natural physiological roles and their 
manipulation may alter the homeostasis or viability of the host. 
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Treatment 
Strategy 
Advantages 
Disadvantages 
Vaccination 
-Directly targets 
pathogen 
-Long term protection 
-Relatively 
inexpensive 
-Relatively easy and 
quick production 
-Excellent safety 
record 
-Public acceptance 
-Antigen diversity 
-Efficacy 
-Reversion to 
pathogenic strain 
-Incomplete 
deactivation of 
pathogen 
-Safety occasionally 
an issue 
-Ineffective against 
patients already 
infected 
Anti-microbial 
Agents 
- Directly targets 
pathogen 
-Generally well 
tolerated 
-Relatively 
inexpensive 
-Relatively easy and 
quick production 
-Antimicrobial 
resistance 
-Ineffective against 
patients already 
infected 
-Safety occasionally 
an issue 
-Efficacy 
Immunotherapy 
-Induce appropriate immune 
response to pathogen 
-Effective in clinically ill 
patients 
-Single treatment may be 
effective against many 
infections 
-Unaffected by antigen 
diversity 
-Largely untested 
-Effect on co-infections 
-Infection history 
-Genetic status of patient 
-Health of patient 
-Relatively expensive 
Table 1.5. Treatment strategies to alleviate respiratory pathogen driven illness 
and pathology: advantages and disadvantages. 
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1.10 Objectives. 
Illness and pathology induced by respiratory infections may be attributable to the 
cytotoxicity and persistence of pathogen and/or the over-exuberance or inappropriate 
nature of the host's response to infection. We have previously manipulated T cell 
responses as an immunotherapeutic strategy during respiratory infection: blockade of 
the late co-stimulatory signal OX40 reduced influenza induced inflammation and 
illness, whereas promotion of OX40 signalling boosted immunity to C. neoformans. 
Myeloid cells fulfil a critical role in the establishment and maintenance of an 
inflammatory response to respiratory infection, and as such offer plausible therapeutic 
targets. We hypothesise that myeloid cells can be manipulated to enhance anti-
pathogen immunity and/or reduce immune pathology in the lung. In the following 
thesis I will seek to address the following aims: 
1. To elucidate the role of ROS during influenza and C. neoformans infection, 
and ascertain the therapeutic potential of limiting the levels of these species. 
2. To investigate the basic expression and biology of CD200 and its CD200R, 
which deliver an inhibitory signal to the myeloid compartment. 
3. To determine effect of manipulating the CD200/receptor interaction during 
influenza and C. neoformans infection. 
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Chapter 2 - Materials and Methods 
All chemicals were purchased from Sigma, Poole, Dorset, UK unless stated 
otherwise. 
2.1 Mice 
8-12 week old female BALB/c and C57BL/6 mice were purchased from Harlan Olac 
Ltd (Bicester, UK). Cybb tml mice53 (back-crossed to C57BL/6 background at least 
10 times) were originally purchased from Jackson laboratories (Bar Harbour, ME, 
USA) but bred in house thereafter. OX-2 (CD200) knock out mice76 were a kind gift 
from J. Liversidge (University of Aberdeen, Aberdeen, Scotland). D011.10 
transgenic mice, originally generated by K. Murphy488, were a kind gift from C. Lloyd 
(Imperial College, London, England). SKG mice489 were a kind gift from S. 
Sakaguchi (Kyoto University, Kyoto, Japan). All mice were kept in pathogen-free 
conditions according to Home Office guidelines. 
2.2 Cybb tml Mutation Detection by PCR 
DNA was extracted from 10mg spleen of tissue from naïve C57BL/6 and Cybb tml 
mice using a DNeasy kit (Qiagen, Hilden, Germany). Flanking probes specific for 
either exon 3 of wild type gp91phox or for the-neomycin gene cassette that replaces 
exon 3 in cybb mice were used, producing 240bp and 195bp bands representing wild 
type and mutated gp91 genes, respectively. The PCR conditions were as follows for a 
10111 reaction: 94°C for 3 minutes> 35 x 1.5min cycles (30sec at 94°C > 30sec at 
56°C > 30sec at 72°C) > 72°C for 2 min. Using wild type splenic DNA, the 
concentrations of magnesium chloride and DNA were optimized for the reaction. 
25mM magnesium chloride and 8Ong DNA were identified as optimal. The PCR 
products were then detected in the presence of ethidium bromide on a 1% agarose 
(Invitrogen, California, USA) gel in Tris-Borate EDTA (TBE). 
81 
2.3 Pathogen Stocks 
2.3.1 Influenza 
Recombinant influenza A strain X31 (hemagglutinin [HA] titre 1024) was a kind gift 
from Dr Alan Douglas (National Institute for Medical Research, London, UK). The 
virus was titrated by haemagglutination assay. Human group '0' red blood cells 
(RBC) were collected in Alsever's solution to prevent clotting (ratio 1:1). Cells were 
washed three times in Alsever's solution, each time centrifuging for 5 min at 1200 
rpm, and re-suspended as a 10% stock solution in PBS. Influenza stock solution was 
doubly diluted in PBS in a round-bottom plate. An equal volume (501.1.1) of 0.5% 
RBC/PBS was added and incubated at room temperature for 1 hour, or until RBCs 
had settled at the bottom of the plate. The HA titre was defined as the highest dilution 
of virus capable of causing agglutination, i.e. inhibit RBC precipitation into a defined 
button at the bottom of the well. The titre was expressed as the reciprocal of the 
highest dilution of virus showing agglutination, and represents 1 HAU/50 j.t1 of virus. 
2.3.2 Cryptococcus neoformans 
C. neoformans strain 52, was obtained from the American Type Culture Collection 
(Rockville, USA) and for murine infection, grown to stationary phase (48-72 hours) at 
room temperature on a shaker in Sabouraud dextrose broth (1% neopeptone and 2% 
dextrose; Difco, Detroit, USA). The cultures were washed in saline, counted on a 
haemocytometer and diluted in sterile PBS to the required infective dose. Stock 
concentrations and viability were confirmed by plating on Sabouraud agar plates 
(Difco) and incubated for 48 hours at room temperature prior to colony counts. 
2.4 Reagents for in vivo studies 
2.4.1 CD200 reagents 
OX90 (rat blocking anti murine CD200 IgG2a) and OX110 (rat agonistic anti murine 
CD200R IgG1) hybridomas were a kind gift from Neil Barclay (Sir William Dunn 
School of Pathology, Oxford, UK). Hybridomas were cultured in RPMI 1640 with 
20% FCS, L-Glutamine, non-essential amino acids (Invitrogen, Paisley, UK) and 
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50µM 2-13-Mercaptoethanol acids (Invitrogen, Paisley, UK) in Integra CL1000 
bioreactor flasks. Culture media for the OX110 hybridoma was supplemented with 
10% IL-6 tissue culture soup from Sp.2 mIL-6 cell line (ATCC, Teddington, UK). 
CD200 fusion protein (CD200:Fc) was obtained from Trillium Therapeutics Inc. 
(Toronto, Canada). Murine CD200:mIgG1 (CD200:Fc) fusion protein was 
constructed by using a chimeric cDNA that contained the extracellular domain of 
CD200 fused to the constant region of murine IgG1 . This construct was used to 
transfect clonal chinese hamster ovary cells and fusion proteins was purified from the 
culture supernatant using protein G sepharose 321. 
2.4.2 Manganese (III) tetrakis (N-ethyl pyridinium-2-y1) porpyhrin (MnTE-2-PyP) 
MnTE-2-PyP was purchased from Merck Biosciences AG (Weidenmattweg, 
Switzerland). 
2.4.3 CpG ODN 
Highly purified CpG ODN 1826 (sequence 5' TCCATGACGTTCCTGACGTT) was 
provided by Coley Pharmaceutical Group (Wellesley, MA) and had a fully 
phosphorothioate-modified backbone for nuclease resistance and no detectable 
endotoxin. CpG 1826 was also methylated between nucleotide positions 8-9 and 17-
18 (5'-TCCATGACoGTTCCTGACoGTT-3') in order to nullify the unmethylated 
immunostimulatory capacity. The methylated 1826 CpG is referred to as control ODN 
2.4.4 Modified heat labile toxin of Echerichia coli (LTK63) 
Escherichia coli non-toxic heat-labile toxin, LTK63, was provided by Chiron S.p.A. 
(Siena, Italy). LTK63 was free of physiologically significant levels of endotoxin as 
measured by the LAL system; 6.4 endotoxin U/mg 
2.4.5 OX40 reagents 
Pegylated antibody to OX40 (human gamma 1 A9 Fab'-PEG) was provided by UCB 
Celltech (Slough, UK). A9 is a human IgG1 Fab fragment linked to polyethylene 
glycol, and is 40KDa. A9 was free of physiologically significant levels of endotoxin 
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as measured by the LAL system; 0.08 endotoxin U/mg. The murine OX4OL: mIgG1 
fusion protein, OX4OL: Ig, was obtained from Xenova Research Ltd (Cambridge, 
UK) and was constructed using a chimeric cDNA that contained the extracellular 
domain of OX4OL fused to the constant region of murine IgG1 . This construct was 
used to transfect clonal Chinese hamster ovary cells and fusion proteins was purified 
from the culture supernatant using protein G sepharose. 
2.5 Mouse Infections and Treatment 
On day 0, BALB/c or C57BL/6 mice were anaesthetised with isoflourane and 
intranasally (i.n) infected 50 HA units of influenza virus (in 50 pi PBS). In some 
experiments, virus-infected mice were re-infected with an identical titre of 
homologous virus 4-5 weeks after the initial infection. C. neoformans infections were 
performed in C57BL/6 mice. Anaesthetised mice were infected i.n with 1 x 104 cfu 
C.neoformans in , 50µ1 sterile PBS. In some experiments, wild type C57BL/6 mice 
were treated with the indicated dose of MnTE-2-PyP (Merck Biosciences AG, 
Weidenmattweg, Switzerland) or PBS i.n on day 0 and then at varying days after 
influenza or C. neoformans infection, as indicated in the text. In some experiments, 
mice were injected i.p. with 10pg CD200:Fc, 100µg OX90 or 100gg rat IgG (Caltag, 
South San Francisco, CA) on various days as indicated in the figure legend. In some 
experiments mice were treated i.p. with 1001.ig anti-IL-12 (rat mAb C15.6.7) 1 day 
before and 1, 4, 8 and 11 days following C. neoformans infection. Mice were 
sacrificed on days indicated in the text by injection of 3 mg pentobarbitone and 
exsanguinated via the femoral vessels. 
2.6. Quantification of Weight Loss and Illness Severity 
Weight loss was monitored daily and percent reduction calculated from their original 
weight on day 0. Illness severity of influenza- infected mice was scored daily using 
the following criteria: 0 = healthy, 1=barely ruffled fur, 2 =ruffled fur but active, 3 = 
ruffled fur and inactive, 4 = ruffled fur, inactive and hunched, 5 = dead (never 
allowed due to home office restrictions). In some experiments lung function was 
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measured in unrestrained animals by whole body plethysmography (Buxco 
Techologies, Petersfield, UK) as described previously 322. 
2.7 Serum, Nasal Wash and Cell Recovery 
BAL, lung tissue and serum were harvested by methods described previously 323. 
Blood was first harvested by exsanguination via the femoral vessel and centrifuged 
for 8 min at 8000 rpm. The serum was isolated and frozen at —70°C for analysis of 
antibody and cytokines. The lungs of each mouse were then inflated 6 times with 
1.5m1 1mM EDTA in MEM and placed in sterile tubes on ice. 100 µ1 BAL fluid from 
each mouse was cytocentrifuged onto glass slides and stained with Haematoxylin and 
Eosin (H and E). The remainder was centrifuged and the supernatant removed and 
stored at —70°C for analysis of cytokines by ELISA. Cell viability was assessed using 
trypan blue exclusion and the pellet resuspended in R1OF at a final concentration of 
106 cells per ml. Lung tissue, spleen, thymus, Peyer's patch and lymph node were 
disrupted to a single cell suspension by passage through a 100µM sieve (BD labware, 
New Jersey, USA). The cell suspension was then spun for 5 min at 1200rpm and red 
blood cells lysed by resuspending pellets in ACK buffer (0.15M ammonium chloride, 
1M potassium hydrogen carbonate and 0.01mM EDTA, pH 7.2) for 3 minutes at room 
temperature before spinning (1200rpm 5 min) and washing with R1OF. Cell viability 
was assessed by trypan blue exclusion and cells resuspended in R1OF at 106 cells/ml. 
The nasal cavity was also sometimes washed with 200111 PBS, collected and frozen at —
70°C for antibody ELISA analysis. 
2.8 Differential Counts of Cellular Composition of BAL Fluid 
The proportion of eosinophils induced by C. neoformans infection was first 
enumerated as granulocytes by flow cytometry, using forward and side scatter. 
Percentages were confirmed by counting eosinophils in H and E stained 
cytocentrifuge preparations of BAL fluid. The proportion of macrophages and 
lymphocytes in both C.neoformans and influenza infections was also enumerated by 
morphological analysis of H and E stained BAL fluid preparations. 
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2.9 Isolation of lung of Type II epithelial cells 
Lung type II epithelial cells were isolated as described previously 324. Briefly, lungs were 
perfused by the infusion of 10 ml PBS into the right ventricle of the heart. Lungs were 
subsequently inflated with 2.5 ml of 5 mg/ml dispase II solution (Roche, Basel, 
Switzerland) and then allowed to collapse naturally. 0.5m1 of 1% low melting point 
agarose was then slowly injected into the lungs and immediately allowed to solidify by 
packing the lungs in ice. Lungs were then removed and incubated for 40 minutes in 
dispase solution before being transferred to DMEM containing 50 µg/m1 of DNAse I 
solution (Roche, Basel, Switzerland) and the digested tissue teased away from the upper 
airways. Digested lung tissue was disrupted to a single cell suspension by passage 
through a 10011M sieve (BD labware, New Jersey, USA). Epithelial cells were enriched by 
negative selection, with removal of hematopoietic and endothelial cells by MACS 
separation (section 2.15). Briefly, lung homogenate was incubated with rat anti-mouse 
CD45 or CD90 antibodies (BD Pharmingen, Heidelberg, Germany), followed by anti-rat 
Dynabeads (Invitrogen) and applied to an MS column (Miltenyi Biotec, Gladbach, 
Germany) in the presence of a magnetic field. Unlabelled epithelial cells were washed 
through with buffer (PBS containing 0.5% BSA and 2mM EDTA). 
2.10 Generation of bone marrow (BM) derived macrophages and DCs 
Femurs were removed from BALB/c or C57BL/6 mice and bone marrow extracted by 
flushing extensively with RPMI-1640 media. RBC depleted bone marrow cells were 
washed and counted by trypan blue exclusion. To generate BM macrophages, 3 x 105  
cells/ml were plated out with 2Ong/ml M-CSF in 10 mis RPMI with 20% FCS, 
0.1U/m1 penicillin / 0.14m1 streptomycin and 10% HEPES, and incubated at 37°C 
for 72 hours. At this time, a further 5mls of medium containing M-CSF (20ng/m1; 
PeproTech Inc., Rocky Hill, NJ) was added on top of the existing 10mls and 
incubated at 37°C for another 72 hours. Media was subsequently removed and cells 
incubated in versene for 20 minutes at room temperature. Cells were then scraped 
from the plates, washed and resuspended in R1OF and counted. To generate BM 
dendritic cells, 2 x 105 cells/ml were plated out in 10 mis RPMI with 10% FCS, 
0.1U/m1 penicillin / 0.1µg/m1 streptomycin and 10% J558 supernatant (containing 
GM-CSF), and incubated at 37°C for 72 hours. At this time, 5 mis of media were 
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carefully removed and replaced with 5mls of fresh media with 10% J558 supernatant 
and incubated at 37°C for another 72 hours. Floating and weakly adherent cells were 
collected by gentle pipetting, washed and resuspended in R1OF and counted. 
2.11 Stimulation of BM macrophages/DCs 
BM derived macrophages and DCs were cultured at 2 x 106 cells/ml in 200µ1 R1OF in 
96 well flat bottomed plates. Cells were stimulated with IFN-y (1 Ong/ml or 
100ng/m1), LPS (1 Ong/ml or 10Ong/m1) or influenza (8 HA or 16 HA). Some cells 
were also cultured with OX110 to a final concentration of 10µg/ml. Cells were 
incubated at 37°C and at varying times after stimulation (as indicated in the text), 
supernatants were removed for cytokine/chemokine analysis and cells stained for 
surface markers by flow cytometry as described below. 
2.12 Flow Cytometric Analysis 
2.12.1 Cell Surface Antigens 
Cells were stained for surface markers and analysed by flow cytometry as described 
previously 323. All antibodies were purchased from BD Pharmingen (Heidelberg, 
Germany) except anti-CD200-FITC/PE and anti-CD200R-PE (Serotec UK, Oxford, 
UK). Briefly, 1 x 106 BAL, lung, spleen, thymus, Peyer's patch or lymph node 
derived cells were stained using APC-conjugated anti-CD4 and anti-CD8-PerCP. 
Cells were also stained with combinations of FITC-labelled antibodies specific for 
CD44, CD45RB, CD200, ai3 TCR, yS TCR, CD3 or B220, and PE-labelled anti-
CD45RB, anti-CD25, anti-CD200, anti-CD200R, anti-CD62L, anti-CD103, or anti-
DX-5 and biotinylated anti-0X40 and anti-ICOS. Some cells were also stained with 
anti-Ly6G-FITC, anti-CD1 lb-PercP, anti-CD11c-APC and one of anti-MHC class II-
PE, anti-CD200/R-PE, anti-CD80/86-PE, anti-CD4O-PE and anti-OX40L-biotin. All 
antibodies were diluted in PBS containing 1% BSA/0.05% sodium azide (PBA). Cells 
were stained for 30 min on ice, washed with PBA and spun for 5 min at 1200rpm. 
Where appropriate, secondary stains with streptavidin constructs were performed. 
After washing, cells were then fixed for 20 min at room temperature with 2 % 
formaldehyde/PBS. Cells were then washed in PBA and data was acquired on a FACS 
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Calibur and 30,000 lymphocyte events analysed with CellQuest Pro software (BD 
Biosciences, Belgium). 
2.12.2 Intracellular Cytokine Expression 
To detect intracellular cytokines, 106 cells/ml were incubated with 50 ng/ml PMA, 
500 ng/ml ionomycin (Calbiochem, Nottingham, UK), and 10mg/ml brefeldin A for 3 
hours at 37°C. Cells were then stained with anti-CD4-APC and anti-CD8-PerCP and 
fixed as described above. After permeabilization with PBS containing 1 % saponin/1 
% BSA/0.05 % azide (saponin buffer) for 10 min, cells were stained with anti-IFN-y-
FITC/PE, anti-TNF-FITC/PE, or PE-conjugated anti-IL5 or anti-IL-4 diluted 1:50 in 
saponin buffer. 30 minutes later cells were washed once in saponin buffer and once in 
PBA. Data was then acquired as described above. 
2.12.3 FoxP3 
Binding of PE-labelled intracellular FoxP3 was detected according to manufacturers' 
instructions (BD Pharmingen, Heidelberg, Germany). Briefly, 1 x 106 cells were 
stained for surface CD4-PercP as described above and washed extensively with PBA. 
Cells were subsequently incubated for 16 hours in 200111 Fix/Perm working solution 
at 4°C. Cells were permeabilized with permeabilization buffer for 15 min at 4°C 
(containing Fc block), and then stained with anti-Foxp3 (FJK-16s)-PE antibody 
diluted 1:50 in permeabilization buffer for 30 min at 4°C. 
2.12.4 Apoptosis Analysis 
For apoptosis analysis, binding of PE-labelled Annexin V was detected according to 
manufacturers' instructions (BD Pharmingen, Heidelberg, Germany). Briefly, cells 
were washed in PBS and resuspended in Annexin-binding buffer containing Annexin 
V-PE, anti-CD4-FITC and anti-CD8-PercP. After washing in binding buffer, 7-AAD 
was added to determine dead cells. Apoptotic cells were identified as 7-AAD" 
/Annexin V+. Data was then immediately acquired, collecting 30,000 lymphocyte 
events. 
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2.13 Hematoxylin and Eosin staining of lung tissue 
In some studies, lungs were inflation fixed with 2 % formalin in PBS, and spleen, 
thymus and Peyer's patches excised and placed in 2% Formalin. The organs were then 
embedded in paraffin wax and 4 µ1‘4 sections stained were with H and E (Lorraine 
Lawrence, Imperial College, UK). 
2.14 Purification of cells by MACS separation 
CD4+ T cells were purified from single cell suspensions from C57BL/6 or D011.10 
spleens. Cells were resuspended at 108 cells/ml in PBS containing 0.5% BSA and 
2mM EDTA (buffer), with 10% CD4 microbeads (Miltenyi Biotec, Gladbach, 
Germany). Cells were incubated for 15 minutes at 4°C. Cells were washed and 
resuspended in buffer up to 2 x 108 cells/ml and applied to an MS column (Miltenyi 
Biotec, Gladbach, Germany) in the presence of a magnetic field. Unlabelled cells 
were washed through with buffer. The column was removed from the magnetic field 
and the fraction containing the magnetically labelled cells was flushed out with a 
plunger. Cells were counted and purity assessed by flow cytometry. 
2.15 T cell activation 
2.15.1 OVA peptide stimulation ofD011.10 TCR-Tg CD4+ T cells 
RBC depleted splenocytes (2 x 105 / well) of naïve D011.10 TCR-Tg mice were 
cultured in 96 well flat-bottomed plates in a final volume of 200µ1 RPMI 
supplemented with 10% FCS. Cells were stimulated with OVA peptide 
(ISQAVHAAHAEINEAGR) at a final concentration of 0.1, 1, 10 and 100µg/ml. At 0, 
24, 48, 72 and 96 hours after stimulation cells were stained for the surface expression 
of CD4, CD200, ICOS and OX40 as described above and analysed by flow 
cytometry. In some experiments, T cells were stimulated with 10µg/m1 OVA peptide 
in the presence of neutralizing antibodies to IL-12 (10 µg/ml), IL-4 (10 µg/ml) or IL-
10 (10 µg/ml). In some experiments, cyclosprorin A (1µg/m1) was added to the 
splenocyte cultures at 24 hours after addition of OVA peptide. 
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2.15.2 Generation of Thl and Th2 biased CD4+ T cells 
For short-term polarized T cell lines, CD4+ cells were purified from the spleen of 
naïve D011.10 TCR-Tg mice as described above. Cells were cultured with OVA 
peptide (ISQAVHAAHAEINEAGR, 100µg/m1) and irradiated BALB/c spleen cells 
in the presence of murine recombinant IL-12 (10 ng/ml) plus neutralizing anti-IL-4 
antibody (10 µg/ml) for Thl phenotype, or recombinant IL-4 (10 ng/ml) plus anti-IL-
12 (10 µg/ml) and anti-IFN-y (10 µg/ml) antibodies for Th2 phenotype, for 5 d at 
37°C. 
2.15.3 PMA/Ion induced activation of T cells 
CD4+ T cells (2 x 105 / well) were isolated from the spleens of naïve C57BL/6 mice 
as described above and were cultured in 96 well flat-bottomed plates in a final volume 
of 200111 RPMI supplemented with 10% FCS. Cells were stimulated with 20nM PMA 
and 500nM lonomycin. At 0, 24, 48, 72 and 96 hours after stimulation cells were 
stained for the surface expression of CD4 and CD200 as described above and 
analysed by flow cytometry. In some experiments, PMA/Ion were washed out of the 
cultures after 24 hours and the cells re-cultured in RPMI supplemented with 10% FCS 
alone for a further 48 hours before being analysed by flow cytometry. 
2.15.4 Activation of T cells through CD3/CD28 
CD4+ T cells (2 x 105 / well) isolated from the spleens of naïve C57BL/6 mice, or 
total RBC depleted splenocytes (2 x 105 / well) of naïve BALB/c or SKG mice were 
cultured in 96 well flat-bottomed plates in a final volume of 200µ1 RPMI 
supplemented with 10% FCS. Cells were cultured with different combinations, as 
defined in the text, of plate bound anti-CD3 antibody (5µg/m1; BD Pharmingen, 
Heidelberg, Germany), soluble anti-CD28 antibody (1 ps/m1; BD Pharmingen, 
Heidelberg, Germany) and / or OX4OL:Ig (10µg/m1). At 0, 24, 48 and 72 hours after 
stimulation cells were stained for CD4, CD200 and OX40 as described above and 
analysed by flow cytometry. 
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2.15.5 Antigen presentation assay 
Following purification, D011.10 OVA-specific CD4+ T cells were labelled with the 
intracellular fluorescent dye 5-carboxyfluorescein diacetate succinimidyl ester 
(CFSE) to analyse cell division. Cells were resuspended in PBS at 5 x 107/ml and 
CFSE added quickly to a final concentration of 10µM. Cells were incubated for ten 
minutes at room temperature and washed twice in R1OF to block the reaction. Cells 
were then resuspended in R1OF for plating. BM DCs (2x105/m1) were loaded with 
ovalbumin (1 lig/m1) and stimulated with LPS (10Ong/m1) for 3 hours at 37°C. CFSE 
labelled OVA-specific CD4+ T cells were subsequently added to the DCs along with 
control IgG or OX110 (to a final concentration of 10µg/m1). Cells were incubated for 
96 hours at 37°C and CFSE incorporation assessed by flow cytometry. 
2.16 Immunoprecipitation and immunoblotting 
BM macrophages (1 107 cells/ml) were stimulated at 37°C with 100ng/m1 IFN-y for 
16 hours. The cells were subsequently treated with control IgG or OX110 (10 µg/ml) 
for indicated periods of time at 37°C. Cells were then rinsed once with ice-cold PBS 
containing 1 mM Na3VO4 and lysed in lysis buffer (50 mM Tris-HC1 (pH 8.0), 150 
mM NaC1, 1% Nonidet P-40, 10% glycerol, 5 mM EGTA, 50 mM NaF, 1 mM 
Na3VO4, plus protease inhibitor mixtures) for 20 mM on ice. Lysates were clarified at 
14,000 rpm for 10 min. The protein concentration of the supernatant was determined 
by Bradford assay. For immunoprecipitations, polyclonal anti-Dok2 Ab (Upstate 
Biotechnology, Lake Placid, NY) was incubated with 0.5-1 mg of cell lysate for 2 at 
4°C. The immune complexes were recovered by incubation with protein G Plus-
agarose beads (Santa Cruz Biotechnology) for 1 h at 4°C. After washing three times in 
lysis buffer and once in PBS containing 1 mM Na3VO4, the immune complexes were 
dissociated in SDS sample buffer. Equal amounts of protein were analyzed by Nu-
PAGE (Invitrogen Life Technologies) and Western blotting. For Western blotting, 
primary Abs (anti-phosphotyrosine mAb (4G10) and polyclonal anti-Dok2 Ab, 
Upstate Biotachnology) were detected with HRP-conjugated secondary Abs and 
chemiluminescence (Pierce, Rockford, IL). 
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2.17 Immunofluorescence microscopy 
2.17.1 Immunofluorescent staining for CD200/CD200R 
Lungs from 8- to 12-wk-old C57BL/6 mice, at days 0, 3 and 7 after influenza 
infection, were inflated with 1.5m1 OCT (Tissue-Tek) and snap frozen in OCT 
freezing medium by liquid nitrogen flotation. All frozen tissues were stored at —80°C. 
Cryostat sections (5-8 gm) were fixed in cold 80% acetone and 20% methanol, air 
dried, then blocked with 15% normal goat serum for 30 min at room temperature. 
Sections were then incubated in primary Abs to murine CD200 (0X90) or CD200R 
(0X110) (3 µgimp for 2 h at room temperature, extensively washed in PBS, and then 
incubated for 1 h in Alexa-488 conjugated goat anti-rat IgG (Molecular Probes). 
Sections were then washed three times in PBS and wet mounted for fluorescent 
microscopy. Sections were examined under a Nikon ECLIPSE TE2000-U 
fluorescence microscope. 
2.17.2 Immunofluorescent staining for pro-surfactant C 
Isolated epithelial cells, as described in section 2.9, were cytocentrifuged onto poly-
lysine coated slides and fixed in 4% parafolmadehyde for 20 mins at room 
temperature. Cells were subsequently washed in PBS and permeabilized with 0.2% 
Triton-X-100 in PBS for 30 mins. Cells were again washed with PBS and blocked 
with 10% normal goat serum for 30 min at room temperature. Rabbit anti-human pro-
surfactant protein C antibody (Chemicon Europe Ltd., Hampshire, UK) diluted 1/500 
in 10% goat serum was added to cells and incubated for 16 hours at room 
temperature. Cells were washed extensively with PBS and cells incubated for 1 hour 
in Alexa 488 conjugated goat anti-rabbit IgG (Molecular Probes) in PBS with 
propidium iodide (1/1000). Cells were washed again in PBS and mounted in PBS 
with 10% glycerol and 0.02% azide and examined under a Nikon ECLIPSE TE2000-
U fluorescence microscope. 
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2.18 Measurement of Pathogen Load in Lung Homogenates 
2.18.1 Influenza-Specific Plaque Assay 
Lung homogenates were freeze thawed three times, centrifuged at 4000 g and 
supernatants titrated in doubling dilutions on Madine Darby canine kidney (MDCK) 
cell monolayers in flat bottomed 96 well plates. After incubation at room temperature 
for 3 hours, samples were over-layed with 1% methycellulose and incubated for 72 
hours at 37°C. Cell monolayers were washed and incubated with anti-influenza 
antibody (Serotec) followed by anti-mouse-HRP (Dako) and infected cells were 
detected using 3-amino-9-ethylcarbazole substrate. Infectious units were then 
enumerated by light microscopy and total plaque forming units per lung quantified 
(number of plaques x dilution factor x total volume of lung homogenate). 
2.18.2 Enumeration of C.neoformans Colony Forming Units (cfus) 
Lungs were homogenized by passage through 100pm cell strainers. 100111 of cell 
suspension was diluted in sterile PBS and incubated at room temperature for 48 hours 
on sabouraud dextrose agar plates (Sigma). The total colony forming units per lung 
were then determined (number of colonies x dilution factor x original cell suspension 
volume). 
2.19 Cytokine detection 
2.19.1 ELISA 
IL-4, IL-5, IFN-'y, IL-10, IL-12 and TNF in BAL fluid, and in some cases serum, were 
quantified using OptEIA kits (Pharmingen). Briefly, microtiter plates (Nunc, 
Roskilde, Denmark) were coated with 100111 of capture antibody diluted in the 
recommended buffer overnight at 4°C. After 5 washes with PBS containing 0.5 % 
Tween-20, plates were blocked with 200 1.t.1 PBS containing 10 % FCS and left for 1 
hour at room temperature. Samples and standards (diluted in PBS + 10 % FCS) were 
then incubated for a further 2 hours at room temperature. After 5 washes, bound 
cytokine was detected using biotinylated antibodies pre-mixed with avidin-HRP 
followed by tetramethylbenzidine and hydrogen peroxidase. Optical densities were 
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read at 450 nm. The mean optical density of wells containing no cytokine was 
subtracted from the results obtained for samples and standards. The concentration of 
cytokine in each sample was calculated from a standard curve. 
2.19.2 Cytometric Bead Array(CBA) 
Levels of interleukin (IL)-6, IL-10, IL-12p70, TNF, monocyte chemoattractant 
proteins (MCP)-1, and interferon (IFN)-y in murine serum, BAL fluid and 
supernatants from macrophage cultures were assayed by mouse inflammation CBA 
kit (BD Pharmingen, Heidelberg, Germany) using a flow cytometer (FASCalibur, 
Becton Dickinson). IL-2, IL-4, IL-5, TNF and IFN-y in lung homogenate were 
measured by mouse Thl /Th2 CBA. In CBA, five/six bead populations with distinct 
fluorescence intensities have been coated with capture antibodies specific for five/six 
different cytokines. These bead populations could be resolved in the fluorescence 
channels of the flow cytometer. After the beads had been incubated with 50 µ1 of 
supernatant, different cytokines or chemokines in the sample were captured by their 
corresponding beads. The cytokine/chemokine captured beads were then mixed with 
phycoerythrin-conjugated detection antibodies to form sandwich complexes. 
Following incubation, washing and acquisition of fluorescence data, the results were 
generated in graphical format using the BD CBA software. 
2.19.3 Luminex 
The mouse cytokine Twenty-Plex kit (BioSource International, Inc., California, US.) 
was utilized to determine the levels of cytokines in BAL fluid, according to the 
manufacturer's instructions. Briefly, 251.d of Twenty-Plex beads were applied to each 
well of a pre-wet 96 well filter plate and washed with 200 µI of wash buffer by 
aspiration with a vacuum manifold. 500 of incubation buffer and 500 of 
standard/sample were subsequently added to the beads in each well and incubated for 
2 hours at room temperature. After 2 hours, wells were washed and 1000 of lx 
Biotinylated Detector Antibody added to each well and incubated for 1 hour at room 
temperature. Wells were subsequently washed again and beads incubated with 100111 
of lx Streptavidin-RPE for a further 30 minutes at room temperature. Beads were then 
extensively washed and resuspended in 1000 of lx working wash solution. Data was 
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collected with a minimum of 100 beads per analyte using StarStation 1.0 (Applied 
Cytometry, Sacramento, CA). Standard curves for each cytokine were generated by 
using the reference cytokine concentrations supplied by the manufacturers. The 
analyzed data were graphed and statistically analyzed using PrismGraph 4.0 
(GraphPad Software, Inc., San Diego, CA). 
2.20 Antibody ELISAs 
2.20.1 Influenza-Specific Antibody ELISAs 
Microtiter plates were coated with 100HA/well UV inactivated influenza overnight at 
4°C. Plates were washed with PBS/tween and blocked with 10%BSA/PBS and diluted 
nasal wash or serum from naïve and influenza-infected mice was incubated for 3hrs at 
room temperature. Plates were washed and incubated with either biotinylated anti-
mouse IgG1 or IgG2a (both serotec), anti-mouse immunoglobulin-HRP (Dako) or, in 
the case of nasal washes/BAL, anti-mouse IgA-HRP (Serotec) for 90 min at room 
temperature (all diluted in 5%BSA/PBS). In the case of IgG1 and IgG2a ELISAs, 
plates were washed and incubated with streptavidin-HRP (Dako) for 60 min. After 
washing, bound antibody was detected on all plates by incubating with O-phenylene-
diamine (OPD, Sigma) substrate in the dark for 20 minutes. The reaction was then 
stopped with 50µ1 2M sulphuric acid and plates were read at 490nm. Absorbance 
values of naïve mice were subtracted from all values. 
2.20.2 C.neoformans-specific ELISAs 
2 x 105 cfu/ml heat killed C.neoformans in PBS was used to coat 96 well microtiter 
plates overnight at room temperature on a shaker. After blocking with 3% BSA/PBS 
for 2 hours at room temperature, dilutions of sera from naive and C.neoformans-
infected mice were added for a further hour at room temperature. Bound antibody was 
detected as described in section 2.20.1. Optical densities were read at 490 nm and 
mean BSA/PBS blank values were subtracted from the optical density values of test 
samples. 
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2.20.3 Total IgE Antibody ELISA 
Nasal washes/BAL from C.neoformans-infected mice were used to coat microtiter 
plates overnight at 4°C. Plates were washed with PBS tween, blocked for 2 hours with 
3%BSA/PBS and incubated for 2 hrs at room temperature with anti-IgE-HRP in 
BSA/PBS (Serotec). Plates were washed again and bound antibody detected with 
OPD substrate. The reaction was stopped with 2M sulphuric acid and absorbance read 
at 490nm. 
2.21. Protein detection 
BAL fluid protein concentration was determined using the Pierce BSA protein assay 
kit. Working reagent was added to samples and standards at a 4:1 ratio and incubated 
at 37 °C for 30 minutes. Absorbance was measured at 490 nm, and protein 
concentration calculated by comparison with an albumin standard. 
2.22. Lactate Dehygrogenase (LDH) detection 
The amount of LDH in the BAL was measured using Sigmas in vitro toxicology LDH 
based assay kit. Samples (tested in triplicate) were added to an equal volume of LDH 
assay mixture (assay dye, substrate and enzyme) and incubated at RT for 30 minutes. 
Absorbance was measured at 490nm. 
2.23. Nitric oxide detection 
The concentration of nitrite in BAL and macrophage culture supernatants was used as 
a measure of NO production and was quantified using the Greiss reagent kit. Briefly, 
samples and standards (50µ1) were added to a microtiter plate and treated with 1% 
sulphanilamide for 10 minutes at room temperature. Subsequent addition of 0.1% 
naphthylethylenediamine (NED) in 2.5% H3PO4 yielded a magenta colour in the 
presence of NO. Optical densities were read at 550 nm. The mean optical density of 
wells containing media alone was subtracted from the results obtained for samples 
and standards. The concentration of NO in each sample was calculated from a 
standard curve. 
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2.24 Microarrays 
2.24.1 RNA extraction 
Total RNA was extracted from C57BL/6 and Cybb tml adult female mouse lung 
using RNA STAT-60 (AMS Biotechnology, Oxon, UK) according to the 
manufacturer's instructions. Briefly, snap frozen lung tissue was homogenised under 
liquid nitrogen and incubated for 5 minutes at room temperature in RNA STAT-60 to 
allow nucleoprotein complexes to dissociate. RNA was subsequently separated from 
protein and DNA using chloroform and precipitated with isopropanol. RNA was 
washed with 75% ethanol and resuspended in DEPC-treated RNase-free water. RNA 
integrity was quantified by measuring its absorbance at 260nm and its integrity 
confirmed by running a small aliquot on a 1% agarose gel. 
2.24.2 Labelling of RNA 
RNA was labeled using a standard reverse transcriptase labelling method whereby 100 
pg of total RNA was heated for 5 min at 95°C in the presence of 4 jig oligo(dTi5) 
(total volume 12 p.1). Samples were cooled to 42°C and 18 pl labelling reaction 
mixture added [6 p.1 5x RT buffer (BRL); 3 pl 0.1 M DTT (BRL); 5 mM dATP, dGTP 
and dTTP, 2 mM dCTP (Abgene); 2 mM Cy3 or Cy5-dCTP (Amersham); 400 U M-
Superscript II(Invitrogen)]. Samples were subsequently incubated for 10 minutes in 
the dark at room temperature followed by 90 minutes in the dark at 42°C. Following 
first-strand cDNA synthesis, 20 jig RNase A was added to each sample and incubated 
at 37°C for 20 min. Reactions were stopped by the addition of 5 pi 0.5 M EDTA. 
2.24.3 Hybridisation 
Following termination of the labelling reactions individual samples were mixed with 
the correctly labelled corresponding sample and passed through a nucleotide removal 
kit (Qiagen). Mouse Cot-1 DNA (10 1.1g) was then added to the mixed samples and 
sample volume was made up to 30 p,1 with hybridisation solution to give a final 
concentration of 40% formamide, 5x SSC, 0.1% SDS. Samples were heated to 100°C 
for 5 min then allowed to cool for 10 minutes. Samples were briefly subjected to 
centrifugation and pipetted beneath coverslips onto HGMP total mouse genome v2 
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microarray slides (MRC). Microarrays were placed into hybridisation chambers 
(Corning), the end wells were filled with 16 pl hybridisation buffer and the chambers 
sealed. Microarrays were placed in a waterbath at 50°C overnight. 
2.24.4 Microarray washing 
Microarrays were removed from the hybridisation chambers and washed twice in 2x 
SSC for 5 min; 2x 0.1x SSC, 0.1% SDS for 5 min; 2x 0.1x SSC for 5 min. Slides 
were dried by centrifugation for 5 min at 60 g and entered for scanning. 
2.24.5 Data capture and analysis 
Microarrays were scanned using a GenePix 3000 scanner. BlueFuse image analysis 
software was used to generate Cy3 and Cy5 expression values for the genes on each 
of the arrays. During image processing, an automatic flagging process was used to 
remove spots whose background-subtracted mean signal intensity was less than four 
times the standard deviation of the background pixel intensity. Manual flagging was 
also used to highlight spot irregularities such as dust, scratches and misaligned 
features. The BlueFuse output data was then imported into GeneSpring GXv7.3. The 
data was normalised using the Lowess algorithm and the normalised data was checked 
for any sample anomalies. The data was filtered on confidence, using the p-value (p < 
0.05) of a t-test as the confidence value, with a Benjamini and Hochberg (BH) 
correction applied to reduce the false discovery rate. This was first applied to the wild 
type data to determine which genes were up-regulated and down-regulated with 
respect to the reference sample. This was repeated for the cybb arrays 
2.25. Statistics 
All experiments were performed at least twice, analysing 5 individual mice per time 
point. Statistical significance was evaluated using the student t test, 2 tailed assuming 
unequal variance within the Minitab software program. The Bonferroni correction 
was applied where appropriate. 
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Chapter 3 — The Role of Reactive Oxygen Species in 
Pulmonary Influenza Infection 
3.1 Introduction 
3.1.1 The NADPH Oxidase and the generation of Reactive Oxygen Species 
The generation of reactive oxygen species (ROS) represents an important component 
of the host's arsenal to combat invading microorganisms 53-55. In addition to their 
potent anti-microbial activity, ROS also possess a significant cell-signaling role in 
biological systems, capable of regulating the phenotype and function of immune cells 
60,62,325. However, the extreme toxicity and lack of specificity, means they are also 
capable of eliciting significant immunopathology to surrounding tissue 326. 
The most abundant sources of ROS following pathogenic challenge are the NADPH 
oxidase of professional phagocytes and xanthine oxidase. Both are potent producers 
of superoxide, which can subsequently be converted into a host of other ROS. The 
NADPH oxidase is a multimeric enzyme complex, composed of membrane associated 
and cytosolic components, that utilize molecular oxygen and NADPH to generate the 
superoxide radical (Oi-) 18. The core of the enzyme contains the membrane bound 
flavocytochrome b558 327. This flavocytochrome is the site of the oxygen reduction 
and is comprised of 2 subunits, a 22kDa protein (p22phox) and a 91kDa glycoprotein 
(gp9lphox) 328. After appropriate stimulation, cytosolic factors (p4Ophox, p47phox 
and p67phox) migrate to the membrane-associated components to form an active 
complex that catalyses the formation of 02' 329. 
3.1.2 The Role of ROS in Respiratory Infections 
A combination of transgenic and knock out mice and scavengers of reactive oxygen 
species have been utilisied to elucidate the role of reactive oxygen species in 
protection and pathology to respiratory infections. Cybb tml mice offer a murine 
model of the autosomal genetic condition of chronic granulomatous disease (CGD) 54. 
These mice lack the gp9lphox sub-unit of the phagocyte NADPH oxidase rendering 
them incapable of eliciting a respiratory burst with ensuing production of superoxide 
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through this route. These mice demonstrate enhanced susceptibility to certain fungal 
and bacterial pathogens 53'54 with increased susceptibility to Aspergillus fumigatus 
and Staphylococcus aureus 54, and compromised clearance of Escherichia coli 330  
Mice lacking the p47phox sub unit of the NADPH oxidse display impaired NF-x(3 
activation and host defence to Pseudomonas pneumonia 331, and a transient loss of 
resistance to pulmonary tuberculosis with a significant increase in bacterial growth 
over the early period of infection 332. 
Whilst the production of ROS in pulmonary bacterial and fungal infections constitutes 
significantly to the host's protective immune response, their role in viral infections is 
less clear. In 1979, Peterhans et al first demonstrated the potential of viral infection 
to induce production of ROS by phagocytes with in vitro studies utilising Sendai virus 
333. Ten years later there was documented evidence citing for the first time the 
potential of influenza to elicit superoxide production by PMNs and monocytes in vitro 
334. Influenza infection induces the production of superoxide from phagocyte NADPH 
oxidase and xanthine oxidase pathways 335 that may have partial virucidal activity or 
limit viral propagation by inducing apoptosis of the infected cell 336,337  Conversely, 
low levels of ROS may facilitate viral replication because of their mitogenic effects 
on cells. Most viruses grow better in proliferating cells, and indeed, many viruses 
induce in the host cell changes similar to those seen early after treatment with 
mitogenic lectins. Furthermore, ROS may inactivate the anti-proteases that are 
localised on the surface of the alveoli 338'339. These anti-proteases are protective to the 
host as they inhibit proteases that exist in the pulmonary surfactant, which 
proteolytically cleave the naive viral coat protein HAO into HAl and HA2. Influenza 
virions expressing HAl and HA2 possess enhanced infectivity and virulence, and 
hence the inhibition by ROS on anti-proteases will culminate in more cleavage of this 
viral coat protein. 
ROS, however, fail to discriminate between exogenous pathogens and endogenous 
host tissue, and consequently are key contenders in the induction of pathology in a 
host of infections. Superoxide is a precursor for an array of more potent oxidants such 
as the hydroxyl radical, and furthermore can react with nitric oxide to form 
peroxynitrite which causes extensive tissue injury and mutagenesis through oxidation 
and nitration of various biomolecules 274. Indeed, excessive superoxide is linked to 
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lipid peroxidation, mitochondrial dysfunction, and inflammatory injuries 56. 
Furthermore, a decrease in levels of peroxynitrite reduces mortality rates with 
influenza induced pneumonia 335, and transgenic mice over-expressing extracellular 
superoxide dismutase (SOD), exhibit reduced inflammation and lung injury similar to 
influenza pneumonia. 
3.2.3 Scavengers of ROS as potential therapeutics 
The potential of reactive oxygen species to elicit oxidative stress and pathology has 
resulted in the generation of compounds that confer protection through scavenging 
these reactive and toxic species. Previous studies that have attempted to limit 
oxidative stress via manipulation of endogenous SODs for therapeutic purposes have 
had limited success, due to the large molecular weight and short half life of such 
compounds. A new generation of SOD mimetics offer a more plausible therapeutic 
approach owing to their increased half life and lower molecular weight, which 
facilitate entry to intracellular sites. Furthermore, such a mimetic would be ideal as a 
therapeutic as it can be administered via a variety of routes. Manganese (III) tetrakis 
(N-ethyl pyridinium-2-yl) porpyhrin (MnTE-2-PyP) is a low molecular weight, cell 
permeable, catalytic metalloporphyrin antioxidant with potent superoxide dismutase 
(SOD) mimetic activity 340,341.  This anti-oxidant has a broader range than SODs, also 
possessing catalase activity and the ability to scavenge lipid peroxides and 
peroxynitrite. The potential of this molecule to scavenge superoxide and other ROS 
provides an alternative strategy to elucidate the role of these mediators in immunity 
and pathology to respiratory infection. Though MnTE-2-PyP offers protection in a 
variety of oxidative stress injuries, such as liver ischemia, diabetes, lung radiation 
injury and stroke 340,342,  this is the first study to describe its use in the treatment of 
respiratory infection. 
3.2.4 Hypothesis. 
The failure of ROS to discriminate between exogenous pathogens and endogenous 
host tissue implicates them in pathology following influenza infection 343-345. 
Furthermore, ROS act as second messengers evoking the activation of redox sensitive 
transcription factors implicated in the establishment of an inflammatory response 
suggesting they may add to the over-exuberance of the elicited immune response 
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275,346. This chapter tests the hypothesis that reducing the levels of ROS during 
influenza infection will reduce immunopathology and offer a potential 
immunotherapeutic strategy. Whilst there have been some studies investigating the 
role of ROS in influenza infection, they have failed to define the role these species 
have on the phenotype of the host's immune response and in dictating the balance 
between protection and pathology. 
102 
3.2 Results 
3.2.1 Influenza induced pathology and illness is linked to the exuberant immune 
response elicited by the host 
Influenza infection of C57BL/6 and BALB/c mice elicits an acute weight loss that 
peaks at day 6-7 after infection. The inflammatory infiltrate into the airways is also 
maximal at this time point implying a strong correlation between illness severity and 
the exuberance of the host's immune response (Fig. 3.1a). By day 10 post infection 
pulmonary inflammation has largely subsided and mice have returned to their original 
weight. A significant extent of the observed illness and pathology evoked by 
influenza infection of the lung is attributable to the over-exuberance of the host's 
immune response. T cells are critical to viral clearance but are also a significant 
component of the observed pathology, causing occlusion of airways and producing 
inflammatory mediators that cause the observed cachexia and fever. The dependence 
of illness on T cell accumulation can easily be demonstrated by inhibiting the late co-
stimulatory signal delivered through 0X40 (Fig. 3.1b). Administration of a pegylated 
anti-0X40 blocking antibody significantly reduced weight loss following influenza 
infection of BALB/c mice (Fig. 3.1c). Those mice treated with the pegylated anti-
OX40 antibody also exhibited significantly reduced inflammatory infiltrate in their 
airways at day 7 post infection (Fig. 3.1d). Flow cytometric analysis confirmed that 
blockade of the 0X40 signal to the T cell reduces the number of CD4+ and CD8+ T 
cells in the airways (Fig. 3.1e), and their production of intracellular IFN-y and TNF 
cytokines (data not shown), 7 days after infection. 
3.2.2 Influenza infection elicits infiltration of myeloid populations into the lung and 
airways 
The dominance of T cells in influenza induced pathology is likely to be directly 
influenced by the activity of the myeloid compartment. Myeloid cells are central to 
the establishment and maintenance of the inflammatory response to infection by 
secreting cytokines and chemokines and presenting antigen to recruited T cells. 
Manipulation of different facets of the myeloid response to influenza may be 
beneficial in quelling the immune response and reducing pathology. The numbers of 
myeloid cells in the lung and airways of C57BL/6 mice infected with influenza was 
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Figure 3.1 Influenza infection induces weight loss and pulmonary inflammation that 
can be reduced by blocking the late T cell co-stimulatory molecule 0X40. (a) Mice 
were infected with 50HA influenza, BAL removed 2, 4, 7, 11 and 15 days after infection 
and total viable cells enumerated (right axis). Weight loss was monitored daily and 
expressed as % original body weight (left axis). (b) Pegylated anti-0X40 antibody binds 
0X40 on the T cell, blocking the interaction with the ligand on the APC and preventing the 
co-stimulatory signal which usually enhances T cell cytokine secretion, anti-apoptotic gene 
expression and clonal expansion. (c) BALB/c mice were infected with influenza virus, 
treated with a pegylated control antibody or pegylated anti-0X40 antibody on days 0 and 3 
and weight loss monitored and expressed as % original weight. BAL was removed at day 7 
and total viable cells enumerated by trypan blue exclusion (d), and the number of CD4+ and 
CD8+ T cells in the BAL calculated by multiplying the total cell numbers by the percent 
positive cells detected by flow cytometry (e). Closed symbols, control antibody treated 
BALB/c mice; open symbols, anti-0X40 antibody treated mice Results represent mean 
values ± SEM from 5 mice per group and are representative of 3 experiments. *=p<0.05, 
**—p<0.01. 
104 
* * 
* * I 
1 
I 
1 
I  
assessed by flow cytometry, with distinction primarily based upon differential 
expression of CD1 lb and CD1 1 c as described by Gonzalez-Juarrero et al 347 (Fig. 
3.2a and b). Cells were also sorted on the basis of differential CD1lb and CD11c 
expression and cytocentrifuged onto glass and stained with H and E to confirm their 
morphology (data not shown). Differential CD1 lb and CD1 1 c staining of a naive 
mouse lung, excluding lymphocytes, revealed four distinct populations: 
CD1 1 bintCD11 chi 	(R1), 	CD 1 1 bhiCD11 chi 	(R2), 	CD1lbintCD11c1° 	(R3), 
CD 1 lbhiCD1le (R4) (Fig. 3.2a). Cells in the region R1 exhibited the same 
CD1 lb/CD1 1 c profile as the majority of cells isolated in the BAL (Fig. 3.2b) of a 
naive mouse and appeared morphologically like alveolar macrophages (data not 
shown). Cells in region R2 were also determined to express low Gr-1 and high MHC 
II and appeared morphologically like dendritic cells, with cytoplasmic processes (data 
not shown). Cells in region R3 expressed an intermediate level of Gr-1 and appeared 
to be highly autofluorescent. Morphologically they were fairly small cells with horse-
shoe shaped nuclei and we believe them to be monocytic in nature. Finally, cells in 
region R4 also stained very strongly for Gr-1 and were negative for MHC II and 
appeared morphologically to be neutrophils, possessing multilobed nuclei (data not 
shown). This differential expression profile was subsequently utilised to distinguish 
between distinct myeloid populations during influenza infection. However, during the 
course of influenza infection macrophages within the lung up-regulate CD1 lb upon 
activation. Subsequently, activated macrophages were distinguished from neutrophils 
by differential Gr-1 staining. 
The number of each myeloid population was determined in the lung (Fig. 3.2c) and 
airways (Fig. 3.2d) at days 0, 2, 7 and 14 after influenza infection. The number of 
neutrophils in both the lung and airways appeared to peak at day 2 after influenza 
infection and had subsided significantly be day 7. The number of DCs was low 
throughout the course of infection and remained largely unaltered, although a small 
increase was seen at day 7 in the lung and airways. Alveolar macrophages exhibited a 
drop in numbers in the airways at day 2, possibly reflecting virus induced death, and 
were then shown to peak in the lung and BAL at day 14. The numbers of monocytes / 
small macrophages peaked at day 7 after infection in the lung and BAL. However, the 
most striking increase in myeloid infiltrate was the significant increase in the number 
of activated macrophages in the lungs and airways at day 7 after influenza infection. 
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Figure 3.2 Myeloid populations in the lungs of mice following intranasal infection 
with influenza. On days 0, 2, 7 and 14 after intranasal infection of C57BL/6 mice with 
influenza, lung and BAL cells were stained with anti-CD1 lb-PercP, anti-CD1 1 c-APC, 
anti-Gr- 1 -FITC and anti-MHC-II-PE. Representative dot plots of CD11b and CD11c 
expressing FSchighSSchigh myeloid cells from a naive lung (a) and BAL (b). R1 = alveolar 
macrophages, R2 = dendritic cells, R3 = small monocytes/macrophages, and R4 = 
granulocytes. Populations were further confirmed by differential Gr-1/Ly6G and MHC 
II expression. The total number of each myeloid population in the lung (c) and BAL (d) 
at different time points after influenza infection was subsequently determined by: % 
positive as adjudged by flow cytometry x total number of viable cells. Activated 
macrophages up-regulated CD1 lb and can be differentiated from granulocytes by the 
lower expression of Gr-1 and FSc/SSc profile. Results represent mean values ± SEM 
from 5 mice per group and are representative of 3 experiments. 
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3.2.3 Phenotypic characterisation of mice lacking gp9lphox (Cybb tml) 
After defining the recruitment of myeloid cells to the lung during influenza infection, 
we next examined the influence of depleting the phagocyte NADPH oxidase. Cybb 
tml mice lack the gp9lphox sub-unit of the NADPH oxidase and are subsequently 
incapable of generating superoxide through the respiratory burst. Much research 
utilising knock out mice fails to acknowledge the phenotype of the naïve animal and 
hence the ensuing repercussions on immunity to the infection of interest. We show 
that in the absence of infection, naïve Cybb tml mice exhibit a generalised 
inflammation with a Thl bias. There was a significant increase in cellular infiltrate in 
the lungs, Peyer's patch and spleen of naive Cybb tml mice (Fig. 3.3; Table 3.1). The 
increment in cell numbers in the lungs of Cybb tml mice was not as extensive as seen 
in the Peyer's patch and spleen, but became considerably more pronounced with 
increased age where airways were also affected (data not shown). 
Enhanced cellularity encompassed both the CD4+ and CD8+ T cells (Table 3.1), 
which were more activated in Cybb tml mice (defined as CD45RBI°, Fig. 3.4a and b), 
and produced significantly higher levels of intracellular IFN-y (Fig. 3.4c and d) and 
TNF (data not shown). The number of CD11b± myeloid cells (predominantly 
macrophages) in the lungs, Peyer's patches and spleens of the Cybb tml mice was 
also increased (Table 3.1 and Fig. 3.5a and b), an effect more significant with age, 
with the appearance of multinucleated giant cells (Fig. 3.5c). Hexagonal colourless 
crystals were observed in lung tissue of 4 month old mice either extra-cellular or 
intracellular imparting significant tissue disruption (Fig. 3.5d and e). 
It was therefore apparent that in the absence of any antigenic stimuli Cybb tml mice 
exhibited significant alterations in hematopoietic populations resident in the naive 
lung. Microarray analysis was subsequently utilised to investigate differential gene 
expression in the lungs of Cybb tml mice relative to wild type controls. RNA was 
extracted from the naïve lung of wild type or Cybb tml mice and directly labelled 
with Cy3 dCTP. The labelled RNA from the wild type or Cybb tml lung was 
subsequently mixed with Cy5 dCTP labelled universal mouse reference RNA and 
hybridised to a HGMP total mouse genome v2 array, which was subsequently 
scanned with Genepix 3000. Three biological replicates and two technical replicates 
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Lung 	 Peyers Patch 
	
Spleen 
Figure 3.3 Lymphoid organs of Cybb tml mice exhibit enhanced inflammation. 
Representative hematoxylin and eosin (H and E) stained lung, Peyer's patch and spleen 
sections of naive Cybb tml and wild type C57BL/6 mice (x200 magnification). 
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Lung Spleen Peyers Patch 
Total cell no. 2.78x105 +/-0.75 *  1.67x107 +/-0.17* * 
4.00x106 +/-1.70 
* 
8.20x105 +/-3.22 5.58x107 +/-0.31 7.97x106 +/-0.07 
CD4+ T cells 0.48xiO4 +/-0.02 *  2.75x106 4.18x105 +/-1.40 +/-0.29* * * 
4.55x104 +/-1.02 8.1x106 +/-0.24 6.07x105 +/-0.63 
CD8+ T cells 0.47x104 +/-0.01 1.41x106 +1-0.15* 1.16x105 +/-0.28 * * * 
1.02x104 +/-0.32 5.27x106 +/-0.17 2.78x105 +/-0.22 
CD11b+ Mac. 0.50x104 +/-0.09* * 3.09x105 +/-0.75* * 2.25x104 +1-0.55* * 
2.87x104 +/-1.25 22.26x105 +/-5.40 14.7x104 +/-2.65 
Table 3.1 Cybb tml mice contain enhanced cellularity in lymphoid tissue. 
Lungs, spleens and Peyer's patches were removed from naïve Cybb tml and wild type 
C57BL/6 mice and single cell suspensions obtained. Viable cells from each organ were 
determined by trypan blue exclusion. Single cell suspensions were stained with anti-
CD8-PercP, anti-CD4-APC, anti-Ly-6G-FITC, anti-MHC-II PE, anti-CD11b-Percp and 
anti-CD11 c-APC and the number of each population extrapolated from the total viable 
cell counts. Results represent the mean +/- SEM of 5 individual mice in 3 independent 
experiments. *=p<0.05, **=p<0.01 
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Figure 3.4 T cells from the lungs of Cybb tml mice show heightened activation and 
enhanced Thl cytokine production. Lungs were removed from naïve wild type 
C57BL/6 (closed symbols) and Cybb tml (open symbols) mice and single cell 
suspension stained with CD45RB-FITC, CD4-PercP and CD8-APC. (a) The percentage 
CD4 and CD8 T cells expressing CD45RBI° were determined by flow cytometry. (b) 
Representative histogram overlays of CD45RB expression on CD4+ and CD8+ T cells 
are shown for wild type (red) and knock out (blue) mice. Lung cells were also stained 
with CD4-PercP, CD8-APC and intracellular IFN-y-FITC. (c) The percentage CD4+ and 
CDS' T cells producing IFN- y were determined by flow cytometry. (d) Representative 
plots of lung CD4+ or CD8+ T cells versus IFN-7 expression in naïve wild type or Cybb 
tml mice. Closed symbols, wild type C57BL/6 mice; open symbols, Cybb tml mice 
Results represent mean values ± SEM from 5 mice per group. *=p<0.05, **=p<0.01. 
110 
4 • 
* * 
1• 
a. 	 b. 
0 
8 
0 
* * 
0 
c. 	 d. 	 e. 
Figure 3.5 Cybb tml mice have a heightened number of macrophages. 
Naïve wild type and Cybb mice were sacrificed and lung cells stained with Ly-6G-FITC, 
MHC-II-PE, CD11b-PercP and CD11c-APC. (a) The percent of cells that could be 
defined as macrophages were determined by flow cytometry. (b) Total number of 
macrophages in the lung was calculated by multiplying the percentage by the total 
number of viable cells. Closed symbols, wild type C57BL/6 mice; open symbols, Cybb 
tml mice Results represent mean values ± SEM from 5 mice per group. *—p<0.05, 
**=p<0.01. Mice that were in excess of 6 months old were harvested and lung and BAL 
analysed. Analysis of H and E stained cytocentrifuged BAL samples from naïve Cybb 
tml mice showed and abundance of multinucleated giant cells (c) that were absent in age 
matched wild type controls. Analysis of H and E stained lung sectioned revealed the 
presence of crystals (4— ), frequently stacked within macrophages and multinucleated 
cells (d) or lying extracellularly (e). 
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were performed for each of wild type and Cybb tml RNA. BlueFuse image analysis 
software (http://www.cambridgebluegnome.com/bluefuse.htm) was used to generate 
Cy3 and Cy5 expression values for the genes on each of the arrays. The BlueFuse 
output data was then imported into GeneSpring GXv7.3. The data was normalised 
using the Lowess algorithm and the normalised data was checked for any sample 
anomalies. All the arrays exhibited a good even normal distribution centred around 1 
on the log ratio scale (an assumption which should be satisfied for t-test to perform 
correctly), with no evidence of skewing and a similar spread of data. The Pearson 
correlation was used to develop a sample cluster tree, which is a useful indicator of 
how replicates are behaving. As would be expected the technical replicates had the 
highest level of correlation, but a good correlation (> 0.75) was also observed 
between biological replicate samples. The data was filtered on confidence, using the 
p-value (p < 0.05) of a t-test as the confidence value, with a Benjamini and Hochberg 
(BH) correction applied to reduce the false discovery rate. This was first applied to 
the wild type data to determine which genes were up-regulated and down-regulated 
with respect to the reference sample. This was repeated for the cybb arrays. It was 
apparent that a significant number of genes were specifically up-regulated (1416) 
(Fig. 3.6a) or down-regulated (1216) (Fig 3.6b) in the lungs of the Cybb tml mice. 
Therefore, the absence of a single gene, encoding the gp91 subunit of the phagocyte 
NADPH oxidase, alters the expression of a striking number of unrelated genes. 
Analysis into the differential expression in naïve wild type and Cybb tml mouse lung 
is on-going. 
3.2.4 Influenza infected Cybb tml mice exhibit heightened inflammation in their 
airways 
Having determined the phenotype of naïve Cybb tml mice, the profile of the immune 
response to intranasal influenza infection was characterised in the knock outs and wild 
type controls (for experimental protocol see Fig. 3.7). Cybb tml mice displayed 
enhanced weight loss compared to wild-type C57BL/6 mice in the early stages of 
infection (days 2-4), but were ultimately comparable to wild-type mice 6 days after 
infection (Fig. 3.8a). As discussed previously, weight loss during influenza infection 
is attributed largely to an over-exuberant immune response and release of Thl 
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Figure 3.6 Cybb tml mice show considerable gene dysregulation in the naive lung. 
RNA was extracted from the naive lung of wild type or Cybb tml mice and labelled with 
Cy3 dCTP. The labelled RNA from the wild type or Cybb tml lung was subsequently mixed 
with Cy5 dCTP labelled universal mouse reference RNA and hybridised to a HGMP total 
mouse genome v2 array. BlueFuse image analysis software was used to generate Cy3 and 
Cy5 expression values for the genes on each of the arrays. The BlueFuse output data was 
then imported into GeneSpring GXv7.3. The data was Filtered on Confidence, using the p-
value (p < 0.05) of a t-test as the confidence value, with a Benjamini and Hochberg (BH) 
correction applied to reduce the false discovery rate. This was first applied to the wild type 
data to determine which genes were up-regulated and down-regulated with respect to the 
reference sample. This was repeated for the cybb arrays. Venn diagrams were then used to 
determine which genes were or were not common to the differentially expressed up- and 
down-regulated cybb and wt groups. Venn diagrams are presented for genes that are up-
regulated (a) or down-regulated (b) in the experimental samples relative to mouse reference 
RNA. 
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Figure 3.7 Experimental protocol. 
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Figure 3.8 Influenza infected Cybb tml mice exhibit heightened inflammatory 
infiltrate in their airways. (a) C57BL/6 and Cybb tml mice were infected with influenza 
and weight loss monitored daily and expressed as a percent of original weight. (b) BAL 
was performed on days 0, 1, 3 and 7 and total viable cells enumerated by trypan blue 
exclusion. BAL cells were stained with CD4-PercP and CD8-APC and analysed by flow 
cytometry. The total number of CD4+ (c) and CD8+ (d) T cells in the airways were 
calculated by multiplying the percent positive cells as adjudged by flow cytometry by the 
total number of viable cells. Closed symbols, wild type C57BL/6 mice; open symbols, 
Cybb tml mice Results represent mean values ± SEM from 5 mice per group. *=p<0.05, 
**=p<0.01. 
115 
cytokines such as TNF-cc 268. Accordingly, the Cybb tml mice possessed greater 
numbers of cells in their airways from day 3 onwards (Fig. 3.8b). 
Flow cytometric analysis was utilised to determine the extent of T cell infiltrate into 
the airways of wild type and Cybb tml mice throughout the course of the influenza 
infection. The numbers of CD4+ and CD8+ T cells were low and comparable in the 
BAL of both groups of mice at day 3 after infection (Fig. 3.8c and d). Whilst the 
numbers of both T cells subsets increased dramatically by day 7 after influenza 
challenge in wild type and Cybb tml mice, the knock out mice possessed a 
significantly greater number of CD4+ T cells and a marginal increase in the number of 
CD8÷ T cells at this point relative to the wild type controls (Fig. 3.8c and d). Both the 
proportion (Fig. 3.9a and c) and total number (Fig. 3.9b and d) of activated CD4+ (Fig 
3.9a and b) , as defined as CD45RB1°, and CD8+ (Fig. 3.9c and d) T cells were 
increased 7 days after infection in Cybb tml mice compared to wild type controls. 
Furthermore, an increased percentage of CD4+ and CD8+ T cells were producing Thl 
cytokines IFN-y (Fig. 3.9e) and TNF (data not shown), in the airways of Cybb tml 
mice from day 3 of influenza infection. This in turn led to a significant increase in the 
total numbers of Thl cytokine producing T cells in Cybb tml mice by day 7 after 
influenza infection (Fig. 3.9f). 
The elevation of total cell numbers 3 days after influenza infection of Cybb tml mice 
was not explained by expanded T cell numbers unlike day 7. Instead, at day 3 
numbers of macrophages (Fig. 3.10a) and neutrophils (Fig. 3.10b) were increased, 
which correlated with higher levels of TNF, IL-6, and MCP-1 in the BAL (Fig. 3.11a-
c) and serum (Fig. 3.11e-g) and most likely explains the enhanced weight loss 
observed in Cybb tml mice relative to their wild type counterparts early in infection. 
Furthermore, elevated levels of IL-12 were present in the BAL of Cybb tml mice 
relative to wild type controls (Fig. 3.11d), which may lead to the observed Thl bias 
seen in the knock out mice. The heightened macrophage population may be 
responsible for the elevated 1L-12 in Cybb tml mice, although dendritic cells are 
generally the predominant source of this cytokine during influenza infection and it is 
plausible that the activity of this cell type is also modified. 
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Figure 3.9 Influenza infected Cybb tml mice possess heightened numbers of 
activated and Thi cytokine producing cells in their airways. BAL was performed on 
wild type and Cybb tml mice at day 7 after infection with influenza. BAL cells were 
stained with CD45RB-FITC, CD4-PercP and CD8-APC. The percent of CD4+CD45RBI° 
(a) and CD8+ CD45RB1° (c) T cells in the BAL were determined by flow cytometry. The 
number of CD4+ CD45RBI° (b) and CDS' CD45RBI° (d) T cells in the BAL were 
determined by: % positive cells x total viable cells. BAL cells were also stained with 
CD8-PercP, CD4-APC and intracellular IFN-y-FITC. (e) Representative plots of BAL 
CD4+ T cells versus IFN-y expression in wild type and Cybb tml mice at day 3 after 
influenza infection. (f) The number of CD4+ and CD8+ T cells producing IFN-y in the 
BAL at day 7 after infection were determined in wild type and Cybb tml. Closed 
symbols, wild type C57BL/6 mice; open symbols, Cybb tml mice. Results represent 
mean values ± SEM from five mice per group. *=p<0.05, **=p<0.01. 
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Figure 3.10 Influenza infected Cybb tml mice evoke a greater macrophage and 
neutrophil infiltrate into their airways. BAL was performed on wild type and Cybb 
tml mice at day 3 after influenza infection. The percentage of macrophages (a) and 
neutrophils (b) in the BAL of wild type (closed bars) and Cybb tml (open bars) mice was 
determined from H and E stained cytocentrifuged preparations and the number of each 
population calculated from total viable cell counts. Results represent mean values ± SEM 
from five mice per group. *=p<0.05, **=p<0.01. 
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Figure 3.11 Cybb tml mice produce heightened levels of pro-inflammatory 
cytokines at day 3 of influenza infection. Pro-inflammatory cytokines in the BAL (a-c) 
and serum (e-g) of influenza infected wild type (closed bars) and Cybb tml (open bars) 
mice at day 3 after infection were determined using the BD mouse pro-inflammatory 
cytometric bead array. The levels of IL-12 in the BAL was determined by ELISA (d). 
Results represent mean values ± SEM from five mice per group. *-p<0.05, 
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3.2.5 Influenza infected Cybb tml mice have reduced cellularity in the lung 
parenchyma 
Despite the heightened Thl inflammatory infiltrate observed in the airways of Cybb 
tml mice compared to wild type controls, the number of cells in the lung tissue itself 
was significantly reduced in the knock out mice (Fig. 3.12a). Hematoxylin and eosin 
stained lung sections revealed a striking reduction in perivascular and peribronchiolar 
infiltrate in Cybb tml mice at days 3 and 7 after influenza infection relative to wild 
type controls (Fig. 3.12b). Flow cytometric analysis revealed a significant reduction in 
both CD4+ and CD8+ T cells in the lung tissue of Cybb tml mice relative to wild type 
controls at day 7 after influenza infection (Fig. 3.13a and b, respectively). A greater 
percentage of those T cells present in the lung tissue, like in the BAL, of Cybb tml 
mice were in a heightened activation state (defined as CD45RBI°) relative to those in 
the lungs of wild type mice (Fig. 3.13c and e), but the total number of activated T 
cells was still significantly lower in Cybb tml mice (Fig. 3.13d and f). Similarly, the 
percentage of both CD4+ and CD8+ T cells producing Thl cytokines was higher in the 
lungs of Cybb tml mice than wild type controls, but again total numbers were still 
reduced (data not shown). This would imply that Cybb tml mice focus the immune 
response to influenza in the airways and not the parenchyma. Despite the general 
reduction in inflammatory infiltrate into the lung tissue of Cybb tml mice relative to 
wild type controls, the numbers of macrophages and neutrophils were comparable at 
this site (data not shown). 
3.2.6 Cybb tml exhibit improved influenza clearance and reduced lung damage 
Whilst a Thl immune response is the cause of extensive immunopathology during 
influenza infection, it is also a pre-requisite for viral clearance. It was intriguing to 
assess how the distinct immune profile observed in Cybb tml mice would affect 
resolution of viral infection. The peak viral titres in the lung of Cybb tml mice were 
significantly lower on day 3 post infection compared to wild type controls, and were 
undetectable at day 7 post infection in the knock out mice (Fig. 3.14a). The reduced 
viral titres within the lung tissue of Cybb tml mice may be a consequence of the 
heightened macrophage driven Thl response in the airways restricting viral 
replication and promoting clearance or the elevation of mucosal IgA we detected in 
the BAL (Fig. 3.14b) and nasal wash (Fig. 3.14c) of Cybb tml mice. IgG sub-types 
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Figure 3.12 Influenza infected Cybb tml possess reduced inflammatory infiltrate in the 
lung tissue. C57BL/6 and Cybb tml mice were infected with influenza and at days 1, 3 and 
7 after infection, BAL was performed and lungs removed. (a) Total viable cells were 
enumerated in the lung on days 0, 1, 3 and 7 after influenza infection by trypan blue 
exclusion. (b) Representative H and E stained lung sections from C57BL/6 and Cybb tml 
mice at days 3 and 7 after infection (x 200 magnification). Closed symbols, wild type 
C57BL/6 mice; open symbols, Cybb tml mice. Results represent mean values ± SEM from 
five mice per group. *=p<0.05, **=p<0.01. 
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Figure 3.13 Influenza infected Cybb tml possess a reduced T cell infiltrate in their 
lung tissue. (a) C57BL/6 and Cybb tml mice were infected with influenza and on days 
0, 1, 3 and 7 after infection lungs were removed. Single cell suspensions were stained 
with CD45RB-FITC, CD4-PercP and CD8-APC and analysed by flow cytometry. The 
total number of CD4+ (a) and CD8+ (b) T cells in the lungs were calculated by 
multiplying the percent positive cells as adjudged by flow cytometry by the total number 
of viable cells. The percent of CD4÷ CD45RB10 (c) and CD8+ CD45R131° (e) T cells in 
the lung tissue was determined by flow cytometry. The number of CD4+ CD45RBI° (d) 
and CD8+ CD45RB1° (f) T cells in the lung was determined by: % positive cells x total 
viable cells. Closed symbols, wild type C57BL/6 mice; open symbols, Cybb tml mice 
Results represent mean values ± SEM from 4 mice per group. *---p<0.05, 
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Figure 3.14 Cybb tml possess a reduced viral load and elevated IgA levels. 
(a) Wild type C57BL/6 and Cybb tml mice were infected with influenza and viral titres 
were assessed in lung homogenates by plaque assay on days 1, 3 and 7 after infection. 
BAL (b) and nasal washes (c) were performed on influenza infected wild type and Cybb 
tml mice at 7 days after infection and the levels of total IgA determined by ELISA. 
Closed symbols, wild type C57BL/6 mice; open symbols, Cybb tml mice Results 
represent mean values ± SEM from 5 mice per group. *- p<0.05, **=p<0.01. 
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in the BAL and serum, however, were similar in knock out and wild type mice (data 
not shown). 
Total protein (Fig. 3.15a) and lactate dehydrogenase (Fig. 3.15b) levels in BAL fluid 
were reduced in Cybb tml mice relative to wild type controls, reflecting a reduction 
in tissue damage. This could be a function of the reduced levels of ROS, the lower 
lung viral titres or the reduced inflammatory infiltrate resident to the lung tissue itself. 
Furthermore, whole body plethysmography was utilised to assess the lung function of 
both groups of mice at day 7 post influenza infection, and we observed an 
improvement in both the tidal volume (Fig. 3.15c) and peak expiratory flow (Fig. 
3.15d) in Cybb tml mice compared to wild type controls. 
3.2.7 Reduced apoptosis in influenza infected Cybb tml mice 
It was of interest to determine what caused the elevated myeloid response and T cell 
activation observed in Cybb tml mice in response to influenza infection. Since the 
generation of superoxide by phagocytes has been affiliated with the induction of 
apoptosis, we enumerated the number of Annexin CD11b+ myeloid cells and CD4+ 
and CD8+ T cells in lungs and airways of Cybb tml mice and found them reduced 
compared to wild-type controls (Fig. 3.16a). Furthermore, lung cells derived from 
Cybb tml mice exhibited a greater proliferative response to influenza antigen 
compared to those of wild type C57BL/6 mice, as determined by 3H-thymidine 
incorporation (Fig. 3.16b). Enumeration of CD200 expression provided another 
explanation for the heightened macrophage compartment in Cybb tml mice. CD200 is 
widely expressed by a number of cell types. Binding of CD200 to CD200R on 
myeloid cells delivers an inhibitory signal to myeloid compartment 67. Interestingly, 
Cybb tml influenza infected mice displayed a significant reduction in the levels of 
CD200 expression on the surface of B lymphocytes and CD4+ and CD8+ T cells (Fig. 
3.16c). 
3.2.8 Recall responses to influenza are not compromised in Cybb tml mice 
We next examined whether recall responses to a second influenza challenge was 
affected in Cybb tml mice. Wild type and Cybb tml mice were re-infected with 
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Figure 3.15 Influenza infected Cybb tml mice exhibit reduced lung damage and 
improved lung function. At day 7 after influenza infection BAL was removed and total 
protein (a) and LDH (b) measured in the supernatant. Whole body plethysmography was 
utilised to assess the tidal volume (c) and peak expiratory flow (d) of influenza infected 
wild type and Cybb tml mice at day 7 after infection. Closed bars, wild type C57BL/6 
mice; open bars, Cybb tml mice. Results represent mean values ± SEM from five mice 
per group. *=p<0.05, **=p<0.01. 
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Figure 3.16 Cybb tml mice exhibit reduced apoptosis, heightened proliferation and 
reduced levels of the myeloid inhibitory protein CD200. Lungs were removed from 
influenza infected wild type and Cybb tml mice at 7 days after infection and single cell 
suspensions obtained. (a) The percent apoptotic annexin V-stained CD1113+ myeloid 
cells, CD4+ and CD8+ T cells were assessed in wild type C57BL/6 and Cybb tml mice 
by flow cytometry. (b) Proliferation of lung cells to UV inactivated influenza was 
determined by 3H-thymidine incorporation. (c) Lung cells was stained with CD200-PE, 
CD4-FITC, CD8-APC and B220-PercP and the percent CD4+ and CD8+ T cells and B 
cells expressing CD200 was determined by flow cytometry. Closed symbols, wild type 
C57BL/6 mice; open symbols, Cybb tml mice Results represent mean values ± SEM 
from 5 mice per group. *=p<0.05, **=p<0.01. 
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influenza 35 days after a primary influenza infection. Three days after re-challenge 
influenza virus was undetectable in lung homogenates in wild type and Cybb tml 
mice (data not shown). Furthermore, no signs of illness or weight loss were observed 
(Fig. 3.17a). Cybb tml mice did, however, exhibit reduced lung inflammation, with 
decreased numbers of CD4+ and CD8+ T cells (Fig. 3.17b). Of those T cells present, a 
greater percentage were in a heightened activation state (CD45RB1°) (data not shown) 
and were producing Thl cytokines (Fig. 3.17c and d). The levels of influenza specific 
IgG1 and IgG2a in the serum were assessed by ELISA and found to be comparable 
between wild type and Cybb tml mice (Fig. 3.17e and f). 
3.2.9 The cell permeable mimetic MnTE-2-PyP prevents pulmonary inflammation 
during influenza infection 
Since multiple immune compartments are disrupted in Cybb tml mice we next tested 
whether comparable results were observed with a scavenger of ROS. MnTE-2-PyP is 
a cell permeable manganic-porphyrin that acts as a potent anti-oxidant and superoxide 
mimic, and has previously been reported to confer protection in a variety of oxidative 
stress injuries such as liver ischemia, diabetes and stroke. Mice administered with 25 
pg or 50 tig of mimetic on days 0 and 3 of influenza infection (Fig. 3.18) showed a 
comparable immune response to Cybb tml mice, with heightened cellularity in the 
airways and reduced inflammation of the lung tissue at day 7 after infection relative to 
control treated mice (Fig. 3.19a and c). Mice treated with MnTE-2-PyP exhibited 
significantly reduced perivascular and peribronchiolar infiltrate compared to PBS 
treated mice as depicted by H and E stained lung sections (Fig. 3.19b). Viral titres 
were slightly reduced by administering 25 lig mimetic although not significant, but 
actually heightened with a 50 pg dose (Fig. 3.19c). The increase in viral titres at a 
higher dose of mimetic may reflect the scavenging of ROS from other sources (such 
as xanthine oxidase) than just the phagocyte NADPH oxidase disrupted in Cybb tml 
mice. 
Similar to Cybb tml mice, MnTE-2-PyP caused a reduction in CD4+ and CD8+ T cell 
numbers in the lung parenchyma (Fig. 3.20a), but numbers of both T cell subsets were 
comparable in the airways (Fig. 3.20b). Of those T cells that remained in Cybb tml 
mice a greater percentage were producing intracellular Thl cytokines relative to PBS 
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Figure 3.17 Cybb tml mice show reduced pulmonary T cell infiltrate upon 
secondary exposure to influenza, but antibody production is not compromised. 
Wild type C57BL/6 and Cybb tml mice were infected with influenza, left for 4 weeks 
and re-infected with influenza and weight loss monitored daily and expressed as a percent 
of original weight (a). After 3 days post influenza re-challenge, BAL was performed and 
lungs removed and single cell suspension stained with CD8-PercP, CD4-APC and 
intracellular IFN-y-FITC. Total numbers of lung CD4+ and CD8+ in wild type (solid bars) 
and Cybb tml(open bars) mice were determined by multiplying the percent of positive 
cells by flow cytometry by the total number of viable cells as determined by trypan blue 
exclusion (b). The percentage of CD4+ (c) and CD8+ (d) T cells producing IFN-y was 
determined by flow cytometry. At day 3 after influenza re-challenge, the levels of 
influenza specific IgGi (e) and IgG2a (f) were measured in the serum by ELISA. Closed 
symbols, wild type C57BL/6 mice; open symbols, cybb tml mice. Results represent mean 
values ± SEM from five mice per group. *=p<0.05, **=p<0.01. 
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Figure 3. 18 Experimental Protocol. 
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Figure 3.19 MnTE-2-PyP administration to influenza infected mice provides a 
comparable immune profile to that seen in Cybb tml mice. (a) Control (closed bars) 
and MnTE-2-PyP (open bars) treated C57BL/6 mice were infected with influenza and 
the number of viable cells in the lung and BAL after 7 days determined by trypan blue 
exclusion. Results are shown for treatment with 251.tg and 50}_ig of MnTE-2-PyP. Closed 
bars, PBS treated; open bars, MnTE-2-PyP treated. Results represent mean values ± 
SEM from five mice per group. (b) Representative H and E stained lung sections from 
PBS treated and MnTE-2-PyP (25pig) treated C57BL/6 mice 7 days after infection (x 200 
magnification). (c) The relative numbers of cells in the lung (open bars) and BAL 
(closed bars) and viral titres (dotted line) is expressed as a ratio of cell numbers or viral 
titre in the Cybb tml or MnTE-2-PyP treated mice over the number in wild-type or PBS 
treated mice, respectively. *—p<0.05, **-p<0.01. 
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Figure 3.20 MnTE-2-PyP treated mice exhibit reduced T cell infiltrate in lung tissue 
but an elevated macrophage response. Control and MnTE-2-PyP (251.tg) treated 
C57BL/6 mice were infected with influenza and the number of viable cells in the lung 
and BAL after 7 days determined by trypan blue exclusion. Cells were stained with 
CD4-PercP and CD8-APC and the total number of each T cell subset in the lung (a) and 
BAL (b) determined by multiplying the percent positive, as adjudged by flow cytometry, 
by the total number of viable cells. Cells were also stained with Gr-l-FITC, CD1 lb-
Percp and CD11c-APC and the percent macrophages in the lung (c) and BAL (e) 
determined by flow cytometry. The total number of macrophages in the lung (d) and 
BAL (f) was determine by: percent positive x total number of viable cells. (g) 5 x105 
J774 macrophages were incubated in medium alone, IFN-y, LPS or influenza. Some 
macrophages, as indicated, were also incubated with MnTE-2-PyP. After 48 hrs 
macrophages were stainined for Annexin-V. Closed symbols, untreated mice; open 
symbols, MnTE-2-PyP treated mice. Results represent mean values ± SEM from five 
mice per group. *--p<0.05, **=p<0.01. 
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treated controls (data not shown) although this was not as striking as seen in Cybb 
tml mice and failed to be significant. However, the macrophage response induced by 
influenza infection was greater in mice treated with MnTE-2-PyP, with a greater 
percentage of the cellular infiltrate present in the lung and airways being macrophages 
(Fig. 3.20c and e). Ultimately, the total number of macrophages present in the lung 
tissue was comparable in treated and untreated mice (Fig. 3.20d) but significantly 
greater in the airways of MnTE-2-PyP treated mice (Fig. 3.200. It was also 
demonstrated that J774 macrophages exhibited reduced apoptosis in response to an 
array of stimuli when incubated in the presence of MnTE-2-PyP, as adjudged by 
staining with Annexin-V (Fig. 3.20g). This supports our findings from Cybb tml mice 
that ROS have a critical role in controlling macrophage apoptosis. 
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3.3 Discussion 
3.3.1 Modulation of myeloid cells in influenza infection 
This chapter has shown that exaggerated immune responses contribute significantly to 
lung pathology. Blockade of the co-stimulatory signal delivered through OX40 to the 
T cell with a pegylated blocking antibody ameliorates weight loss and significantly 
reduces the T cell infiltrate into the airways. Since the early myeloid response will 
ultimately dictate the induction and potency of the acquired immune response 
targeting such cells could prove a powerful strategy of immune manipulation. One 
facet of the myeloid response to pathogenic infection is the generation of ROS 
through the phagocyte NADPH oxidase. The potential of ROS to elicit direct 
immunopathology as well their pleiotropic functions in immune modulation and 
inflammation makes them ideal targets for immunotherapies that seek to alleviate 
influenza driven illness and pathology. 
3.3.2 Characterisation of naïve Cybb tml mice 
The preceding results show that Cybb tml mice, a murine model for X-linked chronic 
granulomatous disease, display a pronounced augmentation in inflammatory infiltrate 
in mucosal sites such as the lung and peyers patch, as well as in the spleen in the 
absence of infection. The expanded macrophage population in naïve animals is 
associated with an increase in activated T cells producing IFN-y and TNF. The 
influence on macrophages becomes more pronounced with increasing age with the 
appearance of multinucleated giant cells, which form by the fusion of monocytes or 
macrophages, but little is known about the fusion process itself 348. It is hypothesised 
that multinucleated giant cells have an advantage in microbicidal activity over 
macrophages; in part due to enhanced oxidative capacity 349. The abundance of these 
cells in Cybb tml mice is most likely attributable to a condition known as acidophilic 
macrophage pneumonia which has been reported to be common in 
immunocompromised mice by 6 months of age 350, and has actually been cited to 
occur in very old Cybb tml mice 351. Another feature of older naïve Cybb tml mice is 
the abundance of crystal like structures within their respiratory system. Unstained the 
crystals appeared colourless and were of varying sizes and hexagonal in shape, but 
with H and E staining the crystals were pink denoting their positive charge and 
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ensuing attraction of eosin. The crystals were found both extra-cellularly and located 
intra-cellularly within the macrophages and multinucleated giant cells, frequently in 
stacks and distorting the natural morphology of the cell. It has previously been 
suggested that these crystals represent a protein known as Yml which possesses 
homology with chitin 352. Acidophilic macrophage pneumonia is again characterised 
by accumulation of macrophages that are laden with such crystals, and hence are 
again an artefact of macrophage dysfunction 351. 
The general systemic state of heightened inflammation in Cybb tml mice may imply 
a pre-disposition to infection by some other pathogen, and susceptibility to A. 
fumigatis, Paecilomyces sp., Peudomonas aeruginosa and Enterococcus has been 
noted 351  However, Cybb tml mice utilised in all experiments were confined in strict 
pathogen free conditions and regularly screened for infection by the most common 
murine pathogens. Heightened reactivity to commensal organisms however cannot be 
ruled out. Indeed, multinucleated giant cells display enhanced microbicidal activity 
against natural fauna 349 such as Candida albicans, and hence as the Cybb tml mice 
age there may be an increase in macrophages and multinucleated giant cells in an 
attempt to control lung fauna. 
It is also plausible that ROS fulfil a role in the macrophage homeostasis even in the 
absence of infection. ROS are linked with apoptosis through the non-specific 
bystander damage they evoke onto lipids, proteins and nucleic acids, the release of 
cytochrome c from mitochondria and the activation of caspase-3 60'62'353. ROS may 
therefore assist self-enforced homeostasis of cell numbers by apoptosis in the absence 
of infection explaining the enhanced cellularity we observed in Cybb tml mice. A 
lack of immune regulation could also explain the enhanced susceptibility of patients 
suffering from CGD to autoimmune disorders such as lupus and polyarthritis 354. It is 
generally acknowledged that ROS have a detrimental role in the progression of 
rheumatoid arthritis, with SOD administration proving beneficial in arthritis induced 
by streptococcal cell wall components or immunization with collagen type II and the 
observed reduction in joint inflammation in mice given apocynin (an NADPH oxidase 
inhibitor) 355-361  Experimental arthritis induced by intra articular zymosan or poly-L-
lysine coupled lysozyme is significantly enhanced in mice lacking a functional 
phagocyte NADPH oxidase, with more severe joint inflammation, granulomatous 
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synovitis and multinucleated giant cell accumulation 361  These discrepancies could be 
attributable to the defect that develops in knock-out mice owing to a lack of 
homeostatic control in the absence of NADPH oxidase derived superoxide. 
We show considerable dysregulation in gene expression in the lungs or Cybb tml 
mice by microarray analysis. Whilst investigation into this differential gene 
expression is in it's infancy it is clear that the absence of the cybb gene, encoding the 
gp9lphox sub-unit of the phagocyte NADPH oxidase, results in the up-regulation and 
down-regulation of a significant number of genes in these knock out mice. This likely 
reflects in part the significant role fulfilled by ROS in immune regulation. In addition 
to their potent anti-microbial activity, ROS also possess a significant cell-signaling 
role in biological systems, capable of regulating the phenotype and function of 
immune cells 60,62,325  Even in a naive animal it would appear that ROS may fulfil a 
role in regulating gene expression. These analyses may facilitae our understanding of 
why people with CGD exhibit aberrant inflammatory responses and an increased 
susceptibility to autoimmune conditions. Furthermore, it proves an important point 
that the depletion of a single gene in knock out animals can have serious 
repercussions in dictating expression of other genes even in a naive setting. This 
altered resting state phenotype should always be considered when utilizing knock out 
or transgenic animals to elucidate the role of a specific gene. 
Infection of Cybb tml mice with influenza provided the opportunity to assess the role 
of phagocyte derived oxidants in the resolution of this strongly Thl skewed viral 
infection, for which there have been discrepancies concerning the protection and 
pathology afforded by ROS. Furthermore, we can gain insight into whether the 
dysfunctional immune regulation is persistent and modulated following such an 
infection and how the immune response may be modulated in patients suffering from 
CGD. 
3.3.3 Heightened cellularity in the airways of Cybb tml and MnTE-2-PyP treated 
mice in response to influenza 
Cybb tml mice exhibited heightened cellularity in the airways in response to 
influenza infection from day 3 onwards with a pronounced early increase in 
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macrophage and neutrophil numbers and an increased T cell infiltrate by day 7. It is 
important to stress that the augmented infiltrate seen in Cybb tml mice compared to 
wild type controls is significantly greater in infected mice than that seen in the naïve 
animals. Similarly, MnTE-2-PyP treated mice elicited a greater macrophage response 
in their airways in response to influenza infection. This increase in numbers of 
macrophages and neutrophils may arise due to a reduction in apoptosis. We report 
reduced apoptotic macrophages in influenza infected Cybb tml mice, and reduced 
apoptosis of J774 macrophages to an array of stimuli when incubated in the presence 
of the ROS scavenger MnTE-2-PyP. In support of our observations neutrophils from 
CGD patients demonstrate reduced spontaneous and Fas-induced apoptosis in vitro 
compared to those derived from healthy individuals 325. Furthermore, oxidants fulfil 
an important function in phosphatidyl serine exposure on neutrophils and their 
subsequent clearance by macrophages 362. 
Alternatively, enhanced macrophage activity could also be explained by reduced 
inhibitory signals from other immune cells. For example, we observed reduced 
expression of CD200 on B cells, CD4+ and CD8+ T cells in the lung of Cybb tml 
mice infected with influenza. CD200 delivers an inhibitory signal on binding CD200 
receptor on the surface of myeloid cells 363 and CD200 knock out mice display a 
similar phenotype to Cybb tml mice with heightened macrophage numbers and a Thl 
bias 364. CD200 is up-regulated on apoptosing cells to restrict the induction of 
inappropriate inflammatory sequelae by the phagocytosing macrophage 365. Therefore, 
a reduction in apoptosis and CD200 may in turn hinder the ability to switch off 
myeloid cells. 
The enhanced cellularity we describe to viral infection in NADPH oxidase knockout 
mice is also evident during bacterial 54,330  and fungal 53'54 infection. Furthermore, 
NADPH oxidase knockout mice exhibit enhanced inflammatory gastritis, and sterile 
heat killed fungal products cause excessive inflammation in the lungs. The phagocyte 
oxidase may therefore fulfil some anti-inflammatory role and of significance it has 
been implicated in oxidatively inactivating chemotactic factors 366, inducing anti-
inflammatory cytokine production by neutrophils and macrophages 367 and in 
modulation of Thl cytokine production 368. However, it is pertinent to question the 
extent to which the heightened inflammatory infiltrate present in the naïve knock out 
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mice dictates the potency of the subsequent response to infection. Do the augmented 
macrophage numbers and Thl skewed immunity facilitate a more exuberant response 
to influenza challenge? The similarities in immune phenotype between Cybb tml 
mice and those treated with MnTE-2-PyP would imply that this is not solely the case, 
although could explain why the heightened cellularity is more potent in the knock 
outs than in those treated with mimetic. 
3.3.4 Reduced cellularity in the lungs of Cybb tml and MnTE-2-PyP treated mice in 
response to influenza 
Despite the significantly enhanced cellularity in the airways of Cybb tml mice, the 
lungs of these mice exhibited a marked reduction in inflammatory infiltrate compared 
to those of wild-type controls. However, it should be noted that regardless of the 
general reduction in inflammation in the lung tissue the number of macrophages 
remained comparable and there persisted to be an augmentation in the percentage of 
activated T cells producing Thl cytokines. The reduction of inflammation in the lung 
despite heightened cellularity in the airways is interesting and may be explained by: 
1) better containment of influenza in the airways such that cells do not accumulate in 
the lung tissue and/or 2) faster movement of cells from the blood, through the lung 
parenchyma and into airways, especially since the absence of ROS would release 
chemokines from oxidative inactivation 366. 
Influenza induces apoptosis in macrophages and neutrophils, partially through the 
generation of ROS in these cells. Since apoptosis of myeloid cells was reduced 
leading to elevated numbers of macrophages and neutrophils in the airways early 
infection, it is plausible that influenza was contained within the airways without 
requirement for further cellular recruitment. The heightened 'Thl environment seen in 
the absence of ROS will act to further promote and activate resident macrophages. 
Indeed, elevated levels of TNF, IL-6, MCP-1 and IL-12 in the airways at day 3 of 
influenza infection in Cybb tml mice were observed. 
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3.3.5 Reduced influenza titres in the absence of a functional NADPH oxidase 
We show that the absence of a functional phagocyte NADPH oxidase results in 
reduced lung viral tires. Though we are the first to document the accelerated clearance 
of a viral infection in the absence of NADPH oxidase, a similar effect during 
Helicobacter pylori infection has previously been demonstrated, with knock out mice 
exhibiting an enhanced inflammatory gastritis and reduced bacterial load 369. This 
effect, however, is not observed for all pathogens. Despite amplified macrophage 
reactivity in CGD patients increased susceptibility to Aspergillus fumigatus and 
Staphylococcus aureus arise 54. Furthermore, mice lacking a functional phagocyte 
oxidase exhibit compromised clearance of Escherichia coli 330, impaired host defence 
to Pseudomonas pneumonia 331, and a transient loss of resistance to pulmonary 
tuberculosis 332. The divergent effects upon protection to different infections may 
depend on whether the pathogen has developed sophisticated strategies for avoiding 
intracellular killing machinery. 
Improved viral clearance in Cybb tml mice may be explained by heightened immune 
activation in the airways facilitating clearance. Macrophages are critical to the 
establishment and maintenance of the host's protective response to influenza. 
Activated macrophages are capable of phagocytosing infective virions and producing 
Type I IFNs that are critical in conferring viral protection. Furthermore, a Thl 
response is imperative to the resolution of an influenza infection, and Cybb tml mice 
display enhanced numbers of activated T cells producing Thl cytokines in their 
airways. Finally, the role of IgA in conferring protection to influenza is significant, 
and elevated levels of this antibody were measured in the BAL and nasal washes of 
Cybb tml mice during influenza infection. The elevated levels of IgA in these mice 
may also reflect the heightened macrophage response, with potentially augmented 
levels of CD40 and IL-6, which is known to induce differentiation of B cells into 
antibody producing plasma cells. 
Alternatively, the absence of ROS could lead to the reduced titres of influenza due to 
the ability of these species to modulate the infectivity and replication of the virus 
itself. Low levels of ROS may facilitate viral replication because of their mitogenic 
effects on cells, with most viruses growing better in proliferating cells. Alternatively, 
another plausible explanation could be the potential role of superoxide in promoting 
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viral infectivity by inactivating the anti-proteases that prevent cleavage of the 
influenza attachment HAO protein to HA1/HA2 338,339  Only viruses expressing 
HA1/HA2 are infective and the higher the proportion of infective virions, the faster 
the virus will spread throughout the lungs and airways 
Mice treated with MnTE-2-PyP did not show the improved viral clearance seen in 
Cybb tml mice. At a lower dose the levels of virus were marginally lower in treated 
relative to untreated mice. At higher doses of MnTE-2-PyP, however, viral clearance 
was compromised. This would imply that ROS do in fact have some virucidal role 
against influenza, and the compromised clearance observed with mimetic may reflect 
its capacity to scavenge ROS from other sources than the NADPH oxidase, such as 
xanthine oxidase. It is plausible that NADPH oxidase and xanthine oxidase systems 
are mutually redundant and that pathogen clearance is only compromised if both are 
absent, similar to that reported for Burkholderia cepacia 37°. In this scenario, ROS 
may fulfil some virucidal role but the levels generated through xanthine oxidase are 
sufficient to deal with the virus, or the heightened macrophage respOnse and Thl bias 
can compensate for the reduction in ROS. 
3.3.6 The role of ROS in T cell responses and the Thl / Th2 paradigm 
Another salient feature of the naive Cybb tml lung was the heightened activation of 
the resident T cell population, which was more pronounced after influenza infection. 
A slight increase in T cell activation was observed in MnTE-2-pyP treated mice 
although it failed reach significance. Signals delivered by the larger population of 
macrophages in the lungs and airways of Cybb tml mice could enhance the 
recruitment of pulmonary T cells populations or elevated T cells may reflect the 
observed reduction in apoptosis and enhanced proliferation. ROS have been linked to 
T cell hypo-responsiveness with peroxynitrite (formed by the reaction of superoxide 
with nitric oxide) inhibiting T cell activation and proliferation by nitrating tyrosine 
residues in downstream TCR signalling molecules 371. Similarly manganic porphyrins 
with anti-oxidant ability (such as the mimetic used in our study) protect T cells from 
superoxide generation and apoptosis 372. Thus it can be envisaged how a reduction in 
the levels of ROS would facilitate the observed increase in T cell numbers and 
activation. 
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The enhanced Thl phenotype observed in Cybb tml and mimetic treated wild type 
mice is likely to reflect the heightened levels of IL-12 production observed. The 
mimetic used in this study reduces eosinophilia in a mouse model of asthma, implying 
a potential for ROS in defining the Thl/Th2 paradigm 373. A role for superoxide in 
maintenance of homeostasis and in immune regulation is reminiscent of the potential 
of nitric oxide to exert immunosuppressive capabilities. NO has been shown to inhibit 
T cell proliferation during the Gl/S transition490. Furthermore, NO may also govern 
the balance of the Thl/Th2 paradigm, with mice lacking iNOS developing an 
enhanced Thl response491 and peritoneal macrophages from these mice generating 
elevated levels of IL-12492. ROS/RNS are highly potent and toxic mediators with the 
potential to be detrimental to bystander tissue. Consequently, low levels of such 
mediators may play a role in minimising or blunting the immune response to prevent 
heightened, potentially damaging, production of themselves. 
3.3.7 Conclusion 
In summary, mucosal sites must efficiently respond to harmful organisms but not the 
myriad of other harmless antigens. The data presented suggests that ROS may fulfil a 
fundamental role in making this distinction: low basal levels acting in an autocrine 
manner to induce a homeostatic or immunosuppressive role, whereas up-regulation 
after a more serious threat directs the establishment of an inflammatory response. The 
absence of ROS results in improved illness during influenza infection, with reduced 
inflammation of the lung parenchyma, reduced viral titres and oxidative stress, 
ultimately leading to reduced lung damage, as denoted by the reduced levels of total 
protein and LDH in the BAL wash, and improved lung function. This may also be 
advantageous in improving resistance to bacterial co-infections, which are believed to 
gain a foothold as a consequence of the extensive cytopathology caused by the virus, 
and the immune response to it. In particular, the respiratory burst induced in 
neutrophils by influenza is thought to induce apoptosis and hence limit the 
bactericidal capacity of these important cells. The Cybb tml mice also seem to 
respond equally well to an influenza re-challenge, with negligible weight loss and 
rapid resolution of viral burden, with a reduced T cell recruitment into the lung. 
MnTE-2-PyP could therefore offer therapeutic potential by evoking a "poised" 
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macrophage and subsequent development of Thl mediated immunity that is better 
equipped to limit influenza virus replication resulting in reduced lung consolidation 
and bystander tissue damage. 
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Chapter 4 — The Role of Reactive Oxygen Species in 
Pulmonary Cryptococcus neoformans infection 
4.1 Introduction 
4.1.1 The role of ROS in pulmonary fungal infection 
The protection afforded by reactive oxygen species (ROS) to respiratory fungal 
pathogens has been highlighted by the enhanced susceptibility of CGD patients to 
infection with Aspergillus fumigatus 53. A. fumigatus is capable of eliciting disease in 
mice lacking the NADPH oxidase at significantly lower doses than in wild type 
controls, and higher doses of this fungal pathogen prove fatal to Cybb tml knock out 
mice 53. Similarly, phagocytes unable to generate superoxide exhibit reduced ability to 
kill C. albicans 374'375 and Sporothrix schenckii infection of CGD mice leads to 
systemic infection and death 374. 
Despite the recurring fungal infections in CGD patients, there are no clinical studies 
showing enhanced susceptibility to C. neoformans. There are discrepancies regarding 
the efficacy of superoxide and its derivatives in the eradication of C. neoformans, yet 
there is cited evidence defining the potential of PMNs and macrophages to kill the 
organism by oxidative mechanisms 251. Furthermore, this fungus displays an array of 
protective mechanisms (Superoxide Dismutase (SOD), mannitol, melanin) to confer 
resistance to ROS, suggesting that in some instances they may be toxic and adverse to 
its survival. C. neoformans deficient in melanin exhibit reduced virulence in vivo 3765 
and CuSOD lacking mutants are more susceptible to oxygen radicals in macrophages 
377.  
4.1.2 Murine models of C. neoformans: protection versus patholog. 
The genetic background of the inbred mouse strain determines the outcome of the 
immune response to C. neoformans. Some murine strains (CBA, C.B-17 and 
BALB/c) are inherently resistant to infection, producing significant levels of Thl 
cytokines that confer protection 252-254 Conversely, other strains (C57BL/6, C3H and 
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B10-D2) are susceptible to C. neoformans, producing significantly lower levels of 
Thl cytokines and developing a Th2 driven pulmonary eosinophilia 255. These mice 
fail to clear infection and the fungus disseminates to extra-pulmonary tissues. 
Furthermore, the chronic eosinophilia leads to tissue damage as a result of 
degranulation and crystal deposition. These murine models emphasize the clear 
dichotomy that exists between a protective Thl response and a non-protective Th2 
response 
4.1.3 The role of ROS in defining the Thl / Th2 paragigm 
Several studies have demonstrtaed that NADPH knock out mice do not show a shift in 
T cell cytokine responses. Although p47phox-/- mice show reduced clinical signs of 
EAE, this was not attributed to any change in bias of Th subsets 378. Similarly, 
p47phox-/- mice display a normal cytokine response to Mycobacterium avium (potent 
stimulus of Thl responses) and Schistosoma mansoni eggs (elicits Th2 mediated 
granuloma) 379. However, this lack of an effect is not true for all scenarios. King et al 
have demonstrate a role for oxidative stress in defining human T cell differentiation to 
Thl/Th2 subsets, with DMNQ (induces oxidative stress) shown to cause the up-
regulation of Th2 cytokines IL-4, IL-5 and IL-13 but not Thl cytokines 38°. Similarly, 
exposure of peripheral blood T cells to anti-oxidant Vitamin E reduces IL-4 
production, intake of Vitamin E reduces IgE serum levels and allergic asthma is 
linked to a low intake of anti-oxidant vitamins 20,21,25.  Furthermore, in a model of 
experimental arthritis, NADPH oxidase knock out mice display increased TNF and 
IL-1 381 and we have previously seen an enhancement of Thl responses in Cybb tml 
mice to influenza. 
4.1.4 Hypothesis 
The prevalence of fungal infections amongst patients suffering from chronic 
granulomatous disease implies that ROS are critical to the control and eradication of 
fungal pathogens. Whilst this appears to be the case with certain fungi, such as A. 
fumigatus, there is little conclusive data defining the role of ROS in protection versus 
pathology in an in vivo model of C. neoformans infection. We have demonstrated that 
ROS would appear to fulfil a role in dictating the Thl / Th2 paradigm, with 
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deprivation of these mediators leading to enhanced macrophage numbers and Thl 
bias. A Thl driven immune response to C. neoformans is protective, with a Th2 
response giving rise to unchecked fungal growth and dissemination to the brain. It is 
anticipated that the absence of ROS, either through the utilisation of Cybb tml mice 
or administration of MnTE-2-PyP, may therefore paradoxically prove beneficial in the 
control of this respiratory fungal pathogen. 
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4.2. Results 
4.2.1. C. neoformans infection of C57BL/6 mice induces pulmonary infiltrate 
consisting of T cells and eosinophilia 
Intranasal infection of C57BL/6 mice with C.neoformans elicits a non-protective Th2-
dominated immune response in the lung characterized by extensive pulmonary 
eosinophilia 255. We first characterized the kinetics of this infection over a 48-day 
time-course experiment. C. neoformans burden peaked at 14 days after infection 
following exponential growth from day 3 (Fig. 4.1a). As reported previously, 
C57BL/6 mice do not clear the pathogen completely and C. neoformans was still 
present in the lungs 48 days post-infection. Pulmonary eosinophilia is associated with 
C. neoformans infection in this mouse strain. The accumulation of eosinophils in the 
airways (Fig. 4.1a) and lung tissue (not shown) closely mirrored that of fungal burden. 
It is interesting to note that percent eosinophilia preceded that of peak pathogen 
burden. This probably reflects the fact that only low antigen doses are required to 
induce their recruitment. Eosinophilia was evident in H and E stained lung sections 11 
days post-infection with extensive eosinophilic accumulation around the 
peribronchiolar and, to a lesser extent, the perivasular regions of the lung (Fig. 4.1b). 
C. neoformans also elicited a substantial expansion of both CD4+ and CD8+ T cells. 
The increase in T cell numbers in the lung also peaked at the time of maximum 
pathogen burden and pulmonary eosinophilia (Fig. 4.1c). The number of CD4+ T cells 
at this time was approximately ten times higher than that of CD8+ T cells, underlining 
the CD4+ T cell dominated response in this mouse strain; which probably reflects the 
extracellular life cycle of this pathogen. 
4.2.2 Manipulation of the innate immune compartment can promote immunity to C. 
neoformans through induction of a Thl dominated response 
Protective immunity to C. neoformans critically depends on the development of a Thl 
driven response, with depletion of Thl cytokines being shown to severely compromise 
resolution of infection 252-254  Immune manipulation that promotes immunity to C. 
neoformans or encourages a more protective Thl response offers a plausible 
immunotherapeutic strategy. Modulation of the T cell response to C. neoformans has 
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Figure 4.1. C. neoformans infection of C57BL/6 mice induces eosinophilia 
and pulmonary T cell inflammation. Mice (n=5) were infected with C. 
neoformans and on days 3,7,11,14,19 and 48, BAL and lung tissue were 
removed. (a) Cryptococcocal cfus were measured from lung homogenate and 
percent BAL eosinophilia was enumerated from forward/side scatter 
properties by flow cytometry and confirmed by eosinophil enumeration of 
cytocentrifuged BAL fluid. (b) Lungs from infected mice 14 days after 
infection were inflation fixed with formalin and stained with H and E. 
Eosinophils are indicated by arrows. (c) Total numbers of CD4+ and CD8+ T 
cells were calculated by multiplying percent positive by total numbers of lung 
lymphocytes. Results represent mean values ± SEM and are representative of 
at least 5 experiments. 
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been demonstrated to improve pathogen clearance 313, but would manipulation of 
earlier innate immune compartments offer a similar or greater effect? 
We have shown that a modified bacterial labile toxin (LTK63) affords protection 
against an array of subsequent respiratory pathogens 382. Administration of intranasal 
LTK63 two weeks prior to infection with C. neoformans greatly reduces pathogen 
driven pulmonary inflammation as evident in of H and E stained lung sections (Fig. 
4.2a). Furthermore, clearance of C. neoformans within the lung is actually improved 
at day 12 after infection (Fig. 4.2b). This reduced inflammation and improved 
pathogen clearance correlates with the development of a more pronounced Thl 
response and a reduction in airway eosinophilia (Fig. 4.2c). The protective effect 
conferred by LTK63 lasted for up to 12 weeks after administration and is associated 
with the maturation of myeloid cells (data not shown). The protective effects conferred 
by LTK63 does not depend on T and B cells, since innate imprinting can be induced in 
mice lacking T and B cells (RAG knock out mice) (data not shown). 
Similarly, 	administration 	of 	Cytosine-phosphate-guanosine-containing 
oligodeoxynucleotides (CpG ODN) confers protection against pulmonary challenge 
with C. neoformans 383. CpGs are motifs present within bacterial DNA that are 
recognized by TLR 9 on the surface of a variety of cells of the innate immune system. 
Immunization with CpG ODN 3 days prior to intranasal challenge with C. neoformans 
greatly reduces the pathogen burden within the lung (Fig. 4.3a) and BAL (data not 
shown) and reduces dissemination to the brain (data not shown) 12 days after 
infection. This promotion of anti-cryptococcal immunity was attributable to a shift in 
the immune phenotype from a Th2- toward a Thl -type response with a significant 
reduction in eosinophilia in the lung (Fig. 4.3b) and BAL (data not shown). 
Intracellular cytokine staining revealed a significant shift in the ratio of IFN-y to IL-5 
production by CD4+ and CD8+ T cells, with significantly more IFN-y production in 
those mice treated with CpG ODN (Fig. 4.3c and d). This improved pathogen 
clearance is T cell-independent and may reflect a direct effect of CpG on enhancement 
of macrophage antimicrobial activity. These strategies clearly demonstrate that 
manipulation of the innate immune compartment offers clear therapeutic potential 
against C. neoformans. 
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Figure 4.2. LTK63 administration to C. neoformns infected mice 
improves lung histology and enhances pathogen clearance from the lung 
with a concomitant reduction in eosinophilia. Mice were given PBS or 5 
i_tg of LTK63 intranasally 2 weeks before C. neoformans. Lungs were 
formalin fixed and embedded in paraffin at day 12, and sections were stained 
with H&E (a). Pathogen titers were enumerated in C. neoformans-infected 
mice at day 12 after infection (b). LTK63 treatment before C. neoformans 
infection of C57BL/6 mice also reduced the proportion of eosinophils in the 
airways as adjudged by flow cytometry (c). The results are representative of 
two to three independent experiments. * * =p < 0.05. 
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Figure 43. CpG ODN modifies the lung microenvironment and prevents 
C. neoformans-induced lung eosinophilia. Five mice per group were treated 
i.n with PBS, CpG ODN or a control ODN 3 days prior to i.n C. neoformans 
infection. Lungs were removed 12 days later and disrupted into a single-cell 
suspension and the cryptococcal burden determined in the lung by plating 
dilutions onto Sabouraud agar plates (a). Eosinophils were enumerated in 
H&E-stained cytospin preparations of lung (b). (c) The ratio of IFN-y to IL-5-
expressing CD4+ or CD8+ T cells was calculated by dividing the percentage of 
each T cell subset expressing IFN-y by the percentage of the same subset 
expressing IL-5. Representative dot plots of CD4 (y-axis) and intracellular 
IFN-y or IL-5 (x-axis) are shown for each group. The results are 
representative of four independent experiments. Control ODN is the non-
stimulatory methylated CpG control. CpG ODN is the immune stimulatory 
CpG. * =p < 0.05; * * =p <0.01. 
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4.2.3 Cybb tml mice develop pulmonary granulomas that encompass C. 
neoformans and promote pathogen clearance 
Having elucidated the role of the phagocyte NADPH oxidase and ROS in dictating 
the phenotype and resolution of a strong Thl driven intracellular viral infection such 
as influenza, we next assessed their role in immunity to a potent Th2 inducing 
infection, C. neoformans. Wild type C57BL/6 and Cybb tml mice were infected with 
C. neoformans, and culled at various times after infection to elucidate differences in 
immune phenotype and pathogen burden (Fig. 4.4). Both Cybb tml mice and 
C57BL/6 controls exhibited comparable lung cellular infiltrate at days 5, 8 and 12 
after infection (Fig. 4.5a), but the distribution of the infiltrate within the lung tissue 
was distinct between groups. Wild type mice displayed a generalised cellularity with 
perivascular and peribronchiolar infiltrate with significant occlusion of alveoli. 
Conversely, the Cybb tml mice exhibited small distinct pockets of infiltrate, 
granulomatous in nature, surrounding cryptococci (Fig. 4.5b). It is important to stress 
the numbers of cells in the lungs of naïve mice are at least an order of magnitude 
lower than that recruited during C. neoformans infection (at peak infection, wild type: 
8.9 x 106 ± 2.9 SEM; Cybb tml 11.5x 106 ± 2.5 SEM). 
Strikingly, the Cybb tml mice exhibited minimal recruitment of cells into their 
airways compared to wild type controls (Fig. 4.6a). This was clearly visible from 
observation of H and E stained cytocentrifuged BAL samples, which clearly show a 
reduction in airway cellularity in Cybb tml mice (Fig. 4.6b). Furthermore, it was 
clearly apparent that the Cybb tml mice exhibited a marked reduction in the number 
of cryptococci in their airways (Fig. 4.6b), which may imply that containment within 
the lung tissue hinders dissemination into the airways with consequently reduced 
number of cells recruited into the BAL. 
Cybb tml mice have previously been demonstrated to develop a granulomatous 
response to other fungal pathogens, but have been compromised in their ability to 
resolve infection. In contrast, Cybb tml mice showed an enhanced ability to combat 
C. neoformans infection with a significantly reduced fungal load in the lung tissue 
(Fig. 4.7a), the BAL (Fig. 4.7b) and, importantly, the brain (Fig. 4.7c) at days 5, 8 and 
12 after infection. The pathogen load within the spleen was low compared to that 
150 
Cybbtm' Wild-type 
C57BL/6 
1x104 C. neoformans (i.n) Day 0 
Day 5, 8, 
12 or 35 
BAL: - Surface Staining (flow cytometry) 
- Cytocentrifugation 
- Cytokines (ELISA) 
- C. neoformans CFUs 
Lung: - Surface/intracellular cytokine staining 
- C. neoformans CFUs 
- Histology (H/E ) 
Brain / Spleen: 
- C. neoformans CFUs 
Serum:- Cryptococcus-specific antibody 
Nasal Washes: - IgE 
Figure 4.4. Experimental protocol. 
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Figure 4.5. Lungs of Cybb tml mice possess reduced perivascular and 
peribronchiolar infiltrate compared with wild type controls, but 
possessed sporadic areas of focused severe granulomatous inflammation. 
C57BL/6 and Cybb tml mice (n=5) were infected with 1 x 104 CFU C. 
neoformans intranasally. At days 5, 8 and 12 after infection lungs were 
removed and homogenised to a single cell suspension and the total number of 
viable cells enumerated by trypan blue exclusion (a). Closed symbols, wild 
type C57BL/6 mice; open symbols, Cybb tml mice Results represent mean 
values ± SEM from 5 mice per group. Representative H and E stained lung 
sections of C neoformans infected Cybb tml and wild type C57BL/6 mice 12 
days after infection (x25 and x200 magnification) (b). Arrows = cryptococcal 
bodies. 
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Figure 4.6. C. neoformans infected Cybb tml mice exhibit reduced 
inflammatory infiltrate in their airways. (a) BAL was performed on C. 
neoformans infected wild type or Cybb tml mice on days 0, 5, 8 and 12 and 
total viable cells enumerated. Closed symbols, wild type C57BL/6 mice; 
open symbols, Cybb tml mice Results represent mean values ± SEM from 5 
mice per group. *=p<0.05, **=p<0.01. (b) Representative H and E stained 
cytocentrifuged BAL samples from wild type and Cybb tml mice at days 8 
and 12 after C. neoformans infection. 	Eosinophils; 	► C. neoformans. 
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Figure 4.7. Cybb tml mice display improved clearance of C. neoformans. 
C57BL/6 and Cybb tml mice (n=4) were infected with 1 x 104 CFU C. 
neoformans. At days 5, 8 and 12 post infection, homogenate of lung (a), BAL 
(b), brain (c) and spleen (d) were plated out on sabauraud dextrose agarose 
and incubated for 48 hours at room temperature. C. neoformans cfus were 
subsequently counted. Closed symbols, wild type C57BL/6 mice; open 
symbols, Cybb tml mice Results represent mean values ± SEM from 5 mice 
per group. *=p<0.05, **=p<0.01. 
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observed in the lung but comparable between wild type and Cybb tml mice (Fig. 
4.7d). 
4.2.4 Cybb tml mice exhibit reduced eosinophilia and a more pronounced Thl 
response to C. neoformans 
Macrophages are central to the development of a granulomatous response 
orchestrating cellular recruitment and containment of the pathogen. We have 
previously observed an aberrant macrophage response in naive Cybb tml mice, which 
is augmented upon pathogen challenge. Analysis of H and E stained lung sections 
(Fig. 4.5b) demonstrates an accumulation of macrophages and multinucleated giant 
cells at the centre of the granuloma formations in Cybb tml mice. Conversely, the 
cellularity in the wild type lung, whilst containing macrophages, was dominated by 
lymphocytes and eosinophils. This was confirmed by FACS analysis of lung tissue, 
which clearly showed a significantly greater percentage of macrophages in Cybb tml 
mice (Fig. 4.8a), which ultimately led to an enhanced number of these cells 
throughout the course of infection (Fig. 4.8b). 
Differential cell counts of H and E stained cytospin preparations (Fig. 4.6b) and 
FACS analysis (Fig. 4.8c and d) revealed a marked reduction in the percentage 
eosinophilia in the lung and airways in Cybb tml mice. This in turn led to a reduction 
in the total numbers of eosinophils in the lung and airways of Cybb tml mice relative 
to wild type controls (data not shown). Eosinophilia is dependent on CD4+ T cells. In 
Cybb tml mice, however, the percentage of CD4+ T cells was reduced at day 12 after 
infection whereas that of CD8+ T cells was increased (Fig. 4.9a). Cybb tml mice 
exhibited a significant increase in the total number of CD8+ T cells in their lungs at 
day 12 after infection (Fig. 4.9b). Both CD4+ and CD8+ T cells exhibited a heightened 
activation state (CD45RBI°) in Cybb tml mice at days 8 (data not shown) and 12 (Fig. 
4.9c and d) after infection. 
To determine whether a shift in the cytokine profile accounted for reduced 
eosinophilia in Cybb tml mice we employed intracellular cytokine staining. Both 
CD4+ and CD8+ T cells produced increased levels of IFN-y (Fig. 4.10a) and TNF 
(data not shown) in Cybb tml mice compared to wild type mice. Conversely, Cybb 
155 
35 
30 
25 
20 
15 
10 
5 
0 
0 2 
%
 E
os
in
op
hi
ls
  
4 6 8 10 12 
90 
80 
70 
60 
50 
40 
30 
20 
10 
* * 
2 4 6 8 10 12 
%
 Eo
sin
op
hi
ls
  
a. 	 b. 
14 
re 12 
rz. 10 8 
a,1 8 	 0 
6 
4 4 
(-) 2 e 
0 
* 
16 
14 
g 12 
stl, 10 
8 
6 6 
6 4 
2 
0 
Wild-type 	Cybb 
	 2 4 6 8 10 12 
Days post infection 
c. 	 d. 
Days post infection 	 Days post infection 
Figure 4.8. Cybb tml mice exhibit a heightened macrophage infiltrate but 
reduced eosinophilia in response to pulmonary C. neoformans infection. 
Lungs were removed and BAL performed on C. neoformans infected wild 
type and Cybb tml mice at days 5, 8 and 12 after infection and single cell 
suspension stained with Gr-l-FITC, CD1 lb-PercP and CD11c-APC. The 
percentage of CD1 lb÷ macrophages in the lung at day 12 after infection was 
determined by flow cytometry (a). The total numbers of lung CD1113+ 
macrophages were determined by: % single positive cells by flow cytometry x 
total number of viable cells (b). The percentage of eosinophils in the lung (c) 
and BAL (d) of C. neoformans infected wild type and Cybb tml mice was 
determined from their characteristic forward and side scatter profile as 
adjudged by flow cytometry, and verified from H and E stained cytocentrifuge 
preparations. Closed symbols, wild type mice; open symbols, Cybb tml mice. 
Results represent mean values ± SEM from five mice per group. (*=p<0.05, 
**=p<0.01) and are representative of 3 experiments. 
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Figure 4.9. Cybb tml mice show an enhenced CD8+ T cell response 
following C. neoformans infection. C57BL/6 and Cybbtml mice (n=4) were 
infected with 1 x104 CFU C. neoformans. Lungs were removed from C. 
neoformans infected wild type or Cybb tml mice 12 days after infection and 
single cell suspension stained with CD45RB-FITC, CD4-PercP and CD8-APC. 
The percentage CD4+ and CDS+ lymphocytes were determined by flow 
cytometry (a). The total numbers of lung CD4+ and CDS+ T cells 12 days after 
infection were determined by multiplying the percentage positive cells by flow 
cytometry by the total viable cells recovered from the lungs (b). The percentage 
CIA' and CD8+ T cells that were CD45RB1° were also determined (c). (d) 
Representative histogram overlay depicting the levels of CD45RB expression 
on CD4+ (top) and CD8+ (bottom) T cells in wild-type and Cybb tml mice at 
day 12 after infection with C. neoformans. Blue =wild type; red = Cybb tml. 
Closed symbols, wild type mice; open symbols, Cybb tml mice. Results 
represent mean values ± SEM from five mice per group and are representative 
of 3 experiments. *=p<0.05, **=p<0.01. 
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Figure 4.10. Cybb tml mice exhibit a Thl biased cytokine response. 
Lungs were removed from C. neoformans infected wild type and Cybb tml 
mice 12 days after infection and single cell suspensions stained with IFN-y-
FITC, IL-5-PE, CD4-PercP and CD8-APC. Representative plots are shown of 
lung CD4+ or CD8+ T cells versus IFN-y expression in wild type or Cybb tml 
mice (a). The number of IFN-y and IL-5 expressing T cells was determined 
by: % positive cells by flow cytometry x total number of viable cells. (b) The 
ratio of the number of IFN-y expressing T cells over the number IL-5 
producing T cells in wild type and Cybb tml mice. Cytokines in lung 
homogenates of wild type and Cybb tml mice 12 days after C. neoformans 
infection were determined using the BD mouse Thl / Th2 cytometric bead 
array (c). Results represent mean values ± SEM from five mice per group. 
(*=p<0.05, **=p<0.01) and are representative of 3 experiments. 
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tml derived T cells produced lower levels of IL-5 (data not shown). The ratio of IFN-
y producing T cells to IL-5 producing T cells was greatly augmented in Cybb tml 
mice (Fig. 4.10b) showing a significant Thl bias. Soluble cytokine levels in lung 
homogenate were also monitored by Cytometric Bead Array (CBA) throughout the 
course of infection and displayed a similar Thl bias in Cybb tml mice. There were 
significantly elevated levels of TNF at days 8 and 12 after infection in Cybb tml mice 
and reduced levels of IL-5 at days 5 and 8 (Fig. 4.10c). 
Since CD4+ T cells assist in anti-cryptococcal antibody production we next compared 
the effect in Cybb tml mice. Cybb tml mice exhibited significantly reduced B cells in 
the lung and airways (Table 4.1). Furthermore, reduced pathogen specific total 
antibody and IgG1 isotype in the serum at day 12 post infection, and IgE isotype in 
the BAL fluid was observed at day 5 post infection (Table 4.1). 
The severe pulmonary eosinophilia that occurs during C. neoformans infection is 
largely attributable for the observed pathology owing to degranulation and crystal 
deposition. Furthermore, C. neoformans is directly responsible for much of the 
observed lung pathology observed during the course of infection owing to its 
considerable size and extensive numbers. To assess whether the reduced eosinophilia 
and pathogen load observed in Cybb tml mice reduced lung damage we assessed the 
levels of total protein (Fig. 4.11a) and lactate dehydrogenase (LDH) (Fig. 4.11b) in 
the BAL fluid. Both markers of pathology were significantly reduced in Cybb tml 
mice. 
4.2.5 The Thl bias and enhanced protection observed in Cybb tml mice is IL-12 
independent 
IL-12 is a critical cytokine in the induction of a Thl response 134-138  IL-12 is also 
critical in controlling dissemination of C. neoformans to the brain 263,264.  The  
heightened macrophage response observed in Cybb tml mice could presumably affect 
levels of this cytokine and thus control dissemination with greater aptitude. 
Neutralising anti-IL-12 antibody was thus utilised to infer the role of IL-12 in the 
enhanced protection observed in Cybb tml mice. 
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Group % B220 Total Antibody IgG1 IgE 
Wild-type 46.1 +/- 2.1 0.59 +/- 1.7 0.11 +/- 0.009 0.35+/-0.056 
Cybb 28.3 +/-4.0 0.13 +/- 0.02 0.09 +/- 003 0.087 +/- 0.021 
Table 4.1 Cybb tml mice elicit a reduced B cells and antibody response to C. 
neoformans. Lungs were removed from naïve Cybb tml and wild type C57BL/6 mice 
at day 12 post infection and single cell suspensions obtained. Viable cells from each 
organ were determined by trypan blue exclusion. Single cell suspensions were stained 
with anti-B220-PercP and the percentage of lymphocytes expressing this marker were 
determined by flow cytometry. The levels of C. neoformans specific total antibody 
and IgG1 in the serum were determined at day 12 post infection and the levels of total 
IgE in the BAL assessed at day 5. ODs were read at 490 nm, and mean blank values 
(ODs from normal mouse serum) were subtracted from the OD values of test samples. 
Results represent the mean +/- standard deviation of 5 individual mice in 3 
independent experiments. 
a. 	 b. 
15' 
	 0.35 - 
Wild-type Cybb 
	
Wild-type Cybb 
Figure 4.11. Cybb tml mice show a reduction in lung pathology during C. 
neoformans infection. C57BL/6 and Cybb tml mice (n=5) were infected with 
1 x 104 CFU C. neoformans intranasally. At day 12 after C. neoformans 
infection BAL was removed and total protein (a) and LDH (b) measured in 
supernatants. Closed symbols, wild type mice; open symbols, Cybb tml mice. 
Results represent mean values ± SEM from five mice per group. (*=p<0.05, 
**=p<0.01) and are representative of 3 experiments. 
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The administration of a neutralising anti-IL-12 antibody to C. neoformans infected 
wild type mice had no effect on total cell numbers in the lung (Fig. 4.12a), but gave 
rise to a general increase in cellularity in the airways (Fig. 4.12b) of the treated mice. 
Furthermore, administration of this neutralising antibody to Cybb tml mice failed to 
reverse the reduced airway cellularity seen in these mice relative to wild type controls 
(Fig. 4.12b). The enhanced ability of Cybb tml mice to control cryptococcal infection 
was not compromised by anti-IL-12 antibody treatment. Wild type mice administered 
anti-IL-12 antibody exhibited a dramatic increase in C. neoformans dissemination to 
the brain, but this was not the case with Cybb tml mice (Fig. 4.13a). CFUs in the lung 
and BAL were not affected by anti-IL-12 treatment in either strain, and Cybb tml 
mice continued to exhibit a reduced pathogen burden at these sites (Fig. 4.13b and c). 
The Thl bias observed in Cybb tml mice relative to wild type controls persisted even 
with administration of anti-IL-12 antibody by intracellular cytokine staining of T 
cells. Anti-IL-12 treatment of wild type mice evoked heightened IL-5 production and 
reduced IFNI production, but the cytokine profile of Cybb tml mice receiving the 
treatment remained unaltered. This was most prominent in the percentage CD8+ T 
cells producing IFNI (Fig. 4.14a). Furthermore, macrophage numbers were 
augmented in the lungs of both treated and untreated Cybb tml mice relative to wild 
type controls (data not shown), and eosinophil numbers markedly reduced in the lungs 
(data not shown) and BAL (Fig. 4.14b). 
4.2.6 Cybb tml mice continue to show a heightened Thl response and improved C. 
neoformans clearance in the airways at day 35 after infection. 
C57BL/6 mice fail to clear C. neoformans infection, whereas BALB/c mice elicit a 
protective Thl response and do so. To infer whether the enhanced Thl driven 
protective immunity observed in Cybb tml mice at day 12 would eventually lead to 
complete resolution of C. neoformans infection, we extended the infection to day 35. 
At this time point, the Cybb tml mice actually possessed a greater cellular infiltrate 
within their lungs compared to wild type controls (Fig. 4.15a), which continued to be 
highly granulomatous in nature (Fig. 4.15c). There was also reduced cellularity within 
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Figure 4.12. IL-12 depletion does not compromise the reduced cellular 
infiltrate into the airways that is observed in Cybb tml mice in response 
to C. neoformans infection. C57BL/6 and Cybb tml mice (n=5) were 
infected with 1 x 104 CFU C. neoformans intranasally, with some groups 
additionally treated with anti-IL-12 antibody. At 12 days after infection, BAL 
was performed and lungs removed and homogenised to a single cell 
suspension. The number of viable cells in the lung (a) and airways (b) was 
determined by trypan blue exclusion. Closed symbols, wild type mice; open 
symbols, Cybb tml mice; two tone symbols, administration of anti-IL-12 
antibody. (*=p<0.05, **=p<0.01). 
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Figure 4.13. IL-12 Depletion does not compromise the enhanced C. 
neoformans clearance observed in Cybb tml mice. C57BL/6 and Cybb 
tml mice (n=5) were infected with 1 x 104 CFU C. neoformans intranasally, 
with some groups additionally treated with anti-IL-12 antibody. At day 12 
after infection, homogenate of brain (a), lung (b) and BAL (c) were plated out 
on sabauraud dextrose agarose and incubated for 48 hours at room 
temperature. C. neoformans cfus were subsequently counted. Closed bars, 
wild type C57BL/6 mice; open bars, Cybb tml mice; two tone bars, 
administration of anti-IL-12 antibody. Results represent mean values ± SEM 
from 5 mice per group. *=p<0.05, **=p<0.01. 
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Figure 4.14. Depletion of IL-12 fails to reduce the heightened Thl 
response seen in Cybb tml mice to C. neoformans. C57BL/6 and Cybb tml 
mice (n=5) were infected with 1 x 104 CFU C. neoformans intranasally, with 
some groups additionally treated with anti-IL-12 antibody. At day 12 after 
infection, BAL was performed and cells stained with IFN-'y-FITC, IL-5-PE, 
CD4-PercP and CD8-APC. The percentage of CD8+ T cells producing IFNI,  
was determined by flow cytometry (a). The percent BAL eosinophilia was 
enumerated from forward/side scatter properties by flow cytometry and 
confirmed by eosinophil enumeration of cytocentrifuged BAL fluid. The total 
numbers of eosinophils was subsequently calculated by: percentage 
eosinophils x total number of viable cells (b). Closed symbols, wild type 
mice; open symbols, Cybb tml mice; two tone symbols, administration of 
anti-IL-12 antibody. (*=p<0.05, **=p<0.01). 
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the airways of the Cybb tml mice at this time point compared to wild type controls 
(Fig. 4.15b). Cybb tml mice continued to exhibit a strong Thl bias, with a greater 
percentage of both CD4+ and CD8+ T cells producing IFN-y (data not shown). As 
seen at earlier time points, the Cybb tml mice also possessed a greater percentage 
(Fig. 4.15d) and number (data not shown) of macrophages relative to wild type mice 
and a reduction in the percentage of eosinophils (Fig. 4.15e). 
At this late time point the number of C. neoformans cfus were comparable in the 
lungs of wild type and Cybb tml mice (Fig. 4.16a), but persisted to be significantly 
lower in the airways of the knock out mice (Fig. 4.6b). The number of cfus in the lung 
at day 35 after infection were comparable in wild type mice to that seen at day 12 but 
had significantly increased in the knock outs at, this later time point. The number of 
cfus in the airways was comparable in both groups of mice at days 12 and 35. 
Pathogen burden in the brain of both groups of mice was low at day 35 after infection 
and whilst generally lower in Cybb tml mice this difference failed to be significant 
(data not shown). 
4.2.7 Mice treated with MnTE-2-PyP exhibit reduced inflammation in response to 
C. neoformans infection and show reduced dissemination to the brain 
We have previously noted marked differences in the phenotype of naïve wild type and 
Cybb tml mice, and appreciate many inherent problems of utilising knock out mice to 
elucidate the role of immune components in the outcome of infection. We therefore 
further assessed the role of ROS in C. neoformans infection utilising the metallic 
manganese porphyrin MnTE-2-PyP, which acts as an SOD mimic and possesses ROS 
scavenging potential. C57BL/6 mice were inoculated intranasally with C. neoformans 
and subsequently administered either PBS or 50µg of the manganic porphyrin MnTE-
2-PyP at days 0, 4 and 8 after infection (Fig. 4.17). Mice administered MnTE-2-PyP 
exhibited a marked reduction in cellular infiltrate into the lung tissue (Fig. 4.18a) and 
airways (Fig. 4.18b) in response to C. neoformans infection, relative to controls. This 
is distinct to the scenario in Cybb tml mice which possessed a significant 
granulomatous lung infiltrate. Visualisation of H and E stained lung sections revealed 
a striking reduction in perivascular and peribronchiolar infiltrate in MnTE-2-PyP 
treated mice, with reduced occlusion of alveoli (Fig. 4.18c). The reduced cellularity 
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Figure 4.15. Cybb tml mice continue to display a heightened macrophage 
infiltrate and Thl bias at day 35 after C. neoformans infection. C57BL/6 
and Cybb tml mice (n=5) were infected with 1 x 104 CFU C. neoformans 
intranasally. 35 after later, BAL and lungs were removed and homogenised to 
a single cell suspension. The total number of viable cells in the lung (a) and 
BAL (b) was enumerated by trypan blue exclusion. Results represent mean 
values ± SEM from 5 mice per group. Representative H and E stained lung 
sections of C. neoformans infected Cybb tml and wild type C57BL/6 mice 35 
days after infection (x25 magnification) (c). Lung cells were stained with Gr-
1 -FITC, CD11b-PercP and CD11c-APC. The percentage of CD1113+ 
macrophages in the lung at day 12 after infection was determined by flow 
cytometry (d). The percent BAL eosinophilia was enumerated from 
forward/side scatter properties by flow cytometry and confirmed by 
eosinophil enumeration of cytocentrifuged BAL fluid (e). Closed symbols, 
wild type C57BL/6 mice; open symbols, Cybb tml mice. *--p<0.05, 
** 	<0 01 =P • • 
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Figure 4.16. At day 35 after infection, Cybb tml mice continue to exhibit 
a reduced C. neoformans burden in the airways. C57BL/6 and Cybb tml 
mice (n=4) were infected with 1 x 104 CFU C. neoformans. At day 35 after 
infection, homogenate of lung (a) and BAL (b) were plated out on sabauraud 
dextrose agarose and incubated for 48 hours at room temperature. C. 
neoformans cfus were subsequently counted. Closed bars, wild type C57BL/6 
mice; open bars, Cybb tml mice Results represent mean values ± SEM from 
5 mice per group. *=p<0.05, **=p<0.01. 
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Day 0 	 1x104 C. neoformans (i.n) 
PBS (i.n) dO, 4 	MnTE-2-PyP 
and 8 	dO, 4 and 8 
Day 12 BAL: - Surface Staining (flow cytometry) 
- Cytocentrifugation 
- Cytokines (ELISA) 
- C. neoformans CFUs 
Lung: - Surface/intracellular cytokine staining 
- C. neoformans CFUs 
- Histology (H/E ) 
Brain / Spleen: 
- C. neoformans CFUs 
Serum:- Cryptococcus-specific antibody 
Nasal Washes: - IgE 
Figure 4.17. Experimental protocol. 
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Figure 4.18. The anti-oxidant MnTE-2-PyP reduces C. neoformans 
induced inflammation. C. neoformans-infected mice were treated i.n. with 
PBS or MnTE-2-PyP on 0, 4 and 8 days after infection. At day 12 after 
infection, BAL was performed and lungs removed and homogenised to a 
single cell suspension. The total number of viable cells in the lung (a) and 
BAL (b) was enumerated by trypan blue exclusion. Closed bars, PBS treated 
mice; open bars, MnTE-2-PyP treated mice. Results represent mean values ± 
SEM from 5 mice per group. *=p<0.05, **=p<0.01. (c) Representative H and 
E stained lung sections of C. neoformans infected PBS and MnTE-2-PyP 
treated mice 12 days after infection (x200 magnification). 
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evoked by MnTe-2-PyP treatment encompassed a significant reduction in total 
numbers of eosinophils (Fig. 4.19a and b) and lymphocytes (Fig. 4.19c and d) in the 
lungs and airways. The percentage of cells that were macrophages was slightly 
augmented in the mice treated with MnTE-2-PyP, but total numbers were generally 
reduced owing to the significant reduction in total cell numbers in these mice (data 
not shown). Similar to Cybb tml mice, those treated with MnTE-2-PyP showed a 
marked bias towards a CD8+ T cell response relative to CD4+ when compared to 
control mice (Fig. 4.20a-c). Furthermore, both CD4+ and CD8+ T cells from mimetic 
treated mice exhibited a Thl cytokine bias with a greater percentage of cells 
expressing intracellular IFN-y relative to PBS treated mice (Fig. 4.20d). The 
percentage of CD8+ T cells activated, as defined by being CD45RBI°, was elevated in 
MnTe-2-PyP treated mice, as seen in Cybb tml knock outs (Fig. 4.20e). Conversely, 
the percentage CD4+ CD45RBI0 T cell was significantly reduced in mimetic treated 
mice (Fig. 4.20e). Finally, MnTE-2-PyP treated mice showed comparable fungal 
loads in their lungs and airways (Fig. 4.21a), but exhibited reduced dissemination to 
the brain relative to control treated mice (Fig. 4.21b). 
The Thl bias and improved protection seen in Cybb tml mice or those administered 
MnTE-2-PyP suggests a role for ROS in defining the Thl / Th2 paradigm. This may 
be partly explained by the heightened macrophage numbers in C. neoformans infected 
Cybb tml mice. Since ROS have been implicated in apoptosis 60,62,325,353,362  we have 
investigated macrophage apoptosis during C. neoformans infection with or without 
administration of MnTE-2-PyP. Whilst we found the total number of annexin 
macrophages were slightly reduced, this was a reflection of the total reduction in 
cellular infiltrate rather than an alteration in the proportion of cells undergoing 
apoptosis (data not shown). It would appear that a reduction in macrophage apoptosis 
is therefore not the sole reason for the elevated Thl response and improved pathogen 
clearance. 
At day 45 after infection with C. neoformans, mice that had been administered 
MnTE-2-PyP continued to exhibit a reduction in cellular infiltrate into the lung tissue 
(Fig. 4.22a) and airways (4.22b). Despite a significantly reduced CD4+ and CD8+ T 
cell infiltrate into the lung tissue (Fig. 2.22c), those mice treated with the mimetic 
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Figure 4.19. MnTE-2-PyP treated mice exhibit reduced lymphocytic and 
eosinophilic infiltrate in response to C. neoformans infection. C. 
neoformans-infected mice were treated i.n. with PBS or MnTE-2-PyP on 0, 4 
and 8 days after infection. At day 12 after infection, BAL was performed and 
lungs removed and homogenised to a single cell suspension. The percent 
eosinophilia was enumerated from forward/side scatter properties by flow 
cytometry and confirmed by eosinophil enumeration of cytocentrifuged BAL 
fluid and lung homogenate. The total number of eosinophils in the lung (a) 
and BAL (b) was calculated by: percentage eosinophils x total number of 
viable cells. The percentage lymphocytes was determined by flow cytometry. 
The number of lymphocytes in the lung (c) and BAL (d) was calculated by: % 
of positive cells by flow cytometry x total number of viable cells. Closed bars, 
PBS treated mice; open bars, MnTE-2-PyP treated mice. Results represent 
mean values ± SEM from 5 mice per group. *=p<0.05, **=p<0.01. 
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Figure 4.20. MnTE-2-PyP treated mice exhibit a more prominent CD8+ T 
cell response and Thl bias in response to C. neoformans infection. C. 
neoformans-infected mice were treated i.n. with PBS or MnTE-2-PyP on 0, 4 
and 8 days after infection. At day 12 after infection, lungs were removed and 
homogenised to a single cell suspension. Single cell suspensions of lung tissue 
were stained with IFN-y-FITC, CD45RB-PE, CD4-PercP and CD8-APC. (a) 
Representative plots of CD4+ versus CD8+ in C. neoformans infected PBS and 
MnTE-2-PyP treated mice 12 days after infection. The percentage 
lymphocytes that are CD4+ (b) and CD8+ (c) T cells were determined by flow 
cytometry. The percentage of these T cells expressing IFN-y was determined 
by flow cytometry (d). Results represent mean values ± SEM from 5 mice per 
group. Similarly, the percentage of the T cells that were CD45RBI° was 
determined by flow cytometry. Closed symbols, PBS treated mice; open 
symbols, MnTE-2-PyP treated mice. *=p<0.05, **=p<0.01. 
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Figure 4.21. MnTE-2-PyP reduces dissemination of C. neoformans into the 
brain. C57BL/6 mice (n=4) were infected with 1 x104 CFU C. neoformans and 
treated with either PBS or MnTE-2-PyP on 0, 4 and 8 days after infection. At 
day 12 post infection, mice were sacrificed and homogenate of lung, BAL (a), 
and brain (b) were plated out on sabauraud dextrose agarose and incubated for 
48 hours at room temperature. C. neoformans cfus were subsequently counted. 
Closed bars, PBS treated mice; open bars, MnTE-2-PyP treated mice. Results 
represent mean values ± SEM from 5 mice per group. *=p<0.05, **=p<0.01. 
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Figure 4.22. MnTE-2-PyP treated mice continue to exhibit a reduced 
pulmonary infiltrate at day 45 after infection, and show a reduction in 
CFUs in the lung and brain. C57BL/6 mice (n=5) were infected with 1 x104 
CFU C. neoformans and treated with either PBS or MnTE-2-PyP on day 0 and 
then every 4 days after infection. At 45 days after infection, BAL was 
performed and lungs removed and homogenised to a single cell suspension. The 
number of viable cells in the lung (a) and airways (b) was determined by trypan 
blue exclusion. The percentage CD4+ and CD8' lymphocytes were determined 
by flow cytometry and their total numbers determined by multiplying the 
percentage positive cells by flow cytometry by the total viable cells recovered 
from the lungs (c). Homogenate of lung (d), and brain (e) were plated out on 
sabauraud dextrose agarose and incubated for 48 hours at room temperature. C. 
neoformans cfus were subsequently counted. Results represent mean values ± 
SEM from 5 mice per group. Single cell suspension of lung homogenate was 
stained with Gr-l-FITC, MHC II-PE, CD11b-PercP and CD1 1 c-APC. The 
intensity of MHC 11 expression on the surface of macrophages was assessed by 
flow cytometry (f). A representative histogram overlay of MHC II expression is 
shown (g). Closed symbols, PBS treated mice; open symbols, MnTE-2-PyP 
treated mice. *--p<0.05, **=p<0.01. 
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showed a striking increase in fungal clearance from this site (Fig. 2.22d). As seen at 
day 12, MnTE-2-PyP treated mice also exhibited a significant decrease in C. 
neoformans dissemination to the brain (Fig. 2.22e). The mimetic treated mice 
continued to exhibit a Thl bias, and it was of interest that pulmonary macrophages in 
these mice were in a heightened activation state and expressing elevated MHC II on 
their surface (Fig. 2.22f and g). 
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4.3 Discussion 
4.3.1 The role of ROS during pulmonary C. neoformans infection 
In this study we have investigated the anti-microbial action of ROS against C. 
neoformans, utilising mice that lack a functional phagocyte NADPH oxidase (Cybb 
tml mice) or through administration of a manganic porphyrin with broad anti-oxidant 
activity. ROS are believed to fulfil a critical role in conferring protection against 
fungal infections; the most important evidence provided by patients with chronic 
granulomatous disease, who lack a functional NADPH oxidase, and display 
heightened susceptibility to fungal pathogens such as Aspergillus fumigatus 53'54. We 
have previously demonstrated that mice lacking a functional phagocyte NADPH 
oxidase possessed a basal Thl skewed immunity affiliated with an augmented 
macrophage population. Furthermore, this phenotype was promoted in response to a 
pulmonary influenza challenge. A non-protective response to C. neoformans shows 
Th2 bias with prominent airway eosinophilia, whereas a Thl response is linked with 
pathogen clearance and prevention of dissemination to the CNS. It is plausible that the 
absence of a NADPH oxidase may therefore actually prove to be beneficial in the 
control and resolution of infection from this fungal pathogen. 
4.3.2 Pulmonary granuloma formation and containment of C. neoformans 
We show that Cybb tml mice elicit a lung granulomatous response to C. neoformans 
with enhanced macrophages and a distinct shift towards a protective Thl driven 
response. In this environment, C. neoformans is contained in the lung and 
dissemination to the brain dramatically reduced. The appearance of a granulomatous 
response to C. neoformans in Cybb tml mice is not unexpected, since one of the 
clinical manifestations of CGD patients is aberrant inflammation and the formation of 
granulomatous lesions at disparate sites 384. A. fumigatus evokes enhanced 
inflammatory responses in the lungs of both CGD patients and in murine models of 
CGD 53'54. This correlates with heightened macrophage responses leading to 
granuloma formation. Similarly, mice lacking a functional phagocyte NADPH 
oxidase display enhanced inflammatory gastritis to Helicobacter pylori 369, and 
elevated levels of PMN sequestration in an Escherichia coli sepsis model 55. The 
aberrant inflammatory response is not restricted to pathogenic challenge, with 
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excessive inflammation and granuloma formation observed in the lungs of Cybb tml 
mice following injection of sterile heat killed fungal products 53 and enhanced 
peritoneal leukocytosis in response to thioglycolate 385. The occurrence of 
granulomatous responses in Cybb tml mice is poorly understood but appears to be 
tightly affiliated with an exuberant macrophage response. 
Macrophages are central to granuloma formation and their numbers were significantly 
elevated in C. neoformans infected Cybb tml mice relative to wild type controls. As 
discussed previously, naïve Cybb tml mice possess an intrinsic increase in the 
number of macrophages in lymphoid tissues implying a possible role in the 
homeostasis of this cell population in resting conditions. This basal increase is further 
augmented following infection with C. neoformans. The elevated macrophages would 
appear at least in part to be attributable to a reduction in apoptosis of macrophages, 
with ROS having been implicated in cellular damage and induction of the apoptotic 
pathway. The absence of ROS ultimately leads to persistence of this population and 
greater clustering and activation in response to C. neoformans infection. 
4.3.3 Thl skewed immunity in C neoformans infected Cybb tml mice 
Perhaps the most significant alteration in the phenotype of the immune response 
elicited to C. neoformans in Cybb tml mice is the distinct shift in the Thl /Th2 
balance. It is notable that Cybb tml mice exhibit a marked bias towards a Thl 
response, relative to the wild type controls. This is conveyed by the significant 
increase in CD8÷ T cells, a striking shift towards a Thl cytokine expression profile, 
and a marked reduction in B cells and total antibody, specifically Th2 associated IgG1 
and IgE. Most prominent, however, is the marked reduction in lung and airway 
eosinophilia, a perpetual trait of the non-protective Th2 response normally elicited in 
C57BL/6 mice. Therefore, it would appear that the absence of ROS leads to a more 
potent Thl response. 
Macrophages are an abundant source of IL-12, a potent Thl skewing cytokine with 
the potential to inhibit the development of the Th2 driven chronic eosinophilia elicited 
by C. neoformans in C57BL/6 mice. IL-12 and IFN-y have been reported to act at 
several levels to reduce eosinophilia, with cited potential to restrain eosinophil 
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differentiation from bone marrow stem cells, and inhibit expression of eotaxin at the 
mRNA and protein level 386,387  Thus it is foreseeable how an enhanced macrophage 
number, possibly due to reduced apoptosis, and ensuing Thl response would impede 
the non-protective Th2 phenotype. Furthermore, there is evidence claiming that 
superoxide is necessary for the activation of very late antigen-4 (VLA-4) on the 
surface of eosinophils, which is required for the targeted adhesion to VCAM-1 and 
recruitment to tissues 388. The absence of a functional NADPH oxidase and ensuing 
superoxide production would therefore reduce eosinophil recruitment to the lung. It 
has also been reported that reactive oxygen intermediates can induce NK cell 
apoptosis and dysfunction 62. NK cells are a potent source of IFN-y and as such could 
also facilitate the skew towards a Thl phenotype, as well as being critical cytotoxic 
mediators in the resolution of C. neoformans infection. 
The increased CD8+ T cell response in C. neoformans infected Cybb tml mice 
probably reflects the heightened macrophage numbers and augmented Thl response. 
The activation of naive CD8+ T cells and ensuing proliferation and effector CTL 
function requires both TCR engagement and co-stimulatory signal imparted by CD28 
or IL-2. Priming of naive CD8+ T cells will largely occur in secondary lymphoid 
organs and MHC class I antigen presentation will be predominantly mediated by 
mature dendritic cells that express co-stimulatory molecules. C. neoformans is an 
extracellular pathogen and as such APCs will internalize and process the antigen from 
other cells or the extracellular space. This processing of exogenous antigen for MHC I 
"cross-presentation" occurs by mechanisms that are termed alternate MHC class I 
processing and leads to the cross priming of CD8+ T cell responses 389,390  It is 
plausible that cytokines present during infection will alter MHC class I antigen 
presentation. Indeed, IFN-y has been demonstrated to regulate the expression of 
multiple components of MHC class I antigen presentation, including MHC class I 
heavy chain,132 microglobulin, TAP-1, TAP-2, LMP2 and LMP7 39"95, generally 
leading to heightened expression of MHC class I on various cells. Furthermore, IFN-y 
has been shown to promote assembly and surface expression of stable MHC class I 
complexes through more rigorous quality control during their progress through the 
endoplasmic recticulum 396  The heightened Thl immunity seen in Cybb tml mice 
infected with C. neoformans would therefore be anticipated to give rise to elevated 
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MHC class I expression and a greater CD8+ T cell response in these animals. 
Furthermore, type I IFNs play an important role in increasing MHC class I mRNA 
and protein levels 397  and it would be of interest to determine whether the augmented 
macrophage numbers seen in Cybb tml mice would increase the levels of these 
cytokines. We also saw elevated TNF levels in the C. neoformans infected Cybb tml 
mice, and this cytokine has also been linked with stimulation of MHC class I 
expression 398. 
Cytokines present can also have a direct effect on the amplitude of the CD8+ T cell 
response. It is argued that an effective CD8+ T cell response actually requires three 
distinct signals: TCR engagement, co-stimulation / IL-2 and a third signal which can 
be provided by IL-12. This third signal appears to be a requisite for complete 
activation of naïve CD8+ T cells both in vitro and in vivo 399401  It is anticipated that 
IL-12 is required for optimal IL-2 dependent proliferation and clonal expansion of 
CD8+ T cells. IL-12 stimulates the expression of the IL-2R cc chain (CD25) to much 
higher levels than TCR and co-stimulatory signals, and to maintain CD25 expression 
for longer. Subsequently, CD8+ T cells proliferate more effectively in response to low 
levels of IL-2 402. Another study has also revealed that the primary expansion of 
effector CD8+ T cells is greater following IL-12 priming owing to a reduced 
susceptibility to apoptosis 403. It is possible that the greater macrophage response seen 
in C. neoformans infected Cybb tml mice will lead to elevated IL-12, which could be 
one factor that dictates the heightened CD8+ T cell response. 
Whilst the CD8+ T cell response is augmented in Cybb tml mice, deprivation of ROS 
appears to give rise to a relative reduction in the percentage of CD4+ T cells. This is 
likely to be largely attributable to the increase in the number of CD8+ T cells in the 
knock out mice since total numbers of the CD4+ subset are comparable between the 
two groups. However, administration of MnTE-2-PyP appeared to cause a definite 
shift from a CD4+ T cell to a CD8+ T cell bias. It is plausible that the shift away from 
a CD4+ T cell predominated response is attributable to reduced MHC II expression. 
Superoxide reacts very rapidly with NO to produce peroxynitrite, but in the absence 
of superoxide NO will persist for longer. Therefore, it is plausible that there would be 
elevated levels of nitric oxide in the Cybb tml or MnTE-2-PyP treated mice. There is 
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a surfeit of cited literature that argues a role for nitric oxide in the inhibition of IFN-y 
induced increase in MHC II expression 404406. This regulatory role of NO is mediated 
through its potential to inhibit the IFN-y stimulated expression of CIITA. CIITA 
regulates a family of genes that are implicated in antigen processing and presentation 
with MHC H 4°5. Similarly, TNF has been demonstrated to have variable effects on 
MHC II expression, in a manner that is dependent upon the cell type and cellular 
differentiation. In peritoneal macrophages TNF has the potential to suppress MHC II 
expression 407, whilst other literature states that TNF will only suppress IFN-y induced 
increment in MHC II expression if NO is also present 404. The TNF mediated down-
regulation is again ascribed to its potential to act at the transcriptional level to 
suppress the IFN-y induced increment in CIITA production 408. We see elevated levels 
of TNF in the C. neoformans infected Cybb tml mice, and it would be of interest to 
infer if this leads to reduced CD4+ T cell priming. 
4.3.4 Enhanced clearance of C. neoformans in Cybb tml mice 
Whilst an augmented inflammatory response to pathogen is not atypical in the 
absence of a functional phagocyte NADPH oxidase, reduced burden of the pathogen 
is uncharacteristic. Cybb tml mice limit C. neoformans in the lung tissue and airways 
reducing dissemination to the brain. CGD is characterised by recurring life 
threatening bacterial and fungal infections such as Staphylococcus aureus and A. 
fumigatus, with neutrophils from CGD patients demonstrated to display defective 
killing against certain bacterial and fungal pathogens53'54. Whilst compromised 
pathogen clearance is the norm in the absence of a phagocyte NADPH oxidase, 
improved immunity and reduced bacterial load has been reported for Helicobacter 
pylori 369, and we have reported an improved clearance of influenza virus from the 
lungs of Cybb tml mice. The improved killing of C. neoformans in the absence of 
ROS has been described previously in vitro, whereby incubation of peritoneal 
macrophages with SOD and catalase augments anti-cryptococcal activity owing to a 
concomitant increase in nitric oxide production 409. 
The differences in susceptibility of NADPH oxidase deficient mice to C. neoformans 
relative to other fungal pathogens is probably partially attributable to the fact that 
protection against A. fumigatus and C. albicans, at least in the early stages of 
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infection, is mediated primarily through ROS of phagocytes, whereas protection 
against C. neoformans is dependent on Thl cell-mediated immune response, which 
we have demonstrated to be augmented in Cybb tml mice. It is plausible that other 
non-oxygen mediated cytotoxic mechanisms are more important to eradicate C. 
neoformans, and in an in vivo scenario these may compensate for the absence of a 
functional NADPH oxidase. The array of protective mechanisms exhibited by C. 
neoformans may negate the potential of superoxide and other ROS to kill this fungus, 
and oxidative cytoxicity will only become apparent if these oxidative defences are 
absent. C. neoformans is an encapsulated yeast, with the large high molecular weight 
polysaccharide capsule protecting against different facets of the host's immune 
response 237,410  Such a capsule is not present around A. fumigatus and could explain 
the heightened significance of ROS in conferring protection to this species. The 
capsule surrounding the Cryptococcus renders the pathogen less susceptible to 
,. phagocytosis and so may deprive ROS accessibility to the fungus 239 240,410 c  
neoformans also has the potential to elicit deposition of opsonins, which may trigger 
the phagocyte respiratory burst, at sites below the capsule surface, where they will be 
incapable of binding complement or Fc receptors on the surface of myeloid cells 
245,410.  
The improved clearance of C. neoformans is probably largely attributable to the 
enhancement of macrophages and Thl cytokines in Cybb tml mice. In addition, we 
report elevated CD8+ T cells that have been shown to directly bind C. neoformans and 
inhibit growth 262. The Thl phenotype of the recruited T cell population in Cybb tml 
mice is significant as mice lacking Thl cytokines succumb to cryptococcal infection 
253,263,411-413. IFN-7 will contribute to granuloma formation and the activation of 
macrophages 414  Furthermore, the chronic eosinophilia normally observed during a C. 
neoformans infection elicits extensive tissue disruption and damage through 
degranulation and crystal formation and facilitates replication and spread of 
Cryptococcus 255. The significant reduction in eosinophilia in Cybb tml mice 
correlates with reduced lung pathology and damage and could also explain the 
enhanced ability to control this pathogen. 
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4.3.5 Enhanced protection observed in Cybb tml mice is IL-12 independent 
Considering the pivotal role of IL-12 in the generation of Thl responses 253 it was 
surprising that anti-IL-12 treatment had a negligible effect on the immune profile 
observed in Cybb tml mice; especially since similar treatment of wild type mice 
enhanced Th2 cytokines and impaired pathogen clearance. Cybb tml mice still 
displayed a potent Thl response and enhanced protection even when deprived of IL-
12. It would appear that the aberrant immune phenotype evoked by the absence of the 
NADPH oxidase is able to overcome the customary requirement for IL-12. TNF in 
Cybb tml mice may assist in the maintenance of a protective Thl response. TNF 
knock out mice are more susceptible to C. neoformans infection 265, and Huffnagle 
and colleagues have demonstrated a significant early role for TNF in recruitment of 
leukocytes and the development of Thl biased immune response 244'266. Indeed, it has 
previously reported that CpG promotes a heightened Thl response to C. neoformans 
and prevents dissemination to the brain, an effect that was abolished by depleting 
TNF 415.  
4.3.6 NInTE-2-PyP and control of pulmonary C. neoformans infection 
The manganic porphyrin antioxidant, MnTE-2-PyP, also enhanced Thl cytokines to 
C. neoformans, again with heightened CD8+ T cells, Thl cytokines and significantly 
reduced eosinophilia. Furthermore, treated mice exhibited reduced dissemination of 
C. neoformans to the brain. However, compared to Cybb tml mice, some differences 
were apparent. Whereas Cybb tml mice displayed a granulomatous response that 
contained the pathogen within the lung, those treated with MnTE-2-PyP did not. The 
granulomatous response observed in Cybb tml mice appears to be a function of the 
cumulative absence of a functional NADPH oxidase since birth leading to a 
heightened basal macrophage population that subsequently expanded greatly in 
response to encountered stimuli. A permanent lack of superoxide may compromise 
homeostatic regulation of this myeloid immune compartment. MnTE-2-PyP, however, 
was only administered during infection and so would not be anticipated to elicit the 
same extent of macrophage deregulation. The fact that inflammation was so 
significantly reduced in mice administered the anti-oxidant most likely reflects the 
pro-inflammatory action of ROS in activating certain redox sensitive transcription 
factors. This will be of particular importance with administration of MnTE-2-PyP 
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since it targets superoxide generated by the phagocyte oxidase, xanthine oxidase and 
that derived from the NOX family that are more classically affiliated with a role in 
signalling. The effects of MnTE-2-PyP reported here are analogous to its effects in a 
murine model of asthma, where it reduced inflammation and, significantly, 
eosinophilia 373. Significantly, mice administered the MnTE-2-PyP anti-oxidant for a 
longer period were not compromised in their ability to combat C. neoformans 
infection with treated mice exhibiting reduced pulmonary inflammation as well as 
reduced lung and brain fungal titres at day 45 after infection. 
4.3.7 Conclusions 
In summary, it would appear that the absence of a functional phagocyte NADPH 
oxidase paradoxically results in enhanced C. neoformans clearance and most 
significantly, reduced dissemination to the brain. This is in contrast to the 
compromised immunity that such mice show to other fungal pathogens, and is a 
function of a heightened macrophage infiltrate and the ensuing Thl driven immune 
response. These findings emphasize a significant role for ROS in defining the Thl / 
Th2 paradigm and offer a novel mechanism to modulate myeloid immune responses. 
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Chapter 5 — The Basic Biology of CD200 and its Receptor 
5.1 Introduction 
5.1.1 Control of the myeloid immune compartment 
The development of an efficient and robust immune response is critical to the 
successful resolution of infection, but a degree of subtlety and tolerance is required to 
distinguish self from non-self and prevent bystander tissue damage 65'66. Myeloid cells 
are central to the induction, maintenance and subsidence of the inflammatory response 
to infection, as well as defining regulatory mechanisms that are crucial in the 
prevention of an inappropriate immune response. The phenotype and function of 
leukocytes is controlled by both secreted factors and more intimate cell contact 
interactions 67,416-419  The role of such signals in dictating immunity and tolerance at 
, the level of the T cell are well characterised 420422 but we know comparatively little 
regarding the interactions that govern cells of the myeloid lineage despite them having 
a critical role in immunity and immunopathology. 
Myeloid cells are an extremely heterogeneous population; their phenotype and 
function exquisitely regulated through the multitude of receptors on their surface 67. 
Among such receptors are pattern recognition receptors for the recognition of 
pathogen derived products, cytokine and chemokine receptors, complement and Fc 
receptors to facilitate pathogen clearance, accessory molecules that facilitate T cell 
activation, receptors that mediate phagocytosis, and those that dictate the migration of 
cells from the circulation and into tissues. There are a family of receptors that dictate 
myeloid cell function through the action of paired activating and inhibitory receptors. 
These receptors are members of the Immunoglobulin Superfamily (IgSF) and include 
paired immunoglobulin-like receptors (PIRs), signal regulatory proteins (SIRPs), 
triggering receptors expressed my myeloid cells (TREMs) and the CD200 receptor 
family 68-70,423425. Little is known about many of these receptors and in a lot of cases 
the physiological ligand remains unknown. However, the CD200-CD200R interaction 
is beginning to be characterised, with the majority of data demonstrating it to invoke a 
potent inhibitory signal to the myeloid immune compartment 68,76,84,94,96  Interest in  
this myeloid inhibitory interaction has escalated owing to the clear 
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immunotherapeutic potential in alleviation of autoimmunity, allergy and 
immunopathology, however, much of our knowledge thus far is contradictory, 
speculative and in many cases completely absent. 
5.1.2 CD200 and receptor expression 
CD200 (OX-2) was first isolated and characterised in rats in 1982 as a type 1 
transmembrane glycoprotein with two IgSF domains 71'72. CD200 was demonstrated 
to be expressed on a variety of cells in distinct tissues: thymocytes, recirculating B 
cells, some T cells, follicular dendritic cells, neurons in the central nervous system, 
endothelium, the granulosa of the degenerating corpora lutea, trophoblasts and smooth 
muscle 71,76-80.  This unusual and specific distribution was found to be highly 
conserved in mice and humans, with expression also seen in the kidney glomeruli in 
humans and reported in murine keratinocytes 89. This conserved expression of CD200 
on specific cellular populations would suggest a significant biological role for this 
molecule. 
The CD200 receptor (OX-2 receptor) was subsequently purified from rat splenocytes 
using a high affinity monoclonal antibody (0X102) to a macrophage antigen, which 
was demonstrated to block CD200 binding 68. This novel protein was subsequently 
cloned and shown to have homology to CD200, being a type 1 transmembrane protein 
with two IgSF domains, but possessing a longer cytoplasmic tail with signalling 
68,81,82.  capacity 	The CD200 receptor is almost exclusively expressed by cells of the 
85 82- .  myeloid lineage 68, However, RT-PCR of cDNA libraries from a variety of cell 
types of mice and humans demonstrate that whilst primarily on myeloid cells there is 
also receptor expression on polarized Th2 T cells 82. Flow cytometric analysis confirm 
these findings, with high levels of CD200R expression on cells of the myeloid 
lineage, with weak labelling of T cells, some NK cells, NKT cells and B cells. No 
other studies, however, report CD200R expression on populations other than myeloid 
cells. 
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5.1.3 Biological function of the CD200-CD200R interaction 
Much of our knowledge concerning the role of the CD200-CD200R axis in immunity 
comes from studies performed in CD200 knock out mice generated by Sedgwick at 
DNAX 76. The only phenotypic difference found in the leukocyte compartments is an 
enlarged CD11b÷ population. The spleens of CD200 knock out mice contain twice the 
number of CD1113+ myeloid cells with elevated numbers of macrophages and 
granulocytes 76. The red pulp is significantly enlarged and the marginal zone 
expanded from a single cell layer to a multilayer. Higher levels of the ITAM 
containing DAP12 are present in the marginal zone macrophages and in dendritic 
cells within T cell areas of the white pulp, implying heightened cellular activation. 
Lymph nodes of CD200 knock out animals are also enlarged, especially mesenteric 
lymph nodes, and exhibit a marked alteration in organisation. Wild type lymph nodes 
are interconnected spherical structures, but the knock outs nodes exhibit a tubular 
formation with no demarcation between nodes. Once again macrophages are 
expanded and more activated in the nodes of the CD200 knock outs. Microglia, the 
macrophages of the CNS, also exhibit alterations in CD200 knock out mice forming 
aggregates that are generally only seen in inflammation or neurodegeneration. The 
microglia also shows many features of activation with shorter glial processes and 
elevated expression of CD1 lb and CD45. The fact that the phenotype is observed in 
those cells that express the CD200R rather than those that express the knocked out 
gene led Hoek et al to postulate that the CD200 knock out phenotype was a 
consequence of myeloid cells lacking a restraining signal from CD200 76. 
Subsequently, CD200 knock out mice have been demonstrated to exhibit a more 
severe or accelerated disease phenotype in a variety of conditions where macrophage 
products are critical elements of the disease process, such as experimental 
autoimmune encephalitis (EAE) and collagen induced arthritis (CIA) 76. However, 
much of the findings concerning the role of CD200 in immune regulation are 
observational and there is little in the literature to divulge the mechanisms by which 
CD200 exerts a suppressive signal to the myeloid compartment. One recent study 
demonstrates the potential of signalling through CD200R to suppress cytokine 
production by CD200R transfected U937 cells, and the potency of this suppression to 
correlate with density of CD200R expression 96. Furthermore, the same study 
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demonstrates the potential of agonists to CD200R to suppress IFN-y and IL-17 
induced secretion of IL-6 by peritoneal macrophages. Similarly, engagement of 
CD200R in murine bone marrow derived mast cells over-expressing the receptor 
reduces degranulation and secretion of IL-13 and TNF 84. Similar findings were 
subsequently confirmed in human mast cells expressing normal levels of CD200R. 
Finally, some evidence supports a role for CD200R ligation in up-regulating indole 
dioxygenase (IDO) in plasmacytoid dendritic cells resulting in heightened tryptophan 
catabolism and tolerance 97. 
5.1.4 Hypothesis 
The CD200-CD200R interaction appears to deliver a potent inhibitory signal to the 
myeloid immune compartment, and many studies have manipulated this interaction to 
alleviate illness and disease in conditions characterized by excessive inflammation. 
There is clear therapeutic potential for manipulation of this inhibitory myeloid signal 
in respiratory infections, whether by delivering the inhibitory signal to suppress 
immunity during influenza infection or blocking the signal to promote immunity to C. 
neoformans. However, at present studies describing this therapeutic potential are 
significantly outpacing our understanding of the basic biology that underpins the 
observed phenotype. CD200 expression is unusual yet specific and conserved. 
However, its expression is yet to be defined within the lung and little is known 
regarding the parameters that modulate the levels of its expression. Similarly, our 
knowledge of what regulates the levels of expression of the receptor on myeloid cells 
is still in its infancy. These findings would be crucial if we are to understand the 
physiological role this interaction may fulfil during infection and how we may 
optimally manipulate the signal therapeutically. Furthermore, very little is known 
regarding the biological function of CD200R signalling, with research required into 
its effect on myeloid cell cytokine/chemokine production, proliferation, survival, 
phagocytosis, chemotaxis and generation of microbial products. Much of our 
understanding of the immunological role of this interaction comes from CD200 knock 
out mice, but we still do not know why these mice exhibit heightened numbers of 
myeloid cells and many organs and tissues have yet to be studied, including the lung. 
I seek to address some of these issues and in so doing gain a fuller understanding of 
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the physiological significance of CD200 and its receptor before attempting to 
manipulate this potent signal during respiratory infection. 
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5.2 Results 
5.2.1 CD200 expression on distinct cellular populations within the lung 
The expression of CD200 within the lung has not been definitively investigated. We 
therefore examined the CD200 expression patterns on both stromal and hematopoietic 
cells within the lung compartment. Single cell suspensions were obtained from the 
lungs of C57BL/6 mice and hematopoietic cells were defined by expression of CD45 
by flow cytometric analysis (Fig. 5.1a). Hematopoietic cells were shown to exhibit 
differential levels of CD200 expression, reflecting the distinct subsets of cells within 
the hematopoietic population (Fig. 5.1b). The lung is a highly vascular organ and it 
was of interest to determine whether CD200 is expressed on endothelial cells in the 
lung, as has been reported at other sites 76. Endothelial cells were identified as 
CD31±CD45" by FACS analysis (Fig. 5.1a) and were demonstrated to express high 
levels of CD200 on their surface (Fig. 5.1c). Fibroblasts, identified by the expression 
of CD90, were also shown to express CD200 on their surface (data not shown). 
Comparable expression profiles were observed in the lungs of BALB/c mice (data not 
shown). 
Expression of CD200 has been reported on some subsets of epithelial cells in murine 
skin 89. Antibodies to specific epithelial cell markers stain poorly for flow cytometry, 
making it difficult to investigate CD200 expression on epithelial cells by this method. 
We have therefore utilised a method 426 that selectively isolates epithelial cells from 
lower aspects of the lung, primarily the alveoli and terminating bronchioles. Lungs 
were digested with dispase and CD45±, CD31+ and CD90+ cells were selectively 
depleted by MACS separation (Fig. 5.1d). The remaining cells appeared 
morphologically like epithelial cells and exhibited an appropriate FSc / SSc profile as 
adjudged by flow cytometry (data not shown). Furthermore, immunofluoresent 
staining for the type II epithelial cell marker pro-surfactant C, before and after 
depletion, showed a significant enrichment in these cells. Approximately 15% of cells 
freshly isolated from a naïve lung stained positive for pro-surfactant C, compared to 
around 65% after depletion (Fig. 5.1e). FACS analysis of isolated cells revealed 
CD200 to be expressed, but at two distinct levels of intensity (Fig. 5.1f). The differing 
CD200 expression levels most likely reflect distinct epithelial cell types and will 
demand further attention. 
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Figure 5.1 CD200 is expressed on hematopoietic and stromal cells within the naive lung. 
Lungs of naive C57BL/6 mice were digested with dispase and the single cell suspension 
stained with CD45-FITC, CD200-PE and CD31-APC. A representative FACS plot is shown 
for the differential CD31 and CD45 expression (a). Hematopoietic cells are defined as CD45+, 
CD31- [R1] and endothleial cells as CD31+, CD45- [R2]. Representative histogram overlays of 
CD200 expression gated upon the hematopoietic [R1] (b) and endothelial [R2] (c) cells. 
Epithelial cells were enriched through the negative selection of CD45+ and CD31+ cells by 
MACS separation. A representative FACS plot is shown for CD45 and CD31 expression after 
this selective depletion (d). To visualise the enrichment of epithelial cells, lung cells were 
stained for the type II pneumocyte marker pro-surfactant protein c (e I and III) and the vital 
dye propidium iodide (e II and IV) both before (e I and II) and after (e III and IV) CD45 and 
CD31 depletion. Representative immunofluoresent images are shown at x200 magnification. 
Isolated cells after depletion were stained with CD45-FITC and CD200-PE and two distinct 
intensities of CD200 expression were visible (f A and B). Naive C57BL/6 lungs were OCT 
inflated and cryostat section stained with CD200-biotin followed by streptavidin-Alexa-468. 
(g-i) Representative immunofluoresent images (x400 magnification) showing CD200 
expression in a naive lung. BV=blood vessel; B=bronciole; A=alveoli. 
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Immunofluoresent CD200 staining of OCT inflated naïve lung corroborated our 
findings by flow cytometry with strong staining visible upon endothelia surrounding 
blood vessels (Fig. 5.1g). Furthermore, epithelia around large bronchioles exhibited 
strong staining for CD200, whereas alveoli epithelia showed minimal expression (Fig. 
5.1g-i). These may reflect the differing levels of CD200 expression observed on 
epithelial cells by flow cytometric analysis, with lower expression corresponding to 
alveoli. 
We next investigated CD200 expression on hematopoietic cells. Myeloid cells in the 
lung did not express CD200 (data not shown), but expression was seen on 
lymphocytes. Flow cytometric analysis revealed that over 90% of C57BL/6 splenic 
B220+ cells expressed CD200 (Fig. 5.2a and c). CD19+ cells exhibited comparable 
CD200 expression (data not shown). This high expression was also observed on lung 
B cells (Fig. 5.2b) and conserved in numerous tissues including those B cells 
circulating in the blood (data not shown). However, a significantly lower percentage 
of B220+ cells in the bone marrow expressed CD200 (approximately 25%), implying 
that CD200 is up regulated during a developmental stage of B cells at this site (data 
not shown). 
CD200 is also reportedly expressed on some T cells (approximately 20% of human 
peripheral blood CD3+ T cells, and a significant percentage of murine splenic T cells 
(especially the CD4+ subset) 71'76'77). We showed expression on approximately 40 % 
of CD4+ and about 5-10 % of CD8+ T cells from the spleen (Fig. 5.2a) and lungs (Fig. 
5.2b) of C57BL/6 mice. BALB/c splenic and lung T cells also expressed comparable 
levels of CD200 expression (data not shown). No CD200 expression was detected on 
NK or NK T cell populations within the lung (data not shown). 
Studies in humans, rats and mice have reported CD200 expression on thymocytes 
71'76'77. Indeed, almost all human thymocytes are CD200 positive with higher levels on 
single positive (SP) cells than double positive (DP) and more intense staining on CD4 
SP than CD8 SP T cells. We found that levels of CD200 expression on thymocytes 
were considerably lower in C57BL/6 mice, and almost absent on DP thymocytes. 
Furthermore, comparable percentages of CD4 and CD8 SP T cells expressed CD200 
to that seen in the lung and spleen (30-35% on CD4+ and 10% on CD8+) (Fig. 5.2e 
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Figure 5.2 CD200 is expressed on B cells and some T cells within the naive lung. Single 
cell suspensions from lungs, spleens and thymus of C57BL/6 mice stained with anti-CD4-
FITC, anti-CD200-PE, anti-B220-PercP and anti-CD8-APC. The % of B220+, CD4+ and CD8+ 
cells expressing CD200 in the spleen (a) and lung (b) were adjudged by flow cytometry. (c) 
Representative FACS plots of spleen cells showing CD200 on each lymphocyte population. 
(d) Representative FACS plot of CD4 versus CD8 staining on thymocytes. Rl=CD4 single 
positive (SP); R2 = CD4/CD8 double positive (DP); R3=CD8 single positive. The % CD4 and 
CD8 SP and DP cells expressing CD200 in the thymus was adjudged by flow cytometry (e) 
and representative histogram overlays are shown for CD200 expression on each population (f). 
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and f). Whilst CD200 expression on mice thymocytes was lower than in humans the 
same pattern of relative levels of expression was conserved with CD4 SP > CD8 SP > 
DP T cells. 
Since CD200 expression was not ubiquitous on all T cell populations in the lung and 
spleen it was of interest to further dissect those populations that were positive. Flow 
cytometric analysis showed that whilst the majority of splenic CD200+ T cells 
expressed the a13 TCR, all CD4+ and CD8+ T cells possessing a 78 TCR were CD200 
positive (Fig. 5.3). CD200 was not expressed on CD103+ intraepithelial T cells (data 
not shown), and remarkably no expression was detected on CD25+ or Foxp3+ (data 
not shown). Comparable CD200 expression patterns were observed in T cells derived 
from the lung and in both lymphoid organs of BALB/c mice (data not shown). We 
did, however, observe some bias in CD200 expression with VD usage. Whilst the 
majority of V13 expressing T cells showed the same 35-40% expressing CD200, VI36, 
7, 9 and 11 showed an elevated percentage of CD200+ cells (Fig. 5.4). 
5.2.2 CD200 is up-regulated on T cells during pulmonary influenza infection 
We next examined expression of CD200 during influenza infection of C57BL/6 mice. 
CD200 expression remained unaltered on all stromal cells investigated (endothelia, 
epithelia, fibroblasts) throughout the course of the infection and no CD200 expression 
was observed on myeloid cells at any point (data not shown). A significant increase in 
CD200 expression was observed on T cell populations in the lungs of influenza 
infected mice; up to 80% of CD4+ and 40% of CD8+ T cells by day 7 after infection 
(Fig. 5.5a). The intensity of CD200 expression (determined by the geometric mean) 
also increased (data not shown). During an influenza infection, there is a significant T 
cell infiltrate into the lungs and subsequently the number of CD200+ T cells was 
greatly enhanced throughout the course of infection (Fig. 5.5b). The up-regulation of 
CD200 on T cells correlated with increased activation markers on these cells (data not 
shown). Similarly, there was a comparable increase in the percentage and number of 
CD200+ T cells in the draining mediastinal lymph node through out the course of 
infection (data not shown). In contrast, T cells sampled from the airways by BAL at 
the peak of inflammation (day 7) showed a marked drop in CD200 expression 
compared to the lung (Fig. 5.5c). Thus it would appear that in the most inflammatory 
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Figure 5.3 CD200 expression on 1,8 T cells. Spleens were removed from naïve 
C57BL/6 mice and homogenised to obtain a single cell suspension. Cells were 
subsequently stained with different combinations of anti-a13 TCR-FITC, anti-y6 TCR-
FITC, anti-CD200-PE, anti-CD4-PercP and anti-CD8-APC. Representative FACS dot 
plots are shown for CD4+ and CD8+ T cells stained for CD200 versus oci3 TCR and y5 
TCR. Plots are representatives from 5 mice in each of three separate experiments. 
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Figure 5.4 CD200 expression with different Vbeta TCRs. Spleens were removed from 
naïve C57BL/6 mice and homogenised to obtain a single cell suspension. Cells were 
subsequently stained with different combinations of each anti-Vbeta-FITC with anti-CD200-
PE, anti-CD4-PercP and anti-CD8-APC. (a) Representative FACS dot plots are shown for 
CD4+ T cells stained for CD200 versus each Vbeta. Plots are representatives from 5 mice in 
each of three separate experiments. (b) The average percentage of each Vbeta expressing 
CD200. Percentages are only depicted for Vbetas that represented in excess of 1 percent of all 
CD4+ T cells. Red dashed line = average CD200 expression. 
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Figure 5.5 CD200 expression during pulmonary influenza infection. C57BL/6 mice were 
infected with 50 HA influenza, BAL and lung removed 3 and 7 days after infection. Single 
cell suspension from lung and BAL were stained with anti-CD4-FITC, anti-CD200-PE, anti-
B220-PercP and anti-CD8-APC. (a) The % CD4+ and CD8+ T cells and B cells expressing 
CD200 in the lung throughout the course of the influenza infection was determined by flow 
cytometry. (b) Total viable lung cells were enumerated by trypan blue exclusion and the 
number of CD200+ cells calculated by: % CD200+ x no. of cells. Results represent mean 
values ± SEM from 5 mice per group and are representative of 3 separate experiments. (c) 
Representative histogram overlays showing CD200 expression on CD4+ and CD8± T cells 
and B cells in the lung and BAL of influenza infected mice 7 days after infection. 
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of sites during an influenza infection CD200 expression is strikingly down regulated. 
By day 14 post influenza infection, CD200 expression upon T cells within the lung 
tissue and BAL had returned to normal levels (data not shown). 
The percentage CD200+ B cells in the lung remained high throughout the course of 
influenza infection (Fig. 5.5a), and only increased in numbers with the general 
increase in cellularity (Fig. 5.5b). However, once again CD200 expression was 
significantly reduced on B cells sampled from the BAL at day 7 post influenza 
infection (Fig. 5.5c). We have conducted numerous studies to infer what stimuli may 
cause down-regulation of CD200 on the surface of B cells in vitro, treating both 
purified B cells and those in splenic cultures with an array of TLR ligands, cytokines, 
CD40, and crosslinking antibodies to surface Ig. All stimuli failed to evoke any 
alteration in the levels of CD200 on B cells (data not shown). 
During influenza infection there is a dramatic influx of lymphocytes to the infected 
lung, peaking at day 7 after infection. This cellular infiltrate has largely subsided by 
day 10, largely due to apoptosis by activation induced cell death. It would be rational 
for these apoptotic cells to up-regulate CD200 so as to deliver an inhibitory signal to 
macrophages that clear them from the inflamed site. Indeed, we observed a significant 
percentage of annexin V positive lymphocytes expressing CD200 in the draining 
lymph nodes, lung and BAL (MLN>lung>BAL) (Fig. 5.6). Interestingly, virtually all 
CD200+ cells in the airways (BAL) are apoptotic, which may offer one plausible 
reason why the % CD200 expressing cells drop markedly at this site (Fig. 5.6b). 
5.2.3 CD200 expression on T cells is dependent on dose and exposure to antigen 
It has been shown previously that approximately 60% of CD25+ human peripheral 
blood CD3+ T cells express CD200 after a 72 hour exposure to Concanavilin A, 
indicating that CD200 is up-regulated on activated T cells 77. To further characterise 
the induction of CD200 on activated T cells we used the D011.10 transgenic system, 
where —95% of CD4+ T cells possess a TCR that recognizes Ovalbumin. D011.10 
splenocytes were cultured with different doses of OVA peptide and CD200 
expression assessed at different time points by flow cytometry. The percentage of 
CD200+ CD4+ T cells and the geometric mean of CD200 expression increased with 
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Figure 5.6 CD200 exhibits strong expression on apoptotic cells during influenza 
infection. C57BL/6 mice were infected with 50 HA influenza, and BAL, lung and 
mediastinal lymph node were removed 7 days after infection and single cell suspension 
stained with anti-CD200-FITC and annexinV-PE. Lymphocytes (defined by Fsc/Ssc 
profile) undergoing apoptosis were identified by expression of Annexin-V as adjudged 
by flow cytometry. (a) The percentage of apoptotic lymphocytes expressing CD200 was 
subsequently determined by flow cytometry. (b) Representaive dot plots showing 
CD200 versus Annexin-V staining gated upon the lymphocyte population of the lung, 
BAL and mediastinal lymph node. 
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the dose of OVA peptide and with exposure time (Fig. 5.7a and b). The percentage of 
CD4+ T cells expressing CD200 showed a significant increase as early as 6 hours at 
the higher doses (10 and 100µg/m1) of OVA peptide and peaked by 48 hours (Fig. 
5.7a). The intensity of CD200 expression, as determined by the geometric mean, did 
not show an increment until 24 hours, before peaking at 48 hours and then dropping 
again by 72 hours (Fig. 5.7b). 
We then examined the kinetics of T cell CD200 expression relative to other activation 
markers. ICOS and OX40 are T cell co-stimulatory molecules that are induced on the 
surface of T cells after antigen exposure, with ICOS expressed by 12 hours after 
CD28 ligation and OX40 at 24 to 48 hours. Very little ICOS or OX40 expression was 
observed on the surface of CD4+ T cells until 24 hours from which point both 
increased dramatically as a function of both time and dose of OVA peptide. ICOS was 
induced quicker than OX40 as may be anticipated but was seen to decline at higher 
doses of antigen (Fig. 5.8a and b). Interestingly, with increasing doses of OVA 
peptide (for 24 hours) there appeared to be a shift from ICOS single positive CD4+ T 
cells to those co-expressing ICOS and CD200 (Fig. 5.8c). Conversely, most OX40+ 
CD4+ T cells expressed CD200 (Fig. 5.8c). The same pattern of sequential expression 
was apparent if the levels of ICOS, CD200 and OX40 were assessed at sequential 
time points (data not shown). This would imply that upon TCR triggering, ICOS is up 
regulated first, followed by CD200 and then OX40. 
We next examined CD200 expression on Thl or Th2 skewed D011.10 T cells. 
Intriguingly, whilst both Thl and Th2 cells expressed CD200, levels of expression 
were significantly higher on Thl cells (Fig. 5.9a). To ascertain the role of Thl and 
Th2 cytokines in defining the expression levels of CD200, D011.10 splenocytes were 
cultured with OVA peptide for 48 hours in the presence of neutralising antibodies to 
IL-12, IL-4 and IL-10 and CD200 expression investigated by flow cytometry. 
Neutralisation of IL-12, a strong Thl defining cytokine, had no effect upon CD200 
expression (Fig. 5.9b). Conversely, neutralisation of IL-4 and IL-10 led to an increase 
in the intensity of CD200 expression (Fig. 5.9c and d). Thus it would appear that the 
presence of Th2 cytokines limits the expression of CD200 on activated T cells. 
Lymphocyte expression of CD200 was subsequently investigated in the lungs of 
C57BL/6 mice at day 12 after C. neoformans infection, which induces a strong Th2 
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Figure 5.7 CD200 is up-regulated on activated T cells. Splenocytes from D011.10 
mice were cultured with different doses of OVA peptide, and at different time points 
cells were stained with anti-CD200-PE, anti-CD4-PercP and KJ126-APC (anti 
D011.10 TCR). The percentage KJ126+ CD4+ T cells expressing CD200 (a) and the 
intensity (geometric mean) of this expression (b) was determined by flow cytometry at 
0, 3, 6, 10, 24, 48 and 72 hours after the addition of OVA peptide. The different doses 
of OVA used are shown on the x-axis and the different time points are shown as 
separate lines as depicted in the figure. Results represent mean values ± SEM from 5 
mice per group and are representative of 3 separate experiments. 
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Figure 5.8 CD200 is up-regulated on activated T cells temporally after ICOS but before 
0X40. Splenocytes from D011.10 mice were cultured with different doses of OVA peptide, 
and at different time points cells were stained with anti-ICOS-biotin or anti-0X40-biotin and 
anti-CD200-PE, anti-CD4-PercP and KJ126-APC (anti D011.10 TCR), followed by 
streptavidin-FITC. The % K.1126+ CD4' T cells expressing ICOS (a) and 0X40 (b) were 
determined by flow cytometry at 0, 3, 6, 10, 24 and 48 hours after the addition of OVA 
peptide. Results represent mean values ± SEM from 5 mice per group and are representative 
of 3 separate experiments. (c) Representative dot plots showing CD200 versus ICOS/OX40 
expression at different doses of OVA after 24 hours of stimulation with OVA peptide. 
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Histogram overlay showing CD200 expression on Thl (red) and Th2 (blue) skewed cells. 
Table shows differential expression of intracellular cytokines as adjudged by flow cytometry. 
D011.10 splenocytes were cultured with 1 µg/ml OVA peptide in the presence of a control 
antibody or a neutralizing antibody to IL-12 (b), IL-4 (c), or IL-10 (d). After 48 hours, cells 
were stained with anti-CD200-PE, anti-CD4-PercP and KJ126-APC (anti D011.10 TCR). The 
intensity (geometric mean) of CD200 expression on the CD4±KJ126+ T cells was determined 
by flow cytometry. (e) Mice were infected with 104 C. neoformans, and lung removed 12 days 
after infection. Single cell suspension from lung was stained with CD4-FITC, CD200-PE, 
B220-PercP and CD8-APC. The percentage CD4+ and CD8+ T cells and B cells expressing 
CD200 in the lung was determined by flow cytometry. Results represent mean values ± SEM 
from 5 mice per group and are representative of 3 separate experiments. *=p<0.05, **=p<0.01. 
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response. Again, only limited induction of CD200 on CD4+ and CD8+ T cells was 
observed in this Th2 environment (Fig.5.9e), relative to the potent up-regulation seen 
in the strongly Thl driven influenza infection (Fig. 5.5). CD200 expression on B cells 
was high and comparable throughout the course of C. neoformans infection 
(Fig.5.9e). 
5.2.4 CD200 expression on T cells is TCR dependent 
To confirm TCR signalling is required to induce CD200 on T cells, CD4+ T cells were 
purified from the spleens of C57BL/6 mice by magnetic bead separation and 
incubated with antibodies to CD3 and CD28 for 48 hours. CD3 ligation alone was 
sufficient to increase the % and GM of CD200 expression (Fig. 5.10a, b and c). Co-
incubation with antibodies to CD3 and CD28 caused a modest, but not significant 
increase in CD200 expression (Fig. 5.10a), and no alteration in the intensity of CD200 
expression (Fig. 5.10b). Addition of OX4OL:Fc fusion protein, which has been shown 
to impart a signal through OX40, to this culture induced a striking increase in the 
CD200 GM (Fig. 5.10b), implying that late co-stimulatory signals can augment 
expression of CD200. To confirm that induction of CD200 on T cells is TCR 
signalling dependent we utilised SKG mice. SKG mice possess a mutation in the gene 
encoding (-associated protein of 70 kDa (ZAP-70). These mice have a diminished T 
cell response to antigen due to the attenuated signal transduction through ZAP-70, and 
are hypo-responsive to polyclonal TCR stimulation in vitro. Splenocytes from wild 
type and SKG mice were incubated with combinations of anti-CD3 and anti-CD28 
antibodies for 48 hours and CD200 expression levels assessed by flow cytometry. 
Whereas CD3 ligation caused an increase in CD200 expression on both CD4+ (Fig. 
5.11a, b and e) and CD8+ (Fig. 5.11c, d and e) T cells from wild type mice, no such 
induction was observed on those from SKG mice (Fig. 5.11). Reassuringly, 
PMA/Ionomycin, which transduces a signal to TCR distal pathways, induced a 
comparable increase in CD200 expression on T cells derived from both wild type and 
SKG mice (data not shown). 
203 
b. 
350 
300 
250 
= 200 
N 150 
100 
50 
0 
0.3 0.1 
Kr' 
6.9 
,n i 	 4 :2
1 
00 
a-CD3/ CD28 
1)1 	102 	.3 	.4
0 
.'210 Ip1 	1p2 	Ipp 	1p4 
OX4OL:Ig a-CD3/ CD28/ OX4OL:Ig 
0.3 20.3 
,02 	too 
	,041 
a. 
90 
80 
cz 70 
(-4,, 60 
rt 50 
40 
c,\* 30 
20 
10 
0 
   
  
 
NMI 
  
  
UT a-CD3 a-CD28 a-CD3/ a-CD3/ 
CD28 CD28/ 
OX4OL:Ig 
I 1  
UT a-CD3 a-CD28 a-CD3/ a-CD3/ 
CD28 CD28/ 
OX4OL:Ig 
C. UT a-CD3 a-CD28 
    
• 
CD200 	  
Figure 5.10 CD200 up regulation on activated T cells requires TCR ligation. C57BL/6 
splenic CD4+ T cells were isolated by MACS separation and cultured with different 
combinations of plate bound, anti-CD3 antibody (5 µg/ml), soluble anti-CD28 antibody (1 
µg/m1) and OX4OL:Ig fusion protein (10 µg/ml) . After 48 hours of incubation with the 
respective stimuli, T cells were stained with anti-CD200-PE, anti-CD4-PercP and anti-
OX40-biotin (followed by streptavidin-APC). The percentage of CD4+ T cells expressing 
CD200 (a) and the intensity (geometric mean) of CD200 expression (b) following treatment 
with each stimulus were determined by flow cytometry. Results represent mean values ± 
SEM from 5 mice per group and are representative of 3 separate experiments. (c) 
Representative dot plots showing CD200 versus OX40 expression after 48 hours with 
different stimuli is shown. 
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Figure 5.11 TCR signalling is critical for up-regulation of CD200 on T cells. Splenocytes 
from naïve BALB/c or SKG mice were cultured with different combinations of plate bound 
a-CD3 antibody, soluble a -CD28 antibody. After 48 hours of incubation with the respective 
stimuli, T cells were stained with anti-CD200-PE, anti-CD4-PercP and anti-CD8-APC. The % 
of CD4+ (a) and CDS+ (c) T cells expressing CD200 and the intensity (geometric mean) of 
CD200 expression on CD4+ (b) and CD8+ (d) T cells following treatment with each stimulus 
were determined by flow cytometry. Results represent mean values ± SEM from 5 mice per 
group and are representative of 3 separate experiments. (e) Representative histogram overlays 
showing CD200 expression on CD4+ and CD8+ T cells from wild type and SKG mice 
following stimulation with an anti-CD3 antibody. *---p<0.05, **=p<0.01. 
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5.2.5 Down-regulation of CD200 expression 
Splenic T cells purified by MACS separation exhibited a potent induction of CD200 
expression when incubated with PMA / Ionomycin. However, as seen with the 
D011.10 system whilst the percentage T cells expressing CD200 plateaus with time, 
the intensity of expression declines (Fig. 5.12a). Comparable results were also 
observed following treatment with agonistic anti-CD3 antibody (data not shown). The 
reduced CD200 expression at later time points may reflect the natural kinetics of 
CD200 expression or exhaustion of antigen. In the presence of PMA/Ion T cells 
showed reduced CD200 expression at 72 hours compared to 24 hours (Fig. 5.12b). T 
cells were subsequently stimulated with PMA/Ionomycin for 24 hours, washed to 
remove the activating stimuli and re-cultured for a further 48 hours. Removal of 
PMA/Ion after 24 hours, further reduced CD200 expression at 72 hours relative to 
when PMA/Ion was maintained in cultures (Fig. 5.12b). This would imply that the 
reduction in CD200 expression may be a result of reduced antigenic stimulus rather 
than just the natural kinetics of expression. 
Cyclosporin was subsequently utilised to study the effect of terminating T cell 
signalling on CD200 expression. D011.10 splenocytes were cultured with different 
doses of OVA peptide for 24 hours to induce CD200 expression, and then for a 
further 72 hours with or without cyclosporin. Upon addition of cyclosporin to the 
splenocyte cultures, CD200 expression was largely suppressed at later time points and 
was generally maintained at a comparable level to that seen at 24 hours after initial 
stimulation (Fig. 5.12c and d). This once again proves the necessity for TCR 
signalling in the induction of CD200 expression. 
5.2.6 CD200R expression in the naïve lung 
The CD200 receptor is primarily restricted to the myeloid lineage with studies in 
mice, rats and humans describing expression on monocytes, macrophages, dendritic 
cells, neutrophils, basophils and mast cells. However, some studies in mice and 
humans have reported weak CD200R expression on T cells, with RT-PCR analysis of 
cDNA libraries of a variety of purified cell types showing preferential expression on 
Th2 cells. As with CD200, the levels of the receptor are poorly described in the 
murine lung although RT-PCR analysis has demonstrated its existence at this site. We 
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Figure 5.12 Resolution of CD200 expression. (a) Splenic T cells derived from C57BL/6 
mice were isolated by MACS separation and stimulated with PMA/Ion. At 24, 48 and 72 hours 
after the addition of PMA / Ionomycin, T cells were stained with anti-CD200-PE and anti-
CD4-PercP. The % of CD4+ T cells expressing CD200 and the intensity / geometric mean of 
CD200 expression were determined by flow cytometry. (b) Splenic CD4+ T cells were 
stimulated as before with PMA/Ion and CD200 expression determined at different time points 
by FACS. In some cultures, PMA/Ion was removed after 24 hours of stimulation and cultured 
for a further 48 hours in media alone. Representative histogram overlay is shown depicting 
CD200 expression after 24 hours (blue) and 72 hours (red) of PMA/Ion stimulation, and for 
cells cultured with PMA/Ion for 24 hours and media alone for a further 48 hours (green). (c 
and d) D011.10 splenocytes were cultured with different doses of OVA peptide for 24 hours 
and the % expressing CD200 (c) and intensity of expression (d) adjudged by flow cytometry. 
At this time point, splenocytes were cultured for a further 72 hours with or without 
cyclosporin A. CD200 expression was assessed at 24 hour periods by flow cytometry. Green 
line at time 0 hours depicts CD200 expression of un-stimulated T cells. Results represent 
mean values ± SEM from 5 mice per group and are representative of 3 separate experiments. 
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therefore characterised CD200R expression on a variety of cell types within the lung 
and at other distal sites by flow cytometry. 
Distinction between efferent myeloid compartments within the lung was achieved 
based upon the variable expression of CD1 lb and CD11c as discussed previously, 
with further discrimination being based upon levels of Gr-1 and MHC-II expression. 
Neutrophils within the lung compartment of C57BL/6 mice were devoid of CD200R 
expression (Fig. 5.13), in stark contrast to granulocytes derived from the spleen, blood 
and bone marrow that were all demonstrated to exhibit some levels of expression 
(data not shown). Monocytes/ small macrophages in the lung were demonstrated to 
express some CD200R on their surface (Fig. 5.13), at comparable levels to that seen 
in the spleen, blood and bone marrow (data not shown). Dendritic cells were present 
in very low numbers, but did appear to exhibit minimal levels of CD200R expression 
(Fig. 5.13). Most striking was the significant CD200R expression on the surface of 
alveolar macrophages (Fig. 5.13), which was present at a higher level to that observed 
on myeloid cells from any other site investigated. Immunofluorescent staining for 
CD200R on OCT inflated naive lungs verified this high level of receptor expression 
on alveolar macrophages (Fig. 5.14d). CD200R expression was also analysed on T 
cells, B cells, NK cells and various stromal cells at different sites and contrary to 
some previous reports no CD200R expression was observable (data not shown). 
5.2.7 Increase in CD200R expression during influenza infection 
We next examined CD200R expression during influenza infection. Lungs were 
isolated from naive and influenza infected C57BL/6 mice at days 2, 7 and 14 after 
infection. As seen in the naive mice, CD200R was not expressed on lymphoid 
populations, being restricted to the myeloid compartment (data not shown). The 
majority of alveolar macrophages expressed CD200R in naïve mice, but the intensity 
of this expression was increased during influenza infection peaking at day 14, a time 
when inflammation has largely resolved (Fig. 5.14a-c). The percentage of monocytes / 
small macrophages expressing CD200R in the lung also increased during influenza 
infection (Fig. 5.14a), and upon activation / maturation (adjudged by elevated CD11b, 
but still intermediate Ly-6G), macrophages showed a dramatic increase in CD200R 
expression, which peaked at day 14 (Fig. 5.14a-c). Neutrophils did not express 
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Figure 5.13 CD200 Receptor expression on myeloid cells within the naïve lung. 
Lungs were removed from naïve C57BL/6 mice and homogenised to obtain a single cell 
suspension. Cells were subsequently stained with anti-Ly6G-FITC, anti-CD200R-PE, 
anti-CD11b-PercP and anti-CD11c-APC. Distinction between different lung myeloid 
populations was based broadly on the basis of differential CD1 lb and CD11c expression 
and verified with Ly6G expression. (a) A representative FACS dot plot of CD1 lb versus 
CD11c from a naïve lung shows the distinction between different myeloid cells. 
Representative histogram overlays of CD200R expression are subsequently shown for 
each of these myeloid populations (blue =isotype control; red =stained). 
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Figure 5.14 CD200 Receptor is up regulated on myeloid cells during influenza infection. 
Lungs were removed from C57BL/6 mice at days 0, 2, 7. and 14 of influenza infection and 
homogenised to obtain a single cell suspension. Cells were subsequently stained with anti-Ly6G-
FITC, anti-CD200R-PE, anti-CD11b-PercP and anti-CD11c-APC. The % of each myeloid 
population expressing CD200R (a) and the intensity (geometric mean) of this expression (b) were 
determined by flow cytometry. Results represent mean values ± SEM from 5 mice per group and 
are representative of 3 separate experiments. (c) Representative histogram overlays of CD200R 
expression are shown for each of these myeloid populations during the course of influenza 
infection (black = isotype control; blue = naive; yellow = day 2; red = day 7; green = day 14). (d) 
Lungs from naive and influenza infected (day 7 after infection) C57BL/6 mice were OCT inflated 
and cryostat section stained with rat anti-mouse-CD200R followed by goat anti-rat-Alexa-468. 
Representative immunofluoresent images (x400 magnification) of CD200R expression are 
shown. 
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CD200R in the naive lung, but the percentage and intensity of expression increased 
during the course of influenza infection (Fig. 5.14a-c). Likewise, dendritic cells 
expressed minimal CD200R in a naïve lung, but the percentage bearing the receptor is 
increased slightly upon influenza infection (Fig. 5.14a) and the intensity of expression 
again peaked at day 14 (Fig. 5.15b). Immunofluorescent staining for CD200R in OCT 
inflated lung from naïve and day 7 influenza infected C57BL/6 mice showed an 
increase in the number of cells bearing CD200R as may be anticipated and staining 
appears to be more dense implying greater expression levels (Fig. 5.14d). 
As with our CD200 studies we next investigated what may up-regulate CD200R. 
using bone marrow derived macrophages. The majority of bone marrow (BM) 
macrophages expressed a basal level of CD200R (Fig. 5.15), but stimulation of the 
macrophages with IFN-y and LPS, and to a lesser extent influenza, caused an 
augmentation in the % positive cells (Fig. 5.15a and c) and more strikingly the level 
of expression (Fig. 5.15b and c). The induction of CD200R expression by the 
different stimuli appeared to be largely dose dependent with 1 Ong/ml IFN-'y causing 
only a modest increase in the CD200R expression, but 10Ong/m1 causing a striking 
up-regulation (Figure 5.15a, b and d). Increasing the dose of influenza also caused a 
modest increase in the extent of CD200R up-regulation on BM macrophages, but LPS 
seemed to be a potent inducer of expression even at low concentrations. Furthermore, 
the increase in CD200R expression induced by these stimuli was temporally 
dependent, with a greater level of expression observed at 48 hours than at 24 hours 
(Fig. 5.15a, b and e); although CD200R expression seemed to subsequently drop 
marginally by 72 hours with IFN-T and LPS treatments. 
5.2.8 CD200R signalling in bone marrow macrophages reduces the production of 
pro-inflammatory cytokines 
Manipulation of CD200R signalling has been utilised therapeutically to deliver an 
inhibitory signal to the myeloid compartment in conditions characterised by excessive 
inflammation. However, the exact manner by which the myeloid cell phenotype and 
function is modulated is poorly defined. We therefore investigated the effect that 
signalling through CD200R had on BM macrophages stimulated with a variety of 
inflammatory products/mediators. 
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Figure 5.15 CD200 receptor is up-regulated on bone marrow derived macrophages by 
inflammatory stimuli in a dose and time dependent manner. BM derived macrophages were 
cultured in the presence of varying doses of IFN-7, LPS and influenza and at different time 
points cells were stained with anti-CD200R-PE. The percentage BM macrophages expressing 
CD200R (a) and the intensity (geometric mean) of this expression (b) was determined by flow 
cytometry at 0, 24, 48 and 72 hours after the addition of the relevant stimulus. Results represent 
mean values ± SEM from 5 mice per group and are representative of 3 separate experiments. (c) 
and (d) Representative histogram overlay showing CD200R expression on BM macrophages 
after culturing for 48 hours with stimuli shown (e) Representative histogram overlay showing 
CD200R expression on BM macrophages after culturing with IFN-1 for 0 hours (untreated; 
blue), 24 hours (yellow), 48 hours (orange) or 72 hours (red). 
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Cytokine production by BM macrophages was assessed by performing cytokine bead 
array (CBA) on cell supernatants at 24 and 48 hours following stimulation. 
Comparable cytokine production profiles were observed at 24 and 48 hours but only 
the latter time point are presented and discussed here. Unstimulated BM macrophages 
produced negligible cytokines either in the presence of a control antibody or an 
agonistic antibody to CD200R (0X110) (Fig. 5.16). IFN-y stimulated BM 
macrophages produced significantly less TNF, IL-6 and MCP-1 when co-incubated 
with the agonistic OX110 antibody. There were no differences in the levels of IL-12 
and IL-10 with incubation with OX110 (data not shown). Similar, but more potent, 
reductions in TNF, IL-6 and MCP-1 were observed in influenza treated macrophages 
that were incubated with OX110 (Fig. 5.16). Again no differences in IL-12 or IL-10 
production were apparent, although CD200R signalling did cause a modest reduction 
in IFN-y production (data not shown). Treatment of BM macrophages with LPS 
caused potent cytokine production that remained largely unaltered by treatment with 
OX110, although there was a small but significant reduction in IL-6 (Fig. 5.16). 
Signalling through CD200R also caused a subtle but reproducible reduction in the 
levels of nitric oxide produced by untreated and IFN-y and LPS treated bone marrow 
macrophages. Reduction in pro-inflammatory cytokine production following 
signalling through CD200R was not attributable to enhanced macrophage apoptosis as 
negligible differences were seen with TUNEL assay or with annexin-V staining (data 
not shown). 
A previous study conducted in BM derived mast cells demonstrated that signalling 
through CD200R reduced production of TNF and IL-1384. Furthermore, the signalling 
pathway induced by CD200R ligation was partially characterised, with the receptor 
being tyrosine phosphorylated and Dok-1 and Dok-2 adaptor proteins subsequently 
recruited 83. Dok-1 and -2 are then phosphorylated and bind to RasGAP and SHIP, 
leading to inhibition of Ras and ERK (Fig. 5.17a). We determined whether the same 
signalling pathway was utilised in BM macrophages stimulated with IFN-y overnight 
to up-regulate CD200R expression and then incubated with a control or an agonistic 
antibody to CD200R for different periods of time. Dok-2 was immunoprecipitated 
from cell lysates and immunoblotted with an antibody to Dok-2 or to phospho-
tyrosine. Signalling through CD200R did not alter the levels of Dok-2, but there was 
an observable increase in the phosphorylation of this adaptor protein (Fig. 5.17b). 
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Figure 5.16 Signalling through CD200R reduces pro-inflammatory cytokine 
production by BM macrophages. BM derived macrophages were stimulated with 10 
ng/ml IFN-y, 100 ng/ml LPS or 5 HA influenza in the presence of 10 pg/ml of an isotype 
control antibody (closed bars) or an agonistic antibody to CD200R (0X110; open bars). At 
48 hours after addition of stimuli, culture supernatants were removed and inflammatory 
cytokine levels were measured by cytometric bead array (CBA). Levels of nitric oxide in 
the supernatant were also measured. Results represent mean values ± SEM from triplicate 
samples and are representative of 3 separate experiments. *=p<0.05, **=p<0.01. 
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Figure 5.17 Signalling through CD200R induces tyrosine phosphorylation on Dok-2. (a) 
Proposed model for CD200R-mediated inhibition of myeloid cell activation83. Triggering 
CD200R by CD200 induces its phosphorylation and recruitment of Dok 1 and Dok2. Dokl 
and Dok2 are phosphorylated and bind to RasGAP and SHIP, which leads to inhibition of 
Ras and ERK activation. Other unknown molecules may mediate the inhibition of p38 
MAPK and JNK activation. (b) Bone marrow (BM) derived macrophages were stimulated 
with 10Ong/m1 IFN--y for 16 hours to up-regulate CD200R expression. Cells were then 
stimulated with 10 µg/m1 control Ig or OX110 for different lengths of time as indicated in 
the figure. Dok2 was then immunoprecipitated from cell lysates and immunoblotted with the 
indicated Abs. 
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Whilst this would corroborate the pathway seen with mast cells, further investigation 
is required to investigate other signalling partners in the postulated pathway. 
Signalling through CD200R did not cause a striking universal reduction in any BM 
surface activation markers in the same manner it did pro-inflammatory cytokines. 
Indeed, with IFN-y and LPS stimulation, addition of OX110 appeared to slightly 
augment the surface expressed levels of CD86, CD1lb and OX4OL (Fig. 5.18). 
Representative histogram overlays of CD86, CD1 lb and OX4OL are shown following 
IFN-y stimulation in the presence of a control antibody or OX110 (Fig. 5.18c, f and i). 
However, there did appear to be a general reduction in CD86 and OX4OL expression 
with the addition of OX110 to influenza stimulated bone marrow macrophages (Fig. 
5.18a, b, g and h). 
5.2.9 Effects of CD200R agonists on bone marrow dendritic cell phenotype and 
function 
We next determined whether signalling through CD200R altered the phenotype or 
function of dendritic cells similar to macrophages. BM derived dendritic cells were 
stimulated with different concentrations of LPS, flagellin, CpG, Poly:IC, influenza, 
IFN-y, IL-12 and IL-10 in the presence of a control antibody or OX110. None of these 
stimuli altered the level of CD200R expression on the surface of bone marrow 
dendritic cells (data not shown). We also analyzed expression of the cell surface 
markers CD11b, CD1 1 c, CD80, CD86, OX4OL and MHC II, as well as secretion of 
IL-la, IL-6, IL-10, IL-12p70, MCP-1, IFN-y and TNF. We did not observe any effect 
of CD200R agonists on these parameters (data not shown). CD200R agonists also had 
no effect on DC-induced CD4+ T cell proliferation, with ovalbumin loaded, LPS 
stimulated dendritic cells providing comparable CFSE incorporation and activation of 
CD4+ T cells in the presence of control antibody or OX110 (Fig. 5.19a). Cytokine 
production by these dendritic cell activated CD4+ T cells were also assessed by 
intracellular cytokine staining and a small but reproducible reduction in IFN-y 
production was observed with CD200R agonist, but no differences were apparent in 
IL-4 production (Fig. 5.19b). In the context of these experiments it is important to 
remember that TLR4, the ligand for LPS, is also expressed by activated T cells. 
However, it has been demonstrated that LPS fails to induce significant T cell 
216 
* 
I 
-M4 
10 100 	- 
CD86 
Control Ig 
1:1 OX110 
c. 
f. 
4. * T 
100 	-1.61 
CD11b 
d. 
90 
85 ' 
,-180 
E 75 ' 
X 70' 
65 
60 
e. 
450 ' 
400 ' 
350' 
© 300 • 
-1= 250 ' 
200 • 
A 150 • 
C-.) 100 ' 
50 ' 
0 	 
a. 
90 
80. 
70• 
a 60. 
50- 
C.) 40. 
30. 
20. 
10. 
0 	 
b. 
350- 
* 	* * 	 300 
* 	250. 
200. 
°A) 150-
C-) 100. 
50. 
	
0 	 
g. 	 h. i. 
85• 	* * 	 170 
80' 1 in.. 160 ' 
I 
;71. 65 • 
C 60 • 
55 • 
' 	Ill 
45 • 
	I 
	--1 
7 r=  120 
04 130 ' 
X 110 ' 
° 50 • 	 ©100 • 
90' 
.4 75 . 	 150 ' 
= 70 • C... 140 ' 
40 	 80 	 
Media IFN-y LPS Flu 	Media IFN-y LPS Flu 
* * * 
-}- 
v,. ;OA 
Figure 5.18 Signalling through CD200R enhances expression of surface activation 
markers. Bone marrow (BM) derived macrophages were stimulated with 10 ng/ml 
100 ng/ml LPS or 5 HA influenza in the presence of 10 µg/ml of an isotype control antibody 
(closed bars) or an agonistic antibody to CD200R (0X110; open bars). At 48 hours after 
addition of stimuli, macrophages were stained with anti-CD86-PE, anti-CD1 lb-PercP and 
anti-OX40L-biotin, with a secondary streptavidin-APC staining step. The percentage of 
macrophages expressing CD86 (a), CD1 lb (d) and OX4OL (g) as well as the intensity 
(geometric mean) of expression of CD86 (b), CD1 lb (e) and OX4OL (h) were determined by 
flow cytometry. Results represent mean values ± SEM from 5 mice per group and are 
representative of 3 separate experiments. Representative histogram overlays are also shown 
for expression of CD86 (c), CD1lb (f) and OX4OL (i) on IFN-y stimulated macrophages 
treated with an isotype control antibody (blue) or OX110 (red). *=p<0.05, **=p<0.01. 
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Figure 5.19 Signalling through CD200R does not alter antigen presentation by 
dendritic cells. BM derived dendritic cells were stimulated with 100 ng/ml LPS in the 
presence of 10 µg/m1 ovalbumin for 3 hours and then cultured with CFSE labelled D011.10 
OVA-specific CD4+ T cells. A control antibody or agonistic antibody to CD200R (0X110) 
was also added to the cultures at a concentration of 10 µg/ml. After 96 hours of incubation, 
T cells were stained with anti-CD25-PE and anti-CD4-PercP and analysed by flow 
cytometry. (a) Representative FACS plots are shown for CD25 expression versus CFSE 
incorporation for CD4+ T cells that had been presented antigen in the presence of control 
antibody or OX110. (b) Comparable cultures were set up with T cells that were not labelled 
with CFSE, and at the end of the 96 hour stimulation, cells were incubated for 3 hours in the 
presence of Brefeldin A and stained for intracellular IFN-y and IL-4. Representative FACS 
plots are shown for IFN-y expression versus IL-4 expression for CD4+ T cells that had been 
presented antigen in the presence of control antibody or OX110. 
218 
proliferation or cytokine production upon binding to the T cell TLR4 427. It is likely 
dendritic cells will be modulated in other ways through CD200R, however, to date, 
we have not identified the relevant in vitro conditions needed to observe CD200R-
mediated modulation of dendritic cell function. 
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5.3 Discussion 
5.3.1 CD200R signalling reduces pro-inflammatory cytokine production by 
macrophages. 
We show that addition of an agonistic antibody to CD200R is capable of reducing 
pro-inflammatory cytokine production by BM macrophages in vitro in response to 
IFN-y and influenza but not LPS. We do not, however, see such a marked reduction in 
the activation associated surface markers on BM macrophages following ligation of 
CD200R. These findings are largely supported by a recent study that demonstrates the 
potential of CD200R agonists to suppress TNF and IL-6 production by mouse 
peritoneal macrophages stimulated with IFN-y. Similarly, IL-17 induced IL-6 
production by peritoneal macrophages is also suppressed 96. However, once again, 
LPS induced production of TNF is unaffected by signalling through CD200R. The 
authors postulate that the inability of CD200R agonist to suppress LPS induced 
cytokine production may signify that TLR ligand induced signalling pathways are not 
susceptible to this form of inhibition. However, it is becoming increasingly apparent 
that much of the influenza induced cytokine production may be mediated via TLR 
signalling, which would contradict this hypothesis. However, it is possible that 
influenza induced cytokine production is also largely evoked simply by the infection 
and replication of the pathogen within the macrophage. Signalling through CD200R 
also suppresses IFN-y induced IL-8, MIG and IP-10 at the RNA and protein level by 
the human monocytic cell line U937 transfected with hCD200R 96. These chemokines 
are strongly induced during influenza infection and are important in the recruitment 
(often excessive) of neutrophils and Thl cells to the inflammatory site, thus further 
stressing the therapeutic potential of CD200R agonist administration during an 
influenza infection. 
IgE mediated degranulation and production of IL-13 and TNF can also be suppressed 
in mouse and human mast cells through addition of a CD200R agonist 84. 
Furthermore, through this in vitro mast cell based system the signalling behind 
CD200R mediated inhibition had begun to be unravelled 83. Within the tail of the 
CD200R are three tyrosines that are phosphorylated upon CD200R ligation. These 
tyrosine residues are not in conventional inhibitory ITIM motifs but one tyrosine, 
within an NPXY signature, seems to be of particular prevalence. Upon 
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phosphorylation of this tyrosine residue, adaptor proteins Dok 1 and Dok2 are 
recruited and phosphorylated. This ultimately leads to the inhibition of the 
RAS/MAPK pathway. It would seem probable that signalling through CD200R in 
macrophages is comparable since we demonstrate enhanced Dok-2 phosphorylation in 
BM derived macrophages following CD200R ligation. 
It is surprising that the influence of CD200R ligation on macrophages is not also true 
of dendritic cells since it is known that they express this inhibitory receptor 68,82  and 
that ligation induces the immunosuppressive pathway of tryptophan catabolism in 
plasmacytoid dendritic cells 97. Other studies also confirm the inability of CD200R 
ligation to modulate dendrite cell cytokine production or surface expression of 
activation markers 96. It is plausible that 1) other aspects of DC phenotype or function 
that we have not investigated are altered, 2) we have not identified the relevant in 
vitro conditions needed to exert suppression, and / or 3) additional factors are 
contributing in an in vivo context such as contact with other cells or extracellular 
matrix proteins. Nevertheless, the role of CD200R signalling in dendritic cells is 
something that needs to be further addressed. 
5.3.2 A role for CD200 in governing myeloid cell responsiveness and homeostasis in 
the lung? 
We are the first to report a role of CD200 and its receptor within the lung 
environment. The lung is a mucosal site where a tolerogenic response to innocuous 
antigens is fundamental to maintaining an environment that is optimal for supporting 
gas exchange. CD200 and its receptor may maintain tolerance and impose subtlety in 
immune responses at this site. Furthermore, the role of CD200/R during infection has 
not previously been addressed and it is plausible that CD200 may fulfil a role in 
shaping the host's immune response to pathogen challenge and perhaps in the 
resolution of inflammation. 
The strong CD200 expression on endothelial cells within the lung, and at other sites 
76, is interesting and may fulfil a role in restraining CD200R expressing neutrophils in 
the circulation 90,428,429;  preventing lethality due to their heightened activation as seen 
in the systemic inflammatory response syndrome (SIRS). To support this regulatory 
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role for CD200 in the circulation, we see that CD200R expression is lost from 
neutrophils once actually in the lung, which may subsequently facilitate their full 
activation at this potential effector site. Subsequently, during the course of an 
influenza infection CD200R is restored on neutrophils, conferring a negative feed 
back loop. As yet, nothing is known regarding what dictates the expression of 
CD200R on the neutrophil surface and the effect CD200R signalling has upon 
neutrophil function. Circulating monocytes also express CD200R and it is plausible 
that their function may also be modified by interaction with CD200 bearing 
endothelium. Monocytes are wired differently to neutrophils in that they do not 
possess their full effector potential until they migrate into a tissue and mature into 
macrophages. However, CD200 on endothelium may fulfil a role in restraining 
maturation of monocytes whist in the circulation and this is again a concept that 
requires further investigation. 
We also present evidence for CD200 expression on lung epithelial cells. Whilst the 
specific cells expressing CD200 requires clarification, this observation could prove 
significant in our understanding of how the lung maintains a homeostatic state and 
does not respond inappropriately to the myriad of innocuous stimuli it encounters 
everyday. CD200 expression upon epithelial cells is poorly understood, although one 
study describes its expression on epithelial cells of the murine hair follicle 89; 
suggesting that it may play a role in maintaining immune tolerance to hair follicle 
associated autoantigens. It is possible that CD200 on epithelial cells in the lung plays 
a role in tolerance by suppressing resident macrophages until a pathogenic challenge 
overrides such suppression. Indeed, alveolar macrophages express a very high level of 
CD200R in a naive lung in accordance with their important role in lung tolerance. It is 
also interesting that the level of CD200R expressed by myeloid cells is greatly 
augmented by influenza infection, which may suppress their inflammatory phenotype 
and facilitate resolution of inflammation. Indeed, the potency of CD200R mediated 
suppression correlates with the density of receptor expression 96. 
5.3.3 CD200 expression on T cells 
We demonstrate CD200 expression on certain populations of T cells within the naive 
mouse. In both the spleen and lung approximately 35-40% of CD4+ T cells expressed 
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CD200 with 5-10% of CD8+ T cells possessing this inhibitory molecule. This level of 
expression appeared to be defined at the generation of single positive T cells within 
the thymus where similar percentages of CD4 and CD8 T cells were seen to express 
CD200 as in the periphery, whereas double positive T cells did not express CD200. It 
is intriguing that only a percentage of CD4 and CD8 T cells expressed CD200 in a 
naive mouse but what defines these CD200 positive T cells remains elusive. The 
majority of CD200 positive T cells appear to express an oc13 TCR, but interestingly all 
T cells with a 78 TCR are CD200 positive in the lung and spleen. Expression of 
CD200 on 78 T cells would substantiate the accumulating evidence of a role in 
immune regulation and in the protection of host tissues against the damaging side 
effects of immune responses 430  y8 T cells preferentially accumulate at mucosal sites 
where there is a critical requirement to limit excessive immunity that may cause 
bystander tissue damage. It would appear that 78 T cells are important in reducing 
pulmonary tissue damage associated with inflammation. One study demonstrates an 
increase in pulmonary injury in the absence of 78 T cells in two distinct models of 
epithelial cell damage 431  Furthermore, 78 T cells are required for normal airway 
responsiveness to metacholine following OVA stimulation 432. Within the spleen, 78 T 
cells localise within the red pulp 433, a site where old and damaged RBCs are cleared 
by macrophages. CD200 on 78 T cells at this site may act to suppress macrophages 
from evoking an undesirable inflammatory response. Indeed, CD200 knock out mice 
possess an increased number of macrophages in the splenic red pulp, with those 
present being in an elevated activational state. 
5.3.4 Induction of CD200 expression on activated T cells 
We show conclusively that CD200 is induced on activated T cells, similar to human 
peripheral blood CD3+ T cells incubated with Concanavalin A 77. Induction of CD200 
expression occurs on both CD4+ and CD8+ T cells and is activation dependent. Using 
the D011.10 transgenic system we verify that CD200 expression on activated T cells 
is antigenic dose and time dependent and have further verified the TCR dependency 
of this expression with agonistic anti-CD3/anti-CD28 antibody induced activation, 
PMA/Ionomycin stimulation and using SKG mice. CD200 is up-regulated after the 
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early co-stimulatory molecule ICOS 117, but before the late co-stimulatory molecule 
OX40 118'119, a molecule important in the maintenance of activated T cells. 
It is interesting that Thl cells express higher CD200 levels than Th2 cells. To support 
this Thl bias, influenza elicits a very strong Thl driven immune response and is 
associated with high CD200 expression on T cells in the lung. To understand why 
Thl cells may express more CD200 than Th2 cells one should consider the scenarios 
in which each T cell subset is evoked. A bacterial or viral infection is classically 
associated with Thl immunity 128,129.  Such pathogens generally elicit a rapid and 
potent Thl response that represents an immediate and severe threat to the host 
through immunopathology and as such it would make evolutionary sense for them to 
express high levels of CD200 to switch off the inflammatory myeloid cells. 
Conversely, Th2 cells would have evolutionarily been induced to target larger 
pathogens such as helminths, which generally evoke a chronic and sometimes largely 
asymptomatic infection 128'129. Such infections would not require the same level of 
immediate restriction on myeloid cell activation and cytokine production. Indeed, C. 
neoformans elicits a Th2 skewed immune response in C57BL/6 mice and in this 
scenario there is little up-regulation of CD200 on T cell populations, an idea that may 
be relevant to allergy and atopy. Though yet to be linked in this way, CD200 is 
capable of suppressing cytokine release and degranulation in mast cells 84 and 
histamine release in basophils 85. As such administration of CD200 signalling in an 
allergic experimental setting would be anticipated to improve clinical outcome as seen 
with passive cutaneous anaphylaxis (PCA) 84. What causes Thl cells to express 
CD200 at a greater level than Th2 cells is unclear, but may reflect differences in the 
strength or dose of the initial antigenic signal or a potential role for cytokines in 
dictating the levels of CD200 expression. Indeed, we see that neutralisation of IL-4 
and IL-10 permits a greater induction of CD200 expression on activated CD4+ T cells. 
It is interesting that CD200 is dramatically lost in the airways of influenza infected 
mice at day 7 of infection. What causes CD200 to become down regulated is still 
debateable, but is also observed in vitro following long term T cell activation. The 
reduction in CD200 expression may reflect its natural kinetics whereby after initial 
induction, it is subsequently lost again to restore homeostasis. T cells in the airways 
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may be at their terminal end point and as such have been activated for a greater period 
of time. However, this is unlikely to be the only factor. Other contributing factors 
include: 1) a lack of organised lymphoid tissue in the airways, 2) the presence of high 
TLR ligand loads, 3) reduced co-stimulatory signals at this site, 4) sustained 
inflammatory environment and / or 5) heightened apoptosis at this site. 
Virtually all B cells are seen to express CD200 in a naïve mouse, with in excess of 
90% expressing CD200 in the blood, lung and spleen. A significantly lower 
percentage of B220 positive cells in the bone marrow express CD200 implying that its 
expression is induced at some early developmental stage from a B cell progenitor. 
Throughout the course of an influenza infection, CD200 levels on B cells remain 
largely unaltered within the lung and mediastinal node but do again show a striking 
drop in expression on the limited number of B cells in the BAL. We have thus far 
been unable to determine what modulates the levels of CD200 on B cells. 
5.3.5 T cell mediated suppression of the myeloid inflammatory response 
The up-regulation of CD200 expression on activated T cells may provide a 
mechanism whereby they can actively "switch off' the pro-inflammatory phenotype 
of the myeloid compartment. Indeed, in the course of influenza infection, CD200 
expression on T cells and CD200R expression on myeloid cells are increased 
significantly. It is feasible that through CD200, the adaptive immune response can 
suppress the innate response, promoting resolution of inflammation. It is plausible 
that such an interaction occurs at the immunological synapse during T cell activation 
434. The optimal spacing between the APC and the T cell to support efficient T cell 
activation is 4 IgSF domains 435. The combined extracellular domains of CD200 and 
its receptor is 4 IgSF and as such would spatially be compatible with a model 
whereby the T cell can direct a signal to the myeloid compartment through CD200R 
at the immunological synapse 436. 
Figure 5.20 depicts the events we believe may occur during an inflammatory response 
whereby an activated T cell can suppress the myeloid compartment. IF'N-y and TLR 
ligands evoke pro-inflammatory cytokine production by macrophages, critical to the 
establishment of an inflammatory response. We see that both IFN-y and TLR ligands 
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up-regulate CD200R expression on the myeloid cell. In the course of the 
inflammatory response, T cells become activated and will subsequently sequentially 
up-regulate ICOS, followed by CD200, then OX40. The activated T cell can then 
interact with the myeloid cell through CD200/R and reduce pro-inflammatory 
cytokine production by the myeloid compartment. The temporal expression of CD200 
post ICOS, a co-stimulatory signal important in the early response of activated T 
cells, enables a sizeable adaptive response to be mounted before inflammation is 
switched off. Furthermore, CD200R signalling does not reduce expression of myeloid 
activation markers involved in antigen presentation, and with some stimuli augmented 
CD86 and OX4OL are observed. Therefore, CD200R signalling does not only limit 
the inflammatory phenotype of the myeloid cell but also supports its role in antigen 
presentation. To support this concept, OX40 ligation on the T cell acts to further 
increase CD200 expression. Furthermore, the reduction in TNF and IL-6 by CD200 
signalling may also free regulatory T cells from the suppression that is exerted upon 
them by these mediators, which may further facilitate resolution of inflammation 
437,438.  
It is appealing to envisage such a scenario during influenza infection, whereby the 
sizeable T cell infiltrate expressing CD200 can dampen down inflammation by 
targeting CD200R on myeloid cells. However, in an in vivo scenario, it is important to 
consider the level of structural organisation that is required to support a meaningful 
interaction between a CD200 expressing T cell and a CD200R expressing myeloid 
cell, and whether such an interaction can occur in the node, the lung parenchyma or 
the airways. Indeed, the extent of structural organisation in distinct immune 
compartments could contribute to the level of control mediated by CD200 and hence 
the potential to evoke an inflammatory response. There is an increase in structural 
organisation going from the airways to the lung and to the node, and a concomitant 
reciprocal reduction in the inflammatory environment elicited at these sites. It is 
appealing to consider whether the high density of CD200 bearing lymphocytes within 
a node can actively repress myeloid cells at this site through CD200R, dampening 
inflammation and supporting antigen presentation. 
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Figure 5.20 Schematic representation of possible interaction between CD200 
bearing T cell and CD200R expressing macrophage. (a) TLR ligand or IFN-y 
causes pro-inflammatory cytokine production by macrophage and up-regulation of 
CD200R. (b) Activated T cell expressing CD200 interacts with the myeloid cell 
through CD200R. Signalling through CD200R increases OX4OL expression on 
macrophage and subsequent OX40 signaling induces an increase in levels of CD200 
on the T cell. (c) Signaling through CD200R suppresses production of pro-
inflammatory cytokine production by the macrophage. (d) Reduction in levels of 
inflammatory cytokines such as TNF and IL-6 relinquishes suppression over 
regulatory T cell function. 
5.3.6 Conclusion 
Our basic understanding of CD200 is still in its infancy and we appear to be 
generating as many questions as answers. Nonetheless, we have described for the first 
time the expression profiles of CD200 and its receptor in the naïve lung. Furthermore, 
we have demonstrated how these expression profiles are modified in the course of an 
influenza infection, and dissected the parameters that can cause this modulation. The 
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role for CD200 in delivering an inhibitory signal to myeloid cells, specifically through 
suppression of pro-inflammatory cytokine production is now irrevocable. It will be of 
great interest to ascertain the role of CD200 in maintaining myeloid homeostasis in 
the lung, and its function in dictating the phenotype of the host's elicited immune 
response to infection. 
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Chapter 6 — The Role of CD200 in Respiratory Infections 
6.1 Introduction 
In the previous chapter, we describe the expression profiles of CD200 and its receptor 
in both the naive and infected lung, and define the parameters that dictated changes in 
expression. Furthermore, we demonstrate the potential of signalling through CD200R 
to reduce the production of inflammatory cytokines by macrophages. We 
subsequently postulate a potential role for the CD200-CD200R interaction in 
governing the phenotype of the myeloid response to respiratory infection. Myeloid 
cells constitute a significant arm of the host's armoury against respiratory infections, 
governing the induction, maintenance and ultimately resolution of inflammation, in 
addition to acting as important effector cells against the invading pathogen. In this 
chapter, we investigate the impact of manipulating the CD200-CD200R axis during 
the respiratory infections induced by influenza and C. neoformans. 
6.1.1 Myeloid cells in protection and pathology of pulmonary influenza infection 
Pulmonary macrophages represent a significant primary site of infection by influenza 
virus. Infection of monocytes or macrophages with influenza virus induces an array 
of chemotactic, pro-inflammatory and anti-viral cytokines including IFN-a/13, which 
possesses potent anti-viral activity and is critical in limiting early viral replication 439. 
Influenza infected monocytes/macrophages produce large quantities of chemotactic 
cytokines including MEP-la, MIP-113, RANTES, MCP-1, MCP-3, MEP-3a and rP-l0 
219,440,441, which favour the recruitment of blood mononuclear cells, as well as pro-
inflammatory cytokines including IL-113, IL-6, TNF and IL-18 221'222,442-445. 
IL-113 and TNF further enhance inflammation through augmenting production of 
MCP-1 and MCP-3 and up-regulating the expression of various cellular adhesion 
molecules that facilitate further extravasation of inflammatory cells into the infected 
site 446. They also promote maturation of tissue macrophages and dendritic cells 
which gives rise to further inflammation and enhanced antigen presentation 447-453. 
Furthermore, IL-18 re-enforces these inflammatory sequelae by promoting the 
production of IL-113, TNF and various chemokines 454. Influenza infected DCs do not 
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produce the same level of pro-inflammatory and chemotactic cytokines as 
macrophages but are an abundant source of IL-12, a critical cytokine in Thl 
development 455'456. Much of the tissue damage and illness elicited by influenza 
infection is attributable to the over exuberance of the host's immune response, and as 
such myeloid cells are closely affiliated with the pathology of the disease. Indeed, 
depletion of many myeloid cell derived products has proved beneficial in alleviating 
inflammation and symptoms of influenza induced illness 268-273,275. 
6.1.2 Myeloid cells in protection and pathology of pulmonary C. neoformans 
infection 
Resolution of C. neoformans infection and prevention of dissemination to other sites 
is dependent on development of a Thl immune response (as seen in resistant BALB/c 
mice) 252-254. Conversely, the generation of a Th2 response (as seen in susceptible 
C57BL/6 mice) leads to chronic pulmonary eosinophilia, unchecked fungal growth 
and dissemination to other organs 255. Macrophages are essential to the development 
of a protective immune response to C. neoformans. Upon entering the respiratory tract 
the fungus is phagocytosed by resident alveolar macrophages eliciting the production 
of pro-inflammatory cytokines and chemokines (TNF, MCP-1 and MIP-la) 256,257  
These cytokines are critical for the subsequent recruitment of T cells, macrophages, 
NK cells and granulocytes that will confer protection against C. neoformans. MIP- 1 a 
knock out mice develop a Th2 immune phenotype with pulmonary eosinophilia, high 
serum IgE, increased IL-4 and IL-13 and significantly elevated fungal burden 457. 
TNF, in particular, is of great importance in evoking cell recruitment to C. 
neoformans and also possesses direct cryptococcal killing capacity 244,263-266 The 
protective response to C. neoformans is granulomatous in nature, with granuloma 
formation dependent upon accumulation of CD4+ T cells and macrophages encasing 
the fungi 230,256,258. Subsequently, macrophages fuse around the cryptococci to form 
multinucleated giant cells and releasing hydrolytic enzymes. Macrophages are 
therefore central to the control and resolution of C. neoformans infection and 
promotion of a greater macrophage response would be optimal. 
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6.1.3 CD200 is an inhibitory regulator of myeloid cell function with therapeutic 
potential 
CD200 is now acknowledged to be a potent inhibitory regulator of myeloid cells. 
Naïve CD200 knock out mice exhibit heightened myeloid numbers that are present in 
an augmented activation state 76. Furthermore, these mice develop more rapid and 
severe pathologies in various autoimmune models such as CIA, EAE, EAU and a 
facial nerve transfection model, with disease progression characterised by greater 
myeloid infiltrate and activation 76'87'88. The nature of this inhibitory signal is still 
poorly defined but we have described the potential of CD200 to suppress macrophage 
pro-inflammatory cytokine production in response to IFN-y and influenza but not 
LPS. These findings are corroborated by another group that has described a similar 
reduction in pro-inflammatory cytokines by peritoneal macrophages stimulated with 
IFNI or IL-17 96. 
The inhibitory potential of CD200 has been manipulated immunotherapeutically to 
alleviate inflammation and illness in conditions characterised by excessive immunity. 
Administration of a CD200 fusion protein (CD200:Fc) or an agonistic antibody to 
CD200R reduces disease severity of CIA, halts disease progression and also reduces 
established disease, with concomitant reduction in levels of serum IFNI and TNF 
and anti-collagen antibodies 91'92. In a murine model of spontaneous abortion, foetal 
loss is driven by excessive Thl cytokine production, and administration of CD200:Fc 
dramatically reduces abortion rates implying a role for CD200 in tolerance of the 
foetus 93. Gorczynski and colleagues demonstrate that administration of soluble 
CD200 protein prolongs the survival of allotransplants of skin and kidney between 
mice and kidney xenotransplants from rats to mice 95. A clear therapeutic potential for 
CD200 signalling in allergy has also been demonstrated, with administration of an 
anti-mouse CD200R antibody inhibiting FceR1 -dependent responses in a murine 
model of passive cutaneous anaphylaxis (PCA) 84. It would therefore appear that 
CD200 offers therapeutic potential in many conditions characterised by dysregulated 
immunity through suppression of the myeloid compartment. The potential of 
manipulating the CD200 signal in infectious disease has not yet been addressed. 
Illness and pathology elicited by many respiratory infections, such as influenza, is 
attributable to the excessiveness of the host's immune response 458 and as such would 
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be a plausible target for CD200 driven therapeutic intervention. Conversely, with 
infections where pathogen persistence is the predominant concern it may be plausible 
to block CD200 signalling so as to evoke a more potent immune response. 
6.1.4 Hypothesis 
We anticipate that CD200 plays an important role in dictating the potency of the 
immune response to infection and the resolution of inflammation. We postulate that 
CD200 knock out mice will exhibit heightened inflammation and more severe illness 
in response to influenza, whilst administration of CD200:Fc to influenza infected 
mice will alleviate symptoms. Conversely, we hypothesise that C. neoformans 
infected CD200 knock out mice or mice administered a blocking antibody to CD200 
will show heightened immunity with improved clearance of the pathogen. 
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6.2 Results 
6.2.1 Naive OX-2 (CD200) knock out mice exhibit heightened myeloid numbers in 
their spleens 
OX-2 (CD200) knock out mice, developed by Sedgewick et al at DNAX 76 (Fig. 
6.1a), provide an excellent tool to determine the role of CD200 during respiratory 
infection. We first investigated the phenotype of the naïve lung in CD200 knock outs 
relative to wild type mice. Previous studies have highlighted enhanced myeloid 
numbers in the spleens and mesenteric lymph nodes of these mice but the lung 
compartment has not previously been investigated. Confirmation of the CD200 knock 
out phenotype was obtained by flow cytometric analysis with a complete absence of 
CD200 expression on splenic CD4+ and CD8+ T cells in knock out mice (Fig. 6.1b). 
In accordance with previous studies naive OX-2 knock out mice showed a significant 
increase in the number of CD1 lb+ myeloid cells in their spleens (Table 6.1). Further 
dissection of the myeloid population revealed that this increment was largely 
attributable to increased numbers of macrophages and neutrophils (data not shown). 
Conversely, there were comparable numbers of myeloid cells in the lungs and airways 
of the OX-2 knock out mice relative to the wild type controls (Table 6.1), although 
there was a small but significant increase in MHC II expression on macrophages 
within the lungs (data not shown). There were no differences in the number of 
lymphoid cells in the spleens or lungs of wild type and knock out mice with 
comparable numbers of CD4+ and CD8+ T cells (Table 6.1). Similarly, no differences 
were apparent between the two groups of mice in the activation status of the resident 
T cell populations (data not shown). It has previously been reported that OX-2 knock 
out mice exhibit heightened numbers of myeloid cells in their mesenteric nodes. The 
mediastinal nodes that drain the lymphatic from the lungs are, unlike the messenterics, 
inducible upon infection, and neither wild type nor OX-2 knock out mice possessed 
these lymph nodes. H and E staining of naive OX-2 knock out mice lung tissue 
showed comparable morphology to that observed in wild type mice, with large open 
air spaces and limited cellular infiltrate (Fig. 6.2). 
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Figure 6.1 CD200 (OX-2) knock out mice. (a) Targeted disruption of the CD200 gene. An 
Eco-47III-Sal I fragment of a CD200 genomic clone isolated from a C57BL/6 genomic 
library was used to create the targeting construct, replacing the Nco I fragment with a PGK-
neor cassette. After transfection with this construct, homologous recombinant embryonic 
stem cells were obtained and micro-injected into BALB/c blastocysts. Chimeras were mated 
with C57BL/6 +/+ mice and germ-line offspring determined by genomic Southern blot 
analysis. Heterozygous mice were intercrossed to obtain either +/+, +/- or CD200-/- mice. 
The latter were intercrossed to establish a C57BL/6 CD200-/- breeding colony. Exon 
numbers: I, containing the start codon (ATG); II, signal peptide; III, V-like Ig domain; IV, 
C2-like Ig domain; V, transmembrane and cytoplasmic domain. Neor, neomycin cassette. 
Restriction enzyme sites; P, Pvu II; S, Sal I; E, Eco 47111; N, Nco I; X, Xho I. (b) Spleens 
were removed from naive C57BL/6 wild type and CD200 (OX-2) knock out mice and single 
cell suspensions stained with CD200-PE, CD8-PercP and CD4-APC. Representative dot 
plots are shown for differential CD200 expression on CD4± and CD8+ T cells from wild type 
and knock out mice. 
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Lung BAL Spleen 
Total cell 
no. 
WT 
Ox-2 
1.03x106 
0.603E106 
+1-0.24 
+7-0.08 
0.90x105 
1.62x105 
+/-0.10 
+/-0.58 
6.92x107 
8.68x107 
+/-0.61 
+/-1.81 
CD4+ T 
cells 
WT 
OX-2 
3.88x104 
2.01x104 
+/-1.87 
+/-0.43 
- 
- 
1.88x106 
2.07x106 
+/-0.10 
+/-0.27 
CD8+ T 
cells 
WT 
OX-2 
2.24x104 
1.06x104 
+/-1.31 
+7-0.22 
- 
- 
0.91x106 
0.99x106 
+/-0.05 
+/-0.08 
CD11b+ 
Myeloid 
WT 
OX-2 
2.35x105 
1.99x105 
+/-0.64 
+/-0.32 
7.74x104 
9.02x104 
+/-1.74 
+/-0.60 
3.15x106 
6.20x106 
+/-0.38 *  
+/-1.45 
Table 6.1 OX-2 knock out mice exhibit heightened myeloid cell numbers in their 
spleens. Lungs, BAL and spleens were removed from naive OX-2 knock out and wild type 
C57BL/6 mice and single cell suspensions obtained. Viable cells from each organ were 
determined by trypan blue exclusion. Single cell suspensions were stained with anti-CD8-
PercP, anti-CD4-APC, anti-CD1 lb-Percp and anti-CD1 1 c-APC and the number of each 
population extrapolated from the total viable cell counts. Results represent the mean +/-
SEM of 5 individual mice in 3 independent experiments. *=p<0.05 
\ 
Wild type 	 OX-2 knock out 
Figure 6.2 Lungs of naive wild type and OX-2 knock out mice are morphologically 
similar.Representative H and E stained lung sections from naive wild type and OX-2 
knock out mice (x 200 magnification). 
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6.2.2 Influenza infected OX-2 knock out mice show greater weight loss early in 
infection and fail to recover as quickly as wild type controls 
Age matched C57BL/6 wild type and OX-2 knock out mice were infected intranasally 
with 50 HA influenza (Fig. 6.3) and weight loss recorded daily and expressed as a 
percentage of original weight. OX-2 knock out mice exhibited greater weight loss 
relative to wild type controls, particularly in the first three days of influenza infection 
(Fig. 6.4a), but significant until day 7. However, the OX-2 knock out mice were 
visibly sicker at day 7, appearing very hunched and non-motile and had to be culled in 
accordance with home office guide lines. In order to investigate the three phases of 
influenza infection (induction, peak illness and resolution) in OX-2 knock out mice, it 
was therefore necessary to use a lower influenza innoculum of 25 HA (Fig. 6.3). At 
this dose of influenza, OX-2 knock out mice continued to exhibit greater weight loss 
in the early stages of infection with a significant difference at days 1 and 2 after 
influenza infection (Fig. 6.4b). However, weight loss was comparable in wild type 
and knock out mice from day 3 through to 7. Wild type mice subsequently recovered 
significantly quicker than the OX-2 knock outs. From day 7 onwards wild type mice 
showed a steady increase in weight, whereas OX-2 knock outs continued to lose 
weight until day 9 before gaining weight at a slower rate (Fig. 6.4b). 
6.2.3 Influenza infected OX-2 knock out mice exhibit heightened cellularity in their 
mediastinal lymph nodes at day 2 after influenza infection 
Influenza infected wild type and OX-2 knock out mice were culled at day 2 after 
infection to investigate any deviation in immune phenotype at this early stage of 
infection. Lung, BAL and the draining mediastinal lymph nodes (MLN) were sampled 
and whilst cell numbers in the lung and BAL were comparable, the OX-2 knock out 
mice possessed a significantly greater number of cells in the MLNs (Fig. 6.5a). H and 
E staining of lung tissue at day 2 after infection corroborated the comparable infiltrate 
in the lungs of wild type and knock out mice at this time point. In both wild type and 
knock out lung tissue there still appeared to be minimal cellularity at day 2 after 
infection, but some limited peribronchiolar and perivascular infiltrate was observable 
(Fig. 6.5b). CD200 delivers an inhibitory signal to the myeloid immune compartment, 
and therefore the number and phenotype of different myeloid cells was assessed in 
each immune compartment. The OX-2 knock out mice possessed a significantly 
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Day 0 25 / 50 HA Influenza A x31 (i.n) 
Wild-type 
C57BL/6 
OX-2 KO mice 
Days 2, 
7 and 14 
BAL: - Surface Staining (flow cytometry) 
- Cytocentrifugation 
- Cytokines/chemokines (Luminex) 
Lung: - Surface/intracellular cytokine staining 
- Influenza titres 
- Histology (H/E) 
Node: - Surface Staining (flow cytometry) 
Serum:- Influenza-specific antibody, TNF (ELISA) 
Nasal Washes: - Influenza-specific IgA 
Figure 6.3 Experimental protocol. 
237 
8 1 	2 	3 	4 	5 	6 	7 
Days post infection 
%
 B
od
y  
m
as
s  
b. 110 
■ Wild type 
❑ OX-2 KO 
z 100 z 
E 
90 
80 
70 
* * 
■ Wild type 
❑ OX-2 KO 
a. 
0 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 
Days post infection 
Figure 6.4 Influenza infected OX-2 knock out mice exhibit heightened weight loss 
early in infection and show reduced recovery relative to wild-type controls. Wild 
type C57BL/6 and OX-2 knock out mice were infected with 50 HA (a) and 25 HA (b) 
influenza and weight loss monitored daily and expressed as a percent of original weight. 
Results represent mean values ± SEM from 5 mice per group. *=p<0.05, **=p<0.01. 
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Figure 6.5 Influenza infected OX-2 knock out mice exhibit a heightened myeloid response 
in their MLNs at day 2 after infection. Wild type and OX-2 knock out mice were infected 
i.n. with 25 HA influenza and the total number of cells in the lung, BAL and MLNs at day 2 
after infection were determined by trypan blue exclusion (a). (b) Representative H and E 
stained lung sections from wild type and OX-2 knock out mice 2 days after infection (x 200 
magnification). Single cell suspension from the lung, BAL and node were stained with anti-Gr-
1-FITC, anti-MHC-II-PE, anti-CD11b-Percp and anti-CD11c-APC. (c) Representative FACS 
plots from MLN of CD11b vs. CD11c for wild type and OX-2 knock out mice. R1= 
macrophages, R2= DCs. (d) The number of macrophages and DCs in the MLNs were 
determined by: the % of each population x total number of viable cells. (e) The number of 
alveolar macrophages in the BAL of wild type and OX-2 knock out mice was calculated as 
follows: % CD1lbintCD11chi x total number of myeloid cells. (f) The intensity of MHC II 
expression on alveolar macrophages was determined by flow cytometry. (g) Representative 
histogram overlay of MHC II expression on alveolar macrophages from the BAL of wild type 
and OX-2 knock out mice. Closed symbols, wild type C57BL/6 mice; open symbols, OX-2 
KO mice. Results represent mean values ± SEM from 5 mice per group. *=p<0.05, **=p<0.01. 
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greater number of macrophages and dendritic cells in their MLNs relative to wild type 
controls (Fig. 6.5c and d), but myeloid cell numbers in the lungs were comparable. 
However, an increase in the number of alveolar macrophages in the airways was 
observed in OX-2 knock out mice relative to wild type controls (Fig. 6.5e). The 
phenotype of the myeloid cells at each site was further investigated by flow cytometry 
for a variety of activation markers. There was a general increase in the levels of MHC 
II expression on different myeloid compartments with elevated levels observed on 
alveolar macrophages in the BAL (Fig. 6.5f and g) and on macrophages and dendritic 
cells in the lung and MLN (data not shown). No differences were observed in the 
expression levels of CD80, CD86, CD40 and OX4OL (data not shown). 
The T cell populations at each site were also analysed by flow cytometric analysis. 
Total numbers of CD4+ and CD8+ T cells were comparable in the lung and BAL of 
wild type and knock out mice at day 2 after influenza infection, but a significantly 
greater number of both subsets were observed in the MLNs of OX-2 knock out mice 
(Fig. 6.6a and b), which were more activated (CD45RBI0) (Fig. 6.6c, e and f). 
Subsequently, there were a significantly greater number of CD45RB1° CD4÷ and 
CD8+ T cells in the nodes of the OX-2 knock out mice (Fig. 6.6d). This elevated T 
cell activation in the OX-2 knock out mice was also observed in those T cells present 
in the lung and airways (data not shown). 
6.2.4 OX-2 knock out mice exhibit heightened cellularity in their airways at the 
peak of influenza infection 
Inflammation and illness to pulmonary influenza infection classically peaks at day 6-7 
after infection. We therefore examined the influence of CD200 at this phase of 
infection. The number of MLN cells continued to be higher in the OX-2 knock out 
mice relative to the wild type controls at day 7 after influenza infection (Fig. 6.7a). 
The number of cells in the lungs and airways at day 7 was considerably higher in both 
groups of mice than that seen at day 2 after infection. Furthermore, the number of 
cells in the BAL at day 7 was significantly greater in the knock outs than in the wild 
type controls (Fig. 6.7a). H and E staining of lung sections showed extensive 
perivascular and peribronchiolar infiltrate and significant occlusion of airways in both 
groups of mice (Fig. 6.7b). However, the infiltrate did generally appear be more 
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Figure 6.6 Influenza infected OX-2 knock out mice exhibit a heightened T cell response 
in their MLNs at day 2 after infection. Wild type and OX-2 knock out mice were infected 
i.n. with 25 HA influenza and lungs, BAL and MLNs removed at day 2 after infection. 
Single cell suspensions were stained with CD45RB-FITC, CD4-PercP and CD8-APC. The 
total number of CD4+ (a) and CD8+ (b) T cells in the lung, BAL and MLN were calculated 
by: the percentage of CD4/CD8 positive cells as determined by flow cytometry x total 
number of lymphocytes. (c) The % CD4+ and CD8+ T cells defined as CD45R131° in the 
MLN were determined by flow cytometry. (d) The total number of CD45RBI° T cells in the 
MLN were determined by multiplying this % by the total number of each T cell subset. 
Representative histogram overlays of CD45RB expression on lymph node derived CD4+ (e) 
and CD8+ (f) T cells. Closed symbols/bars, wild type C57BL/6 mice; open symbols/bars, 
OX-2 knock out mice Results represent mean values ± SEM from 5 mice per group. 
*=p<0.05, **=p<0.01. 
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Figure 6.7 Influenza infected OX-2 knock out mice have increased cellular infiltrate in 
their airways at day 7 after infection. Wild type and OX-2 knock out mice were infected 
i.n. with 25 HA influenza and the total number of cells in the lung, BAL and mediastinal 
lymph nodes at day 7 after infection were determined by trypan blue exclusion (a). (b) 
Representative H and E stained lung sections from wild type and OX-2 knock out mice 7 
days after infection (x 200 magnification). Single cell suspension from the lung, BAL and 
node were stained with anti-Gr-l-FITC, anti-MHC II-PE, anti-CD I lb-Percp and anti-
CD 11c-APC. The number of macrophages (c) and dendritic cells (d) in the LNs and BAL 
were determined by multiplying the percentage of each population, as adjudged by flow 
cytometry, by the total number of viable cells. Closed symbols/bars, wild type C57BL/6 
mice; open symbols/bars, OX-2 knock out mice Results represent mean values ± SEM from 
5 mice per group. *=p<0.05, **=p<0.01. 
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extensive and dense in the wild type mice. Consistent with the inhibitory role of 
CD200 on myeloid cells, there were an increased number of macrophages and DCs in 
the MLNs and airways of the OX-2 knock out mice relative to the wild type controls 
(Fig. 6.7c and d). Whilst there was a general increase in the number of myeloid 
subsets in the lung tissue, this difference was not significant (data not shown). 
Similarly, there was a general increase in the levels of MHC II on the surface of these 
myeloid populations in the knock out mice, but this increment was not as pronounced 
as seen at day 2 after infection and failed to be significant (data not shown). 
The number of CD4+ (Fig. 6.8a) and CD8+ (Fig. 6.8b) T cells was also significantly 
greater in the MLNs and airways of the OX-2 knock outs relative to the wild type 
controls at day 7, but comparable in the lungs. As seen at day 2 after infection, the 
percentage of CD8+ T cells that were CD45RB1° was significantly greater in OX-2 
knock outs in the airways (Fig. 6.8c), lung and MLN (data not shown). The 
percentage of CD4+ T cells that were CD45RBI° was, however, comparable between 
the two groups of mice, although an increase in the total number of both CD4+ and 
CD8+ T cells that were CD45RB1° was seen in the BAL (Fig. 6.8d) and MLNs (data 
not shown). Furthermore, there was an increase in the total numbers of both T cell 
subsets expressing intracellular IFN-'y and TNF in the airways of the OX-2 knock outs 
relative to the wild type controls (Fig. 6.8e). Since TNF and IL-6 are thought to 
suppress regulatory T cells 437,438  we ascertained whether levels of these regulatory 
cells were altered in the OX-2 knock out mice. FoxP3 expressing cells were 
comparable in the lung (Fig. 6.8f and g) and MLN (data not shown) of both groups of 
mice. 
6.2.5 OX-2 knock out mice show a reduced capacity to resolve inflammation relative 
to wild type controls 
We next determined whether resolution of inflammation was compromised in OX-2 
knock out mice. Therefore, wild type and OX-2 knock out mice were culled 14 days 
after infection and resident immune cells phenotyped in the lung, BAL and MLN. The 
total number of cells in the lungs and airways, whilst reduced from day 7, was 
significantly greater in the OX-2 knock outs relative to the wild type controls (Fig. 
6.9a). The number of cells in the MLNs of both groups of mice was comparable at 
243 
* * Wild type 
OX-2 KO 
BAL 
	
Node 
e. No. CD4+ (x103) 
50 
45 
40 
35 
30 
25 
20 
15 
10 
5 
0 
CD4+ CD8+ 
WT 
2.06 
Lung BAL 
No. CD8+ 
(x104) 
35 
30 
25 
WT OX-2 
OX-2 
14.46 
WT OX-2 
2.99 
Foxp3 
No. CD4+ 
(x104) 
20 
18- 
16' 
14' 
12' 
10' 
8' 
6 
4' 
2 ' 
No. CD4+ 
a. (x105) 
16 
14 * * 
12 
10 
8 
6 ' 
4 • 7±7  
2 	• 
0 
' Node 	Lung 
c. 	 d. 
70 ' 	I 	cS 35 
I ,-* *,6b , 30 
I tat) 50 	g 	• 0-smm 25 
'T 40 I • 	R 20 
A 	 I , c..) 30. 	 V 	14 15 I co 20' 	 = 10 
10' I 
I 	
. 5 
0 0 CD4+ CD8+ 
f. 
25 
20' • 
O 
g 15' 
;14 10' 
* 
b. 14 
12 • 
10' 
dic 8 
U 6 
6 4 • 
2 
0 
5 . 
0 
WT OX-2 
Figure 6.8 Influenza infected OX-2 knock out mice exhibit a heightened T cell response 
in their MLNs and airways at day 7 after infection. Wild type and OX-2 knock out mice 
were infected i.n. with 25 HA influenza and lungs, BAL and MLNs were removed after 7 
days. Single cell suspensions from lung, BAL and lymph node were stained with anti-
CD45RB-FITC, anti-CD4-PercP and anti-CD8-APC. The total number of CD4+ (a) and 
CD8' (b) T cells in the lung, BAL and MLN were calculated by: % CD4+/CD8+ x total 
number of lymphocytes. (c) The % CD4+ and CD8+ T cells defined as CD45RB1° in the 
BAL were determined by flow cytometry. (d) The total number of CD45RB'° T cells in the 
BAL was determined by multiplying this % by the total number of each T cell subset. BAL 
cells were also stained with CD4-PercP, CD8-APC and intracellular IFN-y-FITC and TNF-
PE. (e) The number of CD4+ and CD8+ T cells producing IFN- y and TNF was determined 
by: % of each T cell subset producing the cytokine x total number of that T cell subset. (e) 
Lung cells were stained with CD4-PercP, CD8-APC and intracellular Foxp3-PE. (f) The % 
CD4+ T cells that were Foxp3 positive was determined by flow cytometry. (g) 
Representative plots of lung CD4+ versus Foxp3 expression in wild type or OX-2 knock out 
mice. Closed symbols/bars, wild type C57BL/6 mice; open symbols/bars, OX-2 knock out 
mice Results represent mean values ± SEM from 5 mice per group. *=p<0.05, **=p<0.01. 
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Figure 6.9 Influenza infected OX-2 knock out mice fail to resolve pulmonary 
inflammation and exhibit a heightened myeloid response at day 14 after infection. 
Wild type and OX-2 knock out mice were infected i.n. with 25 HA influenza and the total 
number of cells in the lung, BAL and mediastinal lymph nodes at day 14 after infection 
were determined by trypan blue exclusion (a). (b) Representative H and E stained lung 
sections from wild type and OX-2 knock out mice 2 days after infection (x200 
magnification). Single cell suspension from the lung, BAL and node were stained with anti-
Gr- I -FITC, anti-MHC II-PE, anti-CD11b-Percp and anti-CD11c-APC. (c) The number of 
macrophages (c) and dendritic cells (d) in the lung and BAL were determined by 
multiplying the percentage of each population, as adjudged by flow cytometry, by the total 
number of viable cells. The intensity of MHC II expression on the surface of lung 
macrophages (e) and dendritic cells (f) was conferred from the MHC II geometric mean on 
each population as adjudged by flow cytometry. (g) Representative histogram overlay of 
MHC II expression on dendritic cells from the lung. Closed symbols, wild type C57BL/6 
mice; open symbols, OX-2 knock out mice Results represent mean values ± SEM from 5 
mice per group. *=p<0.05, **=p<0.01. 
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day 14 after infection (data not shown). The enhanced cellularity of the lung was 
observed in H and E stained lung sections (Fig. 6.9b). Enhanced pulmonary cellularity 
in OX-2 knock outs was partially attributable to increased macrophages (Fig. 6.9c) 
and dendritic cells (Fig. 6.9d) at these sites as seen at previous time points. 
Furthermore, the level of MHC II expression was once again elevated on 
macrophages (Fig. 6.9e) and dendritic cells (Fig. 6.9f and g) in the lung and airways. 
Greater numbers of lung and airway CD4+ (Fig. 6.10a) and CD8+ (Fig. 6.10b) T cells 
were also detected in the OX-2 knock out mice at day 14 after infection, which 
expressed more intracellular IFN-y and TNF (Fig. 6.10c and d). The total number of 
activated (CD45RBI°) CD4+ and CD8+ T cells were also elevated in the airways (Fig. 
6.10e) and lung (data not shown) of OX-2 knock out mice relative to wild type 
controls. The phenotype and function of T cells can be inferred from differential 
expression of CD44 and CD62L. CD4+ and CD8+ T cells from the lung (Fig. 6.11a-d) 
and airways (data not shown) of OX-2 knock out mice exhibited a bias towards 
CD44±CD621; (R2; Fig. 6.11a-d) expression compared to wild type mice, with a 
concomitant reduction in T cell populations that were CD44-CD62L+ (R1; Fig. 6.11a-
d) in the knock outs. A reduced percentage of T cells derived from the MLNs of OX-2 
knock out mice were CD44-CD62L+, as seen in the lung, but at this site a greater 
percentage of knock out T cells expressed both CD44 and CD62L (data not shown). 
6.2.6 OX-2 knock out mice produce elevated levels of inflammatory cytokines in 
response to influenza relative to wild type controls 
We have previously demonstrated that a potent effect of CD200R signalling on 
macrophages is suppression of pro-inflammatory cytokine production. It was 
anticipated that the absence of the inhibitory signal imparted by CD200 in OX-2 
knock out mice would result in greater myeloid derived cytokine production in 
response to influenza infection and may explain the heightened inflammation seen in 
these mice. The levels of an array of inflammatory cytokines and chemokines in the 
BAL were therefore determined by Luminex (Fig. 6.12). We detected a small increase 
in the levels of IL-6 (Fig. 6.12a), TNF (Fig. 6.12b), MIP-1 a (Fig. 6.12c) and IFN-y 
(Fig. 6.12d) in the OX-2 knock out mice, probably reflecting the heightened myeloid 
and subsequent T cell response. However, it must be recognized that in an in vivo 
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Figure 6.10 Influenza infected OX-2 knock out mice exhibit a prolonged T cell response 
in their lungs and airways at day 14 after infection. Wild type and OX-2 knock out mice 
were infected i.n. with 25 HA influenza and lungs and BAL were removed at day 14 after 
infection. Single cell suspensions were stained with anti-CD4-PercP, anti-CD8-APC and 
intracellular anti-IFN-7-FITC and anti-TNF-PE. The total number of CD4+ (a) and CD8± (b) 
T cells in the lung and BAL were calculated by: the % CD4±/CD8+ cells x total number of 
lymphocytes. (c) Representative plots of BAL CD4+ and CD8+ T cells versus IFN-7 or TNF 
expression in wild type and OX-2 knock out mice at day 14 after influenza infection. (d) The 
number of CD4+ and CD8+ T cells producing IFN- y and TNF was determined by: the % of 
each T cell subset producing the cytokine x total number of that T cell subset. Single cell 
suspensions from the lung and BAL were also stained with CD45RB-FITC, CD4-PercP and 
CD8-APC. The % CD4+ and CD8+ T cells defined as CD45RBI' in the BAL were 
determined by flow cytometry. (d) The total number of CD45RB'° T cells in the BAL were 
determined by multiplying this % by the total number of each T cell subset. Closed bars, 
wild type C57BL/6 mice; open bars, OX-2 knock out mice Results represent mean values ± 
SEM from 5 mice per group. *—p<0.05, **=p<0.01. 	
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Figure 6.11 Influenza infected OX-2 knock out mice possess a greater number of 
CD44±CD62L- T cells at day 14 after infection. Wild type and OX-2 knock out mice were 
infected i.n. with 25 HA influenza and lungs were removed at day 14 after infection. Single 
cell suspensions were stained with anti-CD44-FITC, anti-CD69-PE, anti-CD4-PercP and 
anti-CD8-APC. The percentage of CD4+ (a) and CD8+ (b) in the lung that are CD44-CD62L+ 
(R1), CD44+CD621: (R2) and CD44+CD621: (R3) was determined by flow cytometry. 
Representative plots of CD44 versus CD62L expression for lung CD4+ (c) and CD8+ (d) T 
cells from wild type and OX-2 knock out mice at day 14 after influenza infection. Closed 
bars, wild type C57BL/6 mice; open bars, OX-2 knock out mice Results represent mean 
values ± SEM from 5 mice per group. *=p<0.05, **-p<0.01. 
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Figure 6.12 OX-2 knock out mice produce heightened levels of pro-inflanunatory 
cytokines during influenza infection. Cytokines in the BAL fluid of influenza infected 
wild type (closed symbols) and OX-2 knock out (open symbols) mice at days 2, 7 and 14 
after infection were determined by Luminex. Results are shown for IL-6 (a), TNF (b), 
MIP- 1 a (c) and IFN-y (d). Results represent mean values ± SEM from five mice per 
group. *=p<0.05, **=p<0.01. 
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scenario there will be multiple cell types both producing and ligating cytokines, and 
thus results may not fully reperesent the potency of CD200 in suppressing pro-
inflammatory cytokine production. It would be of interest to ascertain production of 
pro-inflammatory cytokies within the lung at the level of mRNA, and also determine 
the systemic levels of these cytokines. 
6.2.7 OX-2 knock out mice show improved influenza viral clearance 
We next determined viral titres in wild type and OX-2 knock out mice at days 2, 7 and 
14 after influenza infection by plaque assay. OX-2 knock out mice had a significantly 
reduced viral burden in their lungs at day 2 after influenza infection relative to wild 
type controls. By day 7 after influenza infection viral titres were very low and 
comparable in both groups of mice and by day 14 no virus was detectable by plaque 
assay (Fig. 6.13a). It was of interest to ascertain whether the absence of CD200 
induced signalling in OX-2 knock out mice would alter their ability to develop an 
influenza specific antibody response. The levels of influenza specific IgG in the 
serum (Fig. 6.13b) and IgA in the BAL (Fig. 6.13c) were comparable in wild type and 
OX-2 knock out mice. 
6.2.8 Administration of CD200:Fc alleviates influenza driven weight loss and 
inflammation 
We next performed the opposite experiment by administering CD200:Fc to wild type 
mice, which ligates CD200R and transmits a negative signal to APCs. Mice were 
infected intranasally with 50 HA influenza and 10µg IgG or CD200:Fc administered 
i.p. on days 0, 2, 4 and 6 (Fig. 6.14). Those mice administered CD200:Fc exhibited 
reduced weight loss (Fig. 6.15a) and a significant reduction in the number of cells in 
their lungs and airways (Fig. 6.15b). H and E staining of lung sections from control 
and CD200:Fc treated mice also clearly showed a striking reduction in lung cellular 
infiltrate with reduced perivascular and peribronchiolar infiltrate (Fig. 6.15c). 
A general reduction in the total number of CD1 lb+ cells in the airways (Fig. 6.16a) of 
the CD200:Fc treated mice failed to be significant, as did the total number of CD1 lb+ 
cells expressing MHC II (Fig. 6.16b) and CD86 (Fig. 6.16c). However, there was a 
reduction in the levels of the pro-inflammatory cytokines IFN-y (Fig. 6.16d) and IL-6 
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Figure 6.13 OX-2 knock out mice possess a reduced influenza viral load. (a) Wild type 
and OX-2 knock out mice were infected with influenza and viral titres were assessed in lung 
homogenates by plaque assay on days 2, 7 and 14 after infection. (b) Serum was isolated and 
BAL performed on influenza infected wild type and OX-2 knock out mice at days 2, 7 and 
14 after infection and the levels of influenza specific IgG (b) in the serum (diluted 1 in 100) 
and IgA (c) in the BAL determined by ELISA. Results represent absorbance values at 
490nm. Closed symbols, wild type C57BL/6 mice; open symbols, OX-2 knock out mice 
Results represent mean values ± SEM from 5 mice per group. *=p<0.05, **=p<0.01. 
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Figure 6.15 Administration of a CD200 fusion protein (CD200:Fc) alleviates weight 
loss and reduces pulmonary inflammation to influenza infection. Influenza infected 
C57BL/6 mice were administered 10}.tg of control antibody or CD200:Fc i.p. at days 0 and 
3 after infection. Weight loss was monitored daily and expressed as a percent of original 
weight (a). The number of viable cells in the lung and BAL after 7 days was determined by 
trypan blue exclusion (b). (c) Representative H and E stained lung sections from PBS 
treated and CD200:Fc treated C57BL/6 mice 7 days after infection (x 200 magnification). 
Closed symbols, control treated; open symbols, CD200:Fc treated. Results represent mean 
values ± SEM from five mice per group. *=p<0.05, **=p<0.01. 
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Figure 6.16 Administration of a CD200:Fc reduces pro-inflammatory cytokines in the 
airways. Control and CD200:Fc treated mice were infected with influenza, BAL performed 
at day 7 after infection, and cells stained with anti-Gr-l-FITC, anti-MHC II-PE / CD86-PE, 
anti-CD1 lb-PercP and anti-CD 1 lc-APC and analysed by flow cytometry. (a) The total 
number of CD1113+ cells in the airways were calculated by: % CD1 lb' cells x total number 
of viable cells. The number of MHC 11 (b) and CD86 (b) expressing CD11b± cells was 
calculated by: ')/0 CD11b+ expressing these markers x total number of CD1 lb+ cells. The 
levels of pro-inflammatory cytokines in the BAL fluid was assessed by CBA at day 7 after 
infection and the levels of IFN-7 (d) and IL-6 (e) in control and CD200Fc treated mice are 
shown. Closed symbols/bars, control treated; open symbols/bars, CD200:Fc treated. Results 
represent mean values ± SEM from five mice per group. *=p<0.05, **=p<0.01. 
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(Fig. 6.16e) in the BAL fluid of CD200:Fc treated mice, possibly reflecting the 
potential of CD200 to deliver an inhibitory signal to the myeloid compartment. 
The most striking reduction in pulmonary infiltrate in the CD200:Fc treated mice was 
observed in the T cell compartment with a reduction in CD4÷ and CD8+ T cell 
numbers in the lungs (Fig. 6.17a) and airways (Fig. 6.17b), their activation (Fig. 6.17c 
and d) and their expression of IFN-y (Fig. 6.17e) and TNF (Fig. 6.17f). Importantly, 
influenza virus was cleared in both control and CD200:Fc treated mice with infective 
virus undetectable in the lungs of both groups by day 7. Furthermore, levels of 
influenza specific IgG in the serum and IgA in the BAL was equivalent in the wild 
type and knock out mice (data not shown). 
6.2.9 Blockade of CD200 signalling boosts immunity to Cryptococcus neoformans 
and prevents dissemination to the brain 
Since Cryptococcus neoformans is a persistent lung fungal pathogen and we have 
previously shown that a heightened myeloid response in Cybb tml mice improves 
pathogen clearance, we next administered a blocking antibody to CD200 (0X90) on 
days 0, 4 and 8 after infection (which should enhance myeloid activity) and mice were 
culled on day 12 to assess the immune phenotype and pathogen clearance (Fig. 6.18). 
The mice administered 0X90 had comparable cell numbers in their lungs (Figure 
6.19a) relative to control treated mice, but elevated numbers of cells in their airways 
(Fig. 6.19b) and spleen (Fig. 6.19c). Whilst the heightened immune infiltrate observed 
with administration of 0X90 did not reduce pathogen burden in the lungs (Fig. 6.19d) 
and airways (Fig. 6.19e), dissemination to the brain was completely blocked (Fig. 
6.19f). 
As may be anticipated the blockade of CD200 signalling with 0X90 caused an 
increase in myeloid cell numbers in the lungs, airways and spleen. Despite 
comparable cellular infiltrate in the lung, there was a general increase in the number 
of macrophages at this site (Fig. 6.20a) and a significant increase in the number of 
dendritic cells (Fig. 6.20b) and eosinophils (Fig. 6.20c and d). This increase in 
myeloid cells was more striking in the airways and spleen reflecting the general 
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Figure 6.17 Administration of CD200:Fc to influenza infected mice reduces pulmonary 
T cell infiltrate at day 7 after infection. Control and CD200:Fc treated mice were infected 
with influenza and at day 7 lung and BAL removed. Single cell suspensions from lung and 
BAL were stained with anti-CD45RB-FITC, anti-CD4-PercP and anti-CD8-APC. The total 
number of CD4+ and CD8+ T cells in the lung (a) and BAL (b) calculated by: % CD4+/CD8+ 
x total number of viable lymphocytes. The % CD4+ and CD8+ T cells defined as CD45RB1° 
in the BAL were determined by flow cytometry. The total number of CD45RBI° T cells in 
the lung (c) and BAL (d) were determined by multiplying this % by the total number of each 
T cell subset. BAL cells were also stained with antiCD4-PercP, antiCD8-APC and 
intracellular IFN-7-FITC and TNF-PE. (e) The number of CD4+ and CD8+ T cells producing 
anti-IFN- y (e) and anti-TNF (f) was determined by: % of each T cell subset producing the 
cytokine x total number of that T cell subset. Closed symbols, control treated; open symbols, 
CD200:Fc treated. Results represent mean values ± SEM from five mice per group. 
*=p<0.05, **=p<0.01. 
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Figure 6.19 Blockade of CD200 signalling during C. neoformans infection causes an 
increase in cellular infiltration and a reduction in dissemination to the brain. C. 
neoformans-infected mice were treated i.p. with IgG or OX90 on 0, 4 and 8 days after 
infection. At day 12 after infection, BAL was performed and lungs and spleen were 
removed and homogenised to a single cell suspension. The total number of viable cells in 
the lung (a), BAL (b) and spleen (c) were enumerated by trypan blue exclusion. At day 12 
after infection, homogenate of lung (d), BAL (e), and brain (f) were plated out on 
sabauraud dextrose agarose and incubated for 48 hours at room temperature. C. 
neoformans efus were subsequently counted. Closed symbols/bars, IgG treated mice; open 
symbols/bars, OX90 treated mice. Results represent mean values ± SEM from 5 mice per 
group. *=p<0.05, **=p<0.01. 
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Figure 6.20 Blockade of CD200 signalling during C. neoformans infection causes an 
increase in myeloid cell numbers. C. neoformans-infected mice were treated i.p. with IgG 
or OX90 on 0, 4 and 8 days after infection. At day 12 after infection, lung was removed and 
homogenised to a single cell suspension. Single cell suspension was stained with anti-Ly6G-
FITC, anti-CD200R-PE, anti-CD11b-PercP and anti-CD11c-APC. The % of each subset of 
myeloid cells was inferred from differential expression of these markers by FACS analysis. 
Total numbers of macrophages (a) and dendritic cells (b) in the lung were subsequently 
calculated from the total number of viable cells. The % eosinophilia in the lung was 
enumerated from forward/side scatter properties by flow cytometry and confirmed by 
eosinophil enumeration of cytocentrifuged lung homogenate. The total number of 
eosinophils in the lung (c) was calculated by: % eosinophils x total number of viable cells. 
(d) Representative plots of Fsc versus Ssc in C. neoformans infected IgG and OX90 treated 
mice 12 days after infection. R1 = granulocyte gate. (e) Representative histogram overlay of 
CD200R expression on eosinophils derived from the lung at day 12 after influenza 
infection. Closed symbols, IgG treated mice; open symbols, OX90 treated mice. *—p<0.05, 
**—p<0.01. 
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heightened cellularity at these sites (data not shown). To ascertain how blocking 
CD200 increases the number of lung eosinophils we investigated CD200R expression 
on eosinophils by flow cytometric analysis. No CD200R expression was apparent on 
the surface of eosinophils implying that the increase in the numbers of this cell type is 
not a direct consequence of the removal of the inhibitory signal imparted by CD200 
(Fig. 6.20e). 
The T cell response to C. neoformans is critical for pathogen control with the 
development of a Thl skewed response leading to eradication of this yeast and 
prevention of dissemination to extra-pulmonary sites. Those mice administered OX90 
possessed comparable numbers of both CD4+ and CD8+ T cells in their lungs (Fig. 
6.21a) but a significant increase in the numbers of both subsets in the airways (Fig. 
6.21b). Furthermore, a greater percentage of the CD4+ T cells in the airways of the 
OX90 treated mice were more activated (Fig. 6.21c). T cells present in the airways of 
those mice treated with OX90 did not exhibit any shift in Thl /Th2 bias with a greater 
percentage producing both IFN-y and IL-5 (Fig. 6.21d-g). 
260 
c. 
100 
• 
* 
CD4+ 
e. 20 
Z 15. 
Fil 
A 
oo 10. 
V 
c° 	5 ' 
0 
I 	CD8+ 
* * 
• ** 
t 
IgG 0300 
0 
q> 
0 
0  
a. 
9 
8. 
If1c=7 7. 
,...-4 6 
0 
,71,0 4 
c.)3 
0 2 Z 
o - 	
stt 5 
1 
CD4+ 
d. 15 
in  oi 
0 
CD8+ 
b. 
10 
9 
8 
!I:4 7 
•!..%1 6 
4 5 
a 4 
0 
g. 10 
• 
• 
• 
• 
• 
* 
0 
0 
0 
   
    
Figure 6.21 Blockade of CD200 signalling during C. neoformans infection causes a 
heightened T cell response. C. neoformans-infected mice were treated i.p. with IgG or 
OX90 on 0, 4 and 8 days after infection. At day 12 after infection, BAL was performed and 
lung was removed and homogenised to a single cell suspension. Single cell suspensions of 
BAL and lung tissue were stained with anti-CD45RB-PE, anti-CD4-PercP and anti-CD8-
APC. The % lymphocytes that are CD4+ and CD8+ T cells were determined by flow 
cytometry. The total number of each T cell subset in the lung (a) and BAL (b) was 
calculated by: % CD4+/CD8+ x total number of viable cells. Results represent mean values 
± SEM from 5 mice per group. The % of each subset of T cells in the BAL that were 
CD45RB1° was inferred from flow cytometric analysis (c). BAL cells were also stained with 
anti-IFN-y-FITC, anti-IL-5-PE, anti-CD4-PercP and anti-CD8-APC. The % of CD4+ (d and 
f) and CD8+ (e and g) T cells producing IFN-y (d and e) and IL-5 (f and g) was determined 
by flow cytometry. Closed symbols, IgG treated mice; open symbols, OX90 treated mice. 
*=p<0.05, **=p<0.01. 
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6.3 Discussion 
6.3.1 Heightened myeloid response in naïve OX-2 knock out mice 
Studies with naive OX-2 knock out mice show an elevated number of myeloid cells in 
spleens relative to wild type controls 76, and may imply a role for CD200 controlling 
myeloid cell homeostasis at the resting state. We, and others have reported the 
expression of CD200 on endothelia, B cells and some T cells within the spleen and it 
is plausible that some or all of these cell types interact with myeloid cells and restrain 
their activation through CD200R. Interestingly, unlike the spleen, the number of 
myeloid cells in the lungs and airways of OX-2 knock out mice were comparable to 
wild type. These differences may reflect the abundance of cell types bearing CD200 
and its receptor or the fact that the spleen is highly compartmentalised whereas the 
naïve lung is not. Consequently, within the splenic compartment, CD200 may fulfil an 
important homeostatic role in controlling myeloid cell turn over. This lack of 
homeostatic control in effector, compared to primary lymphoid sites, may underlie the 
amplified inflammation versus organised immunity that occurs at these distinct sites. 
6.3.2 More rapid and potent induction of immunity to influenza infection in OX-2 
knock out mice 
The investigation into the role of CD200 during influenza infection is extremely novel 
and topical. In the absence of CD200, influenza infected OX-2 knock out mice exhibit 
a more rapid weight loss early during infection and then fail to recover in line with 
wild type mice; implying a role for CD200 in controlling induction and resolution of 
lung inflammation. This reduced myeloid control leads to enhanced production of 
inflammatory cytokines in OX-2 knock out mice infected with influenza, which may 
ultimately cause the greater weight loss and illness observed in these animals 268-
273,275 This idea is supported by our in vitro studies showing that signalling through 
CD200R suppresses production of pro-inflammatory cytokines by IFN-y or influenza 
activated BM macrophages, whilst others have shown a reduction in IL-6 and TNF 
production in peritoneal macrophages in response to IFNI stimulation 96. 
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Furthermore, there are elevated numbers of activated myeloid cells in various lung 
compartments during influenza infection in OX-2 knock out mice at day 2 after 
infection. The increase in alveolar macrophages is interesting. It is possible they are 
normally restrained during respiratory challenge by CD200 expressed on epithelia or 
other CD200 expressing cells in the lung and in its absence there is expansion of this 
myeloid population. CD200 mediated control of alveolar macrophages may be more 
potent during infection relative to in a naïve animal owing to up-regulation of 
CD200/R expression. Likewise, myeloid cells within the nodes of wild type mice are 
possibly restrained by the high density of lymphocytes that bear CD200. The 
heightened myeloid numbers in OX-2 knock out mice at day 2 of influenza infection, 
may reflect the heightened inflammatory environment or another, as yet unknown, 
role for CD200 such as controlling myeloid cell apoptosis, persistence in the BM, 
differentiation/maturation or deflection from the circulation into tissues. 
It would be of interest to further analyse the potential of epithelia to modulate and 
inhibit macrophage function via CD200 and in future we will seek to address this in 
vitro by incubating epithelia isolated from wild type and knock out mice with 
influenza infected alveolar macrophages. Furthermore, it would be of interest to 
ascertain how myeloid cells resident in mediastinal nodes differ in their potential to 
generate cytokines in the absence of CD200. Whilst it is likely that they generally do 
not produce pro-inflammatory cytokines in vivo owing to their limited exposure to 
TLR ligands and activating stimuli, it is possible that they are also actively restrained 
by the high density of surrounding CD200 expression and should be investigated 
further. 
The increased activated CD4+ and CD8+ T cells in the MLNs of OX-2 knock outs at 2 
days after influenza infection is likely to be a consequence of the heightened myeloid 
response and induction of inflammatory cytokines. Though we did not directly assess 
adhesion molecules, these are also likely to be raised by enhanced inflammatory 
cytokines 446 Alternatively, increased T cell numbers in OX-2 knock out mice may 
reflect enhanced presentation by the elevated numbers of CD200R bearing cells in the 
MLNs, which may be further matured by elevated cytokines 447-450. Indeed, TNF 
contributes to DC activation 451, maturation 452 and migration to and accumulation in 
draining lymph nodes 453. 
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The increased myeloid response and more rapid onset of weight loss observed in OX-
2 knock out mice following influenza infection is comparable to the earlier and more 
severe onset of various autoimmune diseases previously reported in these mice. In a 
facial nerve transfection model, the microglial response of the OX-2 knock outs is 
accelerated with disease detectable at day 2 and peaking at day 4, relative to wild type 
mice where disease is first observed at day 4 and most severe at day 7 76. Similarly, 
the onset of EAE in OX-2 knock out mice is seen 3 days earlier than in wild type 
controls and is characterised by increased macrophage numbers and activation 76. 
Experimental autoimmune uveoretinitis (EAU) also shows accelerated onset in OX-2 
knock out mice although overall disease severity is not increased 87'88. Therefore, it 
would appear that CD200 exerts an inhibitory potential over myeloid cells and in its 
absence the inflammatory response is more rapid and potent. 
Enhanced MLN cellularity persists to day 7 of influenza infection, at which time 
there is also an increase in the total number of cells in the airways, accounted for by 
increased numbers of macrophages, DCs and T cells. This is likely to be a 
consequence of enhanced immunity observed at day 2 in the MLN coupled with the 
inability to "switch off' the pro-inflammatory phenotype of pulmonary macrophages. 
It is interesting to note that comparable or even lower cellularity was observed in the 
lungs of OX-2 knock out mice than in the wild type controls. This is comparable to 
the scenario observed in Cybb tml mice previously whereby a greater myeloid 
response early in infection seems to draw cells directly into the airways rather than 
lung tissue. Furthermore, the primary site of influenza infection is the upper 
respiratory tract and as such a more rapid and potent immune response, as seen in 
OX-2 knock out mice, is likely to be targeted to this compartment to combat infection. 
Interestingly, at day 14 after influenza infection there was a significant shift in lung 
resident T cells of the OX-2 knock out mice from a nave (CD44-CD621,4) to a 
CD44+CD621; phenotype relative to wild type controls. CD44+CD62L- expression 
has been identified as the profile of effector memory T cells, which may indeed be 
expanded in the absence of CD200. Alternatively, these cells may simply be recently 
activated. MLNs in OX-2 knock out mice contained a greater number of T cells 
expressing both CD44 and CD62L, the definition of central memory, 14 days after 
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influenza infection. The generation of a greater memory response in the absence of 
CD200 could potentially mean that CD200 blockade could fulfil an adjuvant-like 
capacity with vaccination, and requires further investigation. 
6.3.3 Failure to resolve influenza induced pulmonary inflammation in OX-2 knock 
out mice 
Intriguingly, OX-2 knock out mice fail to recover and regain weight as rapidly as wild 
type controls and possessed elevated numbers of cells in their lungs and airways 
(myeloid cells and activated T cells). This would imply that CD200 plays an 
important role in resolving inflammation, which would be an entirely novel concept. 
Previous studies with OX-2 knock out mice have investigated autoimmune 
conditions, which are chronic in nature and as such resolution is not investigated. This 
failure to resolve inflammation may reflect a lack of inhibition by CD200 at this stage 
and/or prolonged presence of signals maintaining inflammation such as co-
stimulatory molecules or inflammatory cytokines. Alternatively, it may simply take 
more time to clear an expanded inflammatory infiltrate. 
We have previously seen how CD200R is up-regulated on the surface of myeloid cells 
during the course of influenza infection, peaking at day 14, and subsequently 
enhancing their susceptibility to CD200 mediated inhibition and resolution of 
inflammation. It is plausible that CD200 expressing stromal cells or recruited 
lymphocytes are important in switching off myeloid cells that have up-regulated 
CD200R. However, in the absence of CD200, myeloid cells are not as effectively 
"switched off' and inflammation is slower to resolve. Finally, the absence of CD200 
leads to elevated levels of pro-inflammatory cytokines during influenza infection, 
some of which have been demonstrated to inhibit the suppressive effects of regulatory 
T cells 437'438. Whilst we failed to see any difference in the numbers of FoxP3 T cells 
in OX-2 knock out mice during influenza infection, it is plausible that failure to 
resolve inflammation may in part be attributable to aberrant Treg mediated 
suppression. 
The heightened cellularity that persists in the lungs and airways of the OX-2 knock 
out mice at day 14 of infection is not a consequence of an underlying failure to clear 
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influenza virus. Indeed, viral titres are reduced in OX-2 knock out mice at day 2 after 
infection, which is again likely to reflect heightened myeloid activity. Macrophages 
are critical to the establishment and maintenance of the host's protective response to 
influenza 219'440'441 with activated macrophages capable of phagocytosing influenza 
virions and producing Type 1 IFNs that are critical to control of viral infection 439. 
The latter needs further investigation. Indeed, various other viruses such as those of 
the Herpes family express a CD200 homologue that signals through CD200R on the 
host myeloid cell and is anticipated to offer some form of survival advantage against 
the virucidal activity of macrophages 459. 
6.3.4 Induction of CD200 signalling as an immunotherapeutic strategy during 
influenza infection 
Administration of a CD200 fusion protein (CD200:Fc) to influenza infected mice 
offers a plausible immunotherapeutic strategy since the development and maintenance 
of inflammation is directly linked to the activation of the myeloid cells. We have 
shown in vitro that signalling through CD200R suppresses the production of pro-
inflammatory cytokines by BM macrophages stimulated by influenza or IFN-y. 
Furthermore, we and others have previously demonstrated that neutralisation of pro-
inflammatory cytokines during influenza infection alleviates illness and inflammation 
268-273,275 and as such it is no surprise that manipulation of CD200 signalling is 
beneficial. Mice administered CD200:Fc showed a significant reduction in weight 
loss and pulmonary infiltrate. It is plausible that the CD200:Fc binds myeloid 
CD200R that would not normally be exposed to natural CD200 ligand and in so doing 
represses the myeloid response to influenza infection. It is likely that the reduced 
pulmonary T cell infiltrate seen in mice treated with CD200:Fc reflects a reduction in 
pro-inflammatory cytokine production by myeloid cells early in infection. However, 
1) phagocytosis of the influenza virion, 2) migration of the myeloid cell to the 
draining lymph node, 3) the maturation of the myeloid cell into a professional APC 
capable of successfully activating the adaptive arm of the immune response and / or 4) 
reduced migration competent T cells in the node (Fig. 6.22), may also account for 
reduced T cells. 
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Figure 6.22 Mechanisms of action of CD200:Fc during influenza infection. 
Administration of a soluble CD200 fusion protein could modulate the myeloid 
immune response in a number of ways. During influenza infection, myeloid cells 
sample influenza in the lung compartment before migrating to the draining lymph 
node to present antigen to recruited T cells. T cells are primed and proliferate in the 
node before returning to the lung to exert their effector function. CD200 may alter the 
phenotype or function of the myeloid cell in a number of ways, which could all 
potentially explain the reduced T cell recruitment to the lung. 
There have been various reports citing the potential of manipulating CD200 signalling 
as an immunotherapeutic strategy to alleviate excessive inflammation with 
93,95- autoimmunity, alloimmunity and allergy 84,91 	and we can now add inflammatory 
lung disease to this list. However, it is essential that administration of CD200:Fc 
therapeutically be investigated as the delayed administration of the fusion protein may 
be less effective since the myeloid cells would have already produced large quantities 
of pro-inflammatory cytokines and the immune response already set in motion. 
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However, it is more likely that CD200:Fc will continue to offer some relief in 
suppressing inflammation, although the earlier the administration the better. 
Furthermore, it is always a concern that reducing the potency of immune responses 
through immunotherapeutic strategies will compromise immunological memory and 
the development of an antibody response upon any subsequent exposure to the 
pathogen. This is again something that would require investigation with CD200:Fc, 
although it is reassuring that influenza specific antibody responses are not 
compromised during a primary infection. 
6.3.5 Blockade of CD200 signalling to boost immunity to C. neoformans 
Finally, if we can administer CD200:Fc to transmit the inhibitory signal, we can also 
block it to enhance immunity. This we present for C. neoformans infection and show 
a rise in immunity with augmented macrophages, DCs and T cell responses (their 
activation and cytokine production). It is interesting that the heightened T cell 
cytokine production did not show any bias towards a Thl or Th2 phenotype since 
previous studies show that CD200 signalling skews immunity from a Thl towards a 
Th2 response 93. An increase in eosinophils was observed in C. neoformans infected 
mice administered OX90, and probably reflects the increase in IL-5 production by T 
cells since IL-5 is an eosinophil differentiation and activation factor 460 . 
Despite the general increase in immunity seen by blockade of CD200 signalling, there 
were comparable C. neoformans cfus in the lung and BAL of both groups of mice. As 
discussed previously, a Thl driven response against C. neoformans is protective and 
leads to clearance of the pathogen 252-254, whereas a Th2 response is non-protective 
255 Whilst there appears to be heightened Thl cells, there is also an increase in Th2 
cells, which are likely to cancel each other out. Furthermore, the elevated number of 
eosinophils in OX90 treated mice will cause significant lung tissue damage and 
facilitate replication of C. neoformans. Persisting tissue eosinophilia results in tissue 
destruction due to release of eosinophil-derived mediators at the site of inflammation 
including reactive oxygen metabolites, major basic protein, eosinophil cationic protein 
and crystal deposition 461  However, blockade of CD200 led to the prevention of C. 
neoformans dissemination to the brain, which depends on the development of a Thl 
immune response. IL-12 is a critical cytokine in the induction of a nil response 134-138 
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and controlling dissemination of C. neoformans to the brain 263'264. The heightened 
myeloid response observed with OX90 administration could affect levels of this 
cytokine and thus control dissemination with greater aptitude. TNF may also assist in 
the prevention of dissemination. TNF knock out mice are more susceptible to C. 
neoformans infection 265, and Huffnagle and colleagues have demonstrated a 
significant early role for TNF in leukocyte recruitment of leukocytes and the 
development of Thl biased immune response 244'266. 
6.3.6 Conclusions 
In conclusion, we have shown several important concepts relating to lung 
immunity/pathology: 
1. The CD200-CD200R interaction is important in the induction and resolution 
of inflammation to respiratory pathogens. 
2. Innate immunity requires active signals, potentially delivered by the acquired 
immune response, for inflammation to resolve. 
3. The inhibitory signal delivered via CD200R can be harnessed immuno-
therapeutically to dampen excessive inflammation. 
4. Myeloid inhibitory receptors can be blocked to facilitate clearance of 
persistant pathogens. 
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Chapter 7 — General Discussion 
Manipulation of the myeloid immune response during respiratory infection offers 
plausible therapeutic potential. The form of this manipulation will differ depending 
on the nature of the pathogen: stimulation of the myeloid immune response promotes 
general immunity and pathogen clearance, whilst suppression can alleviate 
immunopathology. We have utilised two distinct strategies to target the myeloid 
compartment: 1) By modulating the levels of toxic, inflammatory mediators (ROS) 
produced by the cell and 2) By ligating or blocking the inhibitory CD200R on 
myeloid cells. There are many concepts arising from this work that could merit further 
consideration, but in this final discussion I will address the following: 
Active suppression of the myeloid immune compartment in maintaining 
cellular homeostasis. 
The roles of ROS and CD200 in disparate compartments of the lung. 
What factors dictate when ROS or CD200 can exert their inhibitory 
potential in the context of an immune response? 
The therapeutic potential or limitations of manipulating CD200 and ROS 
in respiratory infectious diseases. 
7.1 Active suppression of the myeloid compartment 
Our data shows that both ROS and CD200 actively suppress the myeloid immune 
compartment and maintain homeostasis in the absence of infection. This suggests that 
specific signals are required to maintain myeloid cells in a resting state. This concept 
is supported by our data showing that an absence of CD200 or the phagocyte NADPH 
oxidase elevates myeloid cell numbers and their activation in a naïve animal. 
Furthermore, a greater myeloid response is elicited to infection and potentially 
sustained. Therefore, important mechanisms are in place to not only maintain 
homeostasis in a naïve animal, but also restrict excessive myeloid driven immunity 
and resolve inflammation to restore homeostasis. However, the nature of suppression 
exerted by ROS and CD200 are distinct: 
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ROS are soluble factors that are produced by phagocytes and subsequently 
act in an "autocrine" manner. Hence the cells are effectively restraining 
themselves. ROS also, however, appear to act in a "paracrine" manner to 
restrain neighbouring cells. 
CD200-CD200R is a cell contact dependent interaction where the 
inhibitory signal is imparted to the myeloid compartment by disparate cell 
types. Thus this inhibition is promoted in a "paracrine" manner and is 
dependent on other non-myeloid cells. 
7.1.1 ROS mediated suppression 
ROS are classically known for their potent anti-microbial action. However, it is now 
recognized that the role of such species is far more complex than originally 
anticipated, owing to their potential to act in a signalling capacity, and some have 
argued that this may even be their most significant contribution. Whilst it has been 
reported that ROS can be pro-inflammatory through activation of redox sensitive 
transcription factors 462, our findings suggest they exhibit an important anti-
inflammatory role. ROS have been implicated in oxidatively inactivating chemotactic 
factors 366, inducing anti-inflammatory cytokine production by neutrophils and 
macrophages 367 and in modulation of Thl cytokine production 368. However, we 
argue that the cells that appear most actively suppressed by ROS are those actually 
producing them, and that this repression is, at least in part, mediated through 
induction of apoptosis. ROS may represent ideal mediators for imposing a level of 
control over myeloid cell homeostasis due to their capacity to act as second 
messengers. Indeed, reactive oxygen species derived from a family of superoxide-
generating enzymes, termed NADPH oxidases (NOXs), that are isoforms of the 
classical phagocyte NADPH oxidase (NOX2,) are actively produced to function in 
redox signalling with their primary roles focused at regulating other cell types and 
processes 463. 
In naive Cybb tm 1 mice we observe elevated numbers of macrophages at distinct 
lymphoid sites, implying that, in a resting state, ROS are produced at a basal level, 
even at non-mucosal sites, and fulfil a role in governing myeloid cell turnover. Such 
self imposed control to limit cellular numbers is seen in hematopoietic cells, as with 
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fratricide of memory T cells. In this scenario, immunological memory depends on a 
self-renewing pool of antigen-specific T memory (Tm) cells and it has been 
postulated that Tm-cell fratricide by Fas-mediated apoptosis results in a density-
dependent death rate that controls the size of the T cell pool 464. Microarray analysis 
revealed that, even in the absence of infection, significant alterations in gene 
expression were present in the lungs of mice lacking a functional NADPH oxidase, re-
iterating the important role that ROS fulfil in the redox regulation of transcription. 
The concept that ROS act to negatively regulate the myeloid response is supported by 
evidence from individuals with CGD, who exhibit aberrant inflammation with 
development of granulomas 384. Furthermore, patients with CGD exhibit heightened 
susceptibility to autoimmune conditions such as polyarthritis and lupus 354, findings 
that are corroborated by studies in mice 361. It would be of interest to infer whether the 
genetic variation that occurs in promoter regions of genes encoding sub-units of the 
NADPH oxidase correlates with susceptibility to autoimmunity and inflammation in 
general. 
Interestingly, on this background of heightened myeloid activity, the response to 
infectious disease is immediate. C. neoformans infection is contained in granulomas, 
preventing dissemination to the brain, and influenza is targeted in the airways by a 
greater macrophage and neutrophil response. This may suggest that removing signals 
that restrain the myeloid compartment in a resting state and maintain homeostasis may 
improve immunity to infection. However, the greater myeloid driven immune 
response to these pathogens is also likely due to depleteion of ROS induced by the 
actual infection. During infection, excessive production or persistence of such toxic 
and unstable mediators as ROS is detrimental, and thus it is plausible that they switch 
off the cells that are producing them. Whilst this may simply be conveyed through 
induction of apoptosis, the suppressive mechanisms are likely to be more complex. 
Whilst ROS are utilised by the immune system to destroy certain pathogenic 
organisms, it is important that the immune system subsequently responds to high 
levels of ROS to prevent unnecessary bystander injury. 
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7.1.2 CD200 mediated suppression 
As with ROS, the absence of CD200 results in elevated myeloid cell numbers in the 
spleens of naive mice, and a greater myeloid driven response to respiratory infection. 
It is appealing that both CD200 and its receptor are up-regulated in response to 
respiratory infection thus making the myeloid compartment more amenable to 
suppression. Indeed, the potency of CD200 induced suppression is increased with 
higher CD200R expression 96. There are now a growing family of myeloid surface 
proteins that mediate interactions with other cells and modulate the myeloid cell 
phenotype, but our understanding of the biological basis of such signals are poorly 
defined. Some receptors such as SIRP-13 transmit a positive signal to the myeloid cell, 
whereas SIRP-a and CD200 lead to myeloid cell inhibition 465  The activity of such 
cells will ultimately therefore depend upon the balance between the positive and 
negative signals received. We and others have reported the potential of signalling 
through CD200R to suppress production of pro-inflammatory cytokines by myeloid 
cells, but there are many other facets of the myeloid response that have not been 
investigated, and we do not yet know why an absence of the CD200 signal leads to 
elevated myeloid cell numbers. 
Expression of CD200 on stromal cells is interesting and could fulfil an important role 
in restraining myeloid cell populations in the vicinity or during migration. The 
potential for CD200 on endothelia to suppress neutrophils within the circulation 
would be an exciting and novel concept. Similarly, the high expression of CD200 on 
epithelia within the lung may suppress pulmonary myeloid cells at a site where 
tolerance or non-responsiveness is frequently desirable (Fig. 7.1A). Furthermore, the 
high expression of CD200R on alveolar macrophages would facilitate suppression by 
epithelia and support their cited immunosuppressive potential 466. 
A second appealing concept is that acquired T and B cells actively suppress myeloid 
cells. It is interesting that CD200 is up-regulated on T cells upon activation thus 
enhancing their suppressive potential. Therefore, during infection the adaptive 
immune response could effectively switch off and direct the innate response (Fig 7.1). 
Myeloid cells have been reported to actively suppress the T cell response, through 
signals such as CTLA-4, but such cellular interactions in the reciprocal direction have 
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not been reported. It is plausible that once a selective T cell response has been 
induced, the T cell switches off the inflammatory phenotype of the myeloid cell to 
prevent unchecked inflammation. Indeed, CD200 can suppress production of pro-
inflammatory cytokines by macrophages, but increases CD86 and OX4OL. Thus the T 
cell may cause a switch in the phenotype of the myeloid cell from one that is 
inflammatory to one that would support antigen presentation and maintenance of T 
cell populations. This is the first time such a concept has been proposed. However 
activated T cells will express a multitude of surface proteins that can signal to 
macrophages and dendritic cells. As an example, if we consider OX40, we have 
demonstrated that signalling through OX4OL on a macrophage can augment the IFN-y 
induced production of pro-inflammatory cytokines such as TNF. This is the exact 
opposite to the effect mediated by CD200, so what would be the effect of signalling 
through CD200R and OX4OL? 
7.2 The roles of ROS and CD200 in disparate compartments of the 
immune response 
The host's immune response to a respiratory infection must be viewed in the context 
of distinct compartments. The airways, lung parenchyma and draining MLN are very 
distinct in structure and the nature of the immune response that occurs at these sites. 
Whereas the MLN is a highly structured and organised lymphoid site, the lung tissue 
is less so and the airways are completely devoid of any structural organisation. During 
an immune response the airways are the most inflammatory site with high levels of 
inflammatory cytokines, whereas classical "inflammation" does not occur in the 
MLNs, but rather they exhibit controlled expansion of lymphoid populations. To this 
end, there appears to be a reciprocal correlation between the level of structural 
organisation and the potency of the inflammatory response. The lung is a functional 
274 
A. 
t 0 
Macrophage 	(-:, ,— DC 	0 CD8+ 	3 Influenza 	CD200 
I/ 
Neutrophil 	® Monocyte 	CD4+  '04,  Inflammatory 	CD200R 
cytokines 
Figure 7.1 CD200R mediated suppression during influenza infection. A. Naïve lung. 
Alveolar macrophages express CD200R and may be restrained by CD200 expressing stromal 
cells. B. Induction phase (day 2). Influenza enters the lung, replicates and induces pro-
inflammatory cytokine production by myeloid cells, over-riding CD200 mediated suppression. 
Monocytes and neutrophils enter lung and all myeloid cells start to up-regulate CD200R. C. Peak 
inflammation (day 7). Myeloid cells further up-regulate CD200R owing to inflammatory 
environment. CD200 expressing lymphocytes enter the lung parenchyma and are able to switch 
off the myeloid inflammatory response through CD200R. However, many of the lymphocytes 
entering the airways lose CD200 expression. D. Resolved Lung. Inflammation has subsided but 
remaining alveolar macrophages express very high levels of CD200R, which may dampen 
inflammation to subsequent exposure to pathogen. Administration of CD200:Fc may prove 
beneficial by exerting heightened suppression on the myeloid cells during the induction of the 
immune response, or through compensating for the loss of CD200 on lymphocytes in the airways. 
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organ and is not suited to the large scale unregulated recruitment and expansion of 
cells, whereas LNs are specialised for such processes, exhibiting a greater level of 
control over resident cells. It is important that the roles of ROS and CD200 are 
considered within the context of immune compartmentalisation. The relationship 
between lymphoid organisation, TLR load, CD200 expression and ROS is 
summarised in Figure 7.2. 
7.2.1 ROS and immune compartmentalisation 
The elevated myeloid numbers in non-mucosal tissue, such as the spleen, of Cybb tml 
mice would imply that ROS are functioning at these sites. It is likely, however, that 
this will be at a very low basal level and it is their cumulative absence that gives rise 
to the observed phenotype. During respiratory infection, however, ROS will be 
induced to a much higher level in response to pathogenic burden. In this context, the 
presence of ROS is likely to be restricted to the lungs and airways since these are the 
sites where phagocytes will be stimulated. Depletion of ROS appears to lead to a 
more prominent response in the airways rather than the lung tissue, which may give 
us a clue as to the function of these species in different pulmonary sites. Influenza is 
primarily an infection of the upper respiratory tract and as such, myeloid cells in the 
airways will encounter the virus foremost. Influenza can induce the production of 
ROS in these cells through the phagocyte NADPH oxidase, which, as we postulate, 
can subsequently lead to apoptosis of the myeloid cells or exert some other inhibitory 
potential. In the absence of ROS, however, these cells may persist for longer and be 
more activated, possibly leading to enhanced containment of the virus and a more 
rapid and potent immune response targeted to the airways. Thus it would appear that 
ROS are generated by cells in the airways and fulfil an important role in regulating 
the myeloid response at this site. 
7.2.2 CD200 and immune compartmentalisation 
The suppression mediated through CD200R to the myeloid cell is distinct to that 
induced by ROS since it is dependent on cell contact and is thus dictated by the 
presence of the ligand, and the ability to form a productive interaction. Little is known 
regarding the nature of this interaction and what level of structural organisation is 
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Figure 7.2 Inflammation in different immune compartments during influenza 
infection. The immune response to influenza can be viewed in the context of different 
immune compartments. There is a reciprocal relationship between the level of structural 
organisation and the potency of the elicited inflammatory response: the BAL has no 
organisation and is very inflammatory whereas the MLN is highly structured and shows no 
classical "inflammation". The greater inflammation in the airways, and to a lesser extent 
the lung, is also affiliated with a greater TLR load. Furthermore, it is at these sites that T 
cells express co-stimulatory molecules and exert effector function. It is interesting that 
CD200 is expressed at a greater level in the MLNs than other compartments, and may 
contribute to the reduced inflammation at this site. Conversely, ROS are produced in the 
airways, explaining why depletion of their levels gives a most striking phenotype at this 
site. 
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required to support such an interaction. In CD200 knock out mice, elevated myeloid 
numbers are seen in the spleen and mesenteric lymph nodes but not in the lung. The 
manner in which CD200 dictates the number of myeloid cells is unknown, but it 
would appear that in a naïve animal, unlike ROS, the interaction fulfils a more 
significant role within organised lymphoid tissue. At these sites is an abundance of 
cells expressing CD200 that would be proximal to CD200R bearing myeloid cells 
within a highly structured environment. Furthermore, during influenza infection, the 
most obvious immediate phenotypic difference in CD200 knock out mice is an 
elevated number of myeloid cells in the MLNs, implying that once again CD200 
fulfils an important role within such organised lymphoid compartments. 
However, CD200 may also exert a role within the lung in the course of influenza 
infection since the lung may develop into an environment that is more capable of 
supporting an inhibitory signal through CD200R (Fig. 7.1). We see an increase in 
CD200 and CD200R on a per cell basis as well as an increase in the total number of 
cells bearing the ligand and receptor within the lung and airways, and it is plausible 
that this may facilitate a productive interaction. It is also possible that an increase in 
expression of CD200 and CD200R in the lung compartment can compensate for the 
lack of structural organisation at this site. 
The mice utilised in these experiments have not previously encountered any previous 
pathogenic infection, whereas with people, some form of infection history will always 
be present. We see CD200R expression peaking on alveolar macrophages at day 14 in 
our experiments (Fig. 7.1D). Whether the elevated level of CD200R on alveolar 
macrophages is maintained after a primary infection is not known. If maintained, it 
may explain the long lived changes we and others observe within the host's immune 
compartment following exposure to a pathogen, which alter a subsequent response to 
an autologous or heterologous pathogenic challenge 467,468  We believe that the first  
infection modulates the response to the second by alterations in the lung environment 
itself or in innate immune cells. Evidence for long term modification of the innate 
immune compartment is provided by studies where microbial products such as CpG 
DNA or a modified bacterial labile toxin (LTK63) afford protection against an array of 
subsequent respiratory pathogens 382'383. This phenomenon has been coined "innate 
imprinting" and can be strictly defined as "the long term modification of a 
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microenvironment", which will consequently lead to a reduced, but more protective, 
immune phenotype to a subsequent pathogen. Myeloid inhibitory molecules such as 
CD200 and its receptor may contribute to this "matured" or "educated" environment. 
A final concept that merits discussion is the potential role for CD200 in ensuring that 
excessive inflammation does not occur at inappropriate sites. Infection of the lung 
with a pathogenic organism will frequently evoke the release of pro-inflammatory 
cytokines, which are largely produced by myeloid cells. Conversely, at organised 
lymphoid organs such as localised lymph nodes there is expansion of lymphocyte 
populations but the environment is far less inflammatory. Myeloid cells at these sites 
do not produce pro-inflammatory cytokines, which is most likely attributable to the 
absence of a high pathogen load within secondary lymphoid structures and hence less 
PAMP triggering of TLRs etc. It is critical that at such lymphoid sites, myeloid cells 
function as APCs rather than in a pro-inflammatory capacity. CD200 is likely to be 
pivotal in restraining myeloid cells in these organised lymphoid sites. It would be of 
interest to examine whether myeloid cells within the MLNs produce pro-
inflammatory cytokines in the absence of CD200. 
7.3 The therapeutic potential of manipulating ROS and CD200 during 
respiratory infection 
Immunotherapeutic strategies are now considered as a potentially important facet of 
our armoury to combat infectious disease. Development of vaccines and anti-
microbials is, and will continue to be, the primary objective against respiratory 
infections, but their limitations may lead to the utilisation of immunomodulatory 
strategies. Vaccination strategies are hindered by the antigenic variation of the 
pathogen whereas anti-microbial agents are sometimes limited by efficacy and 
increasing incidences of drug resistance. Furthermore, in infections such an influenza 
clinical signs of disease are only really apparent when viral titres have subsided 
rendering anti-virals ineffective. The significant role of immunopathology in many 
infections offers clear targets for manipulation. We have targeted different facets of 
the myeloid response to respiratory infection with influenza and C. neoformans. 
Whilst we have seen clear potential for manipulation of ROS and CD200, it is 
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important to question the expectations and limitations of such strategies in the context 
of human disease. 
Z3.1 Immunomodulation during influenza infection 
We demonstrate that inhibiting ROS or the signal imparted through CD200R induces 
a greater myeloid response to influenza. However, we argue that blockade of ROS is 
beneficial whereas blockade of CD200R signalling is detrimental, and that a better 
therapeutic strategy would be to suppress the myeloid response through 
administration of CD200:Fc. These differential strategies are defined by the disparate 
immune compartments in that we believe ROS and CD200 are primarily acting: ROS 
in the airways and CD200 in the MLNs. Reducing the levels of ROS during an 
influenza infection induces a more rapid and potent myeloid response in the airways 
that contains influenza, reducing viral titres and inflammatory infiltrate in lung tissue, 
thus protecting this fragile organ. Since ROS are also strongly implicated in oxidative 
stress during influenza infection their depletion would be a significant advantage. 
However, blockade of CD200 gives rise to a greater global myeloid response, 
stemming from the MLNs, that leads to augmented inflammation in all compartments 
that is ineffectively resolved. Delivery of a myeloid suppressive signal through 
CD200R reduces pulmonary inflammation and clinical illness with no alteration in 
viral clearance. Manipulation of ROS and CD200R therefore offer two opposing 
immunotherapeutic strategies to combat an influenza infection in mice, but what 
promise do they hold in a clinical setting? 
The relevance of the murine model of influenza to human clinical disease has often 
been questioned. Infection of Macaques with a genetically reconstructed human 
influenza virus causes an uncomplicated disease that simulated symptoms observed in 
humans 469. Gene profiling of these primates, coupled with gross and histological 
analysis of pulmonary infiltrate, however, demonstrates a comparable infection and 
immune phenotype to that observed in the murine model 469. Viral kinetics was 
similar as was the considerable infiltrate into the lungs and airways. Genes that 
encode for mediators of chemotaxis, adhesion and transmigration of immune cells 
(particularly monocytes and macrophages) are strongly up-regulated in the lung and 
draining LNs implying a heavy traffic of immune cells into these tissues. Early in 
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infection, a significant neutrophil and macrophage lung infiltrate is observed, 
followed by the recruitment of activated Thl skewed T cells by day 7 of infection 469. 
Due to similarities between the models we therefore feel that our approaches may be 
translatable to higher organisms. Furthermore, a number of genes encoding protective 
enzymes against oxidative damage are strongly up-regulated in the influenza infected 
macaques, suggesting that oxidative stress is a concern and that our strategy to target 
ROS may be advantageous. 
With the recent concerns regarding avian influenza and a potential pandemic, it is 
prudent to consider the potential of our immunomodulatory strategies against more 
virulent and pandemic strains of influenza. Avian H5N1 influenza causes severe 
disease in humans 470 and a combination of in vitro and animal studies have indicated 
that high and disseminated viral replication is important in disease pathogenesis 471'472. 
However, in vitro and animal studies have also implicated cytokine dysregulation in 
H5N1 pathogenesis, with a significant induction of pro-inflammatory cytokines and 
chemokines 473'474, thus making immuno-modulatory strategies a plausible therapeutic 
alternative. Furthermore, studies with virulent strains of influenza demonstrate that 
the innate immune response is a major contributing factor in the clinical course of 
disease 475. Virological and immunological studies in individuals infected with H5N1 
recently show that a high viral load and resulting intense inflammatory responses are 
central to influenza H5N1 pathogenesis 476. High levels of IP-10, MIG and MCP-1 are 
observed from bronchial epithelial cells and alveolar macrophages, which are strong 
chemoattratants for monocytes/macrophages. Elevated IL-8 is also observed, which is 
fundamental to recruitment of neutrophils. Other post-mortem studies in H5N1 
infected individuals show that the pulmonary infiltrate consists primarily of 
macrophages rather than lymphocytes 477. Furthermore, mice infected with an adapted 
influenza virus recombined with the surface HA and NA proteins of the highly 
virulent 1918 pandemic strain of influenza exhibit a significant neutrophilic 
recruitment, which causes excessive tissue damage, most likely through release of 
ROS 478. Thus it would appear that myeloid cells are a suitable target to manipulate 
during infection with highly virulent influenza. 
Influenza A has been shown to accelerate apoptosis of neutrophils in vitro, potentially 
through induction of ROS, which may facilitate spread of virus 479,480,481  It can thus 
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bee seen why the absence of ROS, as seen in our experiments, may lead to elevated 
neutrophil numbers in the airways and reduced lung viral titres. Our strategy to 
deplete ROS may reduce neutrophil apoptosis, preventing spread of virus, and 
concomitantly prevent oxidative stress caused by persistence of neutrophils within the 
inflamed lung. However, the pleiotropic roles of ROS in homeostasis and immune 
regulation would make manipulation of their levels in a clinical setting very complex 
but still demands further investigation. It may be that CD200 manipulation can confer 
a more targeted strategy than manipulating ROS. As described previously, significant 
pulmonary recruitment of macrophages is elicited by H5N1 influenza 477, and we have 
demonstrated the potency of signalling through CD200R to suppress the activity of 
this myeloid cell. Whilst we have not investigated the potential of CD200 to 
manipulate neutrophil function, similar suppression of this cell type may also be 
anticipated, and it would be of interest to assess the ability of CD200 to limit 
production of ROS. It is interesting that individuals infected with H5N1 influenza 
exhibit elevated levels of IL-6 and IFN-y in their serum 476, both of which were 
reduced by administration of CD200:Fc in our murine model. A company has recently 
been established with Professor Tracy Hussell and Imperial College (named 
"Stormbio") that will seek to translate some of our murine based immunotherapeutic 
studies into a clinical setting, and manipulation of ROS and CD200 are currently 
being investigated with a murine pandemic influenza model by the Southern Research 
Institute at the University of Alabama. 
A general complication with influenza is the occurrence of bacterial co-infections. It 
is often anticipated that immunotherapeutic strategies that dampen inflammation may 
render the host more susceptible to a bacterial co-infection including commensals 
from the upper respiratory tract. However, a large proportion of deaths with pandemic 
strains of influenza are attributable to overwhelming primary viral pneumonia rather 
than bacterial secondary pneumonia. Nonetheless, it is very important to consider the 
effect that manipulating facets of the immune response would have on the 
establishment of bacterial co-infections. Indeed, utilisation of anti-TNF therapy 
during arthritis causes reactivation of latent tuberculosis 482.  Signalling through 
CD200R reduces pro-inflammatory cytokine production by macrophages, which may 
be critical for the clearance of bacterial infections. However, we and others have 
demonstrated that signalling through CD200R is incapable of suppressing pro- 
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inflammatory cytokine production induced by the bacterial product LPS. It is 
therefore conceivable that administration of CD200:Fc would selectively suppress 
influenza induced cytokine production by myeloid cells, without compromising the 
capacity of the host to respond to any subsequent bacterial infection. Also, signalling 
through CD200R would not affect all cell types capable of secreting inflammatory 
cytokines that may be protective against a bacterial co-infection. With this respect, 
manipulation of CD200 signalling would hold a significant advantage over more 
global treatment strategies such as neutralisation of TNF. Furthermore, it is 
anticipated that bacteria gain a foothold within the lung following influenza infection 
owing to heightened lung damage. We have shown that ligation of CD200R reduces 
the inflammatory infiltrate that is responsible for much of the pathology following 
influenza infection. 
A major concern with depletion of ROS is compromised clearance of a bacterial co-
infection, especially since absence of a functional phagocyte oxidase leads to 
enhanced susceptibility to certain bacterial pathogens such as S. aureus. However, as 
discussed, there may be reduced viral-induced and immuno-pathology by such 
treatment, which may diminish the potential of bacteria to establish themselves within 
the lung. Furthermore, it is anticipated that another reason why bacterial co-infections 
occur is that influenza induces apoptosis of neutrophils, which is mediated through 
ROS, the absence of which would leave this important bactericidal activity unscathed. 
We have recently developed an influenza and bacterial co-infection model within our 
laboratory to address such issues. 
7.3.2 Immonomodulation during C. neoformans infection 
We demonstrate in this thesis that the removal of suppressive signals to the myeloid 
compartment boosts immunity to C. neoformans. Depletion of ROS leads to a greater 
myeloid response with ensuing Thl bias and improved control of the pathogen. 
Preliminary studies into the blockade of the inhibitory signal imparted through CD200 
gives rise to a greater myeloid response and prevention of cryptococcal dissemination. 
Whilst C. neoformans is capable of causing significant pulmonary disease in immune-
competent individuals 483, this pathogen predominantly causes morbidity and 
mortality in the immuno-compromised, especially HIV-infected individuals 484. CD4+ 
283 
T cells are the primary targets of HIV replication and numbers are reduced more than 
five-fold during infection 485. Boosting the myeloid immune response would be 
anticipated to promote immunity to C. neoformans in both immune-competent and 
immuno-compromised individuals, since myeloid cells would likely be unaffected by 
the immune disorder in question. Furthermore, with our strategies we observe reduced 
dissemination to the brain, which represents a significant clinical problem of fungal 
menigitis in immuno-compromised individuals. 
Through depletion of ROS, a greater Thl response was induced along with a 
preferential bias for promoting CD8+ T cells. CD8+ T cells have an established role in 
control of HIV viraemia 486, and thus we may not only boost immunity to C. 
neoformans but also potentially HIV. It will be important to establish whether the 
improved immunity to C. neoformans and the elevated CD8+ T cell response in the 
absence of ROS will persist independently of CD4+ T cell help — a hypothesis easily 
testable through depletion of this T cell subset. One concern, however, is that whilst 
depletion of ROS ultimately proves beneficial during a C. neoformans infection, 
generation of ROS is frequently an important effector mechanism against a number of 
pathogens. Accordingly, such a strategy may be wrought with danger in immuno-
compromised individuals who frequently succumb to multiple infections. 
7.4 Conclusion 
In this thesis, I show that CD200 and ROS may actively suppress the myeloid 
immune compartment and fulfil an important homeostatic role. Furthermore, the 
myeloid response to respiratory infection may be modulated through the manipulation 
of ROS and CD200 inhibition. Through promotion of the myeloid compartment we 
are able to promote immunity to infection, whereas inhibition of myeloid cells can 
alleviate immunopathology. These results provide valuable insights into the potential 
of immune manipulation as a treatment strategy for respiratory infections, and further 
our understanding of the role of ROS and CD200 in myeloid homeostasis and in the 
fight against infectious disease. 
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In the Absence of Reactive Oxygen Species, T Cells Default to 
a Thl Phenotype and Mediate Protection against Pulmonary 
Cryptococcus neoformans Infection 
Robert J. Snelgrove,* Lorna Edwards,* Andrew E. Williams,* Aaron J. Rae,I. and 
Tracy Hussein* 
In recent years, the prevalence of invasive fungal infections has increased, attributed mostly to the rising population of immu-
nocompromised individuals. Cryptococcus neoformans has been one of the most devastating, with an estimated 6-8% of AIDS-
infected patients succumbing to Cryptococcus-associated meningitis. Reactive oxygen species (ROS) are potent antimicrobial 
agents but also play a significant role in regulating immune cell phenotype, but cause immunopathology when produced in excess. 
We now show that mice lacking phagocyte NADPH oxidase have heightened macrophage and Thl responses and improved 
pathogen containment within pulmonary granulomatous lesions. Consequently, dissemination of this fungus to the brain is di-
minished, an effect that is independent of IL-12. Similar results are described using the metalloporphyrin antioxidant mangane-
se(111) tetrakis(N-ethyl pyridinium-2-yl)porphyrin, which also promoted a protective Thl response and reduced dissemination to 
the brain. These findings are in sharp contrast to the protective potential of ROS against other fungal pathogens, and highlight 
the pivotal role that ROS can fulfill in shaping the profile of the host's immune response. The Journal of Immunology, 2006, 177: 
5509 —5516. 
T he encapsulated budding yeast Cryptococcus neoformans is a significant respiratory pathogen. The primary site of infection is the lung, where it elicits pulmonary eosino-
philia in immunocompetent individuals, delayed-type hypersensi-
tivity and summer-type hypersensitivity pneumonitis in Japan (1, 2). 
However, it is immunocompromised patients who are at greatest risk 
from this opportunistic fungus, with failure to contain pulmonary 
cryptococcus culminating in dissemination to the brain with ensuing 
meningoencephalitis and frequently death (3). The prevalence of C. 
neoformans infection has been illuminated in the past 10 years in 
patients with underlying T cell deficiencies, with 6-8% of all AIDS 
patients developing C. neoformans-associated meningitis. 
Murine models of C. neoformans infection provide an excellent 
insight into comprehending the protective immune response to this 
pathogen. Protection is dependent upon the genetic background of 
the mouse, with resistant mice (BALB/c, C.B-17, and cytometric 
bead array (CBA))2 generating a Thl-driven response, with higher 
levels of 11,12, IFN-y, and TNF-a and resolution of infection 
(4-6). Conversely, susceptible mice (C57BU6, C3H, and 
B 10.D2) display a more prominent Th2 response, with elevated 
IL-5 and chronic pulmonary eosinophilia (7). This Th2 response 
leads to unchecked fungal growth and dissemination to the brain. 
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The phagocyte NADPH oxidase is a multimeric membrane-asso-
ciated complex on the surface of professional phagocytes. Activation 
of this oxidase culminates in an increase in oxygen consumption 
known as the respiratory burst. The NADPH oxidase synchronously 
uses the reducing power of NADPH to catalyze the conversion of 
molecular oxygen to superoxide radicals (OD (8). The superoxide 
generated by the phagocyte NADPH oxidase exhibits potent an-
tipathogenic actions, mediating the destruction of a host of invading 
microorganisms. Furthermore, superoxide can subsequently be con-
verted to a vast array of other reactive oxygen species (ROS) that are 
detrimental to the invading organism (9, 10). The critical role fulfilled 
by ROS species in the control of pathogen burden is made clearly 
apparent by the genetic condition chronic granulomatous disease 
(CGD), characterized by deficiency of a functional phagocytic oxi-
dase, and greater susceptibility to infection with bacterial and fungal 
pathogens (9, 11). Furthermore, a role of ROS in intracellular signal-
ing and in the regulation of immune cell function is now recognized 
(12-14). Superoxide and hydrogen peroxide (H202) are anticipated to 
act as second messengers through oxidizing redox-sensitive transcrip-
tion factors such as NFKB. However, ROS may also be the causative 
agents of bystander tissue damage owing to their high toxicity and 
lack of specificity and are frequently the underlying determinant of 
immunopathology and disease (15). 
Gene targeting has been used to generate Cybb tml mice with a 
null allele of the gene involved in X-linked CGD, which encodes the 
91-kDa subunit of the oxidase cytochrome b of the NADPH oxidase 
(11). These mice have helped in evaluating the role of phagocyte-
derived oxidants in controlling inflammation and protection to an ar-
ray of pathogenic infections, but not as yet C. neoformans. There are 
discrepancies regarding the efficacy of superoxide and its derivatives 
in the eradication of C. neoformans, yet there is cited evidence de-
fining the potential of polymorphonuclear neutrophils and macro-
phages to kill the organism by oxidative mechanisms (16). Further-
more, this fungus displays an array of protective mechanisms 
(superoxide dismutase (SOD), mannitol, melanin) to confer resistance 
to ROS, suggesting that in some instances they may be toxic and 
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adverse to its survival. C. neoformans deficient in melanin exhibit 
reduced virulence in vivo (17), and CuSOD lacking mutants are more 
susceptible to oxygen radicals in macrophages (18). 
We now report the role of ROS in resolution of C. neoformans 
infection using the Cybb tml mice and a novel antioxidant, man-
ganese(III) tetrakis(N-ethyl pyridinium-2-yl)porphyrin (MnTE-2-
PyP). We show that Cybb tml mice elicit a heightened macroph-
age-driven Till response with containment of cryptococci within 
pulmonary granulomatous lesions. Furthermore, we observed 
improved pathogen clearance in lung and airways and reduced 
dissemination to the brain. We have used the MnTE-2-PyP anti-
oxidant to validate the phenotype observed in Cybb tml mice. 
MnTE-2-PyP is a cell-permeable manganic-porphyrin that is su-
perlative to previously used endogenous SOD treatments owing to 
its prolonged half-life and reduced m.w. It displays a broad anti-
oxidant activity, acting as an SOD and catalase mimic and being 
capable of scavenging lipid peroxides and peroxynitrite (19, 20). 
MnTE-2-PyP-treated mice again evoked a Thl-skewed immune 
response with reduced pathogen load in the brain, but failed to 
develop the granulomatous lesions observed in the Cybb tml mice. 
MnTE-2-PyP has previously been reported to confer protection in 
a variety of oxidative stress injuries such as liver ischemia, diabe-
tes, and stroke (19, 21), and could offer a plausible therapeutic to 
combat C. neoformans infection. 
Materials and Methods 
Mice and pathogens 
Eight- to 12-wk-old female C57BU6 (Harlan Olac) were kept in pathogen-
free conditions according to Home Office guidelines. Cybb tml mice 
(backcrossed to C57BU6 background at least 10 times) were purchased 
from The Jackson Laboratory. C. neoformans strain 52 was obtained from 
the American Type Culture Collection and for infection grown to station-
ary phase (48-72 lft at room temperature on a shaker in Sabouraud dex-
trose broth (1% neopeptone and 2% dextrose; Difco). The cultures were 
washed in saline, counted on a hemocytometer, and diluted in sterile non-
pyrogenic saline to the required infective dose. 
Mouse infections and treatment 
On day 0, wild-type C57BU6 and Cybb tml mice were anesthetized and 
intranasally (i.n.) infected with 2 X 104 CFU C. neoformans in 50 Al of 
sterile PBS. In some experiments, wild-type C57BU6 mice were treated 
with 50 µg of MnTE-2-PyP (Merck Biosciences) or PBS i.n. on day 0, and 
then every 4 days after infection. In some experiments, mice were treated 
with 100 gg of anti-IL-12 i.p. (rat mAb C15.6.7) 1 day before and I, 4, 8, 
and 11 days following C. neoformans infection. Mice were sacrificed var-
ious days after infection by injection of 3 mg of pentobarbitone and ex-
sanguinated via the femoral vessels. 
Cell recovery and flow cytometry 
Lung lavage (bronchoalveolar lavage (BAL)) and residual lung tissue were 
sampled as described previously (22), and single-cell suspensions were 
stained for the following surface markers: anti-CD45RB-FITC, anti-CD4-
PerCP, anti-CD8-allophycocyanin, anti-Gr- 1-FTTC, anti-MHC class II 
(MHC-II)-PE, anti-CD11b-PetCP, or anti-CD1 lc-allophycocyanin for 30 
min at 4°C and fixed with 2% paraformaldehyde (15 min at room temper-
ature). All Abs were purchased from BD Pharmingen. To detect intracel-
lular cytokines, 106 cells/nil were incubated with 50 ng/ml PMA, 500 
ng/ml ionomycin (Calbiochem), and 10 mg/ml brefeldin A for 4 hat 37°C. 
Cells were then stained with anti-CD4-allophycocyanin and anti-CD8-
PerCP and fixed as before. After permeabilization with PBS containing 1% 
saponin/1% BSA/0.05% azide (saponin buffer) for 10 min, cells were in-
cubated with anti-IFN-y-FITC and anti-IL-5-PE diluted 1/50 in saponin 
buffer. Thirty minutes later, cells were washed once in saponin buffer and 
once in PBS containing 1% BSA and 0.05% azide. All data were acquired 
on a FACSCalibur acquiring at least 30,000 lymphocyte events (BD 
Biosciences). 
Lung histology 
Excised lungs were inflation-fixed with 2% formalin in PBS 12 days after 
C. neoformans infection. The inflated lungs were excised and embedded in  
paraffin wax by L. Lawrence (Leukocyte Biology, Imperial College, Lon-
don, U.K.). Four-micrometer sections from four to five mice were stained 
with H&E. 
Enumeration of eosinophils 
Eosinophils were enumerated by flow cytometry based on their distinctive 
size (forward scatter) and granularity (side scatter). The proportion of eo-
sinophils was confirmed from cytospin preparations of BAL fluid follow-
ing H&E staining, using their characteristic nuclear morphology and pres-
ence of acidophilic red granules. 
Enumeration of C. neoformans 
Lungs and brain were homogenized by passage through 100-µm cell 
strainers (BD Labware). A total of 100 µI of cell suspension from lung 
homogenate, brain homogenate, and BAL were diluted in PBS and incu-
bated at room temperature for 48 h on Sabouraud dextrose agar plates 
(Sigma-Aldrich). The total CFU per sample was then determined (number 
of colonies X dilution factor X original cell suspension volume). 
C. neoformans-specific Ab ELISA 
A total of 2 X 105 CFU/ml heat-killed C. neoformans in PBS was used to 
coat 96-well microtiter plates overnight at room temperature on a shaker. 
After blocking with 3% BSA/PBS for 2 hat 37°C, dilutions of sample sera 
were added for a further hour at room temperature. Bound Ab was detected 
using peroxidase-conjugated rabbit anti-mouse Ig and o-phenylenediamine 
as a substrate. The reaction was stopped with 50 µI of 2.5 M sulfuric acid. 
ODs were read at 490 nm, and mean blank values (ODs from normal 
mouse serum) were subtracted from the OD values of test samples. 
BAL IgE Ab ELISA 
Ninety-six-well microtiter plates were coated overnight with BAL fluid 
(200 µI of PBS/mouse) at 4°C. After blocking with 3% BSA/PBS for 2 h 
at 37°C, bound Ab was detected using peroxidase-conjugated rat anti-
mouse IgE (Serotec) and o-phenylenediamine as a substrate. The reaction 
was stopped with 50 µ1 of 2.5 M sulfuric acid. ODs were read at 490 nm, 
and mean blank values (ODs from normal mouse serum) were subtracted 
from the OD values of test samples 
Protein detection 
BAL fluid protein concentration was determined using the Pierce BSA 
protein assay kit. Working reagent was added to samples and standards at 
a 4:1 ratio and incubated at 37°C for 30 min. Absorbance was measured at 
490 nm, and protein concentration was calculated by comparison with an 
albumin standard. 
Lactate dehydrogenase (LDH) detection 
The amount of LDH in the BAL was measured using Sigmas in vitro 
toxicology LDH based assay kit. Samples (tested in triplicate) were added 
to an equal volume of LDH assay mixture (assay dye, substrate, and en-
zyme) and incubated at room temperature for 30 min. Absorbance was 
measured at 490 nm. 
Statistics 
Statistical significance was evaluated using a two-tailed Student's t test 
assuming unequal variance with the Minitab software program. The Bon-
ferroni correction was applied where appropriate. 
Results 
The protection afforded by ROS to respiratory fungal pathogens is 
highlighted by the enhanced susceptibility of CGD patients to in-
fection with Aspergillus fumigatus. However, their role in the res-
olution of C. neoformans infection remains unclear. In this study, 
we use Cybb tml mice, a model of CGD, to identify the signifi-
cance of NADPH oxidase-derived superoxide in protection to C. 
neoformans. We first investigated the phenotype of naive Cybb 
tml mice relative to wild-type controls, before assessing the role of 
NADPH oxidase during C. neoformans infection. The lungs of 
wild-type and knockout mice were examined histologically by 
H&E staining and found to be morphologically similar. Pulmonary 
cell populations were further examined by FACS analysis and 
showed that Cybb tml mice exhibited a small but significant in-
crease in total cellular numbers in their lungs (wild type, 2.78 x 
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105 ± 0.75 SEM; Cybb tml, 8.2 X 105 ± 1.25 SEM). However, 
there were no alterations in cellular infiltrate into the airways with 
numbers very low in wild-type and knockout mice. 
Following C. neoformans infection, both Cybb tml mice and 
C57BL/6 controls exhibited comparable pulmonary cellular infil-
trate, but the distribution of the infiltrate within the lung tissue was 
distinct between groups. Wild-type mice displayed a generalized 
cellularity with extensive perivascular and peribronchiolar infil-
trate with significant occlusion of alveoli. Conversely, the Cybb 
tml mice exhibited small distinct pockets of infiltrate, granuloma-
tous in nature, surrounding cryptococci (Fig. 1A). It is important to 
stress the numbers of cells in the lungs of naive mice are at least 
an order of magnitude lower than that recruited during C. neofor-
mans infection (at peak infection, wild type: 8.9 X 106 ± 2.9 
SEM; Cybb tml, 11.5 X 106 ± 2.5 SEM). 
Cybb tml mice have previously been demonstrated to develop a 
granulomatous response to other fungal pathogens, but have been 
compromised in their ability to resolve infection. In contrast, Cybb 
tml mice showed an enhanced ability to combat C. neoformans 
infection with a significantly reduced fungal load in the lung tissue, 
the BAL, and, importantly, the brain at days 5, 8, and 12 after 
infection (Fig. 1B). The reduced pathogen load in Cybb tml mice 
is clearly visible in cytospins of the BAL (Fig. 1A, inset). 
Macrophages are central to the development of a granulomatous 
response orchestrating cellular recruitment and containment of the 
pathogen. Naive Cybb tml mice displayed a significant increase in 
the number of resident lung macrophages relative to wild-type 
controls (wild type, 0.5 x 104 ± 0.09 SEM; Cybb tml, 2.87 x 104 
± 1.25 SEM) that may indicate a role for NAPDH oxidase in 
homeostatic regulation of these cells, potentially through regula-
tion of apoptosis. Although the increase in macrophage numbers 
was significant, it is again important to stress that they are still 
insignificant compared with those recruited during C. neoformans 
infection. Analysis of H&E-stained lung sections from C. neofor-
mans-infected mice (Fig. 1A) demonstrates an accumulation of 
macrophages and multinucleated giant cells at the center of the 
granuloma in Cybb tml mice. Conversely, the cellularity in the 
wild-type lung, although containing macrophages, was dominated 
by lymphocytes and eosinophils. This was confirmed by FACS 
analysis of lung tissue, which clearly showed a significantly 
greater number of macrophages in Cybb tml mice throughout the 
course of infection (Fig. 1C). 
C. neoformans is directly responsible for much of the observed 
lung pathology observed during the course of infection owing to its 
considerable size and extensive numbers. To assess whether the 
reduced pathogen load observed in Cybb tml mice reduced lung 
damage, we assessed the levels of total protein (Fig. 1D) and LDH 
(Fig. 1E) in the BAL fluid. Both markers of pathology were sig-
nificantly reduced in Cybb tml mice. 
The granulomatous response to C. neoformans seen in Cybb tml 
mice and the universal reduction in pathogen burden at distal sites 
may indicate containment of the pathogen within the lung tissue. 
There was significantly reduced cellularity in the airways of Cybb 
tml mice (Fig. 2A). This, coupled with the considerably lower 
CFUs at this site may imply that containment within the lung tissue 
hinders dissemination into the airways with consequently reduced 
number of cells recruited into the BAL. 
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FIGURE 1. Cybb tml mice display improved clearance of C. neoformans 
and reduced lung pathology. A, Representative H&E-stained lung sections of 
C. neoformans-infected Cybb tml and wild-type C57BU6 mice 12 days after 
infection (x200 magnification). Insets are representative H&E-stained cyto-
centrifuged BAL samples of C. neoformans-infected wild-type and Cybb tml 
mice at day 12 after infection (X200 magnification). Arrows indicate crypto-
coccal bodies. B, C. neoformans-infected wild-type and Cybb tml mice were 
sacrificed at multiple time points, and CFUs were determined by plating out 
lung homogenate, BAL, and brain homogenate. C, Lungs were removed from 
C. neoformans-infected wild-type and Cybb tml mice, and single-cell suspen-
sion was stained with CD1 lb-PerCP and CD11c-allophycocyanin. Total num-
bers of lung CD11b+ macrophages were determined by the following: per-
centage of single-positive cells by flow cytometry X total number of viable 
cells. D and E, At day 12 after C. neoformans infection, BAL was removed 
and total protein (D) and LDH (E) were measured in supernatants. Closed 
symbols, Wild-type mice; open symbols, Cybb mil mice. Results represent 
mean values ± SEM from five mice per group (*, p < 0.05; **, p < 0.01) and 
are representative of three experiments. 
FIGURE 2. C. neoformans-infected Cybb tml mice exhibit reduced eo-
sinophilia and an enhanced CD8+ T cell response. A, BAL was performed 
on C. neoformans-infected wild-type or Cybb tml mice on days 0, 5, 8, and 
12, and total viable cells were enumerated. B, The percentage of eosino-
phils in the BAL 12 days after C. neoformans infection was determined 
from H&E-stained cytospin preparations. Lungs were removed from C. 
neoformans-infected wild-type or Cybb tml mice 12 days after infection, 
and single-cell suspension was stained with CD45RB-FITC, CD4-PerCP, 
and CD8-allophycocyanin. The percentage of CD4+ and CD8+ lympho-
cytes was determined by flow cytometry (C). The percentage of CD4+ and 
CDS' T cells that were CD45Rew was also determined (D). Closed sym-
bols, Wild-type mice; open symbols, Cybb tml mice. Results represent 
mean values ± SEM from five mice per group (*, p < 0.05; **, p < 0.01) 
and are representative of three experiments. 
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Protection against C. neoformans is dependent on the develop-
ment of a Th I immune response. C57BL/6 mice usually exhibit a 
strong nonprotective Th2 response with chronic eosinophilia in the 
lung and airways and dissemination of fungus to the brain. Dif-
ferential cell counts of H&E-stained cytospin preparations (Fig. 
1A, inset), and FACS analysis (Fig. 2B) revealed a marked reduc-
tion in the percentage of eosinophilia in the lung and airways, in 
Cybb tml mice. Eosinophilia is dependent on CD4+ T cells. In 
Cybb tml mice, however, these were reduced relative to CD8± T 
cells, which were increased (Fig. 2C). Both CD4± and CD8± T 
cells exhibited a heightened activation state (CD45R131") in Cybb 
tml mice at days 8 and 12 (Fig. 2D) after infection. 
To determine whether a shift in the cytokine profile accounted 
for reduced eosinophilia in Cybb tml mice, we used intracellular 
cytokine staining. Cytokine profiles of uninfected wild-type and 
Cybb tml mice were compared, but only negligible amounts of 
cytokines were observed by intracellular cytokine staining of T 
cells or through detection of soluble cytokine by CBA. During 
infection, however, both CD4± and CD8+ T cells produced in-
creased levels of IFN-y (Fig. 3A) and TNF-a (data not shown) in 
Cybb tml mice compared with wild-type mice. Conversely, Cybb 
tml-derived T cells produced lower levels of IL-5 (data not 
shown). The ratio of IFN-y-producing T cells to IL-5-producing T 
cells was greatly augmented in Cybb tml mice (Fig. 3B) showing 
a significant Thl bias. Soluble cytokine levels in lung homogenate 
were also monitored by CBA throughout the course of infection 
and displayed a similar Thl bias in Cybb tml mice. There were 
significantly elevated levels of TNF-a at days 8 and 12 after in-
fection in Cybb tml mice and reduced levels of IL-5 at days 5 and 
8 (Fig. 3C). 
Because CD4+ T cells assist in anticryptococcal Ab production, 
we next compared the effect in Cybb tml mice. Cybb tml mice 
exhibited significantly reduced B cells in the lung and airways 
(Table I). Furthermore, reduced pathogen-specific total Ab and 
FIGURE 3. Cybb tml mice exhibit a Thl-biased cytokine response. 
Lungs were removed from C. neoformans-infected wild-type and Cybb 
tml mice 12 days after infection, and single-cell suspensions were stained 
with IFN-y-FITC, IL-5-PE, CD4-PerCP, and CD8-allophycocyanin. A, 
Representative plots are shown of lung CD4+ or CD8+ T cells vs IFN-y 
expression in naive wild-type or Cybb tml mice. The number of IFN-y-
and IL-5-expressing T cells was determined by the following: percentage 
of positive cells by flow cytometry X total number of viable cells. B, The 
ratio of the number of IFN-y-expressing T cells over the number of IL-5-
producing T cells in wild-type and Cybb tml mice. C, Cytokines in lung 
homogenates of wild-type and Cybb tml mice 12 days after C. neoformans 
infection were determined using the BD mouse Thl/Th2 CBA. Closed 
symbols, Wild-type mice; open symbols, Cybb tml mice. Results represent 
mean values ± SEM from five mice per group (*, p < 0.05; **, p < 0.01) 
and are representative of three experiments. 
IgG1 isotype in the serum at day 12 postinfection, and IgE isotype 
in the BAL fluid were observed at day 5 postinfection (Table I). 
IL-12 is a critical cytokine in the induction of a Thl response 
(23-27). IL-12 is also critical in controlling dissemination of C. 
neoformans to the brain (28, 29). The heightened macrophage re-
sponse observed in Cybb tml mice could presumably affect levels 
of this cytokine and thus control dissemination with greater apti-
tude. Neutralizing anti-IL-12 Ab was thus used to infer the role of 
IL-12 in the enhanced protection observed in Cybb tml mice. 
Wild-type mice administered anti-IL-12 Ab exhibited a dra-
matic increase in C. neoformans dissemination to the brain (Fig. 
4A). However, the enhanced ability of Cybb tml mice to resolve 
cryptococcal infection was not compromised by anti-IL-12 Ab 
treatment. CFUs in the lung and BAL were not affected by anti-
IL-12 treatment in either strain (Fig. 4A). Furthermore, macro-
phage numbers were augmented in the lungs of both anti-IL-12 
Ab-treated and untreated Cybb tml mice relative to wild-type con-
trols (data not shown), and eosinophil numbers markedly reduced 
(Fig. 4B). Anti-IL-12 treatment of wild-type mice evoked height-
ened IL-5 production and reduced IFN-y production, but the cy-
tokine profile of Cybb tml mice receiving the treatment remained 
comparable to those of knockout mice that did not receive anti-
IL-12 Ab (data not shown). 
We have previously noted marked differences in the phenotype 
of naive wild-type and Cybb tml mice as discussed, and appreciate 
many inherent problems of using knockout mice to evaluate the 
role of immune components in the outcome of infection. We there-
fore assessed the role of ROS in C. neoformans infection using the 
metallic manganese porphyrin MnTE-2-PyP, which acts as an 
SOD mimic and possesses ROS scavenging potential. Mice ad-
ministered MnTE-2-PyP exhibited a marked reduction in cellular 
infiltrate into the lung tissue (Fig. 5A) as well as the airways, 
relative to controls. This is distinct to the scenario in Cybb tml 
mice, which possessed a significant granulomatous lung infiltrate. 
The reduced cellularity by MnTE-2-PyP treatment was accounted 
for by a reduction in total numbers of lymphocytes (Fig. 5B) and 
eosinophils (Fig. 5C) in the lungs and airways. Similar to Cybb 
tml mice, those treated with MnTE-2-PyP showed a marked bias 
toward a CD8± T cell response relative to CD4+ when compared 
with control mice (Fig. 5D). Furthermore, both CD4± and CD8 
T cells from mimetic-treated mice exhibited a Thl cytokine bias 
with a greater percentage of cells expressing intracellular IFN-y 
relative to PBS-treated mice (Fig. 5E). Finally, MnTE-2-PyP-
treated mice showed comparable fungal loads in their lungs and 
airways, but exhibited reduced dissemination to the brain relative 
to control mice (Fig. 5F). 
The Thl bias and improved protection seen in Cybb tml mice or 
those administered MnTE-2-PyP suggests a role for ROS in de-
fining the Thl/Th2 paradigm. This may be partly explained by the 
heightened macrophage numbers in C. neoformans-infected Cybb 
tml mice. Because ROS have been implicated in apoptosis (12-14, 
30, 31) of cells, we examined the influence of MnTE-2-PyP on the 
J774 macrophage cell line treated with a variety of stimuli and 
indeed found reduced apoptosis (data not shown). We have sub-
sequently investigated macrophage apoptosis during C. neofor-
mans infection with or without administration of MnTE-2-PyP. 
Although we found the total number of annexin V± macrophages 
was reduced, this was a reflection of the total reduction in cellular 
infiltrate rather than an alteration in the proportion of cells under-
going apoptosis. It would appear that a reduction in macrophage 
apoptosis is therefore not the sole reason for the elevated Thl 
response and improved pathogen clearance. 
We finally determined whether administration of the antioxidant 
MnTE-2-PyP affected clearance of C. neoformans at later time 
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Table I. Cybb tml mice elicit a reduced B cell and Ab response to C. neofonnansa 
% B220 	 Total Ab 
	
IgG1 	 IgE 
Wild type 46.1 ± 2.1 0.59 ± 1.7 0.11 ± 0.01 0.29 ± 0.09 
Cybb tml 28.3 ± 4.0 0.13 ± 0.02 0.09 ± 0.003 0.05 ± 0.01 
a  Lungs were removed from naive Cybb tml and wild-type C57BIJ6 mice at day 12 postinfection, and single-cell suspensions were obtained. Viable cells 
from each organ were determined by trypan blue exclusion. Single-cell suspensions were stained with anti-B220-PerCP, and the percentage of lymphocytes 
expressing this marker was determined by flow cytometry. The levels of C. neoformans-specific total Ab and IgG1 in the serum were determined at day 12 
postinfection, and the levels of total IgE in the BAL were assessed at day 5. ODs were read at 490 nm, and mean blank values (ODs from normal mouse serum) 
were subtracted from the OD values of test samples. Results represent the mean ± SD of five individual mice in three independent experiments. 
points, and whether mice deprived of ROS would eventually suc-
cumb to infection. Therefore, mice were infected with C. neofor-
mans and administered PBS or MnTE-2-PyP at 4-day intervals and 
were culled at day 45 after infection. At this time point, total cell 
numbers in the lung (Fig. 6A) and BAL (data not shown) were still 
significantly lower in MnTE-2-PyP-treated mice, particularly 
CD4+ and CD8+ T cells (Fig. 6B). The total number of pulmonary 
macrophages were partially reduced in those mice administered the 
mimetic, reflecting a general reduction in cellular infiltrate at this site. 
However, those macrophages remaining expressed elevated levels of 
MIIC-II (Fig. 6C). At this time point, the mice continued to display 
reduced C. neoformans CFUs in the brain (Fig. 6E) similar to day 12 
after infection, but now also exhibited a significant reduction in patho-
gen burden in the lungs (Fig. 6D) that had not previously been seen at 
earlier time points with mimetic treatment. 
Discussion 
In recent years, there has been an increasing prevalence of invasive 
fungal infections, attributed mostly to the rising population of im-
munocompromised individuals (3). The fungal pathogen C. neo-
formans has been one of the most devastating, with an estimated 
6-8% of AIDS-infected patients succumbing to Cryptococcus-as-
sociated meningitis. In this study, we have investigated the anti-
microbial action of ROS against C. neoformans, using mice that 
lack a functional phagocyte NADPH oxidase (Cybb tml mice) and 
through administration of a manganic porphyrin with broad anti-
oxidant activity. ROS are believed to fulfill a critical role in con-
ferring protection against fungal infections; the most important 
evidence provided by patients with CGD, who lack a functional 
NADPH oxidase, and display heightened susceptibility to fungal 
pathogens such as A. fumigatus (9, 11). We show that Cybb tml 
mice elicit a lung granulomatous response to C. neoformans with 
enhanced macrophages and a distinct shift toward a protective 
Thl-driven response. In this environment, C. neoformans is contained 
in the lung, and dissemination to the brain is dramatically reduced. 
The appearance of a granulomatous response to C. neoformans 
in Cybb tml mice is not unexpected, because one of the clinical 
manifestations of CGD patients is aberrant inflammation and the 
formation of granulomatous lesions at disparate sites (32). A. fu-
migatus evokes enhanced inflammatory responses in the lungs of 
both CGD patients and in murine models of CGD (9, 11). This 
correlates with heightened macrophage responses leading to gran-
uloma formation. Similarly, mice lacking a functional phagocyte 
NADPH oxidase display enhanced inflammatory gastritis to Hel-
icobacter pylori (33), and elevated levels of polymorphonuclear 
leukocyte sequestration in an Escherichia coli sepsis model (10). 
The aberrant inflammatory response is not restricted to pathogenic 
challenge, with excessive inflammation and granuloma formation 
observed in the lungs of Cybb tml mice following injection of 
sterile heat-killed fungal products (9) and enhanced peritoneal leu-
kocytosis in response to thioglycolate (34). 
Although an augmented inflammatory response to pathogen is 
not atypical in the absence of a functional phagocyte NADPH  
oxidase, improved clearance of the pathogen is uncharacteristic. 
Cybb tml mice show improved clearance of C. neoformans in the 
lung tissue and airways with reduced dissemination to the brain. 
CGD is characterized by recurring life-threatening bacterial and 
fungal infections such as Staphylococcus aureus and A. fumigatus, 
with neutrophils from CGD patients demonstrated to display de-
fective killing against certain bacterial and fungal pathogens (9, 
11). A. fumigatus is capable of eliciting disease in mice lacking the 
NADPH oxidase at significantly lower doses than in wild-type 
controls, and higher doses of this fungal pathogen prove fatal to 
Cybb tml knockout mice (9). Similarly, phagocytes unable to gen-
erate superoxide exhibit reduced potential to kill Candida albicans 
(35, 36), and Sporothrix schenckii infection of CGD mice leads to 
systemic infection and death (35). Although compromised patho-
gen clearance is the norm in the absence of a phagocyte NADPH 
oxidase, improved immunity and reduced bacterial load has been 
reported for H. pylori (33), and we have reported an improved 
clearance of influenza virus from the lungs of Cybb tml mice (37). 
Despite the recurring fungal infections in CGD patients, there are 
no clinical studies showing enhanced susceptibility to C. neoformans. 
However, there are studies citing the potential of polymorphonuclear 
leukocytes and macrophages to kill Cryptococcus by oxidative mech-
anisms (16). Furthermore, the fungus appears to possess a host of 
intrinsic mechanisms to protect against an oxidative attack such as an 
SOD, and radical scavenging mediators melanin and mannitol. This 
would imply that, in some instances at least, ROS may be toxic to this 
fungus. Melanin-deficient C. neoformans possess a reduced capacity 
to kill mice (17), and CuSOD lacking Cryptococcus displaying atten-
uated growth within macrophages (18). The improved killing of C. 
neoformans in the absence of ROS has been described previously in 
vitro, whereby incubation of peritoneal macrophages with SOD and 
catalase augments anticryptococcal activity owing to a concomitant 
increase in NO production (38). 
Despite evidence signifying a role for ROS in protection to C. 
neoformans, these host mediators appear less critical than against 
other fungal pathogens. The differences in susceptibility of 
NADPH oxidase-deficient mice to C. neoformans relative to other 
fungal pathogens is probably partially attributable to the fact that 
protection against A. fumigatus and C. albicans, at least in the early 
stages of infection, is mediated primarily through ROS of phago-
cytes, whereas protection against C. neoformans is dependent on 
Thl cell-mediated immune response, which we have demonstrated 
to be augmented in Cybb tml mice. It is plausible that other non-
oxygen-mediated cytotoxic mechanisms are more important to 
eradicate C. neoformans, and in an in vivo scenario these may 
compensate for the absence of a functional NADPH oxidase. The 
array of protective mechanisms exhibited by C. neoformans may 
negate the potential of superoxide and other ROS to kill this fun-
gus, and oxidative cytoxicity will only become apparent if these 
oxidative defenses are absent. C. neoformans is an encapsulated 
yeast, with the large high m.w. polysaccharide capsule protecting 
against different facets of the host's immune response (3, 39). Such 
a capsule is not present around A. fumigatus and could explain the 
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FIGURE 4. IL-12 depletion does not compromise the reduced pathogen 
dissemination observed in Cybb tml mice. Mice were infected as described 
for Fig. 1, but some groups were additionally administered anti-IL-12 Ab. 
A, CFUs were determined 12 days after C. neoformans infection in lung 
homogenate, BAL, and brain homogenate. B, BAL eosinophils were enu-
merated as granulocytes by flow cytometry and confirmed using H&E-
stained cytocentrifuge preparations 12 days after infection. Closed sym-
bols, Wild-type mice; open symbols, Cybb tml mice. Results represent 
mean values ± SEM from five mice per group (*, p < 0.05; **, p < 0.01) 
and are representative of three experiments. 
heightened significance of ROS in conferring protection to this 
species. The capsule surrounding the Cryptococcus renders the 
pathogen less susceptible to phagocytosis and so may deprive ROS 
accessibility to the fungus (3, 40, 41). C. neoformans also has the 
potential to elicit deposition of opsonins, which may trigger the 
phagocyte respiratory burst, at sites below the capsule surface, 
where they will be incapable of binding complement or FcRs on 
the surface of myeloid cells (3, 42). 
The improved clearance of C. neoformans is probably largely 
attributable to the enhancement of macrophages and Thl cytokines 
in Cybb tml mice. In addition, we report elevated CD8÷ T cells 
that have been shown to directly bind C. neoformans and inhibit 
growth (43). The Thl phenotype of the recruited T cell population 
in Cybb tml mice is significant because mice lacking Th 1 cyto-
kines succumb to cryptococcal infection (5, 28, 44-46). IFN-y 
will contribute to granuloma formation and the activation of mac-
rophages (47). Furthermore, the chronic eosinophilia normally ob-
served during a C. neoformans infection elicits extensive tissue 
disruption and damage through degranulation and crystal forma-
tion and facilitates replication and spread of Cryptococcus (7). The 
FIGURE 5. The antioxidant MnTE-2-PyP reduces C. neoformans-in-
duced inflammation and reduces dissemination to the brain. C. neofor-
mans-infected mice were treated i.n. with PBS or MnTE-2-PyP on 0, 4, and 
8 days after infection. A, Representative H&E-stained lung sections of C. 
neoformans-infected PBS and MnTE-2-PyP-treated mice 12 days after in-
fection (x200 magnification). B, Lungs were removed from C. neofor-
mans-infected mice after 12 days, and the percentage of lymphocytes was 
determined by flow cytometry. The number of lymphocytes was calculated 
by the following: percentage of positive cells by flow cytometry x total 
number of viable cells. C, BAL eosinophils were enumerated as granulo-
cytes by flow cytometry and confirmed using H&E-stained cytocentrifuge 
preparations 12 days after infection. Single-cell suspensions of lung tissue 
were stained with IFN-y-FITC, CD4-PerCP, and CD8-allophycocyanin. D, 
Representative plots of CD4+ vs CD8' in C. neoformans-infected PBS 
and MnTE-2-PyP-treated mice 12 days after infection. E, The percentage 
of these T cells expressing IFN-y was determined by flow cytometry. F, C. 
neoformans CFUs/brain were determined by plating out brain homogenate 
on Sabouraud dextrose. Closed symbols, Wild-type mice; open symbols, 
Cybb tml mice. Results represent mean values ± SEM from five mice per 
group (*, p < 0.05; **, p < 0.01) and are representative of three 
experiments. 
significant reduction in eosinophilia in Cybb tml mice correlates 
with reduced lung pathology and damage and could also explain 
the enhanced ability to control this pathogen. 
It has previously been published that NADPH knockout mice do 
not show a shift in T cell cytokine responses as seen in our study. 
Although p47P'-'-  mice show reduced clinical signs of experimen-
tal autoimmune encephalomyelitis, this was not attributed to any 
change in bias of Th subsets (48). Similarly, p47Ph"-/- mice display 
a normal cytokine response to Mycobacterium avium (potent stimulus 
of Thl responses) and Schistosoma mansoni eggs (elicits Th2-medi-
ated granuloma) (49). However, this lack of an effect is not true for all 
scenarios. King et al. (50) have demonstrated a role for oxidative 
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FIGURE 6. The antioxidant MnTE-2-PyP reduces pulmonary inflam-
mation and fungal burden 45 days after C. neoformans infection. C. neo-
formans-infected mice were treated i.n. with PBS or MnTE-2-PyP on day 
0 and then every 4 days. A, At day 45 after infection, lungs were removed 
and homogenized to a single-cell suspension. The total number of viable 
cells was subsequently enumerated by trypan blue exclusion. B, Single-cell 
suspensions of lung tissue were stained with CD4-PerCP and CD8-allo-
phycocyanin, and percentage of CD4+ and CD8+ T cells was determined 
by flow cytometry. Total numbers of both T cell subsets were determined 
by the following: percentage of positive cells as adjudged by flow cytom-
etry x total number of viable cells. C, Single-cell suspensions of lung 
tissue were also stained with Gr-l-FITC, MHC-H-PE, and CD1 lb-PerCP. 
The geometric mean of MHC-II expression on macrophages was assessed 
by flow cytometry. C. neoformans CFUs were determined by plating out 
lung homogenate (D) and brain homogenate (E) on Sabouraud dextrose. 
Closed symbols, Wild-type mice; open symbols, Cybb tml mice. Results 
represent mean values ± SEM from five mice per group (*, p < 0.05; **, 
p < 0.01) and are representative of three experiments. 
stress in defining human T cell differentiation to Th1/Th2 subsets, 
with dimethyl naphthoquinone (induces oxidative stress) shown to 
cause the up-regulation of Th2 cytokines IL-4, IL-5, and IL-13, but 
not Thl cytokines. Similarly, it has been demonstrated that exposure 
of peripheral blood T cells to antioxidant vitamin E reduces IL-4 
production, that intake of vitamin E reduces IgE serum levels, and that 
allergic asthma is linked to a low intake of antioxidant vitamins (51-
53). Furthermore, in a model of experimental arthritis, NADPH oxi-
dase knockout mice display increased TNF and IL-1 (54), and we 
have previously seen an enhancement of Thl responses in Cybb tml 
mice to influenza (37). 
Considering the pivotal role of IL-12 in the generation of Thl 
responses (5), it was surprising that anti-IL-12 treatment had a 
negligible effect on the immune profile observed in Cybb tml 
mice, especially because similar treatment of wild-type mice en-
hanced Th2 cytokines and impaired pathogen clearance. Cybb tml 
mice still displayed a potent Thl response and enhanced protection 
even when deprived of IL-12. It would appear that the aberrant 
immune phenotype evoked by the absence of the NADPH oxidase 
is able to overcome the customary requirement for IL-12. TNF-a 
in Cybb tml mice may assist in the maintenance of a protective 
Thl response. TNF knockout mice are more susceptible to C. neo-
formans infection (55), and Huffnagle and colleagues (56, 57) have 
demonstrated a significant early role for TNF in leukocyte recruit-
ment of leukocytes and the development of Thl-biased immune 
response. Indeed, we have previously reported that CpG has been 
demonstrated to promote a heightened Thl response to C. neofor-
mans and prevent dissemination to the brain, an effect that was 
abolished by depleting TNF-a (58). 
The manganic porphyrin antioxidant, MnTE-2-PyP, also en-
hanced Thl cytokines to C. neoformans, again with heightened  
CD8+ T cells, elevated production of Thl cytokines, and signifi-
cantly reduced eosinophilia. Furthermore, treated mice exhibited 
reduced dissemination of C. neoformans to the brain. However, 
compared with Cybb tml mice, some differences were apparent. 
Whereas Cybb tml mice displayed a granulomatous response that 
contained the pathogen within the lung, those treated with MnTE-
2-PyP exhibited a dramatically reduced infiltrate into the lung and 
airways. The granulomatous response observed in Cybb tml mice 
appears to be a function of the cumulative absence of a functional 
NADPH oxidase since birth leading to a heightened basal macro-
phage population that subsequently provokes an excessive immune 
response to any encountered stimuli. A permanent lack of super-
oxide may compromise homeostatic regulation of this myeloid im-
mune compartment. However, MnTE-2-PyP was only adminis-
tered during infection and so would not be anticipated to elicit the 
same extent of macrophage deregulation. The fact that inflamma-
tion was so significantly reduced in mice administered the antiox-
idant is most likely an implication of the potential of ROS to act as 
pro-proinflammatory mediators by activating certain redox-sensi-
tive transcription factors. This will be of particular importance 
with administration of MnTE-2-PyP because it targets superoxide 
generated by the phagocyte oxidase, xanthine oxidase, and that 
derived from the NOX family that have been more classically af-
filiated with a role in signaling. The effects of MnTE-2-PyP re-
ported here are analogous to its effects in a murine model of 
asthma, where it reduced inflammation and, significantly, eosino-
philia (59). Significantly, mice administered the MnTE-2-PyP an-
tioxidant for a longer period were not compromised in their ability 
to combat C. neoformans infection, with treated mice exhibiting 
reduced pulmonary inflammation as well as reduced lung and brain 
fungal titers at day 45 after infection. 
In summary, it would appear that the absence of a functional 
phagocyte NADPH oxidase results in enhanced C. neoformans 
clearance and, most significantly, reduced dissemination to the 
brain. This is in contrast to the compromised immunity that such 
mice show to other fungal pathogens, and is a function of a height-
ened macrophage infiltrate and the ensuing Thl-driven immune 
response. These findings emphasize a significant role for ROS in 
defining the Thl/Th2 paradigm and offer a novel mechanism to 
modulate myeloid immune responses. 
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FRONTLINE: 
An absence of reactive oxygen species improves the 
resolution of lung influenza infection 
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Three influenza virus pandemics occurred in the last century, in 1918 killing 40-50 
million people. In the absence of strain-specific vaccines, with potential resistance to 
antivirals and the threat of an imminent pandemic, strategies that alleviate symptoms 
are a priority. Reactive oxygen species are potent antimicrobial agents but cause 
immunopathology when produced in excess. Mice lacking a functional phagocyte 
NADPH oxidase (Cybb tml mice) or treated with the metalloporphyrin antioxidant 
manganese (III) tetrakis (N-ethyl pyridinium-2-yl) porpyhrin (MnTE-2-PyP) show 
heightened inflammatory infiltrates in their airways in response to pulmonary 
influenza infection, with augmented macrophage populations and a Thl-skewed T cell 
infiltrate. Underlying this exuberant macrophage response was a significant reduction 
in apoptosis and down-regulation of the myeloid inhibitory molecule CD200. Both, 
Cybb tml and MnTE-2-PyP-treated mice exhibited a reduced influenza titer in the lung 
parenchyma. Inflammatory infiltrate into the lung parenchyma was markedly reduced 
and lung function significantly improved. Manipulation of the homeostatic control of 
myeloid cells by inflammatory mediators therefore represents a novel therapeutic 
strategy in the treatment of influenza virus infection. 
Received 13/2/06 
Accepted 21/3/06 
[DOI 10.1002/ejL200635977] 
sk Key words: 
Infectious diseases 
• Knockout mice 
• Mucosal 
immunology 
Introduction 
Acute respiratory tract infections cause global morbidity 
and mortality, with influenza virus representing one of 
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the most persistent and important of such infectious 
diseases [1]. A pandemic with the H5N1 strain of 
influenza virus is predicted and, to date, of the 165 
confirmed cases approximately 50% have died, although 
human to human transmission has not yet been 
demonstrated. Influenza virus causes death of the 
infected cell by cytopathology, but a major part of the 
disease is attributed to an over-exuberant immune 
response that causes localized tissue damage and 
systemic illness via the induction of a "cytokine 
storm" 2]. Current strategies to limit mortality include 
vaccination and the administration of antivirals. Vac-
cines, however, are only successful if they boost 
immunity to antigenic components present in the final 
infectious strain. In addition, a number of influenza 
variants have evolved resistance to antivirals [3]. Since 
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exaggerated T cell responses and the subsequent 
cytokine storm are strongly affiliated with pathology, 
weight loss and fever during influenza infection [4, 5], 
strategies to modulate or prime an appropriate immune 
response irrespective of the infecting strain could have a 
significant clinical impact. 
The generation of ROS represents an important 
component of the host's arsenal to combat invading 
microorganisms [6-8]. In addition to their potent 
antimicrobial activity, ROS also possess a significant 
cell-signaling role in biological systems, capable of 
regulating the phenotype and function of immune cells 
[9-11]. However, the extreme toxicity and lack of 
specificity means they are also capable of eliciting 
significant immunopathology to surrounding tissue [12]. 
The most abundant sources of ROS following 
infection are the NADPH oxidase of professional 
phagocytes and xanthine oxidase. Both potently induce 
superoxide, which can subsequently be converted into a 
host of other ROS. The NADPH oxidase is a multimeric 
enzyme complex, composed of membrane-associated 
and cytosolic components that utilize molecular oxygen 
and NADPH to generate the superoxide radical (021 
[13]. The core of the enzyme contains the membrane-
bound flavocytochrome b558 [14]. This flavocyto-
chrome is the site of the oxygen reduction and comprises 
two subunits, a 22-kDa protein (p22phox) and a 91-kDa 
glycoprotein (gp9lphox) [15]. After appropriate stimu-
lation, cytosolic factors (p4Ophox, p47phox and 
p67phox) migrate to the membrane-associated compo-
nents to form an active complex that catalyzes the 
formation of 02— [16]. 
Influenza infection induces the production of super-
oxide from phagocyte NADPH oxidase and xanthine 
oxidase pathways [17] that may have partial virucidal 
activity or limit viral propagation by inducing apoptosis 
of the infected cell [18, 19]. However, the failure of ROS 
to discriminate between exogenous pathogens and 
endogenous host tissue implicates them in pathology 
following influenza infection [20-22]. Furthermore, 
ROS act as second messengers that activate redox-
sensitive transcription factors implicated in the estab-
lishment of an inflammatory response, suggesting that 
they may add to the over-exuberance of the elicited 
immune response [5, 23]. 
Mice lacking a functional phagocyte NADPH oxidase 
(Cybb tml mice) offer a murine model of the autosomal 
genetic condition of chronic granulomatous disease 
(CGD) [7]. These mice lack the gp9lphox subunit of the 
phagocyte NADPH oxidase, rendering them incapable of 
eliciting a respiratory burst and subsequent superoxide 
production. These mice demonstrate enhanced suscept-
ibility to certain fungal and bacterial pathogens [6, 7], 
but the effect on lung viral infection is not known. Since 
the absence of a selected gene may affect multiple 
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pathways and due to the pleiotropic roles of ROS, we 
additionally tested the influence of manganese (III) 
tetrakis (N-ethyl pyridinium-2-yl) porpyhrin (MnTE-2-
PyP), a low-molecular-weight, cell-permeable, catalytic 
metalloporphyrin antioxidant with potent superoxide 
dismutase (SOD) mimetic activity, in immunocompetent 
mice [24, 25]. This antioxidant has a broader range than 
SOD, also possessing catalase activity and the ability to 
scavenge lipid peroxides and peroxynitrite. The poten-
tial of this molecule to scavenge superoxide and other 
ROS provides an alternative strategy to elucidate the 
role of these mediators in immunity and pathology to 
respiratory infection. Although MnTE-2-PyP offers 
protection in a variety of oxidative stress injuries, such 
as liver ischemia, diabetes, lung radiation injury and 
stroke [24, 26], this is the first study to describe its use in 
the treatment of respiratory infection. 
We now show that a reduction of ROS by genetic 
depletion (Cybb tml mice) or administration of MnTE-
2-PyP improves the outcome of influenza infection by 
containing inflammation to the airways. Macrophage 
and neutrophil numbers and Thl-driven inflammation 
in the airways were enhanced, but lung parenchyma 
infiltration was reduced and lung function improved. 
Paradoxically, therefore, it would appear that depriva-
tion of ROS improves the outcome of pulmonary 
influenza infection, potentially through promotion of 
professional phagocyte populations. 
Results 
Influenza infection in Cybb tm1 mice results in 
enhanced weight loss and airway cellularity 
Intranasal (i.n.) infection with influenza virus results in 
weight loss that is driven by an excessive cellular 
infiltration into the airways and the subsequent 
production of inflammatory mediators, most notably 
TNF [5, 27]. In Cybb tml mice, weight loss was further 
enhanced compared to wild-type controls, particularly 
between days 2 and 4 (Fig. 1A). We therefore investi-
gated the level of airway inflammation by lavage and 
found it significantly greater in Cybb tml mice (Fig. 1B). 
This increase was restricted to the airways as reduced 
cellularity and consolidation was observed in the lung 
parenchyma (Fig. 1C, D). 
Histological and flow cytometric analysis revealed 
that macrophages (Fig. 2A) and neutrophils (Fig. 2B) 
contributed most significantly to the enhanced airway 
cellularity in Cybb tml mice at early time points. By 
day 7, however, CD4+ and CD8+ T cells dominated 
(Fig. 2C). Similar to overall cell numbers, the opposite 
was true for the lung parenchyma where, at day 7, 
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reduced T cell subsets were observed in Cybb tml mice 
(Fig. 2D). Of the heightened T cell numbers observed in 
the airways of Cybb tml mice, significantly more of 
them displayed an activated phenotype (CD45RBI"; 
Fig. 2E), whereas in the lung parenchyma activation was 
reduced (data not shown). 
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considering their heightened activation state in the 
airways of Cybb tml mice, we were not surprised to see a 
greater percentage producing intracellular IFN-y 
(Fig. 3C) and TNF (data not shown) in CD4 T cells 
3 days after infection. The total number of both T cell 
subsets producing IFN-y was elevated in Cybb tml mice 
Inflammatory cytokines are elevated during 
infection of Cybb tm1 mice 
Weight loss during influenza infection is attributed 
largely to an over-exuberant immune response and 
release of Thl cytokines such as TNF [4]. We therefore 
next examined soluble inflammatory cytokines/chemo-
kines in bronchoalveolar lavage (BAL) fluid and serum 
by cytometric bead array. Of those examined, TNF, IL-6, 
IL-12 and monocyte chemoattractant protein-1 (MCP-1) 
were elevated in the BAL fluid of Cybb tml mice at day 3 
compared to age-matched controls (Fig. 3A). A similar 
profile was observed in the serum of the same animals, 
although at a lower level (Fig. 3B). TNF and IL-6 are 
derived largely from macrophages and have been 
implicated in the cachexia observed during an influenza 
infection. Production from these sources may therefore 
explain the enhanced weight loss in Cybb tm1 mice early 
in infection. However, T lymphocytes are also a 
significant source of inflammatory cytokines, and 
0 1 2 3  4 5 6 7  
Days post infection 
ot;  7 
Figure 1. Enhanced airway cellularity but reduced lung 
consolidation after influenza infection of Cybb tm1 mice. 
(A) C57BL/6 and Cybb tm1 mice were infected with influenza; 
weight loss was recorded daily and is expressed as percent of 
original weight. Total viable cells were enumerated in the BAL 
fluid (B) and lung (C) on days 0, 1, 3 and 7 after influenza 
infection. (D) Representative H&E-stained lung sections from 
C57BL/6 and Cybb tm1 mice 7 days after infection (magnifica-
tion x200). Closed symbols, wild-type C57BL/6 mice; open 
symbols, Cybb tm1 mice. Results represent mean values ± SEM 
from five mice per group and are representative of three 
independent experiments. *, p <0.05; **, p <0.01. 
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Figure 2. Influenza-infected Cybb tm1 mice have expanded 
macrophage, neutrophil and T cell infiltrates in their airways. 
The percentages of macrophages (A) and neutrophils (B) in the 
BAL fluid of wild-type (closed bars) and Cybb tm1 (open bars) 
mice at day 3 after influenza infection were determined from 
H&E-stained cytospin preparations, and the number of each 
population was calculated from total viable cell counts. BAL 
was performed and lungs were removed from wild-type and 
Cybb tm1 mice 7 days after infection with influenza, and 
single-cell suspensions were stained with anti-CD45RB-FITC, 
anti-CD4-PerCP and anti-CD8-APC antibodies. The number of 
CD4.  and CD8' T cells in the BAL fluid (C) and lung (D) were 
determined by: % positive cells x total viable cells. (E) The 
percentages of CD4' and CD8+ T cells in the BAL fluid that were 
CD45RB1° were determined by flow cytometry (each point 
represents an individual mouse). Results represent mean 
values ± SEM from five mice per group and are representative 
of three independent experiments. *, p <0.05; **, p <0.01. 
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Figure 3. Cybb tm1 mice produce heightened levels of pro-inflammatory cytokines and exhibit a Th1 bias. Pro-inflammatory 
cytokines in the BAL fluid (A) and serum (B) 3 days after infection were determined using the BD mouse pro-inflammatory 
cytometric bead array. BAL was performed on influenza-infected wild-type C57BL/6 (closed symbols) and Cybb tm1 (open symbols) 
mice, and single-cell suspensions were stained with anti-IFN-y-FITC, anti-CD8-PerCP and anti-CD4-APC antibodies. 
(C) Representative plots of BAL CD4+ T cells versus IFN-y expression in wild-type (left) or Cybb tml (right) mice 3 days after 
influenza infection. (D) The numbers of CD4' and CD8' T cells producing IFN-y in the BAL fluid at day 7 after infection were 
determined in wild-type (closed bars) and Cybb tm1 mice (open bars) by: % positive cells x total viable cells. Results represent 
mean values ± SEM from five mice per group. Lungs were removed from influenza-infected wild-type and Cybb tm1 mice 7 days 
after infection. (E) Proliferation of lung cells to UV-inactivated influenza was determined by [3H]thymidine incorporation. 
Apoptotic annexin V-stained CD11b+ macrophages, CD4+ and CD8+ T cells (F) were also assessed in wild-type C57BL/6 and Cybb 
tm1 mice by flow cytometry. CD200 expression on lung cells was enumerated by flow cytometry using and-CD200-PE, anti-CD4-
FITC, anti-CD8-APC and anti-B220-PerCP antibodies (G). Closed symbols, wild-type C57BL/6 mice; open symbols, Cybb tm1 mice. 
*, p <0.05; **, p <0.01. 
7 days after infection (Fig. 3D). Furthermore, lung 
T cells from Cybb tml mice displayed enhanced 
proliferation to influenza virus compared to wild-type 
controls (Fig. 3E). 
Excess soluble cytokines may be explained by an 
elevated number of cells producing them or by 
maintenance of a static population for greater periods 
of time. To support the latter idea, we enumerated 
apoptotic cells using annexin+ staining. Apoptotic 
CD11b+ macrophages and CD4+ and CD8÷ T cells in 
Cybb tml mice were reduced compared to wild-type 
controls (Fig. 3F). 
© 2006 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim 
CD200 expression was also reduced on B and CD4+ 
and CD8+ T cells in the lung (data not shown) and 
airways (Fig. 3G) of influenza-infected Cybb tml mice. 
Binding of CD200 to CD200R on myeloid cells delivers 
an inhibitory signal [28]. We therefore believe that 
soluble cytokines are enhanced due to a combination of 
(1) heightened T cell responses in the airways, 
(2) reduced apoptosis of cells producing inflammatory 
mediators and/or (3) a reduction of signals that 
negatively regulate myeloid cells, such as CD200. 
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An absence of superoxide in Cybb tml mice 
reduces viral load and improves lung function 
The enhanced airway inflammation and Thl-type 
cytokines suggest an environment more conducive to 
viral clearance. Peak viral titers in the lungs of Cybb tml 
mice were significantly lower 3 days after infection 
compared to wild-type controls, and whilst virus 
persisted in the lungs of wild-type mice at day 7 after 
infection, it was undetectable in those of the knockout 
mice (Fig. 4A) (wild-type mice: average of 15 415 PFU 
± 4610 SEM). We also observed enhanced IgA in nasal 
wash (Fig. 4B) and BAL (data not shown) in Cybb tml 
mice that could also limit viral infectivity. 
Reduced total protein (Fig. 4C) and lactate dehy-
drogenase (LDH) (Fig. 4D) levels in BAL fluid of Cybb 
tml mice are indicative of a reduction in tissue damage, 
possibly attributable to the reduced viral titers, lung 
inflammation and oxidative stress. Furthermore, whole 
body plethysmography revealed an improvement in lung 
function with enhanced tidal volume (Fig. 4E) and peak 
expiratory flow (Fig. 4F) in Cybb tml mice infected with 
influenza compared to wild-type controls. 
The cell-permeable mimetic MnTE-2-PyP 
prevents pulmonary inflammation during 
influenza infection 
Since genetically modified mice may harbor other 
defects, we next tested whether comparable results 
were observed with a scavenger of ROS. MnTE-2-PyP is a 
cell-permeable manganic porphyrin that acts as a potent 
antioxidant and superoxide mimic, and has previously 
been reported to confer protection in a variety of 
oxidative stress injuries. Mice administered with 25 or 
50 Lig mimetic on days 0 and 3 of influenza infection 
showed a comparable immune response to Cybb tml 
mice, with heightened cellularity in the airways and 
reduced inflammation of the lung tissue (Fig. 5A). Viral 
titers were reduced by administering 25 us mimetic, 
similar to Cybb tml mice (data not shown), but actually 
heightened at a higher dose (Fig. 5B), which may reflect 
the scavenging of ROS from other sources (such as 
xanthine oxidase) than just the phagocyte NADPH 
oxidase disrupted in Cybb tml mice. 
Similar to Cybb tml mice, 25 jig MnTE-2-PyP caused 
a marked reduction in perivascular and peribronchiolar 
infiltrate and occlusion of alveoli (Fig. 5C) and 
enhanced macrophages in the airways (Fig. 5D). 
Reduced CD4+ and CD8+ T cell numbers in the lung 
parenchyma (Fig. 5E) but not airways (Fig. 5F) were 
also apparent and consistent with the results obtained in 
Cybb tml mice. Of those T cells that remained, more 
intracellular Thi cytokines were observed (data not 
shown). 
© 2006 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim 
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Figure 4. Cybb tm1 mice exhibit increased viral clearance, 
reduced lung damage and improved lung function. (A) Viral 
titers were assessed in lung homogenates by plaque assay on 
days 1, 3 and 7 after infection. At day 7 after influenza 
infection, BAL fluid was removed and influenza-specific 
IgA (B), total protein (C) and LDH (D) were measured in the 
supematant. Whole body plethysmography was utilized to 
assess the tidal volume (E) and peak expiratory flow (F) of 
influenza-infected wild-type and Cybb tm1 mice at day 7 after 
infection. Closed symbols, wild-type C57BL/6 mice; open 
symbols, Cybb tm1 mice. Results represent mean values ± 
SEM from five mice per group. ", p <0.05; **, p <0.01. 
Discussion 
In this study, we show that Cybb tml mice exhibit a 
heightened cellularity with Th1 bias within their airways 
in response to influenza infection. On this background, 
clearance of pulmonary influenza virus infection is 
enhanced, lung damage reduced and lung function 
improved. Since gene-depleted animals may harbor 
multiple defects, we confirmed this effect by adminis-
tering low doses of the cell-permeable manganic 
porphyrin MnTE-2-PyP, which also targets superoxide 
generated via other sources such as xanthine oxidase, to 
wild-type mice. Mice administered the mimetic exhib-
ited a comparable immune phenotype to influenza as 
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Figure 5. MnTE-2-PyP administration to influenza-infected mice provides a comparable immune profile to that seen in Cybb tml 
mice. (A) Control (closed bars) and MnTE-2-PyP-treated (open bars) C57BL/6 mice were infected with influenza virus and the 
numbers of viable cells in the lung and BAL fluid after 7 days were determined by Trypan blue exclusion. Results are shown for 
treatment with 25 lig and 50 lig MnTE-2-PyP. (B) Viral titers were assessed in lung homogenates by plaque assay on day 7 after 
infection in mice treated with PBS (closed symbols) or MnTE-2-PyP (open symbols). (C) Representative H&E-stained lung sections 
from PBS-treated and MnTE-2-PyP (25 4-treated C57BL/6 mice 7 days after infection (magnification x200). (D) Cells from the BAL 
fluid of PBS- (closed bars) and MnTE-2-PyP (25 1.4-treated (open bars) mice were stained with anti-Gr-1-FITC, anti-CD11b-PerCP 
and anti-CD11c-APC antibodies, and the numbers of CD11b single-positive cells were determined by multiplying the percentages 
of positive cells by flow cytometry by the total numbers of viable cells. BAL fluid and lungs were removed from PBS-treated (closed 
bars) and MnTE-2-PyP (25 µg)-treated (open bars) mice, and single-cell suspensions were stained with anti-CD4-PerCP and anti-
CD8-APC antibodies. The number of each population in the lung (E) and BAL fluid (F) was determined by: % positive cells x total 
viable cells. Results represent the mean + standard deviation of five individual mice and are representative of three independent 
experiments. *, p <0.05; **, p <0.01. 
seen in Cybb tml mice; however, at higher doses, MnTE-
2-PyP prevented influenza virus clearance. 
The enhanced airway cellularity in Cybb tml and 
mimetic-treated wild-type mice at early time points was 
due to expanded macrophage and neutrophil numbers, 
but later replaced by T cells. This is likely to reflect 
reduced apoptosis in the absence of ROS, similar to 
reduced spontaneous and Fas-induced apoptosis of 
similar populations in patients with CGD [11]. Influenza 
has been demonstrated to induce apoptosis in macro-
phages and neutrophils, and evidence has indicated that 
this may be mediated through the generation of ROS in 
these cells. 
Alternatively, enhanced macrophage activity could 
also be explained by a reduction of inhibitory signals 
from other immune cells. For example, we show reduced 
CD200 expression on B cells, CD4+ and CD8+ T cells in 
© 2006 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim 
the lungs of Cybb tml mice infected with influenza. 
CD200 delivers an inhibitory signal on binding CD200R 
on the surface of myeloid cells [29], and CD200 
knockout mice display a similar phenotype to Cybb 
tml mice, with heightened macrophage numbers and a 
Thl bias [30]. CD200 is up-regulated on apoptosing cells 
to restrict the induction of inappropriate inflammatory 
sequelae by the phagocytosing macrophage [31]. There-
fore, a reduction in apoptosis and CD200 may in turn 
hinder the ability to switch off myeloid cells and explain 
their enhanced numbers in the absence of ROS. 
The enhanced cellularity we describe to viral 
infection in NADPH oxidase knockout mice is also 
evident during bacterial [7, 8] and fungal [6, 7] 
infection. Furthermore, NADPH oxidase knockout mice 
exhibit enhanced inflammatory gastritis, and sterile 
heat-killed fungal products cause excessive inflamma- 
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tion in the lungs. Products of the phagocyte oxidase may 
therefore fulfill an anti-inflammatory role and, of 
significance, it has been implicated in oxidatively 
inactivating chemotactic factors [32], inducing anti-
inflammatory cytokine production by neutrophils and 
macrophages [33], and in modulation of Thl cytokine 
production [34]. It would therefore appear that in the 
absence of ROS, macrophages and neutrophils exist in a 
heightened state of activation such that replication of 
influenza virus is limited. A limited viral load would 
reduce the chemotactic signals that usually induce lung 
consolidation. 
The heightened Th1 environment seen in the absence 
of ROS will act to further promote and activate resident 
macrophages. Indeed, we see elevated levels of TNF, 
IL-6, MCP-1 and IL-12 in the airways 3 days after 
influenza infection in Cybb tml mice, which may 
contain influenza, restrict dissemination into the lower 
airways and lung tissue and explain reduced parench-
yma infiltrates. 
Another salient feature of Cybb tml mice was the 
enhanced T cell populations in the airways 7 days after 
influenza infection. Signals delivered by the larger 
population of macrophages in the lungs and airways of 
Cybb tml mice could enhance the activation of the 
pulmonary T cell population. However, the increase in 
T cell numbers and activation could also be attributable 
to the reduction in apoptosis and enhanced prolifera-
tion. ROS have been linked to T cell hypo-responsiveness 
with peroxynitrite (formed by the reaction of superoxide 
with nitric oxide), inhibiting T cell activation and 
proliferation by nitrating tyrosine residues in down-
stream TCR signaling molecules [35]. Similarly man-
ganic porphyrins with antioxidant ability (such as the 
mimetic used in our study) protect T cells from super-
oxide generation and apoptosis [36]. 
The dominant Thl phenotype observed in Cybb tml 
mice and mimetic-treated wild-type mice is likely to 
reflect heightened macrophage-derived IL-12 produc-
tion. The mimetic used in this study reduces eosinophilia 
in a mouse model of asthma, implying a potential for 
ROS in defining the Thl/Th2 paradigm [37]. 
This is the first study to document the accelerated 
clearance of a viral infection in the absence of NADPH 
oxidase. However, a similar effect has been noted during 
Helicobacter pylori infection with knockout mice ex-
hibiting an enhanced inflammatory gastritis and 
reduced bacterial load [38]. This effect, however, is 
not observed for all pathogens. Despite amplified 
macrophage reactivity in CGD patients, increased 
susceptibility to Aspergillus fumigatus and Staphylo-
coccus aureus arise [7]. Studies in murine models of X-
CGD have demonstrated that A. fumigatus is capable of 
eliciting disease when administered at significantly 
lower levels in knockout mice compared to wild-type 
2006 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim 
mice, and is significantly more lethal at higher doses. 
Furthermore, mice lacking a functional phagocyte 
oxidase exhibit compromised clearance of Escherichia 
coli [8], impaired NF-KB activation and host defense in 
Pseudomonas pneumonia [39], and a transient loss of 
resistance to pulmonary tuberculosis [40]. The diver-
gent effects upon protection to different infections may 
depend on whether the pathogen has developed 
sophisticated strategies for avoiding the intracellular 
killing machinery. In our study, reduced influenza titers 
are likely to reflect heightened macrophages in the 
airways, a Thl-dominated immune response and 
elevated mucosal IgA in the absence of ROS. 
Alternatively, the absence of ROS could lead to 
reduced titers of influenza by modulation of infectivity 
and replication of the virus itself. Low levels of ROS have 
mitogenic effects on cells. Most viruses grow better in 
proliferating cells, and many induce host cell changes 
similar to mitogenic lectins. Alternatively, ROS may 
facilitate viral entry by cleaving the HA receptor 
precursor (HAO) into HAl and HA2 and thereby 
promoting viral infectivity. In the usual setting, HAO 
can be cleaved into the infective form by extracellular 
proteases present in the lung surfactant [41, 42]. These 
proteases are regulated by anti-proteases on the surface 
of the alveoli [41, 42], which in turn are inhibited by 
superoxide. Therefore in cybb tml mice superoxide is 
lacking, which will release anti-proteases and reduce 
viral infectivity. 
Mice treated with MnTE-2-PyP did not show the 
improved viral clearance seen in Cybb tml mice. At a 
low dose, the levels of virus were fairly comparable 
between treated and untreated mice. At higher doses, 
however, MnTE-2-PyP prevented viral clearance. MnTE-
2-PyP scavenges superoxide from sources other than the 
phagocyte NADPH oxidase, such as xanthine oxidase. It 
is plausible that the NADPH oxidase and xanthine 
oxidase systems are mutually redundant and that 
pathogen clearance is only compromised if both are 
absent, similar to that reported for Burkholderia cepacia 
[43]. In this scenario, ROS may fulfill some virucidal role 
but the levels generated through xanthine oxidase are 
sufficient to deal with the virus, or the heightened 
macrophage response and Thl bias can compensate for 
the reduction in ROS. 
In conclusion, ROS appear to playa homeostatic role in 
limiting macrophage activation. An absence leads to a 
"poised" macrophage and subsequent development of 
Thl-mediated immunity that is better equipped to limit 
influenza virus replication, resulting in reduced lung 
consolidation and bystander tissue damage. Raising the 
resting threshold of lung-resident antigen-presenting 
cells by modulating homeostatic negative feedback loops 
may therefore provide generic protection against viral 
infectious disease, irrespective of the infective strain. 
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Materials and methods 
Mice and virus 
Female C57BL/6 mice 8-12 wk of age (Harlan Olac Ltd., 
Bicester, UK) were kept in pathogen-free conditions according to 
Home Office guidelines. Cybb tml mice (back-crossed to the 
C57BL/6 background at least ten times) were originally 
purchased from The Jackson Laboratories (BarHarbour, ME) but 
bred in-house thereafter. Influenza A strain X31 (HA titer 1024) 
was a kind' gift from Dr. Alan Douglas (NIMR, London, UK). 
Mouse infections and treatment 
On day 0, wild-type C57BL/6 and Cybb tml mice were 
anesthetized and infected i.n. with 50 HA units of influenza 
virus. In some experiments, wild-type C57BL/6 mice were 
treated with the indicated doses of MnTE-2-PyP (Merck 
Biosciences AG, Switzerland) or PBS i.n. on days 0 and 3. 
Weight loss was monitored daily and the percent reduction was 
calculated from their original weight on day 0. Mice were 
sacrificed various days after infection by injection of 3 mg 
pentobarbitone and exsanguinated via the femoral vessels. 
Some mice were challenged with 50 HA units of influenza 
virus 4 wk later and sacrificed on various days as indicated in 
the text. 
Cell recovery and flow cytometry 
Lung lavage (BAL) and residual lung tissue were sampled as 
described [44] and single-cell suspensions were stained for 
surface markers with the following antibodies: anti-CD45RB-
FITC, anti-CD200-PE, anti-CD8-peridin chlorophyll a protein 
(PerCP), anti-CD8-allophycocyanin (APC), anti-CD11b-PerCP 
or anti-CD11c-APC, for 30 min at 4°C, and fixed with 2% 
paraformaldehyde (15 min at room temperature). All anti-
bodies were purchased from BD Pharmingen (Heidelberg, 
Germany) except anti-CD200-PE (AMS Biotechnological Ltd., 
UK). To detect intracellular cytokines, 106 cells/mL were 
incubated with 50 ng/mL PMA, 500 ng/mL ionomycin 
(Calbiochem, Nottingham, UK), and 10 mg/mL brefeldin A 
for 4 h at 37°C. Cells were then stained with anti-CD4-APC and 
anti-CD8-PerCP antibodies and fixed as before. After permea-
bilization with PBS containing 1% saponin/1% BSA/0.05% 
azide (saponin buffer) for 10 min, cells were incubated with 
anti-IFN-y-FITC and anti-TNF-a-PE antibodies diluted 1 : 50 in 
saponin buffer. After 30 min, cells were washed once in 
saponin buffer and once in PBS containing 1% BSA and 0.05% 
azide. To detect apoptosis, cells were incubated with 
PE-labeled anti-mouse annexin V antibody (BD Pharmingen, 
Heidelberg, Germany) according to the manufacturer's 
instructions. All data were acquired on a FACSCalibur 
acquiring at least 30 000 lymphocyte events (BD Biosciences, 
Belgium). 
Lung histology 
Excised lungs were inflation-fixed with 2% formalin in PBS 
7 days after i.n. influenza virus infection. The inflated lungs 
were excised and embedded in paraffin wax by Lorraine 
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Lawrence, Leukocyte Biology, Imperial College, London. 
Sections (4 tm thick) from four to five mice were stained 
with H&E. 
Lung influenza titer 
The titer of influenza virus was assessed in lung homogenates 
after 1, 3 and 7 days. Homogenized cells were freeze-thawed 
three times, centrifuged at 4000 x g and supernatants were 
titrated in doubling dilutions on Madine Darby canine kidney 
cell monolayers in flat-bottom 96-well plates. After 3 h at room 
temperature, samples were overlaid with methylcellulose and 
incubated for 72 h at 37°C. Cell monolayers were washed and 
incubated with mouse anti-influenza antibody (Serotec, 
Oxford, UK), followed by horseradish peroxidase-conjugated 
anti-mouse antibody (Dako Ltd., Cambridge, UK), and infected 
cells were detected using 3-amino-9-ethylcarbazole (AEC; 
Sigma). Infectious units were enumerated by light microscopy 
and total PFU per lung quantified (number of plaques x 
dilution factor x total volume of lung homogenate). 
Protein detection 
BAL fluid protein concentration was determined using the 
Pierce BSA protein assay kit. Working reagent was added to 
samples and standards at a 4 : 1 ratio and incubated at 37°C 
for 30 min. Absorbance was measured at 490 nm, and protein 
concentration calculated by comparison with an albumin 
standard. 
LDH detection 
The amount of LDH in the BAL was measured using an in vitro 
toxicology LDH-based assay kit (Sigma). Samples (tested in 
triplicate) were added to an equal volume of LDH assay 
mixture (assay dye, substrate and enzyme) and incubated at 
room temperature for 30 min. Absorbance was measured at 
490 nm. 
Whole body plethysmography 
Lung function was measured in unrestrained animals by whole 
body plethysmography (Buxco Techologies, Petersfield, UK) as 
described [45]. 
Statistics 
Statistical significance was evaluated using a two-tailed 
Student's t-test assuming unequal variance with the Minitab 
software program. The Bonferroni Correction was applied 
where appropriate. 
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Review 
  
Manipulation of immunity to and 
pathology of respiratory infections 
Robert Snelgrove, Andrew Williams, Callum Thorpe and Tracy Hussein- 
Respiratory infections are the third leading cause of death worldwide and are a priority for 
vaccine development. Immune defence mechanisms are critical in recovery from most 
respiratory infections but the role of the immune system in causing bystander lung injury is 
not as well understood, and will be the focus of this review. Immune-mediated injury results 
from physical occlusion of the airways or the ensuing `cytokine storm', which may spill over 
into the systemic circulation and cause devastating consequences. Respiratory 
pathogens employ numerous strategies to avoid detection by the immune system. One of 
these, the alteration of key surface determinants, makes the design of rational vaccines 
problematic. In the following review the immune compartments responsible for clinical 
lung disease are discussed, and current and novel strategies to reduce their potency are 
overviewed. 
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Global burden of respiratory infections 
The Global Burden of Disease study of 1997 
disclosed acute respiratory infections to be 
the third leading cause of global mortality, 
resulting in an estimated 4.3 million deaths 
each year [1]. In addition to the significant 
mortality associated with such infections, is 
the substantial morbidity and ensuing eco-
nomic disruption. The World Health Organ-
isation (WHO) illustrated that acute respira-
tory infections are the most extensive burden 
of disease, with the estimated number of cases 
approaching 100 million in 2001. This 
review will focus upon specific respiratory 
infections that optimally illustrate how the 
overexuberance of the elicited immune 
response can evoke pathology and illness. 
Viral infections of the upper respiratory 
tract are generally transient and rarely fatal 
but are a frequent source of morbidity and a 
significant economic burden. One of the 
most common viruses to target the upper 
respiratory tract are rhinoviruses, which are 
the main cause of the common cold [2,3]. 
Rhinovirus infection rarely disseminates 
into the lower respiratory tract and infre-
quently causes serious illness. Some viruses,  
particularly respiratory syncytial virus (RSV) 
and influenza, however, do invade the lower 
respiratory tract and cause serious pneumonia, 
particularly in young children [4-6]. 
Influenza virus is highly contagious and 
causes seasonal epidemics which affect 10 to 
20% of the population. Furthermore, the 
WHO has recently decreed that 'another 
influenza pandemic is inevitable and possi-
bly imminent,' an alarming prospect consid-
ering the devastation and fatalities experi-
enced in the previous pandemics of recent 
times. Influenza infection is usually self-lim-
iting, culminating in a local and systemic 
reaction, whereby the afflicted individual 
may experience fever, chills, headaches, 
coughing, myalgia and diarrhea. However, 
there remain a significant proportion of 
patients who develop severe illness and com-
plications, such as the elderly, the very young 
and the immunocompromised [7]. Individu-
als possessing underlying medical condi-
tions, such as cardiovascular disease, chronic 
bronchitis and asthma, also possess a height-
ened susceptibility to complications, with a 
greater percentage developing secondary 
bacterial infections. 
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The respiratory tract also acts as an opening to an array of 
pathogenic bacteria. For example, Streptococcus pneumoniae 
is the leading cause of pneumonia and is present in the nasal 
passages of 40% of healthy individuals [8]. Invasive infection 
and disease associated with such organisms are rare bur in 
individuals that possess an underlying immunodeficiency, 
respiratory disease or viral infection, such commensal bacte-
ria can migrate to the usually sterile lower respiratory tract 
and elicit severe inflammation and pathology. The propen-
sity of the influenza virus to compromise neutrophil bacteri-
cidal capacity can augment bacterial-induced pneumonia, 
which is often fatal [9]. 
One bacterial-induced respiratory disease of particular 
prevalence, which is quite unique in terms of the chronic 
nature of the disease, is tuberculosis. Tuberculosis, or con-
sumption as it was previously branded, is one of the oldest 
afflictions known to mankind, yet it remains a significant 
source of morbidity and mortality throughout the world. The 
etiological agent of this condition is the highly accomplished 
and successful pathogen Mycobacterium tuberculosis. It is 
believed that approximately a third of the world's population 
are infected with these bacteria, an estimated 1.86 billion peo-
ple, yet only a minority go on to develop the fully active dis-
ease. The disease continues to flourish worldwide, with around 
8 million new cases each year, leading to an incredible 3 mil-
lion associated deaths. That is equivalent to approximately one 
death every 10 s. Tuberculosis clearly remains one of the most 
important infectious diseases, not only due to the intrinsically 
associated high mortality rate but also due to the huge strain it 
imparts on health resources in many countries. The high inci-
dence of tuberculosis has been recognized as a significant prob-
lem in the developing world for many years, where it has dev-
astating effects as a consequence of primitive protection and 
treatment strategies. However, there has also been an alarming 
re-emergence of the disease in the industrialized world, and 
tuberculosis is now acknowledged as an ever-expanding global 
health crisis. The re-emergence of the disease has largely been 
attributed to the current HIV epidemic and the increase in 
multidrug resistance among certain strains of M. tuberculosis. 
In 1993, the WHO declared the current increment in cases as 
a global emergency, which mandates the development of better 
treatments and higher efficacy vaccines. 
Other pathogens, such as fungi, mycoplasma and even 
helminths, are also known to elicit lung damage. Cryptococcus 
neoformans is an encapsulated budding yeast and the causative 
agent of the potentially life-threatening pneumonia and menin-
goencephalitis called cryptococcosis [10]. The lung represents the 
primary site of infection for this fungus but failure to control 
pathogen burden allows dissemination of cryptococcus to 
extrapulmonary tissues, especially the brain. In the last 10 years, 
clinical cases of cryptococcosis have escalated, the increase asso-
ciated with underlying T-cell deficiencies and chemotherapy use 
[11]. It is within the AIDS-infected population that C. neoform-
ans is most devastating, with between 6 and 8% of all AIDS 
patients developing cryptococcus-associated meningitis. 
Innate immunity to respiratory infections 
The primary obstacle to microorganisms entering the respira-
tory tract is an array of mechanical barriers that act to limit 
pathogen invasion. The nasal passage filters antigens greater 
than 10 pm in diameter, preventing progress past the larynx 
and further size exclusion is imparted by tight junctions 
between epithelial cells. The respiratory epithelia are coated in a 
layer of mucus that traps microorganisms and prevents them 
gaining access to the underlying respiratory epithelia. Conse-
quent ciliary movement and cough and gag reflexes act to dis-
place foreign particles from the lumen of the respiratory tract. 
Cells of the innate immune system possess a potent antimi-
crobial capacity but their activity is greatly induced by recogni-
tion of conserved microbial structures. Activation of innate 
mechanisms can be mediated by recognition of pathogen-asso-
ciated molecular patterns, such as mannose-, lipopolysaccha-
ride- and DNA-containing CpG motifs. Toll-like receptors 
constitute an important family of receptors that recognize such 
pathogen associated molecular patterns and are considered to 
represent a significant mechanism for inducing the production 
of antimicrobial products and in the development of a rapid 
and potent immune response to infection [12]. 
One mechanism of protection against respiratory pathogen 
challenge is the production of antimicrobial peptides by resi-
dent leukocytes, particularly macrophages [13,14]. Production of 
these soluble mediators may be constitutive or induced via rec-
ognition of pathogen motifs, and can impart both direct and 
indirect mechanisms of immunity towards the invading micro-
organism. Some of the most significant microbicidal mediators 
that constitute the host's protective immune response are 
depicted in TABLE 1 [13-17]. 
Alveolar macrophages reside in the respiratory tract and 
comprise 95% of all cells in the airways of uninfected indi-
viduals. These macrophages play an important role in the 
regulation of potentially harmful inflammation and in main-
taining immunological tolerance and respiratory homeostasis 
[18]. Alveolar macrophages express an assortment of receptors 
that facilitate recognition and phagocytosis of microbial 
pathogens, such as Fc receptors, complement receptors, man-
nose receptors, toll-like receptors and an array of scavenger 
receptors. Engagement of these receptors promotes phagocy-
tosis and activates the macrophage to produce a number of 
mediators that establish the host defence, such as antimicro-
bial peptides, lactoferrin, lysozyme, superoxide radicals and 
nitric oxide. 
Macrophages are themselves a source of proinflammatory 
cytokines, such as interleukin (IL)-1, tumor necrosis factor 
(TNF)-a and IL-8 [18]. These cytokines increase the production 
of chemokines and promote the upregulation of adhesion mol-
ecules on the endothelia and epithelia, facilitating the recruit-
ment and diapedesis of neutrophils and lymphocytes into the 
lung tissue. Macrophages are also an abundant source of IL-12, 
a cytokine fundamental to the development of a T-helper 
(Th)1 immune response and natural killer (NK) cell activation. 
Dendritic cells are another important antigen-presenting cell 
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Figure 1. Recognition of antigen by lymphocytes. T-lymphocytes are 
subdivided into helper (CD4+) and cytotoxic (CD8+) cells. CD4+ and CD8+ 
(not shown) T-cells recognize small peptide fragments of antigen using a 
variable T-cell receptor. Unlike B-cells, T-lymphocytes require presentation of 
the antigen by MHC class I (CD8+ T-cells) or class II (CD4+ T-cells). These 
MHC complexes are expressed on antigen-presenting cells. The interaction 
between the T-cell receptor and the MHC/antigen is not enough alone to 
activate the T-cell. A second costimulatory interaction between CD28 on the 
T-cell and B7 on the antigen-presenting cell is required. 
MHC: Major histocompatability complex. 
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Table 1. Microbicidal mediators of the host's innate immune response to infection. 
Antimicrobial agent Source Target Method of protection 
Lactofernn Neutrophils, macrophages, 
epithelial cells 
Bacteria Sequesters iron essential for microbes 
Directly bactericidal 
Stimulates 02- production by macrophages 
Lysozyme Neutrophils, macrophages, 
epithelial cells 
Gram-positive bacteria Degradation of cell wall 
Defensins Phagocytes, lymphocytes, 
epithelial cells 
Gram-positive/negative bacteria, 
mycobacteria, yeast, fungi, some 
enveloped viruses 
Permeabilizes microbial membranes 
Triggers alternative complement pathway 
Collectins (surfactant Alveolar Type II cells Carbohydrate pathogen- Opsonization, agglutination, neutralization 
protein-A/D) associated molecular patterns and clearance of apoptotic cells 
Type 1 IFNs Macrophages, epithelial cells Viruses Limits viral replication 
Activates macrophages and NK cells 
Induces activation and differentiation of 
dendritic cells 
Adjuvants for T- and B-cells 
ROS/NO Phagocytes Fungi, bacteria and some viruses Direct oxidative damage 
Apoptosis of virally infected cells 
Regulation of immune cell function 
IFN: Interferon; NK: Natural killer; NO: Nitric oxide; ROS: Reactive oxygen species. 
(APC) that form a network in the submucosa of the 
nasopharynx, trachea and bronchial tree. They exhibit an 
enhanced capacity to present antigen as a result of their con-
stitutively augmented expression of several costimulatory 
molecules important in the activation of lymphocytes. 
Neutrophils are professional phagocytes and are a source of 
potent antimicrobial mediators, such as reactive oxygen species 
(ROS) and defensins. Neutrophils also secrete an array of pro-
inflammatory cytokines, such as TNF-a, IL-1I3 and IL-6, 
which act to augment and refine the proinflammatory response 
114,19]. Eosinophils and basophils are ocher granulocytes found 
in the lung. Unlike neutrophils, these cells are poorly phago-
cytic but secrete cytotoxic mediators, such as major basic pro-
tein, into the extracellular milieu in a process known as 'frus-
trated phagocytosis'. 
NK cells respond rapidly to viral infection and express a 
variety of surface receptors that survey the levels of human leu-
kocyte antigen-1 on the surface of infected target cells. If the 
NK cell detects an aberrant expression level of human leuko-
cyte antigen-1, as may be evoked by viral infection, then it will 
proceed to kill it. NK cell cytoxicity is mediated by perforin 
and granzyme-induced lysis and there is also evidence that this 
cell type can mediate Fas-dependent apoptosis. Such cell lysis, 
in accordance with the synchronous production of interferon 
(IFN)-7 from NK cells, acts to provoke further recruitment of 
other cells to the site of infection. 
Acquired immunity to respiratory infections 
Fundamental to the resolution of infection and development 
of memory is the establishment of an acquired specific T-
and B-cell response. T-cells recognize peptide fragments of  
antigen bound to major histocompatability complex (MHC) 
molecules on APCs via the 4-T-cell receptor (TCR)/CD3 
complex (FIGURE 1). Endogenous or exogenous antigenic 
products are processed by distinct pathways and are pre-
sented in conjunction with MHC class I or II molecules, 
respectively. MHC I expression is important for the activa-
tion of cytotoxic CD8+ T-cells (Tc cells). Conversely, 
MHC II expression is restricted to professional APCs and is 
responsible for the activation of helper CD4+ (TH) cells. Tc 
cells lyse infected cells via a perforin-dependent mechanism, 
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Figure 2. Th1 versus Th2 cytokine polarisation. Helper CD4*T-cells are 
divided based on the cytokines that they secrete. Differentiation to a Th1 
phenotype occurs in the presence of IL-12 and/or IFN-y. These cytokines are 
produced by NK cells. A Th2 phenotype occurs in the presence of IL-4, which 
is provided by NK T-cells and mast cells. Activation of the appropriate 
phenotype is essential for resolution of infection. Th1 are important for cell-
mediated immunity whereas Th2 function in antibody-mediated immunity. 
APC: Antigen-presenting cell; IFN: Interferon; IL: Interleukin; NK: Natural 
killer; Th: T-helper cell; TNF: Tumor necrosis factor. 
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which punches holes in the membrane of cells. Tc cells are 
also capable of inducing apoptosis of infected cells via a Fas-
dependent mechanism. CD8+ T-cells are critical mediators in 
the resolution of viral infections. CD4+ TH cells exert their 
effector function primarily through the release of cytokines 
that activate and stimulate other cells. They do, however, dis-
play limited cytotoxic activity through the release of TNF-a. 
The Th subset can be divided into Thl and Th2 cells, which 
are defined by the distinct cytokines that each subset produces 
(FIGURE 2). Thl-derived cytokines are responsible for driving 
cell-mediated immune responses to intracellular pathogens, 
whereas Th2 cytokines establish an antibody-mediated 
response that combats extracellular pathogens. 
In addition to all-TCR÷ T-cells, mucosal tissues contain 
78-TCR+ T-cells that recognize structures associated with 
CD1 molecules on APCs. The role of 78+-T-cells in mucosal 
defence still remains obscure. There is a population of a434--
and 78+-T-cells that reside within the epithelia of the respi-
ratory tract known as intraepithelial T-cells Rob These 
intraepithelial T-cells recognize generic immunological dis-
tress signals rather than pathogen-specific motifs and fulfil a 
significant role in the recognition and eradication of 
infected epithelial cells. 
The other arm of the acquired immune response involves 
antibody-mediated immunity, which is imparted by B-cells. 
Antibodies can target specific motifs of the invading patho-
gen and neutralize the pathogen, therefore preventing cell 
invasion, or facilitating clearance through opsonin-mediated 
phagocytosis. Antibodies, predominantly immunoglobulin 
(Ig)A, are always present in the respiratory tract of healthy, 
uninfected individuals, and can neutralize pathogens in 
three ways [21]: 
• IgA can bind pathogens in the lumen of the respiratory 
tract, rendering them incapable of invading the mucosal 
epithelia in a mechanism known as 'immune exclusion' 
• Dimeric IgA may bind endocytozed pathogens during 
transcytosis across epithelial cells and transfer them back 
into the lumen 
• IgA can bind pathogens that have already compromised 
the epithelial barrier into the lamina propria and expel 
them selectively back into the airways (FIGURE 3) 
Pathology: pathogen or immune induced? 
Pathology and disease induced by respiratory infections is 
classically attributed to the replication and cytoxicity of patho-
gens. However, it is now understood that the immune 
response to microbial pathogens mounted by the host, 
although generally protective, causes significant respiratory 
distress. The relative contributions of pathogen-induced 
pathology and immunopathology are variable and defined by 
the infective agent. If the pathogen is to be successfully eradi-
cated, then some immunopathology may be unavoidable, but 
an optimal balance between pathogen clearance and restricting 
collateral damage to the tissue architecture is desireable. 
Viral-induced immunopathology 
Some viruses, such as influenza and adenovirus, are highly 
cytopathic and induce extensive tissue damage at the site of 
infection, with significant submucosal edema and shedding of 
epithelial cells. Influenza is capable of subverting host cell 
function by suppressing host gene transcription and protein 
synthesis, whilst promoting viral replication and production 
of virions [221. Subsequently, infected host cells are subjected 
to a cytolytic death approximately 20 to 40 h post infection. 
Influenza can also elicit apoptosis of the invaded host cells, 
with virion proteins such as neuraminidase (NA) and non-
structural (NS)1 implicated in the regulation of the apoptotic 
program [22]. 
Conversely, there are many viruses that display minimal 
cytopathic potential, implying that a significant proportion of 
the extensive tissue damage and illness is attributable to the 
over-exuberance of the host's immune response (FIGURE 4). 
Some of the most compelling evidence for a direct role of the 
host immune response in pathology came from clinical trials 
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of a formalin-inactivated RSV vaccine in the 1960s [23,24]. 
Vaccinated children displayed a dramatic increase in the sever-
ity of symptoms after live RSV infection, with a significant 
increase in hospitalization and mortality. Augmented eosi-
nophilia in the lungs and blood was associated with this 
heightened pathology. 
Chemokines and cytokines contribute significantly to the 
observable clinical symptoms following rhinovirus, RSV or 
influenza virus infection. Nasal lavage fluid of infected individ-
uals have elevated levels of IL-1, IL-8, IL-6 and TNF-a. TNF-
a secretion by monocytes, macrophages and T-cells, in 
response to RSV infection, has been demonstrated to be the 
fundamental cause of inflammation-induced immunopathol-
ogy and cachexia. TNF-a depletion significantly reduced pul-
monary inflammation and cytokine production without com-
promising RSV clearance, and almost abolished weight loss and 
observable illness [25]. Rhinovirus replication elicits the release  
of similar inflammatory mediators, which 
have been implicated in the ensuing 
pathogenesis. Multiple inflammatory 
mediators are associated with the symp-
toms of the common cold, such as hista-
mine, prostaglandins, IL-1, -6 and -8, 
which all contribute to the observed vas-
cular dilation and exudation, mucus secre-
tion and stimulation of the cough and 
sneeze reflexes pl. 
The release of inflammatory mediators 
is fundamental to the control and resolu-
tion of influenza infection but is also cen-
tral to the development of many of the 
observable clinical and pathological mani-
festations. Mediators that correlate with 
increased illness and disease are TNF-a, 
IL-6, -8, -1a, -lp, IFN-a and chemok-
ines, such as macrophage inflammatory 
protein (MIP)-1a. Investigations, using 
knockout mice and anticytokine strate-
gies, have implicated these cytokines and 
chemokines in lung inflammation, ano-
rexia, excessive sleepiness and fever pro-
gression. In a murine model of influenza-
induced pneumonia, a neutralizing anti-
body to TNF-a significantly reduced lung 
pathology and prolonged survival [26]. 
Similarly, IFN-a and IL-1a are important 
mediators of influenza-induced fever [27]. 
Influenza-infected IL-lp— and -6-knock-
out mice fail to display the same elevation 
in body temperature [28,29], and macro-
phage inflammatory protein (MIP)-la-
knockout mice possess reduced mononu-
clear infiltrate and pulmonary edema [30]. 
One of the primary cells to arrive at the 
site of infection is the neutrophil, which 
has a critical protective role in the clearance and killing of 
microorganisms. However, excessive recruitment of neutrophils 
observed in some viral infections is a potent source of immun-
opathology, owing to the release of various proteases and ROS 
by the neutrophils. High levels of IL-8 during RSV infection 
led to significant recruitment of neutrophils into the airways 
during bronchiolitis. Polymorphisms around the IL-8 gene cor-
relate with the degree of disease severity, suggesting a role for 
neutrophils as mediators of pathology and disease [31]. Further-
more, in vitro studies have demonstrated that incubation of res-
piratory epithelial cells with RSV virus yields minimal epithe-
lial detachment and damage but that coincubation with 
neutrophils significantly enhances this damage [19]. 
Macrophages represent another critical component of the 
host's innate defence against viral infection. Primarily, macro-
phages act as a form of immunosurveillance and are an abundant 
source of cytokines and chemokines that dictate the development 
O 
Figure 3. Recognition of antigen by lymphocytes. Plasma B-cells at mucosal sites such as the lung 
predominantly produce IgA in dimeric form, where two IgA molecules are linked by a joining chain. IgA is 
useful at such sites because it does not fix complement and is therefore noninflammatory and is also 
resistant to degradation by proteases. (A) Dimeric IgA binds to a polymeric Ig receptor (secretory 
component) on the basolateral surface of epithelial cells. This is then endocytosed, passed through the 
epithelial cell and released into the lumen where it can complex antigen. Complexed antigen cannot then 
gain access to the interior of the body (immune exclusion). (B) On its way through the epithelial cell, 
dimeric IgA can pick up antigens already in the cell and transport them to the lumen, excluding them. 
(C) Antigens that have traversed the epithelial layer can be picked up by dimeric IgA before it binds to the 
Ig receptor. It can then be transported to the lumen. 
Ig: lmmunoglobulin. 
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Figure 4. Excessive infiltration of immune cells leads to airway occlusion. Complications arising from infection of the lung are often the result of excessive 
inflammation. (A) A healthy lung contains very few inflammatory cells. (B) Upon infection however (in this case intranasal influenza infection in a murine 
model), inflammatory cell accumulation is so extensive that it completely disrupts alveolar architecture and eventually leads to death. 
Paraffin embedded hematoxylin and eosin stained lung sections x 200 magnification. 
of an inflammatory response [32,33]. This is exemplified during 
infections with RSV and influenza where macrophages are one of 
the predominant sources of cytokines that induce and augment 
the response. It is well documented that viral infection induces 
an augmented release of superoxide and xanthine oxidase from 
phagocytes, particularly during influenza A-induced murine 
pneumonia. ROS fail to discriminate between exogenous patho-
gens and the endogenous host tissue and are consequently key 
mediators in the induction of pathology It has been demon-
strated that treatment with superoxide dismutase, which breaks 
down superoxide, improves lung pathology and reduces lethality 
in influenza-induced pneumonia [34]. Superoxide can react with 
nitric oxide, derived from nitric oxide synthase, to form perox-
ynitrite, which can cause extensive tissue injury and mutagenesis 
through oxidation and nitration of various biomolecules [35]. 
Indeed, excessive superoxide has been linked to lipid peroxida-
tion, mitochondrial dysfunction and inflammatory injuries. 
Many infection-induced lung diseases are believed to be 
largely T-cell mediated, with substantial accumulation of both 
CD4+ and CD8+ T-cells in the alveolar spaces and/or the inter-
stitium, which subsequently impedes efficient oxygen transfer 
and compromises lung function. CD8+ T-cells act as both key 
effectors of viral clearance due CO their potent cytoxicity and as 
significant mediators of pathology and illness. Indeed, influenza 
infection of T-cell-deficient mice compromised viral clearance 
but caused a milder inflammation with reduced lung injury. 
Furthermore, adoptive transfer of hemagglutin-specific CD8+ 
cytotoxic T-lymphocytes into transgenic mice that constitutively 
express hemagglutinin antigen in lung cells led to profound and 
lethal lung injury [36]. Furthermore, it has been demonstrated 
that lung inflammation and impairment of lung function fol-
lowing influenza infection is dependent upon the production of 
the Thl cytokine IFN-y by CD8+ T-cells [37]. 
T-cell depletion studies have suggested that T-cells are a pri-
mary determinant of disease status elicited by RSV infection. 
RSV infection was more protracted in T-cell-depleted mice but 
there was negligible evidence of illness [38]. Similarly, the passive 
transfer of RSV-specific CD4* and CD8+ T-cells to RSV-
infected mice yielded a reduction in viral burden but a marked 
augmentation in lung damage. These results imply that both 
CD4+ and CD8+ T-cells are critical for the resolution of RSV 
infection but an over exuberant response is also a primary factor 
in the pathological sequelae and disease phenotype. Further-
more, as seen with influenza infection, T-cell-derived IFN-y is 
thought to be an important factor in both viral clearance and 
lung damage [39]. 
The T-cell phenotype, in other words, whether Thl or Th2 
cells are recruited, is also important in determining lung pathol-
ogy. It has been demonstrated that prior sensitization of mice 
with the surface glycoprotein G of RSV prior to RSV infection 
culminates in the induction of a Th2 response with chronic 
lung eosinophilia and extensive immunopathology. Conversely, 
prior sensitization to the F fusion protein of RSV provokes a 
Thl response with mild lung pathology and viral clearance [40]. 
A Thl response is protective against RSV infection, while a 
Th2 response aggravates RSV-induced pathology and disease. 
This premise is compliant with the results of the RSV vaccine 
trials of the 1960s, where increased illness severity and mortality 
correlated with chronic Th2-associated eosinophilia. 
Murine studies have demonstrated that RSV-induced illness 
correlates with RSV-specific IgE and a Th2 response. Knockout 
mice lacking the IFN-y receptor had an augmented eosinophilic 
influx around the bronchioles and heightened histopathology 
IFN-y is an important component of the host's Th 1 arsenal 
and through prevention of its signaling potential there is a plau-
sible shift towards a Th2 response with aggravated pathology. 
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There has also been some limited evidence in humans that 
RSV bronchiolitis may be a Th2-driven disease. An inverse 
relationship exists between IFN-y expression by peripheral 
blood mononuclear cells, and the severity of RSV-induced 
disease [42], and an increase in IL-4-to-IFN-y ratio is observed 
in children with bronchiolitis [43]. Finally, the recurrent epi-
sodes of wheezing, reminiscent of asthma, that are frequently 
observed after recovery from bronchiolitis suggest a potential 
predisposition to a Th2 phenotype in disease status [44]. It is 
anticipated that the cytokine milieu early in viral infection 
dictates the phenotype of the elicited immune response and 
the presence of IFN-y is crucial for protective immunity 
against RSV. 
Bacterial-induced immunopathology 
Pneumococcal infection of the lung elicits an exuberant 
immune response that is fundamental to the clearance of the 
pathogen. However, pneumococcal pneumonia is a disease 
that can be exacerbated by the excessive nature of this inflam-
matory response, whereby distinct components of the 
immune system synergize to induce significant lung tissue 
damage. The difficulty, therefore, arises in dissecting the ben-
eficial and deleterious facets of the mounted immune 
response. The pneumococcus produces several factors that are 
fundamental to the development of disease, either via direct 
cytopathicity or through subversion of the host's immune 
response. The pneumococcal toxin, pneumolysin, has been 
implicated in the pathogenesis of pneumonia, as the toxin 
alone is capable of eliciting symptoms of the disease. Further-
more, pneumolysin-deficient pneumococci were avirulent 
and infection with these pneumococci caused a marked 
reduction in inflammatory cell infiltrate into the lungs and 
reduced pathology [45,46]. Although pneumolysin has cytolytic 
potential, sublytic concentrations exert an array of immu-
nomodulatory functions that subvert the immune response 
and induce extensive immunopathology [41. Pneumolysin 
can elicit the induction of a heightened inflammatory 
response and ensuing pathology via stimulating the release of 
TNF-cc and IL-1[3 by monocytes, activation of phospholipase 
A2 in pulmonary cells, initiation of the complement pathway 
and provoking IFN-y secretion. Finally, suppression of the 
neutrophil respiratory burst and superoxide production has 
also been demonstrated. 
Autolysin is another pneumococci toxin that causes lysis 
of the bacterial cell and causes a heightened inflammatory 
response. The pneumococcal cell wall also elicits an aug-
mented inflammatory response and is capable of eliciting 
the recruitment of inflammatory cells into the lung, stimu-
lating cytokine secretion and enhancing epithelial permea-
bility. Finally, a putative zinc metalloprotease has recently 
been identified that is capable of inducing inflammation [48]. 
Therefore, it is apparent that pneumococcal-derived factors 
can be pathological either directly or through stimulation of 
a myriad of host mediators that induce and maintain the 
inflammatory riposte and induce bronchopneumonia. 
M. tuberculosis infection of the lung elicits tuberculosis and 
is another example whereby a generally protective immune 
response can synergistically evoke a degree of immunopathol-
ogy [49]. The immunopathology associated with 
M tuberculosis infection is a classic example of Type IV 
delayed type hypersensitivity (DTH) response. DTH is 
induced when CD4+ Th-cells encounter antigen and elicit a 
localized but nonspecific inflammatory response with a par-
ticular accumulation of macrophages and granuloma forma-
tion. Although the granuloma can restrict pathogen dissemi-
nation, an overexuberant response can invoke extensive tissue 
damage and pathology. Tuberculosis demonstrates the fine 
line that exists between a protective DTH response and one 
that culminates in pathological sequelae. Activated macro-
phages secrete high concentrations of lytic enzymes into the 
surrounding lung parenchyma causing extensive damage to 
blood cells and tissue necrosis. Ultimately, a significant extent 
of tissue damage evoked by M tuberculosis infection can be 
attributable to this immunopathology. 
Treatment of respiratory infections 
Infection-induced pathology in the lung is a culmination of the 
cytopathic nature of the infectious agent and the over exuber-
ance of the host's immune response. Classically, vaccination and 
the administration of antimicrobial agents have been the pri-
mary strategies utilized to directly target the invading pathogen 
and confer protection. However, with ubiquitous problems of 
efficacy and safety and the significance of immunopathology to 
disease status there is now intense research into developing new 
therapeutics that manipulate the host's immune response. 
Vaccination 
A vaccine can be defined as a preparation of dead or attenuated 
pathogens, or of derived antigenic determinants that provide 
immunity to subsequent pathogen challenge. An effective vac-
cine should selectively prime the host's immune response 
without causing immunopathology. Many vaccination strate-
gies have been applied worldwide with variable success [50]. 
Vaccination attempts against influenza virus provide a com-
prehensive example of strategies used to fight infectious dis-
ease in the lung. For example, whole killed influenza vaccines 
have been successful and well tolerated, if underutilized, and 
have been demonstrated to afford 60 to 90% protective effi-
cacy in children and adults [51]. However, there is some evi-
dence that these vaccines have elicited adverse reactions in 
juveniles and confer limited protection in the elderly [51,52]. 
There is immense antigenic variability attributable to influ-
enza as a result of the antigenic drift and shift in the surface 
proteins hemagglutinin and neuraminidase. Subsequently, the 
WHO is continually monitoring this variability in order to 
predict the influenza strains that will circulate the following 
year. These strains are then incorporated into a trivalent vac-
cine currently with HIN1, H3N2 influenza A virus and one 
influenza B virus. In addition, split influenza vaccines con-
taining ether- or detergent-treated viral products are currently 
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in widespread use. However, there are concerns regarding the 
level of protection they confer, with limited immunogenicity 
in naive individuals [53,54]. Furthermore, infrequent hypersen-
sitivity reactions, such as oculorespiratory syndrome and 
Guillain—Barre syndrome, have been reported. 
Cold-attenuated live vaccines have been used extensively for 
many years in the former Soviet Union with considerable suc-
cess [55] and are now starting to be utilized in the USA. It is 
anticipated that these vaccines may afford greater protection as 
they more closely imitate natural influenza infections and 
should therefore elicit a broader immunological response and 
confer more long-lasting protection. Preliminary studies have 
shown that live attenuated vaccines confer high protection [56] 
but concern persists regarding their safety, as it is feared that 
genetic exchange, as seen in pandemics, may occur between the 
attenuated vaccine and coinfecting virulent strains. DNA vac-
cines have been constructed encoding one or multiple influenza 
antigenic determinants, such as hemagglutinin, neuraminidase, 
matrix protein-1 and NS-1. In mice, such vaccines evoke signif-
icant protection, eliciting a full range of humoral and cellular 
immunities [5758]. 
Due to the antigenic variability continually displayed by 
influenza virus, a conserved M2 protein vaccine appears to be 
extremely promising, since its efficacy will be unperturbed by 
the extensive antigenic shift and drift in other proteins [59]. The 
protection of many traditional vaccines is now being aug-
mented by the coadministration of appropriate adjuvants. Sub-
unit influenza vaccines are now delivered with the adjuvant 
MF59 in some European countries and afford increased neu-
tralizing antibody responses to both influenza A and B. 
Mucosal delivery of vaccines may be advantageous due to wide-
spread vaccine coverage and provision of mucosal immunity, 
but such delivery systems have displayed limited success. How-
ever, the incorporation of adjuvant derived from bacteria has 
been demonstrated to improve immunogenicity. 
Antimicrobial products 
The WHO has warned that a new influenza pandemic could 
be imminent and there are concerns that current vaccines 
will be insufficiently immunogenic. In the outbreak of a pan-
demic there will be limited time between the detection of the 
causative strain and the requirement for a protective vaccine. 
The development of antiviral drugs could be crucial at con-
ferring protection in such a scenario and are now receiving 
extensive research. There are currently two distinct classes of 
anti-influenza drugs available, those that inhibit the M2 ion 
channel and those that are neuraminidase inhibitors. Existing 
M2 ion channel inhibitors are amantidine (Lysovir®, Alli-
ance Pharmaceuticals Inc) and rimantidine (Flumadine®, 
Forest Pharmaceuticals), which while exhibiting definitive 
antiviral potential exert significant disadvantages. Amanta-
dine displays poor oral bioactivity with ensuing difficulties in 
successful administration and there are serious deleterious 
side effects elicited by this antiviral agent to the CNS, liver 
and kidneys. The drug's ineffectiveness against influenza B  
strains and the rapid onset of post-treatment drug resistance 
also raise considerable concerns over its applicability as a 
plausible drug candidate [52]. Rimantadine displays reduced 
neurotoxicity relative to amantadine but its availability is 
limited as are extensive investigations profiling its activity. 
Neuraminidase inhibitors, zanamivir (Relenza®, Glaxo-
SmithKline) and oseltamivir (Tamiflu®, Roche), function to 
prevent release of new infective virions from the host cell and 
subsequent dissemination. Clinical studies have demon-
strated the potential of these antiviral agents to alleviate some 
early symptoms of influenza [60,61]. Though generally 
regarded as being safe there persist some concerns, with zan-
amivir being implicated in the occurrence of bronchospasms. 
Therefore, though the development of antiviral drugs 
directed against influenza would be highly desireable there 
still persist concerns over safety and increasing resistance. 
Furthermore, many of the symptoms of influenza may only 
become apparent when influenza burden has started to 
diminish, questioning the applicability of such drugs in the 
practical prevention of illness and viral spread. 
Immunotherapy 
The limited success of vaccination and antimicrobial agents 
in the treatment of many pathogen-induced pulmonary dis-
eases has led to the requirement for new approaches to com-
bat microbial burden. Modulation of the host's immune 
response is now an intense area of research in the develop-
ment of therapeutics for respiratory infections [62]. Various 
strategies have been utilized to manipulate the overexuber-
ance of the host's response, such as modulation of levels of 
inflammatory cytokines, T-cell responses and education of 
the lung environment. 
Cytokine therapy is a popular method utilized to combat 
pathology and illness induced by an inappropriate immune 
response. Cytokines play a paradoxical role in the establish-
ment of host immunity and frequently the ensuing pathol-
ogy. Subtle and regulated manipulation of their levels may 
evoke desirable repercussions by maintaining a balance 
between pathogen clearance and extent of disease. Adminis-
tration or depletion of cytokines has yielded beneficial results 
through the modulation of the potency and phenotype of the 
elicited response. Cytokine depletion is currently utilized in 
the treatment of more than 300,000 patients afflicted with 
autoimmune diseases, such as rheumatoid arthritis and 
Crohn's disease. 
Studies in antibody depletion have yielded promising results 
within the murine RSV model. TNF-a, derived from a host of 
immune cells, is anticipated to underlie a significant extent of 
RSV-associated pathology and as such has been recognized as a 
potential target for cytokine therapy. TNF-a depletion was 
demonstrated to alleviate weight loss and illness elicited by 
both Thl- and Th2-induced immunopathologies [251. Simi-
larly, TNF-a reduced weight loss, illness and pathology that are 
evoked by influenza infection [25]. In addition, depletion and 
knockout studies regarding levels of IFN-a, IL-la, -113, -6, -8 
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and various MIPs and methyl-accepting chemotaxis proteins 
have implicated these cytokines and chemokines in influenza-
associated fever, -lethargy and -anorexia. 
In some instances, insufficient immunity results in inade-
quate host defence and pathogen clearance. In such a scenario, 
cytokine depletion can be manipulated to eliminate an immu-
nosuppressive cytokine and consequently heighten the elicited 
immune response. TGF-I3 is an immunosuppressive cytokine 
produced during M tuberculosis infection by a host of immune 
and nonimmune cells. TGF-fl deactivates macrophages and 
suppresses T-cell function subsequently impairing mycobacte-
riocidal activity. TGF-I3 is secreted as an inactive homodimer 
bound to latency-associated protein (LAP) and is activated 
extracellularly by dissociation from LAP. LAP can therefore be 
utilized as a novel method of cytokine depletion through 
reduction of TGF-I3 activity. It was demonstrated that admin-
istration of LAP to bacille Calmette—Guerin (BCG) infected 
mice inhibited the growth of BCG in the lung and enhanced 
the antigen-specific proliferation of T-cells and IFN-y secre-
tion [63]. It is therefore apparent that the immunosuppressive 
cytokine TGF-13 partially mediates the susceptibility of the 
lung to primary BCG infection and depletion of TGF-I3 repre-
sents a plausible mechanism to confer heightened immunity in 
this and potentially other infections. 
Despite the exciting developments regarding the depletion of 
cytokines in pulmonary infections, it is unlikely that such strat-
egies will be plausible in clinical studies. The existence of pro-
inflammatory cytokines early in infection impedes the use of 
such therapeutics as administration at the onset of observable 
symptoms may be too late. Furthermore, it must be remem-
bered that cytokines fulfil pleiotropic functions, and whilst 
potentially harmful, also exhibit a significant role in pathogen 
clearance. Neutralization of proinflammatory cytokines is not 
always beneficial, with depletion of TNF-a during S. pneumo-
niae or salmonella infection culminating in increased bacterial 
loads and mortality [64,65]. Furthermore, it has been demon-
strated that administration of infliximab (Remicade®, Scher-
ing-Plough Ltd), a humanized antibody that neutralizes TNF-
a, provokes the onset of active tuberculosis [66]. It is imperative 
to understand that the role and contribution of proinflamma-
tory cytokines in the host's response is pathogen specific and as 
such, depletion of these mediators may be beneficial in allevia-
tion of pathology to one infection but may augment disease to 
a heterologous coinfection. 
Administration of recombinant cytokines during infection 
also possesses plausible therapeutic potential. IL-10 is known 
to be a powerful immunosuppressive cytokine, inhibiting the 
production of TNF-a and IL-1[3 by alveolar macrophages and 
upregulating other anti-inflammatory cytokines, such as 
interleukin (IL)-1 receptor (R)a and soluble tumor necrosis 
factor receptor (sTNF-R)1 [67,68]. The introduction of this 
cytokine could feasibly reduce the exuberance of an inflam-
matory response to infection and limit immunopathology. 
Actinobacillus pleuropneumoniae bacteria cause pleuropneu-
monia in pigs with extensive necrosis and hemorrhage. High  
levels of proinflammatory cytokines IL-1, IL-8 and TNF-a 
are detectable during such infections and are believed to con-
tribute significantly to the associated pathology. Subsequent 
administration of recombinant replication-deficient adenovi-
rus expressing IL-10 reduced inflammatory cytokine expres-
sion and pathological signs of pleuropneumonia [69]. Simi-
larly, IL-10 has been demonstrated to reduce lung injury in 
mice infected with Pseudomonas aeruginosa and improve sur-
vival to Klebsiella pneumoniae [70 ,71]. Conversely, introduction 
of exogenous IL-10 impaired host defences to S. pneumoniae 
and was detrimental [72]. Therefore, it can be envisaged that 
the merit of such manipulation is pathogen specific and it is 
critical to maintain a balance between proinflammatory and 
anti-inflammatory cytokine levels. 
It has been demonstrated that sensitization to G-protein of 
RSV induces a prominent Th2 response upon exposure to RSV, 
with chronic eosinophilia. However, administration of IL-12 to 
G-primed, RSV-infected mice prevents the eosinophilic 
response but synchronously augments illness and cachexia. This 
clearly demonstrates the potential to alter the phenotype of an 
elicited immune response by administration of recombinant 
cytokines but also emphasizes that there is the utmost require-
ment for balance in any modulation of immune response by 
cytokine therapy. A Th2 response may be detrimental but too 
strong a Thl response may also be damaging. 
Similarly, chemokines and other molecules that mediate the 
trafficking and accumulation of cells at an infected site pro-
vide attractive targets for such neutralization therapy [73]. 
Indeed, depletion of chemokines or adhesion molecules may 
be advantageous to targeting cytokines since they may poten-
tially permit more precise selectivity and control of immune 
effector mechanisms. 
It has been demonstrated that macrolide antibiotics confer 
protection from the pathological sequelae of several bacterial 
infections. However, it is anticipated that the efficacy of these 
drugs is not so much derived from their antimicrobial poten-
tial but rather their propensity to act as anti-inflammatory and 
immunomodulatory mediators. Macrolides have been demon-
strated to subvert the generation of the multifaceted immune 
response via a number of mechanisms [74]. They exhibit the 
potential to reduce chemotaxis of inflammatory cells, particu-
larly neutrophils, by inhibition of nuclear factor (NF)-KB acti-
vation and ensuing IL-8 release. Furthermore, macrolides 
reduce production of proinflammatory cytokines IL-1I3 and 
TNF-a and inhibit expression of adhesion molecules, such as 
intercellular adhesion molecule (ICAM)-1. There is also evi-
dence that these antibiotics inhibit ROS production and 
decrease airway mucus hypersecretion. It can therefore be 
envisaged that macrolides offer a novel therapeutic that may be 
manipulated to prevent or ameliorate respiratory infection 
associated pathology and illness. 
ROS and reactive nitrogen species (RNS) are potent path-
ogenic mediators elicited by the host's immune response. 
Antioxidants therefore confer a feasible therapeutic agent 
since they will not only limit oxidative stress but will also 
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limit the exuberance of the elicited response by suppressing 
ROS evocation of proinflammatory sequelae. Peroxynitrite 
is anticipated to be a causative agent of significant pathology 
and illness during influenza infections and various studies 
have demonstrated the potential to limit lung damage and 
inflammation in murine models by reducing superoxide or 
nitric oxide levels. One previous study investigated a murine 
model of influenza induced pneumonia in transgenic mice 
overexpressing extracellular superoxide dismutase and dem-
onstrated a reduction in both inflammation and lung injury 
[34]. Suppression of ROS/RNS levels is complicated practi-
cally due to the paradoxical role of these mediators in pro-
tection and pathology and the multifaceted functions they 
fulfil in host physiology and immunomodulation, which are 
only now being appreciated. 
T-cells are another component of the host's immune 
response that are frequently the cause of extensive pathology. 
Several strategies have been employed to modulate host 
T-cell responses to respiratory infection, such as depletion 
of T-cells, reduced antigen presentation and inhibition of 
costimulation by B7. However, all of these mechanisms will 
not only target T-cells activated in response to antigen chal-
lenge but also the peripheral T-cell repertoires and may 
render the host immunologically compromised. A novel 
mechanism to dictate host T-cell responses is via modula-
tion of the costimulatory signal imparted by OX40 [75]. 
OX40 is absent on naive T-cells and upregulated 1 to 2 days 
after antigen encounter. Therefore, investigation into this 
costimulatory signal has received heightened interest since 
its successful blockade could result in the selective targeting 
of only those T-cell subsets that have encountered antigen. 
The authors have demonstrated the potential to interrupt 
OX40/0X4OL signaling, through the administration of 
OX40:Ig, during influenza infection of the lung. An overex-
uberant T-cell response is a significant mediator of pathol-
ogy during influenza infection and administration of 
OX40:Ig ameliorated T-cell-mediated immunopathology 
and illness. Furthermore, murine and human OX40 display 
significant homology and human OX40 has been demon-
strated to reduce influenza-induced immunopathology in 
mice. Therefore, it is plausible that such a treatment may be 
applicable in humans. 
Selective T-cell depletion offers another strategy to 
manipulate the host's immune response and limit the 
pathology. In several diseases, discrimination must be made 
between Th1 and Th2 responses, with one conferring pro-
tection and the other eliciting damage. Selective depletion of 
a Th1 or Th2 population of CD4* cells may be beneficial 
but it is first mandatory to determine stable, reliable mark-
ers for each subset against which therapy can be targeted. 
Markers specific to the Th1 subset include chemokine 
receptors 1, 3 and 5 and IL-18 [76-78], whereas those specific 
to Th2 CD4* T-cells are chemokine receptors 3 and 4, tran-
scription factors c-maf and GATA-3 and orphan receptor 
T I /ST2 [76,79-81]. 
T1/ST2 is a member of the IL-1 receptor family and has 
been found to be expressed by pulmonary CD4+ T-cells dur-
ing Th2-driven eosinophilic RSV disease. Selective antibody 
depletion of this subset of CD4* T-cells has been shown to 
reduce cellular recruitment and ameliorate weight loss asso-
ciated with this Th2-driven immunopathology [82]. There-
fore, depletion of T1/ST2 T-cell subsets possesses plausible 
therapeutic potential in Th2 driven immunopathology. Sim-
ilarly, a recent study has demonstrated that up to half the 
population of pulmonary .CD4+ T-cells in Th2-driven G-
primed RSV infection expressed the V1314 TCR and selec-
tive depletion of this subset abolished the associated Th2-
induced pathology [83]. 
It is sometimes necessary to promote a protective T-cell 
response if an infection is to be successfully resolved. In 
mice, protection from C. neoformans infection depends on 
the genetic background of the inbred strain used. Resistant 
mice (CBA, C.B-17 and BALB/c) generally produce higher 
concentrations of Type 1 cytokines in response to 
C. neoformans infection. In contrast, susceptible strains 
(C57BL/6, C3H and B 1 0.D2) develop a Th2-driven pul-
monary eosinophilia and at the peak of pathogen burden up 
to 40% of airway cells are eosinophils. This response is non-
protective and results in tissue damage resulting from 
degranulation and crystal deposition by eosinophils. It 
would therefore be advantageous to promote a Thl response 
if we are to successfully eliminate C. neoformans infection. 
The authors have again manipulated the OX40 signaling 
pathway through the addition of an OX4OL:Ig that binds 
OX40 on the surface of T-cells and promotes a heightened 
response [84]. Addition of OX4OL:Ig during C. neoformans 
infection was demonstrated to selectively enhance IFN-y 
secreting CD4* T-cells, reducing pulmonary eosinophilia 
and controlling C. neoformans burden. Therefore, one can 
envisage a plausible therapeutic role for manipulation of this 
late costimulatory molecule in promoting T-cell immunity 
and selectively protecting from Th2-driven immunopathol-
ogy. Indeed, the authors have recently attempted to improve 
efficacy of the current BCG vaccine in conferring protection 
to M. tuberculosis challenge through the coadministration of 
OX4OL:Ig. It has been demonstrated that T-cell immunity 
to BCG is significantly enhanced by treatment with 
OX4OL:Ig and preliminary studies have suggested that 
M tuberculosis is more effectively controlled upon challenge 
[UNPUBLISHED DATA]. 
Conclusion 
The effective management and treatment of respiratory 
infections persists as a ubiquitous dilemma, with current 
therapeutics deficient in efficacy and practicality. The devel-
opment of protective vaccines and potent antimicrobial 
agents, whose primary objective is eradication of the invad-
ing pathogen, would be optimal for conferring widespread 
protection and avoidance of all infection-induced pathologi-
cal sequelae and illness. However, there remain significant 
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deficiencies in these treatments, and current vaccines are 
incapable of conferring protection against the considerable 
heterogeneity elicited by the infective agent and doubts con-
cerning the safety and immunogenicity of new vaccine can-
didates. Furthermore, current antimicrobial agents are in 
many cases largely ineffective and there are increasing inci-
dents of microbial resistance. More significantly, much of 
the illness and symptoms of respiratory infections only 
become apparent when pathogen burden has begun to sub-
side, leaving the practicality of administrating these drugs a 
considerable dilemma. The significant immunopathological 
component of respiratory illness makes modulation of 
immune responses an attractive therapeutic candidate. 
These treatments would be highly applicable in the allevia-
tion of symptoms and recuperation from illness, following 
the failure of traditional vaccines and antimicrobial, agents 
to rapidly resolve infection. However, immune manipula-
tion has predominantly been studied in animal models and 
it is uncertain whether such methods will be as effective 
when applied to human studies. Treatments must also con-
sider the specific pathogen infection and the genetics, age 
and immunological status of the host. Infection history and 
the presence of coinfections must also dictate the applicabil-
ity and direction of such treatments, as manipulation of a 
particular facet of the immune response may alleviate illness 
associated with one infection, yet enhance the severity of 
another. Furthermore, many of the plausible targets of 
immune modulation possess natural physiological roles and 
their manipulation may alter the homeostasis or viability of 
the host. 
Expert opinion 
Continued research into the development of protective vac-
cines and antimicrobial agents to counter respiratory infec-
tions is obligatory but therapeutics based on immune manip-
ulation will prove invaluable in a clinical setting through 
alleviation of illness. There is a demand for the translation of 
these treatments into clinical practice, a development that 
has thus far been hindered by the significant costs of these 
drugs. The most cost-effective production and appropriate 
management of immune modulatory therapeutics will 
undoubtedly lead to the development of a potent tool to 
combat respiratory infections. A preliminary and rapid 
screening of immunological status of the infected individual  
upon hospital admission may facilitate and optimize the use 
of these therapeutics. The combination of vaccines, antimi-
crobial agents and immune-modulatory therapeutics will ulti-
mately lead to an integrated, formidable barrier to counter 
any respiratory microbial challenge. 
Five-year view 
In the next 5 years we should see an introduction of novel 
therapeutics into the clinic. At the very least we need to 
increase awareness of the problems associated with respira-
tory infection in order to correctly manage these patients. 
Pivotal to this is the knowledge that by the time the patient is 
hospitalized it is the excessive immune response that causes 
the clinical manifestations and not necessarily replication of 
the pathogen itself. The `cytokine storm' initiated by the 
pathogen but produced by excessive immune cell activation 
is frequently the cause of localized and systemic pathology 
and illness. Such patients would clearly benefit from strate-
gies that dampen inflammatory mediators, such as anti-TNF 
therapy or inhibition of OX40. These, combined with antip-
athogen reagents, would provide the patient with the best 
chance for survival. It is difficult to select specific pathogens 
as a priority since all cause significant mortality. However, 
based on the recent severe acute respiratory syndrome 
(SARS) coronavirus scare, the alarming increase in tuberculo-
sis and the prediction of a new influenza pandemic, these 
pathogens would appear prime candidates. 
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iKey issues 
• Respiratory infections are the third leading cause of death worldwide. 
• Excessive immunity (immunopathology) in the lung leads to airway obstruction and death. 
• Current strategies aim to thwart pathogen replication or infection. 
• Symptoms often do not appear until immunity has begun to control the pathogen. 
• Immune modulation with antitumor necrosis factor or inhibition of 0X40 may be beneficial in serious, infection-related respiratory 
tract disease. 
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thussellgic.ac.uk  The respiratory tract is a portal to the external 
environment, with an estimated 10,000 
microorganisms being inhaled every day. It is 
credit to the host's efficient and multifaceted 
immune system that so few respiratory infec-
tions arise. Nonetheless, acute respiratory tract 
infections cause significant global morbidity 
and mortality. The WHO declared acute respi-
ratory infections to be the most extensive bur-
den of disease (in excess of 100 million cases 
reported in 2001), with the 2002 Global Bur-
den of Disease study revealing Just under 
4 million deaths attributable to such infections. 
Viral infections of both the upper and lower res-
piratory tracts are a constant threat to the popu-
lace, with the most common respiratory 
infections ascribed to viruses of the Paramyxo-
viridae, Orthomyxoviridae, Picornaviridae, 
Adenoviridae and Coronaviridae families. 
Current treatment strategies to combat respi-
ratory viral infection are vaccination or antiviral 
drugs. Vaccines confer protection against only a 
limited number of these pathogens, and where 
vaccines do exist they are hindered by the anti-
genic variability of the virus and/or problems 
with efficacy, safety and distribution. Similar 
dilemmas are encountered in the development 
of antiviral drugs; mutations in the influenza 
virus, for example, render it resistant to neu-
raminidase inhibitors and applicability is 
affected as symptoms occur at a time when viral 
titers are subsiding. It is now generally acknowl-
edged that many symptoms can be accredited 
not only to viral cytopathology but also to an 
excessive host immune response. Therefore, 
modulation of the host's immune response to 
infection will provide plausible therapeutic 
strategies to alleviate illness and pathology 
induced by respiratory viruses. 
This review will highlight some of the most 
studied acute respiratory infections, defining 
their associated immunity and pathology. 
Immunomodulatory strategies will subse-
quently be discussed, with the argument that 
many such 'immunotherapeutics' may provide 
generic relief against symptoms of multiple 
respiratory viral infections. 
Viral respiratory infections: 
a persistent problem 
Epidemiology 
Respiratory viruses colonize both the upper and 
lower respiratory tract. Most upper respiratory 
tract infections are attributable to viruses, 
although symptoms are generally transient and 
rarely fatal. Conversely, some viruses migrate to 
the lower respiratory tract with severe repercus-
sions, especially in the young, elderly and 
immunocompromised. Indeed, 95% of all 
deaths attributable to respiratory infections are 
caused by those targeting the lower respiratory 
tract. Table 1 depicts some of the most common 
human respiratory viruses to inflict morbidity 
and mortality. 
The common cold is the most frequent acute 
respiratory infection and the causative agent is 
generally rhinovirus. This member of the Picor-
naviridae family, whilst rarely causing serious ill-
ness, induces significant discomfort. In 2000, in 
excess of US$2 billion were spent in the USA on 
over-the-counter cold remedies ilk However, 
complications such as otitis media and sinusitis 
are not uncommon and more severe ramifica-
tions are seen in the elderly and those with 
underlying medical conditions [1,2]. 
Respiratory syncytial virus (RSV) and influ-
enza are two common respiratory viruses that 
also evoke significant morbidity and mortality. 
Acute respiratory tract infections cause approximately 4 million deaths globally each year. 
Current strategies to combat these infections include vaccines and antiviral drugs. However, 
a significant proportion of the pathology and illness induced by respiratory viral infection is 
attributed to an excessive host immune response, rather than the cytopathic nature of the 
pathogen. Distinct respiratory viruses elicit common immune mediators and cells, which are 
subsequently the cause of pathology. Therefore, strategies that seek to attenuate the 
potency of the host's immune response may provide generic relief from multiple 
respiratory infections. 
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Table 1. Common respiratory viral pathogens. 
Virus Family Genome Envelope Virion size Receptor for 
entry to cell 
Major antigenic 
determinants 
Rhinovirus Picornoviridae Single-stranded No Approximately ICAM-1 
(positive) RNA 30 nm 
RSV Paramyxoviridae Single-stranded Yes 120-300 nm GAG G & F glycoprotein 
(negative) RNA 
Influenza Orthomyxoviridae Single-stranded 
(negative) RNA 
Yes 80-120 nm Sialyated 
glycoproteins 
H & N 
SARS coronavirus Coronaviridae Single-stranded 
(positive) RNA 
Yes 60-220 nm Angiotensin 
converting 
enzyme-2 
Spike (51) protein 
Adenovirus Adenoviridae Double-stranded 
DNA 
No 90-100 nm Coxsackievirus B 
adenovirus 
receptor 
Capsid protein 
Hexon 
Metapneumovirus Paramyxoviridae Single-stranded Yes Approximately FIG proteins 
(negative) RNA 150 nm 
Human Paramyxoviridae Single-stranded Yes 150-200 nm Neuraminic acid HN and F 
parainfluenza virus (negative) RNA receptor glycoproteins 
F: Fusion; G: Attachment; GAG: Glycosaminoglycan; HN: Hemagglutinin-neuraminidase; ICAM: Intracellular adhesion molecule; 
RSV:  Respiratory syncytial virus; SARS: Severe acute respiratory syndrome. 
RSV is the principal cause of viral respiratory 
infections in infants, and although often 
self-limiting and cleared within 1 week, 1-2% of 
children require hospitalization for bronchiolitis. 
It is estimated that 70% of viral bronchiolitis 
cases are caused by RSV, with 91,000 hospital 
admissions in the USA each year alone [3,4]. RSV 
also causes disease within healthy adults, and is 
the cause of significant morbidity and mortality 
in the elderly, immunocompromised and those 
with underlying medical conditions such as 
cardiopulmonary problems 15-8]. 
Influenza, of the Orthomyxoviridae family, is an 
extremely variable and contagious respiratory 
virus, responsible for the seasonal epidemics that 
afflict 10-20% of the population [91, as well as the 
devastating pandemics that cause significant glo-
bal mortality. Influenza infection is generally 
self-limiting, causing fever, chills, headaches, 
myalgia and coughing. However, infection is 
more severe in the very young, the elderly, the 
immunocompromised and those with underlying 
medical conditions, frequently due to secondary 
bacterial infections [10,11]. The major concern is 
that a new influenza subtype will emerge giving 
rise to another pandemic. The 1918 Spanish 
influenza pandemic killed 20-40 million people 
and infected approximately half of the world's 
population. The source of the Spanish influenza 
pandemic is thought to be an avian reservoir and 
similar pathogenicity was observed during the 
avian flu outbreaks of recent times. 
Human parainfluenza virus (HPIV) is a mem-
ber of the Paramyxoviridae family and is respon-
sible for 30-40% of all acute respiratory 
infections in infants and children, causing the 
common cold with fever, croup, bronchiolitis 
and pneumonia [12]. However, infection can 
occur at any time throughout the life of an indi-
vidual, with the elderly and immunocompro-
mised once again being at greater risk 
from complications. 
Another important cause of respiratory illness 
are members of the Adenoviridae family, which 
elicit a wide range of upper and lower respiratory 
tract infections. A total of 51 distinct adenovirus 
subtypes exist, subdivided into species A-F and 
capable of infecting multiple organs 113.14]. It is 
believed that approximately 5% of acute respira-
tory illness in children under the age of 5 years is 
attributable to adenovirus infection [141. Adeno-
virus, although highly contagious, generally 
causes a self-limiting disease of short duration, 
but again can be more severe in immuno-
compromised individuals where it is frequently 
life threatening [15]. 
Metapneumoviruses are a genus that, until 
recently, were known only to infect avian species 
and were not associated with human disease. 
Human metapneumovirus (hMPV) was discov-
ered in 2001 and detected across every 
continent. Infection symptoms are indistin-
guishable from RSV, ranging from mild respira-
tory symptoms to severe bronchiolitis and 
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pneumonia. hMPV is the causative agent in 
12% of young children with lower respiratory 
tract infections, and can also cause severe disease 
in the elderly and immunocompromised 1161. 
The virus itself exhibits significant antigenic and 
genetic diversity and re-infection is common. 
In November 2002, an outbreak of severe acute 
respiratory syndrome (SARS) occurred in the 
Guangdong province of China [17]. This is an 
example of an emerging respiratory infection that 
causes pneumonia, and is caused by a novel coro-
navirus (SARS-CoV) MM. Up until 31st July 
2003, there had been 8096 reported cases of SARS 
with 774 deaths — a fatality rate of 9.6% [17]. The 
pathogenesis of this infection, however, is unclear 
and so strategies to immunomodulate the ensuing 
illness await characterization. 
Immunity & pathology 
Upon infection, the host mounts a vigorous 
innate and adaptive immune response (Figure 1A). 
Despite respiratory viral infections being a sig-
nificant cause of morbidity and mortality, it is a 
credit to the host's mucosal immune system that 
such a paucity of deaths follow. However, the 
excessive potency of the host's immune response 
to infection is frequently a cause of much of the 
observed pathology and illness, with excessive 
recruitment of inflammatory cells significantly 
compromising efficient gas exchange (Figure 2). 
Many of the mediators released and cells 
recruited are common between disparate viral 
infections, and are also frequently affiliated with 
the shared pathology and illness. 
The production of chemokines and cytokines 
is critical to the establishment and resolution of a 
coordinated and robust inflammatory response, 
but consequently are linked frequently with the 
over-exuberance of the elicited response and ensu-
ing immunopathology. Inflammatory mediators, 
such as tumor necrosis factor (TNF), interleukin 
(IL)-6, -8, -1a, -1f3, interferon (IFN)-a and 
macrophage inflammatory protein (MIP)-1 a 
have all been implicated in influenza driven dis-
ease 120-24]. Similarly IL-1, -8, -6 and TNF are 
observed in the nasal lavage of RSV-infected indi-
viduals and implicated in observed illness and 
lung damage [251, with TNF being demonstrated 
to be the dominant mediator of RSV-associated 
illness [26]. Rhinovirus infection also induces his-
tamine, prostaglandins, IL-1, -6 and -8 that corre-
late with mucus secretion, vascular dilation, fever 
and stimulation of cough and sneeze reflexes [27]. 
SARS is an emerging respiratory viral infection, 
and whilst our understanding of immunity and  
pathology is still in its infancy, it would appear 
that there is a correlation between the same 
inflammatory cytokines, and illness and pathol-
ogy, with elevated levels of IL-1, -6, -8, TNF, 
monocyte chemoattractant protein (MCP)-1 and 
IFN-inducible protein (IP)-10 evident in the 
serum of SARS patients [28-30]. In addition to the 
production of cytokines, macrophages and neu-
trophils recruited to the site of infection elicit 
damage through the production of superoxide 
radicals and nitric oxide. The lack of specificity of 
these mediators implicates them in lung pathology 
through damage to surrounding tissues. 
A major effect of inflammatory cytokines on 
illness during respiratory infection is likely to 
reflect their release into systemic compartments 
with ensuing interactions with distant organs 
such as the hypothalamus of the brain. However, 
they may also act within the lung microenviron-
ment. An absence of IFN-a/(3 receptors results in 
a seven to eight-fold reduction in cellularity in 
pneumovirus infection of mice [31]. Similarly, 
inflammatory pathology to influenza infection is 
reduced in IL-1 receptor knockout mice [32]. 
Furthermore, TNF receptors (R) 1 and 2 are 
expressed by alveolar epithelial cells; a site of pre-
dominant respiratory viral replication. Engage-
ment of viral antigens by CD8+ T cells causes 
TNF release, which directly affects the infected 
cell at the point of contact [33]. The impact of 
local versus systemic effects of inflammatory 
cytokines, however, is yet to be elucidated. 
The coordinated release of cytokines is instru-
mental in the development and shaping of a spe-
cific T-cell response. This response is critical for 
the clearance of many respiratory viral infec-
tions, but excessive recruitment again leads to 
bystander damage. Substantial accumulation of 
both CD4+ and CD8+ T cells within the alveolar 
spaces of the lung severely compromises efficient 
gaseous exchange, and the mediators they pro-
duce are implicated in pathology and clinical 
signs of illness. Indeed, T-cell depleted mice sug-
gest they are the primary determinant of disease 
status during influenza and RSV infection [34,35]. 
In the absence of T cells, there is a delay in viral 
clearance but significantly reduced lung inflam-
mation and injury. Furthermore, the adoptive 
transfer of hemagluttinin (HA)-specific CD8+ 
cytotoxic T cells into transgenic mice that con-
stitutively express HA antigen on their lung cells 
gave way to lethal lung injury 1361. Similarly, 
T-cell-derived IFN-y is affiliated with lung dam-
age and impairment of lung function during 
influenza and RSV-driven lung disease [37,38]. 
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Figure 1. Immune response to respiratory viral infection. 
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Respiratory viruses primarily infect airway epithelia and cells such as 
macrophages that are resident to the naive airways of the host. Infection of 
these cells elicits the production of antiviral mediators such as IFN-a, as well as 
an array of cytokines and chemokines (depicted as small circles) that form a 
gradient and cause further recruitment of inflammatory cells, such as 
neutrophils, from the blood and into the infected site. These cytokines will also 
act to activate cells within the infected tissue, evoking a heightened microbial 
capacity within macrophages, and activating NK cells to kill infected cells. 
NK: Natural killer. 
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Autopsies of SARS patients reveal the alveoli to 
be flooded with inflammatory cells, thus imply-
ing that excessive recruitment and occlusion of 
airways is also a cause of pathology and illness in 
these individuals [39]. 
Immune modulation to combat 
respiratory virus-driven illness 
Limitations persist with the current treatments 
that are available to combat respiratory viral 
infection, and the significant role of the Immune 
response in pathology and illness makes immune 
modulatory drugs a plausible therapeutic strat-
egy. Furthermore, it is apparent that common 
mediators and cells elicit pathology in disparate 
viral infections, and thus modulation may confer  
generic protection against multiple infections. 
Immune therapeutics may also offer protection 
against new variants and emerging respiratory 
viral infections where epidemiology and our 
understanding are in their infancy, such as SARS 
and avian influenza. 
Cytokines 
Cytokines are fundamental in the inflammatory 
response to respiratory infection and are hence 
tightly affiliated with protection and pathology. 
During RSV and influenza virus infection, 
cytokines induce significant pathology and ill-
ness primarily due to their excessive production. 
Neutralization of TNF, through the use of anti-
bodies, reduces weight loss, illness and 
pathology 120,251 during influenza and RSV infec-
tions, and neutralization of TNF is being consid-
ered as a therapeutic strategy to combat SARS 
driven illness and pathology. IFN-a, IL-la, -1(3, 
-6, -8 and various MIPs are also implicated in 
influenza associated fever, lethargy and 
cachexia [21.23,24]. Administration of antiserum to 
IFN-a and IL-la reduces fever in mice. 
Chemokines 
Chemokines are responsible for the recruitment, 
migration and retention of immune cells during 
respiratory viral infection and essentially amplify 
the host's immune response. Subsequently, the 
blockade of chemokines with neutralizing anti-
bodies is a rational strategy to alleviate illness 
that is induced by an excessive immune response. 
The pneumonia virus of mice (PVM) is highly 
lethal and demonstrates a comparable pathology 
and infection profile to the most severe cases of 
RSV in humans. A combination of antivirals 
(ribavirin) and anti-MIP-1 a synergizes to reduce 
mortality in PVM-infected mice, whereas 
antiviral or anti-MIP-1 a alone has no effect [40]. 
Chemokine receptors are also increased during 
respiratory viral infection, for example CXCR3 
during murine gamma-herpes virus b8 
infection [4i]. Antagonism of CCR1 reduces 
mortality of pneumovirus-infected mice [42]. An 
absence of CCR1 also prevents the RSV-induced 
exacerbation of asthma [43]. 
Reactive oxygen/nitrogen species 
Reactive oxygen species (ROS) and reactive nitro-
gen species (RNS) are generated by professional 
phagocytes in response to viral infection, but their 
excessive production, extreme toxicity and lack of 
specificity implicates these mediators in pathol-
ogy. Furthermore, ROS fulfill a significant role in 
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Figure 2. Immune response to respiratory viral infection. 
Antigen-presenting cells, such as dendritic cells, loaded with the viral antigen track 
to the draining mediastinal lymph node to activate CD4+ and CD8* T cells. 
Activated virus-specific T cells are subsequently recruited back to the lung where 
they directly kill virus-infected cells, release cytokines that activate other cells and 
augment further infiltration, and facilitate antibody production by B cells. 
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the amplification of inflammatory responses 
through the modification of redox-sensitive tran-
scription factors. The utilization of anti-oxidants 
offers a potential therapeutic strategy to limit 
inflammation in the lung. Consequently, a 
decrease in peroxynitrite (formed by the union of 
superoxide and nitric oxide) reduces mortality 
rates in influenza-induced pneumonia [44], and 
transgenic mice over-expressing extracellular 
superoxide dismutase (SOD) exhibit reduced 
inflammation and lung injury. Previous studies 
that have attempted to limit oxidative stress via 
manipulation of endogenous SODs for therapeu-
tic purposes have had limited success, owing to 
the large molecular weight and short half life of 
such compounds. A new generation of SOD 
mimetics offer a more plausible therapeutic strat-
egy owing to their increased half life and lower 
molecular weight [45,46]. 
Manipulation of myeloid cells 
Myeloid cells (macrophages, neutrophils, den-
dritic cells, mast cells, eosinophils and basophils) 
represent a population of immune cells with plei-
otropic functions that form a formidable barrier 
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to combat an infective agent, and are the source of 
many of the mediators discussed previously that 
induce pathology. In addition to regulation by sol-
uble mediators, these cells can also be switched on 
or off via receptors expressed on their cell surface. 
This requires contact with other cells and offers 
more specificity compared with inhibiting soluble 
mediators. Manipulation of the myeloid immune 
compartment through these surface receptors may 
confer an alternative therapeutic strategy to selec-
tively restrain the evoked immune response. For 
example, CD200R is present on the surface of 
macrophages, dendritic cells, mast cells and neu-
trophils. Ligation of this receptor by CD200 
delivers an inhibitory signal to the myeloid 
cell [47.48]. Although research on this molecule is 
in its infancy, reagents that bind CD200R amelio-
rate illness severity in a variety of auto-immune 
conditions (49-5q. Similar to certain respiratory 
infections, autoimmune conditions are associated 
with a dysregulated inflammatory response. It is 
therefore feasible that the beneficial effects seen 
with autoimmune disease may translate into these 
infection scenarios. In addition, signal regulatory 
proteins (SIRPs) can promote or inhibit respon-
siveness 152,531 and may also shape the myeloid 
immune response to either promote pathogen 
clearance or reduce immunopathology. 
Innate imprinting 
Instead of manipulating immunity, it is possible 
to educate the lung microenvironment so that it 
responds to a respiratory infection with more 
restraint: a process known as innate imprinting. 
This concept stems from studies demonstrating 
that prior infection with influenza protects against 
RSV-induced immunopathology and lym-
phocytic choriomeningitis virus (LCMV) - 
infected mice exhibit heightened clearance of the 
unrelated vaccinia virus [54,55]. The outcome of 
infection history depends on the precise sequence 
of pathogens encountered. Influenza, for example, 
inhibits vaccinia replication but enhances LCMV 
and murine cytomegalovirus (MCMV). The criti-
cal determinant appears to be the level of lym-
phocytic infiltrate during the second infection [56]. 
Bacterial Bacille Calmette Guerin (BCG) infec-
tion in the lung also promotes immunity to subse-
quent pulmonary infection with the fungal 
pathogen Cryptococcus neoformans [571. In most, 
but not all cases, the improved outcome to the 
second infection is not explained by cross-reactiv-
ity in T- and B-cell antigens. Rather it is believed 
the alteration is in the lung environment itself or 
in innate immune cells. 
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Figure 3. Strategies for the manipulation of immunity to respiratory infection. 
An efficient and robust response to a pathogen is critical to the successful resolution of infection. However, a 
degree of control and subtlety in the mounted immune response is a necessity to avoid unwanted self 
damage. The activity of immune cells or levels of inflammatory mediators can be modulated to reduce the 
exuberance of the host's response and ameliorate illness and pathology. Control of the immune system cells 
is partly mediated through cell—cell contact. Such cell contact interactions are important in T-cell activation by 
antigen presenting cells, with manipulation of their signaling having been utilized to modulate immunity to 
infection. For example, blockade of the signal imparted to the T cell through 0X40 reduces the potency of 
the T-cell response. Similarly, it is becoming apparent that a number of such proteins exist that are involved in 
the regulation of myeloid cells. CD200R and signal regulatory protein-a are examples of myeloid-specific 
receptors with immunoglobulin superfamily domains that can deliver inhibitory signals to the myeloid 
compartment. Immune cell function and activity is also modulated by the release of soluble factors. 
Pro-inflammatory cytokines and chemokines are produced by both myeloid cells and T cells in response to 
viral infection and have been affiliated with excessive inflammation and illness. Depletion of cytokines, such 
as TNF, has been demonstrated to reduce inflammation and pathology in some respiratory viral infections. 
Similarly, reactive oxygen species and reactive nitrogen species produced by myeloid cells can also cause 
pathology within the lung due to their extreme toxicity and lack of specificity. 
IFN: Interferon; IL: Interleukin; MHC: Major histocompatibility complex: MIP: Macrophage inflammatory 
protein; RNS: Reactive nitrogen species; ROS: Reactive oxygen species; SIRP: Signal regulatory protein; TCR: T-
cell receptor; TNF: Tumor necrosis factor. 
Evidence for long-term modification of the 
innate immune compartment is provided by 
studies where microbial products, such as CpG 
DNA or a modified bacterial labile toxin 
(LTK63), afford protection against an array of 
subsequent respiratory pathogens 158,591. This 
phenomenon of 'innate imprinting' can be 
defined as 'the long-term modification of a 
microenvironment, which will consequently 
lead to a nonspecific, but more protective,  
immune phenotype to a subsequent pathogen 
(Figure 4). LTK63 reduces inflammation and pre-
vents immunopathology and illness associated 
with RSV and influenza virus infection 1581. 
Furthermore, elimination of RSV is not com-
promised and clearance of influenza is actually 
improved. The protective effect conferred by 
LTK63 lasts up to 12 weeks after administra-
tion and is associated with the maturation of 
myeloid cells. The protective effect conferred 
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Figure 4. Innate imprinting causes long-term modification of the lung microenvironment, conferring 
protection against subsequent influenza infection. 
Influenza infection in a host without innate imprinting 
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A 
	
C 
(A) In a naive host, viral infection induces a highly inflammatory microenvironment, and antigen-presenting cells loaded with the viral 
antigen track to the draining lymph node to activate CD4' and CM+ T cells. (B) Further inflammatory cytokines, produced by unchecked 
viral replication, recruit a large inflammatory infiltrate that eventually occludes the airways. (C) In hosts where the lung has been 
'imprinted', the epithelia and myeloid cells that constitute the localized microenvironment respond with more subtlety towards the 
invading virus, leading to a reduced inflammatory infiltrate (D), which is sufficient to clear the virus, but causes minimal 
immunopathology. 
by LTK63 does not depend on T and B cells, 
since innate imprinting can be induced in mice 
lacking T and B cells (recombinase activating 
gene [RAG] knockout mice). This clearly 
defines a long-lasting modulation that has 
occurred at the level of the environment or 
innate immune compartment. Activation of 
innate immunity in this manner has clear ther-
apeutic potential and may even be beneficial in 
patients with acquired immune deficiency. The 
immunotherapeutic approach of innate 
imprinting provides an alternative prophylactic 
treatment to classical vaccination strategies for 
combating respiratory pathogens. Furthermore, 
the protection afforded is nonspecific, negating 
ubiquitous problems with antigen specificity 
and could confer generic protection against an 
array of respiratory pathogens. 
Modification of T cells 
T cells are significant mediators of pathology 
and illness during respiratory viral infection 
through the occlusion of airways and release of 
various mediators. Strategies that limit the exu-
berance of the host's T-cell response may poten-
tially limit virus driven immunopathology. 
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Preliminary attempts to limit T-cell-driven 
pathology involved depletion of T cells or block-
ade of antigen presentation. Such strategies, 
however, may be too broad, since they will com-
promise viral clearance and target all T-cell pop-
ulations rather than those just involved in the 
respiratory infection response. By contrast, the 
authors have recently shown that blockade of the 
late T-cell expressed co-stimulatory molecule 
OX40 alleviates illness and pathology to 
influenza without compromising pathogen 
clearance 160]. The benefit of using such a strat-
egy is that it leaves the naive and resting memory 
T-cell pool intact since OX40 is only expressed 
1-2 days after activation of the T cell by an anti-
gen. The short-term depletion of late co-stimula-
tory molecule expressing T cells achieved 
through such a manipulation does not seem to 
impair memory, and mice elicit an appropriate 
recall response to a secondary influenza infec-
tion. However, their complete absence (as seen in 
knockout mice studies) has been demonstrated 
to impair CD81 T-cell memory 161-631. 
Instead of depleting antigen reactive T cells, 
it is also possible to remove specific subsets 
based on their phenotype. Protection against 
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RSV infection is afforded, for example, by a 
type 1 T helper cell (Thl)-driven immune 
response and induction of pathology can occur 
due to the induction of a Th2-skewed response 
resulting in pulmonary eosinophilia. In this 
instance, it may prove beneficial to eliminate 
the Th2 population to drive a more protective 
Th 1 response. Markers specific to the Thl sub-
set include chemokine receptors 1, 3 and 5 and 
IL-18 [69-66], whereas those specific to Th2 
CD4* T cells are chemokine receptors 3 and 4, 
transcription factors c-maf and GATA-3 and 
orphan receptor T1/ST2 [64.67-69]. Selective 
depletion of T1/ST2-expressing CD4+ T cells 
during Th2 driven eosinophilic RSV disease 
reduces weight loss and cellular recruitment. 
Similarly, a recent study demonstrated that up 
to half of pulmonary CD4+ T cells in Th2-
driven RSV infection express the Vi314 T-cell 
receptor (TCR) and selective depletion of this 
subset abolishes Th2-induced pathology [70]. 
Conclusion 
Respiratory viral infections are a ubiquitous 
cause of morbidity and mortality, and a con-
certed effort to develop efficacious therapies is 
required. Traditional therapeutic strategies of 
vaccination and administration of antiviral 
drugs would be optimal in conferring wide-
spread protection through promoting patho-
gen clearance and preventing all subsequent 
pathological sequelae and illness. However, 
attempts to develop protective vaccines against 
respiratory viral infection have proved prob-
lematic, largely due to antigen variation of the 
pathogen. The development of antiviral treat-
ments is hindered by problems with efficacy, 
safety and resistance. Furthermore, it is now 
acknowledged that the symptoms of respira-
tory virus-driven illness are most severe at a 
time when viral titers have already begun to 
subside. The exuberance of the host's immune 
response to respiratory viral infection is now 
anticipated to contribute to the observed 
pathology and illness. Subsequently, the devel-
opment of immune therapeutics that act to 
limit the potency of immunity offer plausible 
treatment strategies. 
It can be seen that with many respiratory 
viral infections, even those that are still poorly 
understood, the same components of the host's 
immune response are tightly affiliated with ill-
ness. For example, elevated TNF levels are seen  
frequently in respiratory viral infections and 
are affiliated with excessive inflammation and 
illness, whilst an over-zealous T-cell response 
also causes significant pathology. Therefore, 
strategies that seek to limit the levels of such 
mediators or cells may provide generic protec-
tion against multiple respiratory infections. 
Such therapies could prove to be an extremely 
important and potent facet of our arsenal to 
combat respiratory viral infections, especially 
when vaccines and drugs are ineffective or an 
extensive knowledge of the invading pathogen 
is lacking. 
Future perspective 
Within the next 5-10 years, it is anticipated 
that some of the immune therapeutic strategies 
discussed will be tested in a clinical setting. 
There will continue to be problems with the 
development of vaccines and antiviral drugs. 
Whilst continued development and progress in 
these areas is essential, immune therapy will 
provide an alternative when traditional treat-
ments have failed. Experiments in mice have 
proven the potential of immune modulation in 
ameliorating respiratory virus-driven illness and 
pathology, however, applicability and efficacy 
in humans may be more challenging. Neverthe-
less, the administration of anti-TNF has proven 
to confer much relief in the treatment of condi-
tions, such as rheumatoid arthritis and Crohn's 
disease, and such a treatment strategy may be 
the optimal choice in studies involving respira-
tory viral disease. The major concern, however, 
is the effect of manipulating immunity to a 
viral infection when a coinfection persists. Bac-
terial coinfections are common in people suffer-
ing from certain respiratory viral infections, 
and neutralization of TNF is known to be det-
rimental to clearance of many bacteria. It is 
therefore essential that further studies assess the 
applicability of strategies that dampen immu-
nity when coinfecting bacteria are present. At 
present, there are fears of a new influenza pan-
demic, and such immunotherapeutic strategies 
may prove to be a real asset in such a scenario 
where no protective vaccine will be available 
and antiviral drugs will be in short supply. 
There will always be inherent risks in the appli-
cation of such treatment regimens, but, if used 
intelligently and appropriately, they may 
provide an additional line of protection against 
respiratory viral-induced illness. 
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Executive summary 
• Respiratory viral infections are a significant cause of global morbidity and mortality, responsible for approximately 4 million deaths 
each year. 
• Current strategies to combat respiratory viral infection include vaccination and administration of antiviral drugs. These strategies 
have limitations in effectiveness and applicability and in many cases are completely lacking. 
• Peak illness is frequently seen at a time when viral titers have begun to subside and correlates with excessive inflammation. 
• Neutralization of inflammatory cytokines or strategies to reduce T-cell infiltrate offer plausible therapeutic potential and have been 
shown to reduce pathology and illness in mice. 
• It is possible to 'educate' the lung microenvironment with microbial products to induce more restraint to a subsequent viral 
infection, thus limiting immunopathology. 
• Many of the immune mediators responsible for pathology and illness are shared between distinct respiratory viral infections and 
thus modulation of their levels may confer generic relief from multiple viruses. 
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Innate Imprinting by the Modified Heat-Labile Toxin of 
Escherichia coli (LTK63) Provides Generic Protection against 
Lung Infectious Disease 
Andrew Evan Williams,2* Lorna Edwards,* Ian Robert Humphreys,* Robert Snelgrove,* 
Aaron Rae,* Rino Rappuoli,t and Tracy Hussell* 
In a healthy individual, the lung contains few lymphoid cells. However, amplified immune responses, as exemplified during lung 
infection, can cause extensive tissue damage. We have previously demonstrated that one lung infection modulates the immuno-
pathological outcome to a subsequent unrelated pathogen. Mimicking heterologous immunity may provide a means of enhancing 
both innate and acquired immunity. We now show that prior lung administration of a modified heat-labile toxin from Escherichia 
coli (LTK63) enhances immunity to respiratory syncytial virus, influenza virus, and the fungus Cryptococcus neoformans. Treat-
ment with LTK63 decreased lung inflammation and tissue damage and improved the ability to resolve the infection. APCs 
expressing the activation markers MHC class II, CD80, and CD40 increased in number in the lung. LTK63 treatment increased 
the pathogen-specific IgA response in the nasal mucosa and simultaneously decreased inflammatory cytokine production (IFN-y 
and TNF-a) after infection. The number of activated CD8+CD44+ T cells and the respiratory syncytial virus- or influenza-specific 
CD8-proliferative responses increased, although the total inflammatory infiltrate was reduced. LTK63 treatment matured lung 
APCs (LTK63 prevented efficient presentation of whole OVA to D011.10 cells, whereas OVA peptide presentation was unaf-
fected), enhanced immunity in both a Thl and Th2 environment, was long lasting, and was not pathogen or host strain specific; 
the protective effects were partially independent of T and B cells. Innate imprinting by toxin-based immunotherapeutics may 
provide generic protection against infectious disease in the lung, without the need for coadministered pathogen-specific Ag. The 
Journal of Immunology, 2004, 173: 7435-7443. 
M ost human pathogens enter and infect their host across a mucosal surface, in particular the gastrointestinal tract or respiratory tract. However, most vaccines are 
poorly immunogenic when delivered mucosally. This is due to a 
combination of factors including Ag dilution or denaturation and 
tight immune regulation at mucosal surfaces. Effective mucosal 
vaccination against pathogens therefore often requires the code-
livery of an adjuvant, although a suitable mucosal adjuvant that is 
both immunogenic and safe for human use has yet to be developed. 
Potential adjuvant candidates have been proposed including chol-
era toxin (CT),3 heat-labile enterotoxin (LT) from Escherichia 
coli, DNA that contains immunostimulatory CpG motifs, and the 
codelivery of cytokines, although they are either too toxic or in-
sufficiently immunostimulatory for approval status. 
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Due to the toxicity of native CT, and specifically wild-type LT 
(1), several LT mutants have been produced with single-point mu-
tations that inhibit or completely prevent the ADP-ribosylating en-
zyme activity of the A subunit. These LT mutants are nontoxic but 
still retain their ability to bind cellular membranes through the B 
subunit and maintain their immunogenicity (1, 2). The nontoxic 
LT mutant LTK63 has a serine to arginine substitution at as 63 of 
the A subunit. Coadministration with candidate vaccines enhances, 
e.g., the cytotoxic T cell response to HIV gag-p55 (3) and respi-
ratory syncytial virus matrix proteins (2), increases the protective 
efficacy of the VacA protein of Helicobacter pylori lysate (4) and 
induces Ab to tetanus toxin when delivered transcutaneously 
(5). Delivery via the respiratory tract improves the efficacy of 
the group C meningococcal conjugate vaccine (6) and enhances 
immunity to the SAG1 Ag of Toxoplasma gondii (7). The re-
sponse induced by LT and related LT mutants depends on the 
degree of retained enzymatic activity. Intact LT synergizes with 
CpG to improve immunity to hepatitis B surface Ag, whereas 
nonenzymatic LTK63 does not (8). Coadministration of LTK63 
with pertussis Ag enhances both Th 1 immunity to Bordetalla 
pertussis, whereas the partially detoxified mutant LTR72 pro-
motes a Th2 environment (9, 10). 
The mechanism of how nontoxic LT adjuvants function in the 
context of enhancing protective immunity to an invading pathogen 
is poorly understood. In particular, the influence of LT mutants 
alone on subsequent immune responses has received little atten-
tion. We, and others, have previously shown that prior lung infec-
tion modulates subsequent immunity and pathology to subsequent 
unrelated pathogens (11, 12). We now show that administration of 
LTK63 prevents the immunopathology associated with a number 
of respiratory pathogens. We use several mouse models of lung 
0022-1767104/502.00 
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infection, including the BALB/c model of respiratory syncytial 
virus (RSV) infection as it provides a useful tool for the study of 
virus-induced lung immunopathology and mimics the pathology 
observed in human infants after formalin-inactivated RSV vacci-
nation. Mice primed with the attachment protein G of RSV (ex-
pressed by a recombinant vaccinia virus construct rVV-G) and 
then challenged with live RSV develop Th2-driven pulmonary eo-
sinophilia, weight loss, and cachexia (13). Influenza virus infection 
of BALB/c mice results in acute pulmonary inflammation and 
weight loss, providing a model for Thl-induced immunopathol-
ogy. Furthermore, a model of nonviral lung infection is pro-
vided by infection of susceptible C57BL/6 mice with the fungus 
Cryptococcus neoformans, which induces severe Th2-driven 
eosinophilia. 
Intranasal treatment of mice with LTK63 reduced the cellular 
inflammation in the lung, abolished pulmonary eosinophilia and 
weight loss, but did not affect RSV clearance. The immunomodu-
latory effect of LTK63 was dose dependent, reliant on administra-
tion into the lung, was associated with a Thl cytokine profile and 
APC maturation. Similarly, prior treatment with LTK63 greatly 
reduced pathology, inflammation, and pathogen burden afater se-
vere influenza virus and C. neoformans lung infection. Alteration 
of the lung microenvironment by nontoxic LTK63 may therefore 
provide generic protection against a number of lung infectious dis-
eases by a phenomenon of immune modulation we now term "in-
nate imprinting." This immunotherapeutic approach provides an 
alternative prophylactic treatment to contemporary vaccination 
against respiratory pathogens. 
Materials and Methods 
Mice and virus stocks 
Female BALB/c, C57BL/6, or RAG1 knockout mice (Harlan Olac, Bices-
ter, U.K.), 8-10 wk old, were kept in specified-pathogen-free conditions, 
according to institutional and Home Office (U.K.) guidelines. RSV (A2 
strain) and rVV-G were grown in HEp-2 cells and assayed for infectivity 
(14). All stocks were free of Mycopiasma as determined by DNA hybrid-
ization (Gen-Probe, San Diego, CA). Influenza A strain X31 (hemagglu-
tinin (HA) titer 1024) was a gift from Dr. A. Douglas (National Institute for 
Medical Research, London, U.K.). C. neoformans strain 52 was obtained 
from the American Type Culture Collection (ATCC), Manassas, VA 
(ATCC 24067). Yeast were cultured in Sabouraud dextrose broth (1% 
neopeptone and 2% dextrose; Difco, Detroit, MI) for 48-72 h until the 
stationary phase was reached, and mice were infected intranasally (i.n.) 
with 1-2 x 104 yeast cells/m1 in 50 gl of sterile PBS. 
Experimental procedure 
BALB/c mice were immunized i.n. with 0.2-5 gg nontoxic heat-labile 
toxin, LTK63 (Chiron S.p.A., Siena, Italy; LTK63 was free of physiolog-
ically significant levels of endotoxin as measured by the LAL system; 6.4 
endotoxin U/mg) or 50 al of PBS as indicated in the text. In some exper-
iments, lung compartments were sampled on days 0-14 after LTK63 treat-
ment. In others, mice were treated with LTK63 or PBS 2 wk before lung 
infection three times at weekly intervals. To examine the effect of LTK63 
on Thl -mediated immune pathology, mice were infected i.n. with 50 HA 
units of influenza virus X31. For Th2-mediated immune pathology, mice 
were dermally scarified with rVV-G and challenged i.n. 2 wk later with 
5 x IV PFU of RSV (A2 strain) or with 1-2 X 104 yeast/ml C. neofor-
mans. To determine the long lasting effects of LTK63, some mice were 
scarified with rVV-G and challenged with RSV 12 wk after LTK63 treat-
ment. Mice were monitored daily, and weight loss was measured through-
out infection. Mice were killed at various time points by the injection of 3 
mg of pentobarbitone and exsanguination of the femoral vessels. 
Cell recovery 
Bronchoalveolar lavage (BAL) fluid, lung tissue, and serum were obtained 
from each mouse as described previously (15). In brief, lungs were inflated 
six times with 1.5 ml of EMEM (Sigma-Aldrich, Dorset, U.K.) containing 
10 mM EDTA and kept on ice; 100 pi of this BAL fluid were cytocentri-
fuged onto glass slides, fixed in methanol, and stained with H&E (Sigma-
Aldrich). The remainder was centrifuged, the supernatant and decanted,  
and the cell pellet was resuspended to 1 X 106 cells/nil in RPMI 1640 
containing 10% FCS, 2 mM 1.-glutamine, 50 gg/tn1 penicillin, and 50 
ps/m1 streptomycin (R1OF). Lung tissue was disrupted using 0.8-gm pore 
size filters to obtain single-cell suspensions, the RBC were lysed, and the 
cell pellet was resuspended at 1 X 106 cells/ml in R1OF. Cell number was 
quantified using a hemocytometer and trypan blue exclusion. A single lobe 
of lung tissue was fixed in 2% formaldehyde and embedded in paraffin. 
Sections were stained with H&E. 
Enumeration of eosinophils 
Eosinophils were enumerated by flow cytometry based on their size (for-
ward scatter) and granularity (side scatter). From cytospin preparations, the 
proportion of eosinophils was confirmed by their distinctive nuclear mor-
phology and presence of acidophilic red granules. Neutrophils were iden-
tified by the presence of a multilobed nucleus and the absence of acido-
philic granules. 
Flow cytometry 
Cells (1 X 106) obtained from the airways or the lung were stained with the 
following Ab combinations: 1) anti-CD44-PE, anti-CD45RB-FITC, anti-
CD4-APC, and anti-CD8-PerCP; 2) anti-B220-PerCP, anti-I-Ad/I-Ed-FTTC, 
anti-CD8O-PE, and anti-CD40-APC; 3) to detect intracellular cytokines, 1 X 
106 cells were incubated with 50 ng/ml PMA (Sigma-Aldrich), 500 ng of 
ionomycin (Calbiochem, San Diego, CA), and 10 gg/m1 brefeldin A (Sig-
ma-Aldrich) for 4 h at 37°C. Cells were stained with anti-CD4-APC and 
anti-CD8-PeiCP on ice for 30 min, washed, and then fixed in 2% formal-
dehyde for 20 min at room temperature. Cells were permeabilized with 
0.5% saponin in PBS containing 1% BSA and 0.1% azide for 10 min. A 
combination of anti-TNF-a-FITC or anti-IFN-y-FITC and anti-IL-4-PE or 
anti-IL-5-PE Abs, diluted in saponin buffer, was then added to the cells. 
After 30 min, cells were washed once in saponin buffer and twice in PBS 
containing 0.1% azide and 1% BSA; and 4) TCR vp expression was de-
termined on cells stained with anti-CD4-PerCP and anti-CD8-APC using 
the screening panel kit from BD Biosciences (Oxford, U.K.), which con-
tains FITC-conjugated Abs to 15 different murine VI3 gene products. Sam-
ples were analyzed on a FACSCalibur (BD Biosciences), collecting data on 
at least 30,000 lymphocytes. 
RSV- and influenza-specific proliferation assays 
Spleens were removed from individual mice under sterile conditions and 
passed through a 0.8-gm pore size filter to produce a single-cell suspen-
sion. After RBC lysis in 0.15 M ammonium chloride, 1 M potassium 
hydrogen carbonate, and 0.01 mM EDTA, pH 7.2, spleen cells were re-
suspended in R1OF medium at 2 x 106 cells/ml. To each well of a round-
bottom 96-well plate, 4 X 105 cells were added together with 25 p..g of 
purified G protein t84 _198 peptide (AICKRIPNICKPGKICT). Control wells 
were incubated with 25 pg of nonstimulatory G protein peptide (AICK 
RIPNKNPGKKT) in which the anchor lysine residue at position 193 had 
been changed to asparagine. All samples were analyzed in triplicate. After 
48 hat 37°C, 50 ACi/tn1 [3H]thymidine (Amersham, Little Chalfont, U.K.) 
were added for a further 24 h. Cells were harvested, the incorporated 
[41]thymidine was transferred to a filter, and the /3 emissions were read 
using a scintillation counter. The proliferation index was calculated by 
dividing the value obtained for the stimulatory peptide by the equivalent 
well containing control peptide. Following an identical method, influenza-
specific proliferation assays were conducted on Ficoll (Sigma-Aldrich) pu-
rified lung lymphocytes using the MHC class I-restricted peptide TYQR 
TRALV as the stimulus and the RSV peptide SYIGSINNI as control 
peptide. The incorporation of [3FI]thymidine was counted in the same way. 
IgA-specific Ab ELISA 
Inununo Maxisorb ELISA plates (Nunc, Roskilde, Denmark) were coated 
with either sonicated RSV Ag or UV-inactivated influenza virus (100 HA/ 
well) in PBS and incubated at 4°C overnight. Plates were washed with 
PBS-Tween (0.05%) and between each subsequent step. To each well, 200 
pi of 10% BSA-PBS were added and incubated at room temperature for 90 
min. BAL fluid was diluted 1/2 in 10% BSA-PBS, and each sample was 
incubated in duplicate for 2 h at room temperature. Then 100 pl of bio-
tinylatecl anti-IgA (Serotec, Oxford, U.K.) diluted 1/500 were added to 
each well and incubated for 1 h at room temperature. To each well, 100 pl 
of streptavidin-HRP (DakoCytomation, Carpinteria, CA) diluted 1/500 
were added and incubated for 1 h at room temperature. Finally 100 p1 of 
substrate o-phenylenediamine (Sigma-Aldrich) solution were added to 
each well and incubated for 30 min; the reaction was stopped with 2 M 
H2SO4. Plates were read at 490 nm, and optical density was compared 
between sample groups (no standard was available for quantification). 
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RSV-specific quantitative RT-PCR 
RNA was extracted from frozen lung lobe using RNA-STAT 60 (AMS 
Biotechnology) according to the manufacturer's instructions and quantified 
on a photo-spectrometer. cDNA was generated for each sample using the 
Omniscript kit (Qiagen, Chatsworth, CA) according to the manufacturer's 
guidelines using 100 ng of starting RNA and random hexamers (Promega, 
Madison, WI). For the real time PCR, the following was used for each 
sample: 12.5 µ1 of PCR master mix (Applied Biosystems, Warrington, 
Cheshire, U.K.); 9 .d nuclease-free water; 0.5 µ1 forward primer (5'-GA 
ACTCAGTGTAGGTAGAATGTTTGCA-3') at 45 AM; 0.5 Al of reverse 
primer (5'-TTCAGCTATCATTTTCTCTGCCAAT-3') at 15 µM; 0.5 
of probe (5'-FAMTTTGAACCTGTCTGAACATTCCCGGTT-TAMR 
A-3') at 5µM (specific for the L gene of RSV). Samples were run in 
triplicate alongside a no-template control reaction and the standard house-
keeping gene GAPDH (Applied Biosciences) on an ABI TaqMan sequence 
detector (Applied Biosciences). The following cycle conditions were used: 
50°C for 2 min and 95°C for 2 min followed by 40 cycles of 15 s at 95°C 
and 60°C for 1 min. Copy number of the RSV L gene was based on a 
standard curve of a known sample and normalized to a corresponding 
GAPDH sample. 
Influenza-specific plaque assay 
The day before infected mice were sampled, a 96-well plate was coated 
with 100 µ1 of 5 X 105 cells Madin-Darby canine kidney cells (MDCK) per 
ml and incubated for 24 hat 37°C. An infected lung lobe was homogenized 
with 500 µI of DMEM (Sigma-Aldrich). Cells were freeze thawed twice 
and centrifuged, and the supernatant was removed. A series of 2-fold di-
lutions were made and added in duplicate to the aspirated 96-well plates. 
Lung supernatant was incubated with MDCK cells for 2 h at room tem-
perature. A methylcellulose solution (2% methylcellulose mixed with 
DMEM-FCS-penicillin-streptomycin-glutamine at a 1:1 ratio) was added 
to each well and incubated for 48 h. After incubation, the overlay was 
aspirated, washed with PBS, and fixed with 100 of 4% formaldehyde-
PBS at room temperature for 10 min. Each well was washed twice with 
PBS and then incubated with 10% FCS-PBS for 90 min at room temper-
ature. Cells were washed with PBS and incubated with 100 µI of anti-
influenza nucleocapsid A Ab (Serotec) diluted 1/500 for 90 min. Cells were 
washed five times with PBS and incubated with 100 µ1 of anti-mouse-HRP 
(DAKO) diluted 1/500 and incubated for 90 min. Cells were washed five 
times in PBS, and substrate solution (0.3 ml of 1 mg/ml 3-amino-9-ethyl-
carbazole-DMSO, 10 µ1 of H202, 5 ml of citrate phosphate buffer, 1.15 ml 
of water) was added to each well. Cells were washed with PBS, and 
plaques were counted under an inverted microscope. 
Analysis of C. neoformans titer 
Lung homogenate, 20 µI, was diluted from 10-4 to 10-7 on Sabouraud-
dextrose-agar plates for 72 h. The number of colonies was counted, and the 
total CFU per lung calculated as no. of colonies X dilution X 50 (to 
determine how many CFU/ml) X total number of milliliters. 
Infection of RAG knockout mice and adoptive transfer 
C57BU6J-Ftagl"im'm (RAG1-/-) mice (16) were originally purchased 
from The Jackson Laboratory (Bar harbor, ME) and were bred under bar-
rier containment facilities by homozygous mating. Cells from the airways 
of mice treated with or without 5µg of LTK63 2 wk previously were 
recovered by lavage. These cells consisted entirely of alveolar macro-
phages and dendritic cells as observed by flow cytometry. Cells (1 X 105) 
were transferred i.n. to a syngeneic immunocompetent host 1 day before 
influenza virus infection. Weight loss profiles were monitored daily. 
OVA assays 
Lymph node cells from D011.10 mice were cultured in triplicate at 5 X 
105/well in flat-bottom 96-well plates in the presence of 2.5 X 105 synge-
neic peritoneal macrophages for 2 h. The macrophages were recovered 
from mice treated with or without 5µg LTK63 i.p. 1 wk earlier and were 
either pulsed with 10µg of OVA peptide 1 h before addition or with whole 
OVA the day before the proliferation assay. Medium or 5 µg/m1 Con A 
were used as negative and positive controls, respectively. Peritoneal cells 
were treated with mitomycin C before addition to prevent division. The 
cells were incubated for an additional 18 h in the presence of 1 µCi/well 
[3H]thymidine (ICN Pharmaceuticals, Costa Mesa, CA) to quantify cell 
proliferation. 
Statistical analysis 
Statistical significance was evaluated using a two-tailed Student t test as-
suming unequal variance with the Minitab software program. Where more  
than one comparison was made within an experiment, the Bonferroni cor-
rection was applied. 
Results 
LTK63 modifies the lung microenvironment in naive mice 
Prior lung immune stimulation by pathogens alters the immune 
response to subsequent heterologous infection (17-19). This re-
duces overexuberant inflammation, which can cause morbidity and 
mortality. Modulation of the lung microenvironment by whole 
pathogens is not therapeutically viable. Therefore, we investigated 
the effect of a nontoxic E. coli-derived labile toxin (LTK63) on the 
lung microenvironment. Naive BALB/c mice were treated i.n. with 
5 iug of LTK63 and lung compartments periodically sampled over 
28 days. Lymphocytic (T and B cell) expansion within the lung 
tissue primarily accounted for the mild increase in total cellularity 
(Fig. 1A). Both CD4+ and CD8+ T cells (Fig. 1B) increased in 
number; the proportion of these subsets was, however, constant 
throughout the analysis (data not shown). The most striking effect 
exerted by LTK63 was on the APC compartment. The proportion 
and total number of B cells increased, as did their expression of 
markers of activation (MHC class II, CD40, and CD80; Fig. 1C). 
Although the proportion of granulocytes and macrophages re-
mained constant, the macrophage population expressing CD80 and 
MHC class II increased (Fig. 1D). LTK63 induced a Th 1-type 
cytokine profile in the lung, with increased IFN-y and TNF-a (Fig. 
1E) but not IL-4 or IL-5 (data not shown). The enhanced state of 
activation of T cells and APCs persisted for 14 days. By day 28, 
the lung had essentially returned to a pretreatment condition. Fur-
thermore, changes in CD4+ and CD8+ T cell clonality after 
LTK63 treatment were analyzed based on the proportion of cells 
expressing different V/3 TCRs. The CD4+VB8.1/8.2+ population 
and the CD8+Vi32- population increased in the lung (Fig. 1, F and 
G). These populations, however, receded with time and were back 
at preinfection levels by day 14. 
LTK63 prevents weight loss during respiratory viral infection 
Respiratory virus infection in mice is associated with profound 
weight loss due to excessive cellular infiltration and the production 
of inflammatory cytokines. In BALB/c mice, prior vaccination 
with rVV-G induces up to 25% weight loss after intranasal whole 
virus challenge (G/RSV) (20). Human infection with influenza A 
virus typically causes tracheobronchitis and occasional fatal pneu-
monia (21, 22). In mice, influenza A virus infection induces similar 
pulmonary inflammation with an infiltration of neutrophils and 
Thl-driven CD8+ T cells. To therapeutically manipulate the lung 
immune cell compartments, mice were treated with 5 isz of LTK63 
before G/RSV or influenza virus infection. LTK63 prevented 
weight loss in G/RSV mice (Fig. 2A) when given i.n. but not i.p. 
and prevented weight loss in mice infected with influenza virus 
(Fig. 2B). In both infections, the reduced weight loss was associ-
ated with reduced cellular infiltration into the lung (Fig. 2, C and 
D) and the higher the dose of LTK63, the greater was the reduction 
in inflammation (Fig. 2C) as shown in the G/RSV model. 
LTK63 prevents eosinophilic inflammation during respiratory 
infection 
Vaccination with rVV-G followed by intranasal RSV challenge 
induces Th2-driven pulmonary eosinophilia in BALB/c mice (23). 
Similarly, a primary infection of C57BL/6 mice with C. neofor-
mans induces extensive lung eosinophilia again driven by induc-
tion of Th2 cells (24). We determined the effect of LTK63 treat-
ment on eosinophilia in these two model systems. Intranasal but 
not intraperitoneal LTK63 treatment reduced airway eosinophilia 
in G/RSV mice (Fig. 3A). This effect was dose dependent (Fig. 3B) 
12 
&10 
7. 8 
0 4 
2 
0  
L120 
• 80 
A 
40 
0 
80 n 50 
40 * 
30 g 
20 
10 -` 
0 
0 2 4 8 10 14 
Days after Infection 
0 2 4 8 10 14 
Days after Infection 
Day 0 	 Day 10 E. 
1.2% 
CD4. 
TNF-a 
a2 
8 
U 
0 
2 4 6 7 8.1 8.3 9 10b 13 14 	2 4 8 7 8.1 8.3 9 10b 13 14 
▪ PBS 
■ LTK63 
/2 V3 TCR Expression 12 
0 
0 2 4 8 10 14 	 0 2 4 8 10 14 
Days after infection 	 Days after Infection 
16 	& 30 
12 	
25 
S 20 
8 IT 115 
gi0 
4 -1 u 5 
0 
D. 
30 
& 25 
20 
LI 15 
5 
0 
C. 
O MHCII 
■ CD40 
• CD80 
7438 	 GENERIC PROTECTION AFTER LTK63 TREATMENT 
FIGURE 1. LTK63 enhances the cellularity of the 
lung. LTK63, 5 µg administered i.n., increased the total 
cells recovered ( • ) from the lung, determined by trypan 
blue exclusion. The total number of lymphocytes (I) 
increased in the lung following administration of 
LTK63 (A). The total number of lymphocytes express-
ing CD4 (left axis; *) or CD8 (right axis; M) was ex-
amined by flow cytometry and increased in the lung af-
ter LTK63 treatment (B). The number of activated B 
cells was determined by multiplying the percent 
CD45R+ cells that also expressed MHC II ( ), CD40 
(E and right axis) or CD80 (A) by the total number of 
lymphocytes (C'). The number of activated macrophages 
expressing MHC class II or CD80 was determined by 
specific gating of the forward and side scatter macro-
phage population (D). Flow cytometric plots of CD4 
(y-axis) vs TNF-a (x-axis) showing how LTK63 in-
creased intracellular TNF-a on day 0 (left) compared 
with day 10 (right) (E). The proportion of lymphocytes 
coexpressing CD4 (F) or CD8 (G) and selected TCR Vi3 
gene products were enumerated by flow cytometry in 
mice 7 days after intranasal inoculation of PBS (0) or 
LTK63 (M). All results are representative of two to three 
independent experiments containing five mice per 
group. **, p < 0.05 compared with the previous time 
point or to the corresponding PBS-treated group where 
applicable. 
given that 0.2 1.14 of LTK63 had minimal effect, 1µg reduced 
pulmonary eosinophilia in 3 of 4 mice, whereas a 5-iug dose com-
pletely ameliorated eosinophilia (neutrophils predominated). To 
determine the long term effects of LTK63, mice were scarified 
with rVV-G and challenged with RSV 12 wk after LTK63 treat-
ment. Mice treated with LTK63 had less weight loss (Fig. 3C), 
reduced pulmonary eosinophilia (Fig. 3D), a reduction in activated 
CD4+CD44+ T cells, and a reduction in TNF-a production (data 
not shown) compared with PBS-treated controls. Although the ef-
fects of LTK63 treatment were shown to be long lasting, the extent 
of these effects was less significant than administration with a 
shorter interim before infection. A similar reduction in airway eo-
sinophilia was observed in LTK63-treated C57BL/6 mice after C. 
neoformans infection (Fig. 3E). Therefore, this effect was not re-
stricted to a particular mouse strain or to a specific pathogen. 
LTK63 enhanced T cell activation and pathogen-specific cell 
proliferation 
LTK63 reduced Th2-driven eosinophilia and immunopathology 
during infection and at the same time moderated illness and pa-
thology to Thl-driven influenza infection. Further analysis re-
vealed that the proportion of CD4+ and CD8+ T cells was unal-
tered in both the G/RSV and influenza virus infection models (data 
not shown). However, a greater proportion of them were activated. 
LTK63 significantly increased the proportion of activated CD8+ T 
cells but not CD4+ T cells following G/RSV (Fig. 4, A and B). 
After influenza virus (Fig. 4, C and D) and C. neoformans infection 
(data not shown), LTK63 increased the proportion of activated 
CD4+ (2-fold) and CD8+ (8-fold) T cells. Prior LTK63 treatment 
enhanced the RSV-specific (Fig. 4E) and influenza-specific (Fig. 
4F) CD8+ T cell-proliferative responses after RSV and influenza 
virus infection, respectively. Addition of LTK63 to Con A-stim-
ulated splenocytes actually reduced proliferation. This is likely to  
reflect excessive antigenic stimulation with rapid activation in-
duced cell death. Further analysis, however, is beyond the scope of 
this article. 
LTK63 modulated the cytokine production and enhanced IgA 
T cells generally exert their effect on eosinophils by secretion of 
cytokines. We therefore examined T cell cytokine profiles from 
whole lung tissue by intracellular staining and flow cytometry in 
the G/RSV infection model. Generally, the higher the dose of 
LTK63, the lower is the amount the Thl and Th2 cytokines present 
during subsequent infection. For example, control mice had 
17,009 ± 120 TNF-a-producing CD4+ T cells at day 7 after RSV 
challenge, whereas those given 5 Ag of LTK63 had only 7,083 ± 
87 (p < 0.05). IFN-7 production dominated over IL-5 in both 
CD4+ (Fig. 5A) and CD8+ (data not shown) T cell subsets, which 
was dose dependent. In addition, this effect was only evident in 
mice given LTK63 i.n. and not i.p. (Fig. 5B). Treatment of mice 
with 5 µg of LTK63 14 days before influenza infection also re-
duced the proportion and total number of CD4+ T cells producing 
IFN-y (Fig. 5C) and IL-5 (Fig. 5D). Despite reduced cytokine 
production, significant RSV- or influenza-specific IgA was de-
tected in nasal washes taken from mice infected with G/RSV (Fig. 
5E) or influenza virus (Fig. 5F). In both cases, prior intranasal 
LTK63 treatment enhanced recovered Ag-specific IgA. 
LTK63 improves lung histology and either does not affect or 
improves pathogen clearance 
Histological (H&E) analysis of lung sections confirmed that prior 
LTK63 treatment significantly reduced the inflammatory infiltrate 
following G/RSV (Fig. 6A), influenza virus (Fig. 6B) and C neo-
formans (Fig. 6C) infections. Analysis of pathogen titer in lung 
homogenates showed that LTK63 had no effect on RSV titers 7 
days after infection (Fig. 6D) but markedly reduced both influenza 
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FIGURE 2. LTK63 reduces weight loss and lung cellularity during viral 
infection. Mice were immunized i.n. ( • , A) or i.p ( 0, trio]) with 5 1.1.g of 
LTK63 (A, A) or an equivalent volume of PBS (O, • ), scarified with 
rVV-G 14 days later and challenged i.n. with RSV after a further 14 days. 
Percent weight loss was calculated from the original starting weight of each 
mouse at the time of the final RSV challenge (A). Weight loss was also 
monitored in LTK63 (5 µg i.n.; 0, • )- or PBS (0, M)-treated mice 
infected i.n. with influenza virus (B). Each line represents weight loss in an 
individual animal. Cellularity of the lung was enumerated by trypan blue 
exclusion of lung homogenates from i.n. LTK63-treated mice subsequently 
infected with G/RSV (C) or influenza virus (D). Each point represents an 
individual mouse and is representative of two additional experiments. Av-
erage values are represented as horizontal bars -± S.E. of the mean; **, p < 
0.05 compared with the PBS-treated sample group. 
virus (Fig. 6E) and C. neoformans (Fig. 6F) titers. Moreover, in-
fluenza virus was undetectable on day 7 after infection. In addition, 
LTK63 pretreatment prevented uncontrolled pulmonary C. neofor-
mans dissemination to the brain (data not shown). 
LTK63 modifies Ag processing and exerts its influence 
independent of T and B cells 
The data presented thus far imply that LTK63 stimulates a mild 
Thl environment in the lung and matures APCs by increasing 
MHC class II, B7 costimulatory molecules, and CD40. The out-
come and immune phenotype of any subsequent lung infection 
tested to date are altered beneficially. Although total T cells are 
reduced during pathogen challenge, of those remaining the pro-
portion of activated cells is increased. This may imply an alteration 
in pathogen processing and presentation. We therefore tested the 
ability of peritoneal lavage cells (>95% macrophages by flow cy-
tometry) to process and present whole OVA to OVA-specific T 
cells (D011.10 T cells) and compared the proliferative responses 
with those of OVA-specific peptide. Untreated peritoneal macro-
phages efficiently induced proliferation of D011.10 T cells in the 
presence of OVA or OVA peptide. However, macrophages re-
moved from LTK63-treated mice were effective at eliciting T cell 
proliferation in response to peptide but not whole OVA (Fig. 7A). 
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FIGURE 3. LTK63 prevents pulmonary eosinophilia during infection. 
LTK63 or PBS was administered i.n. to mice 14 days before scarification 
with rVV-G and challenge with RSV. The reduction in eosinophilia was 
dependent on the i.n. route of administration (A) and the dose of LTK63 
(B). The percent eosinophils (5) and neutrophils (0) were determined in 
H&E-stained cytocentrifuge preparations of lung cells based on their dis-
tinctive nuclear morphology, size, and presence of cytoplasmic granules. 
LTK63 treatment had a long lasting effect; its administration 12 wk before 
rVV-G scarification and RSV challenge caused a reduction in weight loss 
(C) and a reduction in pulmonary eosinophilia (D). LTK63 treatment be-
fore C. neoformans infection of C57BL/6 mice also reduced the proportion 
of eosinophils (E), indicating that the effect of LTK63 is not host strain or 
pathogen specific. Each point indicates an individual mouse and is repre-
sentative of three separate experiments. Average values are represented as 
horizontal bars ± SEM; **, p < 0.05 compared with the PBS-treated 
sample group. 
This suggests that presentation of peptides to Ag-specific T cells is 
not affected by LTK63 but that processing of whole Ags is 
reduced. 
The alteration of lung APCs by LTK63 may explain the differ-
ence in subsequent immune pathology to unrelated infections. To 
prove the impact of LTK63 modulated APCs on subsequent in-
fection we removed alveolar cells by lavage (>95% pure macro-
phages) from RAG-i- mice that had been pretreated or not with 5 
LTK63 3 wk earlier. Cells (1 X 105) were transferred i.n. into 
immunocompetant littermates. Mice were then infected with in-
fluenza virus 1 day later, and weight loss was evaluated. Transfer 
of LTK63 but not PBS-treated lung cells reduced weight loss dur-
ing subsequent influenza virus infection (Fig. 7B). These results 
imply that the protective influence of LTK63 is partially indepen-
dent of T and B cells. 
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FIGURE 4. LTK63 enhances the proportion of activated T cells and 
proliferative responses to specific Ag. LTK63 (5, 1, or 0.2 lig) or PBS was 
administered i.n. to 8-10 wk old BALB/c mice 2 wk before scarification 
with rVV-G and challenged i.n. with whole RSV 2-3 wk later. The pro-
portion of cells expressing both CD44 and CD4 (A) or CD44 and CD8 (B) 
was determined by flow cytometry 7 days after RSV infection. A similar 
analysis was performed on CD4 (C) and CD8 (D) T cells from influenza-
infected mice previously given 5µg of LTK63 i.n. The proliferative re-
sponse of CD8+ T cells from mice pretreated with LTK63 and challenged 
with G/RSV (E) or influenza virus (F) was tested in a [3H]thymidine in-
corporation assay. The stimulation index was calculated by dividing the 
cpm to the immunodominant T cell peptide (AICKRIPNKKPGKKT) from 
the G-protein of RSV by the control peptide (AICKRIPNICNPGICKT) in 
which the major MHC class II I-Ed anchor region had been substituted (E). 
Cells were incubated with the immunodominant CD8 epitope for RSV 
(SYIGSINNI) or influenza (TYQRTRALV), LTK63 itself, or Con A (F). 
F, 0, influenza-infected mice pretreated with PBS; E, those pretreated 
with LTK63. Average values are represented as horizontal bars ± SEM. 
**, p < 0.05 or *, p < 0.1 compared with the PBS-treated sample group. 
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Discussion 
We have shown that prior administration of a modified bacterial 
toxin (LTK63) that lacks toxicity but retains immunogenicity pre-
vents immunopathology to a number of respiratory infections. This 
is the first time that the protective capabilities of a bacterial toxin 
have been tested in isolation without admixed Ag. Treated mice 
still develop powerful Ab responses to each virus but lack the 
exuberant cellular inflammation characteristic of these infections. 
Moreover, LTK63 prevents eosinophilic disease in mice previ-
ously sensitized with the attachment G protein of RSV or infected 
with C. neoformans. We believe that the major influence in pro-
tection is the maturation of APCs, because we were able to transfer 
the LTK63-modified environment from mice lacking B and T cells 
(RAG-/- mice). 
There have been several major obstacles that have prevented the 
development of effective vaccines against respiratory infections: 1) 
natural infection does not always confer immunity to the recur-
rence of disease; 2) the induction of powerful cellular immune 
responses has been associated with an increase in disease severity 
during subsequent infection (25, 26). This effect was seen when 
children were given formalin-inactivated RSV virus vaccines in 
clinical trials during the 1960s (27). Subsequent infection led to 
greatly increased hospitalization rates and a small number of vac-
cine-related deaths; 3) there is a lack of appropriate adjuvants suit- 
PBS 	0.2 pg 1 lag 	5 pg 	 PBS 	LTK63 
FIGURE 5. LTK63 alters the balance of cytokines in G-RSV mice. 
LTK63, 5, 1, or 02 1,4 (A), or 5 jig of LTK63 i.n. or i.p. (B) 2 wk before 
rVV-G scarification and intranasal RSV challenge. The ratios of IFN-y- to 
IL-5-producing CD4+ T cells in the lung were enumerated by intracellular 
staining and flow cytometry. The results represent the mean ± SEM from 
5 mice. 5µg LTK63 was administered 2 wk before influenza virus infec-
tion and the IFN-y (C) or IL-5 (D) production from CD4+ T cells analyzed 
by intracellular flow cytometry. The total number of cells (I) producing 
each cytokine was calculated by intracellular staining and flow cytometry 
and compared with percent production (0). Each point represents an in-
dividual mouse. 5µg LTK63) increased the pathogen-specific IgA in nasal 
wash, determined by ELISA 7 days after RSV (E) or influenza virus (F) 
infection. Average values are represented as horizontal bars ± SEM; **, 
p < 0.05 or *, p < 0.1 compared with the PBS-treated sample group. 
able for the induction of long term immunity, particularly for the 
generation of effective anti-viral CTL responses; 4) stimulating 
immunity at the site of infection, e.g., the mucosa of the respiratory 
tract, is still problematic. Therefore, alternative approaches have 
been sought that exploit the host immune response by means of 
immune modulation or immune intervention, rather than contem-
porary vaccination. 
The use of the nontoxic LTK63 fulfils many of the criteria re-
quired for an effective protection strategy against respiratory in-
fection. It induces appropriate immune responses to both viral and 
nonviral pathogens, and to both Thl- and Th2-driven disease or 
immunopathology. LTK63 treatment effectively matures the APC 
compartment of the respiratory tract and induces potent CD8± T 
cells and local IgA production. Excessive inflammation is elimi-
nated without sacrificing effective pathogen clearance, and it is 
most effective at the site of pathogen entry and replication. In 
addition, the i.n. route of administration benefits from being non-
invasive, and the beneficial effects are long lasting. Furthermore, 
treatment with LTK63 also bypasses the problem of antigenic shift 
or drift in surface exposed pathogen proteins because the mecha-
nism of protection is not restricted to one Ag. This strategy may 
also negate the "unnatural immunity" described by Casadevall and 
Pirofski (28), who highlight that vaccines often induce immune 
responses that differ from the one elicited by natural infection (29). 
LTK63 primes the lung to cope with infection more efficiently but 
not in a way that one would anticipate a vaccine working. 
Treatment with LTK63 significantly alters the APC compart-
ment by increasing MHC II-, CD80-, and CD40-expressing cells. 
The ability of LT and mutant derivatives to modify dendritic cells, 
macrophages, and B lymphoma cells in vitro has been described 
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FIGURE 6. LTK63 improves lung histology and en-
hances pathogen clearance from the lung. Mice were 
given PBS (top row) or 5 p.g of LTK63 (bottom row) 2 
wk before G/RSV (A), influenza virus (B), or C. neo-
formans (C). Lungs were formalin fixed and embedded 
in paraffin at the peak of the inflammatory response (day 
7 in A and B and day 12 in C), and sections were stained 
with H&E. Pathogen titers were enumerated at multiple 
time points in G/RSV (D)-, influenza virus (E)-, or C. 
neoformans (F)-infected mice at days 7, 4, and 12, re-
spectively. The results represent the mean ± SD for 5 
mice (D and E) or individual mice (F) and are repre-
sentative of two to three independent experiments. Av-
erage values are represented as horizontal bars ± SEM; 
**, p < 0.05 compared with the PBS-treated sample 
group. 
before (10, 30, 31), the overall requirement for any effect being at 
least partial ADP ribosyltransferase activity. Our data clearly show 
that the mutant LTK63, devoid of enzymatic activity, can induce 
profound effects on APCs in vivo. The discrepancy can be ex-
plained in many ways, not least that in vivo studies may highlight 
indirect influences of LT mutants on APCs, that the toxins may 
function differently in vivo, and/or that the effects observed require 
the concerted action of several cell types not present in in vitro 
cultures. 
Similar to wild-type LT, nasally administered LTK63 promotes 
a mild Th 1 -type cytokine environment (32) and may therefore be 
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FIGURE 7. LTK63 treatment enhances non-T and B cells. BALB/c 
mice were treated with either PBS or 5 µg of LTK63 1 wk before cell 
recovery. Peritoneal cells were removed by lavage and washed before ad-
dition of OVA or OVA- specific peptide. 24 h later 5 x 105 D011.10 T 
cells were added and cultured for 72 h, with the inclusion of 1 ;Xi of 
[3H)thytnidine for the last 16 h. Results show the mean and SD from four 
separate experiments containing triplicate samples (A). In B, RAG-/- mice 
were given 5 jig of LTK63 or PBS i.n., and the lungs were removed after 
14 days. Single lung homogenate cells (106) were transferred i.n. into four 
immunocompetent congenic mice. Weight loss during intranasal influenza 
virus infection was monitored for 7 days. The results show the mean ± SD 
of five separate mice. **, p < 0.05 compared with the PBS-treated sample 
group. 
useful in imprinting this phenotype on the lung, a phenomenon we 
term innate imprinting. This would be particularly useful in infants 
at risk from the development of asthma or viral-induced atopic 
disorders. Recently, studies indicate that immune responses in 
children are predominantly skewed to a Th2 phenotype at birth and 
become more Th 1 biased as they experience subsequent infection 
(33). In support of this, infants generally produce lower levels of 
IFN-y, but this gradually increases with age (34). LTK63 could 
therefore provide the necessary Thl trigger without the need for 
infection. The ability of LTK63 to induce a Thl cytokine envi-
ronment is also due to the production of TNF-a and likely the 
production of IL-12 by APCs (10). The absence of enzymatic ac-
tivity is critical in this regard because wild-type CT inhibits IL-12 
production by dendritic cells and impedes IL-12 receptor expres-
sion on activated T cells (35). 
The effect of LTK63 treatment on the T cell population is rem-
iniscent of studies modulating the lung microenvironment using 
whole pathogens (11). Although wild-type CT and LT are thought 
to cause lymphocyte apoptosis, mutants with reduced or absent 
toxicity do not (36). Although T cell numbers were reduced, the 
proportion of activated cells was enhanced in LTK63-treated mice. 
We suggest that reduced T cell numbers may arise under the fol-
lowing conditions. 
Reduced Ag processing 
As did Petrovska et al. (30), we noted that LTK63-stimulated peri-
toneal macrophages were less efficient at stimulating Ag-specific T 
cells. Reduced pathogen Ag processing would therefore result in a 
reduced level of inflammation. Presentation of peptide Ag, how-
ever, was unaffected. 
Increased efficiency of T cell activation 
APCs must undergo maturation to efficiently prime T lymphocytes 
(for a review, see Ref. 37). LTK63 therefore enhances APC mat-
uration, thus increasing the efficiency of T cell priming (38, 39). 
The T cell pool therefore does not have to expand excessively to 
combat the infection. Indeed, influenza virus and C. neoformans 
were cleared more rapidly by LTK63 pretreatment. 
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Refractory microenvironment 
Prior LTK63 treatment may reduce the amplitude of subsequent 
cellular responses. This may involve the induction of IFN-a/3 and 
MHC class I expression by respiratory epithelial cells, the activa-
tion of a resident NK cell population, and the production of IL-12 
by dendritic cells. In addition, dendritic cells become refractory to 
subsequent stimulation (40). Furthermore, alveolar macrophages 
are essentially nondividing cells (41) and display a relatively long 
turnover time (42, 43) and thus become refractory relatively easily. 
This results in a diminished cellular recruitment, prevents disease-
induced weight loss and lung pathology, but still allows pathogen 
clearance. These processes are likely to act in concert with the 
direct stimulation of cell surface receptors, such as ganglioside 
receptors, which activate immune cells in a way similar to that of 
pathogen-associated molecular patterns binding to pattern recog-
nition receptors. Alternatively, although not exclusively, LTK63 
treatment may enhance T cell bystander activity analogous to vi-
ral-induced heterologous immunity (11), which may partially ex-
plain the longevity of LTK63 treatment. 
The increase in pathogen-specific, nasal IgA is an important 
effect of LTK63 treatment. Naturally acquired Abs occur sponta-
neously after Ig gene rearrangement, are of low specificity, and are 
predominantly IgM; but IgG and IgA isotypes are known to exist 
and are often cross-reactive (44, 45). Sera from naive mice contain 
Abs capable of reacting with purified preparations of lymphocytic 
choriomeningitis virus, vaccinia virus, Listeria, and vascular sto-
matitis virus (45, 46). So-called natural Abs are an evolutionary 
advantage because they enhance pathogen phagocytosis and pre-
sentation of Ags in organized lymphoid tissue. Enhanced IgA pro-
duction to influenza hemagglutinin and pneumococcal polysaccha-
rides is evident in mice given either of these proteins admixed with 
LTK63 (47, 48). However, in both studies, the production of IgA 
after LTK63 treatment alone was not described. Controlled or re-
duced pathogen titers after LTK63 treatment may therefore reflect 
a combination of efficient T cell priming by activated APCs and 
binding of pathogens by additional nasal IgA. 
Many vaccination strategies increase the frequency of Ag-spe-
cific T cells but fail to increase the availability of mature APCs in 
the appropriate compartment. We show that LTK63 matures APCs 
so that Ag presentation is more efficient but Ag processing is cur-
tailed. Smaller numbers of T cells will therefore be activated but in 
a globally more efficient manner. The transfer of LTK63-treated 
airway cells from RAG knockout mice highlights the influence of 
non-T and -B cells. We therefore propose that prior stimulation of 
the lung microenvironment produces long-lived, or indeed irre-
versible, changes, which may include alterations in APCs and che-
mokine receptors or adhesion molecule expression profiles. The 
first signal to the developing lung will therefore influence all sub-
sequent immune responses, a phenomenon we call innate 
imprinting. 
The use of live, even attenuated, vaccines is contraindicated in 
hosts with impaired immune function, first because they may not 
mount an efficient immune response and, secondly because the 
vaccine pathogen itself may disseminate or persist. LTK63 would 
not necessarily suffer from these problems and may afford generic 
protection against a number of unrelated pathogens. 
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Stimulation via Toll-like receptor 9 reduces Cryptococcus 
neoformans-induced pulmonary inflammation in an 
IL-12-dependent manner 
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Cytosine-phosphate-guanosine-containing oligodeoxynucleotides (CpG ODN) are 
important vaccine adjuvants that promote Thl-type immune responses. Cryptococcus 
neoformans is a serious human pathogen that replicates in the lung but may disseminate 
systemically leading to meningitis, particularly in immunocompromised individuals. 
Immunization of susceptible C57BL/6 mice with CpG ODN deviates the immune 
response from a Th2- toward a Thl-type response following infection with C. 
neoformans. CpG also induces IL-12, TNF, MCP-1 and macrophage nitric oxide 
production. CD4+ and CD8+ T cells producing IFN-y increase in frequency, while those 
producing IL-5 decrease. More importantly, pulmonary eosinophilia is significantly 
reduced, an effect that depends on IL-12 and CD8+ T cells but not NK cells. CpG 
treatment also reduces the burden of C. neoformans in the lung, an effect that is IL-12-, 
NK cell- and T cell-independent and probably reflects a direct effect of CpG on pathogen 
opsonization or an enhancement of macrophage antimicrobial activity. An equivalent 
beneficial effect is also observed when CpG ODN treatment is delivered during 
established cryptococcal disease. This is the first study documenting that promotion of 
lung TLR9 signaling using synthetic agonists enhances host defense. Activation of 
innate immunity has clear therapeutic potential and may even be beneficial in patients 
with acquired immune deficiency. 
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Introduction 
Infections with fungal pathogens, such as Cryptococcus 
neoformans, have received much attention recently due 
to the difficulties or failures in prophylaxis, therapeutic 
treatment and vaccination. C. neoformans infection is 
uncommon in healthy individuals, but frequently causes 
disease in immunocompromised people such as organ 
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transplant recipients, chemotherapy patients or indivi-
duals with acquired immune deficiency syndrome 
(AIDS) [1, 2]. C. neoformans primarily causes a 
pulmonary disease but often disseminates throughout 
the body inducing skin lesions and potentially fatal 
meningitis in the final stages of disease [2-4]. 
Cryptococcosis is the most common mycosis of the 
central nervous system in AIDS patients [5], and in both 
AIDS and non-AIDS patients, dissemination of C. 
neoformans causes meningitis in 15-30% of cases [6, 
7]. In order to prevent C. neoformans dissemination, 
restrict the pathogen to the lung and resolve the 
infection, a Thl-biased immune response is required, 
involving both CD4+ and CD8+ T cell recruitment [8, 9]. 
Several inflammatory mediators, including IL-12, TNF, 
IFN-y and nitric oxide, are important for an effective 
immune response against C. neoformans [10-12]. If one 
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or more of these factors is inhibited, the resolution of 
infection becomes compromised [13, 14]. Following C. 
neoformans infection of susceptible C57BL/6 mice, a 
Th2-type response develops, with associated pulmonary 
eosinophilia [4, 15, 16]. The pathogen is no longer 
restricted to the lung, disseminates to other organs and 
may become persistent and difficult to resolve. This 
model therefore provides a useful means to study 
cryptococcus infection. 
Despite the clinical importance of C. neoformans 
infection, an effective therapeutic that is suitable for all 
clinical situations has yet to be developed [2]. Moreover, 
a protective human vaccine against this pathogen is not 
available. An immune response to C. neoformans can be 
induced in mice by injecting heat-killed yeast or 
cryptococcal filtrate antigen (CneF) with Freund's 
complete adjuvant [17]. Immunization with heat-killed 
cryptococci has produced variable degrees of protection 
depending on the method of delivery [18, 19]. 
Immunization with CneF produces a cell-mediated 
response that protects mice from subsequent C. neofor-
mans challenge, which is associated with elevated 
numbers of CD4÷ T cells [20, 21]. However, the 
protection afforded by CneF relies on Freund's complete 
adjuvant, an unsuitable mode of delivery for human use. 
Furthermore, the capsule that surrounds the yeast 
complicates the development of a vaccine [22]. The 
major capsule polysaccharide component glucuronox-
ylomannan (GXM) may be a potential vaccine target, as 
protective antibodies are generated against it [23, 24], 
and a GXM-tetanus toxoid conjugate vaccine is protec-
tive against C. neoformans challenge in mice [25, 26]. 
However, deleterious antibodies can be produced 
following GXM immunization, and polysaccharide-
based vaccines are poor immunogens in immunocom-
promised hosts [27]. Therefore, the use of non-specific 
modulators of the immune response, particularly the 
innate immune response, may be more advantageous in 
protecting against C. neoformans. 
Immunostimulatory cytosine-phosphate-guanosine 
oligodeoxynucleotides (CpG ODN), which are non-
methylated, have been successful in inducing protective 
immune responses in a number of experimental 
infections. However, the use of CpG at mucosal sites, 
in particular the lung, is more limited. CpG ODN reduce 
eosinophilic inflammation and IL-5 production follow-
ing metacholine-induced airway hyper-responsiveness 
[28] and reduce mycobacterial growth and lung 
inflammation when administered intranasally (i.n.) at 
the time of Mycobacterium tuberculosis infection [29]. 
Similarly, immunization with the Chlamydia trachomatis 
major outer membrane or recombinant aspergillus 
protein with CpG ODN protects against i.n. pathogen 
challenge [30, 31]. CpG ODN stimulate Thl-type 
immune responses via TLR9 (for a review of TLR in 
© 2005 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim 
the lung see [32]) and induce IFNI, but reduce IL-4 and 
IL-5 production [33-35]. Immunization with CpG ODN 
therefore has the potential to modify the immune 
outcome following C. neoformans infection in suscep-
tible mice. 
We now show that an agonist (CpG ODN) that binds 
to a TLR "unnatural" to anti-fungal immunity (TLR9) 
prior to i.n. C. neoformans infection reduces cryptococ-
cal burden and pulmonary eosinophilia. CpG ODN 
treatment increased IFN-y production and CD8+ T cell 
frequencies but reduced production of IL-5. This effect 
depended on IL-12 and CD8+ T cells but not NK cells and 
was effective even after the onset of lung inflammation. 
Current classical vaccination strategies rely on the 
induction of anti-pathogen T cells and/or antibodies 
that may be difficult to induce in immunodeficient 
patients. Even in individuals with a fully competent 
immune system, the challenging microbe may mutate 
pathogenic epitopes contained within the vaccine, 
thereby undermining its effectiveness. A new generation 
of drugs that target the innate immune system and 
therefore should not suffer from these constraints are 
under development. Numerous preclinical studies show 
that such vaccines prevent the symptoms of asthma. We 
are the first to show an effect of promoting TLR signaling 
on pathogen-induced eosinophilic lung disease. 
Results 
Immunization with CpG ODN reduces 
C. neoformans-induced pulmonary inflammation 
Infection of C57BL/6 mice with C. neoformans strain 52 
results in Th2-driven pulmonary eosinophilia and 
elevated levels of IL-5. Mice i.n. immunized with CpG 
ODN 3 days before C. neoformans infection showed a 
marked reduction in the total inflammatory infiltrate in 
lung (Fig. 1) and bronchoalveolar lavage (BAL, data not 
shown). Of those cells remaining, lymphocytes pre-
dominated (Fig. 1A), while eosinophilia was reduced 
(Fig. 1B). CD4+ T cell frequencies were reduced by CpG 
ODN treatment, whereas CD8+ T cell frequencies were 
enhanced (Fig. 1C, D). More of the remaining CD4± and 
CD8+ T cells produced IFN-y in CpG ODN-treated mice 
(Fig. 1E—F), whereas frequencies of CD4+ and CD8+ 
T cells producing IL-5 decreased (Fig. 1G—H). The 
eosinophil population and the cytokine profile of T cells 
were unaltered in mice immunized with the control 
(methylated) ODN and were not significantly different 
from the PBS-treated controls. 
Furthermore, the cellular changes following CpG 
ODN treatment were accompanied by a reduction in the 
cryptococcal burden in the airways (Fig. 2A) and lung 
tissue (Fig. 2B). The reduction of cryptococcus in the 
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(Fig. 3B), MCP-1 (Fig. 3C) and nitric oxide (Fig. 3D) 
compared to macrophages incubated with medium or 
IFN-y alone. Only nitric oxide, and to a certain extent 
TNF, production relied on IFN-y pre-activation. 
CpG ODN reduce pulmonary eosinophilia and 
pathogen load by different mechanisms 
• • 
•• 
• • 
••• 
•• 
0 
Fig. 1. CpG ODN modify the lung microenvironment and 
prevent C. neoformans-induced lung eosinophilia. Five mice per 
group were treated i.n with PBS, CpG ODN or a control ODN 
3 days prior to i.n C. neoformans infection. Lungs were removed 
12 days later and disrupted into a single-cell suspension. 
Suspensions were stained with monoclonal antibodies as 
shown and data collected on 30,000 lymphocytes. The 
proportion of lymphocytes (A) was determined by back-gating 
samples stained with anti-CD4, anti-CD8 and anti-B220 onto 
forward- and side-scatter plots. Eosinophils were enumerated 
in H&E-stained cytospin preparations of lung (B) and BAL (data 
not shown). The proportion of lymphocytes expressing CD4 (C), 
CD8 (D), CD4 and IFN-y (E), CD8 and IFN-y (F), CD4 and IL-5 (G), 
and CD8 and IL-5 (H) was determined for individual mice. The 
results are representative of four independent experiments 
('p<0.01, ** p<0.05 compared to both control groups). Control 
ODN is the non-stimulatory methylated CpG control. CpG ODN 
is the immune stimulatory CpG. 
airways was clearly visible in cytospin preparations of 
BAL fluid from CpG ODN-treated mice (Fig. 2F) as 
compared to control ODN- or PBS-treated mice (Fig. 2D, 
E). The size and morphology of C. neoformans allowed 
their easy enumeration (Fig. 2C). There was no 
significant difference between the cryptococcal burdens 
in control ODN- and PBS-treated mice. 
CpG ODN promote inflammatory cytokine 
production in vitro 
To examine candidate molecules likely to be responsible 
for the results obtained in vivo, we incubated macro-
phages in vitro with or without CpG ODN. Macrophages 
can require pre-activation to respond to certain signals. 
We therefore examined the effect of CpG ODN on IFN-y-
pre-activated and non-activated macrophages. CpG 
ODN caused an increase in IL-12 (Fig. 3A), TNF 
2005 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim 
In order to further investigate the mechanisms respon-
sible for the reduction in pulmonary immunopathology 
following CpG ODN immunization, mice were treated 
with anti-IL-12 antibody prior to and during C. neofor-
mans infection. Pathogen burden was still reduced in 
CpG ODN-treated C. neoformans-infected mice in the 
absence of IL-12 (Fig. 4A). In contrast, the ability of CpG 
ODN to reduce lung eosinophilia was clearly IL-12-
dependent (Fig. 4B). CpG ODN treatment usually 
increases IFN-y production by T cells (Fig. 1). Anti-IL-
12 treatment at the same time reverses this effect, which 
may partly explain the lack of an effect of CpG ODN on 
eosinophilia under these conditions (Fig. 4C). Identical 
effects were also observed in IL-12-knockout mice in 
that CpG ODN treatment reduced the pathogen burden 
but failed to reduce pulmonary eosinophilia (data not 
shown). By dividing the percent of CD4+ (Fig. 4D) or 
CD8+ (Fig. 4E) T cells expressing IFN-y by those 
expressing IL-5, it is clearly evident that CpG ODN 
enhanced Thl/Tcl cytokines and that anti-IL-12 anti-
body reduced that effect. 
CpG ODN-induced reduction of lung eosinophilia 
is effective after onset of lung disease and 
depends on CD8+ T cells 
To consider CpG ODN administration as a therapy, it 
would need to influence established disease. Mice were 
therefore infected with C. neoformans and CpG ODN 
administered on day 5. At this time point, the pathogen 
load has expanded, and eosinophils represent 15% of 
lung cells (data not shown). Delayed administration of 
CpG ODN prevented systemic spread of C. neoformans to 
the Peyer's patches, but not if IL-12 was depleted 
(Fig. 5A), and reduced lung eosinophilia (Fig. 5B). We 
had previously noted that CpG ODN treatment enhances 
CD8÷ T cell frequencies. To investigate their influence, 
CD8+ T cells were depleted in this delayed-treatment 
experiment. Anti-CD8 antibody treatment prevented the 
reduction of lung eosinophilia by CpG ODN (Fig. 5C). 
Interestingly, CpG ODN treatment also increased the 
proportion of activated T cells expressing OX40 
(Fig. 5D). The influence of CpG ODN does not appear 
to depend on the presence of NK cells; in mice given anti-
NK1.1 antibody throughout infection, CpG ODN still 
reduced pulmonary eosinophilia and pathogen load 
(data not shown). 
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Fig. 3. CpG ODN induce inflammatory cytokine production by 
macrophages. Peritoneal exudate cells were cultured in vitro 
with or without IFN-y in triplicate. After 3 h cells were washed 
with PBS and incubated with or without CPG ODN for a further 
48 h. Supernatants were centrifuged to remove cell debris and 
the quantity of IL-12, TNF, MCP-1 and nitric oxide (as shown) 
determined by microbead array and flow cytometry. The data 
show the mean and standard deviation of three independent 
experiments. 
Fig. 4. The effect of CpG ODN relies on the presence of IL-12. 
Mice were infected as described for Fig. 1, but some groups 
were additionally depleted of IL-12 by i.p. administration of 
anti-IL-12 antibody. The number of lung C. neoformans CFU (A) 
and eosinophils (B) was determined for individual mice and is 
representative of three separate experiments, Representative 
dot plots of CD4 (y-axis) and intracellular IFN-y (x-axis) are 
shown for each group (C). The ratio of IFN-y- to IL-5-expressing 
CD4' (D) or CD8' (E) T cells was calculated by dividing the 
percentage of each T cell subset expressing IFN-y by the 
percentage of the same subset expressing IL-5. Mean and 
standard deviations are shown for ten individual mice from 
two independent experiments. 
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Fig. 5. Delayed administration of CpG ODN prevents C. 
neoformans-induced immunopathology. Mice were infected 
with C. neoformans, and PBS or CpG ODN was given 5 days 
later. Some mice were additionally depleted of IL-12 (A) or CD8* 
T cells (C). The number of CFU/ml Peyer's patch was 
determined by plating dilutions of homogenates onto Sabour-
aud agar plates (A). Eosinophils in the presence (B) or absence 
(C) of CD8* T cells were enumerated in H&E-stained cytocen-
trifuge preparations. The expression of OX40 on CD4- (open 
circles) or CD8- (closed circles) expressing T cells was deter-
mined by flow cytometry. Data represent either individual mice 
(B-D) or the mean and standard deviation of five mice (A). All 
experiments were repeated at least twice ("p<0.01, "p<0.05 
compared to both control groups). 
Discussion 
There are a number of chronic and acute human diseases 
associated with activation of Th2 cells. Asthma has 
received particularly close attention in efforts to try and 
restore the Thl/Th2 balance and prevent debilitating 
eosinophilic lung disease. Eosinophils are recruited, 
promoted and maintained by IL-5 derived from Th2 
cells. The contribution of IL-5 from other cell types is still 
unclear. To prevent Th2 development, researchers have 
therefore attempted, with variable success, to drive Thl 
development. IL-12 has pleiotropic effects on NK and 
T cells and induces CD4'' T cells to assume a Thl 
phenotype [36, 37]. Parenteral IL-12 administration 
reduces eosinophilic lung disease to both soluble and 
pathogen-associated proteins [38] . However, recombi-
nant cytokine administration is costly, may be dangerous 
and augments pathology, for example in LCMV- [39] 
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and respiratory syncytial virus- [38] infected mice via 
elevated levels of TNF [40] and IFN-y [41]. 
Since recombinant cytokine administration suffers 
from several drawbacks, therapeutics that "naturally" 
induce cytokine production may provide a more 
physiological deterrent to Th2 development. To this 
end, synthetic non-methylated CpG motifs (found 
naturally in bacterial DNA) that bind TLR9 have been 
proposed for the treatment of atopic disorders [42-45]. 
Our current data extend this proposal to the treatment of 
pulmonary eosinophilia induced by C. neoformans, a 
pathogen associated with progression to AIDS. A further 
important advantage of using synthetic CpG ODN is that 
patients most affected by C. neoformans infection have 
selected acquired immune deficiencies. Targeting innate 
immune receptors will bypass this deficit and stimulate 
non-specific resistance. 
TLR2, TLR4, CD14 and MyD88 have been widely 
implicated in innate immunity to a variety of other fungi 
[46-50]. Their individual contributions appear minimal, 
since MyD88-deficient mice are far more susceptible to 
fungal infection than individual TLR knockout mice [46, 
47]. Signaling via TLR9 is classically associated with 
antiviral/bacterial and not antifungal immunity. It is 
therefore not surprising that CpG ODN protect from 
polymicrobial sepsis [51] and intracellular bacteria 
[33]. It is surprising, however, that agonists that bind 
TLR9 have such a profound effect on C. neoformans-
induced pathology, especially since TLR9-deficient mice 
are resistant to a variety of other fungi [46]. 
CpG ODN have successfully reversed Th2-dominated 
responses to soluble antigens [45, 52-54] and viral 
vaccines [55]. Of interest is their ability to also modulate 
diseases classically associated with Thl cells. Intraper-
itoneal injection of CpG ODN into BALB/c mice reduces 
M. tuberculosis growth in the lungs [29] and protects 
against LPS-induced airway inflammation [56]. How 
synthetic CpG ODN bind and enter cells to exert these 
effects is currently unclear. The effect once CpG ODN are 
internalized is similarly complex and may depend on the 
specific cell type involved and its location. CpG ODN are 
known to activate macrophages and dendritic cells to 
produce IL-12, and yet their influence on Th2 responses 
to Schistosoma mansoni eggs is independent of this 
cytokine [54]. On the other hand, IL-12 is critical for 
prevention of allergen-induced airway eosinophilia [45] 
and LPS-induced lung inflammation [56] by CpG ODN, 
similar to the effect described in the current study. The 
mechanisms explaining these discrepancies are not clear 
but may depend on other immune mediators in the local 
microenvironment. For example, Wynn and colleagues 
propose an elegant model whereby CpG ODN alter IL-10 
and costimulatory molecule expression, preventing 
pulmonary eosinophilia to schistosome eggs even in 
the absence of IL-12 [54]. 
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The site of CpG ODN delivery may also affect the 
mechanism of action. Two studies have shown consti-
tutive expression of TLR9 in endothelial cells from the 
lung [57] and colon [58]. In both studies in vitro 
incubation with CpG ODN induced IL-8, and in the 
former study ICAM-1, expression. Thus, if CpG ODN 
enter the systemic circulation, they could influence cell 
movement into sites of inflammation and even the type 
of cells that traverse the endothelial layer. To date most 
studies have administered CpG ODN into the perito-
neum. A challenge for the future application of CpG 
ODN in a clinical setting will be to determine whether 
similar beneficial effects are observed when they are 
administered via a more realistic route (i.e., i.d., orally 
or i.n.). In our study CpG ODN were administered i.n. 
once before infection. The lung microenvironment has 
traditionally been described as immunosuppressive 
mostly due to the presence of IL-10 from epithelial 
cells in the lungs of healthy people [59]. The ability to 
respond to pathogens and overcome IL-10-induced 
suppression is explained by the ability of TLR ligands 
to inhibit IL-10 receptor signal transduction [60]. In our 
study, administration of CpG ODN directly into the lung 
may therefore remove the immunosuppressive environ-
ment and prime the lung to handle C. neoformans more 
efficiently. 
The reduction of pulmonary eosinophilia by CpG 
ODN is equally effective when given before, at the time 
of or 3-4 days after C. neoformans infection, similar to 
the effect described for Leishmania major-[61] and M. 
tuberculosis-[29] infected mice and in a murine model of 
asthma [52]. CpG ODN may therefore be used 
prophylactically or to modify established disease. 
Modulation of disease by a single administration of 
CpG ODN is important since chronic treatment has been 
associated with structural and functional alterations in 
lymphoid organs with destruction of lymphoid follicles 
and, after 3 weeks, liver necrosis and hemorrhagic acites 
[62] 
It is interesting to note that CpG ODN modulate 
pathogen burden and eosinophilic disease using differ-
ent mechanisms. Modulation of pulmonary eosinophilia 
depends on IL-12, whereas enhancement of pathogen 
clearance does not. CpG ODN binding to TLR9 are likely 
to activate the antimicrobial activity of alveolar macro-
phages, leading directly to enhanced pathogen engulf-
ment and killing; this has previously been described for 
respiratory syncytial and influenza virus [63, 64]. 
Although an absence of IL-12 does not impede C. 
neoformans clearance, its role during lung viral disease is 
not known. Complement, Fc receptors and mannose 
receptors are important for opsonization of C. neofor-
mans. Though not directly tested in this study, CpG ODN 
may increase their expression [65]. In addition, optimal 
activation of macrophages by IFN-y requires MyD88 
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signaling [66], which in our study is facilitated by the 
addition of CpG ODN. The glucuronoxylomannan 
(GXM) capsule of C. neoformans binds TLR2, TLR4 
and CD14 but is also secreted. Both surface-bound and 
secreted GXM modulate antifungal immunity, including 
phagocytosis ([47] and references within), which the 
addition of CpG ODN in our study may overcome, 
explaining reduced pathogen burden. Reduced eosino-
philia, on the other hand, is mediated indirectly by CpG; 
CpG binding to TLR9 induces IL-12 secretion, which 
inhibits Th2 development (and hence cytokines that 
support eosinophils) and/or directly binds eosinophils 
and induces their apoptosis. For this effect IL-12 is 
essential. The dependence of the observed effects on IL-
12 is similar to that described for Leishmania [67]. CpG 
ODN treatment not only enhanced IFN-y secretion by 
T cells but also their expression of OX40, a marker 
associated with prolonged T cell activation. We have 
previously detailed that promotion of OX40-expressing 
T cells using an OX4OL:Ig fusion protein enhances IFN-y 
secretion and mediates the exact effects shown in the 
current study [68]. CpG ODN therefore appear to 
increase the number of antigen-specific T cells in the 
lung microenvironment, probably via enhanced pre-
sentation of cryptococcal antigens and expression of 
costimulatory molecules, which is why CpG ODN have 
been considered as new adjuvants for vaccine develop-
ment ([44] and references within). 
In summary, we show modulation of C. neoformans-
induced lung disease by stimulation through a Toll-like 
receptor not normally associated with antifungal 
immunity. Most studies to date have looked at the 
effects of an absence of specific TLR rather than agonists 
that stimulate cells through them. The development of 
strategies that target innate immunity is vital for those 
patients with a deficient acquired immune system. C. 
neoformans infection is an AIDS-defining infection. AIDS 
patients have reduced T cell responses and often suffer 
from disseminated fungal meningitis. Control of the 
pathogen burden at the site of infection (the lung) may 
prevent disseminated disease. CpG ODN treatment may 
therefore be ideal, since it is effective after a single 
inhalation and reduces pathogen burden in an IL-12-
dependent manner. 
Materials and methods 
Mice and infectious material 
Female C57BL/6 mice and IL-12-/- knockout mice on a C57BL/ 
6 background (Harlan Olac Ltd, Bicester, UK), 8-10 weeks old, 
were kept in specific pathogen-free conditions according to 
Home Office, UK guidelines. C. neoformans strain 52 was 
obtained from the American Type Culture Collection (no. 
24067, Rockville, MD). Yeast were culture in Sabouraud 
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dextrose broth (1% neopeptone and 2% dextrose; Difco, 
Detroit, MI) for 48-72 h and at stationary phase centrifuged at 
3,000 rpm for 10 min, washed in sterile PBS and counted 
using a hemocytometer prior to infection. Under transient 
isofluorane anesthesia, mice were i.n. infected with 1 x 104 to 
2 x104 yeast cells in 50 µI sterile PBS. The infectious dose was 
verified by culturing the yeast on Sabouraud agar plates 
(Difco) and counting the colonies after 48 h incubation at 
room temperature. Sterile PBS (50 µI) was administered i.n. to 
age-matched controls. 
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Enumeration of C. neoformans 
Ten-fold serial dilutions of BAL fluid and lung tissue 
homogenate (100 µI) were applied to Sabouraud agar plates 
(Difco) and the colonies counted after 48-72 h incubation at 
room temperature. The number of CFU/ml was calculated as 
follows: number of colonies x dilution x 10. The results 
obtained from several dilutions were averaged. Microscopic C. 
neoformans bodies were also counted from H&E-stained 
cytospin preparations, using their very distinctive cellular 
architecture. 
Highly purified CpG ODN 1826 (sequence 5' TCCAT-
GACGTTCCTGACGTT) was provided by Coley Pharmaceutical 
Group (Wellesley, MA) and had a fully phosphorothioate-
modified backbone for nuclease resistance and no detectable 
endotoxin [69]. CpG 1826 was also methylated between 
nucleotide positions 8-9 and 17-18 (5'-TCCATGACoGTTCCT-
GACoG1T-3') in order to nullify the unmethylated immunos-
timulatory capacity. The methylated 1826 CpG is referred to as 
control ODN. 
Experimental procedure 
Mice were i.n. immunized, under transient anesthesia, with 
50 µg or 100 lig CpG ODN or control ODN in 50 µI sterile, 
endotoxin-free PBS 3 days before or 5 days after i.n. infection 
with 1 x104 to 2 x104 C. neoformans in 50 µI sterile PBS. Mice 
were killed 12 days later and various tissues removed. In some 
experiments mice were treated with 100 pig anti-IL-12 or anti-
NK1.1 antibody i.p. 1 day before and 1, 4, 8 and 11 days 
following C. neoformans infection. In a separate experiment, 
CpG ODN-treated, C. neoformans-infected mice (with or 
without CpG ODN) were depleted of CD8+ T cells using 
100 pg anti-CD8 antibody on days 2 and 9. 
Cell recovery 
Lung and Peyer's patches were removed and immediately 
placed on ice in RPMI medium (Sigma, Poole, UK). Single-cell 
suspensions were generated from each tissue by passing the 
cells through a 0.8 gm mesh filter. Red blood cells were lysed 
using ammonium chloride and the cells washed, centrifuged at 
1,200 rpm for 5 mM and resuspended at 106 cells/ml. Cell 
numbers were determined by Trypan blue exclusion. BAL fluid 
was obtained by inflating the lungs six times with Eagle's 
Minimal Essential Medium (Sigma) containing 10 mM EDTA. 
BAL fluid was immediately placed on ice. BAL fluid (100 µ1) 
was cyto-centrifuged at 800 rpm for 5 min onto glass slides, 
fixed in ice-cold methanol and stained with hematoxylin and 
eosin (H&E). 
Enumeration of eosinophils 
Eosinophils were enumerated by flow cytometry based on their 
distinctive size (forward scatter) and granularity (side scatter). 
The proportion of eosinophils was confirmed from cytospin 
preparations of BAL fluid following H&E staining, using their 
characteristic nuclear morphology and presence of acidophilic 
red granules. 
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Flow cytometry 
Cells (1 x106) obtained from BAL fluid or the lung were stained 
for cell-surface antigens using allophycocyanin (APC)-con-
jugated anti-CD4 or PerCP-conjugated anti-CD8. Intracellular 
cytokines were detected by incubating 1 x106 cells with 50 ng/ 
ml PMA (Sigma), 500 ng ionomycin (Calbiochem) and 10 i.ig/ 
ml Brefeldin A (Sigma) for 4 h at 37°C. Cells were incubated 
with anti-CD4-APC, anti-CD8-PerCP, anti-CD45RB-FITC and 
anti-0X40-PE on ice for 30 min, washed and then fixed in 50 µ1 
2% formaldehyde for 20 min at room temperature. Cells were 
permeabilized with 0.5% saponin in PBS containing 1% BSA 
and 0.1% sodium azide for 10 min. Anti-IFN-y-FITC and either 
anti-IL-4- or anti-IL-5-PE were diluted 1:50 in saponin buffer 
and incubated with the cells for 10 min. Cells were washed 
once in saponin buffer and twice in PBS containing 0.1% 
sodium azide and 1% BSA and analyzed using four-color flow 
cytometry on a FACSCalibur (Becton Dickinson). All antibodies 
were purchased from PharMingen (San Diego, CA). 
In vitro analysis of the effect of CpG ODN 
To collect peritoneal exudate cells, 10 ml sterile RPMI was 
injected into the peritoneal cavity of C57BL/6 mice and then 
withdrawn using a syringe. The cells were centrifuged and 
then incubated at 5 x105 cells/well in the presence or absence 
of 50 units/ml IFN-y. After 3 h the cells were washed, and 
25 µg/m1 CpG ODN was added. Supernatants were recovered 
after 48 h and cytokines enumerated in a cytometric bead 
array according to the manufacturer's instructions (Becton 
Dickinson). Some samples were incubated in medium or IFN-y 
alone as controls. 
Statistical analysis 
The statistical significance of all data was assessed by two-
tailed ANOVA, assuming unequal variance. Bonferroni correc-
tion was applied where appropriate. 
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Immunity to infection 
A critical role for ICOS co-stimulation in immune 
containment of pulmonary influenza virus infection 
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Lung pathology observed during influenza infection is due to direct damage resulting 
from viral replication and bystander damage caused by overly exuberant antiviral 
immune mechanisms. In the absence of universally effective vaccines and antiviral 
therapies, knowledge of the cellular components required for immune containment of 
influenza is essential. ICOS is a late co-stimulatory molecule expressed by T cells 
12-24 h after activation. We show for the first time that inhibition of ICOS with a 
monoclonal antibody reduces pulmonary T cell inflammation and associated cytokine 
expression. Surprisingly however, this reduction in T cells was not accompanied by an 
alleviation of weight loss and illness. Furthermore, lung viral titres were elevated 
following anti-ICOS treatment, suggesting that the beneficial outcome of reducing T cell 
pathology was masked by enhanced virus-induced damage and innate inflammation. 
This study demonstrates the delicate balance that exists between pathogen burden and 
pulmonary T cell inflammation during influenza infection and highlights the critical 
role of ICOS in this response. 
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Introduction 
The process of initial T cell activation via TCR 
recognition of MHC/peptide and CD28 ligation of 
CD80/86 on the antigen-presenting cell is well char-
acterised, as is the subsequent negative regulation 
through the switch of CD28 for CTLA-4. However, the 
signals required to maintain T cell survival after these 
initial interactions and potentially drive them into the 
memory pool are the subject of intense current 
investigation. It is now clear that several inducible late 
co-stimulatory molecules fulfill this role [1-3]. Their 
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differential and temporal expression patterns render 
them prime targets for inhibiting exuberant inflamma-
tion or for promoting immune responses to vaccines and 
persistent pathogens. 
The outcome of a pulmonary infection depends on 
the extent of damage caused by the pathogen and the 
bystander problems evoked through the presence of 
excessive inflammatory cells in the lung. Influenza virus 
replication has fatal consequences for host cells through 
the destruction of mRNA [4], inhibition of translational 
machinery [5] and eventual induction of apoptosis [6] 
or necrosis [5]. However, biopsies from patients with 
influenza pneumonia often show acute lung injury with 
organised lymphoid infiltrates, suggesting that immu-
nopathology contributes to disease [7]. Furthermore, 
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autopsies from the 1918 influenza pandemic also show 
signs of immunopathologic lung damage [8]. 
T cells contribute significantly to antiviral immunity 
and antibody production in the lung [9] but also to 
pathology when present and activated in excess. In 
addition to physical impairment of lung function via 
consolidation and lysis of virally infected cells, virus-
specific T cells produce copious amounts of inflamma-
tory cytokines [10, 11]. Most notable is TNF that, when 
produced in excess, leads to cachexia. In support of the 
pathogenic influence of T cells, infection of nude mice 
results in reduced lymphocytic inflammation and 
increases early survival compared with immune com-
petent controls [12]. 
In the absence of a suitable vaccine, one strategy to 
prevent the debilitating effects of influenza infection 
would involve reducing the inflammatory burden. We 
and others previously achieved this by neutralising TNF 
[13, 14]; this, however, is not without problems, as long-
term treatment may lead to global immune suppression 
and the reactivation of other latent infections [15] . A 
more specific approach would target only those cells 
responsible for inflammatory cytokine production. 
Since late co-stimulatory molecules such as OX40 
(CD134) and 4-1BB (CD137) are only expressed after 
antigen activation, they provide a more targeted 
approach for the reduction of excessive inflammation. 
We previously demonstrated that inhibiting the pro-
liferation and survival of antigen-activated T cells by 
targeting OX40 co-stimulation reduces influenza-in-
duced pulmonary inflammation and associated disease 
without impairing viral clearance [16], similar to mice 
genetically deficient in this molecule [17, 18]. In 
contrast, inhibition of constitutively expressed CD28 
delays the clearance of influenza from the lung [19]. 
ICOS is another potential target for dampening 
excessive inflammation: expression is also inducible, 
and inhibition has never been tested during pulmonary 
viral infection. ICOS is a CD28-related molecule 
expressed earlier than OX40, 12-24 h after TCR 
signalling, and delivers a co-stimulatory signal [20, 
21]. Expression is reported on CD4+, CD8+ and memory 
T cells [21, 22] and on both Thl and Th2 subtypes, 
though it is thought to persist at higher levels on Th2 
cells [22]. Expression is also apparent on NK cells, where 
ligation promotes their function [23]. ICOS co-stimula-
tion can induce Thl, Th2 [22, 24-27] and regulatory 
cytokines [20, 27-29]. 
Blockade of ICOS in vivo ameliorates autoimmunity 
(EAE, diabetes and collagen-induced arthritis), asthma 
and allergy and prevents transplant rejection (for a 
review see [2]). In murine models of infection, ICOS 
inhibition reduces Thl responses to Listeria monocyto-
genes [30], Th2 responses to Leishmania major [31], Thl 
and Th2 responses to Leishmania mexicana [32] and 
© 2006 W1LEY-VCH Verlag GmbH & Co. KGaA, Weinheim 
global T cell responses to Nippostrongylus brasiliensis 
[31]. 
Since the threat of a new influenza virus pandemic is 
imminent and vaccine development takes months to 
complete, the identification and development of poten-
tial therapeutics is a priority. OX40 inhibition, even after 
the onset of clinical disease [16], is clearly beneficial. It 
is not clear, however, whether manipulation of other 
inducible co-stimulatory molecules is similarly bene-
ficial during lung influenza virus infection. We now 
show that anti-ICOS antibody treatment reduces 
pulmonary T cells and T cell-derived inflammatory 
cytokines, but unlike OX40 inhibition, virus-induced 
illness and weight loss remain. More importantly, mice 
administered anti-ICOS are unable to contain influenza 
virus replication, and levels of soluble inflammatory 
mediators in the lung actually increase. Polymorphisms 
in the gene encoding ICOS [33] could therefore lead to a 
diverse outcome upon influenza infection in man and 
may explain why some infections are more pathogenic 
than others. 
Results 
ICOS is expressed by lung T cells during influenza 
infection 
On the day of infection (day 0) fewer than 5% of T cells 
were present in the airways, and none expressed ICOS. 
During influenza infection, ICOS expression by CD4+ 
(Fig. la) and CD8+ (Fig. lb) T cells in the airways 
occurred by day 3 and peaked 7 days after infection, at 
which time 80% of CD4+ and 60% of CD8+ T cells 
expressed ICOS (Fig. lc). Expression of ICOS by 
influenza-specific CD8+ T cells (identified using MHC 
class I tetramers) mirrored that of total CD8+ T cells. 
Identical kinetics of expression were also observed on 
lung and mediastinal lymph node (MLN) T cells, 
although at a lower proportion in MLN ( 20% by 
CD4+ and CD8+ T cells) compared to other lung 
compartments. Peak ICOS expression in the airways 
(and other tissues) was observed much later than 
maximal viral load (Fig. 1c), suggesting that ICOS 
expression is induced by viral antigen. 
Anti-ICOS reduces cytokine-expressing T cells 
during influenza infection 
We next ascertained whether ICOS signalling mediates 
T cell-mediated immunopathology elicited by intranasal 
influenza virus infection by using a blocking non-
depleting anti-ICOS monoclonal antibody that has an 
approximate half-life of 4 days (previously utilised in 
disease models of EAE, allograft rejection and airway 
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hypersensitivity [34-36]). Pulmonary inflammation 
induced by influenza typically peaks 6-7 days after 
infection [16]. At this time, influenza-infected mice 
treated with anti-ICOS from the time of infection had 
reduced numbers of CD4+ and CD8+ T cells in the 
airways (Fig. 2a) and lung tissue (Fig. 2b) compared 
with IgG-treated littermate controls. This effect was also 
a 
ICOS  
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evident when antibody treatment was delayed until 
3 days post-infection (data not shown). In accordance 
with this generalised reduction in T cell inflammation, 
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Figure 1. ICOS expression by T cells is induced during influenza 
virus infection. Cells from the airways of influenza-infected 
BALB/c mice 7 days after infection were stained with anti-CD4-
allophycocyanin (APC), anti-CD8-PercP and anti-ICOS-biotin 
followed by streptavidin-FITC. Representative plots of CD4 (a) 
and CD8 (b) (both y-axis) and ICOS (x-axis) are shown and 
represent five mice from three separate experiments. Quad-
rants were set using biotinylated isotype control antibody. (c) 
Cells from the airways of influenza-infected mice were taken 
after 0, 3, 7,10 and 15 days and stained with anti-CD4, anti-CD8 
or tetramer-APC and anti-ICOS antibody. Viral lung titres were 
measured by plaque assay of homogenized lung. All results 
represent means ± SEM of four mice per group. 
© 2006 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim  
Figure 2. ICOS inhibition reduces influenza-induced inflam-
mation. BALB/c mice (n=5) were infected with influenza and 
treated with either 100 jig rat IgG (.) or anti-ICOS (0) on days 0, 
2 and 5. Mice were killed 7 days post-infection, and airway (a) 
and lung (b) cells were stained with anti-CD4 and anti-CD8. 
Total numbers were calculated by multiplying total numbers of 
lymphocytes by the percentage of positive cells determined by 
flow cytometry. (c, d) Lungs from mice treated with anti-ICOS 
(c) or IgG (d) were inflation-fixed with 10% formalin, paraffin-
embedded and H&E stained (original magnification x200). 
Airways and blood vessels are indicated as arrows and 
triangles, respectively. Results represent three separate experi-
ments. 
www.eji-journal.eu 
CD4' 	CD8* 
CD4' 
	CD8' 
10be  
I 
o  1 
x 
II 6 
.- I 
lo* to 	 I 
Z 4 
g 	
tO 
P <0.05
I  
* 	P 0.02 
2 
I A 
P0.004 *a 
W P 0.001 
1 
Tau 
0 
0.5 
200 
U. 
0 
P 0.04 
II 
P 0 009 I a 	dip 0.008 
! 
C 
8 
0 
6 
To • 4 
-4 
2 ffi 
0 
CD4* 	CD8* 
Eur. J. Immunol. 2006. 36: 2928-2938 	 Immunity to infection 2931 d::•1 
anti-ICOS also reduced the total number of CD4+ and 
CD8+ T cells expressing ICOS (not shown). The reduced 
inflammation in anti-ICOS-treated mice was also 
evident in H&E-stained lung sections, with markedly 
decreased cellular infiltration around the airways and 
blood vessels on days 7 (Fig. 2c), 10 and 14 (data not 
shown) but not day 4 (not shown) compared with IgG-
treated littermate controls (Fig. 2d). 
ICOS ligation on T cells induces the expression of 
cytokines [20]. During influenza infection, ICOS 
inhibition substantially reduced the number of lung 
CD4 4" and CD8+ T cells secreting the pro-inflammatory 
cytokines IFNI/ (Fig. 3a) and TNF (Fig. 3b). Reduced 
expression of these cytokines was not explained by a 
skewing of T cell responses towards a type 2 phenotype, 
as IL-4-producing lung T cells were also decreased 
following ICOS neutralization (Fig. 3c). ICOS ligation 
has also been reported to induce IL-10 expression [20,  
27], and it was therefore interesting to note that anti-
ICOS treatment profoundly decreased the numbers of 
CD4+ and CD8+ T cells secreting IL-10 in the lung 
(Fig. 3d). 
To study the effect of anti-ICOS on influenza-specific 
cytokine expression, lung cells from infected mice were 
stimulated in vitro with live virus for 48 h and IFN-y 
production examined by ELISPOT. Anti-ICOS treatment 
significantly reduced the frequency of virus-specific IFN-
y-producing cells in the lung (Fig. 3e). 
Anti-ICOS does not ameliorate influenza-induced 
weight loss 
Expression of the pro-inflammatory cytokines IFN-y and 
TNF is associated with weight loss and illness during 
influenza infection [14]. We previously demonstrated 
that inhibition of another late co-stimulatory molecule, 
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Figure 3. Influenza-infected BALB/c mice treated with either rat IgG (closed bars or 
symbols) or anti-ICOS (open bars or symbols) on days 0, 2 and 5 were killed 7 days post-
infection and lung cells stained with anti-CD4 and anti-CD8. Production of IFN-y (a), 
TNF (b), IL-4 (c) and IL-10 (d) was analysed by intracellular cytokine staining. Total 
numbers of cytokine-secreting cells were calculated by multiplying the number of CD4+ 
and CD8+ lymphocytes by the percentage expressing each cytokine. (e) The frequency of 
cells producing IFN-y in response to influenza stimulation was determined by ELISPOT. 
Results are expressed as mean values of four mice per group ± SEM and represent two 
independent experiments. 
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OX40, prevents weight loss and hypothesised that this 
was due to a reduction in the number of cells capable of 
secreting pro-inflammatory cytokines [16]. We were 
therefore surprised that despite reducing the number of 
TNF- and IFN-7-expressing T cells, anti-ICOS did not 
ameliorate the extent of virus-driven weight loss 
(Fig. 4a). Though a marginal improvement in weight 
recovery was observed, this was not significant for every 
experiment, and all mice had returned to pre-infection 
weights by day 14 post-infection. 
Another intriguing observation was that although 
intracellular cytokines in T cells were reduced by anti-
ICOS treatment, soluble IFN-y (Fig. 4b), TNF (Fig. 4c) 
and IL-10 (Fig. 4d) were actually increased 7 days after 
infection. One possible explanation for an increase in 
soluble cytokines is that although the total number of 
cytokine-expressing T cells in anti-ICOS-treated lungs 
was reduced, those remaining actually produce more on 
a cell-to-cell basis. However, fluorescence intensity 
analysis of cytokine expression by lung CD4+ and 
CD8± T cells, which is an indication of the level of  
intracellular cytokine in each cytokine-positive cell, 
revealed no increase in their median expression (not 
shown). This suggests that the enhanced soluble 
cytokines originated from another source. NK cells are 
a major source of IFN-y [37], and it was interesting to 
note that NK cells expressing intracellular IFN-7 were 
increased following anti-ICOS treatment (Fig. 4e). 
Anti-ICOS impairs the control of influenza 
replication 
Influenza infection induces cytokine production by 
macrophages, dendritic cells and lung epithelial cells 
[38-40]. One explanation for the elevated soluble lung 
cytokines following ICOS inhibition is therefore that 
viral load is enhanced in these mice. In accordance with 
this hypothesis, elevated lung influenza titres were 
observed 7 days after infection in anti-ICOS-treated 
mice (Fig. 5a). This increase in viral load did not lead to 
viral persistence, however, as both groups cleared the 
virus by day 10 (not shown). The elevation in pathogen 
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Figure 4. Anti-ICOS treatment does not reduce weight loss and increases cytokine 
expression in the lungs. Influenza-infected BALB/c mice were treated with either IgG 
(closed bars or symbols) or anti-ICOS (open bars or symbols) on alternate days. (a) Weight 
loss was measured throughout and is expressed as the percentage of original weight. Mice 
were killed 7 days post-infection, and concentrations of IFN-y (b), TNF (c) and IL-1.0 (d) were 
measured in BAL fluid by ELISA. All results are expressed as mean values ± SEM of five 
mice per group. (e) Lung cells were stained with anti-CD4, anti-CD8, anti-DXS and anti-
IFN-y. Total numbers of cytokine-producing cells were calculated by multiplying the 
percentage of positive cells by total numbers of lymphocytes. Results are representative of 
at least two independent experiments. 
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load was associated with reduced numbers of influenza 
nucleoprotein (NP)-specific tetramer-binding CDS+ 
T cells at day 7 but enhanced numbers at day 10 
(Fig. 5b), suggesting that rather than controlling 
absolute numbers, anti-ICOS treatment delays the 
recruitment of influenza-specific CDS+ T cells to this 
site. ICOS is critical for T cell-dependent B cell responses 
[41-44], and anti-ICOS-treated mice displayed reduced 
total lung B cell numbers 7 days post-infection (Fig. 5c). 
However, influenza-specific IgG titres were unaffected 
(not shown), implying that a reduction of humoral 
immunity following ICOS inhibition did not contribute 
to the elevation in viral load. 
ICOS inhibition enhances T cell accumulation 
in the MLN 
Why then does the inhibition of two late co-
stimulatory molecules during influenza infection have 
such different outcomes? Although both ICOS and OX40 
are termed "late co-stimulatory molecules", their 
expression patterns differ considerably. Following 
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We next investigated the mechanisms by which ICOS 
neutralization reduced T cell numbers in the lung and 
airways. Anti-ICOS treatment did not enhance cellular 
apoptosis in the airways, with Annexin V-positive CD4+ 
(Fig. 6a) and CDS+ (Fig. 6b) T cells comparable to IgG-
treated littermates. Similarly, T cell proliferation was 
unaffected by ICOS inhibition, as cellular incorporation 
of BrdU (an indication of proliferation) in T cells in the 
lungs of influenza-infected mice 4 and 7 days after 
infection was similar in both treatment groups (Fig. 6c). 
Another explanation is that by inhibiting ICOS, we are 
preventing migration of T cells from the node to the 
lung. Interestingly, the numbers of T cells expressing 
IFN-y (Fig. 6d) and IL-10 (Fig. 6e) were increased in the 	C 16 - 
MLN 7 days after infection in anti-ICOS-treated animals. 
Unfortunately we were unable to gauge the influence of 
ICOS treatment on (tetramer-stained) antigen-specific 
cells, as their frequency at this site was less than 1%. 
Sp
  
• 
to 
• 
Discussion 
In the absence of a universally effective vaccine or 
antiviral therapy, the continual threat of an influenza 
pandemic demands that we investigate endogenous 
control mechanisms. Inhibiting influenza-induced in-
flammation represents a novel strategy to alleviate 
symptoms of this disease. However, a reduction in 
immunity must not allow the pathogen to replicate 
unchecked (as shown in this study by the inhibition of 
ICOS) or prevent the induction of memory T cells. By 
inhibiting ICOS we reduced pulmonary T cell infiltration 
at day 7 but not day 10 and enhanced viral titres and 
cytokine expression in the lung. This is in contrast to our 
earlier study showing amelioration of influenza-induced 
disease via the inhibition of another late T cell co-
stimulatory signal, OX40 [16]. 
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P 0.0004 
IgG 	Anti-ICOS 
Figure 5. Anti-ICOS reduces viral clearance and tetramer-
specific CD8+ T cells. Influenza-infected mice treated with 
either IgG (closed bars or symbols) or anti-ICOS (open bars or 
symbols) on days 0, 2 and 5 were killed after 7 or 10 days. (a) 
Virus titres in the lung 7 days post-infection were measured by 
plaque assay. Results are shown as mean values ± SEM of five 
mice per group. (b) Anti-CD8-FITC-stained lung cells taken 7 or 
10 days post-infection were incubated with APC-conjugated 
influenza nucleoprotein (NP)-specific tetramers. Total num-
bers were calculated by multiplying the percentage of 
CD8+tetramer+ cells by total lung lymphocytes. (c) Lung cells 
were taken 7 days post-infection and stained with anti-B220-
PercP. Total B cells were calculated by multiplying the 
percentage of B220+ cells by the total number of viable lung 
cells. Individual mice and the mean value are shown, and 
results represent at least two experiments. 
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activation, Tcells express ICOS at least 12 h before OX40 
[45, 46]. Furthermore, in our experimental systems, 
approximately 2- to 3-fold more lung CD4+ and CD8+ 
Tcells express ICOS than OX40 at the peak of an antiviral 
T cell response (data not shown). It is therefore not 
surprising that inhibition of ICOS has a larger quanti-
tative effect on virus-induced T cell responses than OX40 
blockade. However, the differential outcomes of ICOS 
and OX40 inhibition may also reflect functional 
differences between the two molecules. Whereas 
OX40 is critical for T cell expansion and survival [1], 
ICOS signalling is intrinsically associated with cytokine  
secretion [47], and anti-ICOS may therefore affect a 
broader range of cell types dependent on those 
cytokines. 
The mechanisms by which OX40 and ICOS inhibition 
reduce pulmonary T cell numbers also differ. OX40 
inhibition reduces virus-induced inflammation by im-
pairing T cell expansion and survival [16]. In contrast, 
ICOS ligation has a limited effect on T cell proliferation 
[21, 22] and anti-apoptotic Bcl-xL expression [48]. It is 
therefore not surprising that we observed no effect on 
either cellular proliferation or apoptosis in the lung 
following anti-ICOS treatment. 
C 
25 
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Figure 6. Anti-ICOS treatment increases accumulation of cytokine-secreting T cells in 
the MLN but does not reduce cellular proliferation or enhance apoptosis in the lung. 
Influenza-infected mice treated with either IgG (closed symbols) or anti-ICOS (open 
symbols) were killed 7 days post-infection. (a, b) BAL cells were stained with anti-CD4, 
anti-CD8 and Annexin V. The percentages of CD4+ (a) and CDR' (b) T cells binding 
Annexin Von days 4 and 7 post-infection are shown and represent mean values ± SEM 
from four mice per group. (c) Mice were injected with BrdU 24 h before sacrifice. On 
days 4 and 7 post-infection, lung sections were stained with anti-BrdU-biotin and 
streptavidin-HRP. Results are expressed as the percentage of BrdU-positive cells with at 
least 300 cells counted and are shown as the mean ± SEM from four mice per group. 
MLN-derived cells were stained with anti-CD4, anti-CD8 and either anti-IFN-y (d) or anti-
IL-10 (e). Total numbers were calculated by multiplying total lymphocytes by the 
percentage of positive cells. All results are representative of two to three separate 
experiments. 
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Impaired viral clearance following inhibition of ICOS 
but not OX40 may represent (in contrast to OX40 [49]) 
the reported direct role for ICOS in CD8+ T cell 
cytotoxicity [50]. Reduced cytotoxicity by influenza-
specific CD8+ T cells after anti-ICOS treatment may 
explain enhanced viral titres. However following 
systemic influenza infection of ICOS-/- mice, CD8+  
T cell cytotoxicity is not impaired [51]. Moreover, ICOS-
deficient mice have no defect in CD8+ T cell expansion, 
and although these mice have a transient defect in late 
primary CD8± T cell responses [51], the kinetics and 
degree of the defect in CD8+ T cells is not comparable to 
those reported here. Whether these dissimilar results 
represent the alternative routes of infection (intranasal 
versus intraperitoneal), different anatomical locations 
of the T cell responses studied (lung versus spleen) or 
differences between utilization of inhibitory antibody 
and gene-deficient mice is currently unknown. Finally, it 
was recently shown that the TNF receptor superfamily 
member 4-1BB can cooperate with ICOS to mediate 
influenza-specific CD8+ T cell responses [52]. Further 
investigation is required to examine whether differing 
expression of other co-stimulatory molecules by influ-
enza-specific CD8+ T cells in the lung versus spleen may 
influence the effect of ICOS inhibition/deletion on these 
responses. 
The enhanced accumulation of T cells in the MLN of 
anti-ICOS-treated animals is interesting and is not 
explained by defective priming, as these cells produced 
large quantities of cytokines. It is possible that ICOS 
ligation provides the "Go" signal required to release 
recently activated early effectors from the node. It is 
likely that ICOS co-stimulation alters chemokine 
expression on activated T cells, which in turn controls 
the migration of T cells from secondary lymphoid tissue 
to the lung during influenza infection [53, 54]. This 
would make evolutionary sense, as cells up-regulating 
ICOS have presumably recognised their antigen and are 
therefore deemed useful in the inflamed tissue, whereas 
ICOS-negative cells may as well remain in the lymph 
node since they are likely to be non-specific. This idea is 
supported by the observation that the majority of T cells 
in the inflamed lung express ICOS. As further evidence, 
anti-ICOS treatment reduces chemokine receptor ex-
pression in models of airway hyperreactivity [36] and 
transplant rejection [55], and ICOS mediates the 
movement of human T cells through endothelial cells 
[56]. To support the idea that inhibition of ICOS impairs 
migration of antigen-activated T lymphocytes, we 
observed reduced lung tetramer-binding CD8+ T cells 
at day 7 after infection but not at day 0. It is interesting 
to note that anti-ICOS treatment ceased at day 5 and 
that the half-life of this antibody is reported to be 4 days. 
Therefore, immediately after clearance of anti-ICOS 
antibodies, T cell migration resumes. Rather than 
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controlling absolute numbers, therefore, ICOS inhibi-
tion may delay migration of T cells to effector sites. To 
our knowledge, this is the first time that a role for ICOS 
in modulating T cell migration from lymph nodes to the 
site of inflammation has been shown in vivo. Whether 
this is due directly to ICOS expression or indirectly via 
molecules produced after ICOS ligation is currently not 
known. 
The accumulation of cytokine-expressing T cells in 
the MLN may influence the weight loss induced by 
influenza. Pulmonary influenza infection of lymphotox-
in-a-deficient mice that lack peripheral lymph nodes 
induces less weight loss than that observed in wild-type 
controls [57], implying a critical role for peripheral 
T cells in promoting weight loss. Therefore, although 
ICOS inhibition reduces the infiltration of cytokine-
expressing T cells in the lung, the accumulation of these 
cells in peripheral lymphoid tissue may enhance 
systemic cytokine expression and therefore reverse 
any beneficial effects of reduced pulmonary T cell 
inflammation. 
Alternatively, increased soluble production of TNF 
and IFN-y (both of which are implicated in influenza-
induced immunopathology [10, 14]) from non-T cell 
sources in the airways may explain the lack of an effect 
on weight loss following ICOS inhibition. This elevation 
in cytokines in the absence of large numbers of cytokine-
secreting T cells is striking and raises two important 
questions: 1) what is the source of these cytokines, and 
2) what causes their increased production? We have 
shown NK cells to be one source. However, this alone is 
unlikely to explain the increased levels of all cytokines. 
Lung epithelial cells do not tend to produce vast 
quantities of pro-inflammatory cytokines [38] but 
may be induced to do so if the pathogen is not cleared 
or replicates unchecked. Similarly, macrophages and 
dendritic cells may also contribute to the soluble 
cytokine load and are sensitive to antigen dose. 
A defect in regulatory T cell activity may also 
contribute, as ICOS ligation has been postulated to 
induce IL-10 secretion [27, 58, 59], and ICOS/ICOSL 
interactions are critical for the development and 
function of OVA-specific regulatory T cells [60]. 
Regulatory T cells appear to be important during 
chronic viral infections [61], but little is known 
regarding their influence during acute infections. 
Though we observed a reduction of IL-10-expressing 
CD4+ and CD8+ T cells, we do not believe this explains 
the outcome in our studies, since all T cell responses 
were suppressed. We cannot rule out the possibility, 
however, that IL-10 derived from T cells in the lung 
dampens pro-inflammatory cytokine production by non-
T cell populations. 
In conclusion, our data clearly show that ICOS 
ligation is critical for the development of protective 
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cellular responses to pulmonary influenza infection. We 
believe that, unlike OX40, inhibition of ICOS affects 
T cells at such an early stage that blockade of this signal 
is detrimental to the development of protective T cell-
mediated immunity. By interrupting their progression, 
we also indirectly affect other cell types dependent on 
their production of soluble mediators. There are two 
important conclusions for the therapeutic treatment of 
influenza-induced disease: firstly, careful consideration 
is required when selecting targets for immune manip-
ulation of inflammatory infectious disease and, sec-
ondly, given the broad antiviral effects promoted by 
ICOS, the induction of expression of this molecule may 
be crucial for the success of future influenza vaccine 
strategies and immune containment of a pandemic 
strain. 
Materials and methods 
Mice, virus and reagents 
6- to 8-wk-old female BALB/c mice (Harlan Olac Ltd, Bicester, 
UK) were kept in pathogen-free conditions according to Home 
Office guidelines. Influenza A strain X31 (haemagglutinin 
[HA] titre 1024) was a kind gift from Dr. Alan Douglas 
(National Institute for Medical Research, London, UK). The 
neutralising anti-ICOS mAb clone 12AE [34] was a kind gift 
from Anthony Coyle (Millennium Pharmaceuticals Inc., MA). 
Mouse infections and treatment 
On day 0 mice were anaesthetised and intranasally infected 
with 50 HA units influenza virus in 50 µL. Mice were injected 
intraperitoneally (i.p.) with 100 mg anti-ICOS antibody clone 
12AE or rat IgG (Caltag, San Francisco, CA) on days 0, 2 and 5. 
The weight of mice was monitored daily. Mice were killed 4 or 
7 days after infection by injection of 3 mg pentobarbitone and 
exsanguinated via the femoral vessels. When assessing cellular 
proliferation, mice were injected i.p. 1 h before termination 
with 75 mg/kg 5-bromo-2'-deoxyuridine (BrdU, Sigma Che-
mical Co., St. Louis, MO). 
Cell recovery and flow cytometric analysis 
Serum was obtained at each time point and stored at -20°C 
until required. Nasal washes were performed by removing the 
lower jaw and washing the nasal cavity with 200 µL PBS that 
was collected upon exit at the nares. This too was stored at 
-20°C. Single-cell suspensions from bronchoalveolar lavage 
fluid (BAL), lung tissue and MLN were isolated and stained for 
surface markers and intracellular cytokines as described 
previously [62]. Briefly, cells were stained for surface markers 
with antibody (all BD Pharmingen, Heidelberg, Germany) 
diluted in PBS containing 1% BSA/0.05% sodium azide (PBA) 
on ice for 30 min. When appropriate, indirect detection with 
streptavidin-FITC (BD Pharmingen) was employed. After 
washing, cells were fixed for 20 min at room temperature 
with 2% formaldehyde. To detect intracellular cytokines, 106 
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cells/mL were incubated with 50 ng/mL PMA (Sigma), 
500 ng/mL ionomycin (Calbiochem, Nottingham, UK) and 
10 mg/mL brefeldin A (Sigma) for 4 h at 37'C prior to surface 
staining and formaldehyde fixation. After permeabilisation 
with PBS containing 1% saponin/1% BSA/0.05% azide 
(saponin buffer), cells were stained with either anti-IFN-y, 
anti-TNF, anti-IL-4 or anti-IL-10 (all Caltag). Cells were washed 
30 min later and data acquired. Influenza-specific CD8+ T cells 
were identified using an APC-labelled MHC class I tetramer (H-
2d) loaded with the immunodominant peptide TYQRTRALV 
from the influenza nucleoprotein (NIAID Tetramer Facility, 
Atlanta, USA). 
Apoptosis analysis 
To enumerate apoptotic cells, binding of PE-labelled antibodies 
to Annexin V was performed according to the manufacturer's 
instructions (BD Pharmingen). Briefly, cells were stained with 
Annexin V-PE, anti-CD4-FITC and anti-CD8-PercP (all BD 
Pharmingen) and washed. 7-AAD was then added to detect 
dead cells; apoptotic cells were identified as 7-AAD-/Annexin 
V+. Data were then immediately acquired (collecting 30 000 
lymphocyte events) on a flow cytometer. 
Lung influenza titre 
Lungs were homogenised and cells freeze-thawed three times. 
After centrifugation at 400 x g, supernatants were titrated in 
doubling dilutions on Madine Darby canine kidney (MDCK) 
cell monolayers in flat-bottomed 96-well plates. After incuba-
tion at room temperature for 3 h, samples were overlayed with 
methycellulose and incubated for 72 h at 37°C. Cell mono-
layers were washed and incubated with anti-influenza anti-
body (Serotec UK, Oxford, UK), followed by anti-mouse-HRP 
(Dako Ltd., Cambridge, UK), and infected cells were detected 
using 3-amino-9-ethylcarbazole (AEC, Sigma). Infectious units 
were then enumerated by light microscopy, and total plaque 
forming units per lung were quantified (number of plaques x 
dilution factor x total volume of lung homogenate). 
Lung histology and immunohistochemical 
determination of cellular proliferation 
In some studies, lungs were inflation-fixed with 2% formalde-
hyde in PBS 7 days after intranasal influenza virus infection 
and embedded in paraffin wax. Sections (6-mM) were stained 
with haematoxylin and eosin (H&E, Lorraine Lawrence, 
Imperial College, London, UK). In vivo incorporation of BrdU 
was assessed using previously described methods [63]. Briefly, 
lungs were inflation-fixed, embedded and sections digested in 
0.01% trypsin and then 1 M hydrochloric acid. BrdU 
incorporation was detected by overnight incubation with a 
biotin-labelled anti-BrdU mAb (Caltag) followed by streptavi-
din peroxidase (Dako) for 1 h. Sections were then incubated 
for 10 min with DAB substrate (Vector Laboratories Inc., 
Burlingame, CA). To compare proliferation between groups, 
sections were analysed microscopically, and the percentage of 
positively stained cells was counted in the perivascular regions 
in each section. At least 400 cells were counted per section. 
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Cytokine ELISA 
IFN-y, TNF, IL-5, IL-4 and IL-2 were detected in the BAL by 
cytometric bead array analysis according to the manufacturers' 
instructions (BD Pharmingen). IL-10 and IL-12 were analysed 
using the OPTEIA ELISA kit (BD Pharmingen). Briefly, 
Immunsorb plates (Nunc, Roskilde, Denmark) were coated 
with capture antibody and left overnight at 4°C. Wells were 
then washed five times with PBS/0.05% Tween 20 and blocked 
with PBS/10% foetal bovine serum for 1 h at room 
temperature. Neat sample or standard (100 µL) was then 
added to blocked wells for 2 h at room temperature. Bound 
cytokine was detected using biotinylated anti-IL-10 or anti-
IL-12 antibody, avidin horseradish peroxidase and tetra-
methylbenzidine (TMB). Colour development was terminated 
with H2SO4 and optical densities read at 450 nm. Cytokine 
concentration in each sample was determined from a standard 
curve. 
Statistics 
Statistical significance was evaluated using a two-tailed 
Student's t-test assuming unequal variance with the Minitab 
software program. Bonferroni correction was applied when 
comparing multiple experiments. 
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Abstract 
The ability of mycobacteria to disseminate from the initial site of infection has an important role in immune priming and in the seeding of 
disease in multiple organs. To study this phenomenon, we used flow cytometry to analyse the distribution of green fluorescent protein-labelled 
BCG amongst different populations of antigen-presenting cells in the lungs of mice following intranasal infection, and monitored appearance of 
live bacteria in the draining mediastinal lymph nodes. BCG predominantly infected alveolar macrophages (CD1101CD11b-) and dendritic cells 
(CD11e/CD11b+) in the lungs. The bacteria that disseminated to the lymph node were found in dendritic cells. The results are consistent with 
a model in which mycobacterial dissemination from the lung is initiated by the migration of infected dendritic cells to the draining lymph nodes. 
© 2006 Elsevier SAS. All rights reserved. 
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1. Introduction 
It is estimated that up to one-third of the global population 
has been exposed to infection with Mycobacterium tuberculo-
sis [1]. The bacteria elicit a strong cell mediated immune re-
sponse which, in most individuals, is sufficient to contain 
the infection in the absence of any clinical symptoms [2]. Im-
munisation with live Mycobacterium bovis bacille Calmette—
Guerin (BCG vaccine) elicits a similar immune response and 
confers a degree of protection against severe forms of dissem-
inated tuberculosis in children [3]. A major challenge is to de-
velop a vaccine that generates consistent protection against the 
Abbreviations: APC, antigen-presenting cell; BCG, bacille Calmette—
Guerin; DC, dendritic cell; GFP, green fluorescent protein. 
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most infectious pulmonary form of tuberculosis, which can de-
velop either as progressive primary disease following initial 
infection, or as secondary reactivation disease in later life. 
Tuberculosis infection is initiated by inhalation of myco-
bacteria into the lungs. Containment of the infection is depen-
dent on T lymphocytes which are initially primed to recognise 
mycobacterial antigens presented by dendritic cells in adjacent 
draining lymph nodes [4-6]. There are several possible routes 
by which antigens can reach the lymph nodes. Antigens se-
creted from infected or apoptotic cells in the lungs may be 
captured by dendritic cells, triggering cell maturation and mi-
gration to the lymph node. Dendritic cells maturated by in vi-
tro incubation and primed with mycobacterial antigens exhibit 
this behaviour when instilled back into the trachea of mice [7]. 
Alternatively, dendritic cells may be infected with intact live 
mycobacteria in the lung and may then transport the whole 
organisms to the draining lymph node. The two mechanisms 
need not be mutually exclusive. Antigens from Leishmania 
parasites, for example, are transported from the skin to the 
lymph node by sequential waves of uninfected and then 
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infected dendritic cells, each priming different T cell re-
sponses [8]. Finally, mycobacteria may disseminate to the 
lymph node within some other type of cell, or even as free ex-
tracellular organisms. 
In addition to the potential influence on immune priming, 
dissemination of live mycobacteria from the lung is also an 
important stage of pathogenesis. Although pulmonary disease 
is the most common presentation, tuberculosis can affect al-
most any organ in the body [9]. Understanding of the mecha-
nism by which the bacteria spread from the initial site of 
infection may therefore assist in identifying improved strate-
gies for disease control. 
The aim of the present study was to use GFP-labelled or-
ganisms to study the in vivo pathway of mycobacterial dissem-
ination to mediastinal lymph nodes following intranasal 
infection. We have used flow cytometry to quantify the cellular 
distribution of GFP-labelled BCG in the lungs of infected mice 
and to demonstrate that mycobacteria reach the lymph node 
within CD11c+ cells that have a dendritic cell phenotype. 
2. Materials and methods 
2.1. Mycobacterial strains and culture 
BCG and M. tuberculosis H37Rv were grown in Middle-
brook 7H9 medium (Difco, Detroit, USA) supplemented 
with 10% albumin—dextrose—catalase (Difco), 0.2% glycerol, 
and 0.05% Tween 80. To measure colony forming units (CFU), 
mycobacteria were grown on Middlebrook 7H11 agar plates 
supplemented with 10% oleic acid—albumin—dextrose—
catalase (Difco) and 0.2% glycerol. To construct the GFP-
expressing BCG strain, M. bovis BCG was transformed with 
the dual reporter plasmid pSMT3LxEGFP (Fig. la). This plas-
mid is based on the pSMT3 Escherichia coli/mycobacteria 
shuttle vector and contains the human codon-optimised and 
fluorescence-enhanced EGFP gene from pEGFP (Clontech, 
Nottingham, UK) cloned under the control of mycobacterial 
19 kDa promoter, and the luxAB genes from Vibrio harveyi 
under the control of hsp60 promoter [10]. Positive clones 
were selected by growing on plates and media supplemented 
with 50 µg/m1 hygromycin (Roche Diagnostics, Mannheim, 
Germany). GFP expression by transformed bacteria was con-
firmed by flow cytometric analysis (Fig. Ib). For all infections, 
bacteria were obtained from the late-logarithmic phase of 
growth and quantified by measurement of the optical density 
at a wavelength of 600 nm, with an optical density of 1 repre-
senting 1 x 108 CFU. Plating of serial dilutions on 7H11 agar 
was done to assess the number of viable bacteria in infective 
inocula, and in aliquots of lung and mediastinal lymph node 
homogenates derived from infected mice. 
2.2. Mice infections and cell recovery 
Six to eight-week-old female BALB/c mice (Harlan Olac 
Ltd, Bicester, UK) were kept in pathogen-free conditions 
according to Home Office guidelines. On day 0, mice 
were anaesthetised and intranasally infected with either 
a 
b 
GFP 
Fig. 1. pSMT3LxEGFP: a dual reporter plasmid containing fluorescent en-
hanced EGFP gene and bacterial luciferase. The pSMT3LxEGFP plasmid 
(a) was used to transform BCG. (b) A histogram plot of GFP expression by 
wild type (filled line) and EGFP- (open line) BCG. 
1 x 106 CFU wild type or GFP-expressing BCG, or 
4 x 104 CFU M. tuberculosis in a volume of 50 µI. On days 
stated in the text, BCG- and M. tuberculosis-infected mice 
were sacrificed by injection of 3 mg pentobarbitone and exsan-
guinated via the femoral vessels or by cervical dislocation, 
respectively. Bronchoalveolar lavage fluid (BAL), lung tissue 
and mediastinal lymph nodes were recovered using the 
methods as described previously [11]. Briefly, the lungs of 
each mouse were inflated six times with 1.5 ml 1 mM EDTA 
in DMEM. BAL fluid was then centrifuged and the superna-
tant removed and frozen at —70 °C for cytometric bead anal-
ysis. Lung tissue was cut into small pieces and incubated for 
60 min at 37 °C with 75 U/ml collagenase/dispase (Sigma, 
Poole, UK) and 50 U/ml bovine DNAse type 1 (Sigma) in 
RPMI. Lung tissue and lymph nodes were then disrupted to 
a single cell suspension by passage through a 100-µM sieve 
(BD Labware, New Jersey, USA) and, in the case of lung cells, 
washed twice in cold RPMI. Cell viability was then assessed 
using trypan blue exclusion and the pellet resuspended in 
RPMI containing 10% FCS, 2 mM/m1 L-glutamine, 50 U/ml 
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penicillin and 50 µg/ml streptomycin (R1OF) at a final concen-
tration of 1 x 106 cells/ml. 
2.3. Flow cytometry 
For flow cytometric analysis of cells from BCG-infected 
mice, 2-5 x 105  cells were stained with anti-CD11c-APC, 
anti-CD11b-PercP and PE-labelled anti-MHC class II, or 
anti-CD 1 lc-APC, anti-CD11b-PE (all from BD Pharmingen, 
Heidelberg, Germany) and anti-F4/80-cychrome (Serotec 
UK, Oxford, UK) diluted in PBA (1% BSA/0.05% sodium 
azide/PBS) for 30 min on ice. Cells were washed in PBA 
and data acquired immediately on an FACSCalibur. The limits 
of background fluorescence were set using appropriately la-
belled isotype matched control antibodies. All data were ana-
lysed with CellQuest Pro software (BD Biosciences, 
Belgium). 
2.4. Cytometric bead analysis 
IL-12, IFN-y, TNF and MCP-1 levels in BAL fluid were 
quantified by cytometric bead analysis according to manufac-
turer's instructions (BD Biosciences, Belgium). 
25. Cell sorting and histology 
Lungs were digested and cells stained with CD1 lb and 
CD1 lc as described above. FSChIgh/SSCh'gh cells were sorted 
based on CD 1 lb/CD1 lc expression as described by Gonzalez-
Juarrero et al. [12] using an FACS Vantage SE (BD Biosci-
ences). Cells were then cytocentrifuged onto glass slides and 
mycobacteria detected using a Kinyoun staining kit (BD, 
Maryland, USA). Slides were then counterstained with Gill's 
haematoxylin (BDH, Poole, UK). 
2.6. Statistical analysis 
Where appropriate, statistical significance was evaluated 
using a two-tailed Student's t-test assuming unequal variance 
with the Minitab software program. 
3. Results 
3.1. Dynamics of intranasal infection and lymph node 
dissemination 
BALB/c mice were infected by intranasal delivery of M. tu-
berculosis (4 x 104 CFU) or BCG vaccine (106 CFU). Over 
the next four weeks, the number of bacteria recovered from 
the lungs increased exponentially to a plateau in mice infected 
with the virulent strain, while the attenuated vaccine strain was 
progressively eliminated (Fig. 2a). In both the groups of mice, 
viable mycobacteria could be cultured from mediastinal lymph 
nodes harvested two weeks after infection, and bacterial load 
in this tissue increased to peak at 30 days (Fig. 2b). In spite 
of a lower initial inoculum, the peak in MLN bacterial load 
was 10-fold higher for M. tuberculosis than for BCG, although 
10 	 20 
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Fig. 2. Bacterial growth in BALB/c mice following intranasal infection with 
M. tuberculosis or BCG. BALE/c mice were infected by the intranasal route 
with 2 x 104 CFU M. tuberculosis (•) or 1 x 106 CFU BCG (0). On days 
7, 14, 21 and 28 post-infection, lung (a) and mediastinal lymph nodes 
(MLN, b) were taken and CFUs measured. Results are shown as mean values 
of four mice per group ± SEM. 
the kinetics of appearance of bacteria was similar for both 
organisms. 
3.2. Distribution of antigen presenting cells in the lung 
The dynamics of recruitment of antigen-presenting cells 
(APCs) to murine lungs during mycobacterial infection has 
previously been characterised by flow cytometry using 
CD1 lb and CD1 lc markers [12]. We used similar criteria to 
define four subpopulations of APCs in the BCG-infected 
lungs: R1, alveolar macrophages (CD11c+/CD11b—); R2, den-
dritic cells (CD11c+/CD11b±); R3, monocyte/small macro-
phages (CD11cmidi—); and R4, granulocytes (CD1 IV/High/ 
CD11c—) (Fig. 3a). Cellular phenotypes were confirmed by 
analysis of expression of the macrophage marker F4/80 and 
high intensity MHC class II expression, which is indicative 
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Fig. 3. APC populations in the lungs of mice following intranasal infection 
with BCG. On days 7, 14, 21 and 28 after intranasal infection with BCG, 
lung cells from BALB/c mice were stained with anti-CD1 lb and anti-
CD1 I c. (a) Representative dot plot of CD1lb and CD11c expressing FSChigh 
SSChi8h lung APCs 14 days post-infection. Cell populations were identi-
fied as described by Gonzalez-Juarrero et al. [12]. RI = alveolar macro-
phages, R2 = dendritic cells, R3 = small monocytes/macrophages, and 
R4 = granulocytes. (b) Total numbers of alveolar macrophages (R1, • ), den-
dritic cells (R2, 0), small macrophages/monocytes (R3, ■ ) and granulocytes 
(R4, ❑) were calculated by the following: total large granular cell num-
bers x % gated cells. (c) Levels of IL-12 ( • ), TNF ( 0 ), IFN-g (•) and 
MCP-1 (0) in bronchoalveolar lavage fluid (BAL) were measured by cyto-
metric bead analysis. Results are mean values + SEM of four mice per group. 
of professional APCs. F4/80 was detected on both alveolar 
(R1) and small monocyte/macrophage (R3) lung populations, 
whereas MHC class IlltIgh expression was detected primarily 
on dendritic cells (R2) (data not shown). As reported previ-
ously [12], this infiltrate of APCs was specific to mycobacte-
rial infection, as alveolar macrophages (R1) were shown to be 
the predominant cell type in a nave lung, with no detectable 
numbers of dendritic cells (data not shown). 
The kinetics of accumulation of these APC populations was 
examined during BCG infection (Fig. 3b). The numbers of 
dendritic cells and small macrophages reached a peak at three 
weeks after infection, with alveolar macrophages and granulo-
cytes peaking a week later. As previously recorded for aerosol 
infection with M. tuberculosis [12], cell recruitment and local 
activation resulted in a predominance of alveolar macrophages 
during the acute phase of infection. In contrast to M. tubercu-
losis, however, acute BCG infection also induced a substantial 
granulocyte influx, peaking at day 21. In accordance with the 
kinetics of inflammatory cell accumulation in the lung, levels 
of pro-inflammatory cytokines TNF, IFN-y and, to a lesser ex-
tent, IL-12 and MCP-1 in the airways also peaked at 21 days 
post-infection (Fig. 3c). 
33. Distribution of GFP-BCG amongst APC populations 
To assist in the identification of infected cells, intranasal 
infection experiments were repeated using GFP-labelled 
BCG. In initial experiments we observed that unlabelled 
BCG induced an increase in cellular autofluorescence in 
lungs harvested 7 days after intranasal infection. To control 
for this, we compared the fluorescence of lungs cells from 
mice infected with labelled and unlabelled BCG, gated for 
forward and side scatter properties characteristic of APCs. 
A clear fluorescence signal was observed in cells from lungs 
of mice infected with GFP-BCG. Fig. 4 (a and b) illustrates 
the GFP signal in lung CD11c+ cells derived from wild 
type BCG and GFP-BCG-infected mice, respectively. GFP 
was also detected in CD11b+ lung cells, and in CD11c+  
and CD1 lb+ populations obtained by bronchoalveolar lavage 
(not shown). 
We next ascertained which of the lung APC populations 
contained BCG by measuring GFP fluorescence in the four 
cell types described above. Fig. 4 (c and d) shows represen-
tative histograms of GFP expression associated with alveolar 
macrophages and dendritic cells, respectively. Fig. 4e records 
the total number of GFP-positive cells in each population 
over the four-week course of infection, and Fig. 4f presents 
GFP-positive cells as a proportion of total cell number. Alve-
olar macrophages were the predominant cell population har-
bouring GFP-BCG, followed by dendritic cells (Fig. 4e). 
When calculating total numbers of BCG-containing cells, 
accumulation of BCG-infected alveolar macrophages peaked 
at 14 days post-infection whereas numbers of BCG-
associated dendritic cells peaked 7-14 days later. The total 
number of infected cells decreased progressively in parallel 
with the clearance of the infection as shown in Fig. 2. Only 
low levels of GFP expression were observed in the small 
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Fig. 4. GFP-BCG is associated with alveolar macrophages and dendritic cells during pulmonary BCG infection. Lung cells from mice 7 days after intranasal in-
fection with (a) wild type BCG, or (b) GFP-BCG, were stained with anti-CD11c and GFP expression was detected. All plots are representative of three experiments 
containing four mice per group. Representative histograms of GFP expression associated with (c) alveolar macrophages, and (d) dendritic cells, prepared 14 days 
after intranasal infection with GFP-BCG and identified as described for Fig. 3. Panel (e) shows the total number of GFP-positive cells in each of the APC pop-
ulations as described in Fig. 3. Panel (f) shows the percentage of GFP-positive cells in each population. Results show mean values ± SEM of four mice per group 
and are representative of three experiments. 
monocyte/macrophage population and, despite high num-
bers in the lung, granulocytes were not identified as a major 
source of GFP expression after intranasal BCG infection. 
Dendritic cells represented the population with the highest 
rate of infection (Fig. 4f). 
To confirm that the GFP signal was an accurate reflection of 
the presence of mycobacteria, APC populations prepared 14 
days after infection and sorted on the basis of CD11c and 
CD1 lb surface expression profiles were examined microscop-
ically after Kinyoun and haematoxylin staining. Mycobacteria 
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Fig. 5. GFP expression in lung-derived APCs correlates with the presence of 
BCG. (a) BALB/c mice were infected with GFP-BCG, and 14 days later alve-
olar macrophages (RI, top left), dendritic cells (R2, top right), monocytes/ 
macrophages (R3, bottom left) and granulocytes (R4, bottom right) were 
sorted from the lung based on their CD1lb and CD1 I c expression profiles, cy-
tocentrifuged onto glass slides and stained with Kinyoun and haematoxylin. 
Arrows show mycobacteria and magnification = x 1000. (b) Percent mycobac-
terial positive cells were counted in three fields of vision and results represent 
two experiments. 
were clearly visible in alveolar macrophages (R1) and den-
dritic cells (R2) (Fig. 5a). Despite the low signal obtained in 
the GFP assay, mycobacteria were also seen in the small 
monocyte/macrophage population (R3). We did not observe 
any mycobacteria in granulocytes (R4) (Fig. 5a). Fig. 5b 
shows a quantitative analysis of the staining results, based 
on counting approximately 300 cells in each population. In ac-
cordance with flow cytometric analysis of GFP expression, al-
veolar macrophages and dendritic cells were again the major 
APC subsets associated with mycobacteria.  
3.4. Dissemination of intracellular BCG to the 
draining lymph node 
We next examined co-expression of CD11c and GFP in 
cells from draining mediastinal lymph nodes during the four 
weeks after intranasal infection (Fig. 6a). Small but significant 
levels of GFP were detected in CD11c± lymph node cells, 
with numbers increasing over time in parallel with the rise 
in viable bacteria recorded in Fig. 2. In contrast to the lung, 
CD1 lb expression by GFP+CD11c+ cells was variable, sug-
gesting that multiple cell types may harbour BCG. However, 
high intensity of MHC class II expression by all CD11c+GFP+ 
cells was consistent with their identification as dendritic cells 
rather than macrophages (Fig. 6b). 
4. Discussion 
Following intranasal infection of BALB/c mice, BCG ba-
cilli were distributed amongst multiple populations of anti-
gen-presenting cells in the lung. The highest number of 
bacteria was present in alveolar macrophages (CD11c±/ 
CD11b—), but the highest frequency of infection was found 
in the dendritic cell population (CD11c+/CD11b±). This is in 
contrast to a previous histological analysis of intratracheal 
infection with M. tuberculosis, in which only a very low pro-
portion of lung dendritic cells were found to be infected [131. 
This could reflect a difference in the pattern of initial infection 
by the two bacteria, or a consequence of progressive growth of 
M. tuberculosis in macrophages rather than in dendritic cells 
as the virulent infection proceeds. 
Both BCG and M. tuberculosis were shown to disseminate 
to the mediastinal lymph node by the second week after intra-
nasal infection. The number of viable bacteria cultured from 
lymph nodes increased progressively over the next two weeks, 
in contrast to the divergent pattern seen in the lungs over this 
period in which there was multiplication of M. tuberculosis 
and clearance of BCG. Flow cytometry analysis of GFP-BCG 
in the mediastinal lymph node demonstrated an association 
with CD11c±/MHC class II+ cells resembling the population 
of infected lung dendritic cells. The simplest interpretation 
of these findings is that the bacteria disseminate to the lung 
within dendritic cells. Such migration of infected dendritic 
cells, in preference to the numerically superior infected mac-
rophages present in the lung, is consistent with a previous 
study based on the behaviour of different cell types after adop-
tive transfer 171. However, not all GFP dendritic cells de-
tected in the mediastinal lymph nodes expressed CD11b. 
One explanation is that CD1 lb may be downregulated during 
maturation and subsequent migration to lymph nodes. Alter-
natively, CD11b± "myeloid" and CD1113— "lymphoid" den-
dritic cells r141  present in mediastinal lymph nodes may 
acquire BCG delivered either as cell-free bacteria or derived 
from dendritic cells and/or macrophages initially infected 
with BCG in the lung. Furthermore, macrophages can acquire 
a dendritic cell phenotype following migration to lymph nodes 
15,161 and we cannot discount the possibility that GFP+ cells 
in the lymph nodes were initially lung-derived macrophages. 
a 
R1 
Fig. 6. GFP-BCG in draining lymph nodes is present in dendritic cells. (a) Me-
diastinal lymph nodes were removed from BALB/c mice infected with GFP-
expressing BCG on days 7, 14, 21 and 28, and stained with anti-CD11c. 
The number of CD11c+GFP+ cells was calculated as follows: total CD1 lc+ 
cells x % GFP+ cells. Results are expressed as mean values ± SEM of five 
mice per group and represent three experiments. (b) Representative histogram 
of MHC class II expression by CD11c+GFP+ cells 28 days after infection with 
BCG-GFP. Shaded and open lines represent rat isotype and anti-MHC class II 
staining, respectively. 
a 
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and possible suppression of Th 1 immunity, for example [17]. 
In addition, failure to acidify the mycobacterial phagosome 
in dendritic cells may limit the repertoire of antigens available 
for presentation by infected cells [18]. In contrast, capture of 
mycobacterial antigen derived from infected cells by by-
stander dendritic cells is critical for cross presentations to 
CD8 T cells [19]. Therefore, association of BCG with den-
dritic cells in the lymph node in this context may result in in-
creased CD8 T cell activation. Indeed, the extent of BCG 
growth in secondary lymphoid tissue is directly correlated 
with antigen-specific T cell proliferation [20]. It is therefore 
interesting to speculate whether dissemination of live myco-
bacteria to the lymph node represents a positive or a negative 
attribute for a live vaccine. The simple intranasal infection/dis- 
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semination model described here provides an opportunity to 
explore this by use in combination with mycobacterial genetic 
tools to identify non-disseminating mutant strains of BCG. 
A second important aspect of mycobacterial dissemination 
is in its contribution to the pathogenesis of the disease. Myco-
bacteria may have hijacked the natural trafficking process in-
volved in immune priming as a means for dissemination to 
a secondary site of infection in lymph nodes. This strategy 
is also used by HIV [21], Leishmania major [22] and Listeria 
monocytogenes [23] to gain access to secondary lymphoid or-
gans. However, this would not explain the wider dissemination 
to other parts of the body, and further work will be required to 
determine whether this is also mediated by dendritic or other 
migratory cells of the immune system. A characteristic feature 
of tuberculosis is the development of latent infection, in which 
there is no progression of disease but there remains a risk of 
subsequent reactivation, for example in response to HIV-medi-
ated immune suppression [24]. There is evidence from both 
human and murine models that dendritic cells are able to re-
strict the growth of intracellular mycobacteria without being 
able to kill them [18,25]. This behaviour may contribute to 
pathogenesis of tuberculosis by preferential dissemination of 
a quiescent or latent form of the bacillus. 
In conclusion, the model presented here provides novel in-
sight into the interactions between BCG and antigen-present-
ing cells in vivo. This study identifies cellular reservoirs of 
mycobacteria that are future therapeutic targets for both inhi-
bition of M. tuberculosis dissemination and promotion of 
T cell immunity elicited by BCG vaccination. 
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There are two important implications to be considered in 
relation to mycobacterial dissemination within dendritic cells. 
The first is the role of infected dendritic cells in immune prim-
ing. Dendritic cells can present antigens that are either pro-
cessed internally from infecting bacteria, or captured 
following release from other infected cells. It is likely that 
these two pathways prime different immune responses. Trig-
gering of the DC-SIGN surface receptor during direct infec-
tion of dendritic cells is associated with production of IL10, 
and consequent downregulation of inflammatory signalling 
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An IL-7 Fusion Protein That Shows Increased Thymopoietic 
Abilityl 
Sian M. Henson,2* Robert Snelgrove,t Tracy Hussell,t Dominic J. Wells,* and 
Richard Aspinall* 
The role of IL-7 during thymopoiesis has led to it being the focus of a number of therapeutic interventions. However, its small size 
and pleiotropic nature present problems for thymus-directed therapies. We have created a fusion molecule between the extra-
cellular N-terminal domain of CCR9 and IL-7, which has the potential to overcome these difficulties. This novel fusion protein 
retains the thymopoietic activity of IL-7 and the ligand-binding ability of CCR9. As a thymopoietic agent, compared with IL-7, 
it shows an enhanced retention in the thymus, increased de novo T cell production, and increased thymic output. Old mice 
receiving the fusion protein show improved CD8 T cell responses and reduced viral load after infection with influenza virus 
compared with those receiving IL-7. This chimeric molecule offers a novel therapeutic strategy that may result in the production 
of an effective hnmunorestorative agent. The Journal of Immunology, 2005, 175: 4112-4118. 
T he use of therapeutic agents, such as cytokines, to im-prove immunity has been approached often in a haphaz-ard manner, introducing the drug into the host at inappro-
priately high dosages at a distal site in the hope of reaching the 
target organ in sufficient quantity to have an effect. To help over-
come the problem of dosage, chimeric variants of cytokines have 
been created. These molecules include cytokines conjugated with 
polyethylene glycol (1) and fusion to albumin (2) or to the Fc 
portion of IgG (3). Although production of such chimeras prolongs 
the t112 of cytokines and reduces dosing schedules, it does not 
completely address the problems associated with improving the 
cytokine's targeting ability. One way of targeting a cytokine is to 
create a chimera between the cytokine and a single chain Ab (4), 
but such Abs, made in other species, often provoke immune re-
sponses. We report in this study a superior method for improving 
the targeting ability of cytokines, by using a chemokine receptor 
whose ligand is organ specific as the targeting moiety. This method 
has the advantage over the use of single chain Abs in that the 
receptor of interest can be cloned from the same species as the 
recipient of the therapy, thus causing no unwanted immune 
reaction. 
IL-7 is a cytokine produced predominantly by class Ir thymic 
epithelial cells (5), which plays a central role in the survival and 
proliferation of thymocytes (6). In addition, IL-7 also has an effect 
on cells in the peripheral T cell pool, permitting the survival of 
naive and memory T cells (7). The role played by IL-7 in T cell 
development and homeostasis has made it the focus of numerous 
therapeutic interventions aimed at boosting thymopoiesis in the 
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elderly (8), after bone marrow transplant (9), or following viral 
infection, for example with HIV (10). However, treatment with 
IL-7 is not without its problems: the use of high doses of this 
cytokine can lead to numerous side effects, such as osteoporosis 
(11), lymphoma (12), hyperproliferation (12), thrombocytopenia 
(13), neutropenia (13), and hemolytic anemia (13). In addition, 
high levels of IL-7 expression have also been shown to inhibit T 
cell development by inducing a dramatic block in the production of 
double-positive (DP)3 cells (14). Phillips et al. (15) have attempted 
to overcome these problems by incorporating an IL-7-secreting 
stromal cell line into the thymus with some success. Their method 
is not without its problems, including alterations to the thymic 
architecture, problems regulating the expression of IL-7, and the 
difficulty in translating the therapy to the clinic, which need to be 
addressed. We have taken an alternate approach to counter the 
adverse effects of IL-7 by creating a fusion protein between IL-7 
and the extracellular region of the chemokine receptor CCR9. The 
chemokine CCL25, which is produced by the thymic stroma, is 
thought to play a major role in T cell development by acting as a 
chemoattractant for thymocytes, which express the CCL25 recep-
tor, CCR9 (16). Unlike other CC chemokine receptors, CCR9 
shows a strict specificity for its ligand CCL25 (17). When consid-
ered together with the high levels of CCL25 expressed in thymic 
tissue, CCR9 was deemed the ideal choice as a targeting compo-
nent for IL-7. We show in this study the creation of a fusion pro-
tein between the N-terminal of CCR9 and IL-7 that shows en-
hanced thymopoietic ability, overcoming the problem of dosage 
previously associated with IL-7 therapy. 
Materials and Methods 
Cloning of CCR9 and IL-7 
RNA was extracted from a male C57BL16 mouse thymus using STAT-60 
(AMS Biotechnology) and reverse transcribed, as previously described 
(18). The resulting cDNA was used for PCR with following primers (Os-
wel): CCR9, forward 5'-atg atg ccc aca gaa ctc aca agc-3', reverse 5'-gct 
tgc aaa ctg cct gac aca tta-3'; IL-7, forward 5'-atg ttc cat gtt tct ttt aga 
tat-3', reverse 5'-tgt tta tat act gcc ctt caa aat-3'. 
Abbreviations used in this paper: DP, double positive; EEC. 8 excision circle; DN, 
double negative; hGH, human growth hormone; met-hGH, methionine-human growth 
hormone. 
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The CCR9 and IL-7 PCR products together with the N-terminal portion 
of CCR9 to serve as a control were ligated into the pGEM-T vector (Pro-
mega) and transformed into JM109 competent cells. 
Creation of the CCR9/IL-7 fission plasmid 
CCR9 and IL-7 DNA were amplified by PCR using primers designed to 
create a novel restriction site Non at the 3' end of CCR9 and at the 5' end 
of IL-7: CCR9, forward 5'-atg atg ccc aca gaa ctc aca agc-3', reverse 
5 '-gcg gcc gcg tgc aaa ctg cct gac att at-3'; IL-7, forward 5 '-ctc cgc ggc cgc 
atg ttc cat gtt tct-3', reverse 5'-tgt tta tat act gcc ctt caa aat-3' (Oswel). The 
resulting PCR products were subjected to restriction digest with NotI (Pro-
mega) and then used in a PCR with the forward CCR9 primer and the 
reverse IL-7 primer. 
The CCR9/IL-7 fusion PCR product was ligated into the pcDNA4/His-
Max TOPO TA expression vector (Invitrogen Life Technologies) and 
transformed into TOPIO competent cells. 
Production of the CCR9/IL-7 fusion protein 
Chinese hamster ovary cells were plated at a density of 5 X 104/ml in 
60-mm culture dishes and transfected after 18 h in culture with 5 µg of 
EndoFree CCR9/IL-7 plasmid (Qiagen) in complete medium using poly(t-
omithine) (19) (Sigma-Aldrich). Stable transfectants were selected with 
Zeocin (Invitrogen Life Technologies). 
Electroporation of mice with CCR9/IL-7 plasmid DNA 
In vivo experiments were conducted using young (6-wk) or old (20-mo) 
C57BL/6 male mice (Harlan Olac), as previously described (20). The an-
terior tibial muscle was first pretreated with 0.4 U/µI bovine hyaluronidase 
(Sigma-Aldrich). Two hours posthyaluronidase injection, 25 µI of circular 
control, IL-7, or fusion plasmid DNA (at 1 µg/µI) in normal saline was 
injected percutaneously in the anterior tibial muscle. An electrical field was 
applied to the muscle immediately following plasmid injection. The in-
jected leg was held steady, and the 7-mm circular electrodes (BTX Twee-
zertrodes, VWR) were applied to the medial and lateral sides of the shaved 
lower hind limb with reasonable pressure to maintain contact with the skin 
surface. A voltage of 175 V/cm was applied in ten 20-ms square wave 
pulses at 1 Hz using a BTX ECM 830 electroporator. Both procedures were 
conducted under general anesthesia using the protocol described in Gollins 
et al. (21). 
ELISA 
ELISA studies were performed on homogenized tissue and serum samples 
using reagents from R&D Systems. 
S Excision circle (SEC) assay 
Thymic output was assessed using the SEC assay (22). Quantification of 
the number of SEC genes was conducted by PCR using the Lightcycler 
(Roche) with primers specific for the CS exon 3 region: forward 5'-gct tcc 
aac ttc tca gtg c-3', reverse 5'-ggg ggc aaa ata aaa tgg at-3', the LightCy-
cler FastStart DNA Master SYBR green I kit (Roche), and the cloned 
205-bp product to generate the standard curve. 
Flow cytometric analysis of thymocytes 
FACSCalibur (BD Biosciences) analysis of T cell phenotype was per-
formed, as previously described (23). A total of 1 X 106 thymocytes was 
incubated with the following Abs: anti-CD8 FITC (clone 53-6.7), anti-CD4 
CyChrome (clone H129.19), anti-CD4 R-PE (clone H129.19), anti-CD8 
R-PE (clone 53-6.7), anti-CD3 R-PE (clone I7A2), anti-CD19 R-PE (clone 
ID3), anti-CD25 FITC (clone 7D4), and anti-CD44 CyChrome (clone 
IM7), or isotype-matched controls (all BD Biosciences). Thymocytes were 
fixed with 1% paraformaldehyde in PBS, and data analysis was performed 
using WinMDI software. 
Influenza infection 
Following electroporation (as described above) with 1 µg/µ1 control, IL-7, 
or fusion constructs, 2 mo prior, 20-mo mice were anesthetized and intra-
nasally infected with 50 hemagglutinin units of influenza A strain X3I. 
After 6 days, single cell suspensions from lung tissue were stained for 
surface markers and intracellular cytokines and analyzed by flow cytom-
etry, as previously described (24). Lung cells were incubated with anti-
CD45RB FITC (clone R2a01; Caltag Laboratories), anti-CD4 PerCP 
(clone RM4-5), anti-CD8 allophycocyanin (clone 53-63), and anti-TNF 
PE (clone MP6-XT22) from BD Biosciences. Data were acquired on a 
FACSCalibur, and 10,000 lymphocyte events were analyzed with WinMDI 
software. 
Lung influenza viral titer 
Viral load was assessed in the lung 6 days after virus challenge by PCR 
using the Lightcycler, using primers specific for the matrix protein of in-
fluenza A: forward 5 '-gga tgt M tgc agg gaa ga-3', reverse 5'-caa gcg cac 
cag ttg agt as-3', and the LightCycler FastStart DNA Master SYBR green 
I kit (Roche). We isolated the 287-bp product to provide the control sample 
required to generate the standard curve. 
Statistics 
Statistical significance was evaluated using ANOVA and applying the 
Bonferroni correction using StatView software. Differences were consid-
ered significant if p < 0.0167. 
Results 
Creation of the IL-7/CCR9 fusion plasmid and in vivo function 
The fusion plasmid was generated by first cloning the extracellular 
portion of murine CCR9 and murine IL-7, followed by the intro-
duction of a Not! restriction enzyme site at the 3' end of IL-7 and 
at the 5' end of CCR9. The resulting products were digested with 
Not! and annealed, and the product was expanded by PCR to create 
the IL-7/CCR9 fusion gene. This fusion product was cloned into 
the mammalian expression vector, pcDNA4/HisMax TOPO TA, 
and was stably transfected into Chinese hamster ovary cells. 
To assess whether the fusion protein exerted an effect in vivo, 1 
p.g/µ1 IL-7, fusion, or control plasmid (containing the N-terminal 
portion of CCR9) was electroporated into the anterior tibial muscle 
of mice. Muscle damage associated with the electrotransfer pro-
cedure arises from the intracellular presence and expression of 
plasmid DNA (25). The three plasmid constructs inserted all car-
ried DNA capable of supporting gene expression and showed sim-
ilar levels of muscle damage between each group (data not shown). 
Analysis of thymic tissue from these animals after 1 wk (Fig. la) 
revealed significantly more IL-7 in the thymi of animals injected 
with the fusion and IL-7 plasmids compared with animals receiv-
ing the control plasmid control (p < 0.001). In addition, the results 
also showed significantly more IL-7 in animals after fusion treat-
ment compared with treatment with IL-7 alone (p < 0.001). How-
ever, IL-7 levels were found to be below the level of detection in 
the plasma (data not shown). Urinary excretion is one of the major 
routes of elimination of IL-7 (26); therefore, we conducted anal-
ysis of IL-7 levels in the kidney (Fig. lb). This revealed that an-
imals receiving the IL-7 and fusion plasmids had significantly 
more IL-7 than animals receiving the control plasmid (p < 0.001), 
whereas there was no difference in the IL-7 levels between the 
IL-7- and fusion-treated groups. These similar rates of excretion 
would suggest similar levels of production; this was confirmed by 
immunohistology of the anterior tibial muscles from treated ani-
mals. Again, a similar level of staining was found in animals re-
ceiving the IL-7 plasmid compared with those receiving the fusion 
plasmid (data not shown). 
To test whether increased intrathymic levels of IL-7 lead to 
increased thymic output, we conducted the SEC assay on animals 
6 wk after treatment (Fig. 2). The SEC assay quantitates the ex-
cised TCR S region from within the TCR a-chain (22), and the 
results revealed that splenic a$ T cells from animals treated with 
the fusion protein yielded significantly higher SEC numbers (p < 
0.01) than animals receiving IL-7 alone (Fig. 2). However, because 
IL-7 increases the rate of peripheral cell turnover, the control 
group, receiving only CCR9, showed higher SEC levels, 0.29 ± 
0.06 SECT cell, than either the IL-7 group, 0.075 ± 0.01 SECT 
cell, or the fusion group, 0.152 ± 0.02 SEC/I' cell. 
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FIGURE 1. IL-7 levels are higher in mice receiving fusion plasmid. a, 
Concentration of IL-7 in the thymi of mice, 6 wk of age, after treatment 
with 1 p.g/pi control plasmid, IL-7, or the fusion plasmid. b, IL-7 levels in 
the kidneys of 6-wk mice after electroporation with 1 Ag/pil sham control, 
IL-7, or the fusion plasmid. *, Denotes significant difference when com-
pared with the control animals, p < 0.001, §, Denotes significant difference 
between IL-7- and fusion-treated animals, p < 0.001. Plots show medians 
with 5, 25, 75, and 95 percentiles of six mice. 
Restoration of thymic architecture and increased thymocyte 
numbers after fusion treatment 
We investigated whether the increased levels of IL-7 seen in the 
thymi of animals treated with either the IL-7 or the fusion plasmid 
had a restorative effect and allowed a renewal in thymopoiesis in 
aged animals. The morphology of thymi taken from old animals, 
20 mo of age, after treatment with either IL-7, fusion, or the con-
trol plasmid, was analyzed by H&E staining (Fig. 3). A represen- 
hiSI ft It 
FIGURE 2. Fusion-treated animals exhibit higher SEC numbers than 
treatment with IL-7. Number of SECS per 5 X 105 ca/3 T cells isolated from 
the spleen of mice 6 wk of age after treatment with 1 µg, / ill IL-7 or the 
fusion plasmid. §, Denotes significant difference between IL-7- and fusion-
treated animals, p < 0.01. Plots show medians with 5, 25, 75, and 95 
percentiles of six mice. 
b 
C 
FIGURE 3. Thymic architecture is restored after fusion treatment. Rep-
resentative examples of thymic sections stained with H&E taken from 
20-mo mice receiving the control (a), IL-7 (b), or fusion plasmid (c). Orig-
inal magnification X10. WAT indicates white adipose tissue; C, cortex; M, 
medullar. 
tative example of a control section revealed a loss in thymic struc-
ture (Fig. 3a). The cellularity of the stroma was greatly reduced, 
with a loss of distinction between the cortical and medullary re-
gions and an infiltration of white adipose tissue into the thymic 
stroma. After 8-wk treatment with IL-7 (Fig. 3b), the cellularity of 
the thymus started to return, as well as a definable distinction 
between the cortex and medullar; however, some white adipose 
*** § § § 
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FIGURE 4. Thymocyte numbers increase after treat-
ment with fusion plasmid. A representative example of 
the DN subset obtained from 20-mo mice after 1-wk 
treatment with 1 p.g/µ1 plasmid control, IL-7, or fusion 
plasmid. 
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tissue remained. Fusion treatment (Fig. 3c) revealed a complete 
restoration of the thymic architecture, with the stroma showing a 
high degree of cellularity, a clearly definable cortex and medullar, 
and the reformation of fine lobules, characteristic of young 
animals. 
Fusion treatment visibly demonstrated its restorative effect, but 
we also wanted to investigate its effect on thymopoiesis. Analysis 
of old mice, 1 wk after treatment, revealed the double-negative 
(DN) subset of fusion-treated animals (Fig. 4) and showed the 
greatest difference compared with the IL-7 and sham plasmid 
control animals, with the largest difference found in the 
CD44+CD25-  subset. When comparing the data from all animals 
(Table I), a significant increase was found in the number of DN1 
(CD44+CD25-) cells of animals treated with IL-7 (p < 0.01) and 
fusion (p < 0.001) plasmids compared with control animals. Fur-
thermore, there were significantly more DN1 cells in the fusion 
group (p < 0.001) compared with IL-7-treated animals. In addi-
tion, cell numbers were significantly enhanced in fusion-treated 
animals for the remaining subsets, DN2 (CD44±CD25+, p < 
0.001), DN3 (CD44-CD25+, p < 0.01), and the DN4 
(CD44-CD25-, p < 0.01) subset, compared with control animals. 
There was no significant increase in the numbers of DP cells after 
treatment with IL-7 or fusion plasmid, but a significant increase 
was seen in the numbers of CD4-positive cells after IL-7 (p < 
0.01) and fusion (p < 0.001) treatment when compared with the 
control group. Comparison between the fusion and IL-7 group also 
showed there to be a significant difference, with more CD4 cells in 
the fusion group (p < 0.05). A trend for an increase in the numbers 
of CD8 single-positive cells was also seen; however, these data 
neared significance. Taken together, these results suggest that the 
fusion plasmid is better able to restore thymopoiesis than IL-7 
alone. 
Fusion treatment causes reduced influenza disease progression 
We then investigated whether the improved thymic output in fu-
sion-treated animals translated into an improved in vivo response 
to pathogen. We infected 20-mo-old mice intranasally with influ-
enza A strain X31 virus 2 mo after treatment with IL-7, fusion, or 
a sham plasmid control. Analysis of these animals 6 days postin- 
fection indicated that there was significantly less viral load in the 
lungs of animals treated with IL-7 (p = 0.001) or fusion (p < 
0.0001) plasmids when compared with those receiving the sham 
plasmid (Fig. 5a). Substantial lung damage accompanies influenza 
infection, which is mediated by TNF (27), and is associated with 
cachexia. The percentage change in weight loss in response to viral 
infection (Fig. 5b) appears to be reduced in fusion-treated animals 
compared with animals receiving IL-7 or the sham plasmid con-
trol; however, no significance was found. In addition, the number 
of CD8+ T cells producing TNF was significantly reduced (Fig. 
5c) in influenza-infected animals previously treated with IL-7 
(p = 0.001) or fusion (p < 0.0001) plasmids compared with the 
sham group. The difference between IL-7 and fusion treatment 
approached significance (p = 0.0372). These results suggest that 
the fusion treatment may enable better control of the infection with 
a more efficient viral clearance and a reduction in the development 
of influenza virus-associated immunopathology. However, we 
found no change in the amount of TNF produced by CD4+ T cells 
(Fig. 5d), nor did we see any difference in IFN-y production by 
either CD4+ or CD8+ T cells (data not shown) following treat-
ment with IL-7 or fusion plasmids. 
CD8+ T cell function is important in the clearance of influenza 
infection (28), and we wished to evaluate whether the improved 
viral clearance was associated with an increase in CD8± T cells, 
given that we had hypothesized that there was renewed thymopoi-
esis in IL-7- and fusion-treated animals. CD45RB expression dis-
tinguishes naive T cells (CD45R13high) from activated cells 
(CD45RB1'). CD8+ T cells from fusion-treated animals were 
more numerous and showed lower levels of CD45RB expression 
than IL-7 and sham animals (Fig. 6, a and b), with a mean fluo-
rescence intensity for fusion-treated animals of 17 compared with 
28 for IL-7 treatment and 64 for the sham plasmid control animals. 
We were unable to detect any change in CD4+CD45RB expres-
sion or any difference in the numbers of CD4+CD45RB1' T cells 
(Fig. 6, c and d) after receiving the fusion or IL-7 plasmid. We did, 
however, find significantly more activated CD8+CD45RBI" cells 
in fusion (p < 0.0001)- and IL-7 (p = 0.0026)-treated animals 
compared with the sham control group (Fig. 6b); in addition, there 
Table I. 	Thymocyte subset numbers following 1-wk treatment with 1 itg/td plasmid control, IL-7, or .fusion plasmid; showing averages and SD (n = 6 )° 
Population Control (±SD) IL-7 (±SD) Fusion (±5D) 
CD44+CD25-  (DN1) 0.81 ± 0.2 X 105 3.3 ± 0.1 x 105** 8.7 ± 0.3 x 105**,4** 
CD44+CD25+ (DN2) 0.82 ± 0.4 X 105 1.4 ± 0.5 x 105 2.2 ± 0.6 X 105** 
CD44-CD25+ (DN3) 2.6 ± 0.9 X 105 3.5 ± 0.7 x 105 4.2 ± 1.2 X 105** 
CD44-CD25-  (DN4) 4.8 ± 5.5 x 105 6.8 ± 1.3 x 105 7.5 ± 1.8 X 105** 
CD4÷CD8+  18 ± 9.1 x 106 20 ± 2.9 X 106 25 ± 4 X 106 
CD44-CD8- 4.5 ± 1.3 X 106 6.7 ± 1.1 x 106** 8.3 ± 0.8 X 106*** 
CD4-CD8÷ 2.3 ± 0.6 X 106 2.6 ± 0.5 x 106 3.1 ± 0.1 x 106 
° Denotes significant difference when compared with the control animals: **, p < 0.01; ***, p < 0.001. Denotes significant difference between IL-7- and fusion-treated 
animals: §, p < 0.05; §§§, p < 0.001. 
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20-mo mice treated with control plasmid, IL-7, or fusion plasmid. b, Per-
centage change in weight lost by animals receiving IL-7, fusion, or control 
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ber of CD8+TNF+ T cells in the lung after receiving IL-7, fusion, or 
control plasmid. d, Number of CD4+TNF+ T cells in the lung after the 
three different treatments. *, Denotes significant difference when compared 
with the control group, p < 0.001. Plots show medians with 5, 25, 75, and 
95 percentiles of five to six mice. 
was a significant difference between fusion and IL-7 treatment 
(p = 0.0092). 
Discussion 
We report in this study the generation of a novel chimeric variant 
of IL-7 that has the ability to overcome the high doses currently 
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treated animals after receiving influenza. a, Histogram showing 
CD8+CD45RB expression in IL-7, fusion, or control plasmid animals fol-
lowing intranasal infection with influenza virus. b, Total number of lung 
CD8±CD45Rew cells following treatment with control, IL-7, or fusion 
plasmid. c, Histogram showing CD4+CD45RB expression in IL-7, fusion, 
or control plasmid animals. d, Total number of CD4+CD45RBI'w cells 
isolated from the lung in animals that had received IL-7, fusion, or control 
plasmid. *, Denotes significant difference when compared with the control 
animals, p < 0.01. §, Denotes significant difference between IL-7- and 
fusion-treated animals, p = 0.0092. Plots show medians with 5, 25, 75, and 
95 percentiles of five to six mice. 
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necessary for a thymus-directed therapy. In addition, we show a 
superior method for improving the targeting ability of cytokines. 
We created the fusion molecule by fusing the extracellular domain 
of CCR9 to IL-7 with the aim of enhancing the retention of the 
fused molecule in the thymus. We chose to fuse CCR9 onto IL-7 
because of the strict specificity for its ligand CCL25, and the high 
levels of CCL25 expressed by thymic tissue (17). 
The fusion protein also showed an improved effect in vivo com-
pared with IL-7 following expression of these plasmids. We found 
there to be significantly higher levels of IL-7 retained in the thymi 
of animals receiving fusion treatment, even though the similar 
amounts of IL-7 were produced by both treatment arms, suggesting 
that the fusion protein is preferentially retained in the thymus. This 
enhancement in IL-7 levels in the thymus after receiving the fusion 
protein was not considered an effect of gene dosage, as IL-7 levels 
in the kidney were not found to differ between the IL-7 and fusion 
group, indicating comparable clearance rates for both groups. 
Moreover, similar levels of expression were noted following im-
munohistology of the anterior tibial muscles of both groups. This 
improvement in thymopoiesis is due to an increased retention of 
the fusion protein, as fusion-treated animals showed significantly 
higher SEC levels than those treated with IL-7. This holds true 
even though the SEC levels were higher in control animals (CCR9 
alone) compared with those receiving IL-7 or the fusion protein. 
This is because IL-7 is a potent regulator of T cell homeostasis and 
is able to enhance peripheral T cell expansion in a thymic inde-
pendent manner (7). We chose to deliver the three therapies via 
plasmids, the downside of which being that vectors containing 
IL-7 continually produced the cytokine leading to complexity in 
interpreting the SEC data, as SEC values can be influenced by 
changes in peripheral T cell turnover. Despite this, the results 
showed the fusion protein to have a higher SEC value than animals 
receiving IL-7 alone. However, a direct assessment of whether the 
fusion protein shows better retention in the thymus would be to 
inject soluble fusion protein and IL-7. In addition, we cannot dis-
count the possibility that the fusion protein binds other sites in the 
body, such as the gut, and this is currently being investigated. 
The high levels of IL-7 detected after fusion treatment translated 
into a restoration of thymic architecture and a renewal of thymo-
poiesis. We demonstrated that fusion treatment caused regenera-
tion of the thymus, defined by an increase in cellularity and the 
identification of distinct cortical and medullary regions. We also 
found there to be increased numbers of DN thymocytes after both 
IL-7 and fusion treatment, with the fusion protein showing a sig-
nificantly greater number of DN1 cells compared with IL-7 treat-
ment. In addition, the proportion of DN2, 3, and 4 cells also sig-
nificantly increased after fusion treatment, whereas IL-7 alone 
failed to have such an effect, further indicating that the fusion 
protein is preferentially retained in the thymus. We also found 
fusion treatment to increase the number of CD4+ T cells, with no 
change in the number of DP cells. This is in contrast to a number 
of reports that show a decreased number of DP cells with overex-
pression of IL-7 (14) and an inhibition in the development of ma-
ture T cells following treatment with IL-7-secreting stromal cells 
(15). This may reflect the differing IL-7Ra expression profiles of 
these cells, the different concentrations of IL-7 and mode of de-
livery, as well as the timing of analysis. Our data were obtained 
only 1 wk after IL-7 supplementation, which might not have pro-
vided enough time for significant increases in the DP population 
from the DN progenitors to become apparent. However, we chose 
this time point to determine whether increases in these early T cell 
subsets translated into increased thymic output. We decided to use 
i.m. injection of plasmid DNA to deliver the IL-7, as it negated the 
difficulty of producing large quantities of highly pure cytokine.  
Intramuscular electrotransfer of DNA has the advantage that plas-
mids are retained for prolonged periods; in the absence of an im-
mune response, the expression can last for over 6 mo and as long 
as 18 mo, in contrast to mitotic tissues in which plasmids can be 
rapidly lost. Additionally, electrotransfer reduces the variation 
seen with simple injection of naked DNA. 
An increase in thymic output was evident from the SEC assay, 
with fusion animals showing significantly higher SEC levels in 
their splenic af3 T cell populations when compared with animals 
receiving IL-7 alone. This improvement in thymic output could be 
translated into an enhanced in vivo response to influenza virus, a 
virus that causes considerable morbidity and mortality in the el-
derly (29). This was demonstrated by a lower viral load in fusion-
and IL-7-treated animals, which agrees with previous data report-
ing a lower viral burden during infection with influenza (30) and 
HSV type-1 (31) following treatment with rIL-7. 
Substantial lung damage accompanies influenza infection, 
which is mediated by TNF (27). When TNF is released in large 
quantities, it is associated with cachexia, enhanced cell recruit-
ment, and proliferation leading to airway occlusion (24). We show 
reduced numbers of CD8+ T cells expressing TNF in mice treated 
with IL-7, an effect that was more prominent by the addition of the 
fusion protein. This result is surprising because the number of 
activated (CD45R13') CD8÷ T cells increased compared with 
control-treated mice, and viral titers were reduced. It is possible 
that TNF plays only a minor role in the clearance of influenza 
virus. In support of this hypothesis, our studies show that TNF 
neutralization does not affect clearance of pulmonary respiratory 
syncytial virus or influenza (24). The fusion protein may cause 
viral replication to be controlled more effectively by restoring the 
age-associated defects in effector memory cells more effectively 
than IL-7. Such age-related defects include the inability to mount 
a primary immune response against Ag (32). Indeed, it has been 
shown that when old and young mice were administered 75 hem-
agglutination units of influenza A virus, there were marked differ-
ences between the groups, with aged animals having fewer influ-
enza-specific CD8+ T cells and a lower percentage of IFN-y-
producing cells, together with a decreased viral specific CTL 
activity (33). Such changes in effector cells in the elderly have 
been correlated to a reduced production of IL-7, suggesting a re-
lationship between IL-7 and effector cells (34). It is also possible 
that these age-related defects in CD8+ effector function are caused 
in part by an alteration in CD4+ T cell-dependent help. Indeed, a 
recent study by Haynes et al. (35) has elegantly shown that the 
removal of aged CD4+ T cells from aged animals induced the 
production of new T cells, which exhibit robust responses to Ag ex 
vivo and in vivo. These data would suggest that the fusion protein, 
which is preferentially retained in the thymus, reduces the immu-
nopathology following influenza infection by causing greater de 
novo T cell production, thus allowing fusion-treated animals to 
generate a more robust response to Ag. 
We have described the creation of a novel fusion protein that 
shows enhanced thymopoiesis; however, if this fusion protein is to 
be developed further, its immunogenicity needs to be determined. 
The possibility that the fusion protein forms Abs that either block 
or neutralize the biological activity of IL-7 cannot be discounted, 
as a number of recombinant proteins are known to elicit Ab re-
sponses to varying degrees. Abs have been shown to develop in 
20-75% of patients being treated with recombinant proteins, in-
cluding erythropoietin (36), coagulation factor VIII (37), human 
growth hormone (hGH) (38), human GM-CSF (39), and IFNs a 
and (3 (IFN-a, IFN-/3) (40, 41). Initial preparations of hGH con-
tained an additional methionine residue at the N-terminal (methi-
onine-human growth hormone; met-hGH), with the occurrence of 
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Abs to met-hGH being measured in up to 75% of patients (38). 
Whereas more recent preparations of hGH that lack the extra me-
thionine have been found to be less immunogenic, the incidence of 
Abs being found is 1.1% of patients (42). Although the mecha-
nisms that underlie the generation of Abs to recombinant protein 
are not well understood, it is thought to involve peptide epitopes of 
the recombinant protein binding to HLA class II molecules (43). 
As with met-hGH, the fusion protein described in this work has the 
potential of being immunogenic, with responses being directed to 
the junctional sequence between the extracellular CCR9 domain 
and IL-7. Only by analyzing the binding ability of this novel pep-
tide epitope contained in the fusion protein can we gauge the level 
of immunogenicity. 
In summary, we have devised a novel therapeutic strategy by 
fusing the N-terminal domain of the chemokine receptor CCR9 to 
IL-7, causing an enhanced retention in the thymus and improved 
thymopoietic ability that we feel is a more effective immunorestor-
ative agent than IL-7 alone. 
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Abstract 
Chlamydiae are atypical intracellular bacteria that infect via mucosal surfaces causing, for example, trachoma, pneumonia, cervicitis, 
urethritis and infertility. Existing antibiotics are only partially effective and no vaccines are available. Using surface expressed or secreted 
proteins previously identified by genomics and proteomics we tested five as vaccines against intranasal challenge with Chlamydia pneumoniae. 
One antigen, LcrE, induced CD4+ and CD8+ T cell activation, type 1 cytokine secretion and neutralising antibodies and was completely 
effective in eliminating infection. Such antigens are highly conserved and essential to all Chlamydial species. The discovery of an effective 
vaccine for Chlamydiae pneumoniae has potential wide benefits for human health. 
© 2006 Elsevier Ltd. All rights reserved. 
Keywords: Chlamydia; Protection; Vaccine 
1. Introduction 
Chlamydia pneumoniae is an obligate intracellular 
pathogen that enters via the host respiratory tract. Present in 
at least 50% of the worldwide population, it is the third most 
common cause of upper respiratory tract disease, including 
bronchitis and sinusitis. Infection is associated with chronic 
obstructive pulmonary disease (COPD), wheezing, asthma 
and asthmatic bronchitis [1]. In the lower respiratory tract it 
causes approximately 10% and 5% of pneumonia and bron-
chitis cases, respectively [1-4]. 
Definitive pathogenesis studies are hindered by the com-
plicated biphasic life cycle of the Chlamydiae [5]. The 
metabolically inert infectious elementary body (EB) enters 
into host cells and occupies a membrane bound inclusion 
* Corresponding author. Tel.: +44 208 383 4487; fax: +44 208 383 4499. 
E-mail address: t.hussell@ic.ac.uk (T. Hussell). 
0264-410X/$ — see front matter m 2006 Elsevier Ltd. All rights reserved. 
doi: 10.10164 vacci ne.2006.12.003 
in the post-Golgi exocytic vesicular compartment [6,7]. EBs 
then differentiate into the larger, metabolically active, retic-
ulate bodies (RBs), which multiply by binary fission before 
undergoing a second differentiation step to yield new infec-
tious EBs. The entire infectious cycle lasts approximately 
72 h [8]. Repeated infections are common and may repre-
sent new infections or reactivation of persistent organisms. 
What is apparent is that immunity is either ineffective or 
only transient after initial infection. Strategies to improve 
anti-Chlamydial immunity are therefore of vital importance. 
Despite of the prominence of the Chlamydiae in a wide 
variety of serious human diseases there are currently no effec-
tive vaccines. Treatment is by antibiotic therapy, but patients 
often present with severe or irreversible complications and 
the use of antibiotics does not necessarily ameliorate estab-
lished pathology [9,10]. Unfortunately not only do untreated 
Chlamydial infections frequently lead to sequelae, but treat-
ment itself may prove detrimental; host- or therapy-induced 
C. Thorpe eral. / Vaccine 25 (2007) 2252-2260 	 2253 
persistence is thought to constitute a major factor in the 
pathogenesis of Chlamydial infections [ 10-13]. Hence, even 
a partially effective vaccination programme would be less 
costly than a screening programme [14] and would cause a 
rapid and beneficial reduction in the prevalence of infection. 
Sequencing of C. pneumoniae genomes has provided an 
opportunity for annotation, analysis and comparison against 
closely related organisms [15-17]. Since adhesion and host 
cell colonisation relies on EB surface organisation, a suc-
cessful vaccine would target invariant and exposed proteins 
[18,19]. Although computer analysis had previously inferred 
the surface localisation of a number of proteins [20,21], only 
a few of these have been characterised [22-28]. 
We now describe how C. pneumoniae surface expressed 
or secreted antigens, originally identified by a genomic—
proteomic approach, has led to the identification of a sig-
nificant vaccine target. These antigens were initially selected 
by protein-localisation algorithms based on their periplasmic 
or inner/outer membrane location, or due to their homology 
with surface-exposed proteins in other bacteria [29]. Using 
a mouse model we have identified LcrE as protective anti-
gen against C. pneumoniae infection. LcrE is the putative lid 
of the type III secretion system (TTSS) that targets effector 
molecules into host cells in a calcium ion dependent fashion; 
hence its expression depends on the immediate environment. 
In the absence of IFNi, LcrE is detectable by RT-PCR within 
24 h, but is down-regulated in its presence [30]. Immunoblot 
studies using specific anti-sera demonstrate LcrE protein 
expression within 48 h, similar to the kinetics of other pro-
teins of the type HI secretion apparatus (YscN and LcrHl). 
By microscopy, LcrE is clearly present in punctuate form in 
the inclusion membrane [31]. 
We now show that vaccination with an LcrE fusion pro-
tein enhances CD4+ and CD8+ T cells in both the lung and 
airways during an intranasal C. pneumoniae challenge in 
a murine model. Furthermore, the challenge inoculum was 
absent within 7 days but remained present in unvaccinated 
and challenged mice or those vaccinated with other Chlamy-
dial proteins.  
fetal calf serum, 1 µ,g/µ1 cycloheximide and 25 µg/µl gen-
tamycin. Chlamydial titres were determined by 72-h infection 
in HEp-2 cells, followed by staining with a FITC-conjugated 
anti-Chlamydial LPS mAb (DAKO). 
2.2. Recombinant proteins 
ORFs annotated as LcrE, DnaK, OmpH and HypProt 
(see table below) in the C. pneumoniae CWL029 genome 
[17] were PCR-cloned into plasmid expression vectors 
and purified from Escherichia coli cultures as described 
[29]. Histidine tagged proteins were obtained by cloning 
in the pET21b+ vector (Novagen), and GST fusion pro-
teins were obtained using the pGEX (Pharmacia) derived 
vector pGEX-KG [32]. E. coli BL21 DE3 (Novagen) was 
the recipient of pET21b+-derived recombinant plasmids, 
whereas E. coli BL21 (Novagen) was used for pGEX-
derived recombinant plasmids. PCR primers were designed 
to amplify gene ORF without the N-terminal signal pep-
tide coding sequence. When a signal peptide or processing 
site was not clearly predictable the ORF sequence was 
cloned as annotated by Kalman et al. [17]. Recombinant 
E. coli cells were grown in LB medium (500 ml), contain-
ing 100 µg/ml Ampicillin, at 37 °C until an OD600 = 0.5 
induced with 1 mM IPTG. Cells were collected by cen-
trifugation 3 h after induction and broken in a French 
Press (SLM Aminco, Rochester, NY). After centrifuga-
tion at 30,000 x g, the supernatants of the pET-transformed 
E. coli extracts were loaded onto Nickel activated chelat-
ing Sepharose columns (Amersham Pharmacia Biotech) 
and after column washing with 20 mM Imidazole, recom-
binant proteins were eluted with 250 mM Imidazole. The 
supernatants of cultures carrying pGEX derivatives were 
loaded onto Glutathione Sepharose 4B columns (Amer-
sham Pharmacia Biotech) and proteins were eluted with 
50 mM Tris—HCI, 10 mM reduced glutathione, pH 8.0. Pro-
tein concentrations were determined using the Bradford 
method and extent of purification was estimated by SDS-
PAGE. 
Protein ID NC131PID Theoretical molecular 
mass (kDa) 
Fusion type Current annotation 
Cpn0301 15618221 17.3 GST OmpH-like outer membrane protein 
Cpn0503 15618474 71.3 HIS dnaK hsp70 heat shock protein 
Cpn0498 15618409 32.9 GST Hypothetical protein, HypoProt 
Cpn0029 15617953 14.2 GST Hypothetical protein, LcrE 
Cpn0029 15617953 14.2 HIS Hypothetical protein, LcrE 
2.3. Infection 
2. Methods 
2.1. Organism 
C. pneumoniae strain AR39 from the American Type 
Tissue Collection was propagated in HEp2 cells grown in 
Iscove's Modified Dulbecco's Medium (IMDM) with 5% 
All in vivo procedures were performed according to Home 
Office, UK and personal licence guidelines. Female BALB/c 
mice aged 10-12 weeks were infected intranasally with 
2 x 105 IFU C. pneumoniae AR39. At days 0 (naïve), 7, 
14 and 28 post-infection mice were killed by intraperitoneal 
administration of pentobarbitone and exsanguination of the 
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femoral artery. Broncho-alveolar lavage (BAL) was per-
formed; lungs were washed in situ six times with 1% EDTA 
in 1.5 ml MEME (minimum essential medium Eagle) using 
a tracheal cannula. BAL fluid was centrifuged at 800 x g 
for 5 min and cells resuspended in IMDM. Viable lympho-
cyte numbers were assessed using Trypan blue exclusion. 
The lower left lung lobe was removed, snap frozen in liquid 
nitrogen, and stored at —70 °C until required. The remaining 
lung tissue was excised and washed through 100 pm nylon 
filters with IMDM to create single cell suspensions. These 
were centrifuged at 800 x g for 5 min, and then re-suspended 
in red cell lysis buffer (8.29 g NH4C1, 1.0 g CHCO3, 37.2 g 
EDTA in 11 dH2O at pH 7.3) for 5 min. IMDM was added, 
and cells were re-pelleted and counted. In some experiments 
mice were vaccinated intraperitoneally with 20 p4 of fusion 
protein in 2011g of Complete Freund's Adjuvant followed 
by the same dose of fusion protein in Incomplete Freunds 
Adjuvant on days 14 and 30, 2 weeks prior to C. pneumoniae 
challenge. 
2.4. Flow cytometry 
Cells from BAL fluid and lung tissue were stained with 
fluorophore-conjugated antibodies; anti-CD3-PE, anti-CD8-
PerCP, anti-CD4-APC or anti-CD45RB-FITC for 30 min on 
ice in PBS containing 1% FCS and 0.1% sodium azide, 
then washed three times in the same buffer and fixed for 
20 min at room temperature in 2% formaldehyde. To detect 
intracellular cytokines 1 x 106 cells were incubated with 
50 ng/ml PMA (Sigma—Aldrich), 500 ng ionomycin (Cal-
biochem) and 10 µg/ml brefeldin A (Sigma) for 4 h at 
37 °C. Cells were stained with anti-CD4 APC and anti-CD8 
PerCP on ice for 30 min, washed and then fixed in 2% 
formaldehyde for 20 min at RT. Cells were permeabilised 
with 0.5% saponin in PBS containing 1% BSA and 0.1% 
azide for 10 min. A combination of anti-TNF-PE and anti-
1FN-y FITC, diluted in saponin buffer, was then added to 
the cells. After 30 min cells were washed once in saponin 
buffer and twice in PBS containing 0.1% azide and 1% 
BSA. All data was acquired on a FACS Calibur (Becton 
Dickinson), on 30,000 lymphocytes, and analysed using Cell 
Quest Pro. Lymphocytes were determined using their for-
ward and side scatter properties and CD3 and B220 markers 
delineating T and B cells, respectively. The proportion of 
CD4+ and CD8+ T cells within this population was then 
examined in separate histogram plots. The activation of T 
cell population was enumerated by analysing the loss of 
CD45RB. 
2.5. Antibody 
In vitro neutralization assays were performed on LLC-
MK2 (ATCC: CCL-7) epithelial cell cultures. Serial 4-fold 
dilutions of mouse immune and corresponding pre-immune 
sera were prepared in sucrose-phosphate-glutamic acid buffer 
(SPG). Mouse polyclonal sera to whole EBs were used  
as positive control of neutralization, whereas SPG buffer 
alone was used as negative control. Purified infectious EBs 
were diluted in SPG buffer to contain 2.5 x 107 IFU/ml, and 
10 pi of EBs suspension were added to each serum dilution. 
After 30 min at 37 °C on a slowly rocking platform 100 pi 
of reaction each sample was added to LLC-MK2 conflu-
ent monolayers (in triplicate for each serum dilution), in a 
24-well tissue culture plate, and centrifuged at 805 x g for 
1 h at 37 °C. After centrifugation, Eagle's minimal essential 
medium containing Earle's salts, 20% foetal bovine serum 
and 1 mg/ml cycloheximide was added. Infected cultures 
were incubated at 37 °C in 5% CO2 for 72 h, and then fixed 
with methanol. Chlamydial inclusions were detected by stain-
ing with a mouse anti-Chlamydia fluorescein-conjugated 
monoclonal antibody (Meridian Diagnostics, Inc.) and quan-
tified by counting 10 fields per well at 20 x magnification. 
Inhibition of infectivity due to EBs interaction with the 
immune sera was expressed as percent reduction in mean 
IFU number as compared to the SPG (buffer only)/EBs 
control. The IFU counts obtained with immune sera were 
corrected for background observed with the corresponding 
pre-immune sera. Sera were considered as "neutralizing" if 
they could cause a 50% or greater reduction in infectivity. 
Experimental variability was evaluated by calculating the 
standard error of measurement (S.E.M.) for three titration 
experiments. 
2.6. ELISA analysis of specific antibodies 
2.5 x 107 IFU C. pneumoniae was sonicated for 5 min in 
a water bath in 1 ml distilled water. This was diluted 1/500 in 
citrate/phosphate buffer (pH 9) and used to coat the wells of 
an ELISA plate. After incubation overnight at 4 °C the wells 
were washed 5 times with PBS/0.05% Tween 20, blotted dry 
and then blocked for 2 h at room temperature with 0.5% rat 
serum. After 3 washes 10-fold dilutions of mouse sera were 
added in triplicate and left for 1 h on a plate shaker. Bound 
antibody was detected with peroxidase-conjugated rat anti-
mouse Ig and the substrate o-phenylene diamine. Plates were 
read at 490 nm and the antibody titre determined by the dilu-
tion that resulted in an optical density 4 times greater than 
uninfected mouse serum. 
2.7. Analysis of LcrE specific T cell responses in vitro 
Mice were vaccinated i.p. with 20 µg of fusion protein in 
20 µg CFA and boosted with the same dose of fusion protein 
in Incomplete Freunds Adjuvant on days 14 and 30. Spleno-
cytes were removed, teased to a single cell suspension and 
incubated at 106 cells/ml with 50 p.g/ml LcrE GST-tagged 
fusion protein. The GST-tagged OmpH fusion protein served 
as a control. After 48 h at 37 °C the cells were washed and 
stained for T cell surface markers and intracellular cytokines 
as described above. The total number of cells producing each 
cytokine was calculated from the viable cell count in each 
culture. 
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2.8. PCR 
DNA was extracted from lung lobes using DNeasy Extrac-
tion Kit (Qiagen) as specified by the manufacturer, and stored 
at —20 °C. PCR was performed to amplify the C. pneumo-
niae OmpA gene. The reaction mixture contained 40 µM 
dNTPs, 1.25 U Taq Polymerase, 2.5 µl 10 x PCR buffer, 
3 mM MgC12 (Sigma—Aldrich) 1 ng template and primers at 
1.2 µM in a total reaction volume of 25 µ1 After 2 min of 
initial denaturation at 95 °C, the samples were subjected to 
45 cycles of denaturation (95 °C for 15 s), annealing (55 °C 
for 40 s) and extension (72 °C for 30 s) with a Thermo-
Hybaid Px2 thermocycler, followed by a final extension for 
2 min at 72 °C after completion of cycling. The forward 
(5'-AATCTGAACTGACCAGATACGTGA-3') and reverse 
(5'-GCCACAGCATTGTCTACTACTGAT-3') primers were 
synthesised by Sigma-Genosys (Haverhill, UK). The 
amplification products were separated and visualised by elec-
trophoresis on a 3% agarose gel containing ethidium bromide.  
3.2. Modulation of the immune response and bacterial 
clearance by immunisation 
Selected ORFs from the C. pneumoniae CWL029 genome 
were cloned into plasmid expression vectors and recombinant 
proteins with either a six-histidine tag at the C terminus (HIS) 
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2.9. Statistics (A) 
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The statistical significance of all data was assessed by 
two-tailed ANOVA, assuming unequal variance. Bonferroni 
correction was applied where appropriate. 
3. Results 
3.1. The immune response to C. pneumoniae infection 
C. pneumoniae infection induced major alterations in the 
cellular content of the lung tissue and airways. Lymphocytic 
expansion in the airways mirrored the decline observed in 
lung tissue (Fig. 1A). The change in activated CD4+ (con-
stituting almost the entire CD4+ population) in the airways 
(Fig. IB) and lung (Fig. 1C) reflected the overall fluctuations 
in cell number. Only marginal CD8+ T cell expansion and 
activation was observed in the airways. Analysis of intra-
cellular cytokines by flow cytometry revealed a dominant 
type 1 cytokine response. Intracellular IFN--y and TNF was 
observed in CD4+ and CD8+ T cells. No IL-4 or IL-5 was 
observed at any time point (data not shown). This general 
immune profile is consistent between separate experimental 
infections and is that to which all manipulations are com-
pared. 
Fig. 1. Recruitment of lymphoid cells into the airways. BALB/c mice were 
infected IN with 2 x 105 IFU C. pneumoniae. 0, 7, 14, 21 and 28 DPI 
broncho-alveolar lavage was performed. Lungs were excised, homogenised 
to a single cell suspension and the proportion of lymphocytes enumerated 
by flow cytometry by identifying their position of forward and side scatter 
plots using antibodies to CD3 and B cells. Total lymphocytes (A) in the 
airways (—) or lung tissue (- - -) were calculated by the total viable cell 
recovery. T cell activation in the airways (B) or lung (C) was determined by 
the down-regulation of the surface marker CD45RB on CD3+ T cells. Data 
(mean + S.D.) is representative of two independent experiments containing 
four mice per group. 
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BOA 
Fig. 2. Immunisation with DnaK or LcrE boosts immunity in the lung. Mice 
were immunised with surface expressed/secreted proteins 7 weeks (with 
Freund's Complete Adjuvant), 5 and 3 weeks (both with Freund's Incomplete 
Adjuvant) prior to IN infection with 2 x 105 IFU C. pneumoniae AR39. 
Mice were killed 14 DPI as above, and lymphocytes (identified using T 
and B cell markers (CD3 and B220)) in the airways (A) and lung tissue 
(B) enumerated by flow cytometry. Data (mean + S.D.) is a pool of two 
independent experiments containing four mice per group. 
or a fused glutathione S-transferase (GST) at their N terminus 
obtained as described previously [29]. Mice were vaccinated 
three times with each construct and challenged intranasally 
with C. pneumoniae 3 weeks after the last vaccination. 
As before, infection of un-vaccinated mice induced cel-
lular recruitment into the airways. Equivalent recruitment to 
the airways was also apparent in mice previously immunised 
with LcrE and HypProt fused to GST. No significant airway 
recruitment was observed with HIS-tagged proteins due to 
the high background reaction to HIS control (Fig. 2A). Vac-
cination with LcrE-GST and DnaK-HIS also enhanced the 
lung tissue cellularity in comparison to mice vaccinated with 
C. pneumoniae alone (Fig. 2B). These two constructs were 
therefore investigated further. 
LcrE was by far the most immunogenic C. pneumoniae 
antigen tested. CD4+ T cell activation was enhanced com-
pared to those induced by primary C. pneumoniae infection 
alone and peaked at day 14 in the lung (Fig. 3A). CD8+ T cell 
activation was evident, although approximately 6-fold less in 
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Fig. 3. Immunisation with LcrE or DnaK alters T cell polarisation. Mice 
were immunised with LcrE, DnaK or appropriate controls, infected IN with 
2 x 105 IFU C. pneumoniae, and lung sampled on days 0, 7, 14 and 28. 
CD4+ (A) and CD8+ (B) T cell activation was assessed by flow cytometry 
by examining the down-regulation of CD45RB. Expression of intracellular 
IFN-y or TNF (C) in single CD4+ or CD8+ T cells was determined by 
intracellular staining and flow cytometry in C. pneumoniae infected mice 
previously vaccinated with LcrE (closed bars) or PBS (open bars). Data 
(mean + S.D.) is representative of three independent experiments. 
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magnitude compared to CD4+ T cells (Fig. 3B). Whilst DnaK 
vaccination increased CD4+ T cell numbers in the lung (data 
not shown), their activation was not beyond that observed 
during primary infection (Fig. 3A). Type 1 cytokines IFN- 
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Fig. 4. Immunisation with LcrE or DnaK enhances T cell cytokine produc-
tion and decreases the bacterial load in lung tissue. Splenocytes from LcrE 
vaccinated mice were cultured in vitro for 48 h with LcrE-GST or OmpH-
GST (control) and then CD4 or CD8 T cells examined for intracellular 
(A) or IL-2 (B). Results shown are the mean and standard deviation of four 
individual cultures. DNA was extracted from C. pneumoniae infected lung 
tissue 0, 7, 14, 21 or 28 DPI. OmpA amplified PCR products were sepa-
rated on an agarose gel. (+) DNA extracted from stock C. pneumoniae (C). 
Mice were vaccinated and infected with C. pneumoniae as in Fig. 3. One 
lobe of lung was snap frozen at day 7 in liquid nitrogen and stored intact at 
—70 °C. Total DNA was extracted and PCR performed to identify samples 
positive for the Chlamydial OmpA gene (D). The data is representative of 
two independent experiments. 
y and TNF were increased during infection by prior LcrE 
(Fig. 3C) but not DnaK (data not shown) vaccination. This 
enhancement of cytokines by both CD4+ and CD8+ T cells 
was also observed when splenocytes from LcrE vaccinated 
mice incubated with LcrE in vitro (Fig. 4A and B). 
Analysis of C. pneumoniae replication by culture or 
immunohistochemistry often presents the best case scenario 
since the techniques offer limited sensitivity. However, by 
PCR amplification of the OmpA gene, C. pneumoniae can 
be detected in lung homogenates on days 7, 14 and 21 of a 
primary infection, but is absent by day 28 (Fig. 4C). This is 
also true of mice given the control GST or HIS constructs 
prior to C. pneumoniae challenge (Fig. 4D shows the data 
at day 7 after challenge). Immunisation with DnaK or LcrE 
reduced the day 7 lung bacterial burden in the lung to a level 
undetectable by conventional immunohistochemistry (data 
not shown) and, after LcrE vaccination, barely detectable by 
PCR amplification (Fig. 4D). By day 14 both DnaK and LcrE 
vaccinated mice had cleared the C. pneumoniae challenge 
(data not shown). 
3.3. Antibody-mediated inhibition of in vitro infectivity 
The role of antibody in protection from an organism with 
such a unique intracellular life cycle is unclear. Several can-
didate vaccines, including outer membrane proteins (MOMP 
and Omp2) and an ADP/ATP translocase (Nptl (Cp)) [33,34], 
have induced good serum neutralising antibody titres. Here, 
we considered an antibody as neutralising if it caused a 50% 
Fig. 5. Vaccination with LcrE or DnaK induces specific antibody. Mice 
were vaccinated and infected with C. pneumoniae as in Fig. 3, and bled as 
above 14 DPI. Sera was incubated with purified EBs for 30 min then added 
to confluent LLC-MK2 monolayers. Infectivity was assessed by counting 
inclusions at 20x magnification. Inhibition of infectivity was expressed as 
percent reduction in mean IFU compared to EBs incubated in control serum 
(left axis, closed symbols). Specific antibody titre was determined by ELISA 
(right axis, hatched bars). This data is representative of two experiments 
containing five mice per group. 
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or greater reduction in the mean IFU. This was observed 
following immunisation with either LcrE-GST or DnaK-
HIS, both of which reduced the mean IFU by almost 90% 
(Fig. 5). 
4. Discussion 
Testing Chlamydial proteins previously identified by 
genomics and proteomics in an in vivo model where 
correlates of immunological protection can be easily deter-
mined provides a powerful combination for effective vaccine 
design. C. pneumoniae is most effectively eliminated by 
type 1 cytokines such as IFN-y and TNF. Prior vacci-
nation with LcrE increases the CD4+ and CD8+ T cell 
pool and, more importantly, their expression of intracellular 
IFN--y and TNF. This correlates with protection from sub-
sequent intranasal challenge with a homologous Chlamydial 
strain. 
The relative importance of specific cell subsets in protec-
tion from a primary infection with Chlamydia species has 
been elegantly dissected by a number of groups [35-41]. 
Rothfuchs et al have shown that IFN-7 from either CD4+ 
or CD8+ T cells is capable of protecting mice from C. 
pneumoniae re-infection; furthermore, in the absence of T 
lymphocytes non-lymphoid cells, especially macrophages, 
can confer protection in an IFN-7 dependent manner [41], 
an observation supported by in vitro IFN--y production by 
C. pneumoniae infected macrophages [42]. NK cells, also 
a source of IFNI, do not appear to be pivotal for pro-
tection against Chlamydia but may contribute generally in 
anti-bacterial immunity [41,43-45]. We did not observe sig-
nificant effects on NK cell recruitment, or their production 
of intracellular IFN-y in vaccinated and C. pneumoniae chal-
lenged mice (data not shown). 
The precise physical and temporal expression of C. pneu-
moniae proteins is likely to affect both their suitability as 
vaccine candidates and likelihood of inducing T and B cell 
responses. Any cytoplasmically exposed proteins may be tar-
geted for ubiquitin dependent proteasomal degradation and 
subsequent loading into MHC class I molecules [18]. It is 
interesting to note in our study that during a primary C. 
pneumoniae infection CD8+ T cells are expanded yet not 
activated in the lung. By contrast LcrE vaccination enhances 
both CD8+ T cell numbers and their production of anti-
Chlamydial cytokines. This is likely to reflect the location 
of LcrE in contact with the cytoplasm; though how it enters 
the MHC class I processing pathway remains unknown. The 
pivotal role of CD8+ T cells in both protection and directing 
appropriate CD4+ T cell responses is evident during pri-
mary C. pneumoniae [35,46], C. trachomatis [47] and C. 
psittaci [48] infection. A similar requirement for CD8+ T 
cells in protection by vaccination to C. pneumoniae have 
been demonstrated before. A DNA minigene constructed 
to enhance entry into the endoplasmic reticulum and con-
taining C. pneumoniae CTL and a CD4+ T cell epitope(s)  
induces IFN-y and TNF production by CD8+ T cells and 
reduces lung bacterial burden. Similar vaccination of I32m 
knockout mice however, does not highlighting the impor-
tance of CD8+ T cells in protection [49]. Potent CD8+ T cell 
responses are also induced to HLA-A2 restricted epitopes 
contained in the outer membrane protein of C. pneumoniae 
[50]. 
The most desirable vaccine would be one that induces a 
balanced T cell response. DNA vaccination of mice with the 
heat shock protein 60 (HSP-60) gene affords some protec-
tion from lung C. pneumoniae infection [33], enhanced by 
co-administration of IL-12. Again, protection correlates with 
a dominant IFN-7 response since similar vaccination in IFN-
-yR deficient mice does not clear a C. pneumoniae challenge 
[33]. If an unbalanced immune response is induced then the 
disease may even be heightened. For example, DNA vacci-
nation with Chlamydial proteins in the absence of CD8+ T 
cells leads to higher numbers of bacteria, reduced IFN--y and 
increased IL-10 [33]. 
Outer membrane proteins (MOMP and Omp2) and an 
ADP/ATP translocase (Nptl (Cp)) [33,34] have both been 
demonstrated to induce good serum neutralising antibody 
titres. We observed reduced infectivity of C. pneumoniae 
pre-incubated with sera from mice vaccinated with LcrE and 
DnaK and challenged with C. pneumoniae. We believe this 
represents a specific response to the individual proteins con-
tained in the vaccination that is enhanced after challenge, 
since mice vaccinated with other Chlamydial proteins did 
not induce a similar effect. Why other Chlamydial proteins 
do not induce neutralising antibody is not currently known. 
The titre of antibody induced by the immunising protein may 
not necessarily correlate with protection as demonstrated in 
mice vaccinated with DNA constructs encoding HSP60 or 
Omp2 [33]. Though anti-Chlamydial antibodies may prevent 
initial infection [51], B cell deficient mice efficiently clear 
Chlamydia [52,53]. Further evidence that antibody is not a 
primary anti-Chlamydial strategy is provided by the lack of 
antigenic variability of the major outer membrane protein 
of C. pneumoniae [18]. Were antibodies directed against this 
protein, modification would be likely similar to that observed 
for the influenza heamagglutinin. 
The current proposed vaccine candidate, LcrE, enhances 
the time to resolution of an acute infection and, by the induc-
tion of CD8+ T cells and IFN-7, may also be effective 
against chronic infection. This is difficult to assess in the 
current model due to the self-limiting nature of this infection 
in mice. Preliminary studies in an intraperitoneal hamster 
model also highlight the efficacy of LcrE vaccination [54]. 
This model suffers from the lack of reagents to monitor the 
induced response and that infection does not occur via the 
usual mucosal route [54]. Originally it was thought that effec-
tor proteins delivered by the TTSS to the cytoplasm of the 
infected cell would make effective vaccine candidates; here 
we show that a TTSS structural protein induces the desired 
immune response that may provide wide benefits for animal 
and human health. 
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preventing viral-induced lung 
inflammation 
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Respiratory infections cause significant morbidity and 
mortality worldwide. Although an immune response 
is required to eliminate respiratory pathogens, if 
unchecked, it can damage surrounding tissues and 
block primary lung function. Based on our knowledge 
of immune T-cell activation, there are several pathways 
to which immune intervention could be applied. How-
ever, relatively few interventions target only those 
immune cells that are responding to antigens. 0X40 
and 4-1BB are members of the tumour necrosis factor 
receptor family and are expressed on the surface of 
T cells in several inflammatory conditions. Recently, the 
inhibition of OX40 has proved beneficial during influ-
enza virus infection. This review highlights the recent 
advances in the manipulation of such molecules and 
how they have been applied to inflammatory conditions 
that are caused by viruses in the lung. 
Respiratory infections account for more than four million 
deaths worldwide each year. Lower respiratory tract 
infections are the third leading cause of death worldwide 
[1] and are a WHO priority for vaccine development. The 
public recognition of the threat of respiratory infection has 
recently increased following the emergence of the severe 
acute respiratory syndrome-associated coronavirus [2-5]. 
The elimination of respiratory viruses relies on the 
recruitment and activation of T lymphocytes. In the lung, 
this activation is often excessive, causing bystander tissue 
damage and airway occlusion. Therefore, a fine balance 
exists between the ability of the immune system to clear 
the virus and the damage that this response causes to the 
delicate architecture of the lung. Such immune-related 
problems are particularly evident in children less than one 
year of age, in whom the airways are small and not fully 
developed, as well as in the elderly. 
The most unfortunate example of how exuberant 
immune responses cause severe complications was pro-
vided by the vaccine trials performed during the 1960s 
with a formalin-inactivated preparation of respiratory 
syncytial virus (RSV), which enhanced the disease 
severity, resulted in hospitalisation and caused vaccine-
related deaths [6]. In mice, vaccination followed by an 
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intranasal RSV challenge causes weight loss, cachexia 
and the occlusion of airways by inflammatory lymphocytes 
and eosinophils [71. The depletion of immune-cell subsets 
or inflammatory cytokines indicates that disease is 
associated with an excessive immune response [8,9]. The 
detrimental outcome occurs as a result of one or more of 
the following: (i) the physical occlusion of the airways; 
(ii) the production of inflammatory mediators that enter 
the systemic circulation. Tumour necrosis factor (TNF), 
for example, causes cachexia, fever and appetite suppres-
sion if concentrations in the lung exceed a certain level 
and systemic spread occurs; (iii) damage caused by the 
biological action of immune cells. T lymphocytes are 
potent sources of cytokines. Helper and cytotoxic T cells 
produce IFN-y and TNF during viral infection [10], which, 
in turn, recruit more immune cells to the lung and, in the 
case of TNF, cause the death of cells that express the 
appropriate receptors. Cytotoxic T cells and natural killer 
(NK) cells lyse virally infected targets by programmed cell 
death (apoptosis). The rate of viral infection and inflam-
matory cell death might exceed the ability of the lung 
microenvironment to remove apoptotic cells, which will 
contribute to occlusion and inflammation. 
The development of anti-viral vaccines has been 
hampered by the detrimental effect of the early clinical 
trials, the age of the intended recipient and by strategies 
used by the virus to evade elimination by the immune 
system. A treatment that is effective during established 
viral infection and is not specific for particular viral 
strains would, therefore, be of great value. Because some 
of the debilitating effects of infection are caused by the 
occlusion of the airways by immune cells, strategies to 
inhibit inflammatory responses have been sought. 
Coordinated activation of T lymphocytes 
There are two main T-cell subsets: Cal T helper (Th) 
lymphocytes and CD8 cytotoxic T lymphocytes (CTLs). 
CD4+ T cells can be further divided based upon the 
cytokines they secrete, into ThO, Thl, Th2 and Th3 cells 
(reviewed in [11]). CDLI+ T cells help other cells by cognate 
interaction and/or the secretion of soluble mediators, such 
as cytokines. CD8+ T cells are also potent producers of 
cytokines and kill pathogen-infected cells or tumour cells 
directly [12]. The production of cytokines by T cells 
contributes significantly to the clinical symptoms that 
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are associated with many lung viral infections. The regu-
lation or inhibition of T cells might, therefore, be of 
therapeutic potential during respiratory infection. 
T-cell responses can be separated into several discrete 
phases: activation, expansion, effector and memory 1131. 
The point at which T cells perform their effector actions 
might occur during the expansion and effector phases of 
the T-cell response, whereas the induction of memory 
occurs during contraction in the late effector phase. T-cell 
receptors (TCRs) recognize small peptide fragments of 
antigen that are presented by major histocompatibility 
molecules (MHCs); MHC class I for CTLs and MHC 
class II for Th cells. MHC molecules are constitutively 
expressed at low levels on 'professional' antigen-present-
ing cells (APCs), such as B cells, dendritic cells and 
macrophages, but are also upregulated or induced on a 
variety of other cell types during inflammation. The 
progression of T cells to full effector function, and 
especially entry into the memory pool, requires a variety 
of additional signals. The precise requirement, sequence 
and cooperation among such signals to maintain T-cell 
responses and to prevent cell death are beginning to 
be determined. Cytokines, such as IL-2, assist initial 
T-cell proliferation, but a variety of additional co-stimu-
latory signals between the T cell and APCs are required 
for expansion, survival and entry into the memory 
pool (Figure 1). 
Co-stimulatory molecules and their role in T-cell 
responses 
There are three broad groups of molecules that are pivotal 
for T-cell responses: the cytokine receptor family that 
controls various aspects of T-cell function, the immuno-
globulin (Ig) superfamily members (CD28, ICOS, PD-1 
and CD2) and the TNF receptor superfamily (for example, 
OX40, 4-1BB, CD27 and CD30). 
CD28 is constitutively expressed on resting T cells, 
binds to B7.1 or B7.2 on APCs and transmits a signal that 
(i) synergises with TCR signalling to promote a sustained 
T-cell response, (ii) decreases the number of TCR engage-
ments that are required for effective T-cell activation and 
(iii) induces the expression of several cytokines 114,151. 
Although CD28 co-stimulation is essential for the acti-
vation of naive T cells that have entered the cell cycle, its 
requirement for memory T-cell responses depends on the 
model system [16,17]. CD27 (which is expressed on resting 
T cells and binds to CD70 expressed on APCs and 
activated T cells) might also function during early T-cell 
activation. Recent evidence in CD28-knockout mice 
suggests that CD27 does not affect the cell cycle but 
sustains T-cell survival through several divisions, rather 
than influencing the number of dividing cells [17,181. 
Inhibitory molecules, such as CTLA-4 and PD1, are 
upregulated to limit clonal expansion (reviewed in 
119-21D. The majority of cells at this stage die by 
TRENDS in Molecular Medicine 
Figure 1. The coordinated sequence of T-cell activation. T-cell activation requires an ordered sequence of events. T cells scan the surface of antigen-presenting cells (APCs) for 
specific antigenic peptides that are expressed by major histocompatibility complex (MHC) class I or class II molecules. This is facilitated by the interaction of leukocyte 
function-associated antigen (LFA)-1 with T-cell binding to intracellular adhesion molecule (ICAM)-1 on the APC. Recognition of peptide—MHC by the T-cell receptor (TCR) is 
not sufficient to fully activate the T cell. A second co-stimulatory interaction between CD28 on the T cell and CD80 and/or CD86 (B7) on the APC is required. Expansion of 
activated T cells is then facilitated by additional co-stimulatory signals. CD27 is upregulated on activated T cells, as is inducible co-stimulatory molecule (ICOS). During the 
later stages of the effector response, T-cell activation is reduced by the expression of CTLA-4, which competes with CD28 for binding to CD/30 and/or CD86 (B7). To maintain 
T-cell activation and form the memory pool, additional signals are required. 0X40, 4-1138 and CD30 are induced on T cells and bind to their respective ligands on APCs, 
providing a survival advantage. The interaction of OX40 with OX40 ligand also reduces the expression of CTLA-4. It is not yet known how long ICOS persists on T cells or 
whether co-stimulatory molecules are present on memory cells (studies suggest that although CD27 is constitutive, it is downregulated on memory T cells). It is also unclear 
whether multiple co-stimulatory molecules exist on the same T cell. 
www.sciencedirect.com  
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apoptosis, and only if they receive further survival 
signals do they progress into the memory pool (from 
which they can be rapidly reactivated to counter future 
antigenic insults). 
T-cell-expressed OX40 and 4-1BB are known to provide 
the necessary signal for continued T-cell survival. Unlike 
CD28 and CD27, OX40 and 4-1BB are not present on 
naive T cells but are expressed within 24 h of T-cell 
activation. Expression requires TCR—MHC—peptide inter-
action and, although CD28 signalling enhances expres-
sion, both OX40 and 4-1BB can be expressed in its absence 
[22-26]. The re-expression of OX40 (data are not yet 
available for 4-1BB) is much faster (within 4 h) on resting, 
previously activated T cells [27]. OX40 and 4-1BB can be 
expressed on both CD4+ and CD8+ T cells, depending on 
the experimental system used [28-31]. It should be noted, 
however, that other cell types, such as macrophages, 
dendritic cells, NK cells and eosinophils, might also 
express 4-1BB (Table 1) (reviewed in [13]). 
The ligands (L) for these late co-stimulatory molecules 
are also inducible on professional APCs by lipopolysac-
charide, CD40 and Ig cross-linking (on B cells) [32-37]. 
Some cell-surface expression of OX4OL and 4-1BBL is 
reported on T cells [38-41]. More importantly, OX4OL is 
also present on inflamed endothelial cells [42,43] and 
might, therefore, mediate the migration of OX40-expres-
sing cells into inflammatory sites. Another inducible 
co-stimulator, ICOS (inducible co-stimulatory molecule), 
is also induced within 12-24 h after T-cell priming and 
binds to B7 h or B7RP-1 on APCs. However, the expression 
of ICOS appears slightly earlier and requires less 
stringent signals than do OX40 and 4-1BB [19]. 
OX40, 4-1BB and CD27 bind to TNF-receptor-associated 
factors (TRAFs), which then initiate several signalling 
Table 1. Characteristics and distribution of T cell co-stimulatory 
molecules* 
°Abbreviations: CTLA-4, cytotoxic T lymphocyte antigen-4; DCs, dendritic cells 
HVEM, herpesvirus entry mediator; ICOS, inducible co-stimulatory molecule; L 
ligand; NK, natural killer; PD-1, program death-1. 
bDownregulated. 
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pathways. 4-1BB can also bind to TRAF1 but, unlike other 
TNF receptor family members, not to TRAF5. For OX40 
and 4-1BB, binding to TRAF2 activates phosphatidyl-
inositol-3-kinase and AKT [44], which upregulate the 
anti-apoptotic genes Bcl-2, Bcl-xL and Bfl-1 [45]. All 
co-stimulatory TNF-receptor molecules induce cell survi-
val through NF-KB, Jun N-terminal kinase and AP1 
(reviewed in [13,37,46]). The precise signalling pathways 
involved are still being elucidated. At present, co-stimu-
latory TNF-receptor molecules seem to share common 
signalling events, although further analysis might show 
some specificity through the precise combination of 
signals and the time at which they occur, relative to 
T-cell activation. 
Where does this happen in the context of the lung 
microenvironment? 
Naive T cells do not initially enter the inflamed sites 
directly, but circulate through secondary lymphoid organs 
and the blood. Once activated by antigenic peptides pre-
sented by MHC molecules in the lymph nodes that are 
associated with the inflammatory site, T cells acquire 
chemokine receptors and homing molecules that enable 
entry into non-lymphoid inflamed tissues. The respiratory 
tract contains lymphoid tissue in the nose itself (nasal-
associated lymphoid tissue, NALT), small foci of follicles 
(predominantly B cells) that are associated with the 
bronchi (although this reduces with age) and scattered 
lymphocytes throughout the lung parenchyma (although 
these are virtually absent in a healthy individual). The 
lower airways are not associated with constitutive second-
ary lymph nodes, nor do they possess classical afferent 
and efferent lymphatics. Mediastinal lymph nodes are 
induced following infection, display typical characteristics 
of secondary lymphoid tissue and retract once inflam-
mation has subsided. The lung encounters a vast array of 
potentially antigenic material. A significant role for lung 
APCs is, therefore, the induction of tolerance, which is 
mediated by lung dendritic cells producing IL-10 
(which induces the development of regulatory T cells) 
and is dependent on co-stimulation by CD86 (B7-2) and 
ICOS—ICOSL interactions [47]. The propensity for IL-10 
production, however, might inadvertently induce allergic 
Th2 cells [48]. Despite the expression of B7 molecules, 
alveolar macrophages are poor at co-stimulating T cells 
[49] and also produce significant quantities of IL-10 [50]. 
Vigorous T-cell responses can occur if the threat exceeds 
the immune-suppressive environment. Nasal and airway 
epithelial cells express B-7 molecules, implying that they 
participate in naive T-cell priming [51]. However, the 
majority of T-cell activation is thought to occur in lung-
associated lymph nodes. Beyer et al. [52] showed that, 
during viral infection, the number and activation of 
pulmonary APCs increases [53]. 
Despite the heterogeneity of various surface molecules 
on lung dendritic cells [54], virtually nothing is known 
about the expression of the more recently discovered 
co-stimulatory molecules. The proposed events regarding 
co-stimulatory-molecule kinetics during lung viral infec-
tion are shown in Figure 2. Despite the near absence 
of knowledge on the temporal and spatial expression of 
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co-stimulatory molecules and their ligands, several 
researchers have investigated the effects of their 
manipulation. 
Late co-stimulatory molecule manipulation and 
immunopathology 
The restricted expression of late co-stimulatory molecules 
on antigen-activated T cells makes them ideal therapeutic 
targets for immune intervention. Manipulation will only 
affect those T cells recently activated by antigen, leaving 
the naive repertoire intact (reviewed in [13]). Here, we 
only discuss the manipulation of co-stimulatory molecules 
during infection of the respiratory tract (for other diseases 
or lung conditions, see [37,55]). 
The strategies used to combat respiratory infection are 
mostly dictated by the pathogen. Pathogens that cause 
direct pathology might be more suited to strategies that 
enhance immunity. A reduction in immunity, however, 
could benefit individuals who are infected with pathogens 
that induce an excessive inflammatory infiltrate. The 
promotion of T-cell-mediated immunity can be achieved 
using agonist antibodies against co-stimulatory molecules 
and soluble or vector-expressed forms of the ligand. For 
example, adenoviral-expressed 4-1BBL (which binds to 
4-1BB on activated T cells) or B7.1 (which binds to CD28 
on all T cells) enhances influenza-specific human CD8+  
T cells [56]. Although agonist antibodies against 4-1BB 
promote influenza specific CD8+ T cells, the effect on ill-
ness or lung inflammation [57] is not known. Similarly, 
an OX40L—Ig fusion protein, which binds to OX40 on 
activated T cells, promotes immunity against lung 
Cryptococcus neoformans infection, enhances pathogen 
clearance and reduces pulmonary eosinophilia; these 
effects are dependent on the induction of IL-12 and/or 
IFN-y [58]. Therefore, the administration of co-stimu-
latory molecule agonists provides a novel adjuvant role, 
which is specific to those cells that respond to vaccination 
or infection. It might be more appropriate to promote 
co-stimulatory molecules that are upregulated on antigen-
activated T cells (especially OX40 and 4-1BB) because 
targeting constitutively expressed molecules (CD28 and, 
possibly, CD27 and ICOS) could promote the survival of a 
larger proportion of cells, which might cause immuno-
pathology or auto-immunity. 
Data regarding the inhibition of co-stimulatory mol-
ecules during infection in the lung are more frequent, as a 
result of the presence of several reagents and knockout 
mice. In order of importance following T-cell activation:  
CTLA-4 
In murine models, CTLA-4—Ig fusion proteins (which bind 
to B7 molecules on the APC and compete for binding with 
CD28 and CTLA4) prevent the pneumonitis that is caused 
by Saccharopolyspora rectivirgula [59] and reduce influ-
enza-virus-specific IFN-y production, antibody titres and 
the number of virus-specific CD8+ T cells. Although 
influenza virus is still eliminated, the kinetics of clearance 
is delayed [60]. The complication with using soluble 
CTLA-4 is that there are two forms of the receptor [B7.1 
(CD80) and B7.2 (CD86)], which seem to have subtly 
different roles. However, this might provide more subtle 
intervention opportunities, because mutated CTLA-4—Ig 
inhibits influenza-induced inflammation without prevent-
ing viral clearance [60]. The possibility of interfering with 
non-pathogen-specific T cells is another potential drawback. 
CD27 
Intranasal influenza virus infection of CD27-knockout 
mice results in reduced anti-viral CD4+ and CD8+ T cells 
in the acute phase and the memory pool [61]. The effect on 
both primary and memory responses lends further sup-
port to the hypothesis that CD27 acts concurrently with, 
or at least very close to, CD28 signals. Recent data from 
Hendriks et al. [17] show that CD27 and CD28 cooperate 
in the CD8+ T-cell response to influenza virus infection. 
CD27 can compensate for the lack of CD28 during 
influenza-specific T-cell responses in the lung and for 
T-cell priming in the mediastinal lymph nodes, whereas in 
mice lacking both molecules, T-cell responses are virtually 
absent. The influence of CD27 on virus-specific T-cell 
responses appears to be restricted to the site of viral 
replication because splenic CD8+ T cells are unaffected. In 
addition, mice lacking CD27 or CD28, or both, show 
reduced recall CD8+ T-cell responses to an influenza virus 
challenge. The mode of action of each molecule might 
differ subtly depending on the site studied. CD28, but not 
CD27, affects the cell cycle, whereas CD27, particularly in 
the lung, assists with the survival of antigen-activated 
CD8+ T cells. 
ICOS 
The majority of studies on the role of ICOS inhibition in 
the lung have been conducted in models of asthma and 
allergy [19,21]. However, one study by Bertram et al. [62] 
reported anti-influenza responses after the intraperi-
toneal infection of ICOS-knockout mice. An absence 
of ICOS reduces antibody responses during primary 
Figure 2. The coordinated activation of T lymphocytes during acute pulmonary viral infection. (a) Infection of the respiratory epithelium, alveolar macrophages and dendritic 
cells (e.g. with influenza virus or respiratory syncytial virus) causes the release of inflammatory cytokines and chemokines that recruit immune cells to the lung. Some 
epithelial cells that are killed during replication of the virus are ingested by antigen presenting cells (APCs). These, together with directly infected APCs, migrate to the 
expanding lung-associated lymph nodes (such as the mediastinal lymph node). Naive T cells enter the lymph node from the blood and are activated by the viral antigens that 
are presented on APCs. The activation of T cells depends on the co-stimulatory interaction between CD28 and B7, and results in the expression of alternative chemokine 
receptors and adhesion molecules that facilitate the entry of activated T cells into the inflamed lung. (b) From 2-4 days after lung infection, T cells are further expanded and 
upregulate late co-stimulatory molecules (0X40 and possibly 4-1BB). These cells migrate to the site of viral replication via the blood. Note that inflamed endothelial cells can 
also express OX4OL, which might facilitate the movement of OX40-expressing T cells into the lung. Once In the lung, further activation occurs through the Interaction with 
activated APCs or epithelial cells (which can upregulate co-stimulatory molecules). (c) By days 4-8, the level of T-cell recruitment and activation is maximal. OX40 
(and probably 4.1881-expressing T cells accumulate in and around the airways and blood vessels, disrupting their function. This, together with excessive inflammatory 
cytokine production, causes the clinical symptoms of infection (sweating, weight loss, cachexia and appetite suppression). (d) If the virus is eliminated and the patient 
survives, by day 8-18, the inflammatory infiltrate subsides (by activation-induced cell death) and the mediastinal lymph node reduces in size. Some antigen-specific cells 
survive this contraction process and migrate to the spleen as memory T cells. For clarity, we have omitted inducible co-stimulatory molecule (ICOS), which is induced much 
faster than OX40. The precise timing of co-stimulatory molecule expression is affected by the precise pathogen and dose. 
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infection and during re-challenge. By day 38 of primary 
infection, influenza-specific CD8+ T cell levels are half 
those observed in wild-type mice, which might be 
associated with a lack of IL-2 production by CD4+  
T cells in the knockout mice [62]. Because of the route 
of infection, no data are available on viral clearance or 
immune pathology 
4-1BB and OX40 
4-1BB appears to be crucial for late or secondary CD8+  
T-cell responses to influenza virus infection. 4-1BB-knock-
out mice display normal CD8+ T-cell responses during a 
primary infection, which are impaired during secondary 
infections. Additionally, soluble 4-1BB inhibits T-cell 
responses to influenza peptide in CD28-deficient mice. 
The effect on T-cell populations is more dramatic when 
both CD28 and 4-1BB are absent [63,64]. Agonistic 
antibodies against 4-1BB restore the defect in secondary 
CD8+ T cells in influenza-infected 4-1BB-knockout mice, 
but only when administered during secondary, and not 
primary, responses. Interestingly, agonistic antibodies 
against 4-1BB can restore the defective primary CD8+  
T-cell response in CD28-knockout mice when adminis-
tered early during infection [65]. 4-1BB is, therefore, 
important for the generation of influenza-specific CD8+  
T cells. Data so far suggest that anti-viral CD4+ T cells 
and antibodies are not affected by the manipulation of 
4-1BB [64]. However, these manipulations have only been 
tested in an intraperitoneal infection model, and there are 
no data available on virus clearance or immunopathology. 
The inhibition of OX40 produces a similar effect to 
4-1BB, but with reduced CD4+ and CD8+ anti-viral 
T cells. Using an OX40—Ig fusion protein to block the 
interaction of OX40 with its ligand on APCs, influenza-
induced weight loss and cachexia are eliminated and the 
virus is still removed from the lung. More importantly, 
such treatment is beneficial three days after the onset of 
clinical symptoms [29]. The reduction of virus-associated 
illness is accompanied by a reduced cellular infiltrate into 
the airways and lung parenchyma. A reduction in the 
proliferation and an enhancement in the apoptosis of lung 
cells accounts for this reduced cellularity. These data are 
partially supported by studies in OX40-knockout mice, in 
which CD4+ T-cell infiltrates were reduced. However, no 
effect was observed on CD8+ T-cell responses [661. Based 
on these findings with OX40, it is tempting to speculate 
that the inhibition of 4-1BB or its ligand would produce 
similar effects. 
It is important to appreciate that a reduction in the 
immunopathology resulting from infection must be 
balanced by the ability of the immune system to clear 
the virus and prevent illness. For OX40 inhibition, 
although MHC tetramer binding to CD8+ T cells is 
reduced, it is not entirely eliminated. Influenza virus is 
inflammatory and, therefore, a moderate reduction in the 
vigour of the inflammatory response might be beneficial 
without affecting virus clearance. The ability to clear viral 
infection despite significantly reduced lung inflammation 
might also reflect redundancy among late co-stimulatory 
signals and the presence of intact innate and antibody-
mediated immune mechanisms. For example, the inhibition 
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of OX40 leaves the 4-1BB co-stimulatory pathway intact. 
This hypothesis is consistent with the efficient control 
of other infections in OX40-knockout mice [66,67]. 
CD27-knockout mice similarly recover from influenza 
virus infection without displaying any signs of illness 
[61]. The interruption of CD30, which is also expressed on 
effector and memory T cells, has yet to be tested in models 
of lung viral infection. To understand the synergy and 
redundancy it will be important to examine anti-viral 
immunity in an environment that is deficient for multiple 
late co-stimulatory molecules (e.g. 4-1BB and OX40). 
Concluding remarks 
A clear conclusion from in vivo lung infection models is 
that a reduction, but not an elimination, of inflammatory 
infiltrate reduces the clinical manifestations without 
compromising pathogen clearance. The manner in which 
this reduction is achieved is important. The manipulation 
of late co-stimulatory molecules is tempting because of 
their predominant expression on effector, but not naïve, 
T cells. It is likely that the inhibition of OX40, 4-1BB or 
CD30 would serve this purpose, although studies on the 
protection from re-infection and clinical disease are 
required following the manipulation of 4-1BB and CD30. 
Other co-stimulatory molecules, such as herpesvirus entry 
mediator (HVEM, which is expressed on naive, and some 
memory T cells) and CD30 (which is expressed on effector 
cells and some memory cells), have yet to be tested. 
Similarly, the engagement of PD-1 on activated T cells by 
either of the two ligands (PDL-1 and PDL-2) inhibits T-cell 
proliferation and cytokine secretion [20,211. Soluble forms 
of these ligands or agonistic antibodies against PD-1 
might, therefore, limit excessive T-cell expansion, although 
this has yet to be tested in models of inflammatory lung 
disease. It might also be possible to manipulate late 
co-stimulatory molecules by interfering with the signal-
ling pathway. TNF receptor family members have been 
shown to bind to TRAFs [37]. At present, it appears that 
the inhibition of signalling might concurrently affect too 
many co-stimulatory molecules. By manipulating mol-
ecules on the cell surface, the redundancy that exists could 
be advantageous. Although the outcome of inhibiting 
co-stimulatory molecules is clear, the mechanism is not. 
Therefore, further studies will need to address whether 
manipulation alters T-cell survival, cytokine production 
and/or chemokine receptor expression patterns [22]. 
The manipulation of late co-stimulatory signals has 
clear therapeutic potential: on one hand we can reduce 
immune-based disorders such as asthma, bronchiolitis 
and pneumonia, and on the other we can promote immun-
ity against the lung infections in which the pathogen is the 
problem. Treatment to inhibit late co-stimulatory signals 
can also be extended to autoimmune conditions, whereas 
the promotion of these signals enhances anti-tumour 
immunity [68] and might improve the efficacy of vaccines 
[69,70]. The nature of the compound that is used to 
manipulate co-stimulatory signals will require significant 
thought, because the production of fusion proteins and 
antibodies is expensive. Future analysis of the exact 
binding regions between co-stimulatory molecules and 
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Box 1. Future research 
• Determine which molecules are involved in tumour necrosis factor 
receptor superfamily signaling, and their potential for intervention. 
• Determine the effect of 4-1BB and CD30 inhibition on immunity to 
infection in the lung. 
• Analyse the coordinated expression of co-stimulatory molecule 
expression in vivo. 
• Investigate the potential of inhibition through PD-1 to inhibit 
inflammatory disease. 
• Elucidate the role of co-stimulatory molecules in cell trafficking, 
positioning and development. 
• Test co-stimulatory agonists and antagonists in human inflamma-
tory disorders. 
their ligands might highlight specific epitopes that could 
be used as inhibitors (Box 1). 
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AGORA initiative provides free agriculture journals to developing countries 
The Health Intemetwork Access to Research Initiative (HINARI) of the WHO has launched a new community scheme with the UN Food 
and Agriculture Organization. 
As part of this enterprise, Elsevier has given 185 journals to Access to Global Online Research in Agriculture (AGORA). More than 100 
institutions are now registered for the scheme, which aims to provide developing countries with free access to vital research that will 
ultimately help increase crop yields and encourage agricultural self-sufficiency. 
According to the Africa University in Zimbabwe, AGORA has been welcomed by both students and staff. 'It has brought a wealth of 
information to our fingertips' says Vimbai Hungwe. 'The information made available goes a long way in helping the learning, teaching 
and research activities within the University. Given the economic hardships we are going through, it couldn't have come at a better time.' 
For more information visit: 
http://www.healthinternetwork.net  
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The therapeutic potential of positive and negative 
immune cell co-stimulation during inflammation 
E. Gwyer, R. Snelgrove and T. Russell' 
Kennedy Institute for Rheumatology, Imperial College London, 1, Aspenlea Road, London W6 8LH, U.K. 
Abstract 
Inflammatory cascades are initiated in response to alarm signals that may result from infection, malignant 
transformation or trauma. Immunity, however, must be controlled; otherwise damage may occur to 
otherwise healthy tissue within the same microenvironment. Similarly, peripheral tolerance mechanisms 
must ensure that autoreactive thymic or bone marrow emigrants do not respond upon encounter 
with the autoantigen. Organized lymphoid structures such as lymph nodes, spleen and Peyer's patches 
appear to regulate inflammation successfully, displaying controlled expansion and contraction. However, 
when immune cells flood into effector sites, the organization of T- and B-lymphocytes is lacking. What 
controls inflammatory cascades in lymph nodes but rarely in effector sites is not clear. We believe the 
difference lies in the Toll-like receptor ligand load, which is high in effector sites and drives uncontrolled 
inflammation. Similarly, we believe that initiation of autoimmune inflammation is initiated by the liberation 
of inflammatory signals due to infection or trauma. In this review, we highlight some of the molecules 
responsible for maintaining an activated T-cell phenotype, strategies to interrupt these therapeutically and 
the impact of ligating inhibitory receptors on antigen-presenting cells. 
Introduction 
The immune system has evolved to recognize and eradicate 
pathogens and altered or dying host cells. However, excessive 
or unregulated immunity is responsible for a wide range of 
diseases, including transplant rejection, autoimmunity and 
immune pathology during infection. The latter usually occurs 
upon first encounter with the organism. Once immuno-
logical memory is established, a further infection with the 
same pathogen usually results in milder disease due to rapid 
clearance before collateral damage can occur. This is particu-
larly evident during infection with influenza virus. Acute res-
piratory infections, especially influenza virus infections, are a 
leading cause of death worldwide. For example, the 1918 
influenza pandemic killed more people than the First 
World War. Most experts now consider the emergence of 
another pandemic to be inevitable. The outcome of infection 
depends on whether cross-protective pre-existing immunity 
is present. In a host without prior immunity, influenza 
virus replicates unchecked in the respiratory tract, eliciting 
extensive bystander tissue damage and immune pathology 
that may ultimately result in death, as shown in Figures 1(A)-
1(C). However, if the host has protective immunity, then viral 
replication is restricted and immune pathology is minimized, 
as shown in Figures 1(D) and 1(E). 
Key words: antigen-presenting cell, autoimmunity, co-stimulation, immune pathology, inhibitory 
receptor, 0X40. 
Abbreviations used: APC, antigen-presenting cell; CD200R, CO200 receptor; EAE, experimental 
autoimmune encephalomyelitis; KOS, inducible co-stimulator; ICOSL, 1C05 ligand; 
interferon-y; TCR, T-cell receptor; TLR, Toll-like receptor; TNF, tumour necrosis factor. 
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The life-threatening symptoms are caused in part by virus-
promoted release of inflammatory cytokines, e.g. IFN-y 
(interferon-y) and TNF (tumour necrosis factor) from NK 
(natural killer) cells, macrophages and activated T-cells. These 
cytokines lead to pulmonary oedema and transudation of 
leucocytes into the alveolar space, which then impair gas 
exchange, a syndrome termed the ARDS (acute respiratory 
distress syndrome) [1-3]. Convincing results in mouse 
models shows that a reduction of pro-inflammatory cyto-
kines (especially TNF) is beneficial, and can greatly increase 
survival rates [4]. 
Why such excessive inflammation is allowed to occur is 
not entirely clear but seems to be a common feature of sites 
devoid of, or with little, constitutive lymphoid tissue. Organ-
ized lymphoid tissue such as lymph nodes, spleen and Peyer's 
patches expand greatly during an immune response and yet 
do not tend to lead to clinical disease. No one ever dies of 
an inflamed lymph node. Such structures expand and contract 
in a regulated manner, immune cells are organized and that 
organization remains regardless of the burden of recruited 
cells. In addition, immune cells within these organized 
structures do not tend to produce high levels of inflammatory 
cytokines. In effector sites lacking organized lymphoid tissue, 
however, cells flood in during the disease process but are 
resident in a non-organized manner and produce high levels 
of inflammatory cytokines. It is not yet clear whether 
organization equates to control of immunity or whether the 
diseased or infected effector site promotes un-regulated in-
flammation. It is intriguing that sites associated with 'disease' 
tend to have the highest TLR (Toll-like receptor) ligand load. 
During influenza infection for example, the virus replicates 
Influenza infection in a host 
a with immune memory 
D 
41/t4r—* 
A 
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Figure 1 Immune-mediated pathology during influenza infection 
The outcome of influenza virus infection depends on whether pre-existing cross-reactive immunity exists. In a naive host, viral 
infection induces a highly inflammatory environment and APCs loaded with viral antigen track to the draining mediastinal 
lymph node (MLN) where they activate CD4+ (green) and CD8+ (yellow) T-cells (A). Further inflammatory cytokines, 
produced due to unchecked viral replication, recruit a large inflammatory infiltrate (B). Memory B- and T-cells (red) then 
migrate to the spleen, but some will remain resident in the lung (C). In hosts with cross-reactive T- and B-cells, however, 
antigen-specific cell migration and activation occur rapidly (D). Viral replication is therefore controlled much earlier, reducing 
bystander tissue damage and cellular infiltration (E). 
O. Memory to spleen 
Influenza infection in a host 
without immune memory 
in the respiratory epithelium and rarely traverses into the 
submucosal tissues and draining lymph node; the TLR ligand 
load will therefore be highest in the airways where disease is 
often maximal. 
What therefore prevents 'inflammation' in lymph nodes 
that is lacking in effector sites? Immunity can be loosely 
categorized into three distinct phases: initiation, maintenance 
and resolution. Inflammatory disease can occur at each or all 
of these stages. Excessive initiation due to high antigen load, 
extensive collateral damage to the affected site or prolonged 
presence of the antigen will initiate an excessive inflammatory 
cascade. Similarly, excessive maintenance or retention of the 
inflammatory infiltrate will cause accumulation of effector 
cells and lead to disease. Inflammatory disease can equally 
occur if inflammation does not resolve in a timely manner. 
In this review, we will discuss some of the regulatory 
mechanisms that contribute to maintenance or cessation of 
inflammatory responses, focusing on our expertise in late 
co-stimulatory signals delivered to antigen-activated T-cells 
(shown in Figure 2). 
The role of 0X40 in human and mouse 
disease and its potential as a therapeutic 
OX40 (CD134) is up-regulated on T-lymphocytes 24-
48 h after TCR (T-cell receptor) stimulation, and remains  
expressed for 96 h [5] (for a summary of expression patterns, 
see Table 1). OX40 is expressed on approx. 10% of T-cells 
in the peripheral blood of healthy patients [6] and a similar 
proportion of unstimulated murine splenocytes (E. Gwyer 
and T. Hussell, unpublished work). During inflammation, 
the proportion and intensity of OX40 expression increases on 
T-cells, predominantly at the actual site of inflammation. For 
example, during lung influenza infection, OX40 expression 
is highest on T-cells infiltrating the airways where the viral 
antigen load and inflammatory cytokine production are 
the highest [7]. Very little expression is observed in the 
draining lymph node, nor is it up-regulated on T-cells in 
the blood. Either up-regulation of late co-stimulatory 
molecules represents a final checkpoint to confirm that the 
cells are fully activated effector cells before they are allowed 
into the inflamed organ or the inflammatory microen-
vironment itself induces their expression. OX40 expression 
at the affected site is also observed during autoimmune in-
flammation [6]. For example, immunohistochemical staining 
for OX40 in mice suffering from EAE (experimental autoim-
mune encephalomyelitis) shows substantial expression in the 
inflammatory foci of the white matter in the spinal cord [8]. 
This up-regulation is again specific to the site of inflammation 
[9] and only occurs on myelin-specific T-cells [10]. 
In the few human diseases examined, the level and 
kinetics of OX40 expression appear to be similar to their 
02006 Biochemical Society 
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Figure 2 1 Reciprocal regulation between T-cell and APCs 
T-cells activated via their TCR by MHC/peptide antigen complexes (MHC) 
and the co-stimulatory signal between CD28 on the T-cell and B7 mol-
ecules on the APC require subsequent signals to avoid activation-induced 
cell death. ICOS and 0X40 are both induced on antigen-activated 
T-cells and when ligated by their cognate receptor on the APC transmit 
a survival signal to the T-cell, resulting in up-regulation of anti-apoptotic 
genes and the production of further inflammatory cytokines. CD200 on 
the T-cell, however, binds to CD200R on the APC and transmits a negative 
signal reducing APC function. OX4OL, 0X40 ligand. 
Antigen presenting cell 
MHC 
TCR 
CD4/8 
Induced 
Antigen presenting cell 
Table 1 1 The distribution of co-stimulatory and inhibitory signals 
on T-cells and APCs 
+, Known expression; —, known absence; '?', unknown. FDC, follicular 
dendritic cells; OX4OL, 0X40 ligand. 
0X40 OX4OL CD200 CO200R ICOS ICOSL 
T-cells 
B-cells 
Monocytes 	 + 	— 
Macrophages + 	— 
Dendritic cells 	 + (FOC) 
Neutrophils 
NK cells 	 + 	— 
Endothelium 
Basophils 
Mast cells 	 + 	— 
Eosinophils 
corresponding murine model, and again restricted to the 
actual site of the disease. Multiple sclerosis patients suffering 
from active disease have 0X40+ T-cells in perivascular 
inflammatory infiltrates, the tissue parenchyma and the 
lumen of small venules [8]; no 0X40+ T-cells, however, are 
found in healthy controls. Similarly, up to 70% of T-cells from 
©2006 Biochemical Society 
the synovial fluid of rheumatoid arthritis patients express 
0X40 [6]. 
The transient expression of 0X40 on antigen-stimulated, 
but not naive or resting memory T-cells, and their specific pre-
sence at sites of disease makes it a prime target for ther-
apeutic manipulation. Unlike more global strategies, such 
as cytokine blockade or total (anti-CD3) T-cell depletion, 
0X40 marks those cells in the late effector stage when 
they are most likely to be producing copious amounts of 
inflammatory cytokines. 0X40 inhibition will therefore leave 
early effector T-cells intact and mediate the resolution of 
highly inflammatory T-cells. Specific targeting of a subset 
of T-cells will also hopefully prevent the reactivation of latent 
infections observed during cytokine blockade of rheumatoid 
arthritis. In addition, such a strategy will not be affected by 
an absence of knowledge of the precise antigen involved (as 
is the case in rheumatoid arthritis) or, in the case of influenza 
virus, mutation of the antigen itself. 
We have previously shown that inhibiting the proliferation 
and survival of antigen-activated T-cells by targeting 
0X40 co-stimulation reduces influenza-induced pulmonary 
inflammation and associated disease without impairing viral 
clearance [7], similar to mice genetically deficient in this 
molecule [11,12]. In contrast, inhibition of constitutively 
expressed CD28, however, delays the clearance of influenza 
from the lung [13]. Similar strategies are currently being 
tested in models of autoimmune disease. Using an anti-
OX40 immunotoxin in the Lewis rat model of EAE, 
Weinberg et al. [14] show depletion of myelin-reactive 
T-cells from the central nervous system, which reduces di-
sease without depleting peripheral, non-responding T-cells 
[14]. This therapy is also effective when administered after the 
onset of clinical signs of disease (at the first signs of paralysis). 
Treatment with 0X40-directed immunotoxins or blocking 
fusion proteins depletes the pool of late effector T-cells by 
increasing their apoptosis and reducing their proliferation 
and expression of anti-apoptotic genes (Bc1-2 and Bcl-XL ) 
[7]. 
The role of ICOS (inducible co-stimulator) 
in human and mouse disease and its 
potential as a therapeutic 
ICOS is a member of the CD28 superfamily and is transiently 
expressed following TCR stimulation (see Table 1). It appears 
on the cell surface earlier than 0X40, peaking at 12-24 h 
after initial activation. For similar reasons to 0X40, the 
transient nature of ICOS expression and its absence on 
naive and resting memory T-cells makes it a potential target 
for inhibition during conditions associated with aberrant or 
excessive T-cell activation. 
Blockade of ICOS in vivo ameliorates autoimmunity 
(EAE, diabetes and collagen-induced arthritis), asthma and 
allergy and prevents transplant rejection (for a review, see 
[15]). ICOS-/- mice on a DBA/1 background are resistant to 
the development of collagen-induced arthritis [16]. In some 
Constitutive 
Control of Immune Responses 	 1035 
cases, ICOS blockade has been performed in conjunction 
with the disruption of other co-stimulatory molecules. 
Inhibition of the ICOS—ICOSL (ICOS ligand) interaction 
alone prolongs the survival of grafts, whereas blockade of 
ICOS and CD40 simultaneously results in indefinite survival 
of fully mismatched rat cardiac allografts [17]. The number of 
occluded vessels, the degree of occlusion of the vessels and 
lesions in the vascular wall are all reduced. This is likely to 
reflect a block in the infiltration of ICOS+ cells into the 
graft and a reduction in the production of pro-inflammatory 
cytokines. 
In murine models of infection, ICOS inhibition reduces 
Thl responses to Listeria monocytogenes [18], Th2 responses 
to Leishmania major [32], Thl and Th2 responses to 
Leishmania mexicana [19] and global T-cell responses to 
Nippostrongylus brasiliensis [20]. However, since ICOS 
appears rapidly after T-cell activation, it is possible that T-cell 
ablation will be too dramatic and allow the pathogen to escape 
immune-mediated elimination. We have recently shown that 
inhibition of ICOS in the murine influenza model leads to 
uncontrolled viral replication due to ablation of antigen- and 
non-antigen-specific T-cells (I.R. Humphreys and T. Hussell, 
unpublished work). 
CO200 in human and mouse disease and 
its potential as a therapeutic 
Instead of inhibiting activation signals delivered to antigen-
activated T-cells, another method of reducing inflammation 
would be to reduce the activity of APCs (antigen-presenting 
cells). By reducing APC activity, inflammatory mediators 
such as reactive oxygen and nitrogen species, chemokines 
and cytokines would be decreased. We have previously 
reported that a reduction of inflammatory metabolites from 
APCs reduces influenza-driven immunopathology [4,21]. 
Endogenous receptors on APCs exist that transmit inhibitory 
signals to curtail inflammation. CD200 (previously known as 
OX2) and its receptor, CD200R, were discovered 20 years 
ago [22], but it is only recently that their function has been 
elucidated. CD200 is widely expressed on a range of cell types, 
including T-cells, B-cells, dendritic cells, macrophages and 
neurons (for a review, see [23]) and has an intracellular domain 
so small that it is unlikely that any signal can be transmitted 
following ligation (see Table 1). Distribution of the receptor 
is more limited than CD200, restricted to myeloid cells such 
as macrophages and dendritic cells. Signalling through the 
receptor imparts a negative signal to the myeloid compart-
ment, reducing the inflammatory immune response. The 
pivotal role of CD200 in dampening immunity is observed 
in CD200 knockout mice that have increased numbers of 
macrophages and suffer from a more rapid onset and severe 
forms of EAE and collagen-induced arthritis [24]. 
Harnessing this negative signal through ligation of 
CD200R is therefore an attractive therapeutic strategy for 
autoimmune and inflammatory conditions. Indeed, one of 
the first descriptions of its use was in the collagen-induced 
arthritis model where prophylactic administration of a  
CD200R—Ig fusion protein prevented arthritis onset and 
significantly reduced the production of TNF and IFN- y 
compared with untreated mice [25]. Therapeutic treatment is 
also effective, with arrest of disease progress and a reduction 
in clinical score [26]. The tissue distribution of CD200 and 
CD200R in mice is similar to that in humans [27], and the 
inhibitory effects on murine macrophages in vitro are re-
plicated in human cell lines [28]. Although harnessing 
the inhibitory signal transmitted by CD200R has not yet 
been translated to human, it remains an attractive possible 
therapeutic for diseases characterized by an exuberant inflam-
matory response including autoimmunity, infection and 
transplant rejection. 
Concluding remarks 
We have highlighted some of the positive and negative 
influences of ligating receptors on acquired or innate immune 
cells. T-cell survival can be reduced by inhibiting late co-
stimulatory signals such as OX40 or ICOS; the latter, 
however, may lead to reduced pathogen clearance as it is 
expressed early during T-cell activation on antigen- and non-
antigen-specific cells. 4-1BB is another late co-stimulatory 
signal expressed with similar kinetics and is likely to represent 
another important therapeutic target during inflammatory 
disease [29,30]. Alternatively, exuberant T-cell activation can 
be dampened indirectly by reducing the activity of APCs (by 
ligating inhibitory receptors such as CD200R). Although we 
have focused on reducing immunity, it is equally possible to 
enhance it by taking the opposite approach. For example, 
immunity to Cryptococcus neoformans or tumour antigens 
can be enhanced by ligating OX40 on antigen-activated 
T-cells with agonistic reagents [31,32]. Whether enhancing or 
reducing immunity, harnessing receptors displayed by T-cells 
and APCs provides generic protection. This is an attractive 
possibility considering the role that the immune system plays 
in sculpting the phenotype of tumour antigens and pathogens. 
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